{"title": "PDF", "author": "PDF", "url": "revistabionatura.com/pluginAppObj/pluginAppObj_558_41/23-.-vol-6-No-3-2021.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "1884\nEquipo editorial\nEditor Jefe / Chief Editor\nDr. Nelson Santiago Vispo. Ph.D. Research / Full Professor. Yachay Tech \nUniversity, Ecuador. Member of the European Association of Science \nEditors (EASE) and  Council of Science Editors (USA).\nPrincipal Editorial Board / Consejo Editorial Principal\nDr. Fernando Albericio. Ph.D. Full Professor. University of KwaZulu-Na-\ntal. Durban, South Africa.\nDr. Spiros N. Agathos, Ph.D. Full Professor. Universit\u00e9 Catholique de \nLouvain - UCLouvain. Louvain-la-Neuve, Belgium.\nDra. Hortensia Mar\u00eda Rodr\u00edguez Cabrera. Ph.D. Full Professor and Dean, \nSchool of Chemical Sciences and Engineering Yachay Tech University, \nEcuador.\nDr. Frank Alexis. Research / Full Professor. Vice Chancellor Of Re-\nsearch and Innovation. Yachay Tech University, Ecuador.\nConsejo Editorial / Editorial Board\nDr. Gerardo Ferbeyre. Full Professor. D\u00e9partement de biochimie.Facul-\nt\u00e9 de M\u00e9decine. Universit\u00e9 de Montr\u00e9al, Canad\u00e1.\nDr Frank Camacho Casanova. Ph.D , Facultad de Ciencias Biol\u00f3gicas.\nUniversidad de Concepci\u00f3n . Chile.\nDr. Eduardo L\u00f3pez Collazo. Director IdiPAZ Institute of Biomedical Re-\nsearch, La Paz Hospital, Espa\u00f1a.\nDr.Yovani Marrero-Ponce. Ph.D. Full Professor. Universidad San Fran-\ncisco de Quito (USFQ), Quito, Ecuador.\nDr. Manuel Limonta. Prof. PhD. Director: Regional Office for Latin \nAmerican and the Caribbean International Council for Science (ICSU). \nDoctor honoris causa Autonomous Metropolitan University of M\u00e9xico \nCity (UAM). Dr. Honoris Causa - Universidad Central Ecuador.\nDr. Dagoberto Castro \u2013 Restrepo. Prof. PhD. Research and Develop-\nment Director. Universidad Catolica del Oriente. Rio Negro. Colombia\nDr. Michael Szardenings. PhD. Ligand Development Unit.Fraunhofer \nInstitute for Cell Therapy and Immunology.Germany.\nDra. Luciana Dente. Research Professor University of Pisa, Italy.\nDr. Costantino Vetriani. Research / Full Professor. Rutgers, The State \nUniversity of New Jersey. USA.\nDr. Si Amar Dahoumane.PhD. Research / Professor. Yachay Tech Uni-\nversity, Ecuador.\nDr. Amit Chandra, MD, MSC, FACEP Global Health Specialist, Emer-\ngency PhysicianMillennium Challenge Corporation, London School of \nEconomics and Political Science.        \nDr. Silvio e. Perea. PhD. Head of the Molecular Oncology Laboratory. \nCentro de Ingenier\u00eda Gen\u00e9tica y Biotecnolog\u00eda. Cuba.\nDra. Daynet Sosa del Castillo. PhD. Directora del Centro de Investiga-\nciones Biotecnol\u00f3gicas del Ecuador. CIBE-ESPOL.\nDra. Consuelo Mac\u00edas Abraham. Especialista de II Grado en Inmuno-\nlog\u00eda, Investigadora y Profesora Titular, Doctora en Ciencias M\u00e9dicas \ny Miembro Titular de la Academia de Ciencias de Cuba. Directora del \nInstituto de Hematolog\u00eda e Inmunolog\u00eda (IHI), de La Habana, Cuba.\nDr. Ren\u00e9 Delgado. PhD. IFAL / Presidente Sociedad Cubana de Farma-\ncolog\u00eda. Cuba.\nDr. Ram\u00f3n Guimil. Senior Director. Oligonucleotide Chemistry bei Syn-\nthetic Genomics, Estados Unidos.\nDr. Eduardo Penton. MD, PhD, Investigador Titular. Centro de Ingenier\u00eda \nGen\u00e9tica y Biotecnolog\u00eda, Cuba.\nDr. Julio Ra\u00fal Fern\u00e1ndez Mass\u00f3, PhD, Investigador Titular. Centro de \nIngenier\u00eda Gen\u00e9tica y Biotecnolog\u00eda, Cuba\nDra. Lisset Hermida. Investigadora Titular. Centro de Ingenier\u00eda Gen\u00e9-\ntica y Biotecnolog\u00eda, Cuba.\nDr. Tirso Pons. Staff Scientist. Structural Biology and Biocomputing \nProgramme (CNIO), Espa\u00f1a.\nDr. Che Serguera. French Institute of Health and Medical Research. \nMIRCen, CEA, Fontenay-aux-Roses Paris, France.\nDr. Jorge Roberto Toledo. Profesor Asociado. Universidad de Concepci\u00f3n, Chile.La Revista Bionatura publica trimestral en espa\u00f1ol \no ingl\u00e9s trabajos in\u00e9ditos de investigaciones b\u00e1sicas \ny aplicadas en el campo de la Biotecnolog\u00eda, la \nInmunolog\u00eda, la Bioqu\u00edmica, Ensayos Cl\u00ednicos y \notras disciplinas afines a las ciencias biolog\u00edcas, \ndirigidas a la obtenci\u00f3n de nuevos conocimientos, \nevaluaci\u00f3n y desarrollo de nuevas tecnolog\u00edas, \nproductos y procedimientos de trabajo con un \nimpacto a nivel mundial.Vol. 6 No. 3   2021\nBionatura\nDr. Oliberto S\u00e1nchez. Profesor Asociado. Universidad de Concepci\u00f3n, Chile.\nDr. Aminael S\u00e1nchez Rodr\u00edguez. PhD. Director del departamento de \nCiencias Biol\u00f3gicas, Universidad T\u00e9cnica Particular de Loja, Ecuador.\nDra. Maritza Pupo. Profesora investigador. Facultad de Biolog\u00eda. Uni-\nversidad de la Habana, Cuba.\nDr. Fidel Ovidio Castro. Founder, Profesor investigador. Tecelvet, Chile.\nDra. Olga Moreno. Partner, Head Patent Division. Jarry IP SpA, Chile.\nDr. Carlos Borroto. Asesor de Transferencia de Tecnolog\u00eda. Direcci\u00f3n Ge-\nneral at Centro de Investigaciones Cient\u00edficas de Yucat\u00e1n (CICY), M\u00e9xico.\nDr. Javier Men\u00e9ndez. Manager Specialist Process and Product 5cP. Sa-\nnofi Pasteur, Canad\u00e1.\nDr. Pedro Valiente. Profesor investigador. Facultad de Biolog\u00eda. Univer-\nsidad de la Habana, Cuba.\nDr. Di\u00f3genes Infante. Prometeo / SENESCYT. Especialista de primer \nnivel en Biotecnolog\u00eda. Universidad de Yachay Tech, Ecuador.\nDra. Georgina Michelena. Profesora Investigador. Organizaci\u00f3n de las \nNaciones Unidas. (ONU), Suiza.\nDr. Francisco Barona, Profesor Asociado. Langebio Institute, M\u00e9xico\nDr. Gustavo de la Riva. Profesor Investigador Titular. Instituto Tecnol\u00f3-\ngico Superior de Irapuato, M\u00e9xico.\nDr. Manuel Mansur. New Product Introduction Scientist (NPI) at Elanco \nAnimal Health Ireland, Irlanda.\nDr. Rolando Paj\u00f3n. Associate Scientist, Meningococcal Pathogenesis \nand Vaccine Researc. Center for Immunobiology and Vaccine Develop-\nment, UCSF Benioff Children\u2019s Hospital Oakland\u201d, Estados Unidos.\nDra. Ileana Rosado Ruiz-Apodaca. Profesor / Investigador. Universidad \nde Guayaquil, Ecuador.\nDr. Carlos Eduardo Giraldo S\u00e1nchez. PhD, Profesor / Investigador. Uni-\nversidad Cat\u00f3lica de Oriente. Rionegro-Antioquia/Colombia.\nDr. Mario Alberto Quijano Abril. PhD, Profesor / Investigador. Universi-\ndad Cat\u00f3lica de Oriente. Rionegro-Antioquia/Colombia.\nDr. Felipe Rojas Rodas. PhD, Profesor / Investigador. Universidad Cat\u00f3-\nlica de Oriente.Rionegro-Antioquia/Colombia.\nDra. Isabel Cristina Zapata Vahos, Profesor / Investigador. Universidad \nCat\u00f3lica de Oriente.Rionegro-Antioquia/Colombia.\nDr. Felipe Rafael Garc\u00e9s Fiallos, PhD. Profesor / Investigador. Vicerrec-\ntorado de Investigaci\u00f3n, Gesti\u00f3n Social del Conocimiento y Posgrado \nUniversidad de Guayaquil (UG), Ecuador.\nDra. Celia Fernandez Ortega. PhD. Investigadora Titular. Centro de \nIngenier\u00eda Gen\u00e9tica y Biotecnolog\u00eda, Editora ejecutiva Biotecnologia \nAplicada. Cuba.\nDra. Ligia Isabel Ayala Navarrete.PhD. Profesor / Investigador. Univer-\nsidad de las Fuerzas Armadas - ESPE. Ecuador.\nDr. Nalini kanta Sahoo, PhD. Professor & Head Department Marri Lax-\nman Reddy Institute of Pharmacy. Hyderabad, Andhra Pradesh, India.\nDr. Saman Esmaeilnejad. PhD. Department of medical sciences, Tar-\nbiat Modares University, Tehran, Iran.\nDr. Olukayode Karunwi. PhD. Research / Professor. Clemson Universi-\nty. Clemson, United States.\nAssociate Editor / Editor Asociado\nVictor Santiago Padilla.\nRedacci\u00f3n y Edici\u00f3n / Copyediting and corrections\nMg. Frey A. Narv\u00e1ez-Villa. Jefe del Fondo Editorial Universidad Cat\u00f3lica \nde Oriente. Rionegro-Antioquia/Colombia.\nMSc. Jos\u00e9 Enrique Alfonso Manzanet. \nDise\u00f1o y Realizaci\u00f3n gr\u00e1fica / Graphic design and production\nDI. Jos\u00e9 Manuel Oubi\u00f1a Gonz\u00e1lez.\nRelaciones Publicas / Public relations\nCamila Barranco Rodriguez.\nAsistente de publicaci\u00f3n / Publication assistant\nEvelyn Padilla Rodriguez.\n1885\nLa Revista Bionatura es un medio especializado, interinstitu-\ncional e interdisciplinario, para la divulgaci\u00f3n de desarrollos \ncient\u00edficos y t\u00e9cnicos, innovaciones tecnol\u00f3gicas, y en general, \nlos diversos t\u00f3picos relativos a los sectores involucrados en la \nbiotecnolog\u00eda, tanto en Ecuador como en el exterior; as\u00ed mis-\nmo, la revista se constituye en un mecanismo eficaz de comu-\nnicaci\u00f3n entre los diferentes profesionales de la biotecnolog\u00eda.\nEs una publicaci\u00f3n sin \u00e1nimo de lucro. Los ingresos obtenidos \npor publicidad o servicios prestados ser\u00e1n destinados para su \nfuncionamiento y desarrollo de su calidad de edici\u00f3n.  (http://\nrevistabionatura.com/media-kit.html)\nEs una revista trimestral, especializada en temas \nconcernientes al desarrollo te\u00f3rico, aplicado y de mercado en \nla biotecnolog\u00eda.\nPublica art\u00edculos originales de investigaci\u00f3n y otros tipos de \nart\u00edculos cient\u00edficos a consideraci\u00f3n de su consejo editorial, \nprevio proceso de evaluaci\u00f3n por pares (peer review) sin tener \nen cuenta el pa\u00eds de origen.\nLos idiomas de publicaci\u00f3n son el Espa\u00f1ol e Ingl\u00e9s.\nLos autores mantienen sus derechos sobre los art\u00edculos sin \nrestricciones y opera bajo la pol\u00edtica de Acceso Abierto a la \nInformaci\u00f3n, bajo la licencia de Creative Commons 4.0 CC BY-\nNC-SA (Reconocimiento-No Comercial-Compartir igual).\nEsta revista utiliza Open Journal Systems, que es un gestor \nde revistas de acceso abierto y un software desarrollado, fi-\nnanciado y distribuido de forma gratuita por el proyecto Pu-\nblic Knowledge Project sujeto a la Licencia General P\u00fablica \nde GNU.\nNuestros contactos deben ser dirigidos a:\nRevista Bionatura: editor@revistabionatura.com\nISSN: 1390-9347 (Versi\u00f3n impresa)\nFormato: 21 x 29,7 cm\nISSN: 1390-9355 (Versi\u00f3n electr\u00f3nica)\nSitio web: http://www.revistabionatura.com\nPublicaci\u00f3n peri\u00f3dica trimestral\nEsta revista utiliza el sistema peer review para la \nevaluaci\u00f3n de los manuscritos enviados.\n \nInstrucciones a los autores en:\nhttp://revistabionatura.com/instrucciones.html\nAsistente de publicaci\u00f3n / Publication assistant\nEvelyn Padilla Rodriguez (sales@revistabionatura.com)Instrucciones para los Autores\nLos Trabajos ser\u00e1n In\u00e9ditos: Una vez aprobados, no podr\u00e1n \nsometerse a la consideraci\u00f3n de otra revista, con vistas a una \npublicaci\u00f3n m\u00faltiple, sin la debida autorizaci\u00f3n del Comit\u00e9 \nEditorial de la Revista. La extensi\u00f3n m\u00e1xima ser\u00e1 8 cuartillas para \nlos trabajos originales, 12 las revisiones y 4 las comunicaciones \nbreves e informes de casos, incluidas las tablas y figuras. Los \nart\u00edculos se presentar\u00e1n impresos (dos ejemplares). Todas \nlas p\u00e1ginas se numerar\u00e1n con ar\u00e1bigos y consecutivamente a \npartir de la primera. Estos deben acompa\u00f1arse de una versi\u00f3n \ndigital (correo electr\u00f3nico o CD) en lenguaje Microsoft Word, \nsin sangr\u00edas, tabuladores o cualquier otro atributo de dise\u00f1o \n(t\u00edtulos centrados, justificaciones, espacios entre p\u00e1rrafos, etc.). \nSiempre se ha de adjuntar la carta del consejo cient\u00edfico que \navala la publicaci\u00f3n y una declaraci\u00f3n jurada de los autores.\nReferencias Bibliogr\u00e1ficas. Se numerar\u00e1n seg\u00fan el orden de \nmenci\u00f3n en el texto y deber\u00e1n identificarse mediante ar\u00e1bigos \nen forma exponencial. Los trabajos originales no sobrepasar\u00e1n \nlas 20 citas; las revisiones, de 25 a 50 y las comunicaciones \nbreves e informes de casos.\nEn las Referencias en caso de que las publicaciones revisadas \nesten online se debe proveer un enlace consistente para su \nlocalizaci\u00f3n en Internet. Actualmente, no todos los documentos \ntienen DOI, pero si lo tienen se debe  incluir como parte de la \nreferencias. Si no tuviese DOI, incluir la URL.\nTablas, modelos y anexos: Se presentar\u00e1n en hojas aparte (no \nse intercalar\u00e1n en el art\u00edculo) y en forma vertical numeradas \nconsecutivamente y mencionadas en el texto. Las tablas se \najustar\u00e1n al formato de la publicaci\u00f3n se podr\u00e1n modificar si \npresentan dificultades t\u00e9cnicas.\nFiguras: Las fotograf\u00edas, gr\u00e1ficos, dibujos, esquemas, mapas, \nsalidas de computadora, otras representaciones gr\u00e1ficas \ny f\u00f3rmulas no lineales, se denominar\u00e1n figuras y tendr\u00e1n \nnumeraci\u00f3n ar\u00e1biga consecutiva. Se presentar\u00e1n impresas en el \nart\u00edculo en p\u00e1ginas independientes y en formato digital con una \nresoluci\u00f3n de 300 dpi. Todas se mencionar\u00e1n en el texto. Los \npies de figuras se colocar\u00e1n en p\u00e1gina aparte. El total de las \nfiguras y tablas ascender\u00e1 a 5 para los trabajos originales y de \nrevisi\u00f3n y 3 para las comunicaciones breves e informes de casos.\nAbreviaturas y siglas: Las preceder\u00e1 su nombre completo la \nprimera vez que aparezcan en el texto. No figurar\u00e1n en t\u00edtulos ni \nres\u00famenes. Se emplear\u00e1n las de uso internacional.\nSistema Internacional de Unidades (SI): Todos los resultados de \nlaboratorio cl\u00ednico se informar\u00e1n en unidades del SI o permitidas \npor este. Si se desea a\u00f1adir las unidades tradicionales, se \nescribir\u00e1n entre par\u00e9ntesis. Ejemplo: glicemia: 5,55 mmol/L (100 \nmg/100 mL).\nPara facilitar la elaboraci\u00f3n de los originales, se orienta a los \nautores consultar los requisitos uniformes antes se\u00f1alados \ndisponibles en: http://www. fisterra.com/recursos_web/\nmbelvancouver. htm#ilustraciones%20 (figura)\nLos trabajos que no se ajusten a estas instrucciones, se \ndevolver\u00e1n a los autores. Los aceptados se procesar\u00e1n seg\u00fan \nlas normas establecidas por el Comit\u00e9 Editorial. El arbitraje \nse realizar\u00e1 por pares y a doble ciego en un per\u00edodo no mayor \nde 60 d\u00edas. Los autores podr\u00e1n disponer de no m\u00e1s de 45 d\u00edas \npara enviar el art\u00edculo con correcciones, se aceptan hasta tres \nreenv\u00edos. El Consejo de Redacci\u00f3n se reserva el derecho de \nintroducir modificaciones de estilo y /o acotar los textos que lo \nprecisen, comprometi\u00e9ndose a respetar el contenido original.\nEl Comit\u00e9 Editorial de la Revista se reserva todos los derechos \nsobre los trabajos originales publicados en esta.Bionatura1886\nEDITORIAL\nHybrid immunity: the immune response of COVID-19 survivors to vaccination           1890\nMarlon Gancino , Nelson Santiago Vispo\nLETTER TO EDITOR / CARTA AL EDITOR \nSARS-Cov-2 y tromboembolia pulmonar en pacientes cr\u00edticamente enfermos,          1894\nexperiencia de una unidad de cuidados criticos                                                                               \nSARS-Cov-2 and pulmonary thromboembolism in critically ill patients, the experience of \na critical care unit\nJorge Luis V\u00e9lez-P\u00e1ez, Edgar L\u00f3pez-Rond\u00f3n, Mario Montalvo-Villag\u00f3mez\n \n \nRESEARCH / INVESTIGACI\u00d3N\nSafety and immunogenicity in piglets of two immunization schedules                         1896\ninitiated at two or three weeks of age with Porvac\u00ae a classical swine fever \nsubunit marker vaccine\nAym\u00e9 Oliva-C\u00e1rdenas, F\u00e9 Fern\u00e1ndez-Zamora, Elaine Santana-Rodr\u00edguez, Yusmel Sordo-Puga, \nMilagros de la C. Vargas-Hern\u00e1ndez, Mar\u00eda P. Rodr\u00edguez-Molt\u00f3, Danny P\u00e9rez-P\u00e9rez, Talia Sar-\ndina-Gonz\u00e1lez,Carlos A. Duarte, Avelina Le\u00f3n-Go\u00f1i , Diurys Blanco -G\u00e1mez, Francisco Contre-\nras-P\u00e9rez, Odalys Vald\u00e9s-Faure, Rosmery Hern\u00e1ndez-Prado, Eric Acosta-Lago, Ileana Sosa-Test\u00e9, \nMarisela F. Su\u00e1rez-Pedroso\nAssessing HeberFast\u00ae Line Gavac, a lateral flow immunochromatographic                1902\nsystem for the rapid detection of anti-Bm86 antibodies in Gavac vaccinated cattle                                        \nMilagros Vargas-Hern\u00e1ndez, Yeni Hern\u00e1ndez Lorenzo, Viviana Pluma Perez, Isabel Rosales-Garcia, \nSunamit Rodr\u00edguez-Mendez, Enrique P\u00e9rez-Cruz, Daymi Abreu-Remedios, Carlos Montero-Espi-\nnosa, Ayme Oliva-Cardenas, Elaine Santana-Rodriguez, Danny P\u00e9rez-P\u00e9rez, Yusmel Sordo-Puga, \nYohandy Fuentes-Rodr\u00edguez, Alianne Fundora-Llera, Carlos A. Duarte, Ernesto Galb\u00e1n-Rodr\u00edguez, \nCarlos Hernandez-Diaz, Dayam\u00ed Dorta Hernandez, Ivis Pasaron Rodriguez, Marisela Suarez-Pedroso\nFormulation and organoleptic evaluation of Poly Herbal Cream of Punica,                  1909\nNeem, Carrot & Jamun as Active Ingredients                                \nPuja Saha, Jayashree Bhowmick, Anupam Saha\nPurificaci\u00f3n parcial de p\u00e9ptidos del veneno de escorpi\u00f3n Hadruroides                          1917\ncharcasus (Karsch, 1879) con actividad antimicrobiana                                           \nPartial purification of peptides from the scorpion venom Hadruroides charcasus \n(Karsch, 1879) with antimicrobial activity\nOrlando P\u00e9rez-Delgado , Clara Andrea Rincon-Cort\u00e9s , Nohora Ang\u00e9lica Vega-Castro , Edgar Anto-\nnio Reyes-Monta\u00f1o , Marcela G\u00f3mez-Garz\u00f3nhttp://www.revistabionatura.com\n\u00cdNDICE / INDEX1887\nTrametes coccinea IDEA, un hongo s\u00faper productor de lacasa aislado de                        1924\nun lago natural de asfalto: Tolerancia y biotransformaci\u00f3n de hidrocarburos \npolic\u00edclicos arom\u00e1ticos                                            \nTrametes coccinea IDEA, a super laccase-producer fungus isolated from a natural \nasphalt lake: Tolerance and biotransformation of aromatics polycyclic hydrocarbons\nBeatriz Pern\u00eda, Hector Urbina, Meralys Gonz\u00e1lez, Lucia Sena, Yanet Villasana, Leopoldo Naranjo-Brice\u00f1o\nComparison of anxiety levels in Patients with coronavirus disease (COVID-19)           1935\nand their families\nAzin Chakeri , Maryam Rostami Qadi, Shima Haghani\nUsage of Cicer Arietinum as a local and eco-friendly natural coagulant in                   1939\nsewage treatment and its ability to increase the formation of floc process\nAmera Marey Mohammed Hassanien\nAssessment of the diagnostic value of CEA, CA125, and CRP and their                        1944\ncut-off point for discrimination of exudative pleural effusions\nHanie Raji, Seyed Hamid Borsi, Mehrdad Dargahi MalAmir, Ahmad Reza Asadollah Salmanpou\nTips for a reduction of false positives in manual RT-PCR diagnostics                            1948\nof SARS-CoV-2\nFrancisco J. Alvarez, Mariela Perez-Cardenas, Marco Gudi\u00f1o, Markus P. Tellkamp\nComparative study between lumpy skin disease virus and sheep pox virus                  1955\nvaccines against recent field isolate of lumpy skin disease virus\nNermeen G Shafik, Heba A Khafagy, Amal AM, Ayatollah I Bassiuony, Farid Fouad Zaki, Christine A Mikhael \nand Mohamed Samy Abousenna\nDifferences between preterm infants receiving a dose for lung maturation and         1960 \nthose receiving an additional rescue dose of corticosteroids\nSandra Liliana Medina Poma, Fabricio Gonz\u00e1lez-Andrade\nDetermination of pro-oxidant-antioxidant balance (PAB) assay in mothers                  1970\nwith spontaneous abortion\nFaezeh Ghasemi, Alireza Kamali, Maryam Shokrpour\nInvestigate workers' health in the western industrial region, Mosul, Iraq                      1983\nSalim Rabeea Znad , Mazin Nazar Fadhel , Ay\u00e7a Erdem \u00dcn\u015far\nSynthesis, in silico studies and antibacterial assessment of \u03b1-amino                            1986\nphosphonates derivatives\nBouchra El Khalfi, Boutaina Addoum, Suhayla Harrati, Abdelhakim Elmakssoudi and Abdelaziz Soukri1888\nC\u00f3digo de barras de ADN de tres especies de \u00e1rboles frutales con potencial              1992\necon\u00f3mico del valle de Huaura, Lima, Per\u00fa                                        \nDNA barcoding of three species of fruit trees with economic potential from the Huaura \nValley, Lima, Peru\nHermila Belba D\u00edaz-Pillasca , Angel David Hern\u00e1ndez-Amasifuen, Miguel Machahua , Alexandra \nJherina Pineda-L\u00e1zaro , Alexis Arg\u00fcelles-Curaca, Brayan Lugo\nRole of Candida glabrata as nosocomial pathogen and its susceptibility                      2001\nto Fluconazole, Voriconazole, Caspofungin, Micafungin and Amphotericin B                                      \nTeeba Hashim Mohammed , Mohsen Hashim Risan , Mohammed Kadhom, Emad Yousif\nConjugation strategies on functionalized iron oxide nanoparticles as a                         2009\nmalaria vaccine delivery system\nAswan Al-Abboodi, Hussain A. Mhouse Alsaady, Shaima R. Banoon, Mohammed Al-Saady\nMolecular Exploring of Plasmid-mediated Ampc beta Lactamase Gene in                   2017\nClinical Isolates of Proteus mirabilis                                        \nIsraa Abdul Ameer Al-Kraety, Sddiq Ghani Al-Muhanna, Shaima R. Banoon\nRisk factors in bacterial colonization of internal ureteral stent                                       2022\nEkremah K. Shaker, Fatima A. Chaloob\nInvestigation about contamination of some food items in local markets, Mosul, Iraq        2027\nAmmar Nafea Alnema, Mazin Nazar Fadhel\nModelo de regresi\u00f3n de Cox para an\u00e1lisis de supervivencia en pacientes                      2031\ncon c\u00e1ncer de mama en la provincia de Manab\u00ed, Ecuador                                       \nCox regression model for survival analysis in patients with breast cancer in the province \nof Manab\u00ed, Ecuador\nCecilia Bucheli Giler, Daniel Fabricio Alarc\u00f3n Cano, Karime Montes Escobar\nCASE REPORTS / REPORTE DE CASO \nInfecci\u00f3n metast\u00e1sica por Staphylococcus aureus en neonatos: a prop\u00f3sito de un caso      2038                                    \nMetastatic infection by Staphylococcus aureus in neonates: about a case\nLaura Taylor, Carlos S. Mamani-Garc\u00eda,Alexandra Guti\u00e9rrez-Pingo.Jerry K. Benites-Meza, Diego \nChambergo-Michilot,Norma del Carmen G\u00e1lvez-D\u00edaz, Joshuan J. Barboza.\nCommon Peroneal Nerve Injury in a Patient with COVID-19 Infection                           2043\nZeynab Bossaghzadeh , Firoozeh Niazvand , Medi Saneie , Shahram Rahimi-Dehgolan , Hooshan \nSahariati Ghadikolaei , Sara Mobarak\nStrongyloides stercoralis infestation in a pediatric patient                                              2046\nRicardo Rubio-S\u00e1nchez , Esperanza Lepe-Balsalobre\nReporte de caso de postcirug\u00eda de ligamento cruzado anterior                                              2048                                    \nCase report of post-surgery anterior cruciate ligament surgery\nClara Gualotu\u00f1a, Thelvia I. Ramos1889\nREVIEW / ART\u00cdCULO DE REVISI\u00d3N\nExperiencias en el uso de energ\u00eda renovable en la Rep\u00fablica del Ecuador                    2056                       \nExperiencies in the use of renewable energies in the Republic of Ecuador\nJulio G\u00f3mez-Assan , Rosa Ajila-Freire\nTecnolog\u00eda IgY: Estrategia en el tratamiento de enfermedades infecciosas humanas       2061                     \nIgY Technology: Strategy in the treatment of human infectious diseases\nNathaly, Cruz, Tipantiza and Marbel, Torres, Arias\nLab on a Chip: Bioreactors miniaturization for rapid optimization of                               2076\nbiomedical processes and its impact on SARS-CoV-2 diagnosis                                \nCP Ortega, DA Corredor, WS Ger, ME Santill\u00e1n, CM Noceda, JM Pais-Chanfrau, LE Trujillof\nMetachromatic Leukodystrophy: Diagnosis and Treatment Challenges                        2083                      \nNayibe Tatiana Sanchez-Alvarez, Paula Katherine Bautista-Ni\u00f1o, Juanita Trejos-Su\u00e1rez, Norma \nCecilia Serrano-Diaz\nHerramientas biotecnol\u00f3gicas en el diagn\u00f3stico, prevenci\u00f3n y tratamiento                  2091\nfrente a pandemias\nBiotechnological tools in the diagnosis, prevention, and treatment of pandemics\nPamela Molina and Marbel Torres Arias\nRelationship of SARS-CoV-2 and chronic diseases of nutritional origin                          2114                      \nJohanna Pilay Baja\u00f1a, Evelyn Ram\u00edrez Carguacundo, Mar\u00eda Jos\u00e9 Vizcaino Tumbaco, Daniel \nSilva-Ochoa , Davide Di Grumo, Luis Dorado-Sanchez, Silvia Orellana-Manzano, Patricia Manzano, \nAndrea Orellana-Manzano\nHormonal and neuroendocrine control of reproductive function in teleost fish            2122                      \nAdrian Rodr\u00edguez Gabilondo, Liz Hern\u00e1ndez P\u00e9rez, Rebeca Mart\u00ednez Rodr\u00edguez1890\nB  y the time writing this editorial, around nineteen \nmonths (Dec 2019) has passed since the first report \nof a Severe Acute Respiratory Syndrome Coronavi-\nrus 2 (SARS-CoV-2) outbreak in individuals of Wuhan, \nChina1. Also, it has been more than sixteen months (Mar 2020) \nsince the declaration of the Coronavirus disease 19 (COVID-19) \npandemic by the World Health Organization (WHO)1. The evo-\nlution and rapid scattering of this novel coronavirus have tra-\npped in an unprecedented global public health crisis, which, so \nfar, has reached 196,553,009 people around the globe, provo-\nking 4,200,412 deaths (31st July 2021)1.\nThe global endeavor of defeating contagion has achieved \ngroundbreaking events such as the fastest development and \nmassive application of effective vaccines in history2. Currently, \n+500 SARS-CoV-2 vaccines are being developed over the full \nspectrum of platforms (i.e., non-viral vector, viral vector, inac-\ntivated and live-attenuated virus, and recombinant vaccines); \nsome of which are already pre-clinical and clinical studies2,3. \nRemarkably, ten vaccines are already available on the market4, \nfrom which, by the end of July 2021, +3800 million doses have \nbeen administered1. Complemented by non-pharmaceutical \nstrategies (e.g., restrictions on international mobility), inducing \nprotective immunity to SARS-CoV-2 massively until attaining \nherd immunity appears to be the definitive solution to overco-\nme this pandemic5.\nWe are reaching milestones daily, so some exciting ques-\ntions have been raised about immunological memory \u2013 the \nfundamental of protective immunology. This response coor-\ndinated by a synchronized orchestra of antibodies, memory B \ncells, memory CD4+ T cells, and memory CD8+ T cells re-\nmains poorly understood6. Either infection (natural immunity) \nor vaccination (vaccine-induced immunity) can trigger immu-\nnological memory against SARS-CoV-2, and all nuances in \nsuch complexity may provoke different biological outcomes7. \nDiverse investigations have concluded that either path to im-\nmunity can confer specific protection to COVID-198\u201311. Moreo-\nver, they have discussed the question: what does it occur when \nthese immunities are overlapped? Acquiring knowledge on the \nimmune response dynamics that convalescent individuals who \nare subsequently vaccinated develop is essential. The deep \nunderstanding of this \u201chybrid immunity\u201d will allow the design \nof appropriate vaccination regimes for the vast population of \npreviously infected individuals12.\nObservations on the response kinetics of immune me-\nmory from naturally immunized cohorts have found that ~95% \nof subjects can develop a stable immunity against reinfection, \nwhich may last moderately declining over a year after symp-\ntoms onset6,13. Relevantly, such protective immunity suffers \na considerable weakening in the face of current circulating \nSARS-CoV-2 variants of concern (VOCs) \u2013 i.e., B.1.1.7 (Alpha), \nB.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta) \u2013 when com-\npared with the wild-type Wuhan-Hu-1 variant4,14\u201316. As identi-\nfied by previous works, multiple spike (S) protein mutations \nin VOCs explain their ability to escape neutralization antibody activity partially, making the acquired natural protective im-\nmunology less effective7,12.\nAlthough to a milder degree, reduction to VOCs neutra-\nlization has also been seen in vaccine immunized people16. \nCurrently, four main types of vaccines govern the market: \nmRNA-lipid nanoparticle-based non-viral vectors (BNT162b2 \nby Pfizer-BioNTech, and mRNA-1273 by Moderna), adenovi-\nrus-based viral vectors (ChAdOx1-nCoV-19 by AstraZeneca, \nAd26.COV2.S by Johnson & Johnson, Ad5-nCoV by CanSino \nBiologics, and Sputnik V by Gamaleya), inactivated virus (Co-\nronaVac by Sinovac, BBV152 by Bharat Biotech,  WIBP-CorV \nby Sinopharm (Wuhan), and BBIBP-CorV by Sinopharm (Bei-\njing)), and recombinant protein subunits (NVX-CoV2373 by \nNovavax)3,4. Phase 3 clinical trials showed good overall vac-\ncine efficacies that ranged from ~95% (BNT162b2) to >50% \n(CoronaVac) at preventing COVID-19 illness, commonly af-\nter a two-dose prime-boost regime17. In such a sense, it has \nbeen observed that vaccination protection effectiveness sli-\nghtly reduces against VOCs, Delta variant being associated \nwith the highest transmissibility and ability to avoid antibody \nneutralization16. However, although less potent to VOCs, pre-\nliminary research suggests that vaccines probably remain \nefficacious8,11,16,18. Now, it is statistically modelized that vacci-\nne-induced neutralization activity would decay in a long non-li-\nnearly fashion, causing the vaccines with initial efficacy of 95% \nto preserve 77% efficacy in a 250-day span19.\nIdentifying the differences between natural and vacci-\nne-induced immunities directs us to the proper interrogation: \nwhat is there at their interface? As mentioned earlier, nume-\nrous research groups have addressed this question, and their \nresults suggest that hybrid immunity has a more robust pro-\ntective performance than either immunity. In a synergistic cha-\nracter, researchers have seen that previously infected vacci-\nnees mount cross-variant neutralization reactogenicity to the \nfirst vaccine dose, which equals or surpasses the observed in \nna\u00efve individuals after the second vaccine shot5,7,8,11,16,20,21.\nReports in this regard informed the occurrence of anam-\nnestic reactions in diverse cohorts of previously infected vacci-\nnees after receiving the first vaccine dose of either BNT162b2, \nmRNA-1273, or ChAdOx1-nCoV-19 with no apparent improve-\nment after the second dose7\u20139,11,17,21. According to Goel et al. \nand Kramer et al., as anticipated, only COVID-19 survivors pre-\nsent detectable levels of immunoglobulin G (IgG) antibodies \nspecialized to recognize the full-length SARS-CoV-2 S protein \n(anti-S IgG) or the SARS-CoV-2 spike receptor-binding domain \n(RBD) (anti-RBD IgG) \u2013 antibodies associated with SARS-\nCoV-2 neutralization responses13\u2013 before vaccination17,22. As \nobserved, titers of anti-S IgG and anti-RBD IgG are higher in \nindividuals with a history of SARS-CoV-2 infection pre- and \npost-vaccination (compared with na\u00efve subjects at the exact \nsampling times)17,20,23. The first vaccine dose induces a variable \nand inadequate response of neutralizing antibodies genera-\ntion in SARS-CoV-2\u2013unexposed individuals, which boosts the \nsecond vaccination24. Contrary, the first vaccine dose triggers Hybrid immunity: the immune response of COVID-19 survivors to vaccination\nMarlon Gancino1, Nelson Santiago Vispo2DOI. 10.21931/RB/2021.06.03.1EDITORIALMarlon Gancino, Nelson Santiago Vispo\nVolumen 6/ N\u00famero 3     \u2022     http://www.revistabionatura.com\n1 Faculty of Health, NANOMED EMJMD, University of Paris, France. \n2 Professor, School of Biological Sciences and Engineering, Yachay Tech University, Ecuador.1891\nHybrid immunity: the immune response of COVID-19 survivors to vaccination\na uniform and rapid amplification of anti-S IgGs and anti-RBD \nIgGs titers in SARS-CoV-2 experienced individuals10,11. While \nna\u00efve and COVID-19 asymptomatic vaccinees\u2019 antibody titers \nare significantly boosted after the second vaccine dose21, no \nsignificant improvement has been detected in participants \nwith preexisting immunity after the boosting dose, suggesting \na possible plateau in the neutralization antibody activity9,11,20.\nInterestingly, as informed by Ebinger et al., neutralizing \nantibodies levels in na\u00efve individuals who received the first vac-\ncine dose were slightly higher when contrasted with the base-\nline state of previously infected individuals23. In their research, \nneutralizing antibody levels were statistically similar in both \ngroups, only if compared to the group of previously infected \nindividuals after the first dose with the group of na\u00efve indivi-\nduals after completing a two-dose vaccination regime23. Also, \nhigher frequencies of vaccine-related systemic side effects \n(e.g., fever, headache, muscle pain, and fatigue) have been as-\nsociated with COVID-19 convalescent individuals and high IgG \nresponses9.\nAs a complement, the humoral immune response of \nSARS-CoV-2\u2013exposed individuals is boosted above the pro-\ntective threshold after the first vaccination dose, even against \nVOCs8,16. Planas et al. noticed that sera from previously infec-\nted one-dose vaccinees displayed a significant increase in neu-\ntralizing antibody titers against Alpha, Beta, and Delta SARS-\nCoV-2 variants, in contrast with non-vaccinated convalescent \npeople16. On the contrary, such cross-variant neutralization \nactivity was observed in na\u00efve individuals just days after the \nsecond vaccine immunization. Therefore, these emerging data \nhighly advise that SARS-CoV-2 experienced individuals subse-\nquently vaccinated may develop a broad protective immunity \nagainst all spreading VOCs7,16.Every compartment of the adaptative immune systems \nis probably involved in prompting this non-anticipated hybrid \nimmunity behaviour7. Broadly, as part of the immune response \nagainst infection, long-live memory B cells by a previous induc-\ntion of T cells (specifically, T follicular helper cells) start com-\npiling mutations in immunoglobulin variable gene sequences \n(somatic hypermutations (SHM)) in favor of a future genera-\ntion of high-affinity antibodies13. Thus, evolved memory B cells \ncan be recruited post-vaccination, which will differentiate into \nplasma cells producing highly potent neutralizing antibodies13. \nIt has been observed that memory B cells continue accumu-\nlating somatic mutations over 12 months in germinal centers \nin individuals who have recovered from COVID-1913,25. Those \nmutations accumulated long after infection are, indeed, thou-\ngh accountable for the high potency in serum neutralization \nactivity of the convalescent vaccinee cohorts against VOCs12. \nAlthough the study performed by Goel et al. it was not found \nany change in the levels of SHMs in memory B cell clones from \nconvalescent individuals as a response to vaccination17, na\u00efve \nvaccinees also would enter into this memory B cell matura-\ntion after antigen exposure (vaccination), if analyzed after long \nspans12.\nThe prime-boost regime strategy chose for most vaccines \nrelies on mounting protective responses through memory re-\ncall to antigen reexposure7. The natural SARS-CoV-2 infection \nprimes convalescent populations. This primary encounter with \nthe virus promotes the previously infected individuals to deve-\nlop a T cell memory response to a vast epitope repertoire of \nthe 25 SARS-CoV-2 proteins (S and non-S viral proteins), which \naccording to several studies, are maintained in VOCs7,15,20. Most \ncommercial vaccines induce a protective response using only \nthe SARS-CoV-2 S-protein8,11. Accordingly, vaccine priming \n1892\nactivates a T cell memory to a restricted number of epitopes \nin na\u00efve individuals (compared to SARS-CoV-2\u2013exposed indivi-\nduals)7. Therefore, the reactivation of broad infection-primed T \ncell memory response and the recruitment of long-live muta-\nted memory B cell after first vaccine dose in SARS-CoV-2\u2013ex-\nposed individuals probably play a role in the astounding res-\nponse kinetics of hybrid immunity20.\nThe boosting vaccine dose produced in B and T cell ki-\nnetics is remarkably similar to the one observed in the sero-\nlogical analysis. That is, boosting effect of the second vacci-\nne dose was only observed in na\u00efve individual8,11,17,20. Humoral \nand cellular immunity of convalescent vaccinees may reach \nan activity plateau after the first vaccine dose20. In this sense, \nthe study of Lozano-Ojalvo et al. reported a reduction in T cell \nresponses in COVID-19 recovered individuals after the second \nvaccine dose20. Taken together, those results reveal that con-\nvalescing individuals may request an alternative vaccination \nregime different that the current prime-boost one developed \nin na\u00efve individuals.\nGlobal health systems are still battling a colossal challen-\nge aggravated by the shortage in vaccine supply and the occu-\nrrence and dissemination of VOCs5,21. Vaccine policies are being \ndiscussed worldwide, proposing several strategies to address \nherd immunity to protect their populations15,24. A clear exam-\nple was seen in the United Kingdom when authorities approved \nextending the time interval between vaccine dosages to apply \nthe first vaccine immunization to the most significant number \nof citizens8. However, as above expose, one dose in na\u00efve indivi-\nduals may not be enough to protect them from VOCs, such as \nthe Delta variant16.\nHybrid immunity can become a turning-point opportunity \nto defeat the infection in context with the current pandemic \nscenario. Adopting policies aligned with the data mentioned \nabove may be particularly beneficial for regions like Latin \nAmerica. While this region shares only ~5% of the world po-\npulation, it accumulates +16% of the ~200 million COVID-19 \ntotal cases, so far reported1. Acknowledging the reduced \ndiagnostic capabilities of these countries, this entire area is \nprobably one of the most affected globally, leading to one of \nthe more numerous populations of convalescent people. From \nboth an economic and pharmacological perspective, applying \na one-dose regime of pertinent vaccines to convalescent indi-\nviduals is sustainable5. As COVID-19 survivors may need just \none vaccination to achieve high levels of protective immunity, \nmassive antibody screening for SARS-CoV-2 spike antibodies \ncould help prioritize and free up doses, optimize vaccine supply \nefficiency, and surpass problems linked to the current vaccine \nmanufacturing bottleneck5,25,26.\nFinally, as all cited reports were performed considering \nvaccines developed over only mRNA-lipid nanoparticle-based \nnon-viral vectors and adenovirus-based viral vectors, it is vi-\ntal to extend the research to the rest of marketed vaccines \nand figure out if the same \u201chybrid immunity\u201d principles apply \nto them.\nBibliographic references\n1. World Health Organization. Coronavirus (COVID-19) Dashboard. \nWorld Health Organization (2021). Available at: https://covid19.\nwho.int/. (Accessed: 31st July 2021)\n2. Hrkach, J. & Langer, R. From micro to nano: evolution and impact \nof drug delivery in treating disease. Drug Deliv. Transl. Res. 10, \n567\u2013570 (2020).3. Li, Q., Wang, J., Tang, Y. & Lu, H. Next-generation COVID-19 vac-\ncines: Opportunities for vaccine development and challenges in \ntackling COVID-19. Drug Discov. Ther. 15, 2021.01058 (2021).\n4. Focosi, D., Tuccori, M., Baj, A. & Maggi, F. SARS-CoV-2 Variants: A \nSynopsis of In Vitro Efficacy Data of Convalescent Plasma, Cur-\nrently Marketed Vaccines, and Monoclonal Antibodies. Viruses 13, \n1211 (2021).\n5. Focosi, D., Baj, A. & Maggi, F. Is a single COVID-19 vaccine dose \nenough in convalescents ? Hum. Vaccines Immunother. 00, 1\u20133 \n(2021).\n6. Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed \nfor up to 8 months after infection. Science 371, eabf4063 (2021).\n7. Crotty, S. Hybrid immunity. Science 372, 1392\u20131393 (2021).\n8. Reynolds, C. J. et al. Prior SARS-CoV-2 infection rescues B and T \ncell responses to variants after first vaccine dose. Science 372, \n1418\u20131423 (2021).\n9. Sasikala, M. et al. Immunological memory and neutralizing ac-\ntivity to a single dose of COVID-19 vaccine in previously infected \nindividuals. Int. J. Infect. Dis. 108, 183\u2013186 (2021).\n10. Saadat, S. et al. Binding and Neutralization Antibody Titers After \na Single Vaccine Dose in Health Care Workers Previously Infected \nWith SARS-CoV-2. JAMA 325, 1467 (2021).\n11. Stamatatos, L. et al. mRNA vaccination boosts cross-variant \nneutralizing antibodies elicited by SARS-CoV-2 infection. Science \n372, 1413\u20131418 (2021).\n12. Purushotham, J. N., van Doremalen, N. & Munster, V. J. SARS-\nCoV-2 vaccines: anamnestic response in previously infected re-\ncipients. Cell Res. 2\u20133 (2021). doi:10.1038/s41422-021-00516-7\n13. Wang, Z. et al. Naturally enhanced neutralizing breadth against \nSARS-CoV-2 one year after infection. Nature (2021). doi:10.1038/\ns41586-021-03696-9\n14. Moyo-Gwete, T. et al. Cross-Reactive Neutralizing Antibody Re-\nsponses Elicited by SARS-CoV-2 501Y.V2 (B.1.351). N. Engl. J. \nMed. 384, 2161\u20132163 (2021).\n15. Noh, J. Y., Jeong, H. W. & Shin, E. C. SARS-CoV-2 mutations, vac-\ncines, and immunity: implication of variants of concern. Signal \nTransduct. Target. Ther. 6, 3\u20134 (2021).\n16. Planas, D. et al. Reduced sensitivity of SARS-CoV-2 variant Delta \nto antibody neutralization. Nature (2021). doi:10.1038/s41586-\n021-03777-9\n17. Goel, R. R. et al. Distinct antibody and memory B cell responses \nin SARSCoV-2 na\u00efve and recovered individuals following mRNA \nvaccination. Sci. Immunol. 6, 1\u201319 (2021).\n18. Jalkanen, P. et al. COVID-19 mRNA vaccine induced antibody respons-\nes against three SARS-CoV-2 variants. Nat. Commun. 12, 1\u201311 (2021).\n19. Khoury, D. S. et al. Neutralizing antibody levels are highly predic-\ntive of immune protection from symptomatic SARS-CoV-2 infec-\ntion. Nat. Med. 27, (2021).\n20. Lozano-Ojalvo, D. et al. Differential Effects of the Second SARS-\nCoV-2 mRNA Vaccine Dose on T Cell Immunity in Na\u00efve and \nCOVID-19 Recovered Individuals. SSRN Electron. J. 1\u20139 (2021). \ndoi:https://doi.org/10.1101/2021.03.22.436441\n21. Levi, R. et al. One dose of SARS-CoV-2 vaccine exponentially in-\ncreases antibodies in individuals who have recovered from symp-\ntomatic COVID-19. J. Clin. Invest. 131, (2021).\n22. Krammer, F. et al. Antibody Responses in Seropositive Persons \nafter a Single Dose of SARS-CoV-2 mRNA Vaccine. N. Engl. J. \nMed. 384, 1372\u20131374 (2021).\n23. Ebinger, J. E. et al. Antibody responses to the BNT162b2 mRNA \nvaccine in individuals previously infected with SARS-CoV-2. Nat. \nMed. 27, 981\u2013984 (2021).\n24. Frieman, M. et al. SARS-CoV-2 vaccines for all but a single dose \nfor COVID-19 survivors. EBioMedicine 68, 103401 (2021).\n25. Turner, J. S. et al. SARS-CoV-2 mRNA vaccines induce persistent \nhuman germinal centre responses. Nature (2021). doi:10.1038/\ns41586-021-03738-2\n26. Zamora-Ledezma, C.; C., D.F.C.; Medina, E.; Sinche, F.; Santiago \nVispo, N.; Dahoumane, S.A.; Alexis, F. Biomedical Science to Tack-\nle the COVID-19 Pandemic: Current Status and Future Perspec-\ntives. Molecules 2020, 25, 4620. https://doi.org/10.3390/mole-\ncules25204620Marlon Gancino, Nelson Santiago Vispo\nVolumen 6/ N\u00famero 3     \u2022     http://www.revistabionatura.com1893\n1894\nLa pandemia por SARS-Cov-2, que inicialmente se plan-\nte\u00f3 como una afecci\u00f3n predominantemente respiratoria, se ha \nconvertido en una noxa con manifestaciones en m\u00faltiples \u00f3r-ganos, el factor com\u00fan para la llegada del virus a los mismos son los receptores ACE 2, que es por d\u00f3nde el virus ingresa a nuestras c\u00e9lulas.\nA nivel vascular, es llamativo la incidencia incrementada \nde trombosis tanto macrosc\u00f3pica como a nivel de la micro-circulaci\u00f3n sist\u00e9mica y pulmonar (microCLOTS) por inmu-notrombosis\n1, la endotelitis producida por el virus2,3, parece \nactivar estados protromb\u00f3ticos por la lesi\u00f3n del glicoc\u00e1lix endotelial, con la consecuente activaci\u00f3n de la cascada de coagulaci\u00f3n y la adhesi\u00f3n y agregaci\u00f3n plaquetaria posterior; sum\u00e1ndose la NETosis, que es un mecanismo de erradicaci\u00f3n bacteriana, pero desregulado puede empeorar el estado pro-tromb\u00f3tico ya narrado. Esto ha planteado si el uso de anticoa-gulantes debe ser una panacea y si la dosis a recibir debe ser con fines profil\u00e1cticos o de anticoagulaci\u00f3n, parece ser que la anticoagulaci\u00f3n con dosis plenas debe indicarse en pacientes con trombosis documentada\n4.\nLa trombosis vascular, en especial tromboembolismo ve-\nnoso y la tromboembolia pulmonar (TEP) observada a nivel cl\u00ednico y en autopsias\n5, es un hallazgo relativamente frecuente \nen el COVID-19, pero su comportamiento desconcierta, ya que las escalas habituales para evaluar riesgo y probabilidad cl\u00edni-ca de trombosis fallan, as\u00ed tambi\u00e9n lo hacen los tratamientos farmacol\u00f3gicos usuales como la tromb\u00f3lisis, la antiagregaci\u00f3n y la anticoagulaci\u00f3n.\nLa ecocardiograf\u00eda al pie de cama del paciente es una \nherramienta robusta, aun cuando no de primera l\u00ednea, para el diagn\u00f3stico de episodios tromboemb\u00f3licos pulmonares masi-vos, y que permite tomar decisiones terap\u00e9uticas inmediatas en pacientes con inestabilidad hemodin\u00e1mica. Datos como el signo de 60/60 y depresi\u00f3n de la contractilidad del ventr\u00edculo derecho con evidencia de signo de McConnell son sugestivos de embolia pulmonar\n6. En la COVID 19 se consiguen pacientes \nsin expresi\u00f3n ecocardiogr\u00e1fica de sobrecarga del ventr\u00edculo derecho y si angiotomograf\u00eda pulmonar positiva para embolis-mo; tal vez, por la formaci\u00f3n de trombosis pulmonares in situ y no provenientes de \u00e9mbolos de miembros inferiores.\nA continuaci\u00f3n, presentamos la estad\u00edstica de los casos \nde tromboembolia pulmonar, en una serie de 227 pacientes atendidos en nuestra terapia intensiva (tabla 1); 15 pacientes (6%) tuvieron TEP, el 76% fueron hombres y el diagn\u00f3stico se realiz\u00f3 con ecocardiograf\u00eda transesof\u00e1gica o con angiotomo-graf\u00eda pulmonar. La mortalidad fue del 80% y antes del evento todos los pacientes ten\u00edan heparina fraccionada a dosis de an-ticoagulaci\u00f3n. A 7 pacientes se les administr\u00f3 terapia trombo-LETTER TO EDITOR / CARTA AL EDITOR \nDOI. 10.21931/RB/2021.06.03.2\nl\u00edtica con estreptoquinasa o con activador del plasmin\u00f3geno tisular, con resultados no alentadores, ya que sobrevivi\u00f3 solo 1 paciente. Los niveles de d\u00edmero D al ingreso y a las 72 horas no parecen guardar relaci\u00f3n con la g\u00e9nesis de trombosis en esta serie.\nPor lo escrito, el diagn\u00f3stico de tromboembolia pulmonar \nen el paciente con COVID-19 cr\u00edticamente enfermo tiene una incidencia relativamente elevada, con alta mortalidad, sin una prueba \u201cgold stantard\u201d para el diagn\u00f3stico y sin la certeza de la utilidad de la anticoagulaci\u00f3n, antiagregaci\u00f3n y tromb\u00f3lisis, que eran estrategias farmacol\u00f3gicas tradicionales para el ma-nejo de esta entidad. Esperamos la publicaci\u00f3n de trabajos en curso sobre esta tem\u00e1tica que aclaren el panorama y nos per-mitan contar con m\u00e1s herramientas diagn\u00f3sticas y terap\u00e9uti-cas que mejoren el pron\u00f3stico de estos enfermos.\nReferencias bibliogr\u00e1ficas\n1. Ciceri, F .; Beretta, L.; Scandroglio, A.M.; Colombo, S.; Landoni,\nG.; Ruggeri, A.; Peccatori, J.; D\u2019Angelo, A.; De Cobelli, F.; Rov-\nere-Querini, P.; et al. Microvascular COVID-19 lung vessels ob-structive thromboinflammatory syndrome (MicroCLOTS): Anatypical acute respiratory distress syndrome working hypothesis. Crit. Care Resusc. 2020. Available online: https://pubmed.ncbi.nlm.nih.gov/32294809/\n2.\nMosleh W\n, Chen K, Pfau SE, Vashist A. Endotheliitis and Endothe-\nlial Dysfunction in Patients with COVID-19: Its Role in Thrombo-sis and Adverse Outcomes. Journal of Clinical Medicine. 2020;9(6):1862. https://doi.org/10.3390/jcm9061862\n3.\nV\narga, Z.; Flammer, A.J.; Steiger, P.; Haberecker, M.; Andermatt,\nR.; Zinkernagel, A.S.; Mehra, M.R.; Schuepbach, R.A.; Ruschitz-ka, F.; Moch, H. Endothelial cell infection and endotheliitis inCOVID-19. Lancet 2020, 95, 1417\u20131418. [Google Scholar]\n4.\n INSPIRA\nTION Investigators.  Effect of intermediate-dose vs stan-\ndard-dose prophylactic anticoagulation on thrombotic events,extracorporeal membrane oxygenation treatment, or mortalityamong patients with COVID-19 admitted to the intensive careunit: the INSPIRATION randomized clinical trial.  JAMA. Published online March 18, 2021. doi:10.1001/jama.2021.4152\n5.\nWichmann D\n, Sperhake JP, L\u00fctgehetmann M,et al. Autopsy find-\nings and venousthromboembolism in patients with COVID-19:aprospective cohort study.Ann Intern Med.2020;173(4):268-277.doi:10.7326/M20-200\n6.\nS\ntavros V. Konstantinides, , Guy Meyer, et al  Cecilia Becattini2019 \nESC Guidelines for the diagnosis and management of acute pul-monary embolism developed in collaboration with the EuropeanRespiratory Society (ERS) The Task Force for the diagnosis andmanagement of acute pulmonary embolism of the European So-ciety of Cardiology. European Heart Journal 2020 :  41, 543 \u2013 603 doi:10.1093/eurheartj/ehz405.Jorge Luis V\u00e9lez-P\u00e1ez, Edgar L\u00f3pez-Rond\u00f3n, Mario Montalvo-Villag\u00f3mez\nVolumen 6/ N\u00famero 3     \u2022     http://www.revistabionatura.com\nSARS-Cov-2 y tromboembolia pulmonar en pacientes cr\u00edticamente enfermos, \nexperiencia de una unidad de cuidados criticos\nSARS-Cov-2 and pulmonary thromboembolism in critically ill patients, the experience of a critical care unit\nJorge Luis V\u00e9lez-P\u00e1ez1, Edgar L\u00f3pez-Rond\u00f3n2, Mario Montalvo-Villag\u00f3mez3\n1 Hospital Pablo Arturo Su\u00e1rez, Unidad de Terapia Intensiva, Centro de Investigaci\u00f3n Cl\u00ednica, Quito, Ecuador y Universidad Central del Ecuador, Facultad de Ciencias \nM\u00e9dicas, Quito, Ecuador.  \n2 Hospital Pablo Arturo Su\u00e1rez, Servicio de Cardiolog\u00eda Cl\u00ednica y Ecocardiograf\u00eda, Quito, Ecuador. \n3 Hospital Pablo Arturo Su\u00e1rez, Unidad de Terapia Intensiva, Centro de Investigaci\u00f3n Cl\u00ednica, Quito, Ecuador.\nCorresponding author: jlvelez@uce.edu.ec1895\nSARS-Cov-2 y tromboembolia pulmonar en pacientes cr\u00edticamente enfermos, experiencia de una unidad de cuidados criticos\nSARS-Cov-2 and pulmonary thromboembolism in critically ill patients, the experience of a critical care unit\nTabla 1. Casos de tromboembolia pulmonar, datos cl\u00ednicos, tratamiento y desenlace.1896\nAym\u00e9 Oliva-C\u00e1rdenas, F\u00e9 Fern\u00e1ndez-Zamora, Elaine Santana-Rodr\u00edguez, Yusmel Sordo-Puga, Milagros de la C. Vargas-Hern\u00e1ndez, Mar\u00eda P. Rodr\u00edguez-Molt\u00f3, \nDanny P\u00e9rez-P\u00e9rez, Talia Sardina-Gonz\u00e1lez,Carlos A. Duarte, Avelina Le\u00f3n-Go\u00f1i, Diurys Blanco -G\u00e1mez, Francisco Contreras-P\u00e9rez, Odalys Vald\u00e9s-Faure, Ros-mery Hern\u00e1ndez-Prado, Eric Acosta-Lago, Ileana Sosa-Test\u00e9, Marisela F. Su\u00e1rez-Pedroso\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nSafety and immunogenicity in piglets of two immunization schedules initiated at \ntwo or three weeks of age with Porvac\u00ae, a classical swine fever subunit marker vaccine\nAym\u00e9 Oliva-C\u00e1rdenas1, F\u00e9 Fern\u00e1ndez-Zamora2, Elaine Santana-Rodr\u00edguez1, Yusmel Sordo-Puga1, Milagros de la C. Vargas-Hern\u00e1ndez1, Mar\u00eda \nP. Rodr\u00edguez-Molt\u00f31, Danny P\u00e9rez-P\u00e9rez1, Talia Sardina-Gonz\u00e1lez1,Carlos A. Duarte1, Avelina Le\u00f3n-Go\u00f1i2, Diurys Blanco -G\u00e1mez2, Francisco \nContreras-P\u00e9rez2, Odalys Vald\u00e9s-Faure2, Rosmery Hern\u00e1ndez-Prado1, Eric Acosta-Lago2, Ileana Sosa-Test\u00e92, Marisela F. Su\u00e1rez-Pedroso1\nDOI. 10.21931/RB/2021.06.03.3 \nAbstract: Classical swine fever is a highly contagious viral disease with a significant impact on food production worldwide. It \ncurrently represents one of the main limitations for the development of the pig industry in Cuba. Porvac\u00ae is a subunit marker \nvaccine that confers a very rapid onset of protection. Since there are different production systems in pig breeding, readjustments in the vaccination program are often required. This study compares the safety and efficacy in piglets of two vaccination schedules with Porvac\u00ae (0-2 weeks and 0-3 weeks), initiated at two or three weeks of age. Clinical monitoring was conducted, and a neutralization peroxidase-linked assay was used to measure the neutralization titers. All immunization regimens were safe and well-tolerated, without local or systemic adverse reactions in the vaccinated animals. Geometric mean neutralizing antibody titers higher than 1/1500 were detected in all groups during the six months of the trial. One month after the second immunization, piglets primed at two weeks of age, and boostered three weeks later, developed significantly higher neutralization titers (1/15644) compared to those vaccinated at a similar age but with a two-week interval between doses (1/5760). However, no significant differences in the titers were found three and six months after vaccination among the four regimens. In summary, all the variants studied are effective, but it is recommended to start vaccination at two weeks old, with the second dose at either two or three weeks later, depending on the production system and the purpose of the farm. \nKey words: Classical swine fever, E2CD154, subunit vaccine, piglets, neutralizing antibodies.RESEARCH / INVESTIGACI\u00d3N\nIntroduction\nClassical swine fever (CSF) is an infectious disease with \nthe most significant economic impact on the swine industry in \nCuba and many other countries. The disease is caused by the classical swine fever virus (CSFV), an enveloped, single-stran-ded RNA Pestivirus. Due to its devastating effects, CSF has been listed as a notifiable disease by the World Organization for Animal Health (OIE)\n1. In endemic areas, prophylactic vacci-\nnation is commonly used to limit the effects of the disease or as a first step within a general program to control and eradi-cate the virus. The modified live vaccines (MLV) are the most widely used in CSF endemic regions and have effectively con-trolled the disease in several countries such as Brazil, Argen-tina, and Uruguay.\nOn the other hand, Cuba is one CSF endemic country whe-\nre the virus has been emerging for more than 20 years despite the use of an attenuated C strain MLV\n2-4. The lack of discrimi-\nnation between infected and vaccinated animals, the require-ment for a cold chain of distribution, and the interference of maternal-derived neutralizing antibodies (MDNA) are the main drawbacks of MLV, which have limited its use in disease-free regions. Several subunit vaccines have been developed to over-come these drawbacks, but they exhibit a late onset of protec-tion as compared to MLV and provide insufficient protection against vertical transmission\n5-8.\nPorvac\u00ae is a Cuban subunit marker vaccine against CSFV, \nwhich is based on a recombinant chimeric antigen comprising the E2 protein of CSFV and the molecular adjuvant CD154. This vaccine has been safe and capable of inducing an unusua-lly rapid onset of protection against a challenge with a highly pathogenic CSFV strain, which is similar to the one described for MLV9-11. Porvac\u00ae induces both high neutralizing antibodies \n(NAb) titers and cell-mediated immune response and can in-terfere with the transmission of the virus from pregnant sows to their offspring\n12.\nPorvac\u00ae has been registered in Cuba and is been currently \nused in both, large state-owned pig production units and small private farms. Since there are different production systems in swine breeding, readjustments in the immunization schedules must make them compatible with those systems. The present study aimed to compare the safety and efficacy of two diffe-rent immunization schedules with Porvac\u00ae (0-2 weeks and 0-3 weeks), starting at either two or three weeks after birth. These experiments must provide the scientific basis for a more flexi-ble approach in terms of vaccination schedules for the diffe-rent production systems.\nMethods \nPorvac\u00ae vaccine\nThe vaccine preparation was obtained from the stable \nHEK 293 cell line (ATCC CRL1573), which expressed the CSFV E2 antigen fused to the porcine CD154 protein. It was produced under Good Manufacturing Practices in a certified production area of the Center for Genetic Engineering of Camaguey, Cuba,  and formulated as a water-in-oil formulation with Montanide ISA50V2 (SEPPIC, France) at a final concentration of 25 \u03bcg of E2-CD154 antigen/ mL.\n1 Departamento de Biotecnolog\u00eda Animal, Centro de Ingenier\u00eda Gen\u00e9tica y Biotecnolog\u00eda (CIGB), Playa, Cuba. \n2 Centro para la Producci\u00f3n de Animales de Laboratorio (CENPALAB), Centro de Toxicolog\u00eda Experimental (CETEX), Boyeros, La Habana, Cuba. \nCorresponding author: ayme.oliva@cigb.edu.cu1897\nSafety and immunogenicity in piglets of two immunization schedules initiated at two or three weeks of age with Porvac \u00ae, a classical swine fever subunit marker\nvaccine\nExperimental animals  \nThe study included the litters from four unvaccinated CS-\nFV-negative sows (Duroc x Yorkshire crossbred swine). The \npiglets were kept with their mothers until weaning, between 33 and 42 days, each group in a separate experimental room. Trials were carried out under appropriate high containment conditions following the animal welfare regulations and stan-dards according to Good Clinical Practices\n13-15. The study was \napproved and supervised by the Committee for Care and Use of Laboratory Animals (CICUAL) of the Center for the Produc-tion of Laboratory Animals (CENPALAB).\nThe general clinical conditions of the animals were evalua-\nted during the immunization period, especially the occurrence of adverse reactions at the injection site. The rectal tempe-rature was measured immediately before the first vaccination and 72 hours after each vaccine administration. Blood samples were taken from the ophthalmic venous sinus in the absence of anticoagulant, previous to the first immunization (T0) and at one, three, and six months after the second immunization (T1, T3, and T6, respectively). Hematological and biochemi-cal analyses were conducted at the analytical laboratory of CENPALAB. The levels of total protein, glucose, alkaline phos-phatase, alanine aminotransferase, aspartate aminotransfera-se, albumin, creatinine, uric acid, and urea were measured a Cobas Integra 400 PLUS Analyzer (Roche DiagnosticSystems).\nVaccination\nFour experimental groups (G2-2, G2-3, G3-2, and G3-3) \nwere formed with complete litters comprising 9 and 12 piglets \nper group. Two groups included 2-week old piglets, and the other two were formed with 3-week old piglets on the day of prime vaccination.  Each group was further subdivided to recei-ve the vaccine with either two or three-week intervals between the priming and the booster. The intramuscular route inocula-ted a dose of 2 mL (50 \u03bcg of E2-CD154). The first immunization was performed on the right side of the neck and the second on the left side, using 18 x 1\u2019\u2019 needles, in agreement with the good veterinary clinical practices.\nCSFV-neutralizing antibodies detection\nThe serum samples were tested by Neutralization Peroxi-\ndase Linked Assay (NPLA) to determine the NAb titers against \nCSFV, following the methods described by OIE Manual\n16,17. \nNational Center provided Margarita CSFV strain for Animal and Plant Health, Mayabeque, Cuba, and the anti E2 Mab CBS-SE2.3 conjugated to horseradish peroxidase by CIGB-Sancti Spiritus, Cuba.\nData analysis\nData analysis was performed using package GraphPad \nPrism 6 (Prism 6 for Windows, Version 6.01, GraphPad Sof-\ntware, Inc., La Jolla, USA). The Kolmogorov-Smirnov test was used to evaluate normality, and the Levene test assessed the homogeneity of variances in the data. One-way ANOVA, followed by Tukey multiple comparison tests, was applied to compare the temperature values among groups. Kruskal-Wa-llis non-parametric test, followed by the Dunn test, was used to compare the geometric means (GM) of the antibody titers among the different groups. Statistical significance was consi-dered when p <0.05.Results\nEvaluation of the clinical signs during the 6 months follow-up\nThe animals exhibited good health conditions at the be-\nginning of the trial. After vaccination, they showed no signs of inflammation, redness, or induration at the inoculation site. No systemic adverse effects or other alterations were observed, regardless of the age of the animals at vaccination and the vaccination schedule applied.\nEvaluation of the body temperature during the \nimmunization period\nThe rectal temperature was monitored before the immu-\nnizations as a part of the assessment of the health status of \nthe animals. Subsequent measures of the body temperature were done at 72 h after each immunization (Figure 1). Mean body temperature in all the groups remained within the phy-siological range, although some hyperthermia values were ob-served in G2-2 and G2-3 before vaccination and 72 h later. No significant differences were found between the immunization days and 72 h later; therefore, the high values of temperature registered for some individuals were not associated with vac-cination. Animals remained healthy until the end of the trial.\nEvaluation of hematological and biochemical parameters\nThe hematological and biochemical parameters of the \nanimals were evaluated before and three months after vac-\ncination (tables 1 and 2). Although some variability was ob-served at the initial measurements at 15 or 21 days of age, no differences were found among the four groups three months after vaccination (ANOVA p < 0.05). At that time all the values were within the normal ranges for the species.\nImmunogenicity of Porvac\u00ae in piglets\nAll piglets were CSFV seronegative at the beginning of the \nstudy, with NAb titers lower than 1/5. One month after recei-\nving two immunizations, all animals developed NAb titers of 1/3200 or higher, regardless of the schedule applied (Figure 2). Statistical differences were documented among groups (Krus-kal-Wallis, p<0.05). NAb titers were lower in group G2-2 (GM =1/5552) as compared with groups G2-3 (GM = 1/12800) and G3-3 (GM =1/8300) (Dunn test, p<0.05).  No significant diffe-rences were found between the groups immunized at two and three weeks (G2.2 vs. G3.2 (GM=1/11943) and G2.3 vs. G3.3). \nIn the evaluation conducted three months after the se-\ncond immunization, all groups exhibited GM NAb titers above 1/9000, without significant differences among them (Krus-kal-Wallis, p>0.05).\nSix months after vaccination, the NAb titers had decrea-\nsed as expected, although they remained equal to or higher than 1/400 in all animals. Finally, six randomly selected ani-mals from the different schemes were followed up one year after vaccination. Interestingly, NAb titers of these pigs remai-ned \u2265 1/400 at this time. \nDiscussion\nVaccination is the most important activity within the CSF \nprevention program in endemic countries like Cuba since diffe-rent pig farms use diverse production systems, the evaluation of different vaccination regimes with Porvac\u00ae is an important step to adjust vaccination to those production systems.1898\nIn this study, we have evaluated the safety and immuno-\ngenicity of four immunization regimens with Porvac\u00ae. Two va-\nriables were explored: (1) age for the first administration and (2) time interval between the priming and booster doses.\nThe four regimens were safe and well-tolerated. Neither\nsystemic nor local adverse reactions were observed nor tem-perature changes associated with vaccination. Those results confirm pre-registration studies in pigs of different ages with this vaccine\n10-12,18. They are also by those obtained in a pre-re-\ngistration study with a CP7_E2alf marker vaccine and animals of similar age\n19.\nConcerning some elevated temperature values registered \nduring the immunization period, the physiological temperature in pigs ranges between 38.7 and 39.7 \u00b0 C, although this range could reach 40.2 \u00b0C in piglets during the first weeks after bir-th\n20. Our study was conducted between spring and summer \nwith maximum values of ambient temperature above 30\u00b0 C. This environmental situation can lead to a  condition called heat stress, which is characterized by modifying the physiolo-gical constants of the animals\n21. Therefore, the experimental \nmanipulations in one of the most sensible pig\u2019s categories, and the heat stress could have influenced the temperature ranges observed.\nThe development of the innate immune system in pigs be-\ngins early during gestation. The newborn piglet already has a naive adaptive immune system with low blood levels of natural antibodies, which recognize the most common pathogens\n22,23. \nPiglets achieve full maturity in their immune system after four weeks of life, which guarantees an adequate immune response to vaccines\n24. Previous studies conducted with other vaccines \nhave found that five-week-old piglets developed a superior NAb response compared to those immunized two weeks ear-lier\n24.\nHowever, in the present study, even two-week-old na\u00efve Figure 1. Evaluation of the rectal temperature before and after the vaccination.\nTable 1. Hematological para-\nmeters of the animals before \nand 3 months after v\naccina-\ntion.Aym\u00e9 Oliva-C\u00e1rdenas, F\u00e9 Fern\u00e1ndez-Zamora, Elaine Santana-Rodr\u00edguez, Yusmel Sordo-Puga, Milagros de la C. Vargas-Hern\u00e1ndez, Mar\u00eda P. Rodr\u00edguez-Molt\u00f3, \nDanny P\u00e9rez-P\u00e9rez, Talia Sardina-Gonz\u00e1lez,Carlos A. Duarte, Avelina Le\u00f3n-Go\u00f1i, Diurys Blanco -G\u00e1mez, Francisco Contreras-P\u00e9rez, Odalys Vald\u00e9s-Faure, Ros-mery Hern\u00e1ndez-Prado, Eric Acosta-Lago, Ileana Sosa-Test\u00e9, Marisela F. Su\u00e1rez-Pedroso\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1899\nTable 2. Biochemical parameters of the animals before and 3 months after vaccination.\nFigure 2. CSFV NAb titers in all experimental groups during the six months follow-up study.Safety and immunogenicity in piglets of two immunization schedules initiated at two or three weeks of age with Porvac \u00ae, a classical swine fever subunit marker\nvaccine1900\npiglets could induce a potent NAb response against CSFV after \nvaccination with Porvac\u00ae. Similar levels of NAb were measu-red in those animals, at any of the time points evaluated, com-pared with the group immunized at the age of three weeks.\nAdditionally, the findings suggest that a three-week inter-\nval between immunizations is more effective than two weeks to induce NAb, although these results were found only one month after vaccination. Those differences faded over time and were found neither at 3 nor at 6 months after vaccination.\nEven so, it should be noted that, from a practical point of \nview, the differences above are irrelevant since the NAb titers elicited by the four regimes studied were manifold higher than the protective threshold of 1/50, previously defined by other investigators\n25,26.\nThe high immunogenicity of Porvac\u00ae, even at this very \nearly age, is probably due to the action of the CD154 protein (CD40L), which functions as a molecular adjuvant. This mo-lecule is directly involved in the activation and maturation of B lymphocytes, which occupy a central role in the immune res-ponse, functioning as precursors of antibody-secreting cells and effective antigen-presenting cells (APC). CD154 also inte-racts with professional APC such as dendritic cells, promoting their maturation and activation\n27,28.\nFinally, those results confirm previous findings that Por-\nvac\u00d2 can promote a long-lasting response, which is welcome for breeding gilts and boars, although immune protection for 7\u20138 months is sufficient for growing and fattening pigs\n29. In the \npresent study, when the vaccinated animals arrived at repro-ductive age still exhibited protective NAb levels against CSFV, demonstrating that a long-lasting humoral immune response can also be generated by immunizing two-week-old na\u00efve pi-glets Porvac\u00ae. This agrees with the results of pre-registration controlled trials conducted by Su\u00e1rez et al., 2011\n11, where pro-\ntective NAb titers were still detected at 9 months post-vacci-nation.\nThis study was conducted in na\u00efve animals born to un-\nvaccinated sows; therefore, they did not have MDNA at vac-cination. It is well known that MDNA can interfere with active immunity, mainly described for MLVs\n24,30,31. However, previous \nstudies have already demonstrated that pre-existing MDNA does not interfere with the immunogenicity of Porvac\u00ae\n18. The-\nrefore, it is very likely that the results shown here could be safely extrapolated to those piglets born to Porvac\u00ae vaccina-ted sows.\nConclusions\nA three-week interval between doses induced higher NAb \ntiters than a 2-week interval in piglets vaccinated with 2 weeks of age. Those differences were only observed at 1 month, but not at 3 and 6 months after vaccination.\nRegarding the time of the prime vaccination, no differences \nin the NAb response were found between 2 and 3 weeks of age.\nThe four immunization schedules evaluated in this study \ninduced high titers of NAbs in na\u00efve piglets, well above the pro-tective threshold; therefore any of them could be used in pig production units, harmonized with their respective productive systems. As a general recommendation, all producers could apply the first dose of Porvac\u00d2 at two weeks of age. The ani-mals born in the genetic farms and reproductive centers would receive the second dose two weeks later. The rest of the farms, including medium and small-scale producers, may apply the se-cond dose with either two or three week\u2019s interval depending on their production systems.Acknowledgment\nThis research was supported by the Center for Genetic \nEngineering and Biotechnology, Havana, Cuba. The author ack-nowledges all researchers and technicians from the CENPALAB Center for their unconditional support in handling and care of the animals.\nBibliographic references\n1. OIE. Clas sical Swine Fever (Infection with Classical Swine Fever\nVirus).\n2.F\nonseca-Rodr\u00edguez O, Centelles Garcia Y, Alfonso Zamora P, et al. \nClassical Swine Fever in a Cuban Zone Intended for Eradication:\nSpatiotemporal Clustering and Risk Factors. Frontiers in veteri-nary science 2020;7:38.\n3.\nP\nerez LJ, Diaz de Arce H, Perera CL, et al. Positive selection\npressure on the B/C domains of the E2-gene of classical swinefever virus in endemic areas under C-strain vaccination. Infection, genetics and evolution : journal of molecular epidemiology andevolutionary genetics in infectious diseases 2012;12:1405-12.\n4.\n Coronado L, Rios L, F\nr\u00edas MT, et al. Positive selection pressure on \nE2 protein of classical swine fever virus drives variations in viru-lence, pathogenesis and antigenicity: Implication for epidemiolog-ical surveillance in endemic areas. Transboundary and emergingdiseases 2019;66:2362-82.\n5.\nV\nan Oirschot J. Vaccinology of classical swine fever: from lab to\nfield. Veterinary microbiology 2003;96:367-84.\n6.Dong XN, Chen YH. Mark\ner vaccine strategies and candidate\nCSFV marker vaccines. Vaccine 2007;25:205-30.\n7.Bouma \nA, De Smit A, De Jong M, De Kluijver E, Moormann R.\nDetermination of the onset of the herd-immunity induced by theE2 sub-unit vaccine against classical swine fever virus. Vaccine2000;18:1374-81.\n8.\n Ut\ntenthal A, Le Potier MF, Romero L, De Mia GM, Floegel-Nies-\nmann G. Classical swine fever (CSF) marker vaccine. Trial I. Chal-lenge studies in weaner pigs. Vet Microbiol 2001;83:85-106.\n9.\nSordo-Puga Y\n, Su\u00e1rez-Pedroso M, Naranjo-Vald\u00e9z P, et al. Por-\nvac\u00ae Subunit Vaccine E2-CD154 Induces Remarkable Rapid Pro-tection against Classical Swine Fever Virus. Vaccines 2021;9:167.\n10.\n Su\u00e1rez M, Sordo Y\n, Prieto Y, et al. A single dose of the novel chi-\nmeric subunit vaccine E2-CD154 confers early full protectionagainst classical swine fever virus. Vaccine 2017.\n11.\n Su\u00e1rez-P\nedroso M, Sordo-Puga Y, Sosa-Teste I, et al. Novel chi-\nmeric E2CD154 subunit vaccine is safe and confers long lastingprotection against classical swine fever virus. Veterinary Immu-nology and Immunopathology 2021;234:110222.\n12.\n Mu\u00f1oz-Gonz\u00e1lez S, Sordo Y\n, P\u00e9rez-Sim\u00f3 M, et al. Efficacy of E2\nglycoprotein fused to porcine CD154 as a novel chimeric subunitvaccine to prevent classical swine fever virus vertical transmis-sion in pregnant sows. Veterinary microbiology 2017;205:110-6.\n13.\n VICH. Good clinical pr\nactices, GL09. 2000.\n14.\n VICH. T\narget Animal Safety for Veterinary live and inactivated\nVaccines, GL44. 2010.\n15.\n VICH. Harmonization of criteria to w\naive target animal batch\nsafety testing (TABST) for inactivated vaccines for veterinary use, GL50 2014.\n16.\n OIE. OIE T\nerrestrial Manual. Chapter 3.8.3. Classical swine fever\n(hog cholera) infection with classical swine fever virus. In: OIE,ed.: OIE; 2019.\n17.\n T\nerpstra C, Bloemraad M, Gielkens AL. The neutralizing peroxi-\ndase-linked assay for detection of antibody against swine fevervirus. Vet Microbiol 1984;9:113-20.\n18.\n Sordo-Puga Y\n, P\u00e9rez-P\u00e9rez D, Montero-Espinosa C, et al. Immu-\nnogenicity of E2CD154 Subunit Vaccine Candidate against Clas-sical Swine Fever in Piglets with Different Levels of MaternallyDerived Antibodies. Vaccines 2021;9:7.Aym\u00e9 Oliva-C\u00e1rdenas, F\u00e9 Fern\u00e1ndez-Zamora, Elaine Santana-Rodr\u00edguez, Yusmel Sordo-Puga, Milagros de la C. Vargas-Hern\u00e1ndez, Mar\u00eda P. Rodr\u00edguez-Molt\u00f3, \nDanny P\u00e9rez-P\u00e9rez, Talia Sardina-Gonz\u00e1lez,Carlos A. Duarte, Avelina Le\u00f3n-Go\u00f1i, Diurys Blanco -G\u00e1mez, Francisco Contreras-P\u00e9rez, Odalys Vald\u00e9s-Faure, Ros-mery Hern\u00e1ndez-Prado, Eric Acosta-Lago, Ileana Sosa-Test\u00e9, Marisela F. Su\u00e1rez-Pedroso\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1901\n19. F arsang A, L\u00e9vai R, Barna T, et al. Pre-registration efficacy study\nof a novel marker vaccine against classical swine fever on mater-\nnally derived antibody positive (MDA+) target animals. Biologicals : journal of the International Association of Biological Standard-ization 2017;45:85-92.\n20.\n Mount L, R\nowell J. Body size, body temperature and age in rela-\ntion to the metabolic rate of the pig in the first five weeks afterbirth. The Journal of physiology 1960;154:408.\n21.\n Carroll J\n, Burdick N, Chase Jr C, Coleman S, Spiers D. Influence of \nenvironmental temperature on the physiological, endocrine, andimmune responses in livestock exposed to a provocative immune challenge. Domestic Animal Endocrinology 2012;43:146-53.\n22.\n Butler \nJ, Lager K, Splichal I, et al. The piglet as a model for B cell \nand immune system development. Veterinary immunology andimmunopathology 2009;128:147-70.\n23.\n Lim SI, Song JY\n, Kim J, et al. Safety of classical swine fever virus \nvaccine strain LOM in pregnant sows and their offspring. Vaccine2016;34:2021-6.\n24.\n Sur\nadhat S, Damrongwatanapokin S, Thanawongnuwech R. Fac-\ntors critical for successful vaccination against classical swinefever in endemic areas. Vet Microbiol 2007;119:1-9.\n25.\n T\nerpstra C, Wensvoort G. The protective value of vaccine-in-\nduced neutralising antibody titres in swine fever. Vet Microbiol1988;16:123-8.26.\n  Biront P , Leunen J, Vandeputte J. Inhibition of virus replication\nin the tonsils of pigs previously vaccinated with a Chinese strainvaccine and challenged oronasally with a virulent strain of clas-sical swine fever virus. Veterinary microbiology 1987;14:105-13.\n27.\n Elgueta R, Benson MJ\n, de Vries VC, Wasiuk A, Guo Y, Noelle RJ.\nMolecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 2009;229:152-72.\n28.\n Xu Y\n, Song G. The role of CD40-CD154 interaction in cell immu-\nnoregulation. Journal of biomedical science 2004;11:426-38.\n29.\n Hua RH, Huo H, Li YN, et al. Gener\nation and efficacy evalua-\ntion of recombinant classical swine fever virus E2 glycoproteinexpressed in stable transgenic mammalian cell line. PLoS One2014;9:e106891.\n30.\n Sur\nadhat S, Damrongwatanapokin S. The influence of mater-\nnal immunity on the efficacy of a classical swine fever vaccineagainst classical swine fever virus, genogroup 2.2, infection. Vet-erinary microbiology 2003;92:187-94.\n31.\n V\nandeputte J, Too HL, Ng FK, Chen C, Chai KK, Liao GA. Ad-\nsorption of colostral antibodies against classical swine fever,persistence of maternal antibodies, and effect on response tovaccination in baby pigs. American journal of veterinary research2001;62:1805-11.\nReceived: 3 April 2021\nAccepted: 2 June 2021Safety and immunogenicity in piglets of two immunization schedules initiated at two or three weeks of age with Porvac \u00ae, a classical swine fever subunit marker\nvaccine1902\nMilagros Vargas-Hern\u00e1ndez, Yeni Hern\u00e1ndez Lorenzo, Viviana Pluma Perez, Isabel Rosales-Garcia, Sunamit Rodr\u00edguez-Mendez, Enrique P\u00e9rez-Cruz, \nDaymi Abreu-Remedios, Carlos Montero-Espinosa, Ayme Oliva-Cardenas, Elaine Santana-Rodriguez, Danny P\u00e9rez-P\u00e9rez, Yusmel Sordo-Puga, Yohandy \nFuentes-Rodr\u00edguez, Alianne Fundora-Llera, Carlos A. Duarte, Ernesto Galb\u00e1n-Rodr\u00edguez, Carlos Hernandez-Diaz, Dayam\u00ed Dorta Hernandez, Ivis Pasaron \nRodriguez, Marisela Suarez-Pedroso\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nAssessing HeberFast\u00ae Line Gavac, a lateral flow immunochromatographic system \nfor the rapid detection of anti-Bm86 antibodies in Gavac vaccinated cattle\nMilagros Vargas-Hern\u00e1ndez*1, Yeni Hern\u00e1ndez Lorenzo2, Viviana Pluma Perez2, Isabel Rosales-Garcia2, Sunamit Rodr\u00edguez-Mendez2, Enrique \nP\u00e9rez-Cruz3, Daymi Abreu-Remedios3, Carlos Montero-Espinosa1, Ayme Oliva-Cardenas1, Elaine Santana-Rodriguez1, Danny P\u00e9rez-P\u00e9rez1, Yus-\nmel Sordo-Puga1, Yohandy Fuentes-Rodr\u00edguez1, Alianne Fundora-Llera1, Carlos A. Duarte1, Ernesto Galb\u00e1n-Rodr\u00edguez4, Carlos Hernandez-Diaz3, \nDayam\u00ed Dorta Hernandez3, Ivis Pasaron Rodriguez3, Marisela Suarez-Pedroso1DOI. 10.21931/RB/2021.06.03.4\nAbstract: Rhipicephalus Boophilus microplus cattle tick is a scourge for livestock production. The infestations produced by this \npathogen are incompletely contained by chemical treatments, with the associated environmental pollution risks. Vaccination against \ncattle ticks has emerged as a feasible and environmentally friendly strategy to control tick-borne diseases. In this setting, Gavac\u00ae \nvaccine has proven effective in decreasing cattle tick populations through antibody responses against the tick Bm86 antigen, as \npart of an Integrated Control Program. However, animal vaccination programs require easy and ready-to-use screening tests to \nfollow up the immune response in vaccinated animals under field conditions. This study reports the evaluation HeberFast\u00ae Line \nGavac, a lateral flow immunochromatographic system for the rapid detection of anti Bm86 antibodies in vaccinated cattle. The \nsystem was tested on 598 serum samples taken from immunized animals, arranged in three groups according to their anti-Bm86 \nantibody response in ELISA (209 high, 150 medium or 239 low and 100 samples from non-immunized animals. The HeberFast\u00ae \nLine Gavac system was assessed for sensitivity, specificity, and concordance against the ELISA reference test. Consistency was \nevaluated among production batches and inter-analyst reading-independent consistency at two moments: ten minutes after \ncompleting the test and after strip drying. The system showed high sensitivity (81.6%, 82.2%, and 81%), specificity (96.7, 94.6, and \n93.3%), and agreement with the ELISA reference test (75%; 74%, and 71%) for high, medium and low anti-Bm86 sera, respectively. \nThe effectiveness of the diagnosis was 87.6; 87.1; 85.9 for high, medium, and low antibody titers, respectively. Consistency among \nproduction batches and analysts was documented, and no significant differences between evaluation times were found. These \nresults indicate that HeberFast\u00ae Line Gavac is a valuable tool for the serological surveillance of Gavac vaccinated cattle.\nKey words: Cattle tick, vaccination, antibody screening strip, lateral flow immunoassay, Bm86, Gavac\u00ae.RESEARCH / INVESTIGACI\u00d3N\nIntroduction\nRhipicephalus (Boophilus) microplus cattle tick is a scour-\nge for livestock production in tropical and subtropical areas. \nTicks cause significant losses due to their direct weakening \neffects in cattle and through tick-borne diseases, ultimately \ncausing animal death1. In Cuba, an Integrated Management \nProgram for cattle tick control has been implemented na-\ntionwide. This program comprises the combination of Gavac\u00ae, \na recombinant vaccine against cattle tick, with chemical acari-\ncide treatments, scheduled according to the infestation index, \nand other measures for the biological, mechanical, immuno-\nlogical, and genetic control of the plague. The application of \nthe vaccine has effectively sparse the number of acaricide \ntreatments required, thereby reducing the environmental po-\nllution risks and diminishing a 98% the deaths rates caused by \nhemoparasites2-4.\nThe active ingredient of Gavac\u00ae is the tick gut Bm86 pro-\ntein. Anti-Bm86 antibodies induced upon vaccination will at-\ntach to the gut epithelium of suckling ticks, with deleterious \neffects on their populations and the size of their progeny5,6. \nRegular immunizations are required to maintain protective an-\nti-Bm86 antibody titers in the blood of the animals6-8.\nCommonly, antibody titers in sera of immunized animals \nare monitored through antigen-specific Enzyme-Linked Immu-\nnosorbent Assays (ELISA) tests, high efficiency, and specificity. \nHowever, such assays are troublesome under field conditions, \ntime-consuming, and require specialized laboratory facilities \nand qualified personnel to perform and evaluate the results objectively. Thus, a fast and easy-to-use screening test is nee-\nded to implement and evaluate ongoing, and future cattle tick \nvaccination campaigns under field conditions.\nTherefore, this study aimed to evaluate the performance \nof HeberFast\u00ae Line Gavac, a fast chromatographic screening \ntest for the detection of anti-Bm86 antibodies, and its concor-\ndance with the reference ELISA test used in the laboratory. \nThe main parameters to compare were sensitivity, specificity, \nand consistency.\nMaterials and methods\nMaterial and Reagents\nEthical statement\nBlood was extracted from cattle following an experimen-\ntal protocol elaborated according to the ethics guidelines for \nanimal care9 and approved by the Ethics Committee of the \nCenter for Genetic Engineering and Biotechnology (CIGB).\nSerum collection and measurement of anti-Bm86 \nantibody titers by ELISA\nPositive and negative anti-Bm86 antibody blood was co-\nllected from animals in units either under tick control programs \n1 Departamento de Biotecnolog\u00eda Animal, Direcci\u00f3n de Investigaciones Agropecuarias, Centro de Ingenier\u00eda Gen\u00e9tica y Biotecnolog\u00eda, La Habana, Cuba.  \n2 Unidad de Laboratorios Centrales de Sanidad Agropecuaria (ULCSA), Ministry of Agriculture, Cuba. \n3 Centro de Ingenier\u00eda Gen\u00e9tica y Biotecnolog\u00eda, Santi Spir\u00edtus, Cuba.\n4Editorial Elfos Scientiae, Direcci\u00f3n de Promoci\u00f3n y Distribuci\u00f3n Nacional, CIGB, Cuba.\nCorresponding author: milagros.vargas@cigb.edu.cu1903\nAssessing HeberFast\u00ae Line Gavac, a lateral flow immunochromatographic system for the rapid detection of anti-Bm86 antibodies in Gavac vaccinated cattle\nwith Gavac\u00ae vaccination or without vaccination. Blood was \ntaken from healthy cattle, regardless of age, sex, or reproduc-\ntive categories, and the sera were stored at \u201320oC until use.\nELISA measured the level of anti-Bm86 antibodies in sera. \nBriefly, ELISA microplates (Polysorp, Nunc, USA) were coated \nwith Bm86 protein at 2 \u03bcg/mL and incubated overnight at 4\u00baC. \nPlates were washed with PBS-Tween 20 (0.05%), and blocked \nwith 1% skimmed milk for 1 h at 37\u00baC. Sera was next diluted \n1:500 in PBS-Tween 20 (0.05%) and 100 \u03bcL added to each well, \nand further incubated for 1 h at 37\u00baC. Next, a rabbit anti-bovine \nIgG antibody conjugated to horseradish peroxidase was added \nfor 30 min at 37\u00baC. Finally, the reaction was developed with 0.5 \nmg/mL ortho-phenylenediamine and 0.015 % H2O2, and the re-\naction stopped 10 min later with H2SO4 (1%). The optical den-\nsity (OD) was measured at 492 nm in an ELISA plate reader \n(Sunrise, Austria). A standard curve made with five 1:2 serial \ndilutions of an anti Bm86 positive reference serum reference, \nstarting with 1:640, was used to interpolate the OD values of \neach serum. The anti Bm86 antibody values were expressed as \nabsorbance units (AU)/mL. Three groups were formed accor-\nding to the results of this evaluation:\nGroup 1. High responders: 209 positive samples with an-\nti-Bm86 antibody values higher than 1000 AU/mL.\nGroup 2. Medium responders (gray zone): 150 samples \nwith anti-Bm86 antibody values between 530 and 1000 AU/\nmL (minimum protective titers).\nGroup 3. Low responders: 239 samples with non-protecti-\nve (negative) antibody values lower than 530 AU/mL.\nAnother group of negative sera with 100 samples from \nnon-immunized animals was conformed.\nHeberFast\u00ae Line Gavac\nBm86 protein and its conjugation to colloidal gold\nThe active pharmaceutical ingredient in GAVAC\u00ae vaccine \nwas supplied by its manufacturer, the Center for Genetic En-\ngineering and Biotechnology of Camag\u00fcey, Cuba. The conju-\ngation of the Bm86 protein to colloidal gold was carried out \naccording to Bailes et al., 201210 using homemade 20 nm \ncolloidal gold particles. The protein was solubilized in 0.005 \nmol/L of sodium chloride. The colloidal gold was also adjusted \nto pH 7 with 0.1 M K2CO3.\nThe following flocculation test first determined the \namount of protein in relation to a fixed volume of gold: 500 \u03bcL \nof 20 nm colloidal gold at pH 7 were mixed with 100 \u03bcL of the \nprotein solution in a range between 4 and 20 \u03bcg. The mixture \nwas homogenized and incubated for 10 min at room tempera-\nture, and 500 \u03bcL of 10% sodium chloride solution was added \nto each reaction mixture. Finally, the conjugate content in the \nmixture was quantified by measuring the absorbance at 530 \nnm in a spectrophotometer (Thermo Scientific GENESYS 10S \nUV-Vis, Madison, USA).\nOnce the optimal amount of protein had been selected, \nthe reaction was conducted for 30 min at -20 \u00b0C -25 \u00b0C, sti-\nrring at 300 rpm. The free sites on the colloidal gold particles \nwere blocked with an adequate volume of 10% BSA, for a final \nconcentration of 0.5 %. The final mixture was centrifuged at \n16000 x g for 1 hour at 4\u2070C. The conjugate obtained (pellet) \nwas suspended in 0.1 M TBS, BSA 1% pH 7.0, and diluted up to \nan absorbance of 40 at a wavelength of 530 nm.\nPreparation of the immunoreactive strip\nThe strip components were nitrocellulose (NC) membra-\nne of 15 \u03bcm (MDI, type CNPC-SS12-L2-H50, dimensions 7,5 x 26 cm, 1,5 cm of NC), pad for the antigen-gold conjugate (MDI, \ntype PTR-5, dimensions 2,7 x 26 cm), and absorbent pad (MDI, \ntype AP080, dimensions 3,5 x 26 cm) . The conjugate was di-\nluted to an absorbance of 20, at a wavelength of 530 nm and \ndispensed onto the antigen-gold conjugate pad.\nThe Bm86 protein, dissolved at 4 mg/mL in phosphate \nbuffer saline (PBS) was absorbed into the membrane in the \ntest line. The mixture of the control line components consisted \nof a monoclonal antibody against Bm86 protein provided by \nthe Center for Genetic Engineering and Biotechnology of Sanc-\nti Sp\u00edritus, Cuba at 4 mg/ml, and 0.2 mg/mL of poly L-lysine, \ndissolved in PBS.\nBoth the macroporous material and the nitrocellulose \nmembrane were sprayed with the BioDotQuanti 2000, BioJet, \nEngland, and then dried in an oven at 37 \u00b0C, for 30 min. The NC \nmembrane cards were blocked for 1h at room temperature in \nblocking solution (0.02% (v/v) Tween 20, 0.02% (w/v) sodium \nazide, 5% (w/v) sucrose, and 0.5% bovine seroalbumin (BSA), \ndissolved in PBS. Later they were dried in the oven at 37 \u00b0C \nfor 1 h.\nTest strip assembly\nThe NC membrane was coupled in the center of polyvin-\nyl chloride support. The absorbent pad and the conjugate pad \nwere glued by overlapping 1 mm at the top and bottom of the \nNC Membrane, respectively. The sample pad was then glued \nby overlapping 2 mm on the bottom of the conjugate pad. The \nmaster assembled card was cut into 4 mm wide strips using a \nCM5000-guillotine-cutter (BioDot, Irvine, USA).\nImmunochromatographic assay\nThe rapid, one-step, and visual reading lateral flow immu-\nnoassay (LFIA), branded HeberFast\u00ae Line Gavac, consists of a \nstrip of nitrocellulose (NC) membranes to detect antibodies \nagainst the Bm86 antigen in bovine serum. The membrane \nconsists of two phases: a fixed phase composed of the Bm86 \nprotein as a capture biomolecule for the specific immunoglo-\nbulins present in the serum and a mobile phase containing a \nprotein-colloidal gold marker conjugate, which finally deve-\nlops the reaction with a specific dye.\nEach strip was introduced into 80 \u03bcL of bovine serum (pre-\nviously diluted 1:8 in buffer). The diluted sera migrated by ca-\npillarity within the macroporous material, dissolving the Bm86 \nconjugate labeled with colloidal gold. Two independent reac-\ntions could be observed in the virtual window. If the sample \nwas positive, the immune complex reacted with the Bm86 pro-\ntein attached to the NC membrane, forming a first horizontal \nredline Positive Line (PL). For all samples, the free conjugate \nwas captured in a second red horizontal line Control Line (CL) \nwhere a polyclonal anti-IgG murine antibody is fixed to the so-\nlid phase.\nPerformance evaluation\nStrips were used to detect antibody responses in 698 \nsamples of bovine sera, from598 vaccinated and 100 unvac-\ncinated animals. The results of the samples were interpreted \nat two moments, at the end of the reaction 10 min after the \nsample was applied and once the strip dried. LFIA tested sam-\nples in triplicate. The specificity, sensitivity, positive predictive \nvalue (PPV), negative predictive value (NPV), efficacy as well \nas kappa coefficient (K), were determined.1904\nKappa coefficient (K)\nThe Kappa coefficient was calculated to assess the level \nof significance of the agreement between the ELISA and the \nLFIA. The following ranges and their respective performance \ncriteria were defined: 0.81-1.00, almost perfect agreement; \n0.61-0.80, reasonable agreement, 0.60-0.41, moderate agree-\nment; 0.40-0.21, discrete agreement, 0.20-0.01 insignificant \nagreement, and lower than 0.01, no agreement11.\nBatch to batch consistency\nThe samples from all panels were all evaluated by the \nthree batches of strips (Gavac1501, Gavac1502, and Ga-\nvac1503). Results were considered valid for samples with \ncoincident results with two different strip batches.\nInter-analyst interpretation\nThree analysts read each sample, and results were regar-\nded as valid when two out of the three observers coincided.\nStatistical analysis\nThe LFIA and the ELISA reference system results were \nstatistically compared using the epidemiological analysis of \ntabulated data (EPIDAT) software, version 3.112. Concordance, \nsensitivity, specificity, efficacy, positive and negative predictive \nvalues, batch to batch consistency, and inter-analyst interpre-\ntation were compared.  Statistical significance was considered \nfor a 95 % confidence interval.\nResults\nEvaluation of the panel of samples from unimmunized \nanimals.\nAll sera from unimmunized animals were negative. Only \none signal appeared in the diagnostic control line, which gua-\nrantees the validity of the test. This represented a 100% of \nspecificity for the system. Four representative samples from \nthis group are shown in figure 1.Evaluation of samples from immunized animals\nAll the strips used were accepted as valid, as the control \nline indicating their quality and reliability was observed. The \nintensity of the test capture region line varied depending on the \nconcentration of immunoglobulins in the sample.\nThe overall false positive rate fluctuated between 3.34% \nand 6.69%, while a range of 4.78%-5.26% was found for fal-\nse-negative results for the different lots and times evaluated. \nAs expected, the percentage of false negative and false po-\nsitive values was highly dependent on anti-Bm86 antibodies \nin the samples. Samples from group 2 (medium responders) \nshowed the greatest incongruities when compared to the re-\nference ELISA (36% - 38.7% of false negatives) (Table 1). The \npercentage of false-negative values dropped to 4.8%-5.2% in \nthe group of high responders. On the other hand, the percen-\ntage of false positives in the ELISA negative sera was only 3.4-\n7.1%. Figure 1 shows 4 representative samples from each of \nthe three groups evaluated. \nThe general agreement of the immunochromatographic \nstrips with respect to ELISA was good for the 3 batches eva-\nluated based on the kappa coefficient (Gav1501, Gav1502, and \nGav1503) (Table 2). \nThe results of sensitivity, specificity, efficacy (test validity \nindex), positive and negative predictive values, and confidence \nintervals of the 3 batches in studies are shown in Table 3.\nConsistency between batches\nThe agreement among the three batches of strips eva-\nluated (Gav1501, Gav1502, and Gav1503) is shown in Table 4. \nAll batches exhibited high kappa coefficients, which indicate a \ngood, or almost perfect degree of concordance. These results \ndemonstrated the consistency of the manufacturing process.\nIndependence of the analysts\nThe concordance among the three analysts that read the \nassays ranged from good to almost perfect as the concentra-\ntion of immunoglobulins increased. The results are shown in \nTable 5. The samples evaluated in the two moments gave no \nsignificant differences.\nFigure 1. Evaluation of sera from Gavac immunizes animals and unvaccinated controls. Four representative samples per group \nwere included. A: unvaccinated control group; B: high responders, (>1000 AU/mL); C: medium responders (530 - 1000 AU/mL); \nD: low responders (>530 AU/mL).Milagros Vargas-Hern\u00e1ndez, Yeni Hern\u00e1ndez Lorenzo, Viviana Pluma Perez, Isabel Rosales-Garcia, Sunamit Rodr\u00edguez-Mendez, Enrique P\u00e9rez-Cruz, \nDaymi Abreu-Remedios, Carlos Montero-Espinosa, Ayme Oliva-Cardenas, Elaine Santana-Rodriguez, Danny P\u00e9rez-P\u00e9rez, Yusmel Sordo-Puga, Yohandy \nFuentes-Rodr\u00edguez, Alianne Fundora-Llera, Carlos A. Duarte, Ernesto Galb\u00e1n-Rodr\u00edguez, Carlos Hernandez-Diaz, Dayam\u00ed Dorta Hernandez, Ivis Pasaron \nRodriguez, Marisela Suarez-Pedroso\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1905\nDiscussion\nTick mitigation strategies are part of a long tradition and \nfocus on the local application of acaricides or the search for \nbiological products that reduce the impact of the problem13. \nThe use of the Gavac\u00ae immunogen within a control program \ndecreases the reproductive parameters of the tick through \nthe specific antibodies developed in the immunized animals14. \nMoreover, the fast development of anti-Bm86 antibody levels \nguarantees herds immunity and the effective control of tick \npopulations4.\nIn this setting, the development of rapid, specific, sensi-\ntive, and economically feasible diagnostic methods such as LFIA is of paramount relevance in veterinary medicine. They \nsupport the massive screening of samples in a shorter time \nunder field conditions and the early detection of pathogens, \nfurther providing specific treatments and monitoring for the \ncontrol epidemiological units15.\nIn this study, the performance of the HeberFast\u00ae Line \nGavac immune screening test was evaluated for detecting an-\nti-Bm86 antibody titers in sera of immunized cattle. The sen-\nsitivity and specificity of the immunochromatographic system \nfor the three batches under study were in the 81-82% and 92-\n95% ranges, respectively. Similar results have been previously \nreported for the use of LFIA strips for massive screening. For \ninstance, the direct Sensitive Membrane Antigen Rapid Test \nTable 1. Evaluation of the diagnostic strips with a panel of positive anti-Bm86 sera.\nTable 2. General agreement between the im -\nmunochromatographic assay and the referen -\nce ELISA.\nTable 3. Performance of the immuno -\nchromatographic system.Assessing HeberFast\u00ae Line Gavac, a lateral flow immunochromatographic system for the rapid detection of anti-Bm86 antibodies in Gavac vaccinated cattle1906\n(SMART\u00ae; New Horizons Diagnostics Corp., USA) and the di-\nrect Pathogen Detection Kit\u00ae (PDK; Intelligent Monitoring Sys-\ntems, USA) were reported to display 100 % sensitivity for cho-\nlera diagnosis in diarrheal and semi-formed stool samples, and \nin intestinal contents of corpses. Furthermore, 100 % specifici-\nty was also attained with SMART\u00ae, while the same parameter \nfor direct PDK\u00ae ranged between 77.4% and 85.7%, depending \non sample type16. In immunochromatographic studies to de-\ntect Giardia spp. and Cryptosporidium spp. in feces, 58-97.2 % \nsensitivity and 99-100 % specificity were reported17,18.\nIn summary, diagnostic tests must perform with high spe-\ncificity and sensitivity to avoid false positives or false negative \nresults. This is more relevant when diagnosing severe illnes-\nses or other conditions able to compromise herd health and \nintegrity and devoid of any contingency measures other than \nanimal sacrifice. A misdiagnosis can lead to serious economic \nlosses in those situations, as forum treatable pests such as \nFoot and Mouth Disease, African Swine Fever, Classical Swine \nFever, and similar19,20.\nSince the HeberFast\u00ae Line Gavac strip will be applied to \ndetermine the immune status of animals vaccinated with Ga-\nvac\u00ae, the specificity of this test is more critical than its sensi-\ntivity. Consequently, the essay must exhibit a low fraction of \nfalse positives when assessing post-vaccination immunity. The assay's specificity was in the range 92.9-95.4% for the three \nbatches tested, well above its sensitivity values (81-82.4%).\nIn veterinary medicine, lateral flow immunoassays have \nbeen developed for various purposes; detection of diseases in \ncompanion and farm animals to achieve better results in the \ncare and development of animals, for example, Parvovirus21, \nNewcastle22, Avian infectious bronchitis virus23, African swine \nfever24 and Babesiosis25, The rapid detection of these disea-\nses reduces the economic losses. Immunochromatographic \nmethods have also been developed to detect antibiotics and \nanalogs in milk26, which is greatly important for food safety.\nIn general, this test offers advantages and benefits, espe-\ncially in the field, due to its fast and safe use and relatively low \nproduction costs. Moreover, it does not require equipment for \nreadouts, and the results are easily interpreted with the naked \neye, with high specificity and sensitivity in just 10 min. Finally, \nthis immunoscreening test has been developed to work with \nserum, a sample that can be easily collected and processed.\nHeberFast\u00ae Line Gavac is the first rapid kit worldwide for \nthe detection of antibodies against the Bm86 protein. Its intro-\nduction in the field could facilitate the follow-up of the immune \nresponse against any vaccine based on this antigen and deter-\nmine the level of immunity achieved in the vaccinated herds.\nTable 4. Consistency in production.Milagros Vargas-Hern\u00e1ndez, Yeni Hern\u00e1ndez Lorenzo, Viviana Pluma Perez, Isabel Rosales-Garcia, Sunamit Rodr\u00edguez-Mendez, Enrique P\u00e9rez-Cruz, \nDaymi Abreu-Remedios, Carlos Montero-Espinosa, Ayme Oliva-Cardenas, Elaine Santana-Rodriguez, Danny P\u00e9rez-P\u00e9rez, Yusmel Sordo-Puga, Yohandy \nFuentes-Rodr\u00edguez, Alianne Fundora-Llera, Carlos A. Duarte, Ernesto Galb\u00e1n-Rodr\u00edguez, Carlos Hernandez-Diaz, Dayam\u00ed Dorta Hernandez, Ivis Pasaron \nRodriguez, Marisela Suarez-Pedroso\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1907\nConclusions\nThe HeberFast\u00ae Line Gavac immunochromatographic sys-\ntem allows the determination of the anti-Bm86 serological sta-\ntus quickly and straightforwardly to a large number of samples in field conditions with minimal effort. The introduction of this test would significantly improve the follow-up of the antibody response to GAVAC in all the country as part of the Integrated Control Program for cattle tick control.\nAcknowledgements\nThis work was carried out thanks to the collaboration with \nthe Unit of Central Laboratories of Agricultural Health (ULC-\nSA), Ministry of Agriculture, Cuba.\nBibliographic references\n1. R odriguez-Vivas RI, Jonsson NN, Bhushan C. Strategies for the\ncontrol of Rhipicephalus microplus ticks in a world of conven-\ntional acaricide and macrocyclic lactone resistance. Parasitology research 2018; 117:3-29.\n2.\nV\nalle MR, Mendez L, Valdez M, et al. Integrated control of Booph-\nilus microplus ticks in Cuba based on vaccination with the an-ti-tick vaccine Gavac. Experimental & applied acarology 2004;34:375-82.3.\nSuarez PM, M\u00e9ndez, M.L., Valdez, M., Souza, R.M., Camargo,A.J\n.R., Constanza, N.V., Ascanio, E.E. Control de las infestaciones \nde la garrapata Boophilus microplus en la ganader\u00eda Cubana y en regiones de latinoam\u00e9rica con la aplicaci\u00f3n del inmun\u00f3geno Ga-vac\u00ae dentro de un programa de lucha integral. Documento sextaconferencia Electr\u00f3nica - Redectopar 2007.\n4.\n Suarez M, Rubi J\n, P\u00e9rez D, et al. High impact and effectiveness of \nGavac\u2122 vaccine in the national program for control of bovine ticks Rhipicephalus microplus in Venezuela. Livestock Science 2016;187:48-52.\n5.\nWilladsen P\n, Kemp D. Vaccination with \u2018concealed\u2019antigens for\ntick control. Parasitology Today 1988; 4:196-8.\n6.de \nla Fuente J, Rodriguez M, Redondo M, et al. Field studies and\ncost-effectiveness analysis of vaccination with Gavac against the cattle tick Boophilus microplus. Vaccine 1998;16:366-73.\n7.\nLamber\nti J, Signorini A, Mattos C, et al. Evaluation of the recom-\nbinant vaccine against Boophilus microplus in grazing cattle inArgentina. Recombinant Vaccines for the Control of the CattleTick (ed De la Fuente, J) 1995:205-27.\n8.\n V\nargas M, Montero C, Sanchez D, et al. Two initial vaccinations\nwith the Bm86-based Gavacplus vaccine against Rhipicephalus(Boophilus) microplus induce similar reproductive suppression to three initial vaccinations under production conditions. BMC veter-inary research 2010;6:43.\nTable 5. Analyst Interpretation.Assessing HeberFast\u00ae Line Gavac, a lateral flow immunochromatographic system for the rapid detection of anti-Bm86 antibodies in Gavac vaccinated cattle1908\n9.E thical Guidelines for the Use of Animals in Research. 2018. (Ac-\ncessed 23/10/2021, 2020.\n10.\n Bailes J\n, Mayoss S, Teale P, Soloviev M. Gold nanoparticle an-\ntibody conjugates for use in competitive lateral flow assays.\nNanoparticles in Biology and Medicine: Springer; 2012:45-55.\n11.\n Landis J\n, Koch G. The measurement of observer agreement for\ncategorical data. Biometrics 1977:159-74.\n12.\n EPID\nAT 3.1. Una herramienta para el an\u00e1lisis epidemiol\u00f3gico de\ndatos tabulados. Infomed, 2005. (Accessed 14//05/2020, 2020,at http://www.sld.cu/sitios/revsalud/temas.php?idv=1178.)\n13.\n Las garr\napatas del bovino y los agentes de enfermedad que\ntransmiten en escenarios epidemiol\u00f3gicos de cambio clim\u00e1ti-co. Gu\u00eda para el manejo de garrapatas y adaptaci\u00f3n al cambioclim\u00e1tico. Instituto Interamericano de Cooperaci\u00f3n para la Agri-cultura (IICA), 2016. (Accessed 12/06/2020, 2020, at http://cre-ativecommons.org/licenses/by-sa/.0/igo/.)\n14.\n V\nargas-Hern\u00e1ndez M, Santana-Rodr\u00edguez E, Sordo-Puga Y, et al.\nStability, safety and protective immunity of Gavac\u00ae vaccine sub-jected to heat stress. Biotecnolog\u00eda Aplicada 2018; 35:1221-7.\n15.\n Sas\ntre P, Gallardo C, Monedero A, et al. Development of a novel\nlateral flow assay for detection of African swine fever in blood.BMC veterinary research 2016; 12:1-8.\n16.\n Bola\u00f1os HM, Acu\u00f1a MT\n, Serrano AM, et al. Desempe\u00f1o de los\nsistemas Cholera-SMART\u00ae y Pathogen-Detection-Kit\u00ae en el diag-n\u00f3stico r\u00e1pido del c\u00f3lera. Revista Panamericana de Salud P\u00fablica 2004; 16:233-41.\n17.\n Corripio \nIF, Cisneros MJG, Ormaechea TG. Diagn\u00f3stico de las\nparasitosis intestinales mediante detecci\u00f3n de coproant\u00edgenos.Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica 2010; 28:33-9.\n18.\n Guti\u00e9rrez-Cisneros \nMJ, Mart\u00ednez-Ruiz R, Subirats M, Merino FJ,\nMill\u00e1n R, Fuentes I. Evaluaci\u00f3n de dos m\u00e9todos inmunocromato-gr\u00e1ficos comerciales para el diagn\u00f3stico r\u00e1pido de Giardia duo-denalis y Cryptosporidium spp. en muestras de heces. Enferme-dades Infecciosas y Microbiolog\u00eda Cl\u00ednica 2011; 29:201-3.19.\n  Kno wles N, Samuel A. Molecular epidemiology of foot-and-\nmouth disease virus. Virus research 2003; 91:65-80.\n20.\n OIE. Chapter 15.2. Infection with clas\nsical Swine fever virus. Ter-\nrestrial Animal Health code. In: OIE, ed.2019.\n21.\n Sharma C\n, Singh M, Upmanyu V, et al. development and evalua-\ntion of a gold nanoparticle-based immunochromatographic striptest for the detection of canine parvovirus. Archives of virology2018; 163:2359-68.\n22.\n Li Q, W\nang L, Sun Y, et al. Evaluation of an immunochromato-\ngraphic strip for detection of avian avulavirus 1 (Newcastle dis-ease virus). Journal of Veterinary Diagnostic Investigation 2019;31:475-80.\n23.\n Liu I-L, Lin Y\n-C, Lin Y-C, Jian C-Z, Cheng I-C, Chen H-W. A nov-\nel immunochromatographic strip for antigen detection of avianinfectious bronchitis virus. International journal of molecular sci-ences 2019; 20:2216.\n24.\n W\nang X, Ji P, Fan H, et al. CRISPR/Cas12a technology combined\nwith immunochromatographic strips for portable detection ofAfrican swine fever virus. Communications biology 2020; 3:1-8.\n25.\n S\ntuart Tayebwa D, Magdy Beshbishy A, Batiha GE-S, et al. As-\nsessing the immunochromatographic test strip for serologicaldetection of bovine babesiosis in Uganda. Microorganisms 2020;8:1110.\n26.\n P\neng J, Liu L, Kuang H, Cui G, Xu C. Development of an icELISA\nand immunochromatographic strip to detect norfloxacin and itsanalogs in milk. Food and Agricultural Immunology 2017; 28:288-98.\nReceived: 2 February 2021\nAccepted: 2 June 2021Milagros Vargas-Hern\u00e1ndez, Yeni Hern\u00e1ndez Lorenzo, Viviana Pluma Perez, Isabel Rosales-Garcia, Sunamit Rodr\u00edguez-Mendez, Enrique P\u00e9rez-Cruz, \nDaymi Abreu-Remedios, Carlos Montero-Espinosa, Ayme Oliva-Cardenas, Elaine Santana-Rodriguez, Danny P\u00e9rez-P\u00e9rez, Yusmel Sordo-Puga, Yohandy Fuentes-Rodr\u00edguez, Alianne Fundora-Llera, Carlos A. Duarte, Ernesto Galb\u00e1n-Rodr\u00edguez, Carlos Hernandez-Diaz, Dayam\u00ed Dorta Hernandez, Ivis Pasaron Rodriguez, Marisela Suarez-Pedroso\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1909\nFormulation and organoleptic evaluation[UdMO1] of Poly[UdMO2] Herbal Cream of Punica, Neem, Carrot & Jamun as Active Ingredients\nFormulation and organoleptic evaluation of Poly Herbal Cream of \nPunica, Neem, Carrot & Jamun as Active Ingredients\nPuja Saha1*, Jayashree Bhowmick2, Anupam Saha3DOI. 10.21931/RB/2021.06.03.5\nAbstract: Assuming that herbal preparation is better with fewer side effects than synthetics, natural treatments are more effective \nthan allopathy in terms of side effects for better human body healing. Herbal products have a growing demand in the world market, \nand the plants have been reported in the literature as having various pharmacological activities such as anti-microbial, anti-oxidant, anti-inflammatory activity, [UdMO4] anti-cancer, anti-diabetic. The purpose of this study was to develop anti-aging poly-herbal cream by mixing the extract of Punica leaf, Neem Oil, Jamun powder, Carrot powder as the main ingredient, and then creams were developed based on the anti-oxidant ability of herbal extracts and performed their evaluation study. Punica granatam leaves were shade dried and extracted using the Soxhlet method with different solvents such as n-hexane, benzene, and alcohol.[UdMO5] Fine extract powder was collected and removed distilled water thoroughly. The cream was formulated into different concentrations, namely F1, F2, F3, and F4. Similar types of research with similar components have been reported, but in this experiment, the formulation is different, and this work is kept cost-efficient and straightforward; it's an attempt to reduce few components and prepare cream and evaluate its potential.  According to The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use ICH[UdMO6] guidelines, the cream was stable during stability studies, and F3 turned out to be a better formulation than the other three.\nKey words: Anti-aging, Poly-herbs, Herbal Remedy, Herbal Cream, Pharmaceutical Cream, Skin Care.RESEARCH / INVESTIGACI\u00d3N\nIntroduction\nDermal layer aging results from continual deterioration \ndue to cellular DNA and protein; aging is classed into 2 dis-\ntinct varieties: sequential skin aging and photo-aging. Each type has distinct clinical and historical options, and sequential skin aging is a universal and specific process characterized by physiological alteration in skin function. Within the aging pro-cess, keratinocytes cannot create a helpful stratum corneum, and the rate of formation from neutral lipids slows down, lea-ding to dry pale skin with a wrinkle. In contrast, photo-aging is caused by the disorganization of stratum and dermal parts associated with physiological state and helio dermatitis. Herbs and plants have already proved helpful as a tool in the practice of medicine\n1\u20133.\nCosmetic merchandise is used to shield pores and skin in \nopposition to exogenous and endogenous dangerous retailers and beautify the splendor and elegance of skin and the usage of cosmetics now not only handiest growing an appealing outsi-de look, but also towards accomplishing sturdiness of suitable fitness via way of means of decreasing skin disorders\n3\u20138. The \nartificial or herbal substances found in skincare formulation that helps the health, texture, and integrity of dermis, moisturi-zing and preserving the pliancy of the skin with the aid of using decreasing the type I collagen, photo-protection, and plenty more, and this belongings of beauty is because of the presence of substances in cosmetics as it allows to lessen the production of loose radicals in the skin and manage the dermal residences which is the obstruction to penetrate the skin for an extended time\n3,5,6. Cosmetic merchandise is the satisfactory desire to \nlessen dermal problems like hyperpigmentation, skin wrinkling, skin aging, problematic pores, rough skin texture, etc. The need for natural cosmetics is swiftly increasing, and the growth is because of the supply of recent ingredients, the monetary rewards for growing hitting merchandise, customer needs, and higher expertise in dermal biology\n3,5,9\u201311. The plant parts utili-zed in cosmetic products should have medicinal properties like anti-inflammatory, anti-oxidant, emollient, anti-seborrheic, antiseptic, anti-bacterial activities, etc. Herbal merchandise de-clares to have fewer adverse effects, normally visible with mer-chandise containing artificial agents. The marketplace studies suggest a rise in the trade with the cosmetic industries, a prime function in fueling this international call for herbals\n12\u201314.\nPunica leaf, part of the tree pomegranate\nP. granatum is one of the most common and potential\nplants for medicine in managing various ailments15. Punica \ngranatum L. (belongs to the family Punicaceae) has been used to treat many ailments. Various plant parts have been scien-tifically tested for various pharmacological activities, such as potent antioxidative\n15,16, anti-inflammatory, anti-bacterial, \nanti-microbial, anti-fungal properties, anti-hypertensive, and antiproliferative properties\n17,18. Pomegranate has excellent po-\ntential to be developed for use in dermal products19. Chloro-\nphyll-a extracted from pomegranate leaf and stem may be a potential source and can supply natural or herbal colorants for the coating enterprises and nail varnish. Pomegranate leaf ex-tracts act on inhibiting the development of obesity and hyperli-pidemia in obese mice fed with a high-fat diet\n20\u201322.\nAlmond oil is the oil isolated from Almonds\nThe almond Prunus dulcis (Mill) D.A. Webb (subfami-\nly Prunoideae of family Rosaceae) contains fixed oil, phenolic compounds abundant in almonds; it also contains  and some micronutrients, vitamins, minerals and has different pharmaco-logical activities\n23\u201326. Almond seeds and oil have cardio-protec-\ntive, immune-stimulant effects, anti-inflammatory, and reduce irritable bowel syndrome symptoms , and they are also helpful in treating constipation\n27,28. Almond oil has also been used to \n1 Assistant Professor, Department of Pharmaceutics, School of Pharmacy, Seacom Skills University, Bolpur, Birbhum.  \n2 Graduated B.Pharm, Bharat Technology, Uluberia, Howrah. \n3 Graduated M.Pharm, Pharmacology, NSHM College Of Pharmaceutical Technology, NSHM Knowledge Campus, B.L. Rd,  Kolkata.\nCorresponding author: milagros.vargas@cigb.edu.cu1910\nPuja Saha, Jayashree Bhowmick, Anupam Saha\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\ntreat dry skin disorders like psoriasis, eczema, and many more \ndisorders in ancient treatment cultures but today it is used in \naromatherapy and for producing many skin-hair cosmetics29.\nJamun powder is made from sun-dried Jamun Seeds\nThe black Jamun (Syzygium cumini L.) is an important in-\ndigenous plant of Myrtaceae, commonly known as jamun or In-\ndian blackberry, originally from Indonesia and India, which has \nanti-oxidant solid antigenotoxic potential32,33. The fruit pulp is \nsweet, and the seeds are acidic and sour. The presence of oxa-\nlic, gallic, tannic acids and other alkaloids creates one to feel \nsuch an astringency taste. The pulp and seeds are used for \ntraditional medicine against diabetes, diarrhea, and ringworm \ninfection also protect against radiation-induced sickness32,34\u201337. \nIt is very beneficial as it has anti-diabetic, cytoprotective, an-\nticoagulant, analgesic and anti-inflammatory, anti-cancerous, \nanti-microbial, anti-oxidant, hypo-lipidemic, hepato-protective \nproperties35,38,39.\nCarrots\n(Daucus carota) are essentially root veggies belonging to \nthe family of Apeaceae or Umbelliferrous. These veggies are \nbelieved to have originated approximately 5000 years ago. \nCarrots are to be had in diverse, colorful variations like pink, \norange, white, purple, etc; however, the maximum usually ob-\nserved variants are pink carrots and orange carrots. Carrots \nhave anti-oxidants, which enables in regaining the misplaced \nglow of the skin. It helps in imparting remedies from scars and \nblemishes. Carrot is a unique anti-growing old compound due \nto the presence of Vitamin A.\nAdditionally, a considerable quantity of Vitamin C. Vitamin \nA acts as an excellent anti-oxidant, fights with the  free radi-\ncals of the body, stabilize them, and stops them from unfa-\nvorable our pores of skin cells and accordingly prevents the \nsymptoms of growing old like wrinkles, pigmentation, and cho-\nppy pores and skin tone. Vitamin C enables the prevention of \nwrinkles using assisting the manufacturing of collagen in the \nbody, which is a crucial protein required for retaining pores and \nskin elasticity. Carrot is likewise a wealthy supply of \u03b2-caro-\ntenoids, which boom  or trigger skin immunity in opposition to \nsolar rays and heals sunburns40\u201343.\nNeem tree\n(Azadirachta indica) is a local, evergreen, tropical tree to \nIndia44. Neem is a versatile, multifarious tree with a great ca-\npacity to own the most beneficial non-wooden products. Neem \nhas various medicinal properties, including anti-cancer pro-\nperties.  In India, Neem is called the village of pharmacy due \nto its recovery versatility, and it's been utilized in Ayurvedic \nmedication for extra than 4,000 years because of its medicinal \nproperties44\u201347. Azadirachtin is the principal compound of the \nneem oil with insecticidal activity48. Neem extracts were also \nreported to possess inhibitory effects on several cancer cell li-\nnes such as breast, gynecological, gastrointestinal, hematolo-\ngical, prostate, and skin cancers. Several active chemical com-\npounds were discovered in neems, such as Nimbin, Nimbin, \nSaladin, azadirachtin (AZA), glycosides, and dihydrochalcone \npolyphenolics, coumarin, and tannins49\u201351. Pharmacological \nactivities have been reported, including anti-bacterial, anti-in-\nflammatory, anti-fungal, anti-arthritic, anti-pyretic, anti-gas-\ntric ulcer, hypoglycemic, and anti-tumor activities46,49,52\u201354.Grapeseed oil\nIs obtained from the seeds of grapes, and it was a by-pro-\nduct of winemaking and had many uses ranging from cooking \ncosmetics in controlling several diseases and wound healing \npotential55\u201357. Vitis vinifera L., which is commonly called grape \nused as a food and a beverage58. It is widely used as cooking oil, \nin skin care applications, and also as cosmetics. The grape seed \noil contains 0.8 to 1.5% of phenols, steroids, and minor amounts \nof vitamin E. The grape seed oil was reported to possess the \nhighest gallic acid, anti-oxidant, epicatechin, proanthocyanidins, \ncatechin, and procyanidins. It has anti-oxidant, anti-fungal, an-\nti-bacterial, antiviral, and anti-inflammatory activities59,60.\nPeppermint oil\n(Mentha piperita) extracted from peppermint leaves is an \nexcellent gastric stimulant, carminative, which has also been \nused in cosmetic formulations as a perfume component and \na general skin conditioning agent61,62. Peppermint (Mentha \n\u00d7 Piperita) is a hybrid mint, which is a cross between Water \nmint (Mentha aquatica) and Spearmint (Mentha spicata) that \nis thought to be grown naturally62,63.\nSimilar types of research with similar Active Pharma-\nceutical Ingredients API  have been reported. However, in this \nexperiment, the formulation is different, and in each formula-\ntion, peppermint oil is used as the flavoring agent, whereas in \nthe literature review, it is found that each formulation has a \ndifferent flavoring agent. This work is kept cost-efficient and \nstraightforward, it's an attempt to omit few components and \nprepare cream and evaluate its potential.  \nMaterials and methods \nThe plan of work and the procedure followed for this expe-\nriment were performed by Matangi and the team in 20143. The \nexperiment was performed in Bharat Technology, Uluberia, in \n2018 as an academic project for the partial fulfillment of a Ba-\nchelor of Pharmacy degree.\nMaterials\nGlycerin, Propylene Glycol, Zinc oxide, Micro Crystalline \nCellulose, Sodium alginate, Methylcellulose, Beeswax, So-\ndium benzoate/paraben, Almond oil, Punica leaves, Neem oil, \nJamun powder, Carrot powder, Vitamin E, Grapeseed oil, Pe-\nppermint oil, and Purified water.\nPreparation of Punica leaf extract\nPunica granatum leaves were bought from the market \nand dried. The dried leaves were ground to a fine powder in \na suitable grinder mixture. Shade dried powder was extracted \nusing a Soxhlet extractor with hexane, alcohol, and distilled \nwater separately to get the semisolid extract. The organic sol-\nvents were then recovered by steam distillation. The extracts \nwere then concentrated to remove wetness under reduced \npressure and controlled temperature, respectively, and they \nwere preserved in a refrigerator.\nPreparation of Jamun Seeds powder\nBlack Jamun (Syzygium cumini L.) were bought from the \nmarket, and the seeds are separated from the freshly part of \nthe fruit, washed adequately, and dried. The seeds were dried \nunder the sun for a week. Seeds were pounded along with the \nouter skin and made into a fine powder.1911\nCream Formulation\nThe formula for the cream is given in Table No. 1.\nMethod For Preparation Of Cream\nShade-dried Punica leaf powder was put separately in a \nsoxhlet extractor, and then ethanol was added successively. \nThe extracts were then concentrated under reduced pressure \nand controlled temperature for dryness and were stored for \nstabilization at a specific temperature. Glycerin was applied to \nthe binder and polymer content, the water mixture in a beaker. \nThis forms liquid dispersion and displays the property of slight \nswelling. The Punica leaf extract, neem oil, and Jamun powder \nwere added to the liquid dispersion. Using a water bath,  mel-\nted oils together with the base in a separate beaker. Skin whi-\ntener and preservative were gradually incorporated along with \nall other components. Triturated all ingredients above and the \nrequisite consistency was established, which forms poly-her-\nbal anti-aging cream.\nResults and discussion\nEvaluation of cream\nThere are various evaluation parameters for cream. For \nthis work, the evaluation parameters chosen are Organoleptic \nevaluation, Microbial Count test, Stability Studies, pH deter-\nmination, homogeneity determination, wetness determination, \nsmear determination, emolliency determination, viscosity de-\ntermination, dilution test, dye solubility test.\nOrganoleptic evaluation\nThe cream formulated was evaluated for its organolep-\ntic properties (color, state, and odor). The appearance of the cream was analyzed by its color and roughness visually and by \ntouch. Results are listed in Table No. 2.   \nTable 1. Formulation Table.\nTable 2. Organoleptic Properties.\nTest for microbial growth in formulated creams\nThis method was applied from the work of Matangi and \nTeam in the year 20143. Here, Streak Plate Method64 was \nused, where the formulated creams were inoculated in a plate \nwith the Muller Hinton agar media. Along with that, a control \ngroup was made without the cream for comparison. The plates \nwere kept in the incubator and are incubated for 24 hours at \n37\u02daC. After the incubation period, plates were taken out and \nanalyzed for microbial growth by comparing them with the \ncontrol. Results are listed in Table 3.\nStability studies\nThermal stability testing of cream was done at room tem-\nperature with relative humidity (RH) 65%; results are listed in \nTable 4. To assess the drug and formulation stability for an \nextended period, accelerated stability studies were done ac-\ncording to ICH guidelines; the results are listed in Table 5.Formulation and organoleptic evaluation[UdMO1] of Poly[UdMO2] Herbal Cream of Punica, Neem, Carrot & Jamun as Active Ingredients1912\nDetermination of Homogeneity\nThe formulations were tested for homogeneity by touch \nfor texture and by visual appearance. Result obtained of each \nformulation is given in Table No. 6,7,8,9.\nDetermination of the type of smear\nIt was determined by applying the cream on the surface of \nthe skin of a human volunteer (Self, no ethical permission need \nas it is non-toxic, natural, and safe components which makes \nit exceptional65. After applying the cream, the type of smear or \nfilm formed on the skin was checked. Result obtained of each \nformulation is given in Table No. 6,7,8,9.\nDetermination of Viscosity\nThe viscosity determinations were carried out using a \nBrookfield viscometer (DV II + Pro model) using spindle num-\nber S-64 at 20 rpm at a temperature of 25\u00b0C. Result obtained \nof each formulation is given in Table No. 6,7,8,9.\nDetermination of pH\nAccurately weighed 1gm of the sample was dispersed in \n100 ml of water. The pH of the suspension was set at 27\u00b0C \nusing a digital pH meter. Result obtained of each formulation \nis given in Table No. 6,7,8,9.\nSpread ability Test\nThis method was applied from the work of Dhase and \nTeam in the year 2014, Chen and Team in the year 201666,67. Spread ability can be expressed by the extent of the area to \nwhich the topical application spreads when applied to the \naffected parts on the skin and the curative value of the for-\nmulation also hang-on upon its spreading value. Hence, it was \nfound obligatory to determine the spread ability of the formu-\nlation. For this purpose, a small amount of about 23cm  of each \nformulation was applied in between two glass slides, and they \nwere pressed together to obtain a film of uniform thickness by \nplacing 1000gm weight for 5 minutes. Thereafter a weight of \n10gm was added to the pan, and the top plate was subjected \nto pull with the help of string attached to the hook. The time \nin which the upper glass slide moves over the lower plate to \ncover a distance of 10 cm was noted. The Spread ability (S) can \nbe determined using the formula66,67. \nS= (m \u00d7 L)/T,\nWhere S\u2013Spread ability;\nm - Weight binds to the upper glass slide,\nL - Length budged on a glass slide\nT - Time is taken.\nResults obtained are given in Table No. 10. The cream was \nfound to be easily spreadable.\nDye solubility test\nThis method was applied from the work of Dhase and \nTeam in the year 201466. In this test, a small sample is mixed \nwith a water-soluble dye and observed under the microscope. \nIf the continuous phase appears red, the cream is O/W (Oil in \nWater) type as the water is in the external phase, and the dye \nwill dissolve in it to give color. If the scattered globules appear \nred and continuous phase colorless, they are W/O (Water in \nTable 3. Microbial Test.\nTable 4. Thermal stability determination.\nTable 5. Accelerated Stability Studies.Puja Saha, Jayashree Bhowmick, Anupam Saha\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1913\nOil) type. Likewise, if an oil-soluble dye such as Scarlet red or \nSudan III is put on to an emulsion and the continuous phase \nappears red, it is w/o emulsion. Following the procedure, red \ncolor was observed; hence, it was O/W type of cream66.\nDilution test\nThis method was applied from the work of Dhase and \nTeam in the year 201466. In this test, the cream is diluted ei-\nther with oil or water. If the cream is o/w type and diluted with \nwater, it will remain stable as water is the dispersion medium, \nbut if it is diluted with oil, the cream will break as oil and water \nare not miscible. Oil in water emulsion can be diluted with an \naqueous solvent, whereas water in oil emulsion can be diluted \nwith an oily liquid. Following the procedure, it was found to be \nO/W type of cream as because the obtained product was sta-\nble66.The cream was the o/w type of emulsion. Due to the base \nmaterial, the proper addition of surfactants to its proper quan-\ntity, and the proper combination of all the excipients, it was \nstable. The proper ratio of all ingredients of excipients with the \nactive ingredients also reasons for the stability. During the for-\nmulation, the oil phase and water phase are mixed, and it was \nalso responsible for the stability of that cream.\nAfter the formulation of cream by checking all these diffe-\nrent evaluation parameters, the 4 formulated creams showed \ngood homogeneity when the creams were observed by touch \nand visual test. The color and physical appearance (color & \nodor) were not changed during storage; it may happen due to \npreservatives' helpful addition.\nAll the individual pH noted for the formulated herbal \ncreams were F1 - 6.1, F2 - 5.7, F3 - 5.6, F4 - 5.9. The formu-\nlation F3 has shown the reading, which was matching to the \nTable 6. Formulation 1.\nTable 7. Formulation 2.\nTable 8. Formulation 3.Formulation and organoleptic evaluation[UdMO1] of Poly[UdMO2] Herbal Cream of Punica, Neem, Carrot & Jamun as Active Ingredients1914\nskin pH. As per the result, it was found that Trial F3 has better \nconsistency of formulation of cream in the combination of di-fferent excipients in their quantities.\nThe prepared formulations showed no affirmation of pha-\nse separation, had good spread ability and had good consis-tency during the study period. Stability parameters like visual appearance, texture, viscosity, and fragrance of the formula-tions reflected no significant variation during the study period. The prepared formulations showed an acceptable pH range that was approximately pH 5.6; it confirms the compatibility of the formulations with skin secretions.\nConclusions\nIn this project work, the selected active ingredients are \nPunica leaf extract, carrot powder, Jamun powder, and neem oil. These all ingredients are cheap and readily available in the market, including all these ingredients, the selected exci-pients-beeswax, grape seed oil, almond oil, stearic acid, lanolin as base material; Sodium benzoate as a preservative; Cetyl alcohol as emollient and surfactants; peppermint oil as a fla-voring agent for all type of formulation like F1, F2, F3 & F4. F3 stood out to be the better formulation concerning results obtained.\nFrom the existing examination and acquired results, it \ncould be concluded that it's possible to broaden poly natural cream containing natural extracts with anti-oxidants belon-gings, which may be  formulated to act as a barrier or to defend skin and make cosmetic cream.\nAcknowledgment\nThe authors would like to thank Mr. Mayukh Jana (Asso-\nciate Professor, Department of Pharmaceutics, Bharat Tech-\nnology, Uluberia) to help during this investigation.\nSource of Funding\nNil\nConflict Of Interest\nNilBibliographic references\n1. W atson REB, Ogden S, Cotterell LF, et al. A cosmetic 'anti-age-\ning' product improves photoaged skin: a double-blind, ran-\ndomized controlled trial. Br J Dermatol. 2009;161(2):419-426.doi:10.1111/j.1365-2133.2009.09216.x\n2.\nK\naur IP, Kapila M, Agrawal R. Role of novel delivery systems\nin developing topical anti-oxidants as therapeutics to combatphotoageing. Ageing Res Rev. 2007;6(4):271-288. doi:10.1016/j.arr.2007.08.006\n3.\nMatangi SP\n, Mamidi SA, Gulshan MD, Raghavamma STV, Na-\ndendla RR. Formulation and Evaluation of Anti Aging Poly Herbal Cream. Int J Pharm Sci Rev Res. 2014;24(22):133-136.\n4.\n Sar\naf S, Kaur C. Phytoconstituents as photoprotective nov-\nel cosmetic formulations. Pharmacogn Rev. 2010;4(7):1.doi:10.4103/0973-7847.65319\n5.\nDr\naelos ZD, Thaman LA, eds. Cosmetic Formulation of Skin Care \nProducts. In: Cosmetic Formulation of Skin Care Products. 0 ed.CRC Press; 2005:25-26. doi:10.3109/9781420020854-5\n6.\nChat\ntopadhyay PK. Herbal Cosmetics & Ayurvedic Medicines\n(EOU). In: Herbal Cosmetics & Ayurvedic Medicines (EOU). 3rdRevised Edition. Niir Project Consultancy Services; 2013. https://books.google.co.in/books?id=cuCoDAAAQBAJ&printsec=front-cover&source=gbs_ge_summary_r&cad=0#v=onepage&q&f=-false\n7.\nRus\nsell R. Cosmetics Use. In: Encyclopedia of Body Image and\nHuman Appearance. Elsevier; 2012:366-371. doi:10.1016/B978-0-12-384925-0.00058-4\n8.\n Dat\nta HS, Paramesh R. Trends in aging and skin care: Ayurve-\ndic concepts. J Ayurveda Integr Med. 2010;1(2):110-113.doi:10.4103/0975-9476.65081\n9.\nK\numar D, Rajora G, Parkash O, Himanshu, Antil M, Kumar V. Herb-\nal cosmetics: An overview. Int J Adv Sci Res. 2016;1(4):36-41.\n10.\n Mishr\na A, Mishra A, Chattopadhyay P. Herbal Cosmeceuticals for \nPhotoprotection from Ultraviolet B Radiation: A Review. Trop JPharm Res. 2011;10(3). doi:10.4314/tjpr.v10i3.7\n11.\n Geesin JC\n, Darr D, Kaufman R, Murad S, Pinnell SR. Ascorbic\nacid specifically increases type I and type III procollagen mes-senger RNA levels in human skin fibroblast. J Invest Dermatol.1988;90(4):420-424. doi:10.1111/1523-1747.ep12460849\n12.\n Dureja H, K\naushik D, Gupta M, Kumar V, Lather V. Cosmeceuti-\ncals: An emerging concept. Indian J Pharmacol. 2005;37(3):155.doi:10.4103/0253-7613.16211\nTable 9. Formulation 4.\nTable 10. Spread ability Test.Puja Saha, Jayashree Bhowmick, Anupam Saha\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1915\n13. R ajvanshi A, Sharma S, Khokra SL, Sahu RK, Jangde R. Formu-\nlation and evaluation of Cyperus rotundus and Cucumis sativus\nbased herbal face cream. Pharmacologyonline. 2011;2:1238-1244.\n14.\n Sar\naf S, Ashawat MS., Baghel M. Herbal Cosmetics: \"Trends in\nSkin Care Formulation.\" Pharmacogn Rev. 2009;3(5):82-89.\n15.\n Visw\nanatha G, Venkataranganna M, Prasad N, Ashok G. Evalua-\ntion of anti-epileptic activity of leaf extracts of Punica granatumon experimental models of epilepsy in mice. J Intercult Ethno-pharmacol. 2016;5(4):415. doi:10.5455/jice.20160904102857\n16.\n Basiri S. E\nvaluation of anti-oxidant and antiradical properties of\nPomegranate (Punica granatum L.) seed and defatted seed ex-tracts. J Food Sci Technol. 2015;52(2):1117-1123. doi:10.1007/s13197-013-1102-z\n17.\n W\nang D, \u00d6zen C, Abu-Reidah IM, et al. Vasculoprotective Ef-\nfects of Pomegranate (Punica granatum L.). Front Pharmacol.2018;9:544. doi:10.3389/fphar.2018.00544\n18.\n Jurenka JS. Ther\napeutic applications of pomegranate (Pu-\nnica granatum L.): a review. Altern Med Rev J Clin Ther.2008;13(2):128-144.\n19.\n Lee \nC-J, Chen L-G, Liang W-L, Wang C-C. Multiple Activities\nof Punica granatum Linne against Acne Vulgaris. Int J Mol Sci.2017;18(1):141. doi:10.3390/ijms18010141\n20.\n F\nellah B, Bannour M, Rocchetti G, Lucini L, Ferchichi A. Phenolic\nprofiling and anti-oxidant capacity in flowers, leaves and peelsof Tunisian cultivars of Punica granatum L. J Food Sci Technol.2018;55(9):3606-3615. doi:10.1007/s13197-018-3286-8\n21.\n Lei F\n, Zhang XN, Wang W, et al. Evidence of anti-obesity effects of \nthe pomegranate leaf extract in high-fat diet induced obese mice. Int J Obes. 2007;31(6):1023-1029. doi:10.1038/sj.ijo.0803502\n22.\n Mohajer S, T\naha RM, Azmi SZ. Phytochemical screening and po-\ntential of natural dye colourant from pomegranate (Punica grana-tum L.). Pigment Resin Technol. 2016;45(1):38-44. doi:10.1108/PRT-10-2014-0100\n23.\n K\nato K, Vo PHT, Furuyashiki T, Kamasaka H, Kuriki T. Co-ingestion \nof whole almonds and almond oil with carbohydrate suppressespostprandial glycaemia in mice in an insulin-dependent and in-sulin-independent manner. J Nutr Sci. 2019;8:e25. doi:10.1017/jns.2019.22\n24.\n Mericli F\n, Becer E, Kabaday\u0131 H, et al. Fatty acid composition and\nanti-cancer activity in colon carcinoma cell lines of Prunus dulcis seed oil. Pharm Biol. 2017;55(1):1239-1248. doi:10.1080/13880209.2017.1296003\n25.\n Musarr\na-Pizzo M, Ginestra G, Smeriglio A, Pennisi R, Sciorti-\nno MT, Mandalari G. The Anti-microbial and Antiviral Activityof Polyphenols from Almond (Prunus dulcis L.) Skin. Nutrients.2019;11(10):2355. doi:10.3390/nu11102355\n26.\n F\nranklin LM, Mitchell AE. Review of the Sensory and Chemical\nCharacteristics of Almond (Prunus dulcis) Flavor. J Agric FoodChem. 2019;67(10):2743-2753. doi:10.1021/acs.jafc.8b06606\n27.\n Ahmad Z. The uses and properties of almond oil. ComplementTher Clin Pr\nact. 2010;16(1):10-12. doi:10.1016/j.ctcp.2009.06.015\n28.\n Barreca D\n, Nabavi SM, Sureda A, et al. Almonds (Prunus Dulcis\nMill. D. A. Webb): A Source of Nutrients and Health-PromotingCompounds. Nutrients. 2020;12(3):672. doi:10.3390/nu12030672\n29.\n Buckle J\n. Clinical aromatherapy. Therapeutic uses for essential\noils. Adv Nurse Pract. 2002;10(5):67-68, 88.\n30.\n Lardos A. The botanical materia medica of the Iatrosophikon\u2014Acollection of prescriptions from a monas\ntery in Cyprus. J Ethno-\npharmacol. 2006;104(3):387-406. doi:10.1016/j.jep.2005.12.035\n31.\n Simon D\n, Nobbe S, N\u00e4geli M, et al. Short- and long-term effects of \ntwo emollients on itching and skin restoration in xerotic eczema.Dermatol Ther. 2018;31(6):e12692. doi:10.1111/dth.12692\n32.\n Gajer\na HP, Gevariya SN, Hirpara DG, Patel SV, Golakiya BA. An-\nti-diabetic and anti-oxidant functionality associated with phenolic constituents from fruit parts of indigenous black jamun (Syzygi-um cumini L.) landraces. J Food Sci Technol. 2017;54(10):3180-3191. doi:10.1007/s13197-017-2756-8\n33.\n Aqil F\n, Gupta A, Munagala R, et al. Antioxidant and Antiprolifera-\ntive Activities of Anthocyanin/Ellagitannin-Enriched Extracts FromSyzygium cumini L. (Jamun , the Indian Blackberry). Nutr Cancer.2012;64(3):428-438. doi:10.1080/01635581.2012.65776634.\n  Jagetia GC , Baliga MS, Venkatesh P. Influence of Seed Extract of\nSyzygium Cumini (Jamun) on Mice Exposed to Different Doses of \u03b3-radiation. J Radiat Res (Tokyo). 2005;46(1):59-65. doi:10.1269/jrr.46.59\n35.\n A\nyyanar M, Subash-Babu P. Syzygium cumini (L.) Skeels: a re-\nview of its phytochemical constituents and traditional uses. Asian Pac J Trop Biomed. 2012;2(3):240-246. doi:10.1016/S2221-1691(12)60050-1\n36.\n Benherlal \nPS, Arumughan C. Chemical composition and in vi-\ntro anti-oxidant studies on Syzygium cumini fruit: Compositionand anti-oxidant studies on S. cumini fruit. J Sci Food Agric.2007;87(14):2560-2569. doi:10.1002/jsfa.2957\n37.\n Gajer\na HP, Gevariya SN, Patel SV, Golakiya BA. Nutritional profile \nand molecular fingerprints of indigenous black jamun (Syzygiumcumini L.) landraces. J Food Sci Technol. 2018;55(2):730-739.doi:10.1007/s13197-017-2984-y\n38.\n Sehw\nag S, Upadhyay R, Das M. Optimization and multivariate\naccelerated shelf life testing (MASLT) of a low glycemic wholejamun (Syzygium cumini L.) confection with tailored quality andfunctional attributes. J Food Sci Technol. 2018;55(12):4887-4900. doi:10.1007/s13197-018-3423-4\n39.\n Ahmed R, T\nariq M, Hussain M, et al. Phenolic contents-based\nassessment of therapeutic potential of Syzygium cuminileaves extract. Bakhsh A, ed. PLOS ONE. 2019;14(8):e0221318.doi:10.1371/journal.pone.0221318\n40.\n P\n\u00e9rez Guti\u00e9rrez RM, Hern\u00e1ndez Luna H, Hern\u00e1ndez Garrido S. An-\ntioxidant Activity Of Tagetes Erecta Essential Oil. J Chil Chem Soc. 2006;51(2):883-886. doi:10.4067/S0717-97072006000200010\n41.\n Singh YP\n, Dwivedi R, Dwivedi SV. Effect of biofertilizers and  grad-\ned dose of nitrogen on growth and flower yield of calendula  (Cal-lendula officinalis)\n ; 8 (2): 957-958. Plant Arch. 2008;8(2):957-\n958.\n42.\n K\narabacak \u00c7E, Karabacak H. Factors Affecting Carotenoid\nAmount In Carrots (Daucus Carota). E-J New World Sci Acad.2019;14(2):29-39. doi:10.12739/NWSA.2019.14.2.5A0113\n43.\n Dos\nti MP, Mills JP, Simon PW, Tanumihardjo SA. Bioavailability of \n\u03b2-carotene (\u03b2C) from purple carrots is the same as typical orange carrots while high-\u03b2C carrots increase \u03b2C stores in Mongoliangerbils (Meriones unguiculatus). Br J Nutr. 2006;96(2):258-267.doi:10.1079/BJN20061562\n44.\n Bothr\na Nursery. Neem Tree. Bothra Nursery. Published 2015. Ac-\ncessed 2 December, 2020. http://www.bothranursery.com/prod-uct/forest-and-roadside-plants/neem-tree/\n45.\n Alr\navat Products. The Magnificent Neem Tree. Top-Tree-House\nDesigns Tree House Designs. Published 10 May, 2016. Ac-cessed 2 December, 2020. https://toptreehouse.wordpress.com/2016/05/10/30/\n46.\n Alzohair\ny MA. Therapeutics Role of Azadirachta indica (Neem)\nand Their Active Constituents in Diseases Prevention and Treat-ment. Evid Based Complement Alternat Med. 2016;2016:1-11.doi:10.1155/2016/7382506\n47.\n P\naul R, Prasad M, Sah NK. Anti-cancer biology of Azadirachta\nindica L (neem): A mini review. Cancer Biol Ther. 2011;12(6):467-476. doi:10.4161/cbt.12.6.16850\n48.\n Zanuncio JC\n, Mour\u00e3o SA, Mart\u00ednez LC, et al. Toxic effects of the\nneem oil (Azadirachta indica) formulation on the stink bug pred-ator, Podisus nigrispinus (Heteroptera: Pentatomidae). Sci Rep.2016;6(1):30261. doi:10.1038/srep30261\n49.\n Lakshmi T\n, Krishnan V, Rajendran R, Madhusudhanan N. Aza-\ndirachta indica\n : A \nherbal panacea in dentistry - An update. Phar-\nmacogn Rev. 2015;9(17):41. doi:10.4103/0973-7847.156337\n50.\n P\natel SM, Nagulapalli Venkata KC, Bhattacharyya P, Sethi G, Bi-\nshayee A. Potential of neem ( Azadirachta indica L.) for preven-tion and treatment of oncologic diseases. Semin Cancer Biol.2016;40-41:100-115. doi:10.1016/j.semcancer.2016.03.002\n51.\n Ashokhan S, Othman R, Abd R\nahim MH, Karsani SA, Yaacob JS.\nEffect of Plant Growth Regulators on Coloured Callus Forma-tion and Accumulation of Azadirachtin, an Essential Biopesti-cide in Azadirachta indica. Plants. 2020;9(3):352. doi:10.3390/plants9030352Formulation and organoleptic evaluation[UdMO1] of Poly[UdMO2] Herbal Cream of Punica, Neem, Carrot & Jamun as Active Ingredients1916\n52. Gomes S A, Paula AR, Ribeiro A, et al. Neem oil increases the ef-\nficiency of the entomopathogenic fungus Metarhizium anisopliae\nfor the control of Aedes aegypti (Diptera: Culicidae) larvae. Para-sit Vectors. 2015;8(1):669. doi:10.1186/s13071-015-1280-9\n53.\n Moga M, B\u0103lan A, Anas\ntasiu C, Dimienescu O, Neculoiu C, Gavri\u0219\nC. An Overview on the Anticancer Activity of Azadirachta indica(Neem) in Gynecological Cancers. Int J Mol Sci. 2018;19(12):3898. doi:10.3390/ijms19123898\n54.\n Jeba Malar TRJ\n, Antonyswamy J, Vijayaraghavan P, et al. In-vi-\ntro phytochemical and pharmacological bio-efficacy studies onAzadirachta indica A. Juss and Melia azedarach Linn for anti-can-cer activity. Saudi J Biol Sci. 2020;27(2):682-688. doi:10.1016/j.sjbs.2019.11.024\n55.\n Yilmaz Y\n, Toledo RT. Oxygen radical absorbance capacities of\ngrape/wine industry by-products and effect of solvent typeon extraction of grape seed polyphenols. J Food Compos Anal.2006;19(1):41-48. doi:10.1016/j.jfca.2004.10.009\n56.\n Shi J\n, Yu J, Pohorly JE, Kakuda Y. Polyphenolics in Grape Seeds\u2014\nBiochemistry and Functionality. J Med Food. 2003;6(4):291-299.doi:10.1089/109662003772519831\n57.\n Shiv\nananda Nayak B, Dan Ramdath D, Marshall JR, Isitor G, Xue\nS, Shi J. Wound-healing Properties of the Oils of Vitis viniferaand Vaccinium macrocarpon: Wound Healing Activity Of GrapeAnd Cranberry Oils. Phytother Res. 2011;25(8):1201-1208.doi:10.1002/ptr.3363\n58.\n Micheli L, Mat\ntoli L, Maidecchi A, Pacini A, Ghelardini C, Di Cesare \nMannelli L. Effect of Vitis vinifera hydroalcoholic extract againstoxaliplatin neurotoxicity: in vitro and in vivo evidence. Sci Rep.2018;8(1):14364. doi:10.1038/s41598-018-32691-w\n59.\n Chao C\nY, Mani MP, Jaganathan SK. Engineering electrospun\nmulticomponent polyurethane scaffolding platform comprisinggrapeseed oil and honey/propolis for bone tissue regeneration.Mishra YK, ed. PLOS ONE. 2018;13(10):e0205699. doi:10.1371/journal.pone.020569960.\n  Leparmar ai PT, Sinz S, Kunz C, et al. Transfer of total phenols\nfrom a grapeseed-supplemented diet to dairy sheep and goatmilk, and effects on performance and milk quality. J Anim Sci.2019;97(4):1840-1851. doi:10.1093/jas/skz046\n61.\n Oh \nJY, Park MA, Kim YC. Peppermint Oil Promotes Hair\nGrowth without Toxic Signs. Toxicol Res. 2014;30(4):297-304.doi:10.5487/TR.2014.30.4.297\n62.\n McK\nay DL, Blumberg JB. A review of the bioactivity and potential \nhealth benefits of peppermint tea (Mentha piperita L.). Phytother Res. 2006;20(8):619-633. doi:10.1002/ptr.1936\n63.\n Chumpitazi \nBP, Kearns GL, Shulman RJ. Review article: the phys-\niological effects and safety of peppermint oil and its efficacy inirritable bowel syndrome and other functional disorders. Aliment Pharmacol Ther. 2018;47(6):738-752. doi:10.1111/apt.14519\n64.\n Sanders ER. Aseptic Labor\natory Techniques: Plating Methods. J\nVis Exp. 2012;(63):3064. doi:10.3791/3064\n65.\n Hanle\ny BP, Bains W, Church G. Review of Scientific Self-Exper-\nimentation: Ethics History, Regulation, Scenarios, and ViewsAmong Ethics Committees and Prominent Scientists. Rejuvena-tion Res. 2019;22(1):31-42. doi:10.1089/rej.2018.2059\n66.\n Dhase A\nS, Khadbadi SS, Saboo SS. Formulation and Evaluation\nof Vanishing Herbal Cream of Crude Drugs. Am J Ethnomedicine. 2014;1(5):313-318.\n67.\n Chen MX, Ale\nxander KS, Baki G. Formulation and Evaluation of An-\ntibacterial Creams and Gels Containing Metal Ions for Topical Ap-plication. J Pharm. 2016;2016:1-10. doi:10.1155/2016/5754349\nReceived: 1 May 2021\nAccepted: 4 July 2021Puja Saha, Jayashree Bhowmick, Anupam Saha\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1917\nPurificaci\u00f3n parcial de p\u00e9ptidos del veneno de escorpi\u00f3n Hadruroides charcasus  \n(Karsch, 1879) con actividad antimicrobiana\nPartial purification of peptides from the scorpion venom Hadruroides charcasus  (Karsch, \n1879) with antimicrobial activity\nOrlando P\u00e9rez-Delgado1, Clara Andrea Rincon-Cort\u00e9s2, Nohora Ang\u00e9lica Vega-Castro3, Edgar Antonio Reyes-Monta\u00f1o4, Marcela G\u00f3mez-Garz\u00f3n5\nDOI. 10.21931/RB/2021.06.03.6\nResumen: Los venenos de muchas especies de escorpiones son fuentes ricas en componentes biol\u00f3gicamente activos, como los \np\u00e9ptidos antimicrobianos, biomol\u00e9culas que a\u00fan no han sido estudiados del veneno de Hadruroides charcasus. El objetivo de este art\u00edculo es evaluar la actividad antimicrobiana de los p\u00e9ptidos parcialmente purificados del veneno del escorpi\u00f3n Hadruroides. asus. A partir de 15,46 mg de prote\u00edna total del veneno del escorpi\u00f3n H. charcasus se purificaron parcialmente sus p\u00e9ptidos por medio de cromatograf\u00eda de filtraci\u00f3n en gel empleando sephadex G-75, consecutivo a una cromatograf\u00eda de intercambio i\u00f3nico en CM-Sephadex C-25. El peso molecular estimado de los p\u00e9ptidos se determin\u00f3 mediante electroforesis PAGE-SDS-Tris-Tricina al 15% y la evaluaci\u00f3n de la actividad antibacteriana y antif\u00fangica se emple\u00f3 el m\u00e9todo de microdiluci\u00f3n y Kirby-Bauer con cepas de Escherichia coli ATCC 25922, Staphylococcus aureus ATCC 29213, Pseudomonas aeruginosa ATCC 27853 y Candida albicans ATCC 10231. En la cromatograf\u00eda de filtraci\u00f3n en gel se obtuvieron 5 fracciones, de lo cual, la fracci\u00f3n IV present\u00f3 una concentraci\u00f3n m\u00ednima inhibitoria de 3,6 mg/mL en S. aureus ATCC 29213 y en C. albicans ATCC 10231. De la cromatograf\u00eda de intercambio se obtuvieron 7 fracciones, destacando la fracci\u00f3n OPDIV-5 con p\u00e9ptidos de 4 kDa; 5 kDa; 5,5 kDa y 6,4 kDa que present\u00f3 actividad antimicrobiana frente S. aureus ATCC 29213, E. coli ATCC 25922, P. aeruginosa ATCC 27853, C. albicans ATCC 10231.El veneno del escorpi\u00f3n H. charcasus presenta p\u00e9ptidos de naturaleza cati\u00f3nica con actividad antibacteriana y antif\u00fangica, seg\u00fan su actividad en las cepas evaluadas.\nPalabras clave: Antibacteriano, antif\u00fangico, cromatograf\u00eda de filtraci\u00f3n, cromatograf\u00eda de intercambio i\u00f3nico, electroforesis.Abstract: Venoms of many scorpion species are rich sources of biologically active components, such as antimicrobial peptides, \nbiomolecules that have not yet been studied from Hadruroides charcasus venom. The aim of this article is to evaluate the antimicrobial \nactivity of partially purified peptides from the venom of the scorpion Hadruroides charcasus. asus. From 15.46 mg of total protein from H. charcasus scorpion venom, its peptides were partially purified by gel filtration chromatography using sephadex G-75, followed by ion exchange chromatography on CM-Sephadex C-25. The estimated molecular weight of the peptides was determined by 15% PAGE-SDS-Tris-Tricine electrophoresis and the evaluation of antibacterial and antifungal activity used the microdilution and Kirby-Bauer methodwith strains of Escherichia coli ATCC 25922, Staphylococcus aureus ATCC 29213, Pseudomonas aeruginosa ATCC 27853 and Candida albicans ATCC 10231. In gel filtration chromatography, 5 fractions were obtained, of which fraction IV showed a minimum inhibitory\nconcentration of 3.6 mg/mL in S. aureus ATCC 29213 and C. albicans ATCC 10231. From the exchange chromatography, 7 fractions\nwere obtained, highlighting the OPDIV-5 fraction with peptides of 4 kDa; 5 kDa; 5.5 kDa and 6.4 kDa that presented antimicrobialactivity against S. aureus ATCC 29213, E. coli ATCC 25922, P. aeruginosa ATCC 27853, C. albicans ATCC 10231. H. charcasus scorpion venom presents peptides of cationic nat\nKey words: Antibacterial, antifungal, filtration chromatography, ion exchange chromatography, electrophoresis.RESEARCH / INVESTIGACI\u00d3N\nIntroducci\u00f3n\nLa resistencia a los antimicrobianos es un problema de \nsalud mundial tanto en medicina humana como veterinaria \ndonde los agentes antimicrobianos han sido ampliamente uti-lizados para tratar enfermedades bacterianas, por ejemplo, Escherichia coli es un microorganismo comensal com\u00fan en personas y animales con ciertas cepas que son pat\u00f3genas y se consideran excelentes indicadores de resistencia a los an-timicrobianos\n1.\nTambi\u00e9n se conoce que Pseudomonas aeruginosa es una \nbacteria metab\u00f3licamente vers\u00e1til que puede causar una amplia gama de infecciones oportunistas graves y a menudo muestran resistencia adaptativa, debido al estado de creci-miento de la bacteria en el paciente, incluida la capacidad del microorganismo para crecer como biopel\u00edcula y adem\u00e1s que conducen a la mortalidad\n2. Otro de los ejemplos son reportes \nde Staphylococcus aureus, que est\u00e1 relacionada con su capa-\ncidad para adquirir y diseminar determinantes resistentes a los antimicrobianos en la naturaleza. En un estudio donde fueron positivos para S. aureus por PCR, m\u00e1s del 50% mostraron re-sistencia fenot\u00edpica a la meticilina, como tambi\u00e9n resistencia registrada a ampicilina y penicilina en un 96,7%, rifampicina y clindamicina 80%, oxacilina 73,3% y eritromicina 70%. Tambi\u00e9n S. aureus revel\u00f3 susceptibilidad variable a imipenem 96,7%,levofloxacina 86,7%, cloranfenicol 83,3%, cefoxitina 76,7%, ci-profloxacina 66,7%, gentamicina 63,3%, tetraciclina y sulfame-toxazol-trimetoprima 56,7 % y vancomicina con doxiciclina enPurificaci\u00f3n parcial de p\u00e9ptidos del veneno de escorpi\u00f3n Hadruroides charcasus  (Karsch, 1879) con actividad antimicrobiana\nPartial purification of peptides from the scorpion venom Hadruroides charcasus  (Karsch, 1879) with antimicrobial activity\n1 Universidad Se\u00f1or de Sip\u00e1n.  \n2 Universidad de Ciencias Aplicadas y Ambientales. \n3 Universidad Nacional de Colombia.\n4Fundaci\u00f3n Universitaria de Ciencias de la Salud.\nCorresponding author: operezd@gmail.com1918\nOrlando P\u00e9rez-Delgado, Clara Andrea Rincon-Cort\u00e9s, Nohora Ang\u00e9lica Vega-Castro, Edgar Antonio Reyes-Monta\u00f1o, Marcela G\u00f3mez-Garz\u00f3n\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nun 50%3. Por otro lado, pero casos relacionados a las bacterias, \nson las infecciones f\u00fangicas, las cuales han aumentado signifi-\ncativamente, lo que contribuye a la morbilidad y la mortalidad, como es el caso de Candida albicans caracterizado como un \npat\u00f3geno oportunista, a pesar de las terapias antif\u00fangicas, ha llegado a ser letal por el aumento de la resistencia antimicro-biana, con una resistencia significativa frente a fluconazol e itraconazol a diferencia de otros antif\u00fangicos que se reporta sensibilidad tales como para ketoconazol y anfotericina B\n4.\nRazones en las que actualmente se ha identificado un \nmecanismo intr\u00ednseco y la adquisici\u00f3n de resistencia antimi-crobiana en muchas cepas bacterianas que son de gran im-portancia cl\u00ednica por tal motivo ha puesto en grave peligro el uso de antibi\u00f3ticos y tambi\u00e9n ha provocado la propagaci\u00f3n de microbios que son resistentes a los medicamentos efectivos de primera elecci\u00f3n\n5, Tal es as\u00ed que la bacterias tanto gram \npositivas como gram negativas han logrado esta resistencia gracias a elementos gen\u00e9ticos m\u00f3viles capaces de insertarse y transferirse de bacteria a bacteria\n6. Casos que han derivado \nel desarrollo de varios estudios experimentales, donde se ha logrado determinar que principios bioactivos tales como p\u00e9pti-dos presentes en los venenos de escorpi\u00f3n logran desarrollar actividad antimicrobiana in vitro frente a diferentes microorga-nismos de importancia en el \u00e1rea de salud. Identificando acti-vidades, independiente tanto de la especie de escorpi\u00f3n como del microorganismo evaluado. Uno de los reportes, es a partir del veneno del escorpi\u00f3n Tityus discrepans con una amplia actividad antibacteriana frente a bacterias Gram positivas y Gram negativas\n7, mientras que los venenos de los escorpiones \nUrodacus yaschenkoi martensii8 y Buthus martensii9 y Androc-\ntonus amoeruxi son m\u00e1s efectivos  con bacterias Gram positi-vas, entre ellas S. aureus meticilino resistente (MRSA), sien-do una cepa multidrogorresistente\n10. Y el veneno de Vaejovis \npunctatus con actividad antif\u00fangica11. Caracter\u00edsticas tomadas \nen cuenta para determinar si el veneno de H. charcasus posee efecto antimicrobiano sobre microorganismos de inter\u00e9s cl\u00edni-co, se plante\u00f3 en el presente estudio cuyo objetivo es, evaluar la actividad antimicrobiana de p\u00e9ptidos aislados del veneno del escorpi\u00f3n H. charcasus frente E. coli ATCC 25922, S. aureus \nATCC 29213, P. aeruginosa ATCC 27853 y C. albicans ATCC 10231.\nMateriales y m\u00e9todos\nEscorpiones y veneno\nLos espec\u00edmenes de H. charcasus fueron recolectados en \nel distrito de Chongoyape, ubicado en la latitud 6\u00ba 37\u2019 40.0\u2019\u2019 y longitud 79\u00ba 25\u2019 21.4\u2019\u2019, Chiclayo (Per\u00fa), la identificaci\u00f3n de la especie por el Dr. Jos\u00e9 Ochoa C\u00e1mara, de la Universidad Na-cional de San Antonio Abad del Cusco el veneno se obtuvo por estimulaci\u00f3n el\u00e9ctrica\n12, luego se recolect\u00f3 en tubos eppen-\ndorf, se liofiliz\u00f3 y se conserv\u00f3 a -20 \u00b0C hasta su uso, de 60 escorpiones se obtuvo 1,2 ml de veneno soluble.\nPurificaci\u00f3n de p\u00e9ptidos del veneno de \nH. charcasus\nPara la cromatograf\u00eda de filtraci\u00f3n en gel, se aplicaron \n15,46 mg de prote\u00edna del veneno a una columna de Sepha-\ndex G-75 (1,5 cm x 50 cm) en presencia de buffer acetato de amonio al 20 mmol/l, pH 4,7, a una velocidad de flujo de 500 \n\u03bc\nl/4min13, las fracciones con actividad antimicrobiana, luego se \nsepararon por cromatograf\u00eda de intercambio i\u00f3nico, en una co-lumna de carboximetilcelulosa (CM-Sephadex C-25; 2 cm x 9 cm), equilibrada y desarrollada en presencia de buffer acetato de amonio, pH 4,7; con un gradiente continuo de 0 mol/l a 0,5 mol/l\n14.\nComposici\u00f3n del veneno y sus fracciones mediante m\u00e9todo \nde electroforesis PAGE-SDS-Tricina\nEn condiciones desnaturalizantes fue realizada la electro-\nforesis SDS-PAGE basados en el m\u00e9todo de Sch\u00e4gger y Von \nJagow15, en una corrida a corriente constante y en gel de po-\nliacrilamida al 15,0%. Para el buffer de corrida se emple\u00f3 so-luci\u00f3n de tris-tricina-dodecil sulfato de sodio y como est\u00e1ndar de prote\u00ednas de rango bajo pre-te\u00f1idas (2 a 40 kDa) Thermo Scientific\nTM.\nLos geles obtenidos, se revelaron por el m\u00e9todo de tinci\u00f3n \ncon plata16. Finalmente, se registraron digitalmente los geles \nen el equipo ChemiDocTM XRS, Bio-Rad.\nActividad antimicrobiana del veneno H. charcasus\nEn esta parte de la metodolog\u00eda, se emple\u00f3 el m\u00e9todo de \nmicrodiluci\u00f3n17,18 con la fracci\u00f3n IV y V de la cromatograf\u00eda de \nfiltraci\u00f3n, se realizaron diluciones dobles seriadas, con un to-\ntal de siete concentraciones, para la fracci\u00f3n IV de 3,6 mg/ml hasta 0,056 mg/mL y para la fracci\u00f3n V de 6,3 mg/mL hasta 0,098 mg/ml.\nPara la preparaci\u00f3n del in\u00f3culo, se emplearon cepas de E. \ncoli ATCC 25922, S. aureus ATCC 29213, P. aeruginosa ATCC \n27853 y C. albicans ATCC 10231, se realizaron ensayos por tri-plicado sembrando 50 \n\u03bc\nL del in\u00f3culo conteniendo 5x104 UFC/\nml en cada pocillo, luego se repartieron 50 \u03bc\nl de cada diluci\u00f3n, \ndespu\u00e9s se incubaron a 37 \u00baC durante 24 horas. Los controles positivos fueron caldo m\u00e1s in\u00f3culo, y los controles negativos solo caldo. El crecimiento del control positivo se determin\u00f3 por un bot\u00f3n de crecimiento de \u2265 2 mm o una turbidez definida.  Se emple\u00f3 el m\u00e9todo Kirby-Bauer\n19, para la sensibilidad antimi-\ncrobiana de las fracciones de la cromatograf\u00eda de intercambio i\u00f3nico, en las placas de agar Mueller-Hinton se sembraron con un in\u00f3culo de 1 a 2 x 10\n8 UFC/ml.\nEl an\u00e1lisis de los datos se realiz\u00f3 usando el complemento \nMegaStat para Excel, con an\u00e1lisis varianza para determinar si los componentes proteicos purificados del veneno y las con-centraciones empleadas si influyeron en el crecimiento micro-biano.\nResultados\nA partir de 15,46 mg de prote\u00ednas total del veneno de H. \ncharcasus, se analizaron por el m\u00e9todo de cromatograf\u00eda de filtraci\u00f3n en gel Sephadex G-75, obteniendo cinco fracciones bien definidas de la cromatograf\u00eda de filtraci\u00f3n Sephadex G-75 (Figura 1), en el an\u00e1lisis del gel de electroforesis de Poliacrila-mida (PAGE-SDS-Tricina), present\u00f3 un n\u00famero variable ban-das proteicas para cada uno de las fracciones purificadas, asi-mismo revel\u00f3 para la fracci\u00f3n IV la presencia de siete bandas con rango de pesos moleculares de 9,8 kDa, 12 kDa, 15,1 kDa, 18,3 kDa, 24,3 kDa, 30,2 kDa y 37,5 kDa y para la fracci\u00f3n V se obtuvieron 6 bandas con rango de peso entre 5,1 kDa, 5,7 kDa, 7,9 kDa, 8,5 kDa, 10,7 kDa y 12,2 kDa respectivamente (Figura 2).\nEn la evaluaci\u00f3n de la actividad antimicrobiana se muestra \nen la fracci\u00f3n IV present\u00f3 una concentraci\u00f3n m\u00ednima inhibitoria (CMI) de 3,6 mg/mL para las cepas de S. aureus ATCC 29213 y C. albicans ATCC 10231 y para las cepas de E. coli ATCC 25922 y P. aeruginosa ATCC 27853 no present\u00f3 inhibici\u00f3n total de1919\ncrecimiento a las concentraciones empleadas respectivamen-\nte (Figura 3), para la fracci\u00f3n V no present\u00f3 inhibici\u00f3n total de crecimiento microbiano (Figura 4). \nEn la figura 5 se muestra el an\u00e1lisis de la separaci\u00f3n de \nlos p\u00e9ptidos por el m\u00e9todo de cromatograf\u00eda de intercambio i\u00f3nico Sephadex C-25, se recuperaron al menos siete fraccio-nes (OPDIV-1 a OPDIV-7), de los cuales al evaluar la actividad antimicrobiana mediante el m\u00e9todo Kirby-Bauer, las cepas de E. coli ATCC 25922, S. aureus ATCC 29213, C. albicans ATCC10231 y P. aeruginosa ATCC 27853 presentaron sensibilidadfrente a la fracci\u00f3n OPDIV-5 a concentraci\u00f3n de 1\n\u03bcg/mL (tabla\n1) y en el an\u00e1lisis de P\nAGE-SDS-Tricina, la fracci\u00f3n OPDIV-5\npresent\u00f3 cuatro bandas de pesos moleculares de 7,5 kDa,6,4 kDa, 5,5 kDa y 4 kDa (Figura 6).Discusi\u00f3n \nActualmente los escorpiones son bien conocidos por \nsus picaduras peligrosas y sus venenos se han aplicado en la medicina tradicional, principalmente en Asia y \u00c1frica y se ha convertido en una valiosa fuente de mol\u00e9culas biol\u00f3gicamente activas desde nuevos antibi\u00f3ticos hasta posibles terapias con-tra el c\u00e1ncer\n20, adem\u00e1s de acuerdo a los reportes publicados \nel veneno de escorpi\u00f3n posee una fuente abundante p\u00e9ptidos antimicrobianos nuevos y potentes tanto como naturales o mo-dificados qu\u00edmicamente con la finalidad ampliar su capacidad antibacteriana, antif\u00fangica, antiparasitaria\n21,22. Los p\u00e9ptidos an-\ntimicrobianos son uno de los componentes del sistema inmune innato en una amplia gama de organismos eucariotas como hu-\nFigure 1. Purificaci\u00f3n de las \nprote\u00ednas del veneno de H. char-casus por cromatograf\u00eda de fil-traci\u00f3n en columna Sephadex G-75 con las fr\nacciones (F-I, F-II,\nF-III, F-IV y F-V).\nFigura 2. Electroforesis en gel de poliacri -\nlamida con SDS - Tricina (PAGE-SDS-Trici -\nna) de las prote\u00ednas purificadas, en el carril M \nmarcador de peso molecular (2 \u2013 40 KDa) \n(marcador de peso molecular) y fracciones de prote\u00ednas (FI - FV) y veneno total (VT).Purificaci\u00f3n parcial de p\u00e9ptidos del veneno de escorpi\u00f3n Hadruroides charcasus (Karsch, 1879) con actividad antimicrobiana\nPartial purification of peptides from the scorpion venom Hadruroides charcasus (Karsch, 1879) with antimicrobial activity1920\nmanos, plantas e insectos y que juegan un papel vital en los pri-\nmeros mecanismos de defensa inmune contra los pat\u00f3genos23.\nEn el presente estudio se logr\u00f3 determinar la presencia \np\u00e9ptidos antimicrobianos del veneno de H. charcasus esto es algo propio del veneno de los escorpiones tal como se eviden-cia de otras especies de escorpiones que demostraron e inclu-sive aislar p\u00e9ptidos con potencial acci\u00f3n antimicrobiana como las pantininas de Pandinus imperator\n24, los p\u00e9ptidos TsAP-1 y \nTsAP-2 de Tityus serrulatus25 p\u00e9ptidos del veneno de Scorpio \nmaurus palmatus26 y los p\u00e9ptidos HsAp del escorpi\u00f3n Hetero-\nmetrus spinifer27.\nAdem\u00e1s, en el presente trabajo mediante el empleo de \ndos m\u00e9todos cromatogr\u00e1ficos, uno de filtraci\u00f3n en gel y otro de intercambio i\u00f3nico permiti\u00f3 separar las prote\u00ednas en fraccio-nes. Cuando el veneno crudo se separ\u00f3 por columna Sephadex G-75, se obtuvieron 5 fracciones, siendo evidente la fracci\u00f3n IVcon actividad antibacteriana frente a S. aureus y antif\u00fangicafrente a C. albicans. Esta fracci\u00f3n relacionada con su activi-dad antimicrobiana fue purificada y analizada en CM Sephadex C-25, obteniendo 7 fracciones, de los cuales la quinta fracci\u00f3ndenominada OPDIV-5 contiendo p\u00e9ptidos con pesos molecula-res de 7,5 kDa, 6,4 kDa, 5,5 kDa y 4 kDa mediante el m\u00e9todoKirby\u2013Bauer se encontr\u00f3 actividad frente E. coli, S. aureus, P.\naeruginosa y C. albicans.\nEsto es caracter\u00edstico de los p\u00e9ptidos antimicrobianos que \npor lo general presentan peso molecular por debajo de 8,5 kDa como es el caso de las familias de las opiscorpinas del escor-pi\u00f3n Opistophthalmus carinatus\n28, vejonina de Vaejovis mexi-canus29 Heterinas de Heterometrus spinifer30, demostrando su \namplia acci\u00f3n antibacteriana y antif\u00fangica.\nLa purificaci\u00f3n parcial de la fracci\u00f3n OPDIV-5 conformado \npor cuatro p\u00e9ptidos con carga positiva que al interactuar con las cargas negativas de la CM Sephadex C-25, solo se pudo eluir aumentando la concentraci\u00f3n del acetato de amonio, adem\u00e1s, present\u00f3 actividad antibacteriana como actividad an-tif\u00fangica. esto se debi\u00f3 al emple\u00f3 mayor concentraci\u00f3n del bu-ffer acetato de amonio con la finalidad de recolectar p\u00e9ptidos de naturaleza cati\u00f3nica y con mayor carga.\nLos p\u00e9ptidos antimicrobianos del veneno de escorpi\u00f3n son \np\u00e9ptidos anfip\u00e1ticos cargados positivamente, se manifiesta en los p\u00e9ptidos meuVAP-6, meuAP-18-1 y meuPep34 de Meso-buthus eupeus\n31, inclusive en los p\u00e9ptidos VpAmp de Vaejovis \npunctatus, por presentar acci\u00f3n contra bacterias gram positi-vas y contra C. albicans y frente a bacterias gram negativas\n32, \nsimilar fue para los p\u00e9ptidos UyCT de Urodacus yaschenkoi por tener predilecci\u00f3n por bacterias gram positivas\n33, p\u00e9ptido anti-\nbacteriano de Centruroides margaritatus34.\nConclusiones\nEl veneno de H. charcasus, posee p\u00e9ptidos de naturaleza \ncati\u00f3nica, con capacidad antimicrobiana frente a microorganis-mos pat\u00f3genos de importancia cl\u00ednica.\nFigura 3. Actividad antimicrobiana de la fracci\u00f3n IV frente Escherichia coli ATCC 25922, Staphylococcus aureus ATCC 29213, Pseudomonas aeruginosa ATCC 27853 y Candida albicans ATCC 10231.Orlando P\u00e9rez-Delgado, Clara Andrea Rincon-Cort\u00e9s, Nohora Ang\u00e9lica Vega-Castro, Edgar Antonio Reyes-Monta\u00f1o, Marcela G\u00f3mez-Garz\u00f3n\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1921\nFigura 4. Actividad antimicrobiana de la fracci\u00f3n V frente a Escherichia coli ATCC 25922, Staphylococcus aureus ATCC 29213, \nPseudomonas aeruginosa ATCC 27853 y Candida albicans ATCC 10231.\nFigura 5. Purificaci\u00f3n de la fracci\u00f3n IV (Sephadex G-75) con acci\u00f3n antimicrobiana, en cromatograf\u00eda de intercambio i\u00f3nico \nCarboximetilcelulosa Sephadex C-25.\nAgradecimientos\nAgradecimiento al Grupo de Investigaci\u00f3n en Prote\u00ednas de \nla Universidad Nacional de Colombia sede en Bogot\u00e1, por la \noportunidad para el desarrollo del trabajo de investigaci\u00f3n.Conflicto de inter\u00e9s \nLos autores declaramos no presentar conflictos de inte-\nr\u00e9s potenciales con respecto a la investigaci\u00f3n, autor\u00eda y/o pu-\nblicaci\u00f3n de este art\u00edculo.Purificaci\u00f3n parcial de p\u00e9ptidos del veneno de escorpi\u00f3n Hadruroides charcasus (Karsch, 1879) con actividad antimicrobiana\nPartial purification of peptides from the scorpion venom Hadruroides charcasus (Karsch, 1879) with antimicrobial activity\n1922\nReferencias bibliogr\u00e1ficas\n1. Y assin AK, Gong J, Kelly P, Lu G, Guardabassi L, Wei L, et al. An-\ntimicrobial resistance in clinical Escherichia coli isolates from\npoultry and livestock, China. PLoS ONE. 2017; 12(9): e0185326.DOI: http://dx.doi.org/10.1371/journal.pone.0185326\n2.\nGellatl\ny SL, Hancock REW. Pseudomonas aeruginosa: new in-\nsights into pathogenesis and host defenses. Path and Dis. 2013;67: 159 \u2013 173. DOI: http://dx.doi.org/10.1111/2049-632X.12033\n3.\nAkanbi OE, Njom HA, F\nri J, Otigbu AC, Clarke AM. Antimicrobi-\nal Susceptibility of Staphylococcus aureus Isolated from Rec-reational Waters and Beach Sand in Eastern Cape Province ofSouth Africa. Int. J. Environ. Res. Public Health. 2017; 14: 1001.DOI: http://dx.doi.org/10.3390/ijerph14091001\n4.\n Zaidi K\nU, Mani A, Parmar R, Thawani V. Antifungal Sus-\nceptibility Pattern of Candida albicans in Human Infec-tions. Op. Biol. Scie. J. 2018; 4: 1 \u2013 6. DOI: http://dx.doi.org/10.2174/2352633501804010001\n5.\nR\nayamajhi N, Bin Cha S, Yoo HS. Antibiotics Resistances: Past,\nPresent and Future. J. Biomed Res. 2010; 11(2): 65 \u2013 80. Dis-ponible en: http://www.jbr.or.kr/journal/article.php?code=5527 \n6.P\nartridge SR, Kwong SM, Firth N, Jensen SO. Mobile genetic\nelements associated with antimicrobial resistance. Clin Mi-crobiol Rev 2018; 31: e00088-17. DOI: https://doi.org/10 .1128/CMR.00088-177.\nD\u00edaz P , D\u2019Suze G, Salazar V, Sevcik C, Shannon JD, Sherman NE,\nFox JW. Antibacterial activity of six novel peptides from Tityusdiscrepans scorpion venom. A fluorescent probe study of micro-bial membrane Na+ permeability changes. Toxicon. 2009; 54: 802 \u2013 817. DOI: http://dx.doi.org/10.1016/j.toxicon.2009.06.014\n8.\n Luna-R\nam\u00edrez K, Quintero-Hern\u00e1ndez V, Vargas-Jaimes L, Batis-\nta CVF, Winkel, KD, Possani LD. Characterization of the venomfrom the Australian scorpion Urodacus yaschenkoi: Molecularmass analysis of components, cDNA sequences and peptideswith antimicrobial activity. Toxicon. 2013; 63: 44 \u2013 54. DOI: http://dx.doi.org/10.1016/j.toxicon.2012.11.017\n9.\nde la Salud R, R\noss M, Luque LE. Synthesis of analogs of pep-\ntides from Buthus martensii scorpion venom with potential an-tibiotic activity. Peptides. 2015; 68: 228 \u2013 232. DOI: http://dx.doi.org/10.1016/j.peptides.2014.10.008\n10.\n Almaa\nytah A, Farajallah A, Abualhaijaa A, Al-Balas Q. A3, a Scor-\npion Venom Derived Peptide Analogue with Potent Antimicrobi-al and Potential Antibiofilm Activity against Clinical Isolates ofMulti-Drug Resistant Gram Positive Bacteria. Molecules. 2018;23: 1603. DOI: http://dx.doi.org/10.3390/molecules23071603\n11.\n R\nam\u00edrez S, Jim\u00e9nez JM, Rivas B, Corzo G, Possani LD, Becerril B, \nOrtiz E. Peptides from the scorpion Vaejovis punctatus with broad antimicrobial activity. Peptides. 2015; 73: 51\u201359. DOI: http://dx.doi.org/10.1016/j.peptides.2015.08.014\nTabla 1. Sensibilidad anti-\nmicrobiana de las fracciones de la cromatogr\naf\u00eda de inter -\ncambio i\u00f3nico (OPDIV-1 a OP -\nDIV-7) frente a Escherichia coli\n ATCC 25922, Staphylo-\ncoccus aureus ATCC 29213, P\nseudomonas aeruginosa \nATCC 27853 y Candida albi-cans ATCC 10231.\nFigur\na 6. Electroforesis \nen gel de poliacrilamida con SDS - Tricina (PA -\nGE-SDS-Tricina) de las prote\u00ednas purificadas de la fr\nacci\u00f3n IV de la \nCromatograf\u00eda de inter -\ncambio i\u00f3nico Sephadex C-25, en el carril M mar -\ncador de peso molecular\n(2 \n\u2013 40 kDa) y fr acci\u00f3n\nOPDIV\n-5.Orlando P\u00e9rez-Delgado, Clara Andrea Rincon-Cort\u00e9s, Nohora Ang\u00e9lica Vega-Castro, Edgar Antonio Reyes-Monta\u00f1o, Marcela G\u00f3mez-Garz\u00f3n\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1923\n12. P \u00e9rez-Delgado O, Espinoza-Vergara M, Castro-Vega N,\nReyes-Monta\u00f1o E. Evaluaci\u00f3n preliminar de actividad antibac-\nteriana in vitro del veneno de escorpi\u00f3n Hadruroides charcasus(Karsch, 1879) contra Pseudomonas aeruginosa y Staphylococ-cus aureus. Rev C M\u00e9d HNAAA, 2019; 12(1): 6 - 12. DOI: https://doi.org/10.35434/rcmhnaaa.2019.121.477\n13.\n P\nossani LD, Dent MAR, Martin BM, Maelicke A, Svendsen I. The\namino terminal sequence of several toxins from the venom ofthe Mexican scorpion Centruroides noxius Hoffmann. CarlsbergRes. Commun. 1981; 46: 207\u2013214. DOI: https://doi.org/10.1007/BF02906498\n14.\n R\namirez-Dominguez ME, Olamendi-Portugal T, Garcia U, Garcia\nC, Arechiga H, Possani LD. Cn11, the first example of a scorpiontoxin that is a true blocker of Na(+) currents in crayfish neurons.The Journal of experimental biology. 2002; 205(Pt 6):869-76. Di-sponible en: https://jeb.biologists.org/content/205/6/869\n15.\n Sch\u00e4gger\n, H.; von Jagow, G. 1987. Tricine\u2013sodium dodecyl sulfate \npolyacrylamide gel electrophoresis for the separation of proteins in the range from 1\u2013100 kDalton. Anal. Biochem. 166: 368 \u2013 379.DOI: https://doi.org/10.1016/0003-2697(87)90587-2\n16.\n She\nvchenko A, Wilm M, Vorm O, Mann M. Mass Spectrometric\nSequencing of Proteins from Silver-Stained Polyacrylamide GelsAnal. Chem. 1996; 68: 850 -858. DOI: https://doi.org/10.1021/ac950914h\n17.\n National Commit\ntee for Clinical Laboratory Standards. Methods\nfor dilution antimicrobial susceptibility tests for bacteria thatgrow aerobically. Document M07-A10. 2015. NCCLS, Wayne, PA.Recuperado a partir de: https://clsi.org/\n18.\n Clinical and Labor\natory Standars Institute. Reference Method for \nBroth Dilution Antifungal Susceptibility Testing Yeasts. Aprpro-ved Est\u00e1ndar - tercera edici\u00f3n 2008 (28)14: 1 - 25. M27-A3. Recu-perado a partir de: https://clsi.org/\n19.\n Clinical and Labor\natory Standars Institute. Performance Stan-\ndards for Antimicrobial Disk Susceptibility Tests DocumentM02-A13. 2018. NCCLS, Wayne, PA. Recuperado a partir de:https://clsi.org/\n20.\n Or\ntiz E, Gurrola GB, Ferroni E, Possani LD. Scorpion venom\ncomponents as potential candidates for drug Development.Toxicon. 2015; 93: 125e135. DOI: http://dx.doi.org/10.1016/j.toxi-con.2014.11.233\n21.\n Luna-R\namirez K, Tonk M, Rahnamaeian M, Vilcinskas A. Bioactivi-\nty of Natural and Engineered Antimicrobial Peptides from Venom of the Scorpions Urodacus yaschenkoi and U. manicatus. Toxins.2017; 9 (22): 1 -12. DOI: http://dx.doi.org/10.3390/toxins9010022\n22.\n Borges A, Delgado O\n, Silva S, Bravo J, Velasco E, Rojas L, De Sou-\nsa L. Aislamiento y caracterizaci\u00f3n de un p\u00e9ptido del veneno deTityus gonzalespongai (scorpiones, buthidae) con actividad sobre promastigotes de Leishmania (Leishmania) mexicana. Saber.2013; 25 (4): 399 \u2013 413. Disponible en: http://ve.scielo.org/scielo.php?script=sci_arttext&pid=S1315-01622013000400008&l-ng=es\n23.\n ar\nazi S. Scorpion venom as antimicrobial peptides (AMPs): A re-\nview article. Inter. arab. J. anti. age. 2015; 5(3): 1 \u2013 5. Disponible en: https://imed.pub/ojs/index.php/IAJAA/article/view/1384/113424.\n  Z eng CC, Zhou L, Shi W, Luo X, Zhang L, Nie Y, Wang J, Wu Sh,\nCao B, Cao H. Three new antimicrobial peptides from the scorpion Pandinus imperator. Peptides. 2013; 45: 28\u201334. DOI: http://dx.doi.org/10.1016/j.peptides.2013.03.026\n25.\n Guo X, Ma Ch, Du Q, W\nei R, Wang L, Zhou M, Chen T, Shaw C. Two \npeptides, TsAP-1 and TsAP-2, from the venom of the Brazilianyellow scorpion, Tityus serrulatus: Evaluation of their antimicro-bial and anticancer activities. Biochimie. 2013; 95: 1784 \u2013 1794.DOI: http://dx.doi.org/10.1016/j.biochi.2013.06.003\n26.\n Harrison PL, Abdel-R\nahman MA, Strong PN, Tawfik MM, Miller\nK. Characterisation of three alpha-helical antimicrobial peptidesfrom the venom of Scorpio maurus palmatus Toxicon. 2016;117:30 - 6. DOI: http://dx.doi.org/10.1016/j.toxicon.2016.03.014\n27.\n Nie Y\n, Chun X, Zeng XC, Yang Y, Luo F, Luo X, Wua S, Zhang L,\nZhou J. A novel class of antimicrobial peptides from the scorpion Heterometrus spinifer. Peptides. 2012; 38: 389 \u2013 394. DOI: http://dx.doi.org/10.1016/j.peptides.2012.09.012\n28.\n Zhu S, T\nytgat J. The scorpine family of defensins: gene structure, \nalternative polyadenylation and fold recognition. Cell. Mol. LifeSci. 2004; 61: 1751e1763. DOI: https://doi.org/10.1007/s00018-004-4149-1\n29.\n Hernandez-\nAponte CA, Silva-Sanchez J, Quintero-Hernandez V,\nRodriguez-Romero A, Balderas C, Possani LD, Gurrola GB. Vejo-vine, a new antibiotic from the scorpion venom of Vaejovis mex-icanus. Toxicon. 2011; 57: 84e92. DOI: https://doi.org/10.1016/j.toxicon.2010.10.008\n30.\n W\nu S, Nie Y, Zeng X-C, Cao H, Zhang L, Zhou L, Yang Y, Luo X, Liu \nY. Genomic and functional characterization of three new venompeptides from the scorpion Heterometrus spinifer. Peptides. 2014; 53: 30-41. DOI: https://doi.org/10.1016/j.peptides.2013.12.012\n31.\n Bar\nadaran M, Jalali A, Naderi M, Galehdari H. A Novel Defen-\nsin-Like Peptide Associated with Two Other New Cationic Antimi-crobial Peptides in Transcriptome of the Iranian Scorpion Venom. 2017; 21(3): 190 \u2013 196. DOI: https://dx.doi.org/10.18869%2Facad-pub.ibj.21.3.190\n32.\n R\nam\u00edrez S, Jim\u00e9nez JM, Rivas B, Corzo G, Possani LD, Becerril B, \nOrtiz E. Peptides from the scorpion Vaejovis punctatus with broad antimicrobial activity. Peptides. 2015; 73: 51\u201359. DOI: http://dx.doi.org/10.1016/j.peptides.2015.08.014\n33.\n Luna K, Sani MA, Sil\nva J, Jim\u00e9nez JM, Reyna F, Winkel KD, Wright \nCE, Possani LD, Separovic F. Membrane interactions and biolog-ical activity of antimicrobial peptides from Australian scorpion.Bioch. et Bioph. Ac. 2014; 1838: 2140 \u2013 2148. DOI: http://dx.doi.org/10.1016/j.bbamem.2013.10.022\n34.\n Riv\nera C, Flores L, Pantigoso C, Escobar E. Aislamiento y carac-\nterizaci\u00f3n de un p\u00e9ptido antibacteriano del veneno de Centruroi-des margaritatus. Rev. Per. Biol. 2010; 17(1): 129 -132. Disponible en: http://www.scielo.org.pe/pdf/rpb/v17n1/a16v17n1.pdf\nReceived: 10 marzo 2021\nAccepted: 5 julio 2021Purificaci\u00f3n parcial de p\u00e9ptidos del veneno de escorpi\u00f3n Hadruroides charcasus (Karsch, 1879) con actividad antimicrobiana\nPartial purification of peptides from the scorpion venom Hadruroides charcasus (Karsch, 1879) with antimicrobial activity1924\nBeatriz Pern\u00eda, Hector Urbina, Meralys Gonz\u00e1lez, Lucia Sena, Yanet Villasana, Leopoldo Naranjo-Brice\u00f1o\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nTrametes coccinea  IDEA, un hongo s\u00faper productor de lacasa aislado de \nun lago natural de asfalto: Tolerancia y biotransformaci\u00f3n de hidrocarburos \npolic\u00edclicos arom\u00e1ticos\nTrametes coccinea  IDEA, a super laccase-producer fungus isolated from a natural asphalt \nlake: Tolerance and biotransformation of aromatics polycyclic hydrocarbons\nBeatriz Pern\u00eda1,2*, Hector Urbina1,3, Meralys Gonz\u00e1lez1, Lucia Sena1, Yanet Villasana4, Leopoldo Naranjo-Brice\u00f1o1,5\nDOI. 10.21931/RB/2021.06.03.7\nResumen: Los hidrocarburos polic\u00edclicos arom\u00e1ticos (HPAs) son compuestos t\u00f3xicos que no se degradan f\u00e1cilmente bajo \ncondiciones naturales tales como fen\u00f3menos f\u00edsicos (fotooxidaci\u00f3n, volatilizaci\u00f3n), qu\u00edmicos (intercambio i\u00f3nico, complejaci\u00f3n, \ntransformaci\u00f3n) y biol\u00f3gicos (degradaci\u00f3n por microorganismos aut\u00f3ctonos) que adem\u00e1s, dependen de la temperatura, humedad \ny niveles de ox\u00edgeno. El objetivo del presente trabajo fue aislar, identificar y caracterizar fenot\u00edpicamente hongos hidrocarbono \ncl\u00e1sticos de ambientes extremos que sean capaces de tolerar HPAs, tales como Trametes coccinea IDEA, que se aisl\u00f3 del \nLago de asfalto natural de Guanoco en Venezuela. A fin de estudiar su tolerancia a los HPAs, el hongo se expuso a diferentes \nconcentraciones de naftaleno, fenantreno y pireno (0, 2.5, 25, 50, 100, 200, 400, 800 y 1600 mg/L). Posteriormente, en ensayo \nen medio de cultivo l\u00edquido, se procedi\u00f3 a estudiar el efecto de los HPAs sobre la actividad de enzimas del sistema enzim\u00e1tico \nde degradaci\u00f3n de lignina (SEDL), as\u00ed como sobre la posible variaci\u00f3n en los niveles de toxicidad empleando Lactuca sativa \ncomo bioindicador. Los resultados mostraron una mayor tolerancia al pireno, seguido por el naftaleno y fenantreno. Se observ\u00f3 \nuna fuerte inducci\u00f3n de la actividad lacasa en presencia de naftaleno (167.96 U/mgP) y pireno (124.89 U/mgP) con respecto \nal control, mientras que con fenantreno se obtuvo una baja actividad (88.67 U / mgP). De manera interesante, se evidenci\u00f3 \nuna generaci\u00f3n de sub-productos m\u00e1s t\u00f3xicos cuando el naftaleno y el fenantreno fueron biotratados por el hongo, mientras \nque el nivel de toxicidad del pireno disminuy\u00f3 significativamente. T. coccinea IDEA tiene un alto potencial para ser utilizado en \nestrategias de biorremediaci\u00f3n de hidrocarburos, las cuales deben ser monitoreadas mediante an\u00e1lisis ecotoxicol\u00f3gicos para \ndetectar posibles variaciones de toxicidad de los productos parcialmente biotransformados.\nPalabras clave: Micorremediaci\u00f3n, biotransformaci\u00f3n, ecotoxicidad, HPAs.\nAbstract: Polycyclic aromatic hydrocarbons (HPAs) are toxic compounds that are not easily degraded under natural conditions. The \ngoal of the present study was to isolate, identify and phenotypically characterize hydrocarbonoclastic fungi from extreme environments \nthat are capable of tolerating HPAs, such as Trametes coccinea IDEA, that was isolated from the Natural Asphalt Lake of Guanoco \nin Venezuela. To study its tolerance to HPAs, the fungus was exposed to different concentrations of naphthalene, phenanthrene, and \npyrene (0, 2.5, 25, 50, 100, 200, 400, 800, and 1600 mg/L). Subsequently, in a test in a liquid culture medium, the effect of these HPAs \non the activity of enzymes of the lignin-degrading enzymes system (LDES) was studied, and the possible variations in toxicity levels \nusing Lactuca sativa as bioindicator. The results showed a high tolerance to pyrene, followed by naphthalene and phenanthrene. Strong \ninduction of laccase activity was observed at the presence of naphthalene (167.96 U/mgP) and pyrene (124.89 U/mgP) compared with \nthe control, while with phenanthrene a low activity was obtained (88.67 U / mgP). Interestingly, a generation of more toxic byproducts \nwas observed when naphthalene and phenanthrene were biotreated by the fungus, while the toxicity level of pyrene decreased \nsignificantly. T. coccinea IDEA has a high potential to be used in hydrocarbon bioremediation strategies, which must be monitored by \necotoxicological analysis to detect the possible toxicity levels variations in the partially biotransformed products.\nKey words: Mycoremediation, biotransformation, ecotoxicity, PAHs.RESEARCH / INVESTIGACI\u00d3N\nIntroducci\u00f3n\nLos hidrocarburos policiclicos arom\u00e1ticos (HPAs) son \ncompuestos de origen natural y antropog\u00e9nico, que se encuen-\ntran en el suelo, el aire y el agua. De estos compuestos, 16 \nhan sido considerados por la Environmental Protection Agency \n(EPA) como t\u00f3xicos, recalcitrantes y cancer\u00edgenos1,2. Adem\u00e1s, \nestos compuestos no se degradan f\u00e1cilmente bajo condiciones \nnaturales y su persistencia en el ambiente incrementa al au-\nmentar su peso molecular. Se ha reportado que los HPAs se encuentran en todos los componentes del medio ambiente y \nse bioacumulan en los organismos3.\nEs por ello, que se han sumado esfuerzos para encontrar \norganismos que sean capaces de tolerar y degradar estos com-\npuestos con la finalidad de emplearlos en nuevas estrategias \nbiotecnol\u00f3gicas de saneamiento ambiental. La biorremedia-\nci\u00f3n emplea organismos para degradar, detoxificar o biotrans-\nformar compuestos t\u00f3xicos y convertirlos en menos t\u00f3xicos o \n1 \u00c1rea de Energ\u00eda y Ambiente, Fundaci\u00f3n Instituto de Estudios Avanzados (IDEA), Caracas, Venezuela. \n2 Instituto de Investigaciones de Recursos Naturales, Facultad de Ciencias Naturales, Universidad de Guayaquil, Guayaquil, Ecuador. \n3 Division of Plant Industry, Florida Department of Agriculture, Gainesville, FL, USA.\n4Grupo Biomass to Bioresources, Universidad Regional Amaz\u00f3nica Ikiam, CP, Tena, Ecuador.\n5Grupo de Microbiolog\u00eda Aplicada, Universidad Regional Amaz\u00f3nica Ikiam, CP, Tena, Ecuador.\nCorresponding author: beatriz.pernias@ug.edu.ec1925\nTrametes coccinea  IDEA, un hongo s\u00faper productor de lacasa aislado de un lago natural de asfalto: Tolerancia y biotransformaci\u00f3n de hidrocarburos polic\u00edclicos arom\u00e1ticos\nTrametes coccinea  IDEA, a super laccase-producer fungus isolated from a natural asphalt lake: Tolerance and biotransformation of aromatics polycyclic hydrocarbons\ninocuos4. Dentro de dichos organismos, se ha demostrado que \nlos hongos cuentan con un sistema enzim\u00e1tico de degradaci\u00f3n \nde lignina (SEDL) que, por su baja especificidad de sustrato, \nes capaz de biotransformar eficientemente HPAs5. Dentro del \ngrupo de hongos, los hidrocarbonocl\u00e1sticos extrem\u00f3filos sur-\ngen como un grupo heterog\u00e9neo que vive de manera \u00f3ptima \nen condiciones extremas y tiene una alta capacidad de usar \nhidrocarburos como \u00fanica fuente de carbono y energ\u00eda5.\nEn este sentido, existen algunas especies de hongos ca-\npaces de tolerar y degradar estos hidrocarburos puesto que \nproducen extracelularmente enzimas que catalizan reacciones \noxidativas. Entre las enzimas con alto potencial en biocat\u00e1lisis \nambiental, han sido reportadas la citocromo P-4506, la lignina \nperoxidasa (LigP)7, la manganeso peroxidasa (MnP)8,9, la cloro-\nperoxidasa10, la lacasa (Lac)11 y las benzopireno hidroxilasa12.\nDentro de \u00e9stas exoenzimas oxidativas, se destacan las \nlacasas (EC 1.10.3.2), las cuales son enzimas glicosiladas, \nmulticobre, cuya funci\u00f3n es catalizar la oxidaci\u00f3n de compues-\ntos fen\u00f3licos, polifen\u00f3licos y aminas arom\u00e1ticas, mediante el \nacoplamiento con la reducci\u00f3n de ox\u00edgeno a agua13. Sin embar-\ngo, esta enzima presenta una amplia inespecificidad de sustra-\nto, por lo que puede oxidar una gran variedad de compuestos, \ntales como colorantes, pesticidas, disrruptores endocrinos e \nHPAs14. La lacasa ha sido utilizada a nivel industrial para el \nan\u00e1lisis de drogas, el blanqueamiento en la industria papelera \ny textil, la s\u00edntesis de pol\u00edmeros y en procesos de biorremedia-\nci\u00f3n y saneamiento de aguas residuales15. En el caso de los \nHPAs, se ha reportado que esta enzima es capaz de oxidar naf-\ntaleno, fenantreno, antraceno, benzopireno, 9 metilantraceno \ny 2 metilantraceno16.\nSin embargo, aunque estas enzimas son capaces de de-\ngradar hidrocarburos, en algunos casos, en el proceso de bio-\ntransformaci\u00f3n se podr\u00edan generar compuestos m\u00e1s t\u00f3xicos \nque los HPAs originales, por lo que deben realizarse pruebas \nde ecotoxicolog\u00eda a fin de verificar la posible generaci\u00f3n de \ncompuestos m\u00e1s t\u00f3xicos que el contaminante original17.\nEn la b\u00fasqueda de hongos que sean capaces de sintetizar \nestas enzimas para su uso potencial en procesos de degrada-\nci\u00f3n de hidrocarburos, se han aislado hongos de ambientes \nextremos, tales como el caso del Lago de Asfalto de Guanoco, \nubicado en el estado Sucre en Venezuela18. Este lago de asfalto \ntiene una superficie de 420 hect\u00e1reas, presenta una baja con-\ncentraci\u00f3n de nutrientes debido a que est\u00e1 conformado casi \nen su totalidad por asfalto y se caracteriza por contener 83% \ncarbono, 11% hidr\u00f3geno y 6% azufre19.\nEn la presente investigaci\u00f3n se aisl\u00f3 del Lago de Asfalto \nde Guanoco el hongo Trametes coccinea, el cual es un hon-\ngo de pudrici\u00f3n blanca, capaz de producir a nivel extracelular \nenzimas tales como celobiohidrolasas, glucanohidrolasas, \u03b2- \nglucosidasas, xilanasas, \u03b1-amilasa, lignina peroxidasa, manga-\nneso peroxidasa, fenoloxidasa20,21 y, adicionalmente, sintetiza \ngrandes cantidades de la enzima lacasa22. Tambi\u00e9n, se ha des-\ncrito que este hongo es capaz de degradar antraceno (67.5%), \npireno (31.1%)23, fenantreno (45.6%) y benzo[a]antraceno \n(90.1%) en 14 d\u00edas a una temperatura de 28\u00b0C24.\nLos objetivos principales de este trabajo fueron: i) aislar e \nidentificar un hongo con alta capacidad de degradar HPAs del \nLago de Asfalto de Guanoco, ii) determinar la tolerancia del \nhongo a distintas concentraciones de HPAs, iii) identificar cam-\nbios en la actividad de las enzimas lacasas ante su exposici\u00f3n \na distintos HPAs, y iv) analizar la variaci\u00f3n en la toxicidad de los \nHPAs tras su biotransformaci\u00f3n por el hongo.Materiales y m\u00e9todos\nAislamiento, caracterizaci\u00f3n taxon\u00f3mica e identificaci\u00f3n \nmolecular\nUn hongo Basidiomycota de identificaci\u00f3n desconocida, el \ncual fue adoptado en nuestro Laboratorio de Petromicrobiolo-\ng\u00eda como el Soldado Desconocido, fue aislado de una ra\u00edz de \nuna dicotiled\u00f3nea que se encontraban inmersa en medio del \nLago natural de Asfalto de Guanoco, ubicado en el estado Su-\ncre en Venezuela, al Norte de Am\u00e9rica del Sur (Figura 1). La \nra\u00edz se coloc\u00f3 en una bolsa pl\u00e1stica en oscuridad y fue con-\nservada en el laboratorio a +4oC. A los tres meses apareci\u00f3 el \nbasidiocarpo creciendo sobre la ra\u00edz del \u00e1rbol (Figura 2A). \nPara su aislamiento, se seccion\u00f3 un trozo del contexto del \nhongo en condiciones de esterilidad y se sembr\u00f3 en placas con \nmedio Power25 donde, tras sucesivos repiques, se obtuvo un \ncultivo ax\u00e9nico (Figura 2B). \nLa identificaci\u00f3n taxon\u00f3mica se realiz\u00f3 mediante la carac-\nterizaci\u00f3n de su morfolog\u00eda macro y microsc\u00f3pica (color del \nbasidiocarpo, hifas, conidias, clamidosporas, conidi\u00f3foros y \nc\u00e9lulas conidiog\u00e9nicas). La informaci\u00f3n fue recopilada en una \ndescripci\u00f3n y se compar\u00f3 con la literatura especializada.\nLa identificaci\u00f3n molecular de este organismo se reali-\nz\u00f3 inoculando esporas en medio MPPY seg\u00fan la metodolog\u00eda \npropuesta por Montenegro et al.26 y Naranjo et al.27 y fueron \nincubadas en un agitador a 30\u00b0C y 250 rpm durante 48 h. Pos-\nteriormente, el micelio fue recuperado por filtraci\u00f3n utilizando \nun filtro Nytal, se lav\u00f3 dos veces con NaCl al 0.9% (P/V), se \ncongel\u00f3 con nitr\u00f3geno l\u00edquido y se almacen\u00f3 a -80\u00b0C. Luego, \nse tomaron 300-500 mg de micelio, se pulveriz\u00f3 con nitr\u00f3ge-\nno l\u00edquido y se a\u00f1adieron 1 mL de tamp\u00f3n de rotura (0.18 M \nTris/HCl pH 8.2, 10 mM EDTA, 1% SDS) y 1 mL de fenol, se \nincub\u00f3 por 30 min a 50\u00b0C con agitaci\u00f3n en V\u00f3rtex cada 5 min. \nLuego, se extrajo el ADN gen\u00f3mico con fenol/CIA (fenol:clo-\nroformo:alcohol isoam\u00edlico, 25:24:1) y se repiti\u00f3 este procedi-\nmiento hasta que la interface qued\u00f3 limpia. El ADN gen\u00f3mico \nfue precipitado con 2.5 vol de etanol y 0.1 vol de 3M acetato de \nsodio (pH 3.2) y se conserv\u00f3 durante la noche a -20 oC. Al d\u00eda \nsiguiente, la muestra se centrifug\u00f3 a 14.000 rpm a RT, se hizo \nun lavado con ETOH al 70% y el ADN se resuspendi\u00f3 en buffer \nTris-EDTA (TE)28.\nPara la identificaci\u00f3n molecular se amplific\u00f3 por PCR la \nregi\u00f3n 26S rRNA, utilizando los cebadores: NL1(sentido): 5\u2019\u2026\nGCATATCAATAAGCGGAGGAAA AG\u20263\u2019 y NL4 (antisentido): \n5\u2019\u2026GGTCCGTGTTTCAAGACGG\u20263\u2019. Las reacciones de PCR se \nllevaron a cabo en un termociclador Applied Biosystems 2720 \nempleando una concentraci\u00f3n final de los deoxiribonucleo-\ntidos trifosfatos (dNTP\u2019s) de 0.25 mM y 100-250 ng de ADN \ngen\u00f3mico como molde. Las condiciones de PCR fueron las si-\nguientes: i) pre-desnaturalizaci\u00f3n a 95\u00b0C por 5 min, seguidos \npor 30 ciclos de ii) desnaturalizaci\u00f3n a 95\u00b0C por 5 min, iii) ani-\nllamiento a 52\u00b0C por 30 s, iv) extensi\u00f3n a 72\u00b0C por 1 min y, v) \nuna extensi\u00f3n final a 72\u00b0C por 7 min.\nEl producto de PCR obtenido (600 pb) fue doblemente pu-\nrificado utilizando el kit de purificaci\u00f3n Wizard Genomic DNA \nPurification Kit Promega (Madison, WI). Posteriormente, las \nmuestras de ADN fueron enviadas a secuenciar en UC Ber-\nkeley DNA Sequencing Facility (California, USA). El an\u00e1lisis \nin silico de las secuencias de nucle\u00f3tidos se realiz\u00f3 utilizan-\ndo los programas DNASTAR Programs (DNASTAR, Inc., UK), \nBLASTN29 utilizando formato FASTA30.1926\nFigura 1. Localizaci\u00f3n espacial de Lago de Asfalto de Guanoco.\nFigura 2. Soldado Desconocido creciendo en una ra\u00edz de dicotiled\u00f3nea inmersa en el Lago natural de Asfalto de Guanoco (A). \nCultivo ax\u00e9nico del Soldado Desconocido en medio Power (B).\nPrueba de tolerancia del hongo a los HPAs en medio \ns\u00f3lido BSM\nPara determinar la tolerancia del hongo a los HPAs, en \nprincipio, se utiliz\u00f3 como base el medio salino b\u00e1sico (BSM)31. \nlos HPAs se diluyeron inicialmente en una mezcla de 20 ml de \nacetona/ tween 80/agua y se ajustaron a las siguientes con-\ncentraciones: 12.5, 25, 50, 100, 200, 400, 800 y 1600 mg/L en \nmedio BSM. Cada 24 horas y durante 8 d\u00edas, se realizaron me-\ndiciones del di\u00e1metro de las colonias con un vernier calibrado \na fin de determinar su tasa de crecimiento.\u00cdndice de Tolerancia\nEl \u00edndice de tolerancia (IT) se determin\u00f3 a los 8 d\u00edas de in-\ncubaci\u00f3n del hongo con los diferentes HPAs a 30\u00b0C, mediante \nla siguiente ecuaci\u00f3n:\nDonde:\nLMt = es la longitud del micelio tratado con los HPAs.\nLRc = es la longitud del micelio control.Beatriz Pern\u00eda, Hector Urbina, Meralys Gonz\u00e1lez, Lucia Sena, Yanet Villasana, Leopoldo Naranjo-Brice\u00f1o\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1927\nPrueba de tolerancia del hongo a los HPAs en medio \nl\u00edquido BSM\nUna vez conocida la concentraci\u00f3n m\u00ednima inhibitoria de \nHPAs que no afectaba el crecimiento del hongo, se inocularon \n95 ml de medio BSM con 20x104 esporas de T. coccinea y se \nincubaron a 30\u00baC por 7 d\u00edas. Al d\u00eda 7 se procedi\u00f3 a a\u00f1adir 5 mg/L de cada uno de los HPAs (naftaleno, fenantreno y pireno) diluidos en una mezcla tween-acetona con un volumen final de 100 ml. Se utiliz\u00f3 como control en hongo en medio BSM con el diluente tween-acetona. Todos los experimentos se realizaron por triplicado. Se tomaron muestras a los d\u00edas 0, 1, 3 y 5.\nEfecto de los HPAs sobre la actividad enzim\u00e1tica de las \nenzimas extracelulares guaiacol peroxidasa, lignina \nperoxidasa, manganeso peroxidasa y lacasa\nPara determinar la actividad de la guaiacol peroxidasa \nse utiliz\u00f3 la metodolog\u00eda de Fielding y Hall (1978) citada por \nChaoui et al.\n32. La actividad de la enzima se determin\u00f3 siguien-\ndo el incremento en la absorbancia a 470 nm por la polime-rizaci\u00f3n  del Guaiacol. Utilizando el coeficiente de extinci\u00f3n (26.6/mM x cm) se llevaron a unidades de enzima por g de peso fresco, defini\u00e9ndose una unidad de enzima como la can-tidad de enzima que produce 1 \n\u03bc\nmol de tetraguaiacol en 1 min \na 25\u00b0C. Para llevar a cabo la reacci\u00f3n, se mezcl\u00f3 25 mM de buffer fosfato (pH 7) con 10 mM de H\n2O2, 9 mM de guaiacol y \n25 \n\u03bc\nl del cultivo enzim\u00e1tico.\nLa actividad de la LiP se midi\u00f3 siguiendo la metodolog\u00eda \npropuesta por Troller et al.33 y fue analizada mediante la oxida-\nci\u00f3n del alcohol veratr\u00edlico en una mezcla de reacci\u00f3n que con-ten\u00eda: alcohol veratr\u00edlico (20 mM) en un buffer 0.5 M de fosfato de sodio (pH 3.0), como agente oxidante per\u00f3xido de hidr\u00f3geno al 30 % y 0.025 mL del cultivo enzim\u00e1tico. La oxidaci\u00f3n del alcohol veratr\u00edlico fue monitoreada de 0-200 s por medio del incremento de la absorbancia a 310 nm. La unidad de actividad enzim\u00e1tica (U) se defini\u00f3 como: 1 \u03bcM alcohol veratr\u00edlico oxida-do por mL de sobrenadante en un min (\u03b5310 = 9.3 mM\n-1.cm-1)\nLa actividad de la MnP se determin\u00f3 seg\u00fan la metodolog\u00eda \npropuesta por Papinutti et al.34 y fue analizada por medio de la \noxidaci\u00f3n del rojo de fenol, en una mezcla de reacci\u00f3n consti-tuida por: 0.1 mL de rojo de fenol (0.1 %) en un buffer 0.5 M de fosfato de sodio (pH 5.0), cofactor 0.1 mL de sulfato de man-ganeso (1 mM) y 0.04 mL del cultivo enzim\u00e1tico. La oxidaci\u00f3n del rojo de fenol fue monitoreada de 0-200 s por medio del incremento de la absorbancia a 610 nm. La unidad de actividad enzim\u00e1tica (U) se defini\u00f3 como: 1 \u03bcM rojo de fenol oxidado por mL de sobrenadante en un min (\u03b5610 = 22.0 mM\n-1.cm-1).\nLa actividad de la Lac fue determinada seg\u00fan la meto-\ndolog\u00eda propuesta por Saparrat et al.35 siguiendo la oxidaci\u00f3n \ndel ABTS en una mezcla de reacci\u00f3n constituida por: 0.01 mL de ABTS (25 mM) en un buffer 0.1 M de tartrato de sodio (pH 5.0) y 0.1 mL del cultivo enzim\u00e1tico. La oxidaci\u00f3n del ABTS fue monitoreada de 0-200 s por medio del incremento de la absorbancia a 436 nm. La unidad de actividad enzim\u00e1tica (U) se defini\u00f3 como: 1 \u03bcM ABTS oxidado.\nEstimaci\u00f3n de prote\u00ednas totales\nLa concentraci\u00f3n de prote\u00ednas se estim\u00f3 en el sobrena-\ndante utilizando el m\u00e9todo de Bradford\n36 y como est\u00e1ndar BSA.\nActividad de la enzima lacasa en un zimograma\nPara observar la actividad de las isoenzimas de la lacasa \npor separado, se corri\u00f3 un gel PAGE al 12 % bajo condiciones \nno denaturalizantes y, posteriormente, se fij\u00f3 por 10 min con una soluci\u00f3n 30% metanol y 10% \u00e1cido ac\u00e9tico. El gel se in-cub\u00f3 en una soluci\u00f3n que conten\u00eda 5 mM de ABTS en buffer tartrato 0.5 M pH 5.0. Finalmente, se ti\u00f1o el gel con azul de coomasie para verificar el peso molecular de las isoenzimas y para confirmar que la diferencia en la actividad no era debido a la concentraci\u00f3n de la enzima sino a su activaci\u00f3n por los HPAs.\nActividad de enzimas peroxidasas en gel\nPara observar la actividad de las enzimas peroxidasas se uti-\nliz\u00f3 el mismo protocolo anterior para el ABTS s\u00f3lo que en este \ncaso, en vez de ABTS, se utiliz\u00f3 5 mM de Guaicol y 10 mM de H\n202.\nEnsayos de toxicidad empleando Lactuca sativa como \nbioindicador\nA fin de determinar variaciones en la toxicidad de los \ncompuestos antes y despu\u00e9s de haber sido biotratados con el \nhongo, se practic\u00f3 una prueba de toxicidad seg\u00fan el protocolo propuesto por la USEPA EPA 00/3-88-029. En primer lugar, se estandariz\u00f3 la concentraci\u00f3n de medio de cultivo a utilizar, partiendo de la premisa de utilizar una diluci\u00f3n a la cual ni el medio de cultivo BSM ni el medio BSM en presencia del hongo fuese t\u00f3xico. En pruebas previas se determin\u00f3 que la diluci\u00f3n \u00f3ptima del sobrenadante era 1:15. Todos los extractos se con-servaron durante la noche a -20\u00b0C previo a los ensayos con el fin de inactivar las enzimas ligninol\u00edticas. Se calcul\u00f3 el \u00cdndice Integral de Fitotoxicidad (IIF) utilizando la f\u00f3rmula propuesta por Pern\u00eda et al.\n17: \nDonde:SGM = n\u00famero de semillas germinadas de la muestra, es \nel promedio del n\u00famero de semillas germinadas en las cuatro r\u00e9plicas para cada tratamiento (n = 4).\nSGC = n\u00famero de semillas germinadas del control, es el \npromedio del n\u00famero de semillas germinadas en las cuatro r\u00e9plicas del testigo (n = 4).\nLRM = Longitud de la rad\u00edcula de la muestra, es el pro-\nmedio de la medici\u00f3n en cent\u00edmetros de las rad\u00edculas de 10 pl\u00e1ntulas por r\u00e9plica de cada tratamiento (n = 40).\nLRC = Longitud de la rad\u00edcula del control, es el promedio \nde la medici\u00f3n en cent\u00edmetros de las rad\u00edculas de 10 pl\u00e1ntulas por r\u00e9plica del testigo (n = 40).\nLHM = Longitud del hipoc\u00f3tilo de la muestra, es el pro-\nmedio de la medici\u00f3n en cent\u00edmetros de los hipoc\u00f3tilos de 10 pl\u00e1ntulas por r\u00e9plica de cada tratamiento (n = 40).\nLHC = Longitud del hipoc\u00f3tilo del control, es el promedio \nde la medici\u00f3n en cent\u00edmetros de los hipoc\u00f3tilos de 10 pl\u00e1ntu-las por r\u00e9plica del testigo (n = 40).\nEste \u00edndice muestra los resultados de -100 a +100 pudi\u00e9n-\ndose interpretar en t\u00e9rminos de porcentaje. Tambi\u00e9n permite observar no solo los efectos de inhibici\u00f3n de crecimiento (va-lores positivos), sino tambi\u00e9n los efectos de estimulaci\u00f3n de crecimiento (valores negativos).\nAn\u00e1lisis estad\u00edsticos\nPara el an\u00e1lisis estad\u00edstico se aplic\u00f3 una prueba de An-\nderson-Darling para verificar la distribuci\u00f3n normal de los \ndatos. Con la finalidad de analizar la homocedasticidad de los tratamientos se aplic\u00f3 una prueba de Levene. Para comparar entre las medias de crecimiento, concentraci\u00f3n de prote\u00ednas, actividad enzim\u00e1tica y crecimiento de las pl\u00e1ntulas se aplic\u00f3 una prueba ANOVA de una v\u00eda con test a posteriori de Dunnet o Tukey (p<0.05). Todas las pruebas estad\u00edsticas se realizaroncon el programa Minitab versi\u00f3n 19.Trametes coccinea  IDEA, un hongo s\u00faper productor de lacasa aislado de un lago natural de asfalto: Tolerancia y biotransformaci\u00f3n de hidrocarburos polic\u00edclicos arom\u00e1ticos\nTrametes coccinea  IDEA, a super laccase-producer fungus isolated from a natural asphalt lake: Tolerance and biotransformation of aromatics polycyclic hydrocarbons1928\nResultados\nLa caracterizaci\u00f3n taxon\u00f3mica y la identificaci\u00f3n molecular \ndel Soldado Desconocido determinaron que pertenece a la \nespecie Trametes coccinea\nEl hongo Basidiomycota creciendo en una ra\u00edz de una di-\ncotiled\u00f3nea fue exitosamente aislado a partir de su micelio \na\u00e9reo. La descripci\u00f3n taxon\u00f3mica del Soldado Desconocido \nfue la siguiente: colonias blancuzcas cuando est\u00e1n j\u00f3venes y a \nmedida que maduran se tornan amarillentas con pigmentaci\u00f3n \nanaranjada, crecen de forma zonada, superficial y con borde \nentero, algodonosas y superficiales (Figura 2B). Conidiog\u00e9ne-\nsis tretrica, enterobl\u00e1stica, baxautica. Las hifas son hialinas, \nde pared delgada y lisa, con f\u00edbulas ramificadas. Los conidi\u00f3-\nforos no est\u00e1n diferenciados. Conidios hialinos, cil\u00edndricos a \nglobosos, algunos con una ligera constricci\u00f3n central, con ex-\ntremos truncados cuando reci\u00e9n est\u00e1n escindidos de las hifas \ny con extremos redondeados cuando est\u00e1n maduros, de pared \ndelgada y lisa, sin g\u00fatulas, aseptados, excisi\u00f3n esquizol\u00edtica. \nClamidiosporas hialinas, obclavadas, solitarias, terminales a \nintercalares, algunas con un extremo truncado, de pared en-\ngrosada y lisa. Basidiocarpo, constituido por hifas esquel\u00e9ticas, \nhialinas, y sin septos (Figura 3).\nLa caracterizaci\u00f3n taxon\u00f3mica y la identificaci\u00f3n molecu-\nlar permitieron determinar que el Soldado Desconocido per-\ntenec\u00eda a la especie Pycnoporus sanguineus (L.) Murrill 1904, \nPolyporaceae, el cual actualmente ha sido re-clasificado como \nTrametes coccinea (Fr.) seg\u00fan Li y He38.\nTolerancia de T. coccinea  a los HPAs estudiados\nLos resultados mostraron que T. coccinea tiene toleran-\ncia al naftaleno y al pireno, a excepci\u00f3n del fenantreno el cual \nfue t\u00f3xico para el hongo a bajas concentraciones. En cuanto al \nnaftaleno pudimos observar un efecto t\u00f3xico a partir de 800 \nmg/L, donde el \u00edndice de tolerancia se redujo a 0.77 y 0.60 a \n800 y 1600 mg/L, respectivamente. El porcentaje de creci-\nmiento del hongo se redujo en el tratamiento con 800 mg/L a \n77.25% y 59.61% a 1600 mg/L (F = 148.71; p = 0.000).\nEl fenantreno gener\u00f3 una reducci\u00f3n de crecimiento del \nhongo a partir de 25 mg/L, con una disminuci\u00f3n de 78.43%, \n70.20%, 72.55%, 66.67%, 66.27% y 61.96% a 25, 50, 100-\n200, 400, 800 y 1600 mg/L, respectivamente (F = 70.50; p = 0.000). De la misma manera, el \u00edndice de tolerancia se redujo \nal aumentar la concentraci\u00f3n de fenantreno hasta 0.62 a 1600 \nmg/L.\nEl pireno fue el HPA menos t\u00f3xico para T. coccinea, ya que \nno present\u00f3 inhibici\u00f3n del crecimiento hasta los 800 mg/L de \npireno. Solo se apreci\u00f3 una ligera reducci\u00f3n a altas concentra-\nciones (1600 mg/L), donde hubo una disminuci\u00f3n significativa \ndel crecimiento de 20.78% (F = 70.50; p =  0.000), concomitan-\nte con una reducci\u00f3n del \u00edndice de tolerancia (0.78).\nUna vez que se determin\u00f3 el efecto t\u00f3xico de los HPAs \nsobre el crecimiento del hongo, se tom\u00f3 la decisi\u00f3n de traba-\njar en medio l\u00edquido con una concentraci\u00f3n m\u00ednima inhibitoria \nde 5 mg/L considerando el efecto t\u00f3xico del fenantreno, a fin \nde poder comparar los efectos de los distintos HPAs sobre las \nactividades enzim\u00e1ticas del SEDL de T. coccinea, la concentra-\nci\u00f3n de prote\u00ednas totales y la fitotoxicidad. \nEfecto de los HPAs sobre la concentraci\u00f3n de prote\u00ednas \ntotales y la actividad de las enzimas ligninol\u00edticas: La \nisoenzima lacasa de 68 Kda se induce en presencia de HPAs\nEn cuanto a la concentraci\u00f3n de prote\u00ednas totales en el \nsobrenadante, se observ\u00f3 un incremento en el tiempo para \ntodos los tratamientos (Figura 5). Sin embargo, se encontr\u00f3 \nuna reducci\u00f3n en la concentraci\u00f3n de prote\u00ednas en el sobrena-\ndante del hongo tratado con naftaleno desde el primer d\u00eda de \nexposici\u00f3n. En el d\u00eda 1, se observ\u00f3 una reducci\u00f3n significativa \nen la concentraci\u00f3n de prote\u00ednas totales en el sobrenadante \ndel tratamiento con naftaleno, de 0.093\u00b10.001 mg/mL en el \ncontrol a 0.068\u00b10.002 mg/mL (F = 14.11; p = 0.001). En el d\u00eda \n5, tambi\u00e9n se apreci\u00f3 una disminuci\u00f3n en el contenido prot\u00e9ico \npara los tratamientos con naftaleno y fenantreno seg\u00fan Anova \nde una v\u00eda y test a posteriori de Dunnet (F=26.64; p= 0.000). Se \nevidenci\u00f3 una reducci\u00f3n en el contenido de prote\u00edna en el tra-\ntamiento con naftaleno, de 0.121\u00b10.006 mg/mL en el control \na 0.085\u00b10.011 mg/mL (F = 7.98; p = 0.000) y en el biotratado \ncon fenantreno se redujo a 0.101\u00b10.01 mg/mL.\nAl estudiar el efecto sobre la s\u00edntesis de enzimas ligni-\nnol\u00edticas, no se evidenci\u00f3 actividades de las enzimas guaiacol \nperoxidasa, LigP ni MnP. Sin embargo, se observ\u00f3 una fuerte \ninducci\u00f3n de la actividad lacasa en presencia de pireno y naf-\ntaleno. En la Figura 6A se observa un incremento en el tiempo \npara la actividad lacasa en todos los tratamientos la cual se vi\u00f3 \nfuertemente inducida en presencia de pireno y naftaleno. En el \nFigura 3. Fotograf\u00eda y dibujos del Soldado Desconocido en medio de cultivo (A). Conidias (c), hifas productoras de conidias, \nclamidosporas (cl), clamidosporas intercalares (icl), f\u00edbulas(cc) e hifas (h) en microscopio \u00f3ptico1000X (B).Beatriz Pern\u00eda, Hector Urbina, Meralys Gonz\u00e1lez, Lucia Sena, Yanet Villasana, Leopoldo Naranjo-Brice\u00f1o\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1929\nFigura 4. Porcentaje de tolerancia e inhibici\u00f3n del crecimiento del hongo T. coccinea en medio s\u00f3lido BSM expuesto a distintas \nconcentraciones de HPAs. Naftaleno (A), Fenantreno (B), Pireno (C). Las barras y puntos representan la media \u00b1 desviaci\u00f3n \nest\u00e1ndar (n=3). Letras iguales se\u00f1alan que no hay diferencias estad\u00edsticamente significativas seg\u00fan ANOVA de 1-v\u00eda p<0.05 y \ntest a posteriori de Tukey.  Trametes coccinea  IDEA, un hongo s\u00faper productor de lacasa aislado de un lago natural de asfalto: Tolerancia y biotransformaci\u00f3n de hidrocarburos polic\u00edclicos arom\u00e1ticos\nTrametes coccinea  IDEA, a super laccase-producer fungus isolated from a natural asphalt lake: Tolerance and biotransformation of aromatics polycyclic hydrocarbons1930\nd\u00eda 1, se evidenci\u00f3 un aumento significativo de la actividad la-\ncasa en el sobrenadante del tratamiento con pireno, incremen-\ntando de 5.95\u00b14.96 U/mgP en el control hasta 96.90\u00b151.10 \nU/mgP (F = 5.70; p = 0.027). Para el d\u00eda 3, la actividad de la \nlacasa increment\u00f3 en el tratamiento con naftaleno de 18.81 a \n104.91 U/mgP (F = 4.98; p = 0.039) y, para el d\u00eda 5, se evidenci\u00f3 \nun fuerte est\u00edmulo de esta acividad enzim\u00e1tica en presencia \nde pireno (124.85\u00b114.76 U/mgP) y naftaleno (167.95\u00b116.23 U/\nmgP) (F = 22.45; p = 0.001).  \nAdem\u00e1s, los zimogramas con ABTS (Figura 6B) muestran \n3 isoenzimas de la lacasa con pesos moleculares estimados \nde 68, 58 y 56 KDa. De estas, la isoenzima que mostr\u00f3 una \nmayor actividad en presencia de los HPAs fue la de mayor peso \nmolecular (68 KDa), especialmente, en presencia de naftaleno \ny pireno. En nuestro laboratorio se realiz\u00f3 esta misma prueba \ncon un sobrenadante enriquecido con almid\u00f3n y se vi\u00f3 un in-\ncremento en la actividad de las dos isoenzimas de menor peso \nmolecular (datos no mostrados), de donde se desprende que la \nactivaci\u00f3n enzim\u00e1tica de las distintas isoenzimas depende del \nsustrato, en este caso, los HPAs estudiados.\nVariaci\u00f3n en la toxicidad de los HPAs tras su \nbiotransformaci\u00f3n por T. coccinea: La biotransformaci\u00f3n de \npireno estimula el crecimiento de las pl\u00e1ntulas de L. sativa.\nSe observ\u00f3 una variaci\u00f3n en la toxicidad de los HPAs sobre \nFigura 5. Concentraci\u00f3n de prote\u00ed -\nnas totales de T. coccinea en medio \nl\u00edquido BSM y medio BSM suple -\nmentado con 5 mg/L de naftaleno, \nfenantreno y pireno, durante 5 d\u00edas.Beatriz Pern\u00eda, Hector Urbina, Meralys Gonz\u00e1lez, Lucia Sena, Yanet Villasana, Leopoldo Naranjo-Brice\u00f1o\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nel crecimiento de L. sativa luego de ser biotratados con el hon-\ngo. Con respecto al porcentaje de germinaci\u00f3n, se observ\u00f3 una \ndisminuci\u00f3n ante la exposici\u00f3n a naftaleno (91.67 %), naftale-\nno biotratado con T. coccinea (93.33 %), fenantreno biotratado \n(91.67 %), pireno (96.67 %) y pireno biotratado (95.00 %). Sin \nembargo, esta disminuci\u00f3n no fue significativa con respecto al \ncontrol (100 %) (p>0.05). \nPor otro lado, la longitud de las rad\u00edculas de las pl\u00e1ntulas \nse redujo ante la exposici\u00f3n a los HPAs (F = 15.54; p = 0.000). \nLa longitud media de los controles fue de 2.01 cm el cual dis-\nminuy\u00f3 en los tratamientos de naftaleno biotratado (1.34 cm), \nfenantreno biotratado (1,49 cm) y pireno (1.57 cm). En el caso \ndel pireno biotratado (2.34 cm), mostr\u00f3 un est\u00edmulo de creci-\nmiento en comparaci\u00f3n al pireno solo (1.57 cm).\nLas pruebas de fitotoxicidad mostraron que ocurri\u00f3 un \nproceso de biotransformaci\u00f3n de los HPAs al observarse di-\nferencias en los niveles de toxicidad de los compuestos al ex-\nponerlos al hongo. En el caso del naftaleno y el fenantreno, el \ncontacto con el hongo gener\u00f3 compuestos m\u00e1s t\u00f3xicos que el \ncompuesto original mientras que, por el contrario, en el caso \ndel pireno se generaron compuestos menos t\u00f3xicos, lo que se \nreflej\u00f3 como un est\u00edmulo significativo en el crecimiento de las pl\u00e1ntulas de L. sativa.\nEn este sentido, el IIF empleado en la presente investiga-\nci\u00f3n, mostr\u00f3 que el naftaleno promueve un est\u00edmulo de creci-\nmiento con un valor de -6 y, luego del tratamiento con T. coc-\ncinea, genera una toxicidad con un valor de IIF de 17. De igual \nmanera que el naftaleno, el fenantreno promueve un est\u00edmulo \nde crecimiento de -20 y, cuando es biotratado por el hongo, se \nevidenci\u00f3 una toxicidad de 16. Por el contrario, el pireno inicial-\nmente fue t\u00f3xico para las plantas (2) y, luego de su exposici\u00f3n \ncon el hongo, se observ\u00f3 un est\u00edmulo del crecimiento de -20, el \ncual pudiera deberse a la generaci\u00f3n de sub-productos menos \nt\u00f3xicos que el original, en este caso, el pireno.\nDiscusi\u00f3n\nEl hongo T. coccinea aislado del Lago de Asfalto de Gua-\nnoco tiene la capacidad de tolerar ambientes extremos con \naltas temperaturas y contaminados con hidrocarburos recal-\ncitrantes. En el presente trabajo, la cepa aislada fue capaz de \ncrecer sobre bajas concentraciones de HPAs sin s\u00edntomas de \ntoxicidad. Esta capacidad podr\u00eda deberse a la presi\u00f3n adap-\ntativa de esta cepa al vivir en presencia de asfalto y a bajas \nconcentraciones de nutrientes. Adem\u00e1s de ello, una cepa de \nesta misma especie fue aislada por Dant\u00e1n-Gonz\u00e1lez et al.38, \ncreciendo en un tronco cubierto de crudo cercano a una refine-\nr\u00eda en Veracruz, M\u00e9xico, lo que demuestra su alta tolerancia a \nlos hidrocarburos.\nEn el presente estudio no se observaron las actividades \nenzim\u00e1ticas guaiacol peroxidasa, LigP ni MnP, resultados que \ncoinciden con los reportados por otros autores que se\u00f1alan \nque la principal enzima extracelular oxidtiva del SEDL de P. \nsanguineus (formalmente T. coccinea) es la lacasa23,24. Sin em-\nbargo, contrastan con los resultados obtenidos por Esposito \net al.20 quienes encontraron actividades LigP y MnP al exponer \nal hongo a extracto de malta, lo que sugiere que, aunque esta \nespecie sintetize exoenzimas oxidativas en presencia de algu-\nnos sustratos como la malta, las mismas no se estimulan en \npresencia de los HPAs estudiados en la presente investigaci\u00f3n \n(naftaleno, fenantreno y pireno) ni en los estudiados por Li et \nal.24, quienes expusieron el hongo a fenantreno, benzo[a]antra-\nceno y a antraceno.\nPor otro lado, una posible explicaci\u00f3n de la baja actividad \nlacasa los primeros d\u00edas del experimento se debe a la presen-\ncia de glucosa en el medio, la cual, al irse consumiendo por \nel hongo, la actividad de la enzima incrementa proporcional-\nmente a la desaparici\u00f3n de la glucosa en el caldo de cultivo. \nA este respecto, Siqueira et al.21 reportaron la inhibici\u00f3n de la 1931\nFigura 6. A. Actividad de la enzima lacasa en medio BSM control y suplementado con 5 mg/L de los diferentes HPAs B. Zimo -\ngrama de los sobrenadantes de T. coccinea expuestos a los HPAs por 5 d\u00edas y 5 mM de ABTS. Al lado, el mismo gel te\u00f1ido con \nazul de coomasie.  PM: peso molecular, Control: T. coccinea en medio BSM y medio BSM con 5 mg/L de NAF: naftaleno, FEN: \nfenantreno y PIR: pireno.\nproducci\u00f3n de la \u03b1-amilasa en presencia de glucosa, por lo que \nsugieren que esta fuente de carbono y energ\u00eda pudiera generar \nrepresi\u00f3n catab\u00f3lica.\nAl igual que en el presente trabajo, otros trabajos reportan \nla presencia de varias isoenzimas de la lacasa. Garc\u00eda et al.39  \nencontraron 3 isoenzimas con distintos pesos moleculares, \nentre ellas una de 68 Kda, lo cual coincide con la isoenzima \nque se activ\u00f3 en T. coccinea en prencia de  naftaleno y pireno \nen nuestro estudio. De igual manera, Litthauer et al.40 encon-\ntraron una lacasa termoestable de 58 KDa, pH \u00f3ptimo 3-5, que \ntoleraba temperaturas de 50-75\u00b0C. As\u00ed mismo, Dant\u00e1n-Gonz\u00e1-\nlez et al.38 aislaron dos isoenzimas de lacasa de 68 KDa con PI \nde 7.00 y 7.08, respectivamente. En nuestro caso, observamos \nla presencia de 3 isoenzimas de pesos moleculares distintos: \n56, 58 y 68 KDa. Se pudiera sugerir, que la activaci\u00f3n de las \ndistintas isoenzimas l\u00f3gicamente podr\u00eda depender del sustrato \nutilizado, en este caso, por los HPAs ensayados.\nEn este sentido, la inducci\u00f3n de la actividad de la lacasa de 68 KDa de T. coccinea en presencia de naftaleno y pireno, \nsugiere que esta enzima podr\u00eda reconocer estos compuestos \ncomo sustratos con una mayor especificidad. En otras pruebas \nrealizadas en nuestro laboratorio, observamos que la actividad \nde la lacasa de T. coccinea en un medio rico en almid\u00f3n se vio \nduplicada al a\u00f1adir 5 mg/L de pireno, lo que confirma la induc-\nci\u00f3n de esta enzima ante la exposici\u00f3n a este HPA.\nLa capacidad de la lacasa para degradar distintos com-\npuestos org\u00e1nicos se debe a su baja especificidad de sustrato. \nSe ha demostrado que ciertos compuestos recalcitrantes tales \ncomo pesticidas, colorantes, bifenilos policlorados y diversos \nHPAs presentan una similaridad estructural con la lignina - \nsustrato original de la lacasa - y son degradados por la misma.\nCon respecto a la toxicidad de los HPAs tratados con T. coc-\ncinea, se evidenci\u00f3 un incremento en la toxicidad del fenantre-\nno al ser biotratado con el hongo. Seg\u00fan Li et al.24, esta especie \ntransforma el fenantreno en 9,10-fenantrenodiona mediado por \nla enzima lacasa y se conoce que las dionas son muy t\u00f3xicas. Trametes coccinea  IDEA, un hongo s\u00faper productor de lacasa aislado de un lago natural de asfalto: Tolerancia y biotransformaci\u00f3n de hidrocarburos polic\u00edclicos arom\u00e1ticos\nTrametes coccinea  IDEA, a super laccase-producer fungus isolated from a natural asphalt lake: Tolerance and biotransformation of aromatics polycyclic hydrocarbons1932\nAdem\u00e1s, se ha demostrado que esta especie degrada el fenan-\ntreno via lacasa y tambi\u00e9n por la enzima citocromo P450, donde se genera el metabolito secundario 2-methyl- phenol\n24.\nAunque T. coccinea es capaz de degradar hidrocarburos y \nes promisorio para fines de biorremediaci\u00f3n, se sugiere el uso de la enzima lacasa purificada (Ej. isoenzima lacasa de 68 Kda) debido a la posibilidad de generar compuestos m\u00e1s t\u00f3xicos al original, como en el caso de naftaleno y fenantreno. Por otro lado, se ha descrito que T. coccinea (previamente P. sangui-neus) tiene propiedades antibi\u00f3ticas sobre varias especies bac-terianas\n41, lo cual podr\u00eda ser contraproducente ya que, por un \nlado, no se pueden generar consorcios con bacterias con fines de biorremediaci\u00f3n y, por otro lado, el hongo podr\u00eda eliminar bacterias aut\u00f3ctonas presentes en los suelos contaminados con capacidad de mineralizar HPAs.Conclusiones\nEl hongo Trametes coccinea fue aislado del Lago natural \nde Asfalto de Guanoco y demostr\u00f3 tolerancia hacia los hidro-carburos naftaleno, fenantreno y pireno. Adem\u00e1s, se evidenci\u00f3 que estos HPAs estimulan a la enzima lacasa, especialmente la isoenzima de 68 kDa que podr\u00eda estar implicada en la oxi-daci\u00f3n inicial en el proceso de degradaci\u00f3n de hidrocarburos. Tambi\u00e9n se observ\u00f3 una variaci\u00f3n en la toxicidad de los hi-drocarburos sobre la especie L. sativa al ser biotratados por T. coccinea, gener\u00e1ndose una mayor toxicidad en el caso delnaftaleno y el fenantreno, mientras que, en el caso del pireno,disminuy\u00f3 su toxicidad. Se recomienda trabajar con la enzimalacasa purificada para fines de biorremediaci\u00f3n de suelos yaguas contaminados con HPAs.\nFigura 7. Efecto de los sobrenadantes de T. coccinea crecido en distintos HPAs sobre  la germinaci\u00f3n y el crecimiento de rad\u00ed -\nculas e hipoc\u00f3tilos de pl\u00e1ntulas de L. sativa  expuestos a agua= control agua, BSM = control medio BSM, Tc = control hongo en medio BSM, NAF = medio BSM con 5 mg/L de naftaleno, Naf-\nTc = medio BSM con naftaleno y T. coccinea, Fen = medio BSM con \nnaftaleno, Fen-Tc= medio BSM con naftaleno y T. coccinea, Pir = medio BSM con  naftaleno, Pir-Tc = medio BSM con  naftaleno y T. coccinea durante 5 d\u00edas. Los resultados se muestran como medias \u00b1 desviaci\u00f3n est\u00e1ndar (n=30). *Estad\u00edsticamente signifi -\ncativas en comparaci\u00f3n al control agua, seg\u00fan ANOVA de 1-v\u00eda y test de Dunnet p<0.05. B. \u00cdndice Integral de Fitotoxicidad (IIF) par\na las plantas de L. sativa expuestas a los distintos sobrenadantes.Beatriz Pern\u00eda, Hector Urbina, Meralys Gonz\u00e1lez, Lucia Sena, Yanet Villasana, Leopoldo Naranjo-Brice\u00f1o\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1933\nReferencias bibliogr\u00e1ficas\n1. Menzie C A, Potocki BB, Joseph S. Exposure to Carcinogenic PAHs \nin The Environment. Environ Sci Technol. 1992 Jul 1;26(7):1278\u2013\n84.\n2.Nadon L, Siemiat\nycki J, Dewar R, Krewski D, G\u00e9rin M. Cancer\nrisk due to occupational exposure to polycyclic aromatic hydro-carbons. Am J Ind Med [Internet]. 1995 Sep 1 [cited 2020 Jun8];28(3):303\u201324. Available from: http://doi.wiley.com/10.1002/ajim.4700280302\n3.\nArun  a, E\nyini M. Comparative studies on lignin and polycy-\nclic aromatic hydrocarbons degradation by basidiomycetesfungi. Bioresour Technol [Internet]. 2011 Sep [cited 2012 Apr18];102(17):8063\u201370. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21683591\n4.\n Gouma S, F\nragoeiro S, Bastos AC, Magan N. Bacterial and Fun-\ngal Bioremediation Strategies. In: Microbial Biodegradation andBioremediation [Internet]. Elsevier Inc.; 2014. p. 301\u201324. Available from: http://dx.doi.org/10.1016/B978-0-12-800021-2.00013-3\n5.\nNar\nanjo-brice\u00f1o L, Pern\u00eda B, Perdomo T, Gonz\u00e1lez M, Inojosa Y,\nSisto \u00c1 De, et al. Potential Role of Extremophilic Hydrocarbono-clastic Fungi for Extra- Heavy Crude Oil Bioconversion and theSustainable Development of the Petroleum Industry. In: S. M.Tiquia-Arashiro MG (eds. ., editor. Fungi in Extreme Environments: Ecological Role and Biotechnological Significance [Internet].Springer Nature Switzerland; 2019. p. 559\u201386. Available from:http://link.springer.com/10.1007/978-3-030-19030-9\n6.\nBaillie GS, Hitchcock C\nA, Burnet FR. Increased cytochrome P-450 \nactivity in Aspergillus fumigatus after xenobiotic exposure. MedMycol [Internet]. 1996 Jan 1 [cited 2020 Jun 8];34(5):341\u20137.Available from: https://academic.oup.com/mmy/article-lookup/doi/10.1080/02681219680000581\n7.\nV\nazquez-duhalt R, Westlake DWS, Fedorak PM. Lignin Peroxidase \nOxidation of Aromatic Compounds in Systems Containing Organ-ic Solvents. 1994;60(2):459\u201366.\n8.\n Baboro\nv\u00e1 P, M\u00f6der M, Baldrian P, Cajthamlov\u00e1 K, Cajthaml T. Pu-\nrification of a new manganese peroxidase of the white-rot fungus Irpex lacteus, and degradation of polycyclic aromatic hydrocar-bons by the enzyme. Res Microbiol. 2006;157:248\u201353.\n9.\nW\nang Y, Vazquez-duhalt R, Pickard MA. Manganese \u2013 lignin perox-\nidase hybrid from Bjerkandera adusta oxidizes polycyclic aromat-ic hydrocarbons more actively in the absence of manganese. Life Sci. 2003;682:675\u201382.\n10.\n Allenmark \nSG, Andersson MA. Chloroperoxidase-Catalyzed\nAsymmetric Synthesis of a Series of Aromatic Cyclic Sulfoxides.Science (80- ). 1996;7(4):1089\u201394.\n11.\n Majcherczyk A, Johannes C\n, Hu A. Oxidation of polycyclic aro-\nmatic hydrocarbons ( PAH ) by laccase of Trametes versicolor.Enzyme. 1998;0229(97):335\u201341.\n12.\n Dut\nta D, Ghosh DK, Mishra AK, Samanta TB. Induction of ben-\nzo(a)pyrene hydroxylase in Aspergillus ochraceus TS: Evidencesof multiple forms of cytochrome P-450. Biochem Biophys ResCommun. 1983 Sep 15;115(2):692\u20139.\n13.\n Goche\nv VK, Krastanov AI. Isolation of Laccase Producing Trich-\noderma Spp. Vol. 13, Bulgarian Journal of Agricultural Science.2007.\n14.\n Majeau \nJA, Brar SK, Tyagi RD. Laccases for removal of recal-\ncitrant and emerging pollutants. Bioresour Technol [Internet].2010;101(7):2331\u201350. Available from: http://dx.doi.org/10.1016/j.biortech.2009.10.087\n15.\n Ma\nyer AM, Staples RC. Laccase: New functions for an old en-\nzyme. Phytochemistry. 2002;60(6):551\u201365.\n16.\n Pickard MA, R\noman R, Tinoco R, Vazquez-Duhalt R. Polycyclic ar-\nomatic hydrocarbon metabolism by white rot fungi and oxidationby Coriolopsis gallica UAMH 8260 laccase. Appl Environ Microbi-ol. 1999;65(9):3805\u20139.\n17.\n P\nern\u00eda B, Rojas-Tortolero D, Sena L, De Sisto A, Inojosa Y, Naranjo \nL. Phytotoxicity of pah, extra-heavy crude oil and its fractions inLactuca sativa: An integrated interpretation using a modified tox-icity index. Rev Int Contam Ambient. 2018;34(1):79-91.18.\n Nar\nanjo L, Urbina H, Sisto ADE, Leon V. Isolation of Autochtho-\nnous Non-White Rot Fungi with Potential for Enzymatic Upgrad-ing of Venezuelan Extra-Heavy Crude Oil Isolation of autochtho-nous non-white rot fungi with potential for enzymatic upgradingof Venezuelan extra-heavy crude oil. 2007;25(2-4):341-349.\n19. \n Gonz\u00e1lez V\n, V\u00e1squez P. La vegetaci\u00f3n del Lago de Asfalto de Gua-\nnoco despu\u00e9s de cuatro d\u00e9cadas. Un primer enfoque fision\u00f3micoy flor\u00edstico | Gonz\u00e1lez. Acta Biologica Venezuelica. 2004; 24(2)[Internet]. [cited 2020 Jun 8]. Available from: http://saber.ucv.ve/ojs/index.php/revista_abv/article/view/4036/3860\n20.\n Esposito E, Innocentini-Mei LH, F\nerraz A, Canhos VP, Dur\u00e1n N.\nPhenoloxidases and hydrolases from Pycnoporus sanguine-us (UEC-2050 strain): applications. J Biotechnol. 1993 Jun1;29(3):219\u201328.\n21.\n De Almeida Siqueir\na EM, Mizuta K, Giglio JR. Pycnoporus san-\nguineus: A novel source of \u03b1-amylase. Mycol Res. 1997 Feb1;101(2):188\u201390.\n22.\n Abr\nah\u00e3o MC, Gugliotta ADM, Silva D, Fujieda Y. Ligninolytic activ-\nity from newly isolated basidiomycete strains and effect of these enzymes on the azo dye orange II decolourisation. Microbiol.2008;58(3):32212393.\n23.\n Zhang S, Ning Y\n, Zhang X, Zhao Y, Yang X, Wu K. Contrasting\ncharacteristics of anthracene and pyrene degradation by woodrot fungus Pycnoporus sanguineus H1. Int Biodeterior Biodegra-dation [Internet]. 2015;105:228\u201332. Available from: http://dx.doi.org/10.1016/j.ibiod.2015.09.012\n24.\n Li X, P\nan Y, Hu S, Cheng Y, Wang Y, Wu K, et al. Diversity of\nphenanthrene and benz [ a ] anthracene metabolic pathways inwhite rot fungus Pycnoporus sanguineus 14. Int Biodeterior Bio-degrad [Internet]. 2018;134(May):25\u201330. Available from: https://doi.org/10.1016/j.ibiod.2018.07.012\n25.\n Casqueiro J\n, Ba\u00f1uelos O, Guti\u00e9rrez S, Hijarrubia MJ, Mart\u00edn JF.\nIntrachromosomal recombination between direct repeats in Pen-icillium chrysogenum: Gene conversion and deletion events. MolGen Genet. 1999;261(6):994\u20131000.\n26.\n Montenegro E, Fierro F\n, Fernandez FJ, Gutierrez S, Martin JF.\nResolution of chromosomes III and VI of Aspergillus nidulans bypulsed- field gel electrophoresis shows that the penicillin biosyn-thetic pathway genes pcbAB, pcbC, and penDE are clustered onchromosome VI (3.0 megabases). Vol. 174, Journal of Bacteriolo-gy. J Bacteriol; 1992. p. 7063\u20137.\n27.\n Nar\nanjo L, De Valmaseda EM, Ba\u00f1uelos O, Lopez P, Ria\u00f1o J,\nCasqueiro J, et al. Conversion of pipecolic acid into lysine inPenicillium chrysogenum requires pipecolate oxidase and sac-charopine reductase: Characterization of the lys7 gene encodingsaccharopine reductase. J Bacteriol. 2001;183(24):7165\u201372.\n28.\n E\nvans GA. Molecular cloning: A laboratory manual. Second edi-\ntion. Volumes 1, 2, and 3. Current protocols in molecular biology.Volumes 1 and 2. Cell. 1990 Apr 6;61(1):17\u20138.\n29.\n Al\ntschul S, Madden T, Sch\u00e4ffer A, Zhang J, Zhang Z, Miller W, et\nal. A simple sequence repeat-based linkage map of Barley. Nu-cleic Acids Res. 1997;25(17):3389\u2013402.\n30.\n P\nearson WR, Lipman DJ. Improved tools for biological sequence\ncomparison. Proc Natl Acad Sci U S A. 1988;85(8):2444\u20138.\n31.\n K\nerem Z, Friesem D, Hadar Y. Lignocellulose degradation during\nsolid-state fermentation: Pleurotus ostreatus versus Phaneroch-aete chrysosporium. Appl Environ Microbiol. 1992;58(4):1121\u20137.\n32.\n Chaoui A, Ghorbal MH, El F\nerjani E. Effect of cadmoium-zinc in-\nteractions on hydroponically grown bean (Phaseolus vulgaris L.).Plant Sci. 1997;126:21\u20138.\n33.\n T\nroller J, Smit JDG, Leisola MSA, Kallent J, Winterhalter KH,\nFiechter A. Crystallization of a lignin peroxidase from the white-rot fungus Phanerochaete chrysosporium. Bio/Technology.1988;6(5):571\u20133.\n34.\n P\napinutti L, Forchiassin F. Optimization of manganese peroxidase \nand laccase production \u00b4 v .) Cke in the South American fungusFomes sclerodermeus ( Le. FEMS Microbiol Lett. 2003;536\u201341.\n35.\n Carlos M, Saparr\nat N, Mart\u00ednez MJ, Cabello MN, Arambarri AM.\nScreening for ligninolytic enzymes in autochthonous fungalstrains from Argentina isolated from different substrata. Culture. 2002;181\u20135.Trametes coccinea  IDEA, un hongo s\u00faper productor de lacasa aislado de un lago natural de asfalto: Tolerancia y biotransformaci\u00f3n de hidrocarburos polic\u00edclicos arom\u00e1ticos\nTrametes coccinea  IDEA, a super laccase-producer fungus isolated from a natural asphalt lake: Tolerance and biotransformation of aromatics polycyclic hydrocarbons1934\n36. Br adford MM. A rapid and sensitive method for the quantitation\nof microgram quantities of protein utilizing the principle of pro-\ntein-dye binding. Anal Biochem. 1976 May 7;72(1\u20132):248\u201354.\n37.\n Dis\ntefano S, Palma JM, G\u00f3mez M, Del R\u00edo LA. Characterization\nof endoproteases from plant peroxisomes. Biochem J. 1997 Oct15;327(2):399\u2013405.\n38.\n Li \nH-J, He S-H. Three species of polypores new to China. Myco-\nsistema. 2014 Sep 15;33(5):967\u201375.\n39.\n Dant\u00e1n-Gonz\u00e1lez \nE, Vite-Vallejo O, Mart\u00ednez-Anaya C, M\u00e9ndez-\nS\u00e1nchez M, Gonz\u00e1lez M, Palomares L, et al. Caracterizaci\u00f3n dela lacasa de una cepa termotolerante de Pycnoporus sanguineus. Int Microbiol. 2008;11(3):163-169.\n40.\n Garcia T\nA, Santiago MF, Ulhoa CJ. Studies on the Pycnoporus\nsanguineus CCT-4518 laccase purified by hydrophobic inter-action chromatography. Appl Microbiol Biotechnol. 2007 May11;75(2):311\u20138.\n41.\n Lit\nthauer D, van Vuuren MJ, van Tonder A, Wolfaardt FW. Puri-\nfication and kinetics of a thermostable laccase from Pycnopo-rus sanguineus (SCC 108). Enzyme Microb Technol. 2007 Mar5;40(4):563\u20138.\n42.\n Sm\u00e2nia A, Monache FD\n, Sm\u00e2nia EFA, Gil ML, Benchetrit LC,\nCruz FS. Antibacterial activity of a substance produced by thefungus Pycnoporus sanguineus (Fr.) Murr. J Ethnopharmacol.1995;45(3):177\u201381.\nReceived: 25 marzo 2021\nAccepted: 6 julio 2021Beatriz Pern\u00eda, Hector Urbina, Meralys Gonz\u00e1lez, Lucia Sena, Yanet Villasana, Leopoldo Naranjo-Brice\u00f1o\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1935\nComparison of Anxiety Levels in Patients with Coronavirus Disease (COVID-19) and their Families\nComparison of Anxiety Levels in Patients with Coronavirus Disease (COVID-19) \nand their Families\nAzin Chakeri1*, Maryam Rostami Qadi2*, Shima Haghani3DOI. 10.21931/RB/2021.06.03.8\nAbstract: Very little research has been done on the anxiety of the families of patients with covid-19. Considering the vital role \nof the family in the continuation of supportive-psychological therapies and the direct impact on the patient's anxiety level, in \nthis study, we examined the anxiety level of the family of patients with Covid-19 and compared their with their patient's anxiety \nlevel. In this comparative study, the samples were 60 people who were given a definitive diagnosis of covid-19 in selected \nhospitals (Masih Daneshvari Hospital and Besat Hospital). From the family members, the person who, according to the patient, is \nmost affected and has an emotional relationship with him (spouse-father-mother-child) was selected. The standard Spielberger \nAnxiety Questionnaire has been used to measure apparent (state) and hidden (trait) anxiety. The questionnaire was completed \nby both groups (patient-family) and compared with each other. The mean of evident anxiety in patients and caregivers was \n70.82 and 74.2, respectively, which this difference was statistically significant (P = 0.023). It is also observed that the mean of \nhidden anxiety in patients and caregivers was 68.83 and 74.71, respectively, which the mean of hidden anxiety in patients was \nsignificantly less than caregivers (P = 0.006). After identifying anxiety, nurses can better and more effectively deal with these \nunwanted conditions in the patient and her family by providing appropriate and correct education.\nKey words: Anxiety, COVID-19, Patient.RESEARCH / INVESTIGACI\u00d3N\nIntroduction\nIn December 2019, a viral outbreak was reported in Wu-\nhan, China. The cause of this disease was a new and gene-\ntically modified virus from the family of coronaviruses called \nSARS-COV, which was named Covid-19 disease1. Unfortuna-\ntely, due to its very high prevalence, the virus spread rapidly \nthroughout the world and infected almost all world countries \nin a short period (less than four months)2,3. The COVID-19 virus \nhas spread easily in some affected areas of the community. \nThe local spread of COVID-19 disease means that individuals \nare infected in this region. Some individuals are not sure how \nor where they became infected4. COVID-19 virus is developed \nquickly in diverse parts of Iran and instigated people to diffe-\nrent levels of anxiety. The symptoms of this virus vary from \nmild to severe. Signs and symptoms of infection include fe-\nver, cough, and breathing difficulty5. Anxiety is a common sign \nin patients suffering from respiratory disorders and can sig-\nnificantly reduce patients' quality of life. The majority of the \nanxiety cases develop clinical symptoms associated with se-\nvere respiratory disease and side effects of medications6. Lung \ndiseases, including pulmonary disorders, are highly associated \nwith anxiety disorders. Illness with severe clinical signs and \nalso duration caused more levels of anxiety7.\nHigher distribution of anxiety and depression in lung disea-\nses has been reported compared to other cases. The previous \nsurvey showed that 20-40% of patients who suffered from \nChronic Obstructive Pulmonary Disease (COPD) had symp-\ntoms of anxiety8. In a study of patients with asthma and COPD, \nPietras et al. found a positive association between anxiety and \ndyspnea9. Clinical anxiety affects up to two-thirds of chronic \nrespiratory patients and reduces the quality of life and phy-\nsical function. Little research has been done on anxiety expe-\nriences in patients with severe respiratory symptoms10. Anxie-\nty is common in cases of COVID-19 and appears to be due to \nthe unknown and cognitive ambiguity of the virus. Anxiety \ncaused a severe reduction in the immunity levels of humans has always been anxious for human11. At this time, people are \nlooking for more information to relieve their anxiety. Anxiety \ncan make people unable to distinguish right from wrong to be \nexposed to false news. Stress and anxiety can weaken the im -\nmune system and make them vulnerable to diseases such as \nCoronavirus12.\nAnxiety is a psychological condition that almost all human \nbeings experience to varying degrees throughout their lives. \nBut when it increases and reaches a level that causes distress \nand conflict, it is known as a disorder. Anxiety disorder is one \nof the most common disorders characterized by persistent, ex -\ncessive, and unrealistic concerns about everyday issues13. This \ndisorder can cause sleep problems, centralization, physical \nproblems such as; burnout, headaches, tension, muscle pain, \nand many problems in the future for people14. Evidence shows \nthat this disorder is more common in people who had crises in \ntheir lives. Li et al. conducted a study to investigate the psy -\nchological consequences of COVID-19 in China through an on -\nline survey and concluded that the disease increased anxiety, \nstress, and decreased happiness among people. Given the glo -\nbal (pandemic) status of Covid-19 disease, which affects al -\nmost all essential economic, political, social, and even military \naspects of all countries of the world, in other words, paralyzed, \nthe psychological effects of this viral disease on mental heal -\nth is very important for people at different levels of society15. \nDue to this virus's pathogenicity, spread rate, and high morta -\nlity rate, individuals' mental health status, including patients, \nhealth care workers, families, children, students, psychiatrists, \nand staff of various occupations, may be endangered16,17. It is \nessential to pay attention to this fact that in connection with \nthe observance of protocols and training given to patients to \nreduce anxiety, the family plays a decisive and vital role. The \nfamily is the context of each person who plays a crucial role in \nguiding him.\nEffective communication between the treatment team \n1 Department of Nursing, Garmsar branch, Islamic Azad University, Garmsar, Iran.  \n2 Department of nursing sari bu-Ali sina Therapeutic and Education center Mazandaran University of medical science, Sari, Iran. \n3 Master of Biostatistics, Nursing Care Research Center, Iran University of Medical Sciences, Tehran, Iran.\nCorresponding author: m.rostami.234@yahoo.com1936\nAzin Chakeri, Maryam Rostami Qadi, Shima Haghani\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nand the patient's family members is critical to provide safe \ncare and prevent further injury to the patient18. This is espe-\ncially important for providing quality care services in stress-\nful and unknown diseases such as Covid-19. Infection of one \nmember of the family with this disease causes anxiety and \npsychological problems in other family members. Therefore, \nit is necessary to know the level of anxiety in patients' families \ndue to their direct impact on increasing or decreasing the level \nof patient's anxiety and follow-up and continuation of suppor-\ntive therapies19. When a patient enters the emergency depart-\nment, the patient's family usually experiences psychological \nconditions such as anxiety and worry, such as fear or response \nto an unknown threat, which is a general reaction to stressful \nsituations such as illness or life-threatening situations20. The \npatient's family members play an essential role in supporting \nthe patient and cause the desired therapeutic response in the \npatient. However, when anxiety is high in family members, they \nmay not play an effective supportive role21. Very little research \nhas been done on the anxiety of the families of patients with \ncovid-19. Considering the vital role of the family in the con-\ntinuation of supportive-psychological therapies and the direct \nimpact on the patient's anxiety level, in this study, we exami-\nned the anxiety level of the family of patients with Covid-19 \nand compared their with their patient's anxiety level.\nMethods \nParticipants\nThis study was a comparative study. The research envi-\nronment of this study included the emergency departments \nof selected hospitals for admission of patients with covid-19 \n(Masih Daneshvari Hospital and Besat Hospital). The study \nsamples consisted of 60 people (men and women) who were \ngiven a definitive diagnosis of covid-19 by performing a corona \ntest with a CT scan of the lungs, and the treating physician \nquarantined them at home and received medication and conti-\nnued treatment at home with their family, which were selected \nby continuous sampling from the research environment. From \nthe family members, the person who, according to the patient, \nis most affected and has an emotional relationship with him \n(spouse-father-mother-child) was selected.Data collection tools\nThe questionnaire used to collect data in this study con-\nsists of two parts. The first part was a researcher-made ques-\ntionnaire containing demographic information (age, level of \neducation, marital status, and occupation). The second part \nwas the standard Spielberger Anxiety Questionnaire, which \nshowed patients' current level of anxiety and their families. \nThis questionnaire has been used extensively in research and \nclinical practice and includes separate self-assessment sca-\nles to measure obvious and hidden anxiety. The questionnaire \nhas been translated into 30 languages of the world and has \nbeen adapted to Iranian culture, in other words, it has been \nstandardized22. Mehram, in 1373 calculated the reliability of \nthis test through Cronbach's alpha on the average population \n(=0.9452). In general, scores (20-42) of mild anxiety, scores \n(43-64) of moderate anxiety, and scores (65-80) are classified \nas severe anxiety23.\nData collection\nAll samples of the study that met the inclusion criteria \n(corona test and positive lung scan) were selected by conti-\nnuous sampling with a selected person from their family (res-\nponsible for patient care) informed consent to participate in \nthe study researcher. Then the standard Spielberger anxiety \nquestionnaire was completed by both groups (patient-family) \nand compared with each other.\nResults\nThe results showed that the mean age of the patients was \n43.25 with a standard deviation of 11.18 years, and 76.7% of \nthem were married, and the educational level was 36.7% at the \ndiploma level. The mean age of the caregiver was 42.8 years \nwith a standard deviation of 10.77 years, and 80% of them were \nmarried, and the educational level was 40% at the bachelor le-\nvel (Table 1).\nTable 2 shows that none of the patients and their caregi-\nvers had apparent (state) anxiety at a superficial level, and the \napparent anxiety of all caregivers and 98.3% of patients was \nhigh. The mean of evident anxiety in patients was 70.82 with a \nstandard deviation of 7.59, and the mean of evident anxiety in \ncaregivers was 74.2 with a standard deviation of 4.24. Based on \nTable 1. Frequency Distribu -\ntion of Demographic Charac -\nteristics of the Participants.1937\nthe result of the Kruskal-Wallis test, this difference was statis-\ntically significant, and the mean of evident anxiety of patients was significantly less than caregivers (P = 0.023). It is also ob-served that all caregivers' hidden (trait) anxiety was high, and 88.4% of patients had hidden anxiety at a high level. The mean of hidden anxiety in caregivers was 74.71 with a standard devia-tion of 2.91 and in patients was 68.83 with a standard deviation of 10.72. Based on the result of the Kruskal-Wallis test, this di-fference was statistically significant, and the mean of hidden anxiety in patients was significantly less than caregivers (P = 0.006).\nDiscussion\nCOVID-19 is a pandemic disease with high mortality ra-\ntes and distribution globally24-27. In this study, it was found that \nthis disease (COVID-19) is anxious for most patients and cau-ses more anxiety in the family (patient caregivers) than the pa-tient. The mean of state anxiety in patients was 70.82, and the mean of state anxiety in caregivers was 74.2. Also, the mean of trait anxiety in patients was 68.83, and this means in caregi-vers was 74.71. Given the importance of the role of the family in the treatment of patients, and considering that most of the educational programs related to corona in medical centers are held only for patients, this study recommends that in addition to the patient, appropriate educational programs should also be considered for their family. The most appropriate providers of education in hospital wards are the nurses of such wards, who, in addition to frequently encountering similar patients and their families, also have the most time to communicate with them\n28. After identifying anxiety, nurses can better and \nmore effectively deal with these unwanted conditions in the patient and her family by providing appropriate and correct education\n29,30.\nConclusions\nThis research showed that the COVID-19 pandemic di-\nseases caused severe effects on patients and their families mental and nervous systems. The majority of cases were faced with apparent anxiety. As anxiety in COVID-19 patients and their families may cause weakening of mood, despair, and hopelessness and finally encouraging the patient not to fail the disease; thus, it is essential to use antidepressant therapeutic agents to reduce the rate of anxiety among patients and their families. This is the first report comparing anxiety levels in pa-tients with Coronavirus Disease (COVID-19) and their families globally. Thus, further investigations should perform to find more aspects of the COVID-19 mental disorders.\nBibliographic references\n1. Zhu, H., W ei, L. and Niu, P. 2020. The novel coronavirus outbreak\nin Wuhan, China. Global Health Research and Policy, 5(1), 1-3.\n2.R\nemuzzi, A. and Remuzzi, G. 2020. COVID-19 and Italy: what\nnext? Lancet (London, England).\n3.Zangrillo, A., Beret\nta, L., Silvani, P., Colombo, S., Scandroglio, A.\nM., Dell'Acqua, A., Fominskiy, E., Landoni, G., Monti, G. and Azzoli-\nni, M. L. 2020. Fast reshaping of intensive care unit facilities in alarge metropolitan hospital in Milan, Italy: facing the COVID-19pandemic emergency. Critical Care and Resuscitation, 22(2), 91.\n4.\n Jernigan, J\n. A., Low, D. E. and Helfand, R. F. 2004. Combining\nclinical and epidemiologic features for early recognition of SARS. Emerging Infectious Diseases, 10(2), 327.\n5.\nW\nu, Z. and McGoogan, J. M. 2020. Characteristics of and im-\nportant lessons from the coronavirus disease 2019 (COVID-19)outbreak in China: summary of a report of 72 314 cases fromthe Chinese Center for Disease Control and Prevention. JAMA,323(13), 1239-1242.\n6.\n Dong, X.-\nY., Wang, L., Tao, Y.-X., Suo, X.-l., Li, Y.-C., Liu, F., Zhao, Y. and \nZhang, Q. 2017. Psychometric properties of the Anxiety Inventory for Respiratory Disease in patients with COPD in China. InternationalJournal of Chronic Obstructive Pulmonary Disease, 12, 49-58.\n7.\nCas\nsem, N. and Bernstein, J. 2004. Depressed Patients (5th ed.).\nPhiladelphia, PA: Mosby/Elsevier.\n8.\n Co\nventry, P. A. 2009. Does pulmonary rehabilitation reduce anx-\niety and depression in chronic obstructive pulmonary disease?Current Opinion in Pulmonary Medicine, 15(2), 143-149.\n9.\nPietr\nas, T., Witusik, A., Panek, M., Ho\u0142ub, M., Ga\u0142ecki, P., Wujcik, R. \nand G\u00f3rski, P. 2009. Anxiety and depression in patients with ob-structive diseases. Polski Merkuriusz Lekarski: Organ PolskiegoTowarzystwa Lekarskiego, 26(156), 631-635.\n10.\n Willgos\ns, T. G., Goldbart, J., Fatoye, F. and Yohannes, A. M. 2013.\nThe development and validation of the anxiety inventory for re-spiratory disease. Chest, 144(5), 1587-1596.\n11.\n Alipour\n, A., Ghadami, A., Alipour, Z. and Abdollahzadeh, H. 2020.\nPreliminary validation of the Corona Disease Anxiety Scale(CDAS) in the Iranian sample.\n12.\n Al-R\nabiaah, A., Temsah, M.-H., Al-Eyadhy, A. A., Hasan, G. M.,\nAl-Zamil, F., Al-Subaie, S., Alsohime, F., Jamal, A., Alhaboob, A.and Al-Saadi, B. 2020. Middle East Respiratory Syndrome-Corona Virus (MERS-CoV) associated stress among medical students ata university teaching hospital in Saudi Arabia. Journal of Infection and Public Health, 13(5), 687-691.\nTable 2. Frequency Distribution of Anxiety of the Participants.Comparison of Anxiety Levels in Patients with Coronavirus Disease (COVID-19) and their Families1938\n13. Y u, W., Singh, S. S., Calhoun, S., Zhang, H., Zhao, X. and Yang, F.\n2018. Generalized anxiety disorder in urban China: Prevalence,\nawareness, and disease burden. Journal of Affective Disorders,234, 89-96.\n14.\n Rijn, B. v\n. and Wild, C. 2013. Humanistic and integrative therapies \nfor anxiety and depression: Practice-based evaluation of transac-tional analysis, gestalt, and integrative psychotherapies and per-son-centered counseling. Transactional Analysis Journal, 43(2),150-163.\n15.\n Li, S., W\nang, Y., Xue, J., Zhao, N. and Zhu, T. 2020. The impact of\nCOVID-19 epidemic declaration on psychological consequences:a study on active Weibo users. International Journal of Environ-mental Research and Public Health, 17(6), 2032.\n16.\n Bao, Y\n., Sun, Y., Meng, S., Shi, J. and Lu, L. 2020. 2019-nCoV epi-\ndemic: address mental health care to empower society. The Lan-cet, 395(10224), e37-e38.\n17.\n Chen, Q., Liang, M., Li, Y\n., Guo, J., Fei, D., Wang, L., He, L., Sheng,\nC., Cai, Y. and Li, X. 2020. Mental health care for medical staff inChina during the COVID-19 outbreak. The Lancet Psychiatry, 7(4), e15-e16.\n18.\n Da\nwood, E., Misuta, R., Alharbi, M., Almurairi, A., Kanori, H. and\nAlsaiari, M. 2018. Relationship between Nurses' Communicationand Levels of Anxiety and Depression among Patient's Family inthe Emergency Department. Ann Psychiatry Ment Health, 6(1),1125.\n19.\n Hosieni, \nF., Ravari, A. and Akbari, A. 2017. The Effect of Communi-\ncating with Patients Using Peplau Model on Patients' Satisfaction with the Provided Nursing Cares at the Cardiac Intensive CareUnit. Iran Journal of Nursing, 29(104), 36-45.\n20.\n T\nownsend, M. and Morgan, K. 2017 Psychiatric mental health\nnursing: Concepts of care in evidence-based practice. FA Davis.\n21.\n Zarei, M., K\neyvan, M. and Hashemizadeh, H. 2015. Assessing the\nLevel of Stress and Anxiety in Family Members of Patients Hospi-talized in the Special Care Units. International Journal of Reviewin Life Sciences, 5(11), 118-122.\n22.\n Basam pour\n, S. 2004. The effect of preoperative training on the\nanxiety level of patients undergoing open heart surge. PayeshJournal, 2, 139-144.23.\n  Behrouz, m. 1994. Spielberger anxiet y test norms in mashhad.\nM.SC Allameh Tabatabai University.\n24.\n R\nanjbar R, Mahmoodzadeh Hosseini H, Safarpoor Dehkordi F. A\nReview on Biochemical and Immunological Biomarkers used forLaboratory Diagnosis of SARS-CoV-2 (COVID-19). The Open Mi-crobiology Journal. 2020;14(1).\n25.\n Mirzaie \nA, Halaji M, Dehkordi FS, Ranjbar R, Noorbazargan H. A\nnarrative literature review on traditional medicine options fortreatment of corona virus disease 2019 (COVID-19). Complemen-tary Therapies in Clinical Practice. 2020:101214.\n26.\n Halaji M, F\narahani A, Ranjbar R, Heiat M, Dehkordi FS. Emerging\ncoronaviruses: first SARS, second MERS and third SARS-CoV-2:epidemiological updates of COVID-19. Infez Med. 2020;28(suppl1):6-17.\n27.\n Sheikhshahrokh A, R\nanjbar R, Saeidi E, Dehkordi FS, Heiat M,\nGhasemi-Dehkordi P, Goodarzi H. Frontier therapeutics and vac-cine strategies for sars-cov-2 (COVID-19): A review. Iranian Jour-nal of Public Health. 2020;49:18-29.\n28.\n Arrebola\n\u03b1\nPajares, A., Tejido\n\u03b1\nSanchez, A., Jimenez\n\u03b1Alcaide, E.,\nMedina\n\u03b1\nPolo, J., Perez\n\u03b1\nCadavid, S., Guerrero\n\u03b1\nRamos, F. and\nDiaz\n\u03b1\nGonzalez, R. 2014. Survey of satisfaction in hospitalized\npatients at a urology department. Archivos Espanoles De Urolo-gia, 67(7), 621\u2013627.\n29.\n Brunner\n, L., Smeltzer, S., Bare, B., Hinkle, P. and Cheever, K. 2017. \nBrunner & Suddarth's textbook of medical\n\u03b1surgical nursing.\nPhiladelphia: PA: Williams & Wilkins.\n30.\n Dehk\nordi FS, Valizadeh Y, Birgani TA, Dehkordi KG. Prevalence\nstudy of Brucella melitensis and Brucella abortus in cow's milkusing dot enzyme linked immuno sorbent assay and duplex poly-merase chain reaction. J Pure Appl Microbiol. 2014;8(2):1065-9.\nReceived: 15 April 2021\nAccepted: 20 May 2021Azin Chakeri, Maryam Rostami Qadi, Shima Haghani\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1939\nUsage of Cicer Arietinum  as a local and eco-friendly natural coagulant in sewage treatment and its ability to increase the formation of floc process\nUsage of Cicer Arietinum  as a local and eco-friendly natural coagulant in \nsewage treatment and its ability to increase the formation of floc process\nAmera Marey Mohammed Hassanien (A.Marey) DOI. 10.21931/RB/2021.06.03.9\nAbstract: Cicer Arietinum (CA) or chickpea seeds were used as a local natural coagulant, cheap and cultivable which available \nin Egypt that can be used to reduce turbidity from wastewater, especially sewage water instead of chemical coagulant that \ncauses different diseases like intestinal constipation, loss of memory, convulsions, so this paper represents the use of chickpea as a natural coagulant and eco-friendly in the environment because it assumed to be safe for the human health and efficient in sewage treatment, So the researchers advices now to use natural coagulant as coagulant aids which has a higher ability to raise the consistency of floc and prevent of the coagulation operation. The optimum removal conditions that applied on the research were temperature =25\n0C, pH= 3, Contact time=120 min, agitation speed for 2 minutes =80 rpm (rapid mixing), (CA) dosage is 90 \nmg/L, and (95.89%) turbidity reduction was achieved on the studied area.\nKey words: Turbidity, Cicer Arietinum, Chickpea, Natural Coagulant.RESEARCH / INVESTIGACI\u00d3N\nIntroduction\nWater is the main element for life on the earth's surfa-\nce; turbidity is a handy indicator for water quality so, there are \nnew techniques for sewage and water treatment, but the coa-gulation/flocculation method is still the essential process for treatment and turbidity removal from water. Nowadays, natu-ral coagulants are becoming better for treatment than other organic and inorganic coagulants like Alum and polyacrylami-de, to reduce the human diseases and no human health danger also it is minimal expensive than the traditional chemicals.\nThe history of natural coagulants' utilization is extended, \nFor more than 2000 years in India, Africa, and China as opera-tive coagulants for turbidity water elevation. They are perhaps produced from plant seeds, leaves, and roots\n14. Many operati-\nve coagulants from plant origin have been specified: Nirmali, Okra, red bean, Sugar and red maize, Moringa oleifera, Cac-\ntus latifera, and seed powder of Prosopis juliflora\n7,8,19. Sewage \n/ Wastewater recognized as an aggregation of water holding wastes from sewage is organic to consists of carbon compo-sitions like human waste, paper, vegetable matter residences, institutions, commercial and industrial factories with ground-water, surface water, and stormwater probably exist\n5. Sewage \nconsists of 99.9% water and 0.1% solids, etc.; even after 1990, to increase scientific knowledge and a developed information base, wastewater treatment has initiated to focus on the heal-th-related toxic chemicals emitted into the environment. The water quality progress objectives of 1970 have continued, but the assurance has shifted to the definition and elimination of toxic and trace compounds, which could cause long-term heal-th wares and opposite environmental influences. As a signi-ficance, However, the early treatment objectives stay helpful today, the required degree of treatment has risen significantly, and further treatment objectives and goals have been added, like especially natural coagulants\n17,18,20. Chickpea seeds can re-\nduce the turbidity in the wastewater. Natural coagulants have shown their coagulation efficiency and are reported in many research articles. Natural coagulants applications in removing turbidity from the water industry are still low. Cicer Arietinum (CA) belongs to the family Leguminosae, which is an annual plant that used as a coagulant for water treatment which con-tains various species of monosaccharides such as glucose, ri-bose, galactose, and fructose and disaccharides like maltose and sucrose likewise oligosaccharides like ciceritol, stachyose, verbascose and raffinose\n15. Medically, C. arietinum exhaus-\ntion minimizes the level of inveterate diseases such as heart troubles and minimizes the cholesterol rates, reducing the hazard of colorectal cancer. (CA) has an efficient weight loss and decreases obesity, so it considers as minimal-Gl food\n6. Ci-\ncer Arietinum is locally available in Egypt, so we used it as an effective natural coagulant to reduce turbidity from wastewa-ter(sewage) in the studied area, Ismailia canal (Mostorod refi-nery site) then becoming easier in household applications. We noticed that natural coagulants have a bright future to their considerable origin, ecofriendly in the surrounding, and biode-gradable from the previous information concerned by many re-searchers. The impartial tools of that research to estimate the efficiency of (CA) to reduce turbidity from natural wastewater by measuring the parameters (pH, turbidity).\nMaterials and methods\nCicer arietinum (chickpea is a commercial name): is locally \navailable in the market, was ground to fine powder, which kept approximate size less than 600\n \u03bcm to achie\nve solubilization of \neffective components in the seed filtered water was added to the powder to make suspension by about 1%. The suspension was busily shaken until 45 minutes by utilizing a magnetic sti-rrer to elevate water extraction of the coagulant proteins, whi-le that was after that push through filter paper (Whatman no. 42, 125\n mm\n dia.). The refine por\ntions were utilized until seeked \npotion of natural coagulants. Fresh solutions were intended every day and preserved to prevent longevity effects (such as changing pH, viscosity, and coagulation action)\n3. Whole coagu-\nlation tests were held out utilizing wastewater from the outlet of Ismailia Canal (Mostourd refinery site) as a water source. pH= (7.34), (TDS) is (100.7) NTU and Temperature= (29\nOC). \nHardness was measured by titration with EDTA. TS (Total so-lid), TSS (Total suspended solid), and heavy metals were me-asured corresponding to Standard processes\n7. Overall solids \nare measured by evaporating the whole of the water outside of a specimen and weighing the residual solids. Unsettled so-\n1 Department of  Basic Science , The Valley H igher Insti tute for Engineer ing and Tech nology, Egypt. \nCorresponding author: amera_muhammad@hotmail.com1940\nAmera Marey Mohammed Hassanien\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nlids are measured by thread sample water through a filter. \nThe solids held by the filter, once dried, are the suspended so-lids: Pekin Elmer, Analyst atomic absorption, measured heavy metals. Turbidity was recorded on a 2100N IS Turbidimeter (Hach). The color was decided by absorption scan (190-350 nm) using UV/ Vis-Spectrophotometer (LLG-UniSPEC 2)\n2. All \nExperiments were carried out in the laboratory. The eligible analysis was utilized to seek the best combination of variables to obtain optimum values due to elimination of responses and thus acquire clear wastewater to be reused for irrigation or in the same industrial methods. Eligibility varies from zero to one owing to every specified response. A significance of one exem-plifies a perfect state; however, zero suggests that one or more answers fall outgoing the eligible boundaries\n1.\nPreparing Cicer Arietinum (CA)\nThe seeds were washed with a significant amount of \nwater to remove impurities, then dried in the sun for 2 days.  This was shown in Figure (1); after that (CA), a mixer (Oster) was ground to obtain an excellent powder then storage in a plastic vacuum container. To get a stock of solution, we ad-ded 10 grams of natural coagulant in 1000 ml distilled water, obtaining the solution of 10,000 mg/L at room temperature ~ 20-25\n0C (cool place) and stirred at high speed 120 rpm for 1\nhour, to be homogenous and ready for use in the treatment ofsewage water.\nMethodology and Coagulation Test\nIn the laboratory, we applied the jar test, which is the \nextreme close method for coagulation-flocculation, Like in \nFigure (2), We prepare six beakers filled with 300 ml was-tewater respectively; before operating the test, the samples were mixed for measuring turbidity, then we added different concentrations of natural coagulant (CA) into the beakers with wastewater at room temperature ~ 20-25\noC. In this test, we \nused different pH of wastewater from 1 to 10. The beakers were agitated at several speed and mixing times, which the suspension was stirred at 200 rpm for 2 minutes of rapid mi-xing and followed by slow mixing at 60 rpm for 12 minutes. This mixing let flocs particles suspend finally removed from the samples in the beakers to be ready for measuring (turbi-dity, TSS, TDS, COD, BOD) (physicochemical parameters). All those experiments were carried out at a temperature in the zone between (25-45\noC), Turbidity test was conducted by \nnephelometric turbidity unit (NTU). Standard procedures mea-sured BOD and COD. Hardness was measured by titration with EDTA. TDS was measured by weighting the filtrate before and after the drying. The reduction of turbidity can be calculated for each sample from the equation:\nLowering of turbidity (NTU)= Primary Turbidity (NTU)- Fi-\nnal Turbidity (NTU) \nResults and discussion\nEffectiveness of Dosage (CA) on Physicochemical Parameters\nThe results of the jar test at various Cicer. Arietinum con-\ncentrations (50, 30, and 20 mg/L). The optimum concentration of (CA) is 50 mg/L, which reduced turbidity from (97 to 93.16 %) and TSS from (110 to 55.6).\nEffectiveness of Various pH Values\nFigure 1. Preparation of Cicer arietinum (CA)\nFigure 2. A traditional jar test device was owing for the treatment of turbid water.1941\nThe coagulation achievement of Cicer arietinum for redu-\ncing turbidity in wastewater preferred the acidic condition; in \nthis experiment, the variation in pH was applied from (3-10), \nwhich works best at pH=3, we noticed that the water appeared \nclearer and the flocs were observed after the settling process, \nbut when the pH increased more than 6 the water turned clou-\ndier and fewer flocs were found and gave lower turbidity % at \npH=10 because the conditions turned alkaline, all these data \nwere noticed in Figure (3).\nReduction of Turbidity Using Different Doses of (CA)\nBefore we studied the effect of different doses on turbi-\ndity, the raw wastewater turbidity was found 97 NTU, using \nvarious Cicer Arietinum doses (50,60,70,80,90,100) mg/ L. It \nwas observed that C. arietinum highly efficient to higher do-\nsage and lower dosage, but increasing in dosage caused again \nincrease in turbidity as shown in Figure (4).\nEffectiveness of Contact time on the turbidity ratio\nIn Figure (5), Different values of contact time were exa-\nmined from (40 to 160 minutes). The test showed turbidity \nelimination raised when the time increased from 100 to 120 \nminutes, then decreased when the contact time was increa-\nsed up to 120 minutes because the coagulant (CA) efficiency in \nabsorbing the colloids decreased flocs were broken. So, from \nthe previous study, further increase for mixing escalates micro \nflocs breakage in primary particles, slowing down floc's grow-\nth during flocculation10. The highest turbidity removal was \nachieved at 120 minutes.\nThe efficiency of Temperature on Turbidity Reduction\nIn this experiment, we used different temperature values \nwere (25,30,35,40), which the optimum temperature for re-\nmoval turbidity was 250C as observed in Figure (6), Which by \nincreasing temperature, the turbidity removal efficiency de-\ncreased.\nOptimization of Agitation Speed on Turbidity Reduction\nMixing speed is one of the most substantial roles for ob-\ntaining turbidity removal competence or failure of the floccu-\nlation, different values were used beginning from (20-140), So \nFigure 7 indicates that the high evaluation at 80 rpm with 95% removal. From the following data, we observed that this case \nwas especially which by higher agitation speed, the turbidity \nremoval efficiency became very weak and minimized to the \nflocs created in the coagulation-flocculation operation was fa-\ncilely destroyed13. A traditional flocculation unit operation con-\ntains three separate steps: 1-quick or flash blending: the con-\nvenient chemicals (flocculation and if required pH adjusters) \nare poured to the wastewater stream, stirred, and emphati-\ncally blended at rising speed. 2-Slow mixing (flocculation): the \nwastewater is only reasonably stirred to compose large flocs \nreadily settled out. 3- Sedimentation: the floc created through \nflocculation is authorized to settle and is separated from the \ncurrent flow9,19,21.\nConclusions\nThe application of natural coagulant (Cicer arietinum) on \nsurface water treatment was checked in this research. The \nsurface water was described by the concentration elevation \nof suspended particles. On varying the coagulant dosage, pH, \nand settling time, these particles get readily dissolved and \nsettled along with the coagulants added4. Based on the fact \nthat Cicer arietinum (CA)  being the most economical and en-\nvironment-friendly alternative natural coagulant, so we used \nit for removing colloids and decrease turbidity by jar test me-\nthod instead of chemical coagulants which have inherent di-\nsadvantages affecting on human health, from the parameters \nthat were discussed in the experiment as atrial to remove or \ndecreased turbidity efficiency from wastewater (Mostourd \nrefinery area), we reach to a result that the optimal dose of \nCicer arietinum (CA) for higher efficiency of turbidity and color \nremoval is 90 mg/L, with other constant parameters like (Tem-\nperature =250C, pH= 3, Contact time=120 min, and agitation \nspeed for 2 minutes =80 rpm (rapid mixing), from These all \nother optimal water quality parameters have a very significant \neffect on improving turbidity reduction percentage by 95.89%. \nSince we have collected the wastewater from the outlet of Is-\nmailia Canal (Mostourd refinery site) as a water source; we su-\nggest that instead of using chemical coagulants that has Avery \nterrible side effects on health, we must and restricted on using \nnatural coagulants like (Cicer arietinum (CA) as an alternative \nmethod for the treatment process.     \nFigure 3. Turbidity re -\nduction at different pH \nof the wastewater.Usage of Cicer Arietinum  as a local and eco-friendly natural coagulant in sewage treatment and its ability to increase the formation of floc process1942\nFigure 5. Shows the effects \nof various contact time on \nthe efficiency of turbidity \nremoval.\nFigure 6. Shows the \nEffects of Various Tempe -\nratures on the Removal of \nTurbidity\nFigure 4. Elimination of \nturbidity using various \ndosages of Cicer Arieti -\nnum.Amera Marey Mohammed Hassanien\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1943\nBibliographic references\n1. Ebeling, JM, Sibrell PL, Ogden SR, Summerfel t ST. Summerfelt\nEvaluation of chemical coagulation-flocculation aids for the re-\nmoval of suspended solids and phosphorus from intensive recir-culating aquaculture effluent discharge, Aquacultural Engineer-ing. 29(2003) 23-44.\n2.\nMcGhee T\nJ, Water Supply and Sewerage. McGraw-Hill, New York, \n260 (1991) 287.\n3.F\nrancois RJ, Ageing of aluminum hydroxide flocs, Water Re-\nsearch. 21(1987) 523-531.\n4.\n Gunar\natna KR, Garcia B, Andersson S, Dalhammar G, Screening\nand evaluation of natural coagulants for water treatment, WaterScience and Technology .7(2007) 19-25.\n5.\nAE \nClecerils, Greenberg and Eaton AD, Standard Methods for the \nExamination of water and wastewater, 20th   Ed. American Public Health Association, USA, Washington DC. (1998).\n6.\nDiaz A, Rincon N, Escorihuela A, F\nernandez N, Chacin E, Forster\nCF. A preliminary evaluation of turbidity removal by natural co-agulants indigenous to Venezuela\" 1999, Process Biochemistry.35(1999) 391-395.\n7.\nCheremisinff \nNP, Hank Book of Water and Wastewater Treatment \nTechnologies, An Overview of Water and Water Treatments. But-terworth-Heinemann Publication, 3 (2002)1-60.\n8.\n R\nowe DR, Abdel- Magid IH, Handbook of Wastewater Reclama-\ntion and Reuse, Boca Raton, Lewis. 3 (1995)167-181.\n9.Apha, S\ntandard Methods for Examination of water and wastewa-\nter, 17th Ed. Washington DC. 3(1) (1992) 501-517.\n10.\n Metcal\nf, Eddy, Wastewater Engineering Treatment, Disposal and\nReuse New York, McGraw Hill. 3(1991) 35-40.\n11.\n Asr\nafuzzaman Md, Fakhruddin ANM, Alamgir Hossain Md. Reduc-\ntion of Turbidity of Water Using Locally Available Natural Coag-ulants. International Scholarly Research Notices.10 (2011) 1-7.\n12.\n Abdel-K\nalek MA, Abdel Rahman MK, Francis AA. Experimental\nDesign and Desirability Analysis for Optimizing the Bio-sorptionof Liquid Paint-related Wastes onto Solid Eggshell Wastes. Envi-ronmental Processes. 7(2) (2020) 493-508.\n13.\n Jaoudi M, Amdouni N, Coagulation T\nreatment by Al2 (SO4) 3\nand Residual Al Determination in Medjerda Water Dam (Tunisia),Journal de la Soci\u00e9t\u00e9 Chimique de Tunisia.15 (2013) 175-181.\n14.\n Mare\ny A, Synthesis Composite of Tio2/ Chitosan and Tio2 / Ben-\ntonite for removing turbidity from Ismailia Canal as Water Treat-ment Plant, African Journal of Chemical Education (AJCE). 10(1) (2020)124-134.15.\n  Jahn S AA, Using Moringa seeds as coagulants in developing\ncountries, Journal of the American Water Works Association. 80(1988) 43-50.\n16.\n Y\narar B, Evaluation of Flocculation and Filtration Procedures Ap-\nplied to WSRC Sludge, Report no, DE-AC09-96SR 18500, Colora-do School of Miness.34 (2001) 234-244.\n17.\n Choube\ny S, Rajput SK, Bapat, KN. Comparison of Efficiency of\nsome natural coagulants-Bioremediation. International Journalof Emerging Technology and advanced Engineering. 2 (2012)159-168.\n18.\n R\nossini M, Garrido J, Garcia, Galluzzo M, Optimization of the co-\nagulation-flocculation treatment influence of rapid mix parame-ters, Water Research. 33(8) (1999)1817-1826.\n19.\n Babitha Merlin S, Abir\nami S, Suresh Kumar R. Studies on the\ntreatment of surface water using rajma seeds. Journal of CivilEngineering, 10 (2018) 10-15.\n20.\n K\nawamura S, Effectiveness of natural polyelectrolytes in water\ntreatment. Journal of the American Water Works Association, 83 (1991) 88-91.\n21.\n Liu \nMM, The Effectiveness of the Natural Polymers Chitosan,\nPolyglutamic Acid, and Moringa Oleifera Seeds in Water Purifica-tion, California State Science Fair. 3(2014) 2-14.\nReceived: 16 March 2021\nAccepted: 10 July 2021\nFigure 7. The influences of various mi-xing speeds on turbidity reduction.Usage of Cicer Arietinum  as a local and eco-friendly natural coagulant in sewage treatment and its ability to increase the formation of floc process1944\nHanie Raji, Seyed Hamid Borsi, Mehrdad Dargahi MalAmir, Ahmad Reza Asadollah Salmanpour\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nAssessment of the diagnostic value of CEA, CA125, and CRP and their cut-off \npoint for discrimination of exudative pleural effusions\nHanie Raji1, Seyed Hamid Borsi1, Mehrdad Dargahi MalAmir1, Ahmad Reza Asadollah Salmanpour* DOI. 10.21931/RB/2021.06.03.10\nAbstract: Pleural effusion is divided into exudative and transudative effusion, and the distinction between exudate and transudate \nrequires multiple investigations of biochemical parameters and their comparison in pleural fluid and serum. This study aimed \nto assess the diagnostic value of CEA, CA125, and CRP and their cut-off point for discrimination of exudative pleural effusions. \nThis epidemiological and cross-sectional study was performed on 50 patients aged between 18 to 90 years with the diagnosis of \nexudative pleural effusion referred to Imam Khomeini Hospital in Ahvaz in 2018 and 2019. Demographic and clinical information \nof patients were collected. The pleural effusion was diagnosed based on physical examination and chest radiography. Pleural \neffusion was confirmed by thoracentesis. A pleural fluid sample was taken from all patients, and the levels of CEA, CA125, and \nCRP markers were measured in the pleural fluid. Differentiation of transudate and exudate pleural effusions was performed using \nLight criteria. The mean CEA and CA125 level of pleural fluid were significantly higher, and the mean CRP level of pleural fluid \nwas significantly lower in patients with malignant diagnoses (P <0.05). Cut-off value with highest sensitivity and specificity in \ndifferentiating types of exudative pleural effusions was obtained for CEA tumor marker (greater than 49.8), CA125 tumor marker \n(greater than 814.02), and CRP marker (less than 7.56). Also, in differentiating types of exudative pleural effusions, CEA tumor \nmarker had sensitivity (89.03%) and specificity (78.42%); CA125 tumor marker had sensitivity (53.18%) and specificity (62.44%), \nand CRP marker had sensitivity (82.16%), and specificity (89.05%) were. Although the tumor markers had high specificity in the \npresent study, the low sensitivity of some of these tumor markers reduced their diagnostic value. On the other hand, given the \nnumerous advantages of tumor markers, such as low cost and non-invasive, combining them with another can increase the \ndiagnostic value and accuracy.\nKey words: Pleural effusion, Exudative, Transudative, Tumor markers.RESEARCH / INVESTIGACI\u00d3N\nIntroduction\nPleural effusion is one of the most common clinical mani-\nfestations associated with some chest diseases1, which is the \naccumulation of fluid in the pleural cavity and is often caused \nby a systemic or intrathoracic process. The prevalence varies \nby clinical setting, but 90% of all pleural effusions are caused \nby heart failure, malignant processes, and pneumonia and can \nlead to serious health problems if not properly treated or diag-\nnosed2. The fluid that enters the pleural space can be of the ori-\ngin of the pleural capillaries, interstitial lung space, intra-aortic \nlymphatics, intrathoracic blood vessels, or peritoneal cavity3,4. \nThe pleural effusion is divided into two types of exudative and \ntransudative effusions3,5. The distinction between exudate and \ntransudate requires multiple investigations of biochemical pa-\nrameters and their comparison in pleural fluid and serum6-9. \nRecently, to help differentiate the etiologies of pleural effusion, \nseveral studies have investigated tumor markers as a potential \nalternative to invasive procedures10-13. Different studies have \ninvestigated the diagnostic value of different tumor markers to \ndifferentiate different types of pleural effusion. However, the \nwide range of sensitivity, specificity, and cut-off values and the \ninconsistency in the results have made their diagnostic accu-\nracy still questionable14-18. CEA has been the most common \nmarker tumor studied for the diagnosis of malignant pleural \neffusion19. It has recently been reported that serum and fluid \nlevels of pleural effusion CA-125 can be used to diagnose pleu-\nral effusion malignancy20,21. In addition, CRP is often produced \nby the liver, and CRP levels in pleural effusions can be used \nto differentiate parapneumonic effusions from other types of \neffusions22,23. Since no high sensitivity and specificity, the mar-\nker has been identified for the diagnosis of exudative effusion \npleural effusions and due to inconsistency in the results of our studies, the aim of the present study was to evaluate the bio-\nmarker value of CEA, CA-125 and CRP tumor biomarkers in \ndifferentiation between exudative effusion pleural effusions.\nMaterials and methods \nStudy designs\nFollowing approval of the study in the Ethics Committee \nof Ahvaz Jundishapur University of Medical Sciences (Code of \nEthics: IR.AJUMS.REC.1397.950), this study is an epidemiolo-\ngical and cross-sectional study on 50 patients aged 18 to 90 \nyears with the diagnosis of exudative pleural effusion who re-\nferred to Imam Khomeini Hospital in Ahvaz in 2018 and 2019. \nInitially, the goals, benefits of participating in the study, and \nhow to conduct the research were explained to participants. \nEligible patients were then enrolled in the study, if desired, \nwith written consent.\nAt first, demographic data and clinical history of all pa-\ntients were obtained and collected in a checklist. Required \ninformation about the underlying disease and the cause of \npleural effusion was also collected and recorded based on \nthe patient's medical record findings. Patients with exudative \npleural effusion with different etiologies were included in the \nstudy, and biomarkers were measured before any treatment. \nPatients with unknown pleural effusion origin were excluded.\nThe diagnosis of pleural effusion was made after a phy-\nsical examination and chest imaging. Pleural effusion was \nconfirmed by thoracentesis. Microbiological, biochemical, and \ncytological studies were also performed for all patients. Di-\n1 Air Pollution and Respiratory Diseases Research Center, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.  \nCorresponding author: dr_salmanpour@yahoo.com1945\nAssessment of the diagnostic value of CEA, CA125, and CRP and their cut-off point for discrimination of exudative pleural effusions\nfferentiation of transudate and exudate pleural effusions was \nperformed using light criteria. Accordingly, the presence of one of the following indicated exudative pleural effusion.\n- Pleural protein/serum protein ratio > 0.5- Serum LDH/pleural LDH ratio > 0.6- Pleural LDH activity exceeds two-thirds of the highest\nnormal level for serum LDH\n10,24,25.\nA pleural fluid sample was obtained from all patients, and \nthe supernatants were collected after centrifugation (3500 rpm for 10 minutes) and stored at -20\u00b0C for final testing. The pleu-ral fluid sample was inserted through a needle between the rib cage based on examination and percussion, and auscultation (sound reduction and dullness). The samples were sent to the laboratory after collection and the levels of CEA, CA125, and CRP markers in the pleural fluid of the patients were measured.\nCEA and CA125 measurements were performed on pleu-\nral specimens by electrochemical luminescence (ECL) and CRP measurements by turbidometric technique. All biomar-kers were analyzed according to the manufacturer's instruc-tions. Finally, all data collected were analyzed statistically to evaluate the diagnostic value of each tumor marker in different types of exudative pleural effusion.\nStatistical analysis\nThe data are analyzed by descriptive statistics, including \nmean, standard deviation, frequency, and percentage. Data \nwere analyzed using the Kolmogorov-Smirnov test and Q\u2013Q plot and variance homogeneity by Leven test. Independent t-test (or Mann-Whitney nonparametric test), chi-square (orFisher exact test), and logistic regression were used for dataanalysis. The ROC curve was used to determine the diagnosticvalue of tumor markers, and the area under the ROC diagram(AUC) was considered as the diagnostic value of the biomar-ker. Sensitivity, specificity, accuracy, positive and negative pre-dictive values of each tumor marker were also calculated. Allanalyses were performed using SPSS software version 22, and the significance level was considered less than 0.05.Results\nThe distribution of patients by gender was approximately \nsimilar, and the percentage of male and female patients was similar (48% vs. 52%). Patients older than 60 years had the highest frequency (72%) compared to other age groups. The etiology of the disease in most patients was adenocarcinoma and parapneumonic (Table 1).\nTo determine the diagnostic value of CEA, CA125, and CRP \nmarkers in differentiating different types of exudative pleural effusions, patients were divided into three groups according to the etiology of the disease. The mean level of CEA in pleural fluid was significantly higher in patients with malignancy (P <0.05). This rate was also higher in patients with the etiology of tuberculosis than in patients with the parapneumonic diag-nosis. The mean CA-125 level of pleural fluid was significantly higher in patients with malignancy (P <0.05). This rate was also higher in patients with the etiology of tuberculosis than in patients with the parapneumonic diagnosis. The mean pleural fluid CRP level was significantly lower in patients with ma-lignancy (P <0.05). Also, this rate was lower in patients with tuberculosis than in patients with parapneumonic diagnosis (Table 2). \nThe cut-off value with the highest sensitivity and specifi-\ncity for CEA tumor marker differentiation in exudative pleural effusions was more significant than 49.8. According to this cut-off value, the sensitivity of the CEA tumor marker in di-fferentiating different types of exudative pleural effusions was 89.03%, specificity was 78.42%, positive predictive value was 82.01, and negative predictive value was 64.36%.\nThe cut-off value with the highest sensitivity and specifi-\ncity for CA125 tumor marker in the differentiation of exudative pleural effusions was greater than 814.02. Accordingly, CA125 tumor marker sensitivity in differentiating pleural effusions was 53.18%, specificity was 62.44%, positive predictive value was 67.34%, and negative predictive value was 59.19%.\nThe value of highly sensitive and specific cut-off for the \nTable 1. Demographic information of the pa-\ntients.1946\nCRP marker differentiating different types of exudative pleural \neffusions was less than 7.56. Accordingly, CRP marker sensiti-\nvity in differentiating pleural effusions was 82.16%, specificity \nwas 89.05%, positive predictive value was 64.32%, and negati-\nve predictive value was 59.71%.\nDiscussion\nMalignant pleural effusion is a common problem in cancer \npatients that can be both a symptom and a complication of a \npreviously diagnosed malignancy. Despite the combination of \npleural fluid cytology and pleural biopsy, it is not possible to \nobtain a diagnosis in many cases24. Researchers have been re-\nsearching to evaluate the value of pleural fluid analysis in the \ndifferential diagnosis of pleural effusions on different tumor \nmarkers24,25.\nIn our study, 26 patients were male, and 24 were female. \nAlso, in the present study, out of 50 people studied, 18 patients \nwere parapneumonic, 27 patients were adenocarcinoma, 2 pa-\ntients were mesothelioma, and 3 patients were tuberculosis.\nBased on our results, mean levels of pleural fluid CEA and \nCA125 were significantly higher in patients with malignancy \n(P<0.05). It also indicated that the rate is higher in patients \nwith tuberculosis etiology than in patients with the parapneu-\nmonic diagnosis. The threshold for identifying exudative pleu-\nral effusion with the highest sensitivity and specificity for CEA \ntumor markers is more remarkable than 49.8. consequently, \nthe sensitivity of the CEA tumor marker was 89.83%, the spe-\ncificity was 78.42%, the positive predictive value was 82.01%, \nand the negative predictive value 64.36%, which shows and \nhighlights high biomarker effectiveness in the diagnosis of be-\nnign and malignant.\nAlso, the highest sensitivity and specificity for the cut-off \nvalue of the CA125 tumor marker when differentiating types \nof exudative pleural effusion was greater than 814.02. there-\nfore, the sensitivity of the CA125 tumor marker when differen-\ntiating exudative pleural effusions was 53.18%, the specificity \nwas 62.44%, the positive predictive value was 67.34%, and the \nnegative predictive value was 59.19%, as obtained from the \nstudy.\nOwing to the chronic nature of the disease, the approach \non individuals affected by unclassical and even unidentified \npleural effusion is applied. Additionally, using this method \neases the distinguish of malignant cases of tuberculosis with \nlower costs of the experiment26.\nIn the study done by Nguyen et al., who determined the diagnostic value of tumor antigens for malignant pleural effu-\nsions, the sensitivity and specificity were 54.9% and 96.2% for \nCEA tumor markers and 57.5% 92.8% for CA-125, respecti-\nvely15. In another study done by Zhai et al., who investigated the \ndiagnostic accuracy of CEA and CA-125 tumor markers in the \ndifferentiation of malignant pleural effusions, The results indi-\ncated that the serum levels of both tumor markers were signi-\nficantly higher in the types of malignant pleural effusions than \nin benign pleural effusions. The CEA and CA15-3 levels were \nmore stable than the CA-125 and CA19-9 tumors. CEA was \nalso the best marker to distinguish between benign and ma-\nlignant pleural effusions. The sensitivity and specificity of CEA \nwere 84.7% and 90.9% in the pleural and 64.0% and 88.0% in \nthe serum. The sensitivity and specificity for the CA-125 tu-\nmor marker were 49% and 73.1% in the pleural and 60.4% and \n54.8% in the serum14. Tozzoli et al. compared the diagnostic \nvalue of pleural fluid CEA in patients with pleural effusion with \nhistological findings.\nThe results indicated that the sensitivity and accuracy of \npleural fluid CEA were significantly higher than that of pleural \ncytology, and the sensitivity of diagnosis of benign and malig-\nnant cases was high. They deduced that measuring pleural \nfluid CEA in patients with unexplained etiology of a pleural \neffusion is a safe and reasonably priced  way for doctors to \nselect patients for further examination. Increased pleural CEA \nvalues in patients with pleural effusion with negative cytology \nindicate the need for further invasive examinations, whereas \npeople with low pleural CEA values should only be examined \nagain12. In a study by Antonangelo et al., A comparison of tu-\nmor markers in benign and malignant pleural effusions with \npositive, suspicious, and negative cytology showed that the \nCEA and CA125 markers were significantly higher in malig-\nnant effusions with positive cytology. Only the CA125 marker \ntumor score was significantly higher in the negative or sus-\npected cytological results than in the benign effusions in the \npleural fluid. As a result of this study, it could be shown that a \ntumor sensitivity and specificity of up to 60% can be used as \na parameter for the assessment of patients with a suspected \nmalignancy or cancer in the history27. The results of a study \nby Shalaby et al. showed that the CA-125 tumor marker was \nsignificantly higher in patients with exudative effusion than in \npatients with transudative effusion. This tumor marker was \nalso more common in malignant effusions than benign effu-\nsions and tuberculosis compared to other infections. As a re-\nsult, the highest CA125 level of pleural fluid was observed in \nmalignancy and then in tuberculosis, and thus the level of this \nTable 2. Comparison of pleural fluid CEA levels based on disease etiology.Hanie Raji, Seyed Hamid Borsi, Mehrdad Dargahi MalAmir, Ahmad Reza Asadollah Salmanpour\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1947\nmarker tumor in the pleural fluid could be used as a diagnostic \nmarker for pleural effusion21. In the present study, the mean \nCRP of pleural fluid was significantly lower in patients with malignancy (P <0.05). This rate was also lower in patients with tuberculosis etiology than in patients with the parapneumonic diagnosis.\nThe limit with the highest sensitivity and specificity for \nCRP markers when distinguishing different types of exudative pleural effusions was less than 7.56. Accordingly, the sensiti-vity of the CRP markers when differentiating pleural effusions was 82.16%, the specificity 89.05%, the positive predictive value 64.32%, and the negative predictive value 59.71%. In a study by Ji et al. To investigate the role of three markers of procalcitonin (PCT), CRP, and CEA in the differential diagnosis of malignant and benign pleural effusions, the CRP and PCT levels were significantly higher in benign pleural effusions than in malignant cases, while the CEA levels were lower were in benign cases. They concluded that the use of a biomarker is not only suitable for the diagnosis of pleural effusion and is not accurate enough. The combination of pleural CRP, pleural CEA and sPCT can effectively support the diagnosis of pleural effusions\n1,28.\nConclusions\nBased on the present study results, the tumor markers \nexamined in this study had high specificity, but the low sen-sitivity of some of these tumor markers decreased their diag-nostic value. However, since tumor markers in the diagnosis of malignant pleural effusion have many advantages, such as low cost and invasive use, the combination of tumor markers can significantly increase the value and diagnostic accuracy.\nAcknowledgment\nThis research was supported by grants (APRD-9710) from \nAir Pollution and Respiratory Diseases Research Center, Ahvaz \nJundishapur University of Medical Sciences, Ahvaz, Iran. This study is the residency thesis of Dr. Ahmad Reza Asadollah Sal-manpour.\nBibliographic references\n1. Ji M, Zhu X, Dong J , Qian S, Meng F, Gu W, et al. combination of\nprocalcitonin, C\n-\nreaction protein and carcinoembryonic antigens\nfor discriminating between benign and malignant pleural effu-\nsions. Oncology letters. 2018; 16(2): 1727-35.\n2.T\nrap\u00e9 J, Sant F, Franquesa J, Montesinos J, Arnau A, Sala M, et\nal. Evaluation of two strategies for the interpretation of tumourmarkers in pleural effusions. Respiratory research. 2017; 18(1):103.\n3.\nNa \nMJ. Diagnostic tools of pleural effusion. Tuberculosis and re-\nspiratory diseases. 2014; 76(5): 199-210.\n4.\n Light R\nW. Pleural diseases. Lippincott Williams & Wilkins(2007).\n5.Light R\nW. Pleural effusions. Medical Clinics. 2011; 95(6): 1055-70.\n6.F\nerreiro L, Toubes ME, Vald\u00e9s L. Contribution of pleural fluid anal-\nysis to the diagnosis of pleural effusion. Medicina Cl\u00ednica (English Edition). 2015; 145(4): 171-77.\n7.\nBr\naunschweig T, Chung J-Y, Choi CH, Cho H, Chen Q-R, Xie R, et\nal. Assessment of a panel of tumor markers for the differential di-agnosis of benign and malignant effusions by well-based reverse phase protein array. Diagnostic pathology. 2015; 10(1): 1-10.\n8.\n P\norcel JM, Light RW. Pleural effusions. Disease-a-month: DM.\n2013; 59(2): 29.9.Thomas R, Lee Y\nG. Causes and management of common benign\npleural effusions. Thoracic surgery clinics. 2013; 23(1): 25-42.\n10.\n Gu Y\n, Zhai K, Shi H-Z. Clinical value of tumor markers for deter-\nmining cause of pleural effusion. Chinese medical journal. 2016;129(3): 253.\n11.\n V\nolari\u0107 D, Flego V, \u017dauhar G, Bulat-Kardum L. Diagnostic value of \ntumour markers in pleural effusions. Biochemia medica: Bioch-emia medica. 2018; 28(1): 73-83.\n12.\n T\nozzoli R, Basso SM, D'Aurizio F, Metus P, Lumachi F. Evaluation\nof predictive value of pleural CEA in patients with pleural effu-sions and histological findings: A prospective study and literature review. Clinical biochemistry. 2016; 49(16-17): 1227-31.\n13.\n Y\noon DW, Cho JH, Choi YS, Kim J, Kim HK, Zo JI, et al. Predictors \nof survival in patients who underwent video\n\u03b1\nassisted thoracic\nsurgery talc pleurodesis for malignant pleural effusion. Thoraciccancer. 2016; 7(4): 393-98.\n14.\n Zhai K, \nWang W, Wang Y, Liu J-Y, Zhou Q, Shi H-Z. Diagnostic ac-\ncuracy of tumor markers for malignant pleural effusion: a der-ivation and validation study. Journal of Thoracic Disease. 2017;9(12): 5220.\n15.\n Nguy\nen AH, Miller EJ, Wichman CS, Berim IG, Agrawal DK. Di-\nagnostic value of tumor antigens in malignant pleural effusion:a meta-analysis. Translational Research. 2015; 166(5): 432-39.\n16.\n Gu P\n, Huang G, Chen Y, Zhu C, Yuan J, Sheng S. Diagnostic utility\nof pleural fluid carcinoembryonic antigen and CYFRA 21\n\u03b1\n1 in pa-\ntients with pleural effusion: a systematic review and meta\n\u03b1\nanal-\nysis. Journal of clinical laboratory analysis. 2007; 21(6): 398-405.\n17.\n SHI \nHZ, LIANG QL, Jiang J, QIN XJ, YANG HB. Diagnostic value of \ncarcinoembryonic antigen in malignant pleural effusion: A meta\n\u03b1\nanal\nysis. Respirology. 2008; 13(4): 518-27.\n18.\n Liang Q, Shi H, Qin X, Liang X, Jiang J\n, Yang H. Diagnostic ac-\ncuracy of tumour markers for malignant pleural effusion: a me-ta-analysis. Thorax. 2008; 63(1): 35-41.\n19.\n Hammars\ntr\u00f6m S. The carcinoembryonic antigen (CEA) family:\nstructures, suggested functions and expression in normal andmalignant tissues. Seminars in cancer biology 1999; 9(2): 67-81.\n20.\n Shok\nouhi S, Samanabadi M, Gachkar L. Pleural fluid CA-125 in\npatients with pleural effusion. Tanaffos. 2005; 4(23\u201327.\n21.\n Shalab\ny AED, Moussa HA, Nasr A, Samad MA. A study of CA-125 \nin patients with pleural effusion. Egyptian Journal of Broncholo-gy. 2015; 9(3): 283-83.\n22.\n Y\nang Y, Xie J, Guo F, Longhini F, Gao Z, Huang Y, et al. Combina-\ntion of C-reactive protein, procalcitonin and sepsis-related organfailure score for the diagnosis of sepsis in critical patients. Annals of intensive care. 2016; 6(1): 51.\n23.\n Izhakian \nS, Wasser WG, Fox BD, Vainshelboim B, Kramer MR. The \ndiagnostic value of the pleural fluid C-reactive protein in parap-neumonic effusions. Disease Markers. 2016; 2016(\n24.\n  Hackner K, Errhal t P, Handzhiev S. Ratio of carcinoembryonic an-\ntigen in pleural fluid and serum for the diagnosis of malignantpleural effusion. Therapeutic Advances in Medical Oncology.2019; 11(1758835919850341.\n25.\n Y\nang Y, Liu Y-L, Shi H-Z. Diagnostic accuracy of combinations of\ntumor markers for malignant pleural effusion: an updated me-ta-analysis. Respiration. 2017; 94(1): 62-69.\n26.\n Shen Y\n, Liang Y, Cheng X, Lu W, Xie X, Wan X. Ovarian fibroma/\nfibrothecoma with elevated serum CA125 level: A cohort of 66cases. Medicine. 2018; 97(34):\n27.\n Antonangelo L, Sales R, Cor\n\u00e1 A, Acencio M, Teixeira L, Vargas F.\nPleural fluid tumour markers in malignant pleural effusion withinconclusive cytologic results. Current Oncology. 2015; 22(5):e336.\n28.\n Dehk\nordi FS, Valizadeh Y, Birgani TA, Dehkordi KG. Prevalence\nstudy of Brucella melitensis and Brucella abortus in cow's milkusing dot enzyme linked immuno sorbent assay and duplex poly-merase chain reaction. J Pure Appl Microbiol. 2014;8(2):1065-9.\nReceived: 30 February 2021\nAccepted: 15 May 2021Assessment of the diagnostic value of CEA, CA125, and CRP and their cut-off point for discrimination of exudative pleural effusions1948\nFrancisco J. Alvarez, Mariela Perez-Cardenas, Marco Gudi\u00f1o, Markus P. Tellkamp\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nTips for a reduction of false positives in manual RT-PCR diagnostics of \nSARS-CoV-2\nFrancisco J. Alvarez, Mariela Perez-Cardenas, Marco Gudi\u00f1o, Markus P. Tellkamp DOI. 10.21931/RB/2021.06.03.11\nAbstract: RT-PCR is the standard gold technique for testing the presence of RNA of the coronavirus causing Severe Acute \nRespiratory Syndrome (SARS-CoV-2) due to its high specificity and sensitivity. Despite its general use and reliability, no lab in \nthe world is immune to the generation of false positives. These errors cause a loss of confidence in the technique's power and \ndamage the image of laboratories. More importantly, they can take a toll on tested individuals and have economic, psychological, \nand health-associated effects. Most false positives are caused during a manual operation inside the laboratory. However, not \nmuch has been published about the errors associated with particular laboratory techniques used to detect the virus since the \nbeginning of the actual pandemic. This work precisely reflects on events that occur during manual RT-PCR diagnostics in a \nCOVID-19 laboratory, providing tips for reducing false-positive results.\nKey words: SARS-CoV-2, false positives, RNA extraction, RT-PCR.RESEARCH / INVESTIGACI\u00d3N\nIntroduction\nIn COVID-19 diagnostics labs, most errors in reporting \nconsist of false negatives due to the low viral load that es-\ncapes detection. Therefore, the sampling time is significant: a \nsample taken too early after the person has been infected may \nhave too low a viral load to be detected1. Likewise, a sample \ntaken after the patient has cleared the virus almost wholly \nwould result in a very low viral titer. The skills of the doctor \nor nurse in charge of taking the samples from patients can \nalso contribute to generating false negatives. In addition, the \nchoice of transport medium where the sample is carried to the \nlabs for analysis, whether the sample contains blood, and the \ntemperature during storage and/or transportation can make a \ndifference in the quality of the sample before its processing. \nFalse negatives are of great concern for public health mana-\ngement, but the impact of false positives has come to the fore \nrecently due to the distress they can cause in the lives of pa-\ntients and public health.\nThe RT-PCR (Reverse Transcriptase Polymerase Chain \nReaction) is the standard gold technique for detecting the \nSARS-CoV-2 virus. It is routinely used for samples from diver-\nse origins, such as nasopharyngeal and throat swabs, sputum, \nbroncho-alveolar lavages2, and anal swabs3. It can detect as \nfew as 5 copies of the virus in a sample4 and is, therefore, the \ntechnique of choice to reveal which individuals are contagious \nat any time of their infection period. They outcompete sero-\nlogical tests, which need a higher viral load to produce a po-\nsitive result or indirectly measure the virus's presence in the \norganism. The RT-PCR has a sensitivity (ability to detect true \npositives) of 70% and a specificity (ability to report well true \nnegatives) close to 100%5,6. Having such sensitivity, the techni-\nque can easily amplify contaminating virus particles that don't \nbelong to the actual samples to be tested. Hence, RT-PCR can \ngenerate false positives with a significant likelihood. Althou-\ngh few studies report on rates of false positives for COVID-19, \nsome estimates of false-positive rates suggest them to be in \na range of about 0.3-4%7-9. For SARS-CoV and MERS-CoV, the \nrate oscillated between 0.3-6.9%10.\nFalse positives can also arise due to errors in reporting the \nresults and uncertainties regarding the cycle-threshold (Ct) \nvalue used as a diagnostic criterium11. The former point can be addressed by judicious data entry; however, the latter poses a \ntrue challenge when Ct values are close to the cut-off. Here, \nthe likelihood of a false positive or false negative is highest. \nFor instance, if a Ct of 40 is chosen as the diagnostic criterium, \ndoes a Ct of 39.5 necessarily mean that 1) the true Ct is indeed \nbelow 40 and 2) is the patient still infectious?11,12\nA false positive report on healthy people can have dra-\nmatic consequences, varied and challenging to quantify. A po-\nlitician may be deprived of a critical meeting for the citizens \nhe represents. A skilled celebrity may be deprived of a signi-\nficant sports competition. Worse even, the economic distress \ncaused to those belonging to low-income groups in the society \nis more significant, for they may have to stop working, may \nhave dependents, and no savings. The stigma of being ca-\nlled positive and the fear of suffering complications can also \nbe detrimental psychologically for many. Besides, healthy \nbut wrongly diagnosed positive, people may be put at risk of \nreal contagion when moved to areas in a hospital with infec-\nted patients or may suffer the delay of an essential medical \nprocedure10,13. Unfortunately, due to the severity of the current \npandemic, it is not feasible to perform confirmatory PCRs for \nevery patient whose sample yielded a positive result. Instead, \ncurrent guidelines by international and national public health \nagencies recommend evaluating every PCR result on a case by \ncase basis in combination with the evaluation of local infection \nrates, clinical signs and symptoms, lung CT scans, and history \nof exposure10. The consequences for the labs that report false \npositives and negatives can also be dramatic. With their ima-\nge damaged, contracts for private labs may be postponed, and \npotential customers' confidence can vanish. Public labs are \nalso questioned when reports of false positives appear. Howe-\nver, false positives are unavoidable and cannot be eliminated in \nany laboratory. However, it should be possible to reduce them \nto a minimum to better comply with the targets of national \nregulatory agencies.\nThe standard laboratory workflow for COVID-19 testing \ngoes in one direction and has multiple barriers to prevent \ncross-contamination. Laboratory technicians have routinely \ntested themselves for covid, for apparent reasons. Still, the \nlaboratory is the primary source of false positives, mainly \n1 Yachay Tech University, School of Biological Sciences and Engineering, Hda. San Jos\u00e9 s/n y Proyecto Yachay, Urcuqu\u00ed, Ecuador  \nCorresponding author: falvarez@yachaytech.edu.ec1949\nTips for a reduction of false positives in manual RT-PCR diagnostics of SARS-CoV-2\ncross-contamination due to human error10. In this review, we'll \ndiscuss working habits that reduce the occurrence of false-po-\nsitive reports of coronavirus infection while navigating the ma-\nnual processing of nasopharyngeal swabs in all phases of the \nworkflow. The tips provided are based on personal experience \nof false positives while working in a COVID-19 test lab at Ya-\nchay Tech University, using typical kits and equipment.\nReduction of false positives in the RNA extraction area\nThe manual processing of samples during RNA extraction \nconstitutes the highest source of false positives in the labora-\ntory, but there is much room for improvement. The processing \nof samples in the RNA extraction area starts with setting the \nlaminar flow hood under UV light for several minutes while the \nairflow stabilizes14. A small centrifuge should be located inside \nthe hood, and it should be left open during UV irradiation to ex-\npose the rotor. The space under the hood should not be crow-\nded to help the airflow exert its function and allow the UV light \nto reach most surfaces. If more than one batch of samples is \ngoing to be processed in the day, it is advisable to have rounds \nof UV irradiation in between batches. Next, parts and equip-\nment to be used to process the samples are cleaned with 70% \nethanol. Only filtered tips are used for the extraction and must \nbe changed for every sampling step of the extraction process. \nTube racks should be stable to avoid spills. Reagents should be \naliquots of the original kit contents to minimize costs if conta-\nmination (reagent contamination is a significant source of false \npositives but easy to identify because most likely, all samples \nof the same batch would come out positive and with similar Ct \nvalues). Lab technicians must wear protective gear with very \nfit pairs of gloves, without folds on the surface of their finger-\ntips. Once the site is clean, the lab technician starts preparing \na master mix that ensures that all the samples get the same \ninitial buffer solution. Fig. 1 shows the process of RNA extrac-\ntion for a typical commercial kit, with few modifications of the \noriginal protocol. Similar steps apply to many other commer-\ncial kits. Double arrows A to C at the bottom indicate the times \nat which different contamination types can occur. The master mix contains an extraction control that helps \nverify whether the extraction process has been optimal for \nevery individual sample. As an example, this control can be \nthe RNA of a cellular household gene such as actin. This will \nlater appear as a specific curve in the PCR reaction since the \nprimers for that gene will be included in the primer mix used \nfor the PCR reaction. The signal generated during PCR amplifi-\ncation will appear in a different channel than that of the SARS-\nCoV-2 target gene of interest. The absence of the extraction \ncontrol curve in all the samples of the batch in the PCR would \nindicate that it was probably not added to the master mix. If \nabsent in only one or a few samples, it could indicate the pre-\nsence of inhibitors of the PCR reaction such as ethanol, and \nthe extraction of those particular samples should be repeated.\nOnce the master mix has been added to all the micro-\ncentrifuge tubes, it is time to place the nasopharyngeal swab \nsamples inside the hood, which had been kept in a refrigerator \nupon arrival. Careless manipulation of swab samples can ge-\nnerate mix-ups leading to false positives. The manipulation of \npatient samples entails a high risk of contamination (arrow A, \nbottom of Fig. 1) that can then be passed down throughout \nthe extraction process. Tubes should ideally be opened with a \nhand that does not hold the micropipette to avoid contamina-\nting it. A brief vortex ensures a good mix for every sample and \npotentially generates aerosols that can contaminate the wor-\nking area. That is why it is essential to work under the hood, \nwith the airflow removing those aerosols. Aerosols can also \nadhere to the shaft of the micropipettes, especially when they \nare introduced deep into the patient's sample tubes or touch \nthe swabs that usually come within. If that happens, the parts \nsuspected of being contaminated should be wiped with 70% \nethanol between pipetting samples. Once the micropipette \ntip is loaded with the sample, keeping it at an angle instead \nof vertically prevents dripping of the content for a sufficiently \nlong time before adding it to the microcentrifuge tube. Also, it \nis common practice in molecular biology or microbiology labs \nto eject the residual volume of the tip with an extra push of the \nmicropipette plunger. This, however, is an essential source of \nFigure 1. Diagram showing the steps for viral RNA isolation using a standard commercial kit (QIAamp\u00ae Viral RNA Mini Kit, \nQiagen), with few modifications. Letters A-C at the bottom indicate different types of contamination for the different steps of \nsample processing mentioned in the text.1950\naerosols. Therefore, it is desirable to avoid ejecting that resi-\ndual volume to avoid cross-contamination during the extrac-\ntion of SARS-CoV-2 viral RNA.\nThe negative control of the extraction (NCE) must be the \nlast microcentrifuge tube of every batch of samples to ensure \nthat contamination is appropriately detected. Nuclease-free \nwater is added to the tube instead of the viral sample. Being \nthe last tube of the batch, the NCE will help identify cross-con-\ntamination events from aerosols of a positive sample of the \nsame batch. In the PCR, the NCE should only yield the curve \ncorresponding to the extraction control. In the case the NCE \nproduced the curve corresponding to the SARS-CoV-2 gene \nbeing tested, the extraction of the whole batch should be re-\npeated. Fig. 2A shows the fluorescence profile of the extrac-\ntion control in the amplification plot of a positive sample. \nFinally, many extraction kits require a few minutes to in-\nactivate the virus. That time can be used to clean surfaces in \ncontact with patient samples, tip boxes, micropipettes, and the \nmicrocentrifuge tubes' exterior. Once the samples have been \ninactivated in the first steps of the RNA extraction process, the \nrisk of acquiring floating virus particles is significantly redu-\nced, and many labs continue their work on the bench. However, \nthe risk of cross-contamination among samples is higher on \nthe bench than on the laminar flow hood. Hence, although not \ndeemed necessary for the protection of the lab technician, a \nlaminar flow hood helps avoid the generation of false positives \namong samples. During the intermediate steps of the extrac-\ntion process, errors during pipetting and handling of samples \nand reagents account for additional cross-contamination risks \n(arrow B, bottom of Fig. 1). It is advisable always to assume \nthat aerosols from positive samples are present in the air to \nincrease the sense of alertness and carefulness during the \nhandling of microcentrifuge tubes, buffer solutions, and micro-\npipettes. When using the micropipette, the tips should not en-\nter too deep into solutions because that facilitates the carryo-\nver of the solution and its posterior dripping. Very importantly, \nbuffer solutions should be opened only when needed, keeping \ntubes closed in the meantime.\nMost extraction kits require the use of small centrifuges \nfor several steps. The centrifuges are challenging to clean \nfrom aerosols generated from positive samples during the \nmanipulation of the tubes. A high risk of contamination occurs in the elution step (arrow C, bottom of Fig. 1) when a column is \ncommonly placed inside an open microcentrifuge tube. Having \nit open, the lid of the microcentrifuge tube sometimes breaks \nduring the final elution spin. Again, it is essential to use tightly \nfitting gloves when picking up the tubes and columns from the \ncentrifuge. Centrifuges should be cleaned thoroughly after the \nprocessing of every batch of samples.\nThe use of automatized systems for RNA extraction im-\nproves the processing speed enormously and reduces the \nchances of cross-contamination. During manual feeding of pa-\ntient samples to the robot in the laminar flow hood, errors can \nstill happen at the initial step of the process. If possible, the \noperator should close all the wells that are not being used. To \navoid pipetting errors, it is advised to mark during the loading \nprocess the wells of the plate where the sample has been al-\nready added. Once the work under the laminar flow hood has \nended, it must be cleaned, and UV irradiated to inactivate any \nvirus particles that could have escaped in aerosols during the \nextraction process15. Automatized systems also need to be UV \nirradiated after use.\nReduction of false positives in the pre-PCR area\nThe most common method for producing reliable test re-\nsults involves the use of an RT-PCR thermocycler. The con-\nversion of the extracted RNA into DNA is carried out by a retro \ntranscriptase, while a DNA polymerase does further amplifica-\ntion of that DNA. Both enzymes can be part of the same mix \n(one-step RT-PCR) or separate reactions (two-step RT-PCR). \nThe PCR mix must include primers and fluorescent probes for \na SARS-CoV-2 gene and for the extraction RNA target gene \nthat was added during viral RNA extraction as a control. The-\nse reagents are added in the pre-PCR area, space physically \nseparated from the room in which the thermocycler is used. In \nthe pre-PCR area, the lab technician will aliquot the PCR mix \nin the wells of PCR plates or tubes and then add the extracted \nRNA and controls.\nThere is absolutely no risk for the lab technicians in the \npre-PCR area to be contaminated with active viruses. They \ncan, however, bring contamination to the sample preparation \narea on her clothes. To avoid carrying over amplicons or viral \nRNA on their clothes, personnel who work in the pre-PCR area \nFigure 2. A) Amplification plot of a positive sample showing the extraction control (blue line) and the amplification of the \nSARS-CoV-2 gene (red line); B) Comparison of the amplification plots of two samples with low Ct (left) and two with high Ct \n(right). The horizontal line indicates the threshold of the PCR reaction.Francisco J. Alvarez, Mariela Perez-Cardenas, Marco Gudi\u00f1o, Markus P. Tellkamp\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1951\nmust use a different lab coat and gloves than those used in \nother areas of the laboratory. Although in principle, the assem-bling of the PCR can take place on the bench, it is advisable to use a laminar flow hood for that purpose, similar to what was recommended for the extraction area, to prevent aerosols from positive RNA samples contaminating the wells of the PCR strips or plates. In Ecuador, a laminar flow hood is a man-datory requirement for this area. We must never forget how sensitive the PCR technique is and detect as few as 5 copies of viral cDNA\n4. Similar to what is done in the extraction area, the \nlaminar flow hood must be irradiated for 10-20 minutes with UV light until the airflow stabilizes before assembling the PCR reaction.\nDespite working under the laminar flow hood, we must \nassume that aerosols containing RNA from positive samples could still be present and cause false positives. Hence, a good piece of advice for the assembly of the PCR is to keep all the wells in the PCR strips or plates covered at all times and only lift the caps (strips) or optical film (plates) when a new sample must be added to the appropriate well. Keeping nearby a log of the position of the samples in the wells helps to prevent mistakes during sample loading. Again, to prevent the spread of aerosols, it is essential to use very fit gloves, without folds on the surfaces of the fingertips, to properly open and cap the tubes (strips) or hand the optical film (plates). The closing of the caps of PCR tubes may require applying great force, which can cause vibrations on the cold rack that supports the strips and make them move or fall off the rack. For that reason, it is good to write a small number or another type of code on top of each PCR strip that indicates the orientation and position of wells in the PCR to be run. Another suggestion to avoid ae-rosols is to not pipet the sample up and down to mix in with the PCR reagents in each tube. This common practice is not needed since the PCR strips or plates will be spun down in a centrifuge before taking them to the thermocycler. Combined with the high temperatures of the PCR process itself, the ho-mogeneity of the reagent solution is assured.\nThe PCR reaction's assembly, a negative and one posi-\ntive control, respectively, needs to be included. The negative control (Non-Template Control, NTC) contains the mix with the buffer, polymerase, and primers for the PCR reaction but nuclease-free water is added instead of extracted RNA. The control also lacks the extraction control added to the samples processed in the RNA extraction area. At the end of the PCR run, the NTC profile should be a flat line for all the channels. The positive control (PC) has the same content as the NTC, but instead of water, the same gene of the SARS-CoV-2 virus that the primers detect in the actual patient samples. The PC also lacks the extraction control added to the samples in the extraction process, and it also emits fluorescence in a different channel. Fig. 2A shows the fluorescence profile from a positive sample for SARS-CoV-2 at the end of the PCR run.\nBoth NTC and PC must be placed at the end of the assem-\nbly of the PCR reaction after all the other samples have been loaded. In this way, the NTC will serve the purpose of letting us know whether cross-contamination has taken place during the assembly process. If the NTC yields a positive signal for the gene of interest, the PCR should be repeated because either the master mix was contaminated or aerosols from a positi-ve sample were spread during the assembly process to other samples. If possible, the negative controls from the RNA ex-traction step (NCEs) should not be added at the end to the PCR strips or plates to minimize their possible contamination with aerosols from positive samples during the assembly process. In this way, if the NCEs yield a positive signal for the viral gene of interest but the NTC produces a negative signal, we could be confident that the cross-contamination event has taken place during the RNA extraction steps and not in the pre-PCR area. If, on the other hand, one suspects contamination events taking place in the pre-PCR area, it is advisable to aliquot known ne-gative samples or NTCs to the PCR plate and check afterward whether they yield a positive signal.\nAlthough we focus mainly on the events that can genera-\nte false-positive results, there is also a chance of generating false negatives in the pre-PCR area. One way is to accidentally not pipetting up any liquid from the RNA sample. This can ha-ppen, for example, if there is an air bubble in the microcentrifu-ge tube and the tip of the micropipette just absorbs air instead of sample. That is why it is important not to lower the concen-tration during work on the bench and always look at the tips to make sure the liquid is absorbed and again check after centri-fugation that every tube in the strip or plate has the same volu-me. Staying focused and being mindful of every movement of the hands above the wells in the strips or plate helps minimize the risk of contamination at every step of the process. Where available, the use of multichannel pipettes also greatly helps to speed up the PCR assembly process. However, they can also fail to acquire the desired volume in some of the channels and be a source of false negatives.\nReduction of false positives in the PCR area\nAn essential source of false positives that can originate in \nthe PCR area is amplicon contamination. This occurs when the \nproducts of a previous PCR are accidentally released and mi-grate to other parts of the laboratory. The tubes with positive samples contain trillions of copies of the amplified genes that could easily contaminate future extraction processes and PCR assemblies. Even an initially slightly positive sample with a low viral load whose manipulation would not represent much risk during the extraction process can cause significant problems once the target genes have been exponentially multiplied\n16. To \navoid this type of risk, PCR tubes or plates should be dispo-sed of outside the PCR room at the end of the PCR run. Both the pre-PCR and PCR rooms must be physically separated and have independent air extraction systems. It is recommended not to cross from the PCR room to the extraction and pre-PCR rooms wearing the same protective clothing. Another possible source of false positives occurs when tube strips or plates are not adequately balanced during the centrifugation before the PCR run. This causes vibrations that can disperse the contents of the PCR tubes onto their walls, leading to underestimated readings by the thermocycler.\nThe best way to prevent amplicon contamination is the \nimplementation of a regular cleaning protocol for all surfaces in the lab-based on 10% (w/v) sodium hypochlorite -a chemi-cal amplicon oxidizer- followed by a rinse with 70% ethanol (to avoid the corrosive effect of the bleach on equipment)\n17,18. \nCommercial products abound that include diluted NaOH in their formulations. The use of UV irradiation in Class II bios-afety cabinets\n14 or portable UV lights can also be of great \nhelp. Inactivating enzymatic methods such as degradation by uracyl-N-glycosylase\n19,20 can be included in the PCR reaction \nmix. On the other hand, inactivation protocols that require theopening of the PCR tubes after amplification are to be avoided.\nThe Ct (cycle threshold) is the cycle number when the \nfluorescence of the amplicons surpasses the threshold fluo-rescence during the PCR run. In our lab, based on the experien-ce of other labs using the same diagnostics kits, a Ct value of 40 or earlier is interpreted as a positive result for COVID-19. Tips for a reduction of false positives in manual RT-PCR diagnostics of SARS-CoV-21952\nThe Ct value also measures how many copies of the target \ngene were in the original sample. The smaller the Ct, the more viral copies the sample has. Fig. 2B shows the amplification plots of four samples, two of them with low Ct values indica-ting high titers of the target gene. A sample with Ct 10 con-tains thousands of more copies in origin than a sample of Ct 20. Extraction of samples with high viral titers constitutes avital source of contamination for the subsequent samples inthe batch due to the unintended release of aerosols\n20. One can\nne\nver know beforehand which sample has a high viral titer; this \nis learned after the PCR. Automatic extraction reduces the risk of cross-contamination from high viral titer samples.\nIn the analysis post-PCR analysis, the lab personnel must \ndecide in every case whether the sample is positive or negati-ve, looking both at the Ct values and the curves. False positives can appear due to the presence of inviable viral particles in patients who are in the process of clearing the remains of the virus from their bodies. If the data look sound, the lab must report those results as positives and let the clinicians make the final decision based on the patients' medical history, local rates of COVID-19 infections, patient's signs and symptoms of the disease, or serological analysis\n6,10,21.\nWhen the signal of the SARS-CoV-2 gene in the PCR \nappears with a Ct value close to (above or below) 40 (like the sample with Ct 39 in Fig. 2B), a definite diagnosis should not yet be made by the lab processing the samples. Such a pro-file could result from contamination with aerosols of a close sample with a very low Ct value. The fastest solution is to re-peat the extraction of that particular sample on the same day. Alternatively, one can request another sample of the same patient within 2-3 days: if the patient happened to be at the beginning of the infection process, she will appear positive in the second PCR, while a negative result would mean clearance of the virus at the end of the infection period. On average, the best time to get a sample that results in a lower chance of false-negative is eight days after infection or three days after the onset of symptoms\n1.\nAll lab members in charge of the analysis post-PCR should \nbe using precisely the same criteria. For that, an algorithm like the one in Fig. 3 can be devised and agreed upon. That way, based on the PCR results, any user can quickly troubleshoot unusual results, find the cause of false positives, and make amendments before reporting the results. Note that despite all the controls being correct at the bottom of Figure 3, one must still be wary of an unusual number of positive samples, especially if they appear grouped. In this case, we recommend that a subset of the samples that also includes negatives be subjected to another round of viral RNA extraction and PCR. As an internal quality control measure, a small fraction of the daily samples arriving at the lab can be randomly selected for retesting. The selection of samples should be made before knowing the results of the PCR test, allowing for the inclusion of both positive and negative samples.\nFigure 3. Algorithm post-PCR for the evaluation of the re -\nsults. NCE, negative control of the \nextraction; NTC, negative \ncontrol of the PCR; PC, positive control of the PCR.Francisco J. Alvarez, Mariela Perez-Cardenas, Marco Gudi\u00f1o, Markus P. Tellkamp\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1953\nDiscussion\nHaving navigated through all the steps of manual sam-\nple processing in a laboratory of COVID-19 testing, one must \nnot forget the importance of selecting the best personnel for the different tasks to be performed. Good leadership is neces-sary to be aware of the strengths and weaknesses of every person working in the lab and get the best out of everyone. False positives are mainly produced through unintentional errors during viral RNA extraction, the assembly of the PCR, and even data management. Hence, a tremendous amount of focus and manual dexterity is expected in laboratory workers to avoid pipetting errors. Maintaining focus is essential in the COVID-19 testing laboratory since many everyday tasks can be repetitive, and the operator may easily engage in detrimental mind-wandering behavior for brief periods of time\n21. At times \nthe amount of COVID-19 samples arriving at the lab is too tremendous, and several shifts are required to process them. The schedules must be made to avoid too much strain on the workers, thus ensuring that the workers enjoy what they do and maintain a positive attitude in the lab. Remembering that sample numbers are numbers and represent people and their families can be another source of motivation.\nIt is common practice to interpret PCR results in the con-\ntext of the pretest probability of the disease\n13. For example, a \npatient that appears positive for COVID-19 by PCR but has no symptoms or medical history of the disease has no antibodies and was not exposed to the disease could be considered a fal-se positive. In our opinion, that is a call that doctors should make but not be the labs reporting their results. In case of doubt, it is always better to repeat the RNA extraction or PCR or ask for a new sample. Similarly, a positive result in someone already known to have contracted the disease weeks ago is still positive, although she may not be infectious anymore and is probably just shedding inviable virus particles\n22.\nSamples with low Ct values cause more trouble in the lab \nin terms of the production of false positives than those of high Ct values during the manual processing of samples. Although sampling introduces a great deal of variability in the first place, low Ct values reflect high titers of the SARS-CoV-2 gene. This seems associated with a high viral load in the original patient samples, for those with low Ct values are more culture-po-sitive than those with high Ct values\n23 and correlate with the \nrisk of intubation and in-hospital mortality12,24. Hence, it could \nseem that reporting the Ct value would be very useful for phy-sicians. However, the issue is up for debate nowadays, mainly due to the high Ct values between and within methods\n11 and \nduring sampling.\nConclusions\nFrom our experience, it is virtually impossible to elimi-\nnate false positives in the COVID-19 diagnostics lab comple-tely. Manual processing requires multiple manipulations of samples and reagents, which translates easily into events of contamination. Automatized systems can significantly reduce (but not eliminate) the appearance of false-positive results. Contamination from samples with very low Ct values is more likely to occur during the extraction process than during the assembly of the PCR. It is advisable to routinely repeat the ex-traction of positive samples from a batch in which very high viral titer samples were included, especially when too many positives appear clustered together. Also, as an internal qua-lity control measure to gain confidence in their results, labs can temporarily keep a small fraction of their daily samples, chosen randomly, for retesting. With the comments of this ar-ticle, we hope to contribute to a reduction in the rate of false positives in labs dedicated to similar tests elsewhere during the manual processing of COVID-19 samples.\nDeclarations\nFunding: No funds, grants, or other support was received.\nConflicts of interest/Competing interests: Francisco Alva-\nrez, Mariela Perez, Marco Gudi\u00f1o, and Markus Tellkamp decla-\nre that they have no conflicts of interest.\nEthics approval: Not applicable.\nConsent to participate: Not applicable.Consent for publication: Not applicable.Availability of data and material:  Not applicable.Code availability: Not applicable.Authors' contributions: Francisco J. Alvarez wrote the \nmanuscript and created the figures. Mariela Perez-Cardenas, \nMarco Gudi\u00f1o-Gomezjurado and Markus P. Tellkamp edited the manuscript.\nAcknowledgments\nWe want to thank GIZ (Deutsche Gesellschaft f\u00fcr Inter-\nnationale Zusammenarbeit) for their support, providing equip-\nment, detection kits, and reagents for the majority of tests at Yachay Tech University. We also want to thank the Prefecture of Imbabura, local governments, and enterprises for their help in adapting our university labs for COVID-19 testing.\nWe also want to acknowledge the rest of the team COVID \nat Yachay Tech University: Karla Mi\u00f1o, Abigail Montero, Danie-la Navas-Le\u00f3n, Mar\u00eda Paula Romero, Carlos Pazmi\u00f1o, Karen S\u00e1nchez and Alexandra Y\u00e9pez.\nBibliographic references\n1. K ucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J (2020) \nVariation in False-Negative Rate of Reverse Transcriptase Poly-\nmerase Chain Reaction-Based SARS-CoV-2 Tests by TimeSince Exposure. Ann Intern Med 173(4):262-267. https://doi.org/10.7326/M20-1495\n2.\nW\nang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W (2020) Detection \nof SARS-CoV-2 in different types of clinical specimens. JAMA.https://doi.org/10.1001/jama.2020.3786\n3.\nKipk\norir V, Cheruiyot I, Ngure B, Misiani M, Munguti J. Prolonged\nSARS-CoV-2 RNA detection in anal/rectal swabs and stool speci-mens in COVID-19 patients after negative conversion in nasopha-ryngeal RT-PCR test. J Med Virol. 2020 Nov;92(11):2328-2331.doi: 10.1002/jmv.26007. Epub 2020 2 August. PMID: 32401374;PMCID: PMC7272912.\n4.\n Corman VM, Landt O\n, Kaiser M, Molenkamp R, Meijer A, Chu\nDKW, Bleicker T, Br\u00fcnink S, Schneider J, Schmidt ML, MuldersDGJC, Haagmans B, van der Veer B, van den Brink S, WijsmanL, Goderski G, Romette JL, Ellis J, Zambon M, Peiris M, Goos-sens H, Reusken C, Koopmans MPG, Drosten C (2020) Detectionof 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.Euro Surveill 25(3):2000045. https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045Tips for a reduction of false positives in manual RT-PCR diagnostics of SARS-CoV-21954\n5.Sethur aman N, Jeremiah SS, Ryo A (2020) Interpreting Diagnos-\ntic Tests for SARS-CoV-2. JAMA. 323(22):2249\u20132251. https://doi.\norg/10.1001/jama.2020.8259\n6.W\natson J, Whiting PF, Brush JE (2020) Interpreting a covid-19\ntest result. BMJ. 369:m1808. https://doi.org/10.1136/bmj.m1808\n7.Albend\u00edn-Iglesias \nH, Mira-Bleda E, Roura-Piloto AE, Hern\u00e1n-\ndez-Torres A, Moral-Escudero E, Fuente-Mora C, Iborra-Bendicho A, Moreno Doc\u00f3n A, Galera Pe\u00f1aranda C, Garc\u00eda V\u00e1zquez E (2020) Usefulness of the epidemiological survey and RT-PCR test inpre-surgical patients for assessing the risk of COVID-19. J HospInf 105(4):773-5. https://doi.org/10.1016/j.jhin.2020.06.009\n8.\n K\natz AP, Civantos FJ, Sargi Z, Leibowitz JM, Nicolli EA, Weed D,\nMoskovitz AE, Civantos AM, Andrews DM, Martinez O, ThomasGR (2020) False-positive reverse transcriptase polymerase chain reaction screening for SARS-CoV-2 in the setting of urgent headand neck surgery and otolaryngologic emergencies during thepandemic: Clinical implications. Head & Neck 42:1621-8. https://doi.org/10.1002/hed.26317\n9.\nCohen AN, K\nessel B (2020) False positives in reverse transcrip-\ntion PCR testing for SARS-CoV-2. medRxiv preprint https://doi.org/10.1101/2020.04.26.20080911\n10.\n Cohen AN, K\nessel B, Milgroom MG (2020) Diagnosing SARS-CoV-2 \ninfection: the danger of over-reliance on positive test results.medRxiv preprint https://doi.org/10.1101/2020.04.26.20080911\n11.\n Rhoads D\n, Peaper DR, She RC, Nolte FS, Wojewoda CM, Ander-\nson NW, Pritt BS (2020) College of American Pathologists (CAP)Microbiology Committee Perspective: Caution must be used in in-terpreting the Cycle Threshold (Ct) value. Clin Infect Dis.  https://doi.org/10.1093/cid/ciaa1199\n12.\n Magleb\ny R, Westblade LF, Trzebucki A, Simon MS, Rajan M, Park\nJ, Goyal P, Safford MM, Satlin MJ (2020) Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load on Risk of Intu-bation and Mortality Among Hospitalized Patients With Coro-navirus Disease 2019. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaa851\n13.\n Surk\nova E, Nikolayevskyy V, Drobniewski, F (2020) False-posi-\ntive COVID-19 results: hidden problems and costs. The Lancet.https://doi.org/10.1016/S2213-2600(20)30453-7\n14.\n P\nadua R, Parrado A, Larghero J, Chomienne C (1999) UV and\nclean air result in contamination-free PCR. Leukemia 13:1898\u20131899. https://doi.org/10.1038/sj.leu.2401579\n15.\n S\ntorm N, McKay LGA, Downs SN, Johnson RI, Birru D, de Samber \nM, Willaert W, Cennini G, Griffiths A (2020). Rapid and completeinactivation of SARS-CoV-2 by ultraviolet-C irradiation. Sci Rep10, 22421. https://doi.org/10.1038/s41598-020-79600-8\n16.\n P\nersing DH (1990) Polymerase chain reaction: trenches to bench-\nes. J Clin Microbiol 29:1281-128517.  Ha yatsu H, Pan S, Ukita T (1971) Reaction of sodium hypochlorite \nwith nucleic acids and their constituents. Chem Pharm Bull (To-kyo). 19(10):2189-92. https://doi.org/10.1248/cpb.19.2189\n18.\n K\nampmann ML, B\u00f8rsting C, Morling N (2017) Decrease DNA con-\ntamination in the laboratories. Forensic Science International: Ge-netics Supplement Series 6:e577-e578. https://doi.org/10.1016/j.fsigss.2017.09.223\n19.\n Longo MC\n, Berninger MS, Hartley JL (1990) Use of uracil DNA\nglycosylase to control carry-over contamination in polymerasechain reactions. Gene 93(1):125-8. https://doi.org/10.1016/0378-1119(90)90145-h\n20.\n Sefers S, S\ntratton CW, Tang YW (2013) Amplification Product In-\nactivation. In: Tang YW., Stratton C. (eds) Advanced Techniquesin Diagnostic Microbiology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-3970-7_26\n21.\n McV\nay, J. C., & Kane, M. J. (2012). Drifting from slow to \"d'oh!\":\nWorking memory capacity and mind wandering predict extremereaction times and executive control errors. Journal of Experi-mental Psychology: Learning, Memory, and Cognition, 38(3),525\u2013549. doi:10.1037/a0025896\n22.\n W\n\u00f6lfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, M\u00fcller \nMA, Niemeyer D, Jones TC, Vollmar P, Rothe C, Hoelscher M, Ble-icker T, Br\u00fcnink S, Schneider J, Ehmann R, Zwirglmaier K, Dro-sten C, Wendtner C (2020) Virological assessment of hospital-ized patients with COVID-2019. Nature. https://doi.org/10.1038/s41586-020-2196-x\n23.\n Jaafar R, Aherfi S, W\nurtz N, Grimaldier C, Van Hoang T, Col-\nson P, Raoult D, La Scola B (2020) Correlation Between 3790Quantitative Polymerase Chain Reaction\u2013Positives Samples andPositive Cell Cultures, Including 1941 Severe Acute RespiratorySyndrome Coronavirus 2 Isolates. Clinical Infectious Diseases.https://doi.org/10.1093/cid/ciaa1491\n24.\n R\nao SN, Manissero D, Steele VR, Pareja J (2020) A Systemat-\nic Review of the Clinical Utility of Cycle Threshold Values in theContext of COVID-19. Infect Dis Ther. 9(3):573-586. https://doi.org/10.1007/s40121-020-00324-3. Erratum in: Infect Dis Ther.PMID: 32725536\nReceived: 10 February 2021\nAccepted: 8 March 2021Francisco J. Alvarez, Mariela Perez-Cardenas, Marco Gudi\u00f1o, Markus P. Tellkamp\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1955\nComparative study between lumpy skin disease virus and sheep pox virus vaccines against recent field isolate of lumpy skin disease virus\nComparative study between lumpy skin disease virus and sheep pox virus \nvaccines against recent field isolate of lumpy skin disease virus\nNermeen G Shafik1, Heba A Khafagy1, Amal AM1, Ayatollah I Bassiuony2, Farid Fouad Zaki1, Christine A Mikhael2 and Mohamed Samy Abousenna1\nDOI. 10.21931/RB/2021.01.03.12\nAbstract: Lumpy Skin Disease (LSD) is a vector born disease of cattle, caused by Lumpy Skin Disease Virus (LSDV), there is \nantigenic relationship between LSDV, Sheeppox virus (SPPV) and Goat pox virus GTPV within a genus Capripoxvirus, accordingly \nit can be used homologous or heterologous Capripoxvirus strains for vaccination of cattle against LSD. This study compare the efficacy of live attenuated Neethling LSDV vaccine and live attenuated Romanian SSPV Vaccine against recent circulating LSDV field isolate. The evaluation was done in calves as the main host of LSD, through using three different batches for each vaccine type. Experimental calf groups were vaccinated with vaccines batches, and after 21 days serum samples were collected for evaluation of humoral immune response by using SNT and commercial ELISA technique, then the vaccinated calves were challenged by virulent LSDV field isolate. The results of SNT for vaccinated calves by LSDV vaccines indicated mean neutralizing antibody titer 1.2, 1.6 and1.5 log10 for the batches 1, 2 and 3 respectively, while vaccinated calves by SPPV vaccines indicated 1.05, 1.05 and 1.5 log10 for the batches 1,2 and 3 respectively; the ELISA mean sample to positive (S/P) percentage for the vaccine batches 1, 2 and 3 of LSDV were 40, 45 and 42% respectively and for SPPV vaccine batches 1,2 and 3 were 35, 37 and 40 % respectively, the challenge test indicated mean difference titer for the groups of calves vaccinated with LSDV vaccine were 4.2, 4.5 and 3.8 log10 and for groups vaccinated with SPPV vaccine were 2.6, 2 and 2.65 log10  respectively, it was concluded that potential using of Neethling LSDV vaccine against LSD is superior for combating and prevention of the lumpy skin disease. \nKey words: Lumpy Skin Disease Virus, Sheep Pox Virus, Challenge test, Serological test.RESEARCH / INVESTIGACI\u00d3N\nIntroduction\nThe genus Capripoxvirus (CaPV) within the subfamily \nChordopoxvirinae, family Poxiviridae contains three closely \nrelated viruses, namely Sheep pox (SPPV)  and  lumpy skin disease (LSD) which are diseases of sheep and cattle respecti-vely in addition to Goat pox virus (GTPV) which causes goat pox disease. The Virus strains affecting sheep and cattle are totally host specific and this is reflecting in the different geographic distribution of lumpy skin disease\n1. All strains of Capripoxvirus \nare antigenically closely related and cross-react serologica-lly\n2, because of the antigenic homology among all strains, the \nprobability to use a single vaccine strain like sheep pox virus to protect cattle and sheep\n3. Lumpy skin disease is a vector \nborn disease transmitted by biting insects such as mosquitoes and biting flies, its clinical signs include persistent fever, wide spread skin nodules (lumps) and enlarged peripheral lymph nodes complications include but are not limited to sever ema-ciation and death, LSD also has pulmonary form especially in young calves with high mortality rate\n4,The disease has highly \neconomic impacts as it affects the milk production and the lea-ther industry\n5.\nThe disease's first appear ance was in Africa in 1929, re-\nported from Zambia given the name 'Ngamiland Cattle Disea-se'. The disease continued to spread and resulted in a panzoo-tic; the first appearance of the disease in Egypt was during two outbreaks in Suez and Ismalia governorates in 1989. In early 2006, a severe LSD outbreak struck foreign (imported from Ethiopia) and local cattle in different Egyptian governorates, causing enormous economic losses; the disease also reappea-red in 2012 and 2013\n6.\nControlling lumpy skin disease depends mainly on vac-\ncination and vector control. Capripoxviruses are cross-reac-tive within the genus. Consequently, it is possible to protect cattle against LSD using strains of capripoxvirus derived from sheep or goats in the vaccine\n7. Live attenuated strains of ca-\npripoxvirus vaccines have been explicitly used for the control of LSD\n8. According to these, there are three types of vaccine \nused against lumpy skin disease, attenuated LSDV (Lumpy Skin Disease) vaccines which provide good protection in cattle, attenuated SPPV (Sheep pox virus) vaccines which have been used in cattle against LSDV in those regions where LSD and SPP are both present as it believed in providing partial protec-tion against lumpy skin disease, and Attenuated Gorgan GTPV vaccine containing GTPV Gorgan strain, this vaccine has been used in those countries where GTP and LSD overlap\n9,10. Howe -\nver, it is recommended to carry out evaluation trials using the most susceptible breeds before introducing a vaccine strain for vaccination into the field.\nIn Egypt, the control of LSD was applied by vaccination of \ncattle with SPPV using a Romanian strain for long time which proved to partially tackle the LSD outbreaks with partial cross protection with some notices on its duration of immunity as re-commendation for revaccination after 8 months\n11, and recent-\nly live attenuated LSDV vaccines containing Neethling strain were introduced to be use in Egypt.\nThe humoral immune response of vaccinated cattle \nagainst LSD either by SPPV and LSD vaccines can be evalua-ted using virus neutralization test (VNT) and ELISA\n1,4,12, in this \nstudy we compare the efficacy of live attenuated lumpy skin disease vaccine and live attenuated sheep pox vaccine against lumpy skin disease virus field isolate, using serological and challenge tests.\n1 Central Labo ratory for Eval uation of Vete rinary Biologics (CLEVB), Agricultural Research Center, Ca iro,  Egypt. \n2 Veterinary Serum and Vaccine Research Institute, Pox department, Agricultural Research Center, Cairo,  Egypt. \nCorresponding author: Mohamedsamy2020@hotmail.com1956\nNermeen G Shafik, Heba A Khafagy, Amal AM, Ayatollah I Bassiuony, Farid Fouad Zaki, Christine A Mikhael and Mohamed Samy Abousenna\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nMaterials and methods\nVaccines\na- Live attenuated Lumpy skin disease virus vaccine\n(Neethling strain).\nThree batches (one imported and two local batches[A -\nGO13] ).\nb- Live attenuated Sheep pox virus vaccine (Romanian\nstrain).\nThree local batches.\nThese vaccine batches were delivered to Central Labo-\nratory for Evaluation of Veterinary Biologics (CLEVB), Abbas-sia-Cairo, and evaluated last year for sterility, safety, and po-tency.\nVirus\nLumpy skin disease virus (LSDV):\n- Animal Health Research Institute supplied virulent\ncirculating field strain; the virus was isolated in 2018\n13. It was \nused for the challenge test for vaccinated calves.\n- Tissue culture adapted strain, the virus was pro-\npagated on Madin-Darby bovine kidney (MDBK) cells with a ti-\nter 105.5 TCID50 as shown in Figure (1 & 2), it was used for the \nserum neutralization test.\nCells\nThe Reference Strain Bank Department supplied Ma-\ndin-Darby bovine kidney (MDBK) cells in the Central Labora-\ntory for Evaluation of Veterinary Biologics (CLEVB). It was used for the serum neutralization test.\nAnimals and vaccination\nTwenty four susceptible mixed breed apparently clinically \nhealthy calves 6-12 months old free from specific antibodies \nagainst LSD virus, were supplied by CLEVB, these calves were divided into eight groups, each group contain three calves, six groups of them were used for vaccination and the other two groups kept as positive control and negative control groups. The six vaccinated groups were divided as follow, three groups of them were vaccinated with field dose of the three batches of live attenuated lumpy skin disease vaccine (one group for each vaccine batch), and the other three groups were vacci-nated with field dose of the three batches of live attenuated sheep pox virus vaccine (one group for each vaccine batch), the route of vaccination followed as instruction of manufacture. After 21 days post vaccination serum samples were collected from vaccinated and unvaccinated calves for serological tests (SNT and commercial ELISA).\nChallenge of vaccinated calves\nAfter 21 days from vaccination, the vaccinated groups and \npositive control (non vaccinated) group were challenged with \nlumpy skin disease virulent virus according to OIE\n1, the ani-\nmals were shaved at flank region then six log10 dilutions were \nprepared for inoculation, each dilution inoculated intraderma-lly at four sites for each shaved part (0.1 ml per each inocu-lum). The challenged animals were kept under observation for seven days after challenge, after that the titer of the challenge virus was calculated for vaccinated and control animals throu-gh recording number of lesions per each dilution at inoculated sites (the lesion developed as inflammation and necrotizing fibrinoid cutaneous nodules), the difference in titer between control and vaccinated animals was calculated for each vac-cine batch. The negative control was kept without vaccination or challenge.\nSerum Neutralization Test (SNT)\nIt measures the humoral immune response against lumpy \nskin disease Virus for sera of vaccinated calves, it was applied \naccording to the method described in OIE\n1, the neutralizeng ti-\nter was calculated according to Reed and Muench14. The sam-\nples neutralizing antibody titer \u2265 1.10 is considered positive15.\nELISA IDVIT KIT\nID screen\u00ae Capripox Double Antigen Multi-species, REF \nCPVDA-5A, LOT E83. was used to detect specific antibodies against capripoxvirus. The test was carried out according to the manufacturer's instructions insert. The results of each sample were calculated as aggregate to positive control ratio S/P[AGO20]  percentage (S/P %) in (Formula 1). The samples less than 30% are considered negative, while samples higher than or equal to 30% are considered positive.\nResults \nThe mean titers of the live attenuated lumpy skin disease \nvirus vaccine batches and the live attenuated sheep pox virus vaccine batches on tissue culture were recorded. The titer was expressed as log\n10 tissue culture infective dose50 (TCID50 )/\ndose, indicated the titers for the three live attenuated lumpy skin disease virus vaccine batches and the three live attenua-ted sheep pox virus vaccine batches, as shown in table No.1.\nThe humoral immune response against lumpy skin disea-\nse virus for the sera collected from vaccinated calves after 21 days post vaccination was determined by SNT and ELISA, the lumpy skin disease virus was adapted on MDBK cells for using in serum neutralization test, Figure 1 (A) showing normal MDBK cells and Figure 1 (B) showing cytopathic effect of lum-py skin disease virus on MDBK cells which represent by clus-tering, cell rounding and degeneration, the results of SNT for serum samples of calves vaccinated by live attenuated lumpy skin disease virus vaccines and live attenuated sheep pox virus vaccine indicated mean neutralizing antibody titer indicated  as shown in table No. (2), while the results of ELISA test were calculated as S/P percentage, the mean percentage for the sera of vaccine batches of live attenuated lumpy skin disease virus vaccines and for live attenuated sheep pox virus vaccine batches recorded in table No.(3).\nVaccine potency in cattle; the challenge of vaccinated \ngroups and positive control group by virulent lumpy skin disea-se virus was done, and after seven days, the difference in titer between vaccinated and positive control group was calcula-ted for each group (reading the lesion in inoculated sites), the mean titer for the groups of calves vaccinated with live atte-nuated lumpy skin disease vaccine and for groups vaccinated with local and imported live attenuated sheep pox vaccines as shown in table No. 4.1957\nTable 1. The titer of vi -\nrus vaccine batches on \ntissue culture.\nTable 2. Evaluation of humoral im -\nmune response in the sera of vacci -\nnated calves by using SNT.\nFigure 1. (A and B):Normal MDBK cells and adapted Lumpy skin disease effect on MDBK cell line\nTable 3. Evaluation of humoral im -\nmune response in the sera of vacci -\nnated calves using ELISA Kit against \nCapripox.\nTable 4. Challenge of vaccina -\nted calves by LSDV.Comparative study between lumpy skin disease virus and sheep pox virus vaccines against recent field isolate of lumpy skin disease virus1958\nDiscussion\nIn Egypt and Middle East live attenuated sheep pox vacci-\nne is used to protect against LSD, although some researches \nrecorded the effectiveness of this vaccine against LSD16, there \nare some other recorded that it may offer incomplete protec-\ntion against LSD17,18,19,20, recently live attenuated LSD vaccine \nwas introduced to be applied in Egypt, but we still need many \nresearches to investigate and compare the efficacy and adver-\nse reactions between live attenuated LSD virus vaccine and \nother Capripox virus vaccines.\nIn this study we compare the efficacy of live attenuated \nLSDV vaccine and live attenuated sheep pox virus vaccine \nagainst LSD in calves as the main host for the disease, using \nthree batches for each vaccine type, showing the vaccines bat-\nches titer, evaluate humoral immune response of vaccinated \ncalves (using SNT and ELISA) and challenge vaccinated calves \nby virulent strain of LSDV.\nThe titers of live attenuated LSDV vaccine batches per \ndose were satisfactory where the recommended field dose for \nLSDV in the vaccine is log10 3.5 TCID50 and minimum protecti-\nve dose is log10 2.0 TCID50. The titers of live attenuated SPPV \nvaccine batches were also satisfactory where the recommen-\nded dose of sheep pox virus in the vaccine for cattle is log10 3 \nTCID501.\nThe SNT was carried out to detect the neutralizing an-\ntibody titer against LSDV for sera of vaccinated calves after \n21 days post vaccination, the results for live attenuated LSDV \nvaccine batches indicated that all the three batches reached \nto positive neutralizing antibody titer  \u22651.1015, and the results \nfor the live attenuated SPPV vaccine batches indicated that \nonly the batch (3) reached positive neutralizing antibody titer \n\u22651.10 while the other two batches (1 and 2) didn\u2019t record the \npositive titer. These results reflect that live attenuated LSDV \nvaccine achieved best results in titer and number of batches \nreaching the positive titer, but we must put in consideration \nif the antibody is low it doesn\u2019t reveal that the animal isn\u2019t \ndefinitely protected as commented by OIE1 which clarify the \nconflict in results of SNT and challenge test as this disease \nmainly depend on cellular immunity and the VNT or SNT only \ntests the positivity. Neutralization test is used for evaluation \nof humoral immune response for LSDV as recommended by \nOIE, as it was applied by other similar studies for evaluation of \nserum samples of cattle vaccinated by live attenuated SPPV \nvaccine against LSDV16, also applied by Christine21 who used \nit in evaluation calves vaccinated by Attenuated Sheep Pox \nand Inactivated Lumpy Skin Disease Vaccines against Lumpy \nSkin Disease, and used in evaluation of the cross-protection \nbetween Sheep pox and bovine Lumpy skin vaccines in vacci-\nnated sheep22.\nELISA kit against Capripox is also used in the evaluation \nof humoral immune response for the sera of vaccinated cal-\nves ( this kit is not specific for LSDV only but it against genus \ncapripox, on the other hand the SNT is specific against LSDV \nonly), the results for live attenuated LSDV vaccines batches \nindicated positive results \u226530% (as mentioned in ELISA kit) for \nthe three batches, also live attenuated SPPV vaccine indica-\nted  results \u2265 30%  for the three batches, but we noticed that \nthe percentages for live attenuated LSDV vaccines batches \nis higher than percentages of live attenuated SPPV vaccine \nbatches. Although the neutralization test is the standard test \nfor evaluation of humoral immune response for LSDV as re-\ncommended by OIE, there are other studies recommending to \nuse commercial ELISA, commercial Capripox Double Antigen ELISA (ID.Vet) was used in evaluation of  serological tests for \ndetection of antibodies against LSDV and find strong correla-\ntion between VNT/MDBK and ELISA23, also ELISA method and \nneutralization test were used for detection antibodies against \nLSDV24.\nChallenge test is used for testing potency of the vaccines, \nand it was carried out in vaccinated calves (as a main host for \nLSDV) by calculating the difference in titer (between control \npositive and vaccinated challenged calves in each group)  of \nthe inoculum (virulent LSDV) which developed specific lesion, \nthe results for live attenuated LSDV vaccines batches indica-\nted a protective titer for the three batches where the minimum \nprotective result is >log10 2.5 as recommended by OIE1, and for \nthe live attenuated SPPV vaccine batches indicated only first \nand third batches are protective with border titer limit but se-\ncond batch didn\u2019t reach  protective titer, and that indicated that \nlive attenuated LSDV vaccine is more protective than live atte-\nnuated SPPV vaccine against LSDV. These results agreed with  \nHamdi22 who used virulent LSDV in challenge of two groups \nof calves, one group vaccinated  with Romanian SPPV vacci-\nne and the other  with Neethling LSDV vaccine and reported \nthat Romanian SPPV vaccine provide partial protection against \nLSDV while Neethling LSDV vaccine provide fully protection \nagainst LSDV, also recombinant LSDV vaccine (LSD-Rift Valley \nFever.mf vaccine) was used in two groups of calves, one group \nchallenged by virulent LSDV and other group by virulent Rift \nValley Fever Virus and recorded that tested vaccine is safe and \nprotective for both diseases25, and Neethling vaccine is repor-\nted significantly more effective than x10 RM65 Sheep Pox vac-\ncine strain in preventing LSD morbidity26.\nConclusions\nIt was believed that the wide cross protection within Ca-\npripoxvirus genus allows using of any Capripoxvirus isolate as \nan effective vaccine against LSDV, otherwise and avoiding this \nconfirmation bias, it is clear from the relevant results that the \npotential using of Neethling LSDV vaccine against LSDV is su-\nperior for combating and prevention the Lumpy skin disease. \nAlso it was be recommended to evaluate both homologous or \nheterologous virus strain vaccines against LSD in cattle, as it \nthe main host of the lumpy skin disease.    \nConflict of interest\nThe authors certify that they have no affiliations with or \ninvolvement in any organization or entity with any financial in-\nterest (such as honoraria; educational grants; participation in \nspeakers' bureaus; membership, employment, consultancies, \nstock ownership, or other equity interest; and expert testimony \nor patent-licensing arrangements), or non-financial interest \n(such as personal or professional relationships, affiliations, \nknowledge or beliefs) in the subject matter or materials dis-\ncussed in this manuscript.\nEthical approval\nInstitutional Animal Care and Use Committee at Central \nLaboratory for Evaluation of Veterinary Biologics acknowledge \nthe research manuscript, and it has been reviewed under our \nresearch authority and is deemed compliance with bioethical \nstandards in good faith.\nAuthor Contributions\nNGS designed experiments, AAM and MSA the experi-\nments were performed HAK, AAM AIB, CAM, and MSA. Data Nermeen G Shafik, Heba A Khafagy, Amal AM, Ayatollah I Bassiuony, Farid Fouad Zaki, Christine A Mikhael and Mohamed Samy Abousenna\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1959\nanalysis was accomplished by NGS, FFZ, HAK, AAM, and MSA. \nAAM,AIB and MSA wrote the manuscript.\nFunding\nThis study received no specific grant from any funding \nagency in the public, commercial, or not-for-profit sectors.Data Availability\nAll data generated or analyzed during this study are inclu-\nded in this published article.\nBibliographic references\n1. OIE. Organization for Animal Heal th. Lumpy Skin Disease. En:\nOIE. World Organization for Animal Health. Manual of diagnos-\ntic tests and vaccines for terrestrial animals (mammals, birds,bees). Paris:OIE; 2018. p. 1158-1171. Available from: https://www.oie.int/.\n2.\nF\nAO (Food and Agriculture Organization of the United Nation)\n(2017): FAO Animal Production and Health (20), Lumpy Skin Dis-ease, a field manual for veterinarians.\n3.\nNorian RN, Afzal NA, V\narshovi HR , and  Azadmehr A. Compar-\native efficacy of two heterologous capripox vaccines to controllumpy skin disease in cattle, Bulgarian Journal of VeterinaryMedicine, 2019, 22, No 2, 171\u2013179.\n4.\n Y\nasser FE, El-Tholoth M,  Saher S, EL- Said A.A, Mohamed AS,\nand Younis EE. Investigation of lumpy Skin Disease virus infection in young calves from cows vaccinated with sheep poxvirus vac-cine..(2015); 5thinternational conference of virology 112.\n5.\nT\nuppurainen ES, Stoltsz WH, Troskie M, Wallace DB, Oura CA,\nMellor PS, Coetzer JA, Venter EH. A potential role for ixodid(hard) tick vectors in the transmission of lumpy skin disease vi-rus in cattle. Transbound Emerg Dis. 2011 Apr;58(2):93-104. doi:10.1111/j.1865-1682.2010.01184.x. Epub 201030 November0.PMID: 21114790.\n6.\nF\nAO Regional Office for the near east (FAO-RNE) .Emergence of\nlumpy skin disease in the eastern Mediterranean Basincountries. VOL. 29. (2013) Rome. Available at: http://www.fao.org/3/a-i6155e.pdf.\n7.\nCoakle\ny W. & Captickp B. Protection of cattle against lumpy skin\ndisease. Factors affecting small scale production of tissue cul-ture propagated virus vaccine. Res. Vet. Sci.,(1961); 2, 369\u2013371.\n8.\n Brenner \nJ, Haimovitz M, Oron E, Stram Y, Fridgut O, Bumbarov V,\nKuznetzova L, Oved Z, Waserman A, Garazzi S, Perl S, Lahav D,Edery N. & Yadin H. Lumpy skin sease (LSD) in a large dairy herd in Israel. Isr. J. Vet. Med.(2006), 61, 73\u201377.\n9.\nT\nuppurainen ES, Pearson CR, Bachanek-Bankowska K, Knowles\nNJ, Amareen S, Frost L, Henstock MR, Lamien CE, Diallo A,Mertens PP. Characterization of sheep pox virus vaccine forcattle against lumpy skin disease virus. Antiviral Res. 2014Sep;109(100):1-6. doi: 10.1016/j.antiviral.2014.06.009. Epub201425 June5. PMID: 24973760; PMCID: PMC4149609.\n10.\n Abutarbush, S.M. Lump\ny Skin Disease (Knopvelsiekte, Pseudo-Ur-\nticaria, Neethling Virus Disease, Exanthema Nodularis Bovis). In:Bayry J (eds.) Emerging and Re-emerging Infectious Diseases ofLivestock. Springer International Publishing, Gewerbestrasse 11,6330 Cham, Switzerland, pp: 309-326. (2017).\n11.\n A\nyatollah IB, Christine AM and Amal A. Comparison between\nfield and laboratory immune response of cattle vaccinated withsheep pox vaccine against lumpy skin disease. Egypt vet. Med.Assoc. Journal (2015):Vol 75, no (4):649-662.\n12.\n Chris\ntine AM, Ibrahim MM, Manal A, Soad MS and Michael A.\nComparative study on the efficacy of some capripox vaccinesin protection against Lumpy Skin Disease. SCVMJ,(2014); XIX(2):177-189.\n13.\n Hodhod A, Elgendy E, Abd El-Moniem MI and Ibr\nahim MS. ISO-\nLATION AND MOLECULAR CHARACTERIZATION OF LUMPYSKIN DISEASE VIRUS IN EGYPT DURING 2017- 2018, ejpmr,(2020),7(1), 96-103.14.\n R\need LJ and Muench H . A simple method of estimating fifty per\ncent endpoints. Am. J. Hyg.(1938). 27: 493-497.\n15.\n Shaimaa El-gbil\ny, Emad M. Al-Ebshahy, Heba A. AbdelHady,\nAboulSoud, E.A. and  Samy A. Khalil. Evaluation of HumoralImmune Response Against Lumpy Skin Disease Virus in CattleVaccinated with Sheep Pox Virus Vaccine. AJVS. (2019).Vol. 61(1): 128-132.\n16.\n Ali AA, Esmat M, A\nttia H, Selim A and Abdelhamid YM. Clinical\nand pathological studies on lumpy skin disease in Egypt. Vet. Rec.(1990) 127, 549\u2013550.\n17.\n Omyma \nME. Recent isolation and identification of lumpy skin\ndisease virus from cattle in Egypt. Egypt J.Comp. Path and Clin.Path. (2008).21,(1): 139-147.\n18.\n Brenner J\n, Bellaiche M, Gross E, Elad D, Oved Z, Haimovitz M, Was-\nserman A, Friedgut O, Stram Y, Bumbarov V, Yadin H. Appearance of skin lesions in cattle populations vaccinated against lumpy skin disease: statutory challenge. Vaccine. 2009 Mar;27(10):1500-1503. DOI: 10.1016/j.vaccine.2009.01.020.\n19.\n Somasundar\nam MK. An outbreak of lumpy skin disease in a hol-\nstein dairy herd in Oman: a clinical report. Asian J. Anim. Vet.Adv.2011; 6, 851\u2013859.\n20.\n Chris\ntine AM, Ibrahim MM and Saad MA..  Efficacy of Alter-\nnative Vaccination with Attenuated Sheep Pox and Inactivat-ed Lumpy Skin Disease Vaccines against Lumpy Skin Disease.SCVMJ,(2016) XXI (2), 125-142.\n21.\n Hamdi J\n, Zahra B, Mohammed J, Zineb B, Khalid O T, Ouafaa FF\nand Mehdi E. Experimental evaluation of the cross-protection be-tween Sheep pox and bovine Lumpy skin vaccines. J. ScientificReports (2020) 10, Art. No.8888, P.1-9. https://doi.org/10.1038/s41598-020-65856-7.\n22.\n Kre\u0161i\u0107 \nN, \u0160imi\u0107 I, Bedekovi\u0107 T and Acinger-Rogi\u0107 \u017d Lojki\u0107\nI. Evaluation of Serological Tests for Detection of Antibod-ies against Lumpy Skin Disease Virus. J Clin Microbiol. 2020Aug 24;58(9):e00348-20. doi: 10.1128/JCM.00348-20. PMID:32434783; PMCID: PMC7448653.\n23.\n Samojlo\nvi\u0107 M, Pola\u010dek V, Gurjanov V, Lupulovi\u0107 D, Lazi\u0107 G, Petro-\nvi\u0107 T, and Lazi\u0107 S. Detection of antibodies against Lumpy skin dis-ease virus by Virus neutralization test and ELISA methods. ActaVeterinaria (2019) 69, 1, 47-60, Available From: Sciendo https://doi.org/10.2478/acve-2019-0003.\n24.\n W\nallace DB, Mather A, Kara PD, Naicker L, Mokoena NB, Pretori-\nus A, Nefefe T, Thema N, Babiuk S. Protection of Cattle ElicitedUsing a Bivalent Lumpy Skin Disease Virus-Vectored Recombi-nant Rift Valley Fever Vaccine. Front Vet Sci. 202019 May9;7:256. doi: 10.3389/fvets.2020.00256. PMID: 32509806; PMCID:PMC7248559.\n25.\n Ben-Ger\na J, Klement E, Khinich E, Stram Y, Shpigel NY. Com-\nparison of the efficacy of Neethling lumpy skin disease virus andx10RM65 sheep-pox live attenuated vaccines for the preventionof lumpy skin disease - The results of a randomized controlledfield study. Vaccine. 2015 Sep 11;33(38):4837-42. doi: 10.1016/j.vaccine.2015.07.071. Epub 20151 August1. PMID: 26238726.\nReceived: 1 May 2021\nAccepted: 9 July 2021Comparative study between lumpy skin disease virus and sheep pox virus vaccines against recent field isolate of lumpy skin disease virus1960\nSandra Liliana Medina Poma, Fabricio Gonz\u00e1lez-Andrade\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nDifferences between preterm infants receiving a dose for lung maturation \nand those receiving an additional rescue dose of corticosteroids\nSandra Liliana Medina Poma1, Fabricio Gonz\u00e1lez-Andrade1,2 DOI. 10.21931/RB/2021.06.03.13\nAbstract: It is unknown if there is a difference between preterm infants with a history of receiving pulmonary corticosteroid \nmaturation or using an additional rescue dose of corticosteroid. This paper aims to determine the difference between infants with \npulmonary maturation and infants who received a rescue dose of corticosteroid. We performed an epidemiological, observational, \nand cross-sectional study. We analyzed time of stay, the requirement of mechanical ventilation, the use of surfactant, and \nneurological complications in newborns hospitalized in Neonatology of the Isidro Ayora Gyneco-Obstetric Hospital, 2019. We \nanalyzed 204 preterm infants of 28-37 weeks who received a total lung maturation dose versus an added rescue dose. We \nanalyzed the information with the statistical program SPSS v 22.0. With rescue dose the stay time was 28.4\u00b121.6 days (p \n<0.05), days of invasive mechanical ventilation 3\u00b15.7 days (p <0.05); Surfactant use 33.3% (p>0.05). We found neurological \ncomplications in 6.9% of patients (p> 0.05). In group 2 with not rescue dose use, the stay time was 21.5\u00b116.6 days (p<0.05), days \nof invasive mechanical ventilation 1.8 \u00b1 4.1 days (p <0.05). Surfactant use was 24.5% (p>0.05), and neurological complications \n2% (p> 0.05). Preterm males weighing <1000 g from 30 to 32 weeks, who used rescue doses of corticosteroids, showed an \nincrease in intraventricular hemorrhage (13.7%), seizures (6.9%), and leukomalacia (13.7%), associated with the fact that in the \ngroup with rescue dose they are younger and had lower weight.   \nKey words: Preterm birth; Respiratory Distress Syndrome, Pulmonary surfactants; Obstetric Labor, Preterm; prenatal exposure \nto corticosteroids.RESEARCH / INVESTIGACI\u00d3N\nIntroduction\nA single cycle of prenatal corticosteroids administered to \nmothers with early preterm birth improves survival, reduces \nrespiratory distress syndrome, necrotizing enterocolitis, and \nintraventricular hemorrhage. It was not associated with any \nsignificant adverse effects for the mother or the unborn child \nin the short term1.\nPrenatal corticosteroid therapy recommends all pregnan-\ncies with threatened preterm birth before 34 weeks of gesta-\ntion, where the newborn's ongoing care is anticipated. Althou-\ngh there are limited data from randomized studies in infants \nwith <25 weeks gestation, observational studies suggest that \nprenatal corticosteroids and other active treatment practices \ndiminish pregnancy mortality to 22 weeks2. In pregnancies be-\ntween 34 and 36 weeks of gestation, prenatal corticosteroids \nalso reduce the risk of short-term respiratory morbidity but \nnot mortality, and there is an increased risk of neonatal hypo-\nglycemia3.\nGiven the potential for long-term side effects, it does not \nrecommend corticosteroids for women in spontaneous pre-\nterm labor after 34 weeks. When administered before elective \ncesarean section, up to 39 weeks, reduce the risk of admis-\nsion to the Neonatal Intensive Care Unit (NICU)4, although fo-\nllow-up data on term newborns exposed to prenatal corticos-\nteroids lack5.\nThe optimal interval between treatment and delivery is \nmore than 24 hours and less than seven days after the start \nof corticosteroid treatment; beyond 14 days, the optimal in-\nterval between treatment and delivery is more than 24 hours \nand less than seven days after the start of corticosteroid treat-\nment; beyond 14 days, the benefits decrease. The beneficial \neffects of the first dose of prenatal corticosteroids begin in a \nfew hours, advanced dilation should not be a reason to refra-\nin from therapy, and the same can happen with magnesium \nsulfate (MgSO4)6. Corticosteroids should be repeated one to two weeks after the first course for women with the threat of \npreterm delivery. A repeated course reduces the risk of respi-\nratory assistance. However, fetal growth decreases and repea-\nted doses do not reduce mortality7.\nIt observed no effect on neurosensory disability at fo-\nllow-up, but data on possible longer-term adverse effects are \nlacking. The WHO recommends that a single corticosteroid \ncycle be used if preterm delivery does not occur within seven \ndays after the initial course, and there is a high risk of pre-\nterm delivery within the next seven days. Repeated courses \nadministered after 32 weeks of gestation do not improve the \nresults8.\nIndeed corticosteroids are medications with several side \neffects, such as impaired fetal and placental growth, apop-\ntosis in the brain, and increased infection, but when properly \nmanaged, they are safe. The use of corticosteroids should be \nreduced by an adequate assessment of the risk of preterm \ndelivery and avoiding unnecessary early elective cesarean \nsection, which is the obstetrician's decision to terminate the \npregnancy in a woman with a history of previous cesarean sec-\ntion. In some cases, when an early cesarean section is nee-\nded, the establishment of fetal lung maturity may be better \nthan administering corticosteroids to all women. There is little \nevidence that cesarean delivery of preterm newborns instead \nof allowing vaginal delivery improves outcomes9. However, \nthe recommendations of the European consensus guidelines \nfor the prevention of hyaline membrane disease in preterm \ninfants are summarized below10: Mothers with a high risk of \npreterm birth <28-30 weeks gestation should transfer to per-\ninatal centers with experience in the treatment of respiratory \ndistress syndrome. A single cycle of prenatal corticosteroids \nshould offer all women at risk of preterm birth when pregnan-\ncy is considered potentially viable until 34 weeks of gestation, \nideally at least 24 hours before birth. A single cycle of corticos-\n1 Universidad San Francisco de Quito USFQ, Colegio Ciencias de la Salud, Quito, Ecuador.  \n2 Universidad Central del Ecuador, Facultad de Ciencias M\u00e9dicas, Unidad de Medicina Traslacional, Quito, Ecuador. \nCorresponding author: fabriciogonzaleza@gmail.com1961\nDifferences between preterm infants receiving a dose for lung maturation and those receiving an additional rescue dose of corticosteroids\nteroids might be administered in the threat of preterm delivery \nbefore 32 weeks of gestation at least 1 to 2 weeks before. Mag-\nnesium sulfate should be administered to women in imminent \nlabor before 32 weeks of gestation11.\nIn women with preterm birth symptoms, cervical length \nand fibronectin measures should consider avoiding unneces-\nsary tocolytic medications and prenatal corticosteroids. Short-\nterm use of tocolytic drugs should be considered in early preg-\nnancies to complete a corticosteroid cycle and transfer the \nuterus to a specialized perinatal center12.\nThere are differences between European and national \nclinical practice guidelines for newborn care with respiratory \ndistress. They recommend administering prenatal corticoste-\nroids, in risky pregnancies, between 26 and 34 weeks, for two \ndays and, it is not advisable to use repeated doses if the birth \nhas not occurred after one week of the last dose since It has \nnot shown additional benefits. The medications recommended \nin these guidelines are Betamethasone12,13. Despite the availa-\nble evidence on the use of pulmonary maturation with corti-\ncosteroids in the threat of preterm birth, there is a possibility \nof using the rescue dose if the birth has not occurred after se-\nven days of the last dose.\nIt observed a 17% reduction in respiratory distress and \n16% in severe complications associated with prematurity in \ninfants with corticosteroid rescue doses. Besides, the use of \nrescue dose is associated with non-significant reductions in \nthe newborn's weight and size, which disappear at discharge \nand have no implications in early childhood14. McKinlay et al.2 \nstudied the results for one or more repeated doses of corti-\ncosteroids in newborns and pregnant women, demonstrating \nthat corticosteroids decrease the incidence of neonatal death, \nrespiratory distress syndromes, intraventricular hemorrhage, \nnecrotizing enterocolitis, and early sepsis. Prenatal corticos-\nteroid therapy increases the effectiveness of postnatal sur-\nfactant therapy. Corticosteroids can induce the maturation of \nfetal organs and improve the transition to life after childbirth.\nIn another systematic review, Hutchinson and Hodgden15 \nshowed that women with preterm labor who received a cycle \nof corticosteroids and are still at risk of preterm delivery after \nseven days might benefit from a rescue dose. Studies disco-\nvered neonatal outcomes immediately after childbirth and no \nlong-term risks in childhood by comparing growth, cardiovas-\ncular and endocrine functions. It also considered that maternal \nrisks are not different between groups. Therefore, it conside-\nred additional corticosteroid therapy.\nIndeed, preterm birth is the leading cause of death in chil-\ndren under five years of age worldwide; the rates of preterm \ninfants' survival increase in high-income countries, neonates \nstill die due to lack of attention or necessary supplies in middle \nand low-income countries. On the other hand, preterm birth \nremains a critical problem in infant mortality; it used antenatal \ncorticosteroids to improve maternal and neonatal care quali-\nty. Despite this, inequality in survival rates is very different; in \nlow-income countries, 32-week-old preterm newborns die due \nto lack of feasible and cost-effective care, while in high-income \ncountries, almost all preterm neonates survive16.\nIt is possible to say that after the administration of prena-\ntal corticosteroids between weeks 24 and 34, the structural \nand biochemical changes that the pneumocytes both I and II \nundergo; fetal lung maturity accelerate by increasing the pro-\nduction of natural surfactant; These changes, in turn, improve \nlung mechanics, which results in a decrease in respiratory dis-\ntress, use of exogenous corticosteroids.\nKnowing that the maximum benefit is obtained after the \nfirst 24 hours post-administration until seven days, years ago, the administration of repeated treatments was used as a daily \npractice, a practice that has become deprecated due to the ad-\nverse effects that the affected products presented both in its \ngrowth as fetal development14.\nPrenatal corticosteroid administration is used to prevent \nrespiratory distress syndrome in fetuses less than 34 weeks \ngestation in newborns who are still preterm newborns until \nbirth and receive a rescue dose of corticosteroids. The purpose \nis to determine if there is a difference in the length of stay, the \nrequirement for mechanical ventilation, the use of surfactant, \nand neurological complications17 to establish a new pharma-\ncological regimen.\nThis new approach to prenatal therapy in patients with \nrisk factors for preterm birth may increase infant survival with \nlight birth weight18,19. The aim is to contribute to the neona-\ntal population to improve birth conditions and avoid neonatal \ncomplications that affect the individual, family, and society20.\nThis work aims to determine the difference between in-\nfants with pulmonary maturation and those who received a \nrescue dose of corticosteroid concerning their time of stay, \nthe requirement of mechanical ventilation, use of surfactant, \nand neurological complications in hospitalized newborns in \nthe Neonatology Service of the Isidro Ayora Gyneco-Obstetric \nHospital in 2019.\nMethods \nStudy design\nEpidemiological, observational, and cross-sectional study.\nContext\nGyneco-Obstetric Hospital Isidro Ayora  (HGOIA), in Quito, \nEcuador. The analyzed period was from 14 November, 2019, to \n29 January, 2020.\nSample size\n204 newborns.\nParticipants\nThe population under study was from 28 to 37 weeks of \ngestational age, divided into two groups; one: received the total \ndose of corticosteroid lung maturation, and group two: com-\nplete lung maturation plus rescue dose.\nInclusion criteria\nPreterm newborns with gestational age at birth from 28 \nto 37 of gestational age and history of prenatal corticosteroid \nuse; that merited or not ventilatory support, use of surfactant, \nwhether or not it presented neurological complications; of \nboth sexes and any ethnic group. Group one received a total \ndose of fetal lung maturation with Betamethasone or Dexame-\nthasone, while group two received a rescue dose before birth \nwith Betamethasone or Dexamethasone.\nExclusion criteria\nWe excluded newborns referred to HGOIA with gestatio-\nnal age at birth over 37 and below 27 weeks of gestational age.1962\nElimination criteria\nThere were newborns with congenital malformations in-\ncompatible with life who died during the study.\nVariables\nIt developed a sheet with socio-demographic characteris-\ntics: sex, ethnicity, gestational age, classification of prematu-\nrity, birth weight. Regarding prenatal factors: week in which \nlung maturation was administered. Postnatal factors were the \nuse of mechanical ventilation, surfactant use, number of sur-\nfactant doses, trans fontanel ultrasound, neurological compli-\ncations, seizures, days of mechanical ventilation, and days of \nhospitalization. The diagnosis at admission and discharge: the \ndegree of prematurity, birth weight, size for gestational age, \nrespiratory pathology, neurological, infectious, metabolic, he-\nmatological, cardiac, and hemodynamic pathology.\nSources, data, and measurements\nFrom the beginning of the study, it revised the medical re-\ncords of preterm patients admitted to HGOIA to identify the \nnecessary data for analysis and interpretation. It is essential \nto mention that gynecologists did not influence the therapeu-\ntic decision regarding preterm deliveries concerning prenatal \ncorticosteroid therapy. We identified a pregnant mother who \nreceived pulmonary maturation and a rescue dose of corticos-\nteroid before week 37 of gestation for the preterm newborn's \nfollow-up during his hospital stay.Biases avoidance\nIt collected information from complete medical records \nand by the same person consistently.\nStatistical methods\nThe information obtained was stored in an Excel databa-\nse and then analyzed with the SPSS\u00ae software version 22.0, \nlicensed: 4-2E097 I. We used descriptive statistics: frequen-\ncies, percentages, average, standard deviation, and inferential: \nChi-square test, a p-value less than 0.05, which was accepted \nas statistical significance. We performed a multivariate analysis.\nEthical criteria\nThis research was approved by the Research Ethics Com-\nmittee on Human Beings (CEISH) of the San Francisco Univer-\nsity of Quito. It was dated 14 November of 2019, and coded \nwith the number P2019-155TPG.\nResults\nTable 1 shows that, for both study groups, the variables \nthat reached statistical significance using corticosteroid res-\ncue doses were gestational age and the degree of prematurity \n(p <0.05). There was no statistical significance between sex, \nethnicity, or birth weight using rescue doses of corticosteroids \n(p> 0.05). See table 1. It included 204 preterm patients in this \nresearch, is divided into two patient groups, according to the \nTable 1. Distribution of socio-demographic characteristics according to the rescue dose of pulmonary maturation. Preterm \nnewborns, Isidro Ayora Gyneco-Obstetric Hospital, 2019.Sandra Liliana Medina Poma, Fabricio Gonz\u00e1lez-Andrade\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1963\nuse of a rescue dose of lung maturation, and it split each group \nof 102 patients.\nTable 2 shows that there were significant differences \nbetween the time when lung maturation in both groups (p \n<0.001); it was administered later among patients who did \nnot receive rescue dose (31.3 \u00b1 2.1 weeks), compared to the \ngroup in which rescue dose was administered (30.5 \u00b1 2.9 wee-\nks). There was also statistical significance between mechani-\ncal ventilation and hospitalization days in both study groups \n(p <0.05). There was no statistical significance between me-\nchanical ventilation modality, surfactant use, surfactant dose \nnumber, trans fontanelar ultrasound, neurological complica-tions, seizures, or days of mechanical ventilation in both study \ngroups (p> 0.05). \nTable 3 shows the time of admission; there was statistical \nsignificance for the association between the use of rescue do-\nses of corticosteroids with the degree of prematurity and the \nnewborn's size (p <0.05). There was no statistical significan-\nce for the association between birth weights, the presence of \nrespiratory, neurological, infectious, metabolic, hematological, \nor renal pathologies using rescue doses of corticosteroids (p> \n0.05). \nTable 4 shows that, at the time of discharge, there was a \nTable 2. Distribution of prenatal and postnatal history according to the rescue dose of pulmonary maturation. Preterm newbor -\nns, Isidro Ayora Gyneco-Obstetric Hospital, 2019.Differences between preterm infants receiving a dose for lung maturation and those receiving an additional rescue dose of corticosteroids1964\nTable 3. According to rescue dose of pulmonary maturation in preterm infants, distribution of diagnosis at admission, Isidro \nAyora Gyneco-Obstetric Hospital, 2019.Sandra Liliana Medina Poma, Fabricio Gonz\u00e1lez-Andrade\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1965\nTable 4. According to \nthe rescue dose of pul -\nmonary maturation in \npreterm infants, the dis -\ntribution of diagnosis at \ndischarge is determined \nby Isidro Ayora Gyne -\nco-Obstetric Hospital, \n2019.Differences between preterm infants receiving a dose for lung maturation and those receiving an additional rescue dose of corticosteroids1966\nstatistically significant association between the degree of pre-\nmaturity, the size of newborns, and the presence of infectious \ndiseases, using rescue doses of corticosteroids (p <0.05). The-\nre was no statistical significance between birth weights, respi-\nratory, neurological, metabolic, hematological, cardiovascular, \nor renal pathologies, using rescue doses of corticosteroids at \ndischarge (p> 0.05). See table 4. \nTable 5 shows the model summary. We used for the mul-\ntivariate analysis a binomial logistic regression model. The va-\nriables that obtained statistical significance were included in \nthe bivariate analysis. A 50% probability of success was obtai-\nned with this model, which is very low, and a Negelkerke statis-\ntic = 28.4%. The goodness of fit test of Hosmer and Lemeshow \nobtained statistical significance (p <0.05), thereby increasing \nthe probability of prediction to 71.1%. The only variable asso-\nciated with corticosteroid rescue doses was the newborn size \n(p<0.05).ticosteroids. In this group, late preterm patients (41.2%) pre-\ndominated, and, at the time of admission, there was a higher \npercentage than was classified as moderate preterm, with \nstatistically significant differences (p <0.05) indicating that it \nwas administered early lung maturation. For this reason, the \ndose of corticosteroids was repeating, but it could also be pa-\ntients with significant respiratory dysfunction or with a high \nrisk of complications such as bronchopulmonary dysplasia. \nAlso, it accepts that preterm infants' respiratory complica-\ntions decrease as gestational age increases, and the survival \nbenefits of using additional doses of corticosteroids after 33 \nweeks have been discussed. However, we reported that yes, It \nis beneficial due to adaptive syndrome in late preterm infants.\nAnother finding was that the birth weight was lower in in-\nfants who received rescue doses of corticosteroids [1571\u00b1362 \ng], the minimum weight was 890 g, and the maximum weight \nwas 2340 g; however, not was statistically significant. The cri-\nteria for using the rescue dose of corticosteroids are based on \ntheir administration when labor has not occurred within seven \nTable 5. Multivariate an\u00e1lisis.\nDiscussion\nWe analyzed the behavior of two groups of infants with \nprematurity. In the first group, we included those who had re-\nceived rescue doses of corticosteroids. In the second group, \nnewborns who had not received this rescue dose, applying a \nnew dose of corticosteroids when birth did not occur after se-\nven days of completing the pulmonary maturation scheme.\nIn both study groups, male sex predominated, which ac-\ncounted for 55.9% of cases. This factor explains in male fetu-\nses an increased risk of prematurity, low birth weight, proba-\nbility of complications, and death. This variable explains fetal \ntestosterone's action on the pituitary hypothalamus axis, with \nan adverse feedback action, which affects the secretion hor-\nmones that prolong pregnancy. It knows that fetal sex influen-\nces the risk of adverse outcomes in response to prenatal corti-\ncosteroid therapy. It states that the chromosomal differences \nin both sexes' placenta are essential in determining fetal res-\nponses to prenatal noxas and prematurity. Female preterm \ninfants respond more effectively to prenatal betamethasone \nexposure than their male counterparts, with lower respiratory \ndistress syndrome rates, by the action of female hormones.\nOn the other hand, gestational age was statistically sig-\nnificantly related to corticosteroid rescue doses (30.1-33.6 \nweeks: 49%), so in the group of patients in the corticosteroid \nrescue dose was used, the most frequent gestational age was \n30.1 to 33.6 weeks. This variable explains that lung immaturi-\nty in these neonates is higher due to the respiratory system's \nformation not completed. The few alveoli that exist do not pro-\nduce pulmonary surfactant in sufficient quantity and quality. \nTherefore, the risk increases bronchopulmonary dysplasia \nand respiratory distress. Besides, since these are newborns in \nwhom the risk was identified early, they were given lung matu-\nration more than seven days before birth occurred.\nOn the other hand, the patients' degree of prematurity \nwas also significantly associated with the rescue dose of cor-days after the first dose of corticosteroids. There is sufficient \nevidence to conclude that, after this period, lung maturation \nbenefits increase the risk of perinatal death and maternal in-\nfections.\nOn the other hand, the size of the infants was significantly \ndifferent in both study groups. 35.3% of those who received \nthe rescue dose were classified as small for gestational age, \nsignificantly higher than the other group (16.7%). The impact \nof corticosteroids on fetal growth has been explained by inhibi-\nting fetal growth and DNA replication due to cortisol, accom-\npanied by lower birth weight and possible intrauterine growth \nrestrictions. This factor also manifests itself in smaller head \ncircumference and skull volume; therefore, it suggested the \ncareful use of exogenous corticosteroids in fetuses with stress \nand restricted growth.\nThe gestational age at which lung maturation in the group \nwhere rescue dose was used was significantly lower than the \nother study group [\uf7c2: 30.5 \u00b1 2.9]. Besides, there is evidence \nthat corticosteroids are beneficial after 26 weeks of gestation \nin reduced neonatal morbidity, including intraventricular he-\nmorrhage. This variable explains because, when administered \nbefore birth, a binding occurs to the transporter proteins, such \nas the corticoid transport globulin (CTG) of the pregnant wo-\nman and the fetus, which favors the action on the respiratory \nsystem, which consists of increase the levels of surfactant and \nits action, lung compliance, clearance of intrapulmonary fluids, \nas well as reduce the permeability of blood vessels.\nThe postnatal history found that the use of mechanical \nventilation in the invasive and non-invasive modality was supe-\nrior among infants who had received the rescue dose of corti-\ncosteroids, although without statistical significance (p> 0.05). \nSimilarly, the days of invasive mechanical ventilation were \nsignificantly longer in this study group [3\u00b15.7 days] (p<0.05). \nIn very preterm or moderately preterm newborns, the degree Sandra Liliana Medina Poma, Fabricio Gonz\u00e1lez-Andrade\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1967\nof the respiratory system's immaturity and the surfactant de-\nficit was higher than in other newborns. Sphingomyelin, ano-\nther component of the surfactant, has a constant production \nthroughout pregnancy, but other components such as lecithin \nand phosphatidylglycerol begin to occur after 25 weeks would \nexplain its deficit in the very preterm.\nThe use of surfactants among infants with corticosteroid \nrescue doses was higher and the other newborns. However, wi-\nthout statistical significance (p>0.05), which shows that offe-\nring another dose of corticosteroids, Prenatal, did not have an \nimportant influence on preventing hyaline membrane disease, \nwhich is the consequence of lung immaturity the absence of \npulmonary surfactant. This factor complements the lack of \nusefulness of the rescue dose of corticosteroids in preventing \nrespiratory complications, which in these cases depends more \non the degree of prematurity and lung immaturity than on the \npulmonary maturation scheme offered. It was also more fre-\nquent in patients with corticosteroid rescue than additional \ndoses of surfactant (10.8%) compared to the group without \ncorticosteroid rescue, indicating no improvement in respiratory \ndistress in patients' first six hours surfactant administered.\nOn the other hand, when analyzing the trans fontanel ul-\ntrasound and corticosteroid rescue dose results, it was obtai-\nned that intraventricular hemorrhage (13.7%), leukomalacia, \nand choroidal cysts were more frequent in neonates with a \nrescue dose of corticosteroids, although it was not statistica-\nlly significant. The effect of corticosteroids on preterm infants' \ncentral nervous system is substantial, with intraventricular \nhemorrhage complications. Indeed, an increase in central ve-\nnous pressure, which usually occurs during labor, and when \nrespiratory complications occur, which increased with the use \nof corticosteroids, which is assigned an essential role in the \nappearance of periventricular leukomalacia, which is related \nto an increase in interleukin 6, which is due to a local inflam-\nmatory process, which can subsequently bleed.\nIntraventricular hemorrhage of the neonate is associated \nwith increased cerebral blood flow and blood pressure, which \nis complicated by the vascular alterations that accompany \nhypoxemia and metabolic acidosis of neonates with respira-\ntory distress. The use of additional doses of corticosteroids \ncan contribute to weakening the capillary wall.\nSeizures among infants who had received the rescue dose \nof corticosteroids were also more frequent than in other new-\nborns. The cause of these seizures is probably due to the higher \nfrequency of intraventricular hemorrhage in preterm infants \nwith rescue doses of corticosteroids. Numerous mechanisms \nmake immature brains hyperexcitable. First, the neonatal pe-\nriod is a period of physiological synaptogenesis, and both the \nsynapse and the density of the dendritic spine are at their peak. \nSecondly, glutamatergic neurons, the primary excitation me-\nchanism of both the neonatal brain, are excessively abundant. \nTheir receptors have subunits that allow relative hyperexcita-\nbility; with the up-regulation mechanism, the number of recep-\ntors increases, and with the down-regulation mechanism, the \nnumber of receivers decreases.\nThird, gamma-amino-butyric acid (GABA), the primary \ninhibitory mechanism of the adult brain, can exert a parado-\nxical exciting action on the developing brain due to the pre-\nponderance of the sodium, potassium, and chloride cotrans-\nporter (NKCC1) and the Delayed expression of KCC2 chloride \ncotransporters, which leads to a high concentration of intra-\ncellular chloride and depolarization in response to GABAergic \nagents.\nThere was a significant difference in the patients' group \nwith corticosteroid rescue doses [28.4\u00b121.6] and the others. It could correspond to the higher frequency of days of mecha-\nnical ventilation, due to the pulmonary immaturity associated \nwith the higher degree of prematurity in this group, with the \nneurological and infectious complications, which were in this \nstudy group, compared to infants who did not receive the res-\ncue dose of corticosteroids. Other factors that could have in-\nfluenced the more magnificent hospital stay of these patients \nare the lower birth weight and gestational age in this group \nthan the other, which also predisposes to the appearance of \nmultiple complications.\nAlso, within respiratory complications, upon admission: \nhyaline membrane disease was present in 22.5% of infants \nwho received rescue doses of corticosteroids and in 13.7% of \nthose who did not receive it without statistical significance (p> \n0.05). Similarly, at the time of discharge from the NICU, no sta-\ntistically significant intergroup differences were obtained, an \nessential effect of the rescue dose of corticosteroids on the \nprognosis, and the reduction of complications of infants who \nreceived it. Corticosteroids accelerate the morphological diffe-\nrentiation of epithelial cells in type II cells, increase the rate of \nphosphatidylcholine synthesis and cause the accumulation of \nmessenger RNAs for B-surfactant proteins (Mr=7000) and C \n(Mr=5000). Induction of phospholipid surfactants and mRNA \nproteins occurs rapidly, reverses, and appears to be mediated \nby receptors.\nHowever, no significant effect was found in reducing hyali-\nne membrane disease in this work, probably due to this group's \ninfants' great prematurity. The production of surfactants me-\ndiates not all the effects of prenatal corticosteroids in the pre-\nvention of respiratory distress. A rapid removal of fluid from \nthe lung to allow efficient gas exchange at the alveolar surface \nis key to the fetus's transition to other uterus life. The signa-\nling of cellular corticosteroid receptors influences the func-\ntion of several proteins involved in the mediation of alveolar \nfluid clearance; they include a subunit of the epithelial sodium \nchannel (aENaC) and the a1 and b1 subunits of the adenosine \ntriphosphate-based basolateral pump (ATP), both expressed in \nthe respiratory epithelium.\nTherefore, at the time of admission, neurological pathology \nwas more frequent among infants in whom the rescue dose of \ncorticosteroids, but this difference was very discrete and did not \nobtain statistical significance. At the time of discharge, neurolo-\ngical complications did not have statistical significance among \nthe study groups (p>0.05), indicating that the rescue dose of \ncorticosteroids did not interfere; Although there is evidence that \nlinks the use of corticosteroids with neurological disorders such \nas intra-parenchymal hemorrhage and neonatal seizures. The-\nse complications were more frequent in the group that received \nthe rescue dose, but it was not statistically significant.\nBesides, neonatal infections at the time of admission \nhad no significant differences between the two study groups \n(p>0.05), although they were more frequent in the group that \nreceived the rescue dose, within these, the risk for urinary \ntract infection (21.6%). However, at the time of discharge from \nneonatal ICU, there were essential differences between the \ntwo groups (p<0.05), with a clear predominance in neonates \nwho received the rescue dose, where early sepsis predomina-\nted (32.4 %) and septic shock (7.8%). The immunosuppressive \neffect of corticosteroids predisposes to the appearance of in-\nfections at all levels.\nThe use of rescue doses of corticosteroids in the neona-\ntal period is associated with a higher probability of developing \nprenatal infections, such as chorioamnionitis and endometri-\ntis. It also increases the risk of early neonatal sepsis due to \nits suppressive effect on cellular and humoral immunity and Differences between preterm infants receiving a dose for lung maturation and those receiving an additional rescue dose of corticosteroids1968\ndecreases the production of lymphocytes, interleukins, and \ntumor necrosis factors, through a decrease in the stability of messenger RNA.\nThere were no significant differences between the two \nstudy groups when admission or discharge concerning meta-bolic pathologies. At admission, intrauterine growth restriction affected 9.8% of infants on corticosteroid rescue doses. This percentage was 15.7% at discharge. It associates corticoste-roids' action on fetal growth with reduced size and weight at birth and intrauterine growth restriction.\nNor was an essential relationship between hematological \npathologies and the use of rescue doses of corticosteroids at the time of admission or discharge. The most frequent cases were multifactorial jaundice in the group of those who recei-ved rescue doses (33.3%) but without statistical significance (p>0.05). In this case, jaundice seems to correspond to the in-teraction of several factors related to enzymatic immaturity, the use of antibiotics, or neonatal sepsis.\nSimilarly, cardiovascular and hemodynamic conditions did \nnot have a significant difference in both study groups; at dis-charge from the NICU, infants in whom the rescue dose was not used had a higher incidence of this type of complications, significantly the persistence of the ductus arteriosus, which is a malformation in which the use of rescue doses of prenatal corticosteroids is not involved.\nIn summary, the most critical findings were, in the group \nthat received rescue doses, which included very preterm new-borns, there was an increase in the number of days of mechani-cal ventilation and infectious complications, which at the same time was associated with an increase in hospitalization days.\nLimitations\nThe sample was adequate but could be extended to ano-\nther population group from other hospitals and provinces.Generalization\nIt is possible to generalize this research following a multi-\ncenter and prospective design.\nConclusions\nPreterm males weighing <1000 g from 30 to 32 weeks, \nwho used rescue doses of corticosteroids, showed an increa-\nse in intraventricular hemorrhage (13.7%), seizures (6.9%), and leukomalacia (13.7%), associated with the fact that in the group with rescue dose they are younger and had lower weight.\nAcknowledgments\nAuthors thanks Gonzalo Mantilla, Luis Eguiguren, Hugo \nBurgos, Ana Mar\u00eda Merch\u00e1n-Tamariz, Alonso Herrera, and \nHumberto Navas L\u00f3pez, for their support to this work.\nFunding\nAuthors self-funding.\nConflict of interest\nThe authors report NO conflict of interest.\nEthical approval\nThis research was approved by the Research Ethics Com-\nmittee on Human Beings (CEISH) of the San Francisco Univer-\nsity of Quito. It was dated 14 November of 2019, and coded with the number P2019-155TPG.Informed consent\nIt obtained Informed consent from all individual partici-\npants included in the study.\nConsent for publication\nThe institutions cited in this document gave their consent \nto use this information.\nBibliographic references\n1. R oberts D, Brown J, Medley N, Dalziel SR. Antenatal corti-\ncosteroids for accelerating fetal lung maturation for women\nat risk of preterm birth. Cochrane Database Syst Rev. 2017 21March;3(3):89-104. DOI: 10.1002/14651858.CD004454.pub3.\n2.\nMcKinla\ny CJD, Crowther CA, Middleton P, Harding JE. Repeat\nantenatal Corticosteroids for women at risk of preterm birth:A Cochrane Systematic Review. Am J Obstet Gynecol. 2012Mar;206(3):187-194. DOI: 10.1016/j.ajog.2011.07.042.\n3.\nEhret DEY\n, Edwards EM, Greenberg LT, Bernstein IM, Buzas JS,\nSoll RF, et al. Association of Antenatal Steroid Exposure WithSurvival Among Infants Receiving Postnatal Life Support at 22 to 25 Weeks' Gestation. JAMA Netw Open. 2018 Oct 5;1(6):e183235. DOI: 10.1001/jamanetworkopen.2018.3235.\n4.\n Sotiriadis A, Makr\nydimas G, Papatheodorou S, Ioannidis JPA,\nMcgoldrick E. Corticosteroids for preventing neonatal respi-ratory morbidity after elective cesarean section at term. Co-chrane Database Syst Rev. 2018 3 August;8(8): CD006614. DOI:10.1002/14651858.CD006614.pub3.\n5.\nK\namath-Rayne BD, Rozance PJ, Goldenberg RL, Jobe AH. Ante-\nnatal corticosteroids beyond 34 weeks gestation: What do we donow? Am J Obstet Gynecol. 2016 1 October;215(4):423-430. DOI: 10.1016/j.ajog.2016.06.023.\n6.\nNorman M, Piedv\nache A, B\u00f8rch K, Huusom LD, Bonamy AKE,\nHowell EA, et al. Association of short antenatal corticosteroidadministration-to-birth intervals with survival and morbidityamong very preterm infants results from the EPICE group. JAMA Pediatr. 2017 1 July;171(7):678-686. DOI: 10.1001/jamapediat-rics.2017.0602.\n7.\nCar\ntwright RD, Crowther CA, Anderson PJ, Harding JE, Doyle\nLW, McKinlay CJD. Association of Fetal Growth Restriction WithNeurocognitive Function After Repeated Antenatal Betameth-asone Treatment vs. Placebo: Secondary Analysis of the AC-TORDS Randomized Clinical Trial. JAMA Netw Open. 2019 Feb1;2(2):e187636. DOI: 10.1001/jamanetworkopen.2018.7636.\n8.\n Asztalos E V\n., Murphy KE, Willan AR, Matthews SG, Ohlsson\nA, Saigal S, et al. Multiple courses of antenatal corticosteroidsfor preterm Birth study outcomes in children at 5 years of age(MACS-5). JAMA Pediatr. 2013 Dec;167(12):1102-1110. DOI:10.1001/jamapediatrics.2013.2764.\n9.\nBesnard AE, Wirjosoekar\nto SAM, Broeze KA, Opmeer BC, Mol\nBWJ. Lecithin/sphingomyelin ratio and lamellar body count for fe-tal lung maturity: A meta-analysis. Eur J Obstet Gynecol ReprodBiol. 2013;169(2):177-183. DOI: 10.1016/j.ejogrb.2013.02.013.\n10.\n Shanks AL, Gr\nasch JL, Quinney SK, Haas DM. Controversies in\nantenatal corticosteroids. Semin Fetal Neonatal Med. 2019 1June;24(3):182-188. DOI: 10.1016/j.siny.2019.05.002.\n11.\n Jobe AH, K\nemp MW, Kamath-Rayne B, Schmidt AF. Antena-\ntal corticosteroids for low and middle-income countries. SeminPerinatol. 2019 1 August;43(5):241-246. DOI:10.1053/j.sem-peri.2019.03.012.\n12.\n The American College of Obs\ntetricians and Gynecologists.\nAntenatal Corticosteroid Therapy for Fetal Maturation. Ob-stet Gynecol [Internet]. 2017;140(3):102-109. DOI: 10.1542/peds.2017-2082. Available from: https://www.acog.org/-/media/Committee-Opinions/Committee-on-Obstetric-Practice/co713.pdf?dmc=1&ts=20200125T1631437144\n13.\n W\natterberg KL, Ballard PL. Optimizing antenatal corticosteroid\ntherapy for improving the outcome of preterm infants. Pediatr Res.2019 Nov 1;86(5):556-557. DOI: 10.1038/s41390-019-0538\u2013x.Sandra Liliana Medina Poma, Fabricio Gonz\u00e1lez-Andrade\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1969\n14. Cro wther CA, McKinlay CJ, Middleton P, Harding JE. Repeat dos-\nes of prenatal corticosteroids for women at risk of preterm birth\nfor improving neonatal health outcomes. Cochrane DatabaseSyst Rev. 2011 15 June;6:CD003935. DOI: 10.1002/14651858.CD003935.pub3.\n15.\n Hutchinson M, Hodgden JD\n. Clinical Question: In women with\npreterm labor, do repeated courses of prenatal corticosteroidsimprove neonatal outcomes compared to a single course? JOkla State Med Assoc [Internet]. 2018 Jan [cited 2020 Jan3];111(1):498-499. ISBN: 0030-1876. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30532343\n16.\n F\nrey HA, Klebanoff, MA. The epidemiology, etiology, and\ncosts of preterm birth. Semin Fetal Neonatal Med. 2016 1April;21(2):68-73. DOI: 10.1016/j.siny.2015.12.011.\n17.\n K\nemp MW, Schmidt AF, Jobe AH. Optimizing antenatal corticoste-\nroid therapy. Semin Fetal Neonatal Med. 2019 1 June;24(3):176-181. DOI: 10.1016/j.siny.2019.05.003.\n18.\n K\namath-Rayne BD, Defranco EA, Marcotte MP. Antenatal steroids \nfor treatment of fetal lung immaturity after 34 weeks of gesta-tion: An evaluation of neonatal outcomes. Obstet Gynecol. 2012May;119(5):909-916. DOI: 10.1097/AOG.0b013e31824ea4b2.\n19.\n McKinla\ny CJ, Manley BJ. Antenatal and postnatal corticoste-\nroids: A swinging pendulum. Semin Fetal Neonatal Med. 2019 1June;24(3):167-169.DOI: 10.1016/j.siny.2019.05.007.\n20.\n Ha\nviv HR, Said J, Mol BW. The place of antenatal corticosteroids\nin late preterm and early term births. Semin Fetal Neonatal Med. 2019 1 February;24(1):37-42. DOI: 10.1016/j.siny.2018.10.001\nReceived: 19 February 2021\nAccepted: 17 April 2021Differences between preterm infants receiving a dose for lung maturation and those receiving an additional rescue dose of corticosteroids1970\nFaezeh Ghasemi, Alireza Kamali, Maryam Shokrpour\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nDetermination of pro-oxidant-antioxidant balance (PAB) assay in mothers \nwith spontaneous abortion\nFaezeh Ghasemi1, Alireza Kamali2, Maryam Shokrpour3* DOI. 10.21931/RB/2021.06.03.14\nAbstract: Oxidative stress has been identified to play a vital role in the pathogenesis of spontaneous abortion were characterized \nas an imbalance between the generation of pro-oxidants, free radicals, and reactive species, and enzymatic and non-enzymatic \nantioxidant defenses in favor of the former. In the present study, the pro-oxidant-antioxidant balance was assessed in women \nwith spontaneous abortion and compared with healthy age-matched controls. A group of 50 females with spontaneous abortion \nwere considered patients, and a group of age-matched healthy pregnant women was considered controls. The pro-oxidant-\nantioxidant balance (PAB) assay was carried out on participants' serum samples. The mean age of the spontaneous abortion \ngroup was 30.84 \u00b1 3.82, and controls were 26.53 \u00b1 4.05 years. The obtained PAB values were 236.74 \u00b1 11.37 HK and 148.69 \n\u00b1 76.50 HK in patients and controls. Our results demonstrate the significant rise of PAB values in subjects with spontaneous \nabortion compared to healthy controls (p< 0.0001). Our study showed that the PAB values might be involved in the termination \nof spontaneous abortion.  \nKey words: Spontaneous abortion, Oxidative stress, Antioxidants, PAB assay.RESEARCH / INVESTIGACI\u00d3N\nIntroduction\nSpontaneous abortion is considered as the fetus's natural \ndeath before 20 gestations. Based on scientific declarations, \nspontaneous abortion defines by pregnancy termination be-\nfore complete 20 weeks gestational period while the fetal \nweight is less than a half kilogram1,2. Massive investigation \nshowed that the rate of spontaneous abortion depends on \npregnancy age and miscarriage3,4. According to the Cardone \net al. rate of spontaneous abortion increased in elder fema-\nles compare with younger cases. In North American pregnant \nfemales, spontaneous abortion happened in 17%- 20% cases \nyounger than 25 years old whereas increased to 30%-35% in \nthose with 35-45 years old3.\nCramer and Wise published data demonstrated that mis-\ncarriage increase spontaneous abortion risk. The incidence \nof spontaneous abortion in females with no miscarriage is \napproximately 13 percent and increased to 25%, 30 %, and 35 \n% in those who suffered from 1, 2, and 3 miscarriages, respecti-\nvely3. Further investigation illustrated the various spontaneous \nabortion risk factors.  Dickey RP and colleagues represented \nthe higher incidence of spontaneous abortion in one-fourth of \nfemales treated with human gonadotropin and clomiphene5.\nMoreover, fragmentation of sperm DNA, hyperhomocys-\nteinemia, immunological disorders, and insufficient antioxidant \ndefenses have also been observed in females with sponta-\nneous abortion4.  \nOxidative stress, a profound imbalance between pro-oxi-\ndants, reactive oxygen specious, free radicals, and enzymatic \nand non-enzymatic antioxidants in favor of the former, plays \nthe leading role in disorders and deficiencies6,7. Despite the \nessential role of oxygen in metabolism and life persistency, \nits toxic derivatives can be caused severe damage to cellular \ncompartments7.\nReactive species damage DNA, mitochondria, and cell \nmembrane, which affects the cellular compartments patho-\nlogically and leads to ultimate cellular demise8,9. In response \nto oxidative damage, the antioxidant system neutralizes the excess pro-oxidants, maintains physiological balance, and \nestablishes cellular homeostasis10,11. Simsek et al. uncovered \nthe essential role of oxidative damage, higher level of lipid pe-\nroxidation, and reactive oxygen specious immediately before \nabortion12,13.\nAlthough the exact causes of spontaneous abortion are \nnot clearly understood, immunological alterations and pro-\nfound disruption of oxidative stress seem to be involved etiolo-\ngically. Our study aims to characterize the prooxidant-antioxi-\ndant balance (PAB) in patients with spontaneous abortion.\nMaterials and methods \nSubjects\nThe presented study was conducted on 80 pregnant fe-\nmales (50 with spontaneous abortion history as a patient \ngroup and 30 normal age-matched healthy women without \na history of abortion as controls) hospitalized between March \n2017 and October 2018 in Taleghani Hospital Arak, Iran. The \nfirst day of gestation was determined based on ultrasound \nobtained data, and obstetricians evaluated the risk of sponta-\nneous abortion in participants. Females who had been exposed \nto teratogenic drugs were excluded, whereas the participants \nwho have had at least 1 terminated abortion before complete \n20 weeks gestation were categorized as the patients. Moreo-\nver, all participants were signed the written consent to contri-\nbute to the survey that the ethics committee approved of Arak \nMedical School.\nSample collection\nFor all subjects, the age, history of spontaneous abortion, \ngestational time, deliveries, and abortions were recorded. To \ncarrying out the PAB assay, 2 ml arterial-venous mixed cord \n1 Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Next to Milad Tower, Tehran, Iran.  \n2 Departments of Anesthesiology and Critical Care, Arak University of Medical Sciences, Arak, Iran. \n3 Department of Gynecology,  Faculty of Medicine, Arak University of Medical Sciences, Arak, Iran\nCorresponding author: ghasemi_808@yahoo.com1971\nDetermination of pro-oxidant-antioxidant balance (PAB) assay in mothers with spontaneous abortion\nblood was collected after delivery and abortion. The collected \nblood samples were centrifuged at 3600 rpm for 10 minutes \nafter clotting to separate sera. To measure the oxidative stress \nparameters in the rapid, accurate method, the obtained sera \nwere kept at -80oC until analysis. The hemolytic samples were \nexcluded from the PAB assay.\nChemicals\nThe chemicals were used in our survey include TMB pow-\nder (3, 3\u2032, 5, 5\u2032-Tetramethylbenzidine, Fluka), chloramine T tri-\nhydrate (AppliChem: A4331, Darmstadt, Germany), peroxida-\nse enzyme (AppliChem: 230 U/mg, A3791, 0005, Darmstadt, \nGermany), hydrogen peroxide (Merck). Double distilled water \nwas applied for dissolving molecular biology grade reagents \nthat need further preparation.\nThe pro-oxidant antioxidant balance (PAB) assay\nPAB assay was carried out based on our previous stu-\ndies14,15. Standard solutions were prepared by blending the \nexact proportion of 250 M H2O2 (0-100%) and uric acid 3 mM \nand added to the NaOH (10 mM). To prepare TMB cation, 60 \nmg TMB powder was dissolved in 10 ml dimethyl sulfoxide \n(DMSO) and was added to 20 ml acetate buffer (0.05 M, pH \n4.5). After that, well-mixed 70 \u03bcl freshly chloramine T solu-\ntion (100 mM) was added to the previously prepared solution, \nshacked immediately, and incubated for 2 hours at room tem-\nperature (23oC-27oC) in the dark places.\nThe horseradish peroxidase working solution was prepa-\nred by blending the 25-unit peroxidase enzyme solution into \nthe 20 ml TMB cation and aliquoted into 1 ml microtubes and \nstored at -20, respectively. TMB working solution was prepa-\nred by gently blending 200 \u03bcl TMB/DMSO into the 10 ml ace-\ntate buffer (0.05 M, pH 5.8).\nTo determine the PAB values in the subjects' sample, 200 \n\u03bcl working solution was added to each well of 96-well ELISA. \nThen, 10 \u03bcl participants' sera, distilled H2O (blank well), and \nstandard solutions were added and mixed gently as well as the plates were incubated in the dark place at 37oC for 15 minutes. \nThe 50 \u03bcl of 2 N HCl was recruited as the stop solution, and the \nPAB was measured at 450 nm wavelength.\nThe PAB values were demonstrated in arbitrary HK units, \nthe percentage of H2O2 in the standard solution. Meanwhile, \nunknown samples were then calculated based on the obtained \nvalues from the standard drowning curve.\nStatistical analysis\nThe Statistical Package for Social Sciences (SPSS version \n20.0, IBM, USA) was used for data analysis while the P-value \n< 0.05 was considered statistically significant. The Kolmogo-\nrov-Smirnov test was carried out to determine the data's nor-\nmality, and unpaired sample T-tests were applied for evalua-\nting the statistical analysis.\nResults\nThe mean age of participants with spontaneous abortion \nand controls were 30.84\u00b13.82 and 26.53\u00b14.05 years, respec-\ntively. The higher range and lower range of participants' PAB \nvalue shows 214 \u2013 253.74 HK in females with spontaneous \nabortion and 2.50 \u2013 264.03 in the standard group. Our obtained \ndata revealed a significantly raised level of PAB values in spon-\ntaneous abortion participants compared to the standard group \n(p-value <0.0001) (figure 1).\nNo abortion was seen in controls, while in the spontaneous \nabortion group, 21 cases had had one abortion, and 5 cases had \nhad 3 abortions. Furthermore, 29 cases had delivered at least \none normal childbirth (Table 1).\nDiscussion\nMassive investigations demonstrate the role of oxida-\ntive stress in the pathogenesis of spontaneous abortion, \npre-eclamptic pregnancy, and related pregnancy hypertensive \nFigure 1. Evaluation of the PAB values between two groups. Results showed a significant increase in PAB values in the spon -\ntaneous abortion group 236.74\u00b111.37 HK compared to the control group 148.69\u00b176.50 (p<0.0001).1972\ndisorders16-18. Higher levels of oxidants such as malondialdehy-\nde, protein carbonyl, erythrocyte glutathione peroxidase, and \nerythrocyte superoxide dismutase were observed in placenta-tion, miscarriage, and recurrent pregnancy loss\n19. Our results \nindicate that a significant increase in pro-oxidants in subjects with spontaneous abortion compared to controls.\nDespite the suggestion of published reports that show \nthe beneficial effects of antioxidants in vitro fertilization (IVF), rare of them demonstrate the role of antioxidants in misca-rriage\n20,21. Recent investigations demonstrate that the proper \nfetus implantation seriously depends on low oxygen concen-tration to complete 10 gestational weeks\n22. It may protect fe-\ntal development and differentiation against reactive specious, free radicals, and immunological reactions\n19. Compelling evi-\ndence uncovered the deficient trophoblastic invasion that oc-curred following the spontaneous abortions\n23. Therefore, in \nthe same direction as our obtained data, oxidative stress may raise the spontaneous abortions before complete 10 weeks of gestation, which might be the consequence of maternal blood-flow disorders\n19.\nHigher lipid peroxidation and oxidative stress biomarkers \nsuch as malondialdehyde increase in females with sponta-neous abortion\n24. Sugino et al. published a report that showed \nthe higher concentration of lipid peroxidation in females with spontaneous abortion suffered from vaginal bleeding\n25. These \nobservations boost our hypothesis about the role of oxidative stress in spontaneous abortion. In other words, higher levels of reactive specious, free radicals and consequent oxidative da-mages lead to placenta oxidation, spontaneous abortion, and fetal termination. A higher level of lipid peroxides such as ma-londialdehyde may involve in urine evacuation.\nThe corpus luteum activity is fundamental for embryoge-\nnesis and fetal development. The early stages of pregnancy and trophoblast implantation are dependent on corpus luteum activity which relies upon superoxide dehydrogenase-enzyme activity. In the ovary, superoxide dehydrogenase prevents the restrictive reaction of hydrogen peroxide-derived peroxide and superoxide ions on gonadotropin hormones and affects the ovary's follicular function\n26, demonstrating the role of supe-\nroxide dehydrogenase-enzyme activity in early gestation.\nInterestingly, Umaoka and colleagues demonstrate that \nin vitro fetal development was restricted during the high level of oxygen. Likewise, reactive oxygen specious and superoxide ions cause severe damage to embryogenesis and trophoblast expansion. Superoxide dehydrogenase can prevent the harm-ful effects of superoxide ions\n27.Conclusions\nA significant increase in pro-oxidants and oxidative stress \nwere reported in several investigations. Based on our data, profound disruption of oxidative stress may involve sponta-neous abortion even though more surveys are needed. \nBibliographic references\n1. K wegyir-Afful E, Adu G, Spelten ER, R\u00e4s\u00e4nen K, Verbeek J. Mater-\nnity leave duration and adverse pregnancy outcomes: An interna-\ntional country-level comparison. Scandinavian journal of publichealth. 2018; 46(8): 798-804.\n2.\nBlenco\nwe H, Cousens S, Oestergaard MZ, Chou D, Moller A-B,\nNarwal R, et al. National, regional, and worldwide estimates ofpreterm birth rates in 2010 with time trends since 1990 for se-lected countries: a systematic analysis and implications. The lan-cet. 2012; 379(9832): 2162-72.\n3.\nGupta S, Agar\nwal A, Banerjee J, Alvarez JG. The role of oxidative \nstress in spontaneous abortion and recurrent pregnancy loss:a systematic review. Obstetrical & gynecological survey. 2007;62(5): 335-47.\n4.\n Cr\namer DW, Wise LA. The epidemiology of recurrent pregnancy\nloss. Seminars in reproductive medicine 2000; 18(04): 331-40.\n5.Dick\ney RP, Taylor SN, Curole DN, Rye PH, Pyrzak R. Infertility:\nIncidence of spontaneous abortion in clomiphene pregnancies.Human reproduction. 1996; 11(12): 2623-28.\n6.\nP\nouya VT, Hashemy SI, Shoeibi A, Tirkani AN, Tavallaie S, Avval\nFZ, et al. Serum Pro-Oxidant-Antioxidant Balance, Advanced Ox-idized Protein Products (AOPP) and Protein Carbonyl in PatientsWith Stroke. Razavi International Journal of Medicine. 2016; 4(2):\n7.\nA\nvval FZ, Mahmoudi N, Tirkani AN, Jarahi L, Alamdari DH, Sad-\njadi SA. Determining Pro-Oxidant Antioxidant Balance (PAB) andTotal Antioxidant Capacity (TAC) in Patients with Schizophrenia.Iranian journal of psychiatry. 2018; 13(3): 222.\n8.\n Sharif ME, Mohamedain A, Ahmed AA, Nasr AM, Adam I. Folicacid le\nvel and preterm birth among Sudanese women. Maternal\nhealth, neonatology and perinatology. 2017; 3(1): 25.\n9.R\nonnenberg AG, Goldman MB, Chen D, Aitken IW, Willett WC,\nSelhub J, et al. Preconception folate and vitamin B6 status andclinical spontaneous abortion in Chinese women. Obstetrics &Gynecology. 2002; 100(1): 107-13.\n10.\n Agar\nwal A, Allamaneni SS. Role of free radicals in female repro-\nductive diseases and assisted reproduction. Reproductive bio-medicine online. 2004; 9(3): 338-47.\n11.\n Lu J\n, Wang Z, Cao J, Chen Y, Dong Y. A novel and compact review \non the role of oxidative stress in female reproduction. Reproduc-tive Biology and Endocrinology. 2018; 16(1): 80.\nTable 1. Comparison the delivery, abortion and gestational time between spontaneous abortion group and controls.Faezeh Ghasemi, Alireza Kamali, Maryam Shokrpour\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1973\n12. \u015eim\u015fek M, Naziro \u03b1 lu M, \u015eim\u015fek H, Cay M, Aksakal M, Kumru\nS. Blood plasma levels of lipoperoxides, glutathione peroxidase,\nbeta carotene, vitamin A and E in women with habitual abortion.Cell Biochemistry and Function: Cellular biochemistry and itsmodulation by active agents or disease. 1998; 16(4): 227-31.\n13.\n Mohd Mutalip S, Ab-R\nahim S, Rajikin M. Vitamin E as an antioxi-\ndant in female reproductive health. Antioxidants. 2018; 7(2): 22.\n14.\n P\nouya VT, Hashemy SI, Shoeibi A, Tirkani AN, Tavallaie S, Avval\nFZ, et al. Serum Pro-Oxidant-Antioxidant Balance, Advanced Ox-idized Protein Products (AOPP) and Protein Carbonyl in PatientsWith Stroke. Razavi International Journal of Medicine. 2016; 4(2):\n15.\n Alamdari DH, Gha\nyour-Mobarhan M, Tavallaie S, Parizadeh MR,\nMoohebati M, Ghafoori F, et al. Prooxidant\u2013antioxidant balance as a new risk factor in patients with angiographically defined coro-nary artery disease. Clinical biochemistry. 2008; 41(6): 375-80.\n16.\n V\nanderlelie J, Venardos K, Clifton V, Gude N, Clarke F, Perkins A.\nIncreased biological oxidation and reduced antioxidant enzymeactivity in pre-eclamptic placentae. Placenta. 2005; 26(1): 53-58.\n17.\n Scholl T\nO, Leskiw M, Chen X, Sims M, Stein TP. Oxidative stress,\ndiet, and the etiology of preeclampsia. The American journal ofclinical nutrition. 2005; 81(6): 1390-96.\n18.\n Bulgan Kilicdag E, A\ny G, Celik A, Ustundag B, Ozercan I, Simsek\nM. Oxidant-antioxidant system changes relative to placental-um-bilical pathology in patients with preeclampsia. Hypertension inpregnancy. 2005; 24(2): 147-57.\n19.\n Ozka\nya O, Sezik M, Kaya H. Serum malondialdehyde, erythrocyte\nglutathione peroxidase, and erythrocyte superoxide dismutaselevels in women with early spontaneous abortions accompaniedby vaginal bleeding. Medical Science Monitor. 2008; 14(1): CR47-CR51.\n20.\n Olson \nS, Seidel Jr G. Culture of in vitro-produced bovine embryos \nwith vitamin E improves development in vitro and after transferto recipients. Biology of Reproduction. 2000; 62(2): 248-52.\n21.\n P\neng Y, Kwok K, Yang P-H, Ng SS, Liu J, Wong O, et al. Ascor-\nbic acid inhibits ROS production, NF-\n\u03b1\nB activation and prevents\nethanol-induced growth retardation and microencephaly. Neuro-pharmacology. 2005; 48(3): 426-34.\n22.\n Bur\nton GJ, Watson AL, Hempstock J, Skepper JN, Jauniaux E.\nUterine glands provide histiotrophic nutrition for the human fetus during the first trimester of pregnancy. The Journal of ClinicalEndocrinology & Metabolism. 2002; 87(6): 2954-59.\n23.\n Bur\nton GJ, Jauniaux E. Placental oxidative stress: from miscar-\nriage to preeclampsia. Journal of the Society for Gynecologic In-vestigation. 2004; 11(6): 342-52.\n24.\n Sane A, Chokshi S\nA, Mishra V, Barad D, Shah V, Nagpal S. Serum\nlipoperoxides in induced and spontaneous abortions. Gynecologic and obstetric investigation. 1991; 31(3): 172-75.\n25.\n Sugino N, Nakata M, K\nashida S, Karube A, Takiguchi S, Kato H. De-\ncreased superoxide dismutase expression and increased concen-trations of lipid peroxide and prostaglandin F2\u03b1 in the deciduaof failed pregnancy. Molecular human reproduction. 2000; 6(7):642-47.\n26.\n MARGOLIN Y\n, ATEN RF, BEHRMAN HR. Antigonadotropic and\nantisteroidogenic actions of peroxide in rat granulosa cells. Endo-crinology. 1990; 127(1): 245-50.\n27.\n Umaoka Y\n, Noda Y, Narimoto K, Mori T. Effects of oxygen toxicity\non early development of mouse embryos. Molecular reproduction and development. 1992; 31(1): 28-33.\nReceived: 22 March 2021\nAccepted: 21 May 2021Determination of pro-oxidant-antioxidant balance (PAB) assay in mothers with spontaneous abortion1974\nAshraf A. Abd El-Tawab, Fatma I. El-Hofy, Mohamed A. Abdelmonem, Hend S. Youssef\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nMolecular characterization of net B and tpe L virulence factors and antimicrobial \nresistance genes of Clostridium perfringens  isolated from herbs and spices\nAshraf A. Abd El-Tawab1, Fatma I. El-Hofy1, Mohamed A. Abdelmonem2, Hend S. Youssef2* DOI. 10.21931/RB/2021.06.03.15\nAbstract: The present study aimed to determine some virulence-associated genes and antimicrobial multidrug resistance of \nClostridium perfringens recovered from herbs and spices widely distributed in the Egyptian market. C. perfringens virulence \nand resistance factors were determined using PCR targeting the netB, tpeL, ermB, bla and tetK genes. Thirty three out of 392 \nsamples (8.42%) from herbs and spices submitted to our laboratory for bacteriological screening were positive for presence C. perfringens. PCR results for the tpeL gene in isolated C. perfringens revealed 9 out of 33 (27.3 %) of isolates, while netB was not detected. The isolates were resistant to Clindamycin, Vancomycin, tetracycline, and erythromycin with inhibition zones of 6.28 \u00b1 0.63, 8.78 \u00b1 0.41, 9.63 \u00b1 0.63, and 9.84 \u00b1 0.66 mm, respectively. The genes mentioned above were selected to correspond to the ineffective antimicrobials; ermB for erythromycin, tetK for tetracycline, and bla for the remainder. PCR results for antibacterial resistant genes in isolated C. perfringens revealed their presence. From 33 isolates, bla gene was detected in 21 (63.4 %), tetK in 13 (39.4 %) and ermB in only one isolate (3.03 %). Sequencing analysis was done for the bla gene as an example for the detected genes as detected at the highest incidence (63.4%). No cross-relationship was detected upon comparing incidence data of both studied virulence genes and those of antimicrobial resistance. The present findings may explain the resistance of C. perfringens to the examined antibacterials and recommend avoiding the application of them to control the microbe. In addition, the authors recommend following strict hygienic procedures during the industry of herbs and spices to ensure their clearance from Clostridium perfringens before distributing the products as food additives into the markets.\nKey words: Clostridium perfringens, Herbs, Spices, Antibiotic Susceptibility Test, Resistance, Genes.RESEARCH / INVESTIGACI\u00d3N\nIntroduction\nAmong food additives, herbs and spices are considered as \nsevere vectors for foodborne microorganisms, including C. per-\nfringens1,2. Incidence of C. perfringens in herbs and spices has \nbeen checked worldwide, including India3, Turkey4, the United \nKingdom5, Italy6, Lebanon7,  Saudi Arabia8, and Egypt9.\nAbundant toxin production and multidrug resistance are \nconsidered as the two major problems caused by Clostri-dium perfringens. This microbe is Gram-positive eubacteria, a rod-shaped, spore-forming anaerobe widely distributed el-sewhere in nature, including soil, surfaces, sewage, feces, foods, and food additives\n10.\nC. perfringens is a highly toxicogenic bacterium as it can\nproduce various toxins (at least 17) that are considered to be its pathogenic virulence factors\n11. Four among these toxins are \ncommonly categorized as significant as they may cause letha-lity; these are \u03b1-, \u00df-, \u00a3-, and i-toxins. Each strain with its parti-cular toxins is associated with a particular disease in humans and animals\n12. For this, most studies are focused on looking \nat these toxins from bacterial isolates, including one carried out by our team (El-Tawab et al., 2021, under publishing). On \nthe other hand, some other genes were considered minor ones because they are thought not to be pivotal for C. perfringens pathogenesis. Among these genes are found netB and tpeL toxins. However, recently, these genes were suggested to con-tribute to disease pathogenesis. For many years, \u03b1-toxin was thought to be the major virulence factor involved in necrotic enteritis, but a clostridial strain cloned for deactivation of \u03b1-toxin still able to produce lesions in broilers. This study led to the discovery of the pathogenicity of a new toxin, NetB\n13. \nIn addition, it was discovered that inoculation of broilers with strains positive for both netB and tpeL were associated with greater severity of gross lesions over strains with only netB\n14, a fact that supports the idea of the pathogenicity of tpeL too.\nEven though a relatively limited number of studies focu-\nsed on investigating these two toxins and their driving genes, no study has looked at these two virulence factors in clostri-dial isolates from herbs and spices.\nThe second major problem of the studied microbe is its \nresistance to drugs. In a previous study, we have conducted the antibiotic susceptibility test and detected the resistance of clostridial isolates to Clindamycin, Vancomycin, tetracycline, and erythromycin. However, the underlying mechanism of this resistance was not investigated\n9.\nThe present study aimed to investigate the netB and tpeL \ntoxin/gene positivity of C. perfringens isolated from herbs and spices retailed all over the Egyptian markets and to determine the molecular mechanisms underlying the antimicrobial drug resistance by investigating the positivity to bla, tetK, and ermB \ngenes. To fulfill this aim, PCR and sequencing, and phyloge-netic analyses have been conducted on C. perfringens isolates from herbs and spices.\nMethods\nSamples and isolates\nThe study was applied to 392 samples obtained from the \ntop herbs and spices suppliers in Egypt. The samples have been screened for the incidence of C. perfringens. Thirty-three C. perfringens isolates were obtained from these samples fo-llowing ISO 6887-2, ISO 6887-3, ISO 6887-4, or ISO 8261\n9. The\nisolates w\nere resistant to Clindamycin, Vancomycin, tetracy-\ncline, and erythromycin9.\n1 Department of Microbiology, Faculty of Veterinary Medicine, Benha University, 13736 Moshtohor, Egypt.  \n2 Department of Microbiology, Central Lab of Residue Analysis of Pesticides & Heavy Metals in Food, Agricultural Research Center, Ministry of Agriculture, Giza, Egypt.\nCorresponding author: hend.micro@outlook.com1975\nMolecular characterization of net B and tpe L virulence factors and antimicrobial resistance genes of Clostridium perfringens  isolated from herbs and spices\nDNA extraction\nDNA was extracted from the pure isolated colonies using \nthe QIAamp DNA Mini kit purchased from Qiagen\u00ae (Hilden, \nGermany) following the manufacturer's instructions with \nsome modifications. The kit provides silica-membrane-based \nnucleic acid purification from different types of samples. The \nspin-column procedure does not require mechanical homoge-\nnization; thus, the total hands-on preparation time is only 20 \nminutes. The DNA concentration was determined using Na-\nnoDrop ND-1000 Spectrophotometer from Thermo-scientific \n(Waltham, MA, USA) by reading absorbances at 260 and 280 \nnm. The extracted samples were stored at \u201320 \u00b0C until used as \ntemplates for PCR amplification.\nPCR\nThe conventional PCR was applied to screen netB and tpeL \ntoxin-encoding genes and those of resistance, namely, bla, tetK \nand ermB in the 33 isolates of C. perfringens, using Emerald \nAmp GT PCR Master Mix kit, Code No. RR310A was purchased \nfrom Takara Bio Inc.\u00ae (Shiga, Japan). The amplification process \nwas performed according to the manufacturer's instructions, \nusing specific primers from Midland\u00ae (TX, USA) and a thermal \ncycler from Biometra\u00ae (Jena, Germany). The thermal cycling \nconditions are briefly described in tables 1, 2, and 3.Agarose gel electrophoresis\nThirty \u03bcl of each PCR test product, negative and positive \ncontrols, and 100-bp DNA ladder (purchased from Fermen-\ntas\u00ae, Massachusetts, USA; cat. no. SM0243) were loaded to \nagarose gel 1.5 % and the process was conducted according \nto (20) following instructions of the manufacturer. The power \nsupply was adjusted between 1~5 volts/cm of the tank leng-\nth. The run was stopped after about 30 min, and then the gel \nwas transferred to the UV cabinet. A gel documentation sys-\ntem photographed the gel, and the data was analyzed through \ncomputer software.\nSequencing reaction of bla gene\nUniplex PCR products of five C. perfringens isolates po-\nsitive of bla gene were taken randomly and purified using the \nQIAquik PCR product purification protocol (Qiagen\u00ae, Hilden, \nGermany) provided by the manufacturer. The purified PCR pro-\nducts were sequenced in the forward and reverse directions \non an Applied Biosystems 3130 automated DNA Sequencer \n(ABI, 3130, USA), using a ready reaction Bigdye Terminator \nV3.1 cycle sequencing kit, Cat. No. 4336817 (Perkin-Elmer / \nApplied Biosystems, Foster City, CA). The master mix using Big \ndye Terminator V3.1 cycle sequencing kit is described below \n(Table 4).\nTable 1. Oligonucleotide \nprimers for the 5 targe -\nted genes.\nTable 2. Preparation of 5 Clostridium \ngenes uniplex PCR Master Mix.\nTable 3. Cycling con -\nditions of the different \nprimers for cPCR and \nRAPD.1976\nPhylogenetic analysis\nThe nucleotide sequences of bla gene were compared with \nthe sequences available at public domains using BLAST (Ba-\nsic Local Alignment Search Tool) server to establish sequence identity to GenBank accessions\n21. A comparative analysis of \nsequences was performed using the CLUSTAL W multiple se-quence alignment program, version 1.83 of MegAlign module of Lasergene DNAStar software Pairwise, designed by (22) and phylogenetic analyses done using maximum likelihood, neigh-bor-joining, and maximum parsimony in MEGA6\n23.\nGenBank submission\nThe sequences of the bla gene have been deposited in \nthe GenBank database under the following accession num-bers: HY1 MT891107; HY2 MT891108; HY3 MT891109; HY4 MT891110; HY5 MT891111.\nData management\nThe obtained results were statistically analyzed using EX-\nCEL\u00ae software version 16. The number of positive samples for \neach gene against the total number of examined samples was calculated as a percentage from the total.\nResults and discussion\nC. perfringens was first isolated by William Welch and\nGeorge Nuttall at a Hospital in Baltimore, USA, following a postmortem autopsy from a dead patient and was termed as Bacillus aerogenes capsulatus\n24. The microbe can secrete va-\nrious toxins of pore-forming nature by causing conformational change and barrel formation through the lipid bilayer of the affected host cells\n25. Among those toxins, 4 types are conside-\nred as significant, which are alpha, beta, epsilon, and iota; and according to the ability of a clostridial strain to secrete one or more of such significant toxins, C. perfringens was subtyped into five types, A, B, C, D and E\n26.\nIdentification and characterization of C. perfringens iso-\nlated from various sources have been made by many resear-chers. In the present work, 33 positive isolates for the studied bacteria were obtained from herbs and spices (33 isolates/392 samples) commonly distributed in the Egyptian market\n9. \nNewer virulence factors, including netB and tpeL have been raised\n13,27. Relatively to the major ones (\u03b1-, \u00df-, \u00a3-, and i-toxins), \nthese two factors have limited the number of studies on some source materials, especially poultry affected with necrotic en-teritis. Moreover, no information is available about them from herbs and spices; therefore, we have encouraged to look at netB and tpeL from this source.\nIrrational antimicrobial use has increased the antimicro-\nbial resistance among bacterial pathogens, including C. per-fringens. Moreover, an antimicrobial may also contribute posi-tively or negatively to virulence factors of a bacterium\n28.\nIn the present study, electrophoresis of the obtained mul-tiplex PCR products confirmed the amplification of the target primer sequences for the positive controls of netB (560 bp) and tpeL (466 bp) gene fragments, while no bands were detec-\nted in the lanes of the negative controls. Bands corresponding to the tpeL fragments were detected in 27.3 % (9 out of 33) of the tested isolates, and no bands were detected for the netB fragments (Table 5 and Figures 1 & 2). The results may indica-te the low prevalence of tpeL positive clostridial strains isola-ted from herbs and spices and the absence of those with netB genes. Although no similar studies were conducted on herbs and spices in Egypt, the absence of netB may be supported by the fact that this gene is only found in C. perfringens strains of poultry and exceptionally in one isolate recovered from a cow in the USA\n29. Comparatively, the presence of tpeL in about one-\nthird of the obtained C. perfringens colonies may be partially consistent with (30), where was reported a 37 % of prevalen-ce of clostridial strains positive for tpeL genes from ostriches. Low prevalence of both genes, netB, and tpeL in Alabama far-ms was also reported in (31). No studies have been conducted on herbs and spices regarding these genes to discuss. Genera-lly, netB has a similar molecular size to beta-toxin, hence the \nname netB (necrotic enteritis toxin B-like), which has cytotoxic \nactivity in chicken\n13. While tpeL is a member of the large clos-\ntridial toxins that is still poorly understood and needs further investigations, it also has cytotoxicity\n27.\nPCR data of the present study detected the presence \nof bla, tetK and ermB genes in C. perfringens isolates from \nherbs and spices. From 33 isolates, bla gene was detected in 21 (63.4 %), tetK in 13 (39.4 %) and ermB in only one iso-late (3.03 %) (Table 5 and Figures 3, 4 & 5). This assay was aimed at exploring the genetic basis of our previous findings of antibiotic susceptibility test (AST) that found C. perfringens isolates resistant to Clindamycin, Vancomycin, tetracycline, and erythromycin with inhibition zones of 6.28 \u00b1 0.63, 8.78 \u00b1 0.41, 9.63 \u00b1 0.63 and 9.84 \u00b1 0.66 mm, respectively\n9. The \nfinding of bla may explain the resistance of C. perfringens to Clindamycin and Vancomycin based on its highest presence (about 64%), but the susceptibility to Penicillin-G (inhibition zone = 16.6 \u00b1 1.16 mm) remains to be understood. The highest susceptibility of the microbe to Ampicillin-Salbactam (19.4 \u00b1 0.98 mm) could be explained post-transcriptionally, where sulbactam inhibits beta-lactamase after its production from the bacterial cell. These findings may be in partial consistency with (32) who reported zero % resistance of C. perfringens to Penicillin, Cefoxitin, Meropenem, and piperacillin with 3.8 % of resistance to Clindamycin. However, our finding of resistance to vancomycin may be inconsistent with that of (33,34) who reported that C. perfringens to vancomycin, is low (0\u20135.6 %) because of the limited use of this antibiotic in farms. The fin-ding of amplified bands of tetK gene fragments in C. perfrin-gens isolated from herbs (39.4 %) may partially explain and parallel with the recorded resistance of isolates to tetracycline (8.8 \u00b1 0.4 mm inhibition zone). In contrast, the finding of only 3 % of ermB-positive strains is not parallel with and cannot \nTable 4. Preparation of master mix using Bigdye Terminator V3.1 cycle sequencing kit.Ashraf A. Abd El-Tawab, Fatma I. El-Hofy, Mohamed A. Abdelmonem, Hend S. Youssef\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1977\nFigure 2. Uniplex PCR \nresults of tpeL gene of C\n.\nperfringens  isolated\nfrom herbs and spicesin samples from 1~17(A) and 18~33 (B); netB\ngene band w\nas detec -\nted at 466 bp.Figure 1. \nUniplex PCR \nresults of netB gene of C\n.\nperfringens  isolated\nfrom herbs and spicesin samples from 1~17(A) and 18~33 (B); \nnetB\ngene band w\nas detec -\nted at 560 bp in control\npositiv\ne lane only.Molecular characterization of net B and tpe L virulence factors and antimicrobial resistance genes of Clostridium perfringens  isolated from herbs and spices1978\nTable 5. Virulence (netB and \ntpeL) and multidrug resistan -\nce (bla, tet K and ermB) genes \nof C. perfringens isolated from \nherbs and spices.\nexplain the resistance of isolates to erythromycin (9.8 \u00b1 0.7 \nmm inhibition zone). This might refer to the presence of other mechanisms exhibited by the bacterium for resistance against erythromycin. The findings of resistance to Tetracycline and Erythromycin are consistent with (35) who reported resistance of C. perfringens isolates to these two antibiotics by 50.8 and \n29.2 %, respectively. However, our finding may not agree with 36, who reported that the most probable mechanism of resis-tance against macrolides is modifying a target site by a me-thylase encoded by the ermB gene. The authors added that the ermB genotype exhibits the highest level of resistance against all macrolides, the statement does not match our findings as the ermB gene was detected in only one isolate among all the \nresistant isolates.\nTaken together, it could be speculated that netB toxin \ndoes not correlate with the resistance of C. perfringens to the tested antibiotics because it was absent in all resistant isola-tes. However, tpeL toxin might contribute to the antimicrobial resistance as it was detected in about 40 % of the resistant isolates. Although this hypothesis needs more in-depth in-vestigations, it could be in agreement with (35) who reported that the tpeL gene was more common among C. perfringens isolates susceptible to tetracycline. From our previous studies, it could be stated that the antimicrobial resistance profiles of C. perfringens varies significantly according to sources, coun-tries, other bacterial factors rather than the resistance-driving genes.\nDespite its apparent minimal contribution to antimicrobial \nresistance, yet, bla- gene was detected in 21 out of 33 isolates (63.4 %) of C. perfringens isolated from herbs and spices; the-refore, its sequencing analysis becomes essential to map the epidemiology of C. perfringens infections caused by herbs and spices or food containing them. In the present study, sequence analysis was done for bla gene to detect its genetic diversity. The obtained sequences were analyzed using BLAST tool of GenBank. The BLAST result showed maximum identity ran-ging from 100% down to 97.3% with C. perfringens bla-gene. \nOur data (Figures 6 A & B) show the sequence alignment of the first 80 nucleotides from a total of 770 and the deduced amino acids of the first bla fragment, firstly isolated from herbs and spices. The overall sequence has high similarity and conservation with little divergences compared with those of bla-gene sequence of other global strains listed in GenBank.\nFigure 7 depicts the phylogenetic analysis of bla-gene se-\nquence, which shows a great degree of sequence conservation with slight divergence. The tree showed that the sequences of our local strain from herbs and spices have the same ances-tors. There are no other sequencing studies conducted on iso-lates from herbs and spices to discuss our results with them.Ashraf A. Abd El-Tawab, Fatma I. El-Hofy, Mohamed A. Abdelmonem, Hend S. Youssef\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1979\nFigure 3. Uniplex PCR results of bla gene \nof C. perfringens isolated from herbs and \nspices in samples from 1~20 (A) and \n21~33 (B); bla gene band was detected at \n780 bp.\nFigure 4. Uniplex PCR results of tetK \ngene of C. perfringens isolated from herbs \nand spices in samples from 1~20 (A) and \n21~33 (B); bla gene band was detected at \n382 bp.\nFigure 5. Uniplex PCR results of ermB \ngene of C. perfringens isolated from herbs \nand spices in samples from 1~20 (A) and \n21~33 (B); bla gene band was detected at \n638 bp.Molecular characterization of net B and tpe L virulence factors and antimicrobial resistance genes of Clostridium perfringens  isolated from herbs and spices1980\nFigure 6. Nucleotides (A) and amino acid (B) graphic view of bla sequencing analysis showing similarities represented by dots \nand diversities represented by letters. Gene sequences submitted by the authors are colored red.\nConclusions\nFrom the data presented above, it could be concluded that \nstrains of C. perfringens isolated from herbs and spices retailed \nin the Egyptian market have a higher occurrence of tpeL but \nnot netB toxin coding genes. Resistance of C. perfringens to te-\ntracycline is partially dependent on the presence of tetK gene. \nAt the same time, sensitivity to Penicillin is evident despite the \npresence of bla-gene at a high rate among isolates that has a \nhigh similarity to the sequences submitted to GenBank among \nglobal isolates of epidemiological concern. These findings ex-\npand knowledge about C. perfringens isolated from herbs and \nspices as food additives, which provide the scientific basis for efficient prevention and intervention of C. perfringens-caused \nproblems in man and animals.\nAcknowledgments\nNot applicable.\nDeclaration\nConflict of interest: There is no actual or potential conflict \nof interest concerning this article.Ashraf A. Abd El-Tawab, Fatma I. El-Hofy, Mohamed A. Abdelmonem, Hend S. Youssef\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1981\nFigure 7. Phylogenetic analysis of nucleotide/amino acid sequences of bla coding gene of C. perfringens isolated from herbs \nand spices, the sequences of the present study are marked by blue squares among the sequences of GenBank.\nBibliographic references\n1. Banerjee M, Sarkar PK. Gro wth and enterotoxin production by\nsporeforming bacterial pathogens from spices. Food Control\n2004;15(6):491-496.\n2.Aguiler\na MO, Stagnitta PV, Micalizzi B, de Guzm\u00e1n AMS. Preva-\nlence and characterization of Clostridium perfringens from spices in Argentina. Anaerobe 2005;11(6):327-334.\n3.\nBanerjee \nM, Sarkar PK. Microbiological quality of some retail\nspices in India. Food Research International 2003;36(5):469-474.\n4.\n Hampiky\nan H, Bingol EB, Colak H, Aydin A. The evaluation of mi-\ncrobiological profile of some spices used in Turkish meat industry.Journal of Food, Agriculture & Environment 2009;7(3&4):111-115.\n5.\nSagoo S, Lit\ntle C, Greenwood M, et al. Assessment of the mi-\ncrobiological safety of dried spices and herbs from productionand retail premises in the United Kingdom. Food microbiology2009;26(1):39-43.\n6.\nVitullo \nM, Ripabelli G, Fanelli I, Tamburro M, Delfine S, Sammarco \nM. Microbiological and toxicological quality of dried herbs. Letters in applied microbiology 2011;52(6):573-580.\n7.\nDebs-Louka \nE, El Zouki J, Dabboussi F. Assessment of the Micro-\nbiological Quality and Safety of Common Spices and Herbs Soldin Lebanon. J Food Nutr Disor 2 2013;4:2.\n8.\n Has\nsan S, Altalhi A. Safety Assessment of Spices and Herbs Con-\nsumed In Saudi Arabia: Microbiological Quality and Toxin Produc-tion. Life Sci J 2013;10:2819-2827.\n9.\nEl-\nTawab A, Abdallah M, Yusuf H. Incidence and antibiogram of\nClostridium perfringens isolated from herbs and spices widelydistributed in the Egyptian market. Benha Veterinary MedicalJournal 2017;32(1):198-206.10.\n  Chen J , McClane BA. Characterization of Clostridium perfringens\nTpeL toxin gene carriage, production, cytotoxic contributions, andtrypsin sensitivity. Infection and immunity 2015;83(6):2369-2381.\n11.\n Bok\nori-Brown M, Savva CG, da Costa SPF, Naylor CE, Basak AK, Tit-\nball RW. Molecular basis of toxicity of Clostridium perfringens epsilontoxin. The FEBS journal 2011;278(23):4589-4601.\n12.\n V\nan Immerseel F, Rood JI, Moore RJ, Titball RW. Rethinking our\nunderstanding of the pathogenesis of necrotic enteritis in chick-ens. Trends in microbiology 2009;17(1):32-36.\n13.\n K\neyburn AL, Boyce JD, Vaz P, et al. NetB, a new toxin that is asso-\nciated with avian necrotic enteritis caused by Clostridium perfrin-gens. PLoS pathog 2008;4(2):e26.\n14.\n Coursodon C\n, Glock R, Moore K, Cooper K, Songer J. TpeL-pro-\nducing strains of Clostridium perfringens type A are highly viru-lent for broiler chicks. Anaerobe 2012;18(1):117-121.\n15.\n Dat\nta S, Rakha N, Narang G, Arora D, Mahajan N. Prevalence of \u03b1, \n\u03b2 and netb toxin producing strains of Clostridium perfringens inbroiler chickens in Haryana. Haryana Vet 2014;53(1):39-42.\n16.\n Baile\ny MA, Macklin KS, Krehling JT. Use of a Multiplex PCR for\nthe Detection of Toxin-Encoding Genes netB and tpeL in Strainsof Clostridium perfringens. International Scholarly Research No-tices 2013;2013.\n17.\n Catal\u00e1n A, Espoz M, Cor\nt\u00e9s W, Sagua H, Gonz\u00e1lez J, Araya J. Tet-\nracycline and penicillin resistant Clostridium perfringens isolated from the fangs and venom glands of Loxosceles laeta: its impli-cations in loxoscelism treatment. Toxicon 2010;56(6):890-896.Molecular characterization of net B and tpe L virulence factors and antimicrobial resistance genes of Clostridium perfringens  isolated from herbs and spices1982\n18. Gholamiandehk ordi A, Eeckhaut V, Lanckriet A, et al. Antimicrobi-\nal resistance in Clostridium perfringens isolates from broilers in\nBelgium. Veterinary research communications 2009;33(8):1031-1037.\n19.\n Soge O\n, Tivoli L, Meschke J, Roberts M. A conjugative macrolide\nresistance gene, mef (A), in environmental Clostridium perfrin-gens carrying multiple macrolide and/or tetracycline resistancegenes. Journal of applied microbiology 2009;106(1):34-40.\n20.\n Sambrook J\n, Fritsch E, Maniatis T. Gel electrophoresis of DNA\nand pulsed-field agarose. Molecular cloning: a laboratory manual 1989;1:441-542.\n21.\n Al\ntschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Ba-\nsic local alignment search tool. Journal of molecular biology1990;215(3):403-410.\n22.\n Thompson JD\n, Higgins DG, Gibson TJ. CLUSTAL W: improving the \nsensitivity of progressive multiple sequence alignment throughsequence weighting, position-specific gap penalties and weightmatrix choice. Nucleic acids research 1994;22(22):4673-4680.\n23.\n T\namura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6:\nmolecular evolutionary genetics analysis version 6.0. Molecularbiology and evolution 2013;30(12):2725-2729.\n24.\n W\nelsh W, Nuttall G. A Gas Producing Bacillus (Bacillus aero-\ngenes capsulatus, nov, spec.) Capable of Rapid Development inthe Blood Vessels after Death. Johns Hopkins Hospital Bulletin1892;3:81-91.\n25.\n P\nopoff MR. Clostridial pore-forming toxins: powerful virulence\nfactors. Anaerobe 2014;30:220-238.\n26.\n Songer JG\n. Clostridial enteric diseases of domestic animals. Clin-\nical microbiology reviews 1996;9(2):216.\n27.\n Amimoto K, Noro T\n, Oishi E, Shimizu M. A novel toxin homologous \nto large clostridial cytotoxins found in culture supernatant ofClostridium perfringens type C. Microbiology 2007;153(4):1198-1206.28.\n  Beceiro A, T om\u00e1s M, Bou G. Antimicrobial resistance and viru-\nlence: a successful or deleterious association in the bacterialworld? Clinical microbiology reviews 2013;26(2):185-230.\n29.\n Mar\ntin TG, Smyth JA. Prevalence of netB among some clinical\nisolates of Clostridium perfringens from animals in the UnitedStates. Veterinary microbiology 2009;136(1-2):202-205.\n30.\n Mirzazadehghas\nsab A, Razmyar J, Kalidari GA, Tolooe A. Prev-\nalence of netb and Tpel Genes among Clostridium perfringensIsolates Obtained from Healthy and Diseased Ostriches (Struthio camelus).  the 12th biennial Congress of the Anaerobe Society of the Americas2014.\n31.\n Baile\ny M, Macklin K, Krehling J. Low prevalence of netB and tpeL \nin historical Clostridium perfringens isolates from broiler farms in Alabama. Avian diseases 2015;59(1):46-51.\n32.\n Marchand-\nAustin A, Rawte P, Toye B, Jamieson FB, Farrell DJ,\nPatel SN. Antimicrobial susceptibility of clinical isolates of anaer-obic bacteria in Ontario, 2010\u20132011. Anaerobe 2014;28:120-125.\n33.\n Y\nanagihara K, Akamatsu N, Matsuda J, Kaku N, Katsumata K, Ko-\nsai K. Susceptibility of Clostridium species isolated in Japan to fi-daxomicin and its major metabolite OP-1118. Journal of infection and chemotherapy 2018;24(6):492-495.\n34.\n Li J\n, Zhou Y, Yang D, et al. prevalence and antimicrobial suscepti-\nbility of Clostridium perfringens in chickens and pigs from Beijing and Shanxi, China. Veterinary Microbiology 2021;252:108932.\n35.\n W\nei B, Cha S-Y, Zhang J-F, et al. Antimicrobial Susceptibility and\nAssociation with Toxin Determinants in Clostridium perfringensIsolates from Chickens. Microorganisms 2020;8(11):1825.\n36.\n R\noberts MC, Sutcliffe J, Courvalin P, Jensen LB, Rood J, Sep-\npala H. Nomenclature for macrolide and macrolide-lincos-amide-streptogramin B resistance determinants. Antimicrobialagents and chemotherapy 1999;43(12):2823-2830.\nReceived: 11 March 2021\nAccepted: 10 July 2021Ashraf A. Abd El-Tawab, Fatma I. El-Hofy, Mohamed A. Abdelmonem, Hend S. Youssef\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1983\nInvestigate workers' health in the western industrial region, Mosul, Iraq\nSalim Rabeea Znad1, Mazin Nazar Fadhel1, Ay\u00e7a Erdem \u00dcn\u015far2DOI. 10.21931/RB/2021.06.03.16\nAbstract: The current study aims to determine the level of heavy metal contamination in the Western Industrial Region of Mosul \nCity, northern Iraq. Heavy metals such as( Pb \u060cCo \u060cHg  ) are measured In the blood serum of 40 workers in the main industrial \nareas of Mosul City. It was compared with the control group of  (40) people from Mosul university, Where is Far away from the \nindustrial areas and all activities.\nThe results indicated a highly significant increase of P<0.001 in the serum of the workers in the industrial areas compared with \nthe control group. The study investigates the impact of heavy metals on the workers' health in the industrial areas who are in \ndirect contact with them.\nKey words: Investigation, Heavy metals Pollution, Blood Serum, industrial Region.RESEARCH / INVESTIGACI\u00d3N\nIntroduction\nIndustry areas are often associated with positive econo-\nmic benefits such as job creation and increased standard of \nliving; however, Industrial activities may also negatively impact \nthe environment and human health. Industrial activities are \ndangerous to human health, as heavy metals, mainly Hg, Pb, \nand Cobalt (Co), are often released into the environment1.\nMetals such as lead (Pb), Cobalt (Co), mercury (Hg) are \nunknown Function in the environment2.\nThese metals are quickly released into the environment \nvia anthropogenic activities, e.g., metal plating facilities, mi-\nning, and agricultural activities3.\nSome of these metals are known to act as human muta-\ngens and carcinogens and are associated with various human \nailments such as cardiovascular, nervous system, blood and \nbone diseases, kidney failure, gingivitis, and tremors, among \nothers4.\nMercury (Hg) is present in the Earth's crust. Although pre-\nsent in the environment and atmosphere in small quantities, it \nis release through anthropogenic emissions. Mercury toxicity is \nnot limited to humans; it is also toxicity to animals and plants5.\nNatural sources of mercury in the environment include \nmercury vapor from volcanoes and forest fires. More recent \nanthropogenic sources include burning coal and fossil fuels, \nmining mercury, precious metal refinement, electrical and au-\ntomotive part manufacture, chemical processing, and release \nthrough waste incineration, landfills, and industrial contamina-\ntion of water systems6.\nCobalt (Co) is a typical toxic trace metal that is widely \nfound in Industrial Waste. Environmental exposure to this toxic \ntrace metal occurs primarily through smoking and industrial \nplant emissions, and contaminated food and water7. (Co) has \na half-life period of 15-30 years and accumulates in the liver \nas the primary target tissue1. This toxic trace metal can cause \nliver or renal cell apoptosis in a low dose of exposure8.\nLead (Pb) is the third most abundant metal on the planet \nand is highly available in soil and water. Due to its impacts on \nthe environment and human health, the scientific communi-\nty is interested in investigating both issues, especially when \nconsidering that humans are mainly exposed to) Pb) through \ndrinking water, household goods, cosmetics, and drugs9. Then, \nthe ( Pb) ability to cross the blood-brain barrier features its tropism for the central nervous system10. Modulating cell bio-\nchemistry and tissue integrity and may drive behavioral dys-\nfunctions11.\nResearchers such as (12) indicated in their study about \nmeasuring the concentrations of heavy metals (Pb, Ni, Co, Fe \nCu, Zn) in serum blood comparison of The industrial workers \nwith the control group (employees of the University of Mosul), \nthat there are Hight significant increase og Heavy metals in the \nserum of the workers who are in the industrial areas compared \nwith the control group.\nMaterials and methods \nStudy Area\nThe study area is the city of Mosul, which is located in the \nwestern part of Iraq, between the longitude of 41\u00b0 - 44\u00b0 and \nthe latitude of 35\u00b0-37\u00b0. In particular, the industrial region of the \ncity is the manufacture of the Wadi Okab on the right side (the \nwestern part) (Figure 1).\nStudy Design\nThe blood samples were taken from (40) industrial agents \nrandomly and from two main areas, namely the manufactu-\nre of the Wadi Okab (right side) industry. In addition to taking \nblood samples from (40) people as a control group working \nat Mosul University and without a history of industrial activi-\nty. The control group is not different from workers in terms of \ngender and age groups.\nDemographic information\nParticipant demographic information was collected using \na researcher-made questionnaire. Information was further \nverified by cross-checking with medical records (age, gender, \nnumber of years spent at work, smoking cases)13.\nEthics approval\nAll participants in the study approved the study gave their \npermission to access their medical records, blood sampling, \nand anonymous use of their samples.\n1 College of Environmental Sciences and Technology, Depart. Of Environmental Sciences, University of Mosul.  \n2 Faculty of Engineering. Department of Environmental Engineering. Akdeniz University.\nCorresponding author: salim.znad@yahoo.comInvestigate workers' health in the western industrial region, Mosul, Iraq1984\nSalim Rabeea Znad, Mazin Nazar Fadhel, Ay\u00e7a Erdem \u00dcn\u015far\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nBlood samples\nSamples were taken from (40) workers in (plastic recy-\ncling plant, mechanics, car thighs). (40) samples were taken \nof those working at Mosul University as a control group. 5 mL of vein has been withdrawn and placed into a test tube with information for each person. They were transferred to the laboratory and separated by centrifuge at 4,000 rpm for 15 minutes, then isolated serum samples and kept samples at -4 until analyzed. The serum samples were then diluted by 5:1 with ions-free water. The Atomic Absorption (flame) device was used to estimate the Heavy Metals in the serum. \nStatistical analysis\nThe data is analyzed with some statistical processes by \nSPSS in its copy 16 and expressed in the mean \u00b1 Standard De-\nviation (SD). The value of 0.05 was considered to indicate the existence of statistically significant differences.\nResults and discussion\nThe results show that there is a clear mental difference \nof (P<0.001) for elements (Pb, Co, Hg) element. There is an apparent increase in the mix of elements measured in the con-trol group's industrial workers' serum (Table 1) and (Figure 2). The toxicity of heavy metals occurs when they build up in \nthe body's soft tissue and are not metabolic14. The human body \nenters through food, water, air, or absorption by the skin when direct contact is made with it in agricultural environments and industrial areas that are the general path of exposure of adults to the risk of these elements\n15.\nEnvironmental pollution poses a health threat to the enti-\nre world16. The concentration of heavy metals in serum above 1 \n\u03bc\ng/L indicates that there are potential environments to which \nthe individual is exposed, and the concentration above 5 \n\u03bc\ng/L \nindicates that toxic substances already exist17.\nConclusions\nThe study results indicate a high increase in the concen-\ntration of heavy metals in the blood of workers in the indus-trial area (paint workers, mechanics, plastic recycling workers, blacksmiths) For those who do not work in this field. In the fu-ture, this may cause severe health and general environmental problems. The Iraqi environment is contaminated with heavy metals, especially in industrial places, where its members are exposed to many dangers of these elements, which cause many health problems.\nRecommendation\nCurrent workplaces in industrial zones are unsafe for wor-\nkers or their families. Professionals and workers need more \nsecure support by providing and introducing other alternati-ves in less polluted and safer industrial processes. More hea-vy metals risk awareness workshops are also required for its harm to the general environment.\nBibliographic references\n1. Doo yema CA, Neri A, Lo YC, Durant J, Dargan PI, Swarthout T,\nBiya O, Gidado SO, Haladu S, Gwarzo NS, Nguku PN, Akpan A,\nIdris S, Bashir AM, Brown. Outbreak of fatal childhood lead poi-soning related to artisanal gold mining in northwestern Nigeria,2010. Environ Health Perspect [Internet]. 2012 Apr [cited 2015May 25].\n2.\nZheng J\n, Chen KH, Yan X, Chen SJ, Hu GC, Peng XW, Yuan JG, Mai \nBX, Yang ZY. Heavy metals in food, house dust, and water froman e-waste recycling area in South China and the potential riskto human health. Ecotoxicol Environ Safety [Internet]. 2013 Oct 1 [cited 2015 May 25];96:205-12.\n3.\nMato\nvi\u0107, V., Buha, A., \u00d0uki\u0107-\u0106osi\u0107, D., Bulat, Z., . Insight into the\noxidative stress induced by lead and/or cadmium in blood, liverand kidneys. Food Chem. Toxicol. 2015; 78, 130-140.\n4.\n Olujimi O\n, Steiner O, Goessler W. Pollution indexing and health\nrisk assessments of trace elements in indoor dusts from class-rooms, living rooms and offices in Ogun State, Nigeria. J Afr Earth Sci [Internet]. 2015 Jan [cited 2015 May 25]; 101:396-404.\n5.\nBose-O'R\neilly. Mercury exposure and children's health. Curr Probl \nPediatr Adolesc Health Care. 2010;40(8):186\u2013215.\n6.Bernard, A.,. R\nenal dysfunction induced by cadmium: biomarkers\nof critical effects. Biometals2004; 519-523.\n7.Eisler \nR .Mercury hazards from gold mining to humans, plants,\nand animals. Rev Environ Contam Toxicol. 2004; 181:139\u201398.\n8.\n E\nck, P. and Wilson, L., Toxic Metal In Human Health And Disease.\nApplied Nutrition and Bioenergetics, Ltd., 1989; 8650 N.\n9.T\nower, S. S., . Cobalt Toxicity in Two Hip Replacement Patients.\nBulletin.2010; No. (14): 28.\n10.\n Fernandez-Lorenzo JR . Aluminum contents of human milk,co\nw's milk, and infant formula. J Pediatr Gastroenterol Nutr\n1999; 28(3):270\u2013275\nFigure 1. Location of Study Area in  the western industrial \nregion, Mosul, Iraq.1985\nFigure 2. Compare the mean of heavy metals between workers & controls groups.\n11. Gauthier E, F ortier I, Courchesne F, Pepin P, Mortimer J,Gauvreau \nD. Aluminum forms in drinking water and risk of Alzheimers dis-\nease. Environ Res2000; 84(3):234\u2013246.\n12.\n Znad, Salim R\nabee. and Al-Sinjary, MazinNazar . The vital accu-\nmulation of some Heavy metals in the blood serum of industrialzone workers in Mosul city. Plant Archive journal volume 2020;20. Supplement 1 , pp 3194- 3200 .\n13.\n K\nozlowski H, Brown DR, Valensin G . Metallochemistry of neu-\nrodegeneration: biological, chemical and genetic aspects.RoyalSociety of Chemistry,2007;  London\n14.\n R\nashed MN. Total and extractable heavy metals in indoor, outdoor \nand street dust from Aswan City, Egypt. Clean \u2013 Soil, Air, Water[Internet]. 2008 Nov [cited 2015 May 25];36(10-11):850-7.\n15.\n Satarug, S., Moore, M.R.. Adv\nerse health effects of chronic expo-\nsure   to low-level cadmium in foodstuffs and cigarette smoke.Environ Health Perspect 2004; 112, 1099-1103.\n16.\n Sun G\n, Li Z, Bi X, Chen Y, Lu S, Yuan X. Distribution, sources and\nhealth risk assessment of mercury in kindergarten dust. Atmo-spheric Environ [Internet]. 2013 Jul [cited 2015 May 25];73:169-76.\n17.\n V\nerougstraete, V., Lison, D., Hotz, P.,. Cadmium, lung and pros-\ntate cancer: a systematic review of recent epidemiological data.J Toxicol Environ Health B Crit Rev 2003; 6, 227-255.\nReceived: 11 March 2021\nAccepted: 10 July 2021Table 1. Determination of heavy me -\ntals in Area of workers & controls groups.Investigate workers' health in the western industrial region, Mosul, Iraq1986\nBouchra El Khalfi, Boutaina Addoum, Suhayla Harrati, Abdelhakim Elmakssoudi and Abdelaziz Soukri\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nSynthesis, in silico  studies and antibacterial assessment of \u03b1 -amino phosphonates \nderivatives\nBouchra El Khalfi1, Boutaina Addoum1, Suhayla Harrati1, Abdelhakim Elmakssoudi2 and Abdelaziz Soukri1\nDOI. 10.21931/RB/2021.06.03.17\nAbstract: The widespread of multi-resistant strains due to the lack of specific treatment and the propagation of infectious \ndiseases requires all resources to remedy this scourge. This study is therefore aimed to assess the antibacterial activity of four \nsynthetic \u03b1-Aminophosphonate 4(a-d). Methods: Firstly, \u03b1-Aminophosphonate has been synthesized and characterized, then \nmolecular docking of these compounds 4(a-d) into the active binding site of Escherichia coli MurB enzyme (PDB Id: 1MBT) was performed to gain a comprehensive understanding of their biological activity. These compounds have been subjected to in vitro antibacterial screening against three multi-resistant strains E. coli, S. aureus, and L. monocytogenes. These compounds showed \ncrucial antibacterial behavior against all studied strains. Thus, their docking estimation supported the in vitro results and showed that the 4c derivative has considerable binding energy towards the active site of Escherichia coli MurB.  These findings provide critical information for the exploration of \u03b1-amino phosphonates as novel antibacterial agents.\nKey words: \u03b1-Aminophosphonate, Docking, Antibacterial.RESEARCH / INVESTIGACI\u00d3N\nIntroduction\nThe emergence and widespread bacterial resistance to \nantibiotics dramatically sapped our ability1 to remedy this in-\nfection and precipitate an alarming public health dilemma2. \nNowadays, the new obsession of researchers is to innovate \nnew therapeutic approaches able to overcome these microbial diseases\n3. Several studies have been focused on the synthesis \nof eco-friendly substances4. Among these molecules, \u03b1-amino \nphosphonates take a leading position5, especially in biological \nand environmental applications6\u20139.\nThese compounds attracted the renewed interest of bio-\nlogists due to their wide-ranging activities; they are recognized as an overwhelming inhibitor of enzymes like serine\n10, UDP- \ngalactopyranose mutase11, and the viral enzyme human immu-\nnodeficiency virus protease. Likewise, they limited metastatic progression, activated different apoptosis pathways, and indu-ced anti-tumoral cytotoxicity.\nIn this regard, the current study pertains to the synthesis \nand characterization of some \u03b1-amino phosphonates derivati-ves 4(a-c), then we evaluated in silico their antimicrobial po-tential\n12 based on a computer-aided simulation13. Then, we tes-\nted their antibacterial behavior on resistant strains and their synergistic effect with some standard antibiotics.\nAll this investigation is essential to understand better the \nmechanism of action of these molecules, which could offer an exceptional framework that may lead us to the discovery of new potent antibiotics.    \nMethods\nThe general protocol of \u03b1-amino phosphonates synthesis\nThe multicomponent synthesis of the 4 derivatives of \n\u03b1-amino phosphonates was carried out through the well-esta-blished literature protocol\n14,15. We grafted an aromatic aldehy-de (1a), aniline (2), and diethyl phosphite (3) in the presence of \nNa2CaP2O7 as a catalyst16. A plausible reactional mechanism of \nthe one-pot domino reaction is illustrated in Scheme S1of ESI.\nCharacterization of th \u03b1-aminophosphonates 4(a-d)\nCharacterization of the Diethyl(phenyl)-N-(phenyl) \naminomethylphosphonate 4a\n1H-NMR (CDCl3) \u03b4: 1.2 (3H, JHH= 7.2 Hz, t, OCH2CH3); 1.4 \n(3H, JHH= 7.2 Hz, t, OCH2CH3); 3.73-4.3 (4H, m, OCH2CH3); \n4.9 (1H, JHP= 24.6 Hz, d, CHP), 5 (1H, s, NH); 6.6-7.8 (10H, m, \nHAr).13C-NMR (CDCl3) \u03b4: 16.46 (d, 3JCP= 6.03 Hz, OCH2CH3); \n16.7 (d, 3JCP= 6.03 Hz, OCH2CH3); 56.35 (d, 1JCP = 149 Hz, \nCHP); 63.5 (d, 2JCP = 6.79Hz, OCH2CH3); 63.53 (d, 2JCP = \n6.79 Hz, OCH2CH3); 114.13 (s); 118.64 (s); 128.1 (s); 128.85 (s); \n129.43 (s); 136.2 (s); 146.6 (s). IR (KBr) \u03c5 3304(NH), 2985(CH), \n1605 (C=C), 1514 (C=C), 1240 (P=O),1020 (P-O) cm-1.\nDiethyl(4-methoxyphenyl)-N-(phenyl) \naminomethylphosphonate 4b\n1H-NMR (CDCl3) \u03b4 : 1.25 (3H, JHH= 7.2 Hz, t, OCH2CH3); 1.4 \n(3H, JHH= 7.2 Hz, t, OCH2CH3); 2.45 (3H, s, C6H4CH3);3.79-4.31 \n(4H, m, OCH2CH3); 4.87 (1H, JHP= 24.6 Hz, d, CHP), 5 (1H, s, \nNH); 6.71-7.5 (9H, m, HAr).13C-NMR (CDCl3) \u03b4: 16.5 (d, 3JCP= \n5.8 Hz, OCH2CH3); 16.71 (d, 3JCP= 5.8 Hz, OCH2CH3); 21.4 (s, \nC6H4CH3); 56 (d, 1JCP = 150 Hz, CHP); 63.48 (d, 2JCP = 6.94 \nHz, OCH2CH3); 114.14 (s); 118.57 (s); 128 (s); 129.4 (s); 129.55 \n(s); 129.58 (s); 133 (s); 137.8 (s);146.8 (s). IR (KBr) \u03c5 3325 (NH), \n2980 (CH), 1604 (C=C), 1498 (C=C), 1234 (P=O), 1016 (P-O) \ncm-1.\nCharacterization of the Diethyl(2-hydroxyphenyl)-N \nphenyl) Aminomethylphosphonate 4c\n1H-NMR (CDCl3) \u03b4 : 1.25 (3H, JHH= 7.2 Hz, t, OCH2CH3); 1.39 \n(3H, JHH= 7.2 Hz, t, OCH2CH3); 3.86 (3H, s, C6H4OCH3);3.8-4.26 \n1 Laboratory o f Physiopathol ogy, Genetic s, Molecular  and Biotechnology (PGMB), Department of Biology, Faculty of Sciences A \u00efn Chock, Rese arch Center of  Health \nand Biotechno logy, Hassan I I University o f Casablanc a, B.P 5366 Maarif, Casablanca, Morocco. \n2 Laboratory of Organ ic Synthesis, Extraction, and Valorization, Department of Chemistry, Faculty of Sciences A\u00efn Chock, Hassan II University of Casablanca, B .P 53 66 \nMaarif, Casablanca, Morocco.\nCorresponding author: addoum636@gmail.com1987\n(4H, m, OCH2CH3); 4.85 (1H, JHP= 23.1 Hz, d, CHP), 4,95 (1H, s, \nNH); 6.7-7.53 (9H, m, HAr).13C-NMR (CDCl3) \u03b4: 16.53 (d, 3JCP= \n5.7 Hz, OCH2CH3); 16.72 (d, 3JCP= 5.7 Hz, OCH2CH3); 55.44 (s, \nC6H4OCH3); 55.62 (d, 1JCP = 151,2 Hz, CHP); 63.43 (d, 2JCP = \n6.9 Hz, OCH2CH3); 63.47 (d, 2JCP= 6.9 Hz, OCH2CH3);114.15 (s); \n114.32 (s); 118.57 (s); 128 (s); 129.2 (s); 129.33 (s); 146.67 (s); \n159.56 (s). IR (KBr) \u03c5 3300 (NH), 2983 (CH), 1600 (C=C), 1510 (C=C), 1232 (P=O), 1020 (P-O) cm\n-1.\nCharacterization of the Diethyl(4-methylph\u00e9nyl)-\nN(phenyl)aminomethylphosphonate 4d\n1H-NMR (CDCl3) \u03b4 : 1.25 (3H, JHH= 7.2 Hz, t, OCH2CH3); 1.39 \n(3H, JHH= 7.2 Hz, t, OCH2CH3); 3.86 (3H, s, C6H4OCH3);3.8-4.26 \n(4H, m, OCH2CH3); 4.85 (1H, JHP= 23.1 Hz, d, CHP), 4,95 (1H, s, \nNH); 6.7-7.53 (9H, m, HAr).13C-NMR (CDCl3) \u03b4: 16.53 (d, 3JCP= \n5.7 Hz, OCH2CH3); 16.72 (d, 3JCP= 5.7 Hz, OCH2CH3); 55.44 (s, \nC6H4OCH3); 55.62 (d, 1JCP = 151,2 Hz, CHP); 63.43 (d, 2JCP = \n6.9 Hz, OCH2CH3); 63.47 (d, 2JCP= 6.9 Hz, OCH2CH3);114.15 (s); \n114.32 (s); 118.57 (s); 128 (s); 129.2 (s); 129.33 (s); 146.67 (s); \n159.56 (s). IR (KBr) \u03c5 3300 (NH), 2983 (CH), 1600 (C=C), 1510 (C=C), 1232 (P=O), 1020 (P-O) cm\n-1.\nBiological experimental data)\nComputational studiesDetermination ADMET parameters\nThe ADMET parameters (absorption, distribution, meta-\nbolism, excretion, and toxicity of the synthesized compounds \n4(a-d) were calculated using the freely accessible web server Swiss ADME (http://swissadme.ch/index.php#undefined)\n17\nProtein-Ligand Docking calculations\nAfter preparing protein/ligands structures, we stimula-\nted the docking interaction using the software AutoDock 1.5.6 (MGL tools- 1.5.6)\n18. Polar hydrogen atoms and Kollman united \ncharges were added to all target proteins, and the resulting file has been saved in pdbqt extension. For the docking cal-culation, a grid box of 60\u00d760\u00d760 \u00c5 in x, y, z directions were created to cover the active site of the target. The default grid points spacing was fixed to 0.375 \u00c5 and centred at x = 42.527 y = -46.679, z = 65.559. We used in this work the Lamarckian Genetic Algorithm (LGA) for flexible docking calculations. The LGA parameters including size, energy screening, mutation rate, and crossover rate. After the calculation procedure, we selected the best conformations of the complex from the 10 calculated based on their binding energy scores. Then the complex interaction map was displayed using Discovery Stu-dio Visualizer\n17,19.\nMicrobiology\nBacterial strains\nThree bacterial strains E. coli, S. aureus, and L. monocyto-\ngenes have been used in this study. The media used for antibac-\nterial screening was the LB and the Brain Heart Infusion (BHI).\nPreparation of stock solutions\nTo prepare a final concentration of 5 \u03bcg / ml, we solubili-\nzed the selected compounds in DMSO (16.66 \u03bcg / ml). Then the \nstock solutions were stored in sterile containers in obscurity.\nAntibiotics\nStocks of antibiotics: ampicillin (100 mg / ml), chloram-phenicol (34 mg / ml) and rifampicin (50 mg / ml) were prepa-\nred, filtered and stored at -20 \u00b0 C until microbiological assays. The chloramphenicol is prepared in ethanol and rifampicin was formulated in methanol.\nAntibacterial sensitivity test\nThe compounds 4(a-d) were tested for their antibacterial \nactivity against E.Coli; S.aureus, and L.monocytogene by using \nthe agar well diffusion method\n20. To explore the antibacterial \neffect of these compounds, we subculture the different strains \nby streaking the supercooled media (LB and BHI) with bacte-rial inoculum adjusted to 10\n6 CFU (bacteria/ml) then poured \ninto Petri dishes. After 15 minutes, wells of 6mm were made on each plate by using a sterile cone. Under aseptic conditions, we injected separately 50 \u03bcl of the tested molecule; positive control (antibiotic), and negative control (DMSO) in each well. The Petri dishes were incubated at 30 - 37 \u00b0 C for 24h. All tests were performed in triplicate.\nTest of synergistic effect\nWe used the diffusion assay described previously to study \nthe synergistic effect between standard antibiotics and the \ntarget compounds. Firstly, wells were produced in each plate and filled with 50 \u03bcl of the tested samples containing the mix-ture of molecules and antibiotics. The Petri dishes are maintai-ned at 30 \u00b0 - 37 \u00b0 C for 24 hours. The use of antibiotics singly serves as a positive control and DMSO is considered a negative control. All tests were obtained in triplicate.\nResults\nADMET studies\nThe ADMET data provides information on the lipophilicity \nof the ligands, which is predicted by the MIlog P parameter, the hydrogen bonding potential of the compounds, and their mole-cular flexibility\n21. The different drug-likeness proprieties for all \nselected compounds were in harmony with Lipinski's rule of five\n12 (see table 1).\nBinding energy evaluation\nModeling studies are essential to understand the me-\nchanism of action of these designed compounds. Our Docking investigation has been confirmed that the highest energies of binding (\u0394G) observed are -6.44 and -6.45 K. cal/mol for the 4c and the 4a (see table 2), which can reflect the good affinity be-tween the protein targeted and ligand in contrast to the ligand of reference (ciprofloxacin).\nAll the docked molecules were subjected to 2D protein-li-\ngand interaction analysis and the obtained conformations com-pared to the Ciprafloxin have been reported in Figures 3. The selected compounds complex to the target enzyme (MurB) represented at least two H-bonds. Accordingly, the docking studies of \u03b1-amino phosphonates gathered previously in table 2 revealed their free energy of binding to E. coli UDP-N-ace-tylenolpyruvoylglucosamine reductase (MurB) was higher for all compounds than the score obtained for standard antibiotic (Ciprofloxacin). Hence, we can conclude that E. coli MurB is the putative target responsible for the antibacterial activity of the-se compounds\n22. Their interaction with the target was stabili-\nzed by forming hydrogen bonds, hydrophobic interactions, Van der walls Pi-sulfur and Pi-alkyl interactions (Figure 1).\nAdditionally, the binding mode of the most active com-\npound 4c (binding energy: -6.45 kcal/mol) showed two hydro-Synthesis, in silico  studies and antibacterial assessment of  \u03b1-amino phosphonates derivatives1988\ngen bonds formed between the oxygen atom and the amino \nacid Ile 59. We also detected the formation of close interac-tion with Val 181 via a hydrogen bond. Moreover, Pi-alkyl and Pi-sulfur interactions are formed with the residues Leu 80Lys 292 and Met 132. These amino acids reside at the enzyme's active site and are crucial in the biosynthesis of peptidoglycan; any modifications in these amino acids could down-regulate the enzyme activity, which induces bacterial cell death23.\nIn vitro studies\nThe antibacterial effect of the four synthesized com-\npounds against the three strains was investigated by using the diffusion method, and the results are reported in Table 3. The obtained data showed clearly that the 4c compound possesses significant activity against the whole strains compared to the other derivatives. We also observed that the 4a and 4b were more actives against E. coli and S. aureus, while the 4d com-\npound showed a substantial activity only against L. monocyto-genes. On the other side, no inhibition zone was detected with vehicle control (DMSO).\nSynergistic Test\nThe effect of the combination between the 4 synthesized pro-\nducts and antibiotics viz ampicillin, chloramphenicol, and rifampicin \non the viability of the strain are summarized in figures 2 and 3.\nBy comparing the above results, it's exciting to underline \nthat the synergistic effect of the synthesized products varies as a function of the studied strain and the antibiotic used. The potent inhibition was detected against S. aureus and L. mo-\nnocytogenes after rifampicin to the 4 b and 4c compounds. Nevertheless, when we combine ampicillin/4b, chloramphe-nicol/4b, and chloramphenicol/4c we obtain a sizable activity only against E. coli (G- bacteria).Discussion\nThe in silico data have been supported our study in vitro \nperformed previously against Multi-resistant strains. Accor-ding to our docking finding, all the selected compounds had H-bond interactions with the MurB enzyme indicating that thebinding affinity increased significatively with the number of the H-bond, which reflects the stability of the complex ligand-pro-tein.\nWe also observed that the studied compounds fulfill Li-\npinski's rule requirements and represent a high binding score with an RSM (root square mean) value < 2\u00c5, which confirms their antibacterial inhibiting activity and the reliability of our virtual screening\n24. Based on molecular docking analysis, we \ncan conclude that the putative mechanism of antibacterial activity observed in vitro is probably the inhibition of the E. \ncoli MurB enzyme. This enzyme catalyzed the second step in \nforming muramyl sugar\n22, which is essential for peptidoglycan \nbiosynthesis25,26.\nOn the other side, the sensitivity of the studied strains \nagainst these molecules provides their antibacterial potency estimated using an inhibition zone formed around the well. If we should classify these molecules as a function of their in-creasing antibacterial potential order: the 4c compound takes the place position due to their great effect against the three multi-resistant strains viz S. aureus, E. coli et L. monocytoge-\nnes(4c>4b> 4a >4d). At the same time, the three other com-pounds possessed a variable antibacterial activity as a func-tion of the strain used. For example, the 4a and 4b derivatives possess antibacterial activity against gram-negative strains (E. coli); Nevertheless, the 4d derivative is more efficient against gram-positive strains(L. monocytogenes and S.aureus). It's gratifying to elucidate that this antibacterial sensitivity presu-Bouchra El Khalfi, Boutaina Addoum, Suhayla Harrati, Abdelhakim Elmakssoudi and Abdelaziz Soukri\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nTable 1. Determination of pharmacokinetic parameters for good oral bioavailability of synthesized compounds 4(a-d).\nTable 2. The binding score of the tested compounds docked into the active site of 1MBT.1989\nmably related to the structure of the tested compounds, as \ndescribed the substitution of bioactive motive such methyl \npreviously; methoxy, or metoxybenzaldhyde in the phenyl ring \nenhance this activity27; as results when the aromatic aldehyde \nis replaced with hydroxyl scaffold, we notice a slight and in-\nconspicuous antibacterial activity28,29.\nOur results are in harmony with some previous studies. \nIt's gratifying to cite the research work published in 201130, and \nthey showed the excellent antibacterial and antifungal beha-\nvior of these compounds30. Another research work achieved in \n20205 also confirmed their main antibacterial activity against \na panel of gram-positive and harmful strains.\nDespite their excellent antibacterial effects, in some ca-\nses, these pathogens strains can escape from the effect of the-\nse substances31,32. This new situation compelled the resear-\nchers to develop new promising strategies. Our study selected a simple method by combining the synthesized compounds \nand some antibiotics of references.\nThe approach adopted herein has given a satisfactory re-\nsult. On the one hand, we noticed an increase in antibacterial \nactivity. On the other hand, we obtained a powerful effect with \na lower concentration of antibiotics.\nConclusions\nIn this study, four derivatives of \u03b1-amino phosphonates \nwere successfully synthesized, then assessed for their anti-\nbacterial activity in vitro and silico.\nThe obtained data revealed that all studied compounds \nare biologically active and possess potent antibacterial activi-\nties, especially the 4a derivative.\nWith biological evaluation and docking results in hand, we \nFigure 1. 2D docking diagrams of compounds 4a, 4b, 4c and,4d at the active site of MurB.\nFigure 2. Synergistic effect between \u03b1-amino phosphonates and commercial antibiotics. A: a mixture between rifampicin and \ncompound 4b, B: chloramphenicol supplemented to 4c, and C:  ampicillin added to the compound 4c. *M: molecule/antibiotic, \nList: L. monocytogenes, Staph: S. aureus.Synthesis, in silico  studies and antibacterial assessment of  \u03b1-amino phosphonates derivatives1990\ncan propose a plausible mode of action of these compounds \nbefore evaluating their biological activity in vitro and in vivo.\nLimit of studies\nGiven the above facts, a single bioassay is not able to re-\nflect the full picture of the derivatives' effects on multi-resis-\ntant bacteria.\nRecommendations for future studies\nWe recommend using another bacterial species (Gram- \nand Gram+) to provide broad information about the antibacte-\nrial potential of these compounds.\nAcknowledgments\nThis work was supported by the CNRST (Moroccan re-\nsearch center of science and technology) under the Research \nExcellence Scholarship Program.\nFinding statement\nThis research was conducted within the university re-\nsearch plans and benefited from the general funds granted to \nthe physiopathology, molecular genetics, and biotechnology laboratories.Conflicts of Interest\nNone\nAuthor contributions\nB. Addoum, A. Soukri, B. El Khalfi, and H. Elmakssoudi\ncontributed to the study's design. S. Harrati wrote and re-viewed the draft of the manuscript.\nBibliographic references\n1. V ouga M, Greub G. Emerging bacterial pathogens: The past and\nbeyond. Clin Microbiol Infect [Internet]. 2016;22(1):12\u201321. http://\ndx.doi.org/10.1016/j.cmi.2015.10.010\n2.Bonneaud C\n, Weinert LA, Kuijper B. Understanding the emer-\ngence of bacterial pathogens in novel hosts. Philos Trans R Soc B Biol Sci. 2019;374(1782).\n3.\nK\nenawy ERS, Azaam MM, Saad-Allah KM. Synthesis and anti-\nmicrobial activity of \u03b1-aminophosphonates containing chitosanmoiety. Arab J Chem. 2015 May 1;8(3):427\u201332.\n4.\n R\neddy GM, Garcia JR, Reddy VH, Kumari AK, Zyryanov G V., Yu-\nvaraja G. An efficient and green approach: One pot, multi com-ponent, reusable catalyzed synthesis of pyranopyrazoles andinvestigation of biological assays. J Saudi Chem Soc. 2019 Mar1;23(3):263\u201373.Bouchra El Khalfi, Boutaina Addoum, Suhayla Harrati, Abdelhakim Elmakssoudi and Abdelaziz Soukri\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nFigure 3. The plot of a synergistic effect of \u03b1-amino phosphonates/antibiotic on the growth inhibition of studied strains.\nTable 3. Antibacterial acti-\nvity of the synthesized com-\npounds 4(a-d).1991\n5.P oola S, Nagaripati S, Tellamekala S, Chintha V, Kotha P, Yagani\nJR, et al. Green synthesis, antibacterial, antiviral and molecular\ndocking studies of \u03b1-aminophosphonates. Synth Commun [Inter-net]. 2020;0(0):1\u201318. Available from: https://doi.org/10.1080/00397911.2020.1753079\n6.\nAbdel-Megeed MF\n, Badr BE, Azaam MM, El-Hiti GA. Antimicrobial \nactivities of a series of diphenyl (4-(aryldiazenyl)biphenyl- 4-yl-amino)(pyridin-3-YL)methylphosphonates. Phosphorus, SulfurSilicon Relat Elem. 2012 Oct 1;187(10):1202\u20137.\n7.\nAddoum B, El Khal\nfi B, Daouda Mar P, Ansari NF, Elmakssoudi\nA, Soukri A, et al. Synthesis, Characterization of Some \u03b1-amino-phosphonate Derivatives and Comparative Assessment of theirAntioxidant Potential in-vivo and in-vitro. Vol. 2, Acta ScientificPharmaceutical Sciences. 2018.\n8.\n R\nezaei Z, Firouzabadi H, Iranpoor N, Ghaderi A, Reza M. Design\nand one-pot synthesis of a -aminophosphonates and bis ( a -ami-nophosphonates ) by iron ( III ) chloride and cytotoxic activity. Eur J Med Chem. 2009;44:4266\u201375.\n9.\nSubba \nG, Uma K, Rao M, Syama C, Suresh C. Neat synthesis and\nantioxidant activity of a -aminophosphonates. Arab J Chem [Inter-net]. 2014;7(5):833\u20138. Available from: http://dx.doi.org/10.1016/j.arabjc.2013.01.004\n10.\n Sie\u0144czyk M, Oleksy\nszyn J. Irreversible Inhibition of Serine Prote-\nases - Design and In Vivo Activity of Diaryl alpha- Aminophospho-nate ... Irreversible Inhibition of Serine Proteases \u2013 Design and InVivo Activity of. Curr Med Chem. 2009;16:1673\u201387.\n11.\n Ais\nsa R, Guezane-Lakoud S, Kolodziej E, Toffano M, Aribi-Zoui-\noueche L. Diastereoselective synthesis of bis(\u03b1-aminophos-phonates) by lipase catalytic promiscuity. New J Chem.2019;43(21):8153\u20139.\n12.\n R\nauham\u00e4ki S, Postila PA, Niinivehmas S, Kortet S, Schildt E, Pas-\nanen M, et al. Structure-activity relationship analysis of 3-phenyl-coumarin-based monoamine oxidase B inhibitors. Front Chem.2018 Mar 1;6:3\u201318.\n13.\n Bouchentouf S, Noureddine \nM. Identification of Compounds\nfrom Nigella Sativa as New Potential Inhibitors of 2019 NovelCoronasvirus ( Covid-19 ): Molecular Docking Study . ChemRxiv.2020;(April).\n14.\n Addoum B, El Khal\nfi B, Derdak R, Sakoui S, Elmakssoudi A, Soukri \nA. The one-pot synthesis of some bioactive pyranopyrazoles andevaluation of their protective behavior against extracellular H2O2 and SNP in T. Thermophila. Jordan J Biol Sci. 2021;14(1):31\u20139.\n15.\n Zahouil\ny M, Elmakssoudi A, Mezdar A, Rayadh A, Sebti S, Laz-\nrek H. Three Components Coupling Catalysed by Na2CaP2O7:Synthesis of &#945;-Amino Phosphonates Under Solvent-FreeConditions at Room Temperature. Lett Org Chem. 2005 Jul9;2(5):428\u201332.\n16.\n Zahouil\ny M, Elmakssoudi A, Mezdar A, Rayadh A, Sebti S, Laz-\nrek H. Three Components Coupling Catalysed by Na2CaP2O7:Synthesis of &#945;-Amino Phosphonates Under Solvent-FreeConditions at Room Temperature. Lett Org Chem. 2005 Jul9;2(5):428\u201332.\n17.\n Jouimyi \nMR, Bounder G, Essaidi I, Boura H, Zerouali K, Lebrazi\nH, et al. Molecular docking of a set of flavonoid compounds withhelicobacter pylori virulence factors CagA and VacA. J HerbMedPharmacol. 2020;9(4):412\u20139.\n18.\n da Sil\nva FMA, da Silva KPA, de Oliveira LPM, Costa E V., Koolen\nHHF, Pinheiro MLB, et al. Flavonoid glycosides and their putativehuman metabolites as potential inhibitors of the sars-cov-2 main protease (Mpro) and rna-dependent rna polymerase (rdrp). MemInst Oswaldo Cruz. 2020;115(9):1\u20138.19.\n  R amesh DMK V. Binding site analysis of potential protease inhib-\nitors of COVID-19 using AutoDock. VirusDisease. 2020;2(31):1\u20136.\n20.\n Filali O\nA, Soukri A, Khalfi B El. Evaluation of Antibacterial Ef-\nfect of Some Essential Oils by Contact and Volatile Methods.2019;9(4):81\u201390.\n21.\n K\numar MH, Jones CS, Ravi A. Molecular docking studies of inter-\naction between protease activated inhibitor receptor as the cru-cial protein and hydroxyl cinnamic acid as ligands. Asian J Pharm Pharmacol. 2019;5(1):137\u201342.\n22.\n El \nZoeiby A, Sanschagrin F, Levesque RC. Structure and function\nof the Mur enzymes: Development of novel inhibitors. Mol Micro-biol. 2003;47(1):1\u201312.\n23.\n Demeester KE, Liang H, Jensen MR, Jones ZS, D'Ambrosio EA,Scinto SL, et al. S\nynthesis of Functionalized N-Acetyl Muramic\nAcids to Probe Bacterial Cell Wall Recycling and Biosynthesis. JAm Chem Soc. 2018;140(30):9458\u201365.\n24.\n Nadiv\needhi MR, Nuthalapati P, Gundluru M, Yanamula MR, Kalli-\nmakula SV, Pasupuleti VR, et al. Green Synthesis, Antioxidant,and Plant Growth Regulatory Activities of Novel \u03b1-Furfuryl-2-al-kylaminophosphonates. ACS Omega. 2021;6(4):2934\u201348.\n25.\n Y\nang Y, Severin A, Chopra R, Krishnamurthy G, Singh G, Hu W,\net al. 3,5-Dioxopyrazolidines, novel inhibitors of UDP-N- acet-ylenolpyruvylglucosamine reductase (MurB) with activityagainst gram-positive bacteria. Antimicrob Agents Chemother.2006;50(2):556\u201364.\n26.\n Y\nao G, Ye M, Huang R, Li Y, Pan Y, Xu Q, et al. Bioorganic & Me-\ndicinal Chemistry Letters Synthesis and antitumor activities ofnovel rhein a -aminophosphonates conjugates. Bioorg Med Chem Lett [Internet]. 2014;24(2):501\u20137. Available from: http://dx.doi.org/10.1016/j.bmcl.2013.12.030\n27.\n Maleki B, Nasiri N, T\nayebee R, Khojastehnezhad A, Akhlaghi HA.\nGreen synthesis of tetrahydrobenzo[b] pyrans, pyrano[2,3-c]pyrazoles and spiro[indoline-3,4\n\u03b1\n-pyrano[2,3-c] pyrazoles\ncatalyzed by nano-structured diphosphate in water. RSC Adv.2016;6(82):79128\u201334.\n28.\n K\nunjapur AM, Tarasova Y, Prather KLJ. Synthesis and accumula-\ntion of aromatic aldehydes in an engineered strain of escherichiacoli. J Am Chem Soc. 2014;136(33):11644\u201354.\n29.\n Manolo\nv I, Danchev ND. Synthesis, toxicological, and pharma-\ncological assessment of some oximes and aldehyde condensa-tion products of 4-hydroxycoumarin. Arch Pharm (Weinheim).1999;332(7):243\u20138.\n30.\n R\nezaei Z, Khabnadideh S, Zomorodian K, Pakshir K, Nadali S,\nMohtashami N, et al. Design , Synthesis , and Antifungal Activityof New $\u03b1$ -Aminophosphonates. 2011;2011.\n31.\n F\neleke T, Eshetie S, Dagnew M, Endris M, Abebe W, Tiruneh M.\nMultidrug \n-\n resistant bacterial isolates from patients suspected\nof nosocomial infections at the University of Gondar Comprehen-sive Specialized Hospital , Northwest Ethiopia. BMC Res Notes[Internet]. 2018;1\u20137. Available from: https://doi.org/10.1186/s13104-018-3709-7\n32.\n Li B, W\nebster  and TJ. Bacteria antibiotic resistance: New chal-\nlenges and opportunities for implant-associated orthopedic in-fections. J orthopeadic Res. 2018;36(1):22\u201332.\nReceived: 18 May 2021\nAccepted: 12 July 2021Synthesis, in silico  studies and antibacterial assessment of  \u03b1-amino phosphonates derivatives1992\nHermila Belba D\u00edaz-Pillasca, Angel David Hern\u00e1ndez-Amasifuen, Miguel Machahua, Alexandra Jherina Pineda-L\u00e1zaro, Alexis Arg\u00fcelles-Curaca, Brayan Lugo\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nC\u00f3digo de barras de ADN de tres especies de \u00e1rboles frutales con potencial \necon\u00f3mico del valle de Huaura, Lima, Per\u00fa\nDNA barcoding of three species of fruit trees with economic potential from the Huaura Valley, \nLima, Peru\nHermila Belba D\u00edaz-Pillasca, Angel David Hern\u00e1ndez-Amasifuen*, Miguel Machahua, Alexandra Jherina Pineda-L\u00e1zaro, Alexis Arg\u00fcelles-Curaca, \nBrayan LugoDOI. 10.21931/RB/2021.06.03.18\nResumen: El Per\u00fa presenta una gran diversidad de recursos gen\u00e9ticos, pero a la vez se desaprovechan especies por \ndesconocimiento o bajo rendimiento econ\u00f3mico. Situaci\u00f3n que se refleja en el valle de Huaura con los \u00e1rboles frutales de \ncansaboca (Bunchosia armeniaca), palillo (Campomanesia lineatifolia) y naranja agria (Citrus aurantium), especies con gran \nimportancia en la gastronom\u00eda tradicional local, pero en la actualidad catalogadas en peligro cr\u00edtico. Con el fin de conservar estas \nespecies se plante\u00f3 como objetivo establecer c\u00f3digo de barras de ADN de tres especies amenazadas con potencial econ\u00f3mico \ndel valle de Huaura. Se extrajo ADN de las tres especies con el m\u00e9todo CTAB y para las amplificaciones en PCR se emplearon \nlos cebadores de c\u00f3digo de barras de ADN universales pertenecientes a cloroplastos: matK, rbcL y trnH-psbA. A partir de los \nproductos purificados y cuantificados se realiz\u00f3 el secuenciamiento de las muestras. Las secuencias fueron analizadas, alineadas \ny agrupadas con los programas Bioedit, Codon Code Aligner y MEGA respectivamente. Las concentraciones de ADN fueron: \npalillo (457 ng/\u03bcl), cansaboca (433 ng/\u03bcl) y naranja agria (442 ng/\u03bcl). La amplificaci\u00f3n de los cebadores produjo productos de \nPCR entre 357 y 810 pb. Las secuencias de NCBI que presentaron mayor porcentaje de identidad con cada especie en estudio \nfueron sometidas a an\u00e1lisis filogen\u00e9tico, los cuales colocaron a las especies en grupos distintos y revelando diferencia gen\u00e9tica \ncon las muestras estudiadas. Se proporcionaron las herramientas b\u00e1sicas para implementar c\u00f3digos de barras de ADN en tres \nespecies de \u00e1rboles frutales en el valle de Huaura.\nPalabras clave: Bunchosia armeniaca, Campomanesia lineatifolia, Citrus aurantium, palillo, naranja agria.\nAbstract: Peru has a great diversity of genetic resources, but at the same time, species are wasted due to ignorance or low \neconomic performance. The situation reflected in the Huaura valley with the fruit trees of cansaboca (Bunchosia armeniaca), palillo \n(Campomanesia lineatifolia) and sour orange (Citrus aurantium), species with great importance in the traditional local gastronomy, \nbut currently classified as endangered critically. To conserve these species, the objective was to establish DNA barcoding of three \nthreatened species with economic potential in the Huaura Valley. DNA from the three species was extracted with the CTAB method, \nand universal DNA barcode primers belonging to chloroplasts were used for the PCR amplifications: matK, rbcL, and trnH-psbA. \nSamples were sequenced from the purified and quantified products. The sequences were analyzed, aligned, and grouped with the \nBioedit, Codon Code Aligner, and MEGA programs. The DNA concentrations were: cansaboca (457 ng / \u03bcl), palillo (433 ng / \u03bcl) and \nsour orange (442 ng / \u03bcl). Amplification of the primers produced PCR products between 357 and 810 bp. The NCBI sequences that \npresented the highest percentage of identity with each species under study were subjected to phylogenetic analysis, which placed the \nspecies in different groups and revealed genetic differences with the studied samples. The essential tools were provided to implement \nDNA barcoding in three species of fruit trees in the Huaura valley.\nKey words: Bunchosia armeniaca, Campomanesia lineatifolia, Citrus aurantium, palillo, sour orange.RESEARCH / INVESTIGACI\u00d3N\nIntroducci\u00f3n\nEl Per\u00fa presenta gran riqueza biol\u00f3gica por la alta diver-\nsidad gen\u00e9tica, debido a esto es considerado como uno de los \npa\u00edses m\u00e1s importantes en recursos gen\u00e9ticos1. Estos recur-\nsos pueden permitir un mayor desarrollo econ\u00f3mico y social, \nsiempre que se incluya una alta responsabilidad con respecto \na especies end\u00e9micas y rescate de especies domesticadas2. El \ndesaprovechamiento de especies por desconocimiento o bajo \nrendimiento econ\u00f3mico conlleva a la perdida de material ge-\nn\u00e9tico valioso, situaci\u00f3n que en la actualidad se refleja en el \nvalle de Huara, provincia de Huaura, departamento de Lima; \ncon \u00e1rboles frutales como cansaboca o ciruela del fraile (Bun-\nchosia armeniaca Cav. DC), palillo (Campomanesia lineatifolia \nRuiz & Pav.) y naranja agria (Citrus aurantium L.), especies con \ngran demanda en d\u00e9cadas pasadas e importancia en la gastro-\nnom\u00eda tradicional local3. Pero en la actualidad existe una baja o nula presencia en mercados locales, mientras que en campos \nde cultivo es dif\u00edcil encontrar estas especies, present\u00e1ndose \nmuy pocos individuos en huertas por herencia familiar, debido \na esto son catalogadas en peligro cr\u00edtico4,5.\nEstas especies vegetales, as\u00ed como muchas especies de \notras regiones del pa\u00eds presentan gran potencial socio-econ\u00f3-\nmico. Por lo que el Per\u00fa, viene desarrollando objetivos estrat\u00e9-\ngicos como parte del Convenio sobre la Diversidad Biol\u00f3gica, de \nlas cuales se ha trazado el pa\u00eds la meta de evitar la extinci\u00f3n de \nespecies mediante el avance de conocimientos, con una gran \nbase cient\u00edfica y tecnol\u00f3gica para aumentar la valoraci\u00f3n y fun-\ncionalidad de estas especies6. Como parte del avance cient\u00edfi-\nco se est\u00e1n desarrollando t\u00e9cnicas avanzadas relacionadas a \nbiolog\u00eda molecular, tales como estudios de c\u00f3digo de barras, \ngen\u00f3mica, prote\u00f3mica, metabol\u00f3mica, transcript\u00f3mica2.\n1 Universidad Nacional Jos\u00e9 Faustino S\u00e1nchez Carri\u00f3n, Facultad de Ciencias, Laboratorio de Biotecnolog\u00eda Vegetal, Huacho, Per\u00fa.\nCorresponding author: adhernandz@hotmail.com1993\nC\u00f3digo de barras de ADN de tres especies de \u00e1rboles frutales con potencial econ\u00f3mico del valle de Huaura, Lima, Per\u00fa\nDNA barcoding of three species of fruit trees with economic potential from the Huaura Valley, Lima, Peru\nEl c\u00f3digo de barras de ADN es un m\u00e9todo para identificar \nlas especies de todo tipo de organismo vivo empleando una \nsecuencia corta de ADN (<1000 pb) que evoluciona lo suficien-\ntemente r\u00e1pido como para diferir entre especies estrechamen-\nte relacionadas7. Cuando se recupera una secuencia de c\u00f3digo \nde barras de una muestra desconocida, se utiliza un algoritmo \npara compararla con una base de datos de referencia que con-\ntiene c\u00f3digos de barras de muestras de especies identificadas, \nlo que permite su comparaci\u00f3n y posible identificaci\u00f3n de ma-\nnera r\u00e1pida y clara6,8,9. En otras palabras, los c\u00f3digos de ba-\nrras de ADN funcionan como identificadores moleculares para \ncada especie, de la misma manera que los c\u00f3digos de barras \nen blanco y negro legibles por m\u00e1quina se utilizan en la indus-\ntria minorista para identificar productos comerciales10,11,12.\nLas secuencias para c\u00f3digo de barras que se emplean \nen las investigaciones est\u00e1n relacionadas a sus alineamien-\ntos m\u00faltiples y n\u00famero de variaciones, las cuales permiten \ndistinguir las especies emparentadas sin influir en su asigna-\nci\u00f3n correcta a trav\u00e9s de la variaci\u00f3n intraespec\u00edfica13. Estas \nsecuencias de ADN son: ribulosa-bisfosfato carboxilasa (rbcL), \nmaturasa K (matK) y el espaciador interg\u00e9nico trnH-psbA (tr-\nnH-psbA). Cada uno de las secuencias presenta diferencias \nen sus regiones codificantes, es as\u00ed como rbcL presenta una \nregi\u00f3n de codificaci\u00f3n universal que no evoluciona r\u00e1pidamen-\nte, matK presenta una regi\u00f3n de codificaci\u00f3n que evoluciona \nbastante r\u00e1pido y trnH-psbA es un espaciador interg\u00e9nico que \nevoluciona r\u00e1pidamente14,15.\nLa identificaci\u00f3n molecular de especies mediante c\u00f3digo \nde barras de ADN facilita la selecci\u00f3n de material vegetal des-\nde pl\u00e1ntulas, permitiendo la conservaci\u00f3n de especies amena-\nzadas. Por lo tanto, en la investigaci\u00f3n se plante\u00f3 el objetivo \nde establecer el c\u00f3digo de barras de ADN de tres especies con \npotencial econ\u00f3mico del valle de Huaura, para facilitar su iden-\ntificaci\u00f3n a nivel molecular.\nM\u00e9todos\nMaterial vegetal y extracci\u00f3n de ADN\nSe emplearon muestras de hojas de las especies Buncho-\nsia armeniaca, Campomanesia lineatifolia y Citrus aurantium, \nlas cuales fueron colectadas de la campi\u00f1a de Huacho y trans-\nportadas al Laboratorio de Biotecnolog\u00eda Vegetal de la Univer-\nsidad Nacional Jos\u00e9 Faustino S\u00e1nchez Carri\u00f3n \u2013 Huacho. La \nextracci\u00f3n de ADN se realiz\u00f3 seg\u00fan el protocolo de bromuro \nde cetiltrimetilamonio (CTAB)16. Se tomaron alrededor de 100 \nmg de tejido de hojas frescas, se a\u00f1adieron 2,85 \u03bcl de \u03b2-mer-\ncaptoetanol y 1.000 \u03bcl de tamp\u00f3n de extracci\u00f3n CTAB 2% (100 mM Tris, 28 mM EDTA, 2% CTAB, 1,4 M NaCl y 2,5% PVP), \nlas muestras se trituraron de forma mec\u00e1nica y se incub\u00f3 a \n65\u00ba C durante 45 min y. Posteriormente, se a\u00f1adi\u00f3 900 \u03bcl de \ncloroformo-alcohol isoam\u00edlico (24:1) y se mezcl\u00f3 suavemente \ndurante 5 min. Las muestras se centrifugaron a 14.000 rpm \ndurante 5 min. Despu\u00e9s de la centrifugaci\u00f3n, se recogi\u00f3 la fase \nacuosa y se adicionaron 60 \u03bcl de CTAB al 10% y se incub\u00f3 a 65\u00b0 \nC por 5 min. Se a\u00f1adi\u00f3 900 \u03bcl de cloroformo-alcohol isoam\u00edli-\nco (24:1) y se mezcl\u00f3 suavemente durante 5 min y centrifugo \na 14.000 rpm durante 5 min, se retir\u00f3 el sobrenadante y se \nadiciono isopropanol frio en el mismo volumen que el sobre-\nnadante obtenido. Las muestras fueron colocadas a -20\u00b0 C \ndurante 30 min. Posteriormente, se centrifug\u00f3 a 14.000 rpm \ndurante 20 min, se decant\u00f3 el sobrenadante y se invirtieron \nlos tubos sobre papel toalla durante 1 min. Seguidamente, se \nlav\u00f3 con etanol al 70% y se centrifugo a 14.000 rpm por 5 min. \nSe a\u00f1adi\u00f3 300 \u03bcl de CH3CO2K 5 M frio y se incub\u00f3 a -20\u00b0 C \ndurante 10 min. Luego se centrifug\u00f3 a 14.000 rpm por 5 min, \nse elimin\u00f3 el sobrenadante y se realiz\u00f3 un lavado con etanol al \n90%. Seguidamente se elimin\u00f3 el etanol y se invirtieron los tu-\nbos sobre papel toalla est\u00e9ril. Una vez seco el pellet se a\u00f1adi\u00f3 \n100 \u03bcl de agua libre de nucleasas, posterior se adicion\u00f3 3 \u03bcl de \nRNAsa al 2% y se incub\u00f3 a 37\u00b0 C durante 60 min. A continua-\nci\u00f3n, las muestras se centrifugaron a 14.000 rpm durante 5 \nmin y los sedimentos de ADN se lavaron dos veces con eta-\nnol al 70% y se invirtieron los tubos sobre papel toalla est\u00e9ril \ndurante 30 min. Los sedimentos de ADN se diluyeron con 50 \n\u03bcl de agua libre de DNAsa y posteriormente se cuantifico en \nNanodrop ND-1000 (NanoDrop Technologies, USA) y estimo \nla calidad mediante electroforesis en gel de agarosa al 1%. El \nADN extra\u00eddo se almacen\u00f3 a -20 \u00b0 C hasta su posterior uso.\nAmplificaci\u00f3n por PCR y secuenciamiento.\nSe emplearon los siguientes cebadores de c\u00f3digo de ba-\nrras de ADN universales pertenecientes a cloroplastos: matK, \nrbcL y trnH-psbA (Tabla 1). Las reacciones de PCR se realiza-\nron en un volumen de 25 \u03bcl que conten\u00eda 12.5 \u03bcl master mix (10 \nmM Tris HCl, 50 mM KCl, 2 mM de MgCl2, 0,2 mM de dNTP, \n0,02 U/\u03bcl de Taq Polimerasa), 0.5 \u03bcl de cada cebador (forward \ny reverse), 1 \u03bcl de ADN gen\u00f3mico y 10,5 \u03bcl de agua pura est\u00e9ril.\nSe utilizaron los siguientes par\u00e1metros del termociclador: \ndesnaturalizaci\u00f3n inicial de 94\u00b0 C durante 5 min, seguido de \n40 ciclos a 94\u00b0 C durante 30 s, hibridaci\u00f3n a 52\u00b0 C para los \ncebadores rbcL y matK durante 30 s, 55\u00b0 C para cebadores \nde trnH-psbA durante 30 s y extensi\u00f3n a 72\u00b0 C durante 1 min, \nseguido de una extensi\u00f3n final a 72\u00b0 C por 10 min. Las ampli-\nficaciones se realizaron en el termociclador PCRMax (BioSys-\ntems, UK).\nLos productos de amplificaci\u00f3n por PCR se sometieron a \nTabla 1. Secuencia de \ncebadores para c\u00f3digo \nde barras de ADN.1994\nelectroforesis en geles de agarosa al 1% durante 30 minutos \na 40 V, detectados por tinci\u00f3n con azul de bromofenol, los re-\nsultados se observaron bajo luz ultravioleta (UV) mediante un \nsistema de documentaci\u00f3n de geles con transiluminador UV \n(Illuminyx, USA). El tama\u00f1o de los productos de PCR se de-\ntermin\u00f3 utilizando DNA ladder de 100 pb (Promega, Madison). \nLos productos de PCR purificados se cuantificaron usando un \nespectrofot\u00f3metro Nanodrop ND-1000 (NanoDrop Technolo-\ngies, USA). El secuenciamiento de los productos de PCR se \nrealiz\u00f3 en la empresa MACROGEN (Corea del Sur).\nAn\u00e1lisis de datos\nLas secuencias obtenidas fueron analizadas con el progra-\nma Bioedit y alineadas con el programa Codon Code Aligner. \nLa identificaci\u00f3n de c\u00f3digos de barras desconocidos a partir de \nhojas se realiz\u00f3 b\u00e1sicamente mediante datos de la Herramien-\nta de b\u00fasqueda de alineaci\u00f3n local b\u00e1sica (BLAST) con un cor-\nte m\u00ednimo de 98% de identidad para una coincidencia superior7. \nEstos resultados se verificaron mediante agrupaci\u00f3n y an\u00e1lisis \nfilogen\u00e9ticos en los que comparamos las ramas de espec\u00edme-\nnes desconocidos con secuencias de especies de referencia, \npara ello las secuencias de ADN se alinearon y curaron em-\npleando el algoritmo MUSCLE del programa MEGA 7.0. Los \n\u00e1rboles filogen\u00e9ticos se construyeron en MEGA 7.0 utilizando \nel m\u00e9todo de Neighbor-Joining (NJ) con 1.000 bootstraps ba-\nsado en el modelo de par\u00e1metros de Kimura 217. Se constru-\nyeron \u00e1rboles filogen\u00e9ticos con los fragmentos combinados.\nResultados\nLos resultados obtenidos permitieron establecer que, la \nt\u00e9cnica de CTAB fue eficiente para la extracci\u00f3n de ADN en las \ntres especies; lo cual se comprob\u00f3 con la verificaci\u00f3n de la in-\ntegridad del ADN extra\u00eddo. La relaci\u00f3n de absorbancia 260/280 \nfue cercana a 1,80, lo que significa ADN altamente puro para el \nan\u00e1lisis de c\u00f3digos de barras. Las concentraciones de ADN en \ndiferentes accesiones fueron: Bunchosia armeniaca (457 ng/\n\u03bcl), Campomanesia lineatifolia (433 ng/\u03bcl) y Citrus aurantium \n(442 ng/\u03bcl). La amplificaci\u00f3n exitosa de los tres cebadores de \nc\u00f3digos de barras produjo productos de PCR entre 300 y 800 \npb (Figura 1).\nLas secuencias de nucle\u00f3tidos obtenidas mostraron di-ferencias en longitud y contenido de guanina-citocina (GC) en \nlas muestras analizadas con cada cebador de c\u00f3digo de barras \n(Tabla 2). En el caso del cebador matK, la longitud de secuen-\ncia m\u00e1s alta de Bunchosia armeniaca (810 pb). Se observ\u00f3 una \nvariaci\u00f3n de longitud de secuencia en Citrus aurantium (357 \npb) con el cebador matK. La longitud media de la secuencia \nde rbcL fue casi uniforme (573 pb). Citrus aurantium presento \nla menor longitud (373 pb) y contenido de GC (26,27 %) con el \ncebador trnH-psbA. \nLas secuencias obtenidas de este estudio se compararon \ncon el banco de datos de ADN publicados en BLAST de NCBI \n(Tabla 3, 4 y 5), presentando en algunos casos una identidad \nsuperior al 98% con las secuencias NCBI de especies de plan-\ntas conocidas y podr\u00edan estar emparentadas a ellas.\nLas especies que han logrado presentar mayor porcentaje \nde identidad con Bunchosia armeniaca del valle de Huaura, se \nencontraron en el rango de 99,75% hasta 98,28% de identidad \n(Tabla 3), manteniendo una baja variabilidad entres especies \ndel mismo g\u00e9nero. Las comparaciones de Campomanesia li-\nneatifolia muestran un descenso en el porcentaje de identidad \ncon las dem\u00e1s especies, mientras se van alejando del g\u00e9nero, \npero manteniendo en com\u00fan la familia (Myrtaceae) (Tabla 4). \nEn el caso de Citrus aurantium se logr\u00f3 encontrar porcentajes \nde identidad de 99,83% hasta 99,47%, dentro del mismo g\u00e9ne-\nro con 99% de cubierta de consulta (Tabla 5), as\u00ed mismo dentro \nde la lista se presentan tres accesiones de Citrus aurantium \nde otras partes del mundo, mostr\u00e1ndose que no comparten \ntantos porcentajes de identidad debido posiblemente a una \nevoluci\u00f3n necesaria al habitad de cada regi\u00f3n.\nLas secuencias de NCBI que presentaron mayor porcen-\ntaje de identidad con cada especie en estudio (Campomanesia \nlineatifolia, Bunchosia armeniaca y Citrus aurantium) fueron \nsometidas a an\u00e1lisis filogen\u00e9tico.\nLa alineaci\u00f3n combinada de las secuencias de las especies \nen estudio (Figura 2) con secuencias de 13 (Citrus aurantium) \ny 15 (Bunchosia armeniaca y Campomanesia lineatifolia) espe-\ncies de mayor porcentaje de similitud y cubierta de consulta, \ndescargadas de NCBI mostr\u00f3 una variabilidad las posiciones de \nnucle\u00f3tidos. De manera similar, se construy\u00f3 un \u00e1rbol filoge-\nn\u00e9tico combinado de m\u00e1xima verosimilitud mediante la conca-\ntenaci\u00f3n de datos de secuencia de tres cebadores de c\u00f3digos \nde barras (matK, rbcL y trnH-psbA) para estimar las divergen-\ncias evolutivas entre cada especie en estudio con las especies \nFigura 1. Productos de PCR \namplificados con los cebado -\nres trnH-psbA en las tres es -\npecies en peligro de extinci\u00f3n \ndel valle de Huaura. La posi -\nci\u00f3n de las muestras en el gel \nde agarosa (1-2) Campomane -\nsia lineatifolia, (3-4) Bunchosia \narmeniaca, (5-6) Citrus auran -\ntium y (-) control negativo; M: \nDNA ladder de 100 pb para la \ndeterminaci\u00f3n del tama\u00f1o de \nlas muestras.Hermila Belba D\u00edaz-Pillasca, Angel David Hern\u00e1ndez-Amasifuen, Miguel Machahua, Alexandra Jherina Pineda-L\u00e1zaro, Alexis Arg\u00fcelles-Curaca, Brayan Lugo\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1995\nTabla 2. Caracter\u00edsticas de secuencia de nucle\u00f3tidos de marcadores de c\u00f3digo de barras de ADN.\nTabla 3. Especies de mayor homolog\u00eda en BLAST con muestras de Bunchosia armeniaca del valle de Huaura.\nde mayor porcentaje de identidad descargadas de NCBI. \nEn el \u00e1rbol filogen\u00e9tico de Bunchosia armeniaca (Figura \n3) se revel\u00f3 que la muestra en estudio es gen\u00e9ticamente dife-\nrente a las especies de referencia determinadas por BLAST yse colocan en grupos distintos. Se consider\u00f3 secuencias de lamisma especie (Bunchosia armeniaca) localizadas en M\u00e9xicoy se mostr\u00f3 una diferencia gen\u00e9tica con la muestra estudiadaen Huaura, Per\u00fa.\nEn el caso de Campomanesia lineatifolia no se encontr\u00f3 \nalguna secuencia de ADN de la misma especie en BLAST, por lo que se presenta los primeros resultados de secuenciamien-to relacionada a esta especie.  El \u00e1rbol filogen\u00e9tico revelo que se encuentra muy emparentado con Campomanesia xantho-carpa, agrupados en un solo clado con 100% de soporte de arranque (Figura 4). \nMientras que el \u00e1rbol filogen\u00e9tico de la naranja agria re-\nvel\u00f3 una diferencia gen\u00e9tica con las muestras de Citrus au-rantium de referencia determinadas por BLAST situadas en Canad\u00e1, Estados Unidos e Italia, coloc\u00e1ndose en grupos sepa-rados y distintos. Con la muestra de naranja agria de referencia de Grecia se revelo una menor diferencia al estar en un grupo cercano con 87% de soporte de arranque (Figura 5).C\u00f3digo de barras de ADN de tres especies de \u00e1rboles frutales con potencial econ\u00f3mico del valle de Huaura, Lima, Per\u00fa\nDNA barcoding of three species of fruit trees with economic potential from the Huaura Valley, Lima, Peru1996\nTabla 4. Especies de mayor homolog\u00eda en BLAST con muestras de Campomanesia lineatifolia del valle de Huaura.\nTabla 5. Especies de mayor homolog\u00eda en BLAST con muestras de Citrus aurantium del valle de Huaura.Hermila Belba D\u00edaz-Pillasca, Angel David Hern\u00e1ndez-Amasifuen, Miguel Machahua, Alexandra Jherina Pineda-L\u00e1zaro, Alexis Arg\u00fcelles-Curaca, Brayan Lugo\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1997\nDiscusi\u00f3n\nSe ha aplicado con \u00e9xito un m\u00e9todo que utiliza secuencias \ncortas de ADN, conocidas como \"c\u00f3digos de barras de ADN\", \npara identificar especies de plantas, especialmente loci en el \ngenoma de los pl\u00e1stidos como matK, rbcL, y trnH-psbA8,13.\nLa evaluaci\u00f3n de la aplicabilidad universal mediante la \ncuantificaci\u00f3n por PCR y el \u00e9xito de la secuencia es el primer \npaso para determinar la idoneidad de un fragmento de ADN \ndado como c\u00f3digo de barras. A este respecto, todas las regio-\nnes analizadas (matK, rbcL y trnH-psbA) se amplificaron de \nmanera efectiva, lo que permiti\u00f3 una secuenciaci\u00f3n simple y de \nalta calidad. Por lo que, los cebadores empleados en las tres \nespecies en estudio presentaron caracter\u00edsticas ideales para \nc\u00f3digo de barras de ADN tales como capacidad de amplifica-ci\u00f3n, alta eficiencia de amplificaci\u00f3n y secuenciaci\u00f3n, tambi\u00e9n \nvariaci\u00f3n gen\u00e9tica suficientemente alta para distinguir secuen-\ncias a nivel de especie, pero tambi\u00e9n suficientemente conser-\nvadora entre individuos de la misma especie6,18.\nLa amplificaci\u00f3n de la regi\u00f3n trnH-psbA fue exitosa, con \namplicones m\u00e1s cortos (aproximadamente 570 pb) que permi-\nti\u00f3 una secuenciaci\u00f3n efectiva, al ser f\u00e1cilmente amplificable \nusando cebadores universales y sus niveles de discriminaci\u00f3n \nde especies son generalmente m\u00e1s altos que para otras regio-\nnes, consider\u00e1ndose un marcador valioso8,19,20,21. Los resulta-\ndos obtenidos presentan similitud con otros grupos de plantas, \ndonde la amplificaci\u00f3n de la regi\u00f3n trnH-psbA y la calidad de \nsecuenciaci\u00f3n fue lo suficientemente alta como para consi-\nFigura 2. Alineamiento combinado de las secuencias con el programa MEGA.\nFigura 3. \u00c1rbol filogen\u00e9tico de m\u00e1xima probabilidad de evoluci\u00f3n divergente en Bunchosia armeniaca del valle de Huaura.C\u00f3digo de barras de ADN de tres especies de \u00e1rboles frutales con potencial econ\u00f3mico del valle de Huaura, Lima, Per\u00fa\nDNA barcoding of three species of fruit trees with economic potential from the Huaura Valley, Lima, Peru1998\nFigura 4. \u00c1rbol filogen\u00e9tico de m\u00e1xima probabilidad de evoluci\u00f3n divergente en Campomanesia lineatifolia del valle de Huaura.\nFigura 5. \u00c1rbol filogen\u00e9tico de m\u00e1xima probabilidad de evoluci\u00f3n divergente en Citrus aurantium del valle de Huaura.\nderarlo un c\u00f3digo de barras7,21,22. Pero algunos grupos taxon\u00f3-\nmicos presentan limitaciones que han reducido severamente \nla utilidad de trnH-psbA como c\u00f3digo de barras. Su alta fre-\ncuencia de variaci\u00f3n de longitud resultante de sus numerosas \ninserciones y eliminaciones dificulta la construcci\u00f3n de una \nalineaci\u00f3n precisa de estas secuencias8.\nEn el presente estudio Bunchosia armeniaca del valle de \nHuara se separ\u00f3 en otro grupo con Bunchosia armeniaca de re-\nferencia de M\u00e9xico, esto podr\u00eda demostrar una combinaci\u00f3n de \ndispersi\u00f3n temprana de larga distancia entre Am\u00e9rica del Sur \ny M\u00e9xico, aunque no podemos determinar la ubicaci\u00f3n geogr\u00e1-\nfica precisa donde estos clados comenzaron a diversificarse. \nPero esto podr\u00eda relacionarse al predominio de la dispersi\u00f3n en \nla formaci\u00f3n de un grupo de especies regionales23. El marcador \nmatK presento 810 pb de longitud y 31,73% de contenido GC, mostrando el marcador con mayor longitud en comparaci\u00f3n \ncon rbcL y trnH-psbA\u00b8 pero presenta variaciones entre espe-\ncies respeto a su amplificaci\u00f3n y longitud; es por ello que el \nmarcador matK presenta divisi\u00f3n entre investigadores res-\npecto a su universalidad como cebador. Present\u00e1ndose estu-\ndios donde se indican que este marcador es clave en el c\u00f3digo \nde barras de ADN, al discriminar grupos espec\u00edficos11,24. Pero \ntambi\u00e9n est\u00e1n otros autores que cuestionan la utilidad de este \ngen como c\u00f3digo de barras debido a la pobre amplificaci\u00f3n y \nsecuenciaci\u00f3n. eficiencia y problemas relacionados con la uni-\nversalidad de los cebadores25,26.\nCampomanesia lineatifolia no ha presentado anteceden-\ntes en relaci\u00f3n al secuenciamiento de su cloroplasto, como \nsi encontraron de Campomanesia xanthocarpa secuencias \nparciales con el espaciador interg\u00e9nico trnH-psbA, con una Hermila Belba D\u00edaz-Pillasca, Angel David Hern\u00e1ndez-Amasifuen, Miguel Machahua, Alexandra Jherina Pineda-L\u00e1zaro, Alexis Arg\u00fcelles-Curaca, Brayan Lugo\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com1999\nlongitud de 569 pb y con menos del 1% de gaps27. Con la se-\ncuencia de matK se obtuvo una longitud de 799 pb, la misma \nlongitud obtenida por (28) empleando la misma secuencia en Campomanesia xanthocarpa; mientras que en el mismo estu-dio empleando rbcL obtuvieron una longitud mayor (645 pb) que la del presente estudio (546 pb), as\u00ed mismo se presenta mucha similitud con las tres secuencias con 99% de identidad, a partir de las investigaciones realizadas en Campomanesia xanthocarpa de Brasil. Demostrando que la diversificaci\u00f3n es claramente un contribuyente importante a la riqueza de es-pecies existentes en esta regi\u00f3n. La secuencia que fue m\u00e1s conservadora (entre las tres regiones analizadas) en t\u00e9rminos de variabilidad molecular fue rbcL, proporcionando una am-plia informaci\u00f3n para la selecci\u00f3n de cebadores espec\u00edficos de orden apropiado. Esto indica que rbcL tiene el menor n\u00famero de sitios variables y que la secuencia de cebador seleccionada tiene una fuerte universalidad. Por lo tanto, es recomendable rbcL como un fragmento efectivo para el c\u00f3digo de barras de \nADN en especies arb\u00f3reas. Esto tambi\u00e9n fue confirmado por (6) y otros autores\n11,19, quienes recomiendan rbcL y matK para\nel c\u00f3digo de barras de ADN central para plantas.\nEl espaciador interg\u00e9nico trnH-psbA en Citrus aurantium \nde la presente investigaci\u00f3n presento una menor longitud en comparaci\u00f3n a Citrus aurantium de referencias de otras par-tes del mundo, pero con la secuencia rbcL se obtuvo la misma \nlongitud, llegando a presentar una identidad de casi 100%\n29,30. \nFinalmente, con la secuencia de matK no se presentaron iden-\ntidades dentro del g\u00e9nero Citrus. La separaci\u00f3n de grupos de esta misma especie podr\u00eda estar relacionada a la diversifica-ci\u00f3n general de especies introducidas de manera individual permitiendo explicar el patr\u00f3n de dispersi\u00f3n frecuente y conti-nua de nuevos linajes, esto plantea la posibilidad de que la ca-racterizaci\u00f3n de grupos de especies est\u00e9 dominada por linajes \u00fanicos que se trasladaron a una regi\u00f3n, lo que parece haber brindado a individuos el tiempo necesario para adaptarse a nuevas condiciones abi\u00f3ticas\n23. As\u00ed mismo la alta frecuencia \nde las variantes de longitud de trnH-psbA en algunas especies impact\u00f3 la identificaci\u00f3n de especies utilizando m\u00e9todos ba-sados en la alineaci\u00f3n, as\u00ed como la comparaci\u00f3n con las espe-cies del presente estudio mediante el an\u00e1lisis de distancia, que tuvo un efecto m\u00ednimo en las b\u00fasquedas de BLAST\n8,20.\nEl an\u00e1lisis filogen\u00e9tico a partir del c\u00f3digo de barras de \nADN permite mejorar la identificaci\u00f3n de especies, al propor-cionar caracteres adicionales que pueden estar conducidas por variaciones variaci\u00f3n intraespec\u00edfica e inversiones interes-pec\u00edficas que pueden confundir las relaciones entre especies estrechamente relacionadas\n31,32. Permitiendo identificar a las \nespecies exactas que se encuentra en peligro de extinci\u00f3n en el valle de Huaura, y, adem\u00e1s, mostrando un distanciamiento entre la misma especie ubicada en otras partes del mundo.\nDe esta manera se puede emplear estos m\u00e9todos como \nbase de cualquier estudio cient\u00edfico de identificaci\u00f3n comple-tamente perfecta de material vegetal, conjuntamente con la enorme biblioteca digital en l\u00ednea de c\u00f3digos de barras de ADN, que sirve como informaci\u00f3n para buscar muestras (no iden-tificadas o identificadas) utilizando uno o unos pocos loci de c\u00f3digos de barras de ADN\n20.\nConclusiones\nEl presente estudio es el primero en analizar especies fru-\ntales con potencial econ\u00f3mico en peligro de extinci\u00f3n del va-lle de Huaura para facilitar la identificaci\u00f3n a nivel molecular. Nuestros resultados proporcionan las herramientas b\u00e1sicas para implementar c\u00f3digos de barras de ADN en especies nati-vas en el valle de Huaura, y pueden ayudar a elegir un c\u00f3digo de barras de ADN apropiado para aplicaciones de alta produc-tividad. Dichas aplicaciones de alto rendimiento podr\u00edan mejo-rar en gran medida los protocolos de monitoreo de la biodiver-sidad que se utilizan para estudiar la ecolog\u00eda y conservaci\u00f3n de especies en peligro de extinci\u00f3n.\nAgradecimientos\nA la Universidad Nacional Jos\u00e9 Faustino S\u00e1nchez Ca-\nrri\u00f3n, por el financiamiento del estudio mediante fondos del \n\u00e1rea prioritaria FOCAM: Preservaci\u00f3n de la biodiversidad, iden-tificaci\u00f3n y desarrollo de las potencialidades econ\u00f3micas de la zona de impacto del Proyecto de Camisea; con Resoluci\u00f3n Vicerrectoral N\u00b0 0044-2013-VTR-UNJFSC. As\u00ed como al Blgo. Fernando Serna y Blgo. Alfredo Martin por sus sugerencias en la culminaci\u00f3n de la investigaci\u00f3n.\nReferencias bibliogr\u00e1ficas\n1. Le\u00f3n B, Pitman N, Roque J. Introducci\u00f3n     a las plantas end\u00e9mi-\ncas del Per\u00fa. Revista Peruana de Biolog\u00eda 2006,     13(2): 9-22.\nDOI: https://doi.org/10.15381/rpb.v13i2.1782\n2.v\non May R, Catenazzi A, Angulo A,     Venegas P, Aguilar C. Investi-\ngaci\u00f3n y conservaci\u00f3n de la biodiversidad en     Per\u00fa: importancia del uso de t\u00e9cnicas modernas y procedimientos     administrativos eficientes. Revista Peruana de Biolog\u00eda 2012, 19(3):     351-358.DOI: https://doi.org/10.15381/rpb.v19i3.1055\n3.\nMinis\nterio del Ambiente     (MINAM). Estrategia Nacional de Diver-\nsidad Biol\u00f3gica al 2021 y su Plan de     acci\u00f3n 2014-5018. Minis-terio del Ambiente, Direcci\u00f3n General de Diversidad     Biol\u00f3gica.Lima, Per\u00fa. 2014. Consultado 19 jul. 2020. Disponible en https://sinia.minam.gob.pe/documentos/estrategia-nacional-diversi-dad-biologica-2021-plan-accion-2014-2018\n4.\n Mos\ntacero J, Mej\u00eda F, Gasta\u00f1adui     D, De La Cruz J. Inventario\ntaxon\u00f3mico, fitogreogr\u00e1fico y etnobot\u00e1nico de     frutales nativosdel norte del Per\u00fa. Scientia Agropecuaria 2017, 8(3):     215-224.DOI: http://dx.doi.org/10.17268/sci.agropecu.2017.03.04\n5.\nD\u00edaz H, Honorio Z, Hern\u00e1ndez A,     Dur\nand M, G\u00f3zalo A, Dom\u00edn-\nguez G. Identificaci\u00f3n de especies frut\u00edcolas     nativas con poten-cialidad productiva en peligro de extinci\u00f3n en la     provincia deHuaura. Aporte Santiaguino 2020, 13(2): 78-91. DOI:     https://doi.org/10.32911/as.2020.v13.n2.700\n6.\nCBOL Plant Working Group. A DNA     barcode for land plants.Proceedings \nof the National Academy of Sciences     of the Unit-\ned States of America 2009, 106: 12794-12797. DOI: https://doi.org/10.1073/pnas.0905845106\n7.\nKres\ns WJ, Garc\u00eda-Robledo C, Uriarte     M, Erickson DL. DNA bar-\ncodes for ecology, evolution, and conservation. Trends     in Ecol-ogy & Evolution 2015, 30(1): 25-35. DOI: https://doi.org/10.1016/j.tree.2014.10.008\n8.\n Kres\ns JW, Wurdack KJ, Zimmer EA,     Weigt LA, Janzen DH. Use \nof DNA barcodes to identify flowering plants. Proceedings     ofthe National Academy of Sciences 2005, 102(23): 8369-8374.DOI: https://doi.org/10.1073/pnas.0503123102\n9.\nLit\ntle DP, Stevenson DW. A     comparison of algorithms for the\nidentification of specimens using DNA     barcodes: examplesfrom gymnosperms. Cladistics 2007, 23(1): 1\u201321. DOI:     https://doi.org/10.1111/j.1096-0031.2006.00126.x\n10.\n Laha\nye R, van der Bank M, Bogarin     D, Warner J, Pupulin F,\nGigot G, Maurin O, Duthoit S, Barraclough TG, Savolainen     V.DNA barcoding the floras of biodiversity hotspots. Proceedings of     the National Academy of Sciences 2008, 105(8): 2923-2928. DOI:     https://doi.org/10.1073/pnas.0709936105\n11.\n Ne\nwmaster SG, Grguric M, Shanmughanandhan     D, Ramalingam \nS, Ragupathy S. DNA barcoding detects contamination and     sub-stitution in North American herbal products. BMC Medicine 2013,11(1):     222. DOI: https://doi.org/10.1186/1741-7015-11-222C\u00f3digo de barras de ADN de tres especies de \u00e1rboles frutales con potencial econ\u00f3mico del valle de Huaura, Lima, Per\u00fa\nDNA barcoding of three species of fruit trees with economic potential from the Huaura Valley, Lima, Peru2000\n12. Michel CI, Me yer RS, Taveras Y,     Molina J. The nuclear internal\ntranscribed spacer (ITS2) as a practical     plant DNA barcode\nfor herbal medicines. Journal of Applied Research on     Medic-inal and Aromatic Plants 2016, 3(3): 94\u2013100. DOI:     https://doi.org/10.1016/j.jarmap.2016.02.002\n13.\n Hollingsw\north PM, Graham SW, Little     DP. Choosing and using\na plant DNA barcode. PLoS One 2011, 6: e19254.     https://doi.org/10.1371/journal.pone.0019254\n14.\n Group CP\n, Hollingsworth PM, Forrest     LL, Spouge JL, Hajibabaei \nM, Ratnasingham S, van der Bank M, Chase MW, Cowan     RS,Erickson DL. A DNA barcode for land plants. Proceedings of theNational Academy of Sciences 2009, 106(31): 12794-12797. DOI: https://doi.org/10.1073/pnas.0905845106\n15.\n de Groot G\nA, During HJ, Maas JW,     Schneider H, Vogel JC,\nErkens RH. Use of rbcL and trnL-F as a two-locus     DNA barcode for identification of NW-European ferns: an ecological     perspec-tive. PLoS One 2011, 6(1): e16371. DOI: https://doi.org/10.1371/journal.pone.0016371\n16.\n Do\nyle JJ, Doyle JL. A rapid DNA     isolation procedure for small\nquantities of fresh leaf tissue. Phytochemical     Bulletin 1987,19: 11-15.\n17.\n K\numar S, Stecher G, Li M, Knyaz     C, Tamura K. MEGA X: Molecu-\nlar Evolutionary Genetics Analysis across     computing platforms. Molecular Biology and Evolution 2018, 35:1547-1549.     DOI:https://doi.org/10.1093/molbev/msy096\n18.\n Co\nwan RS, Chase MW, Kress WJ, Savolainen     V. 300 000 species \nto identify: problems, progress, and prospects in DNA     barcod-ing of land plants. Taxon 2006, 55(3): 611\u2013616. DOI: https://doi.org/10.2307/25065638\n19.\n Bieniek \nW, Mizianty M, Szklarczyk     M. Sequence variation at the \nthree chloroplast loci (matK, rbcL,     trnH-psbA) in the Tritice-aetribe (Poaceae):  comments on the relationships and     utility in DNA barcoding of selected species.  Plant Systematics and Evo-lution 2015,     301(4):1275-1286. DOI: https://doi.org/10.1007/s00606-014-1138-1\n20.\n Kres\ns WJ, Erickson DL. DNA     barcodes: genes, genomics, and\nbioinformatics. Proceedings of the     National Academy of Sci-ences 2008, 105(8): 2761\u20132762. DOI: https://doi.org/10.1073/pnas.0800476105\n21.\n P\nang XH, Song JY, Zhu YJ, Xu HX,     Huang LF, Chen SL. Applying \nplant DNA barcodes for Rosaceae species     identification. Cla-distics 2010, 27(2): 165\u2013170. DOI: https://doi.org/10.1111/j.1096-0031.2010.00328.x\n22.\n P\nang XH, Liu C, Shi LC, Liu R, Liang     D, Li H, Cherny S, Chen\nS. Utility of the trnH\u2013psbA intergenic spacer     region and itscombinations as plant DNA barcodes: a metaanalysis. PLoSONE 2012, 7(11): e48833. DOI: https://doi.org/10.1371/journal.pone.0048833\n23.\n Willis C\n, Franzone B, Xi Z, Davis     C. The establishment of Central \nAmerican migratory corridors and the     biogeographic origins ofseasonally dry tropical forests in Mexico. Frontiers     in Genetics2014, 5:433. DOI: http://dx.doi.org/10.3389/fgene.2014.0043324.\n  De Mattia F, Bruni I, Galimberti     A, Cattaneo F, Casiraghi M,\nLabra M. A comparative study of different DNA     barcodingmarkers for the identification of some members of     Lamiaceae.  Food Research     International 2011, 44: 693-702. DOI: https://doi.org/10.1016/j.foodres.2010.12.032\n25.\n Du ZY\n, Qimike A, Yang CF, Chen JM,     Wang Q. Testing four bar-\ncoding markers for species identification of     Potamogetonaceae. Journal of Systematic and Evolution 2011, 49(3):246-251.     DOI: https://doi.org/10.1111/j.1759-6831.2011.00131.x\n26.\n Y\nan HF, Hao G, Hu CM, Ge XJ. DNA     Barcoding in closely re-\nlated species: A case study of Primula L. sect.     Proliferae Pax(Primulaceae) in China. Journal of Systematics and     Evolu-tion 2011, 49: 225-236. DOI: http://dx.doi.org/10.1111/j.1759-6831.2011.00115.x\n27.\n Bolson M, Smidt-E\nde C, Brotto ML,     Silva-Pereira V. ITS and\ntrnH-psbA as Efficient DNA Barcodes to Identify     ThreatenedCommercial Woody Angiosperms from Southern Brazilian Atlan-tic     Rainforests. PLoS One 2015, 10(12): e0143049. DOI: https://doi.org/10.1371/journal.pone.0143049\n28.\n Lima RA, Oliv\neira AA, Colletta GD,     Flores TB, Coelho RL, D\u00edas\nP, Frey GP, Iribar A, Rodrigues RR, Souza VC, Chave     J. Canplant DNA barcoding be implemented in species-rich tropicalregions? A perspective from S\u00e3o Paulo State, Brazil. Geneticsand     Molecular Biology 2018, 41(3): 661-670. DOI: https://doi.org/10.1590/1678-4685-GMB-2017-0282\n29.\n Kres\ns WJ, Erickson DL. A     two-locus global DNA barcode for\nland plants: the coding rbcL gene     complements the non-cod-ing trnH-psbA spacer region. PLoS One 2007, 2(6):     e508. DOI:https://doi.org/10.1371/journal.pone.0000508\n30.\n Cornar\na L, Borghesi B, Canali C,     Andrenacci M, Basso M, Fed-\nerici S, Labra M. Smart drugs: green shuttle or     real drug?. Int J Legal Med. 2013, 127(6): 1109-1123. DOI: https://doi.org/10.1007/s00414-013-0893-9.\n31.\n Whitlock B\nA, Hale AM, Groff PA.     Intraspecific inversions pose\na challenge for the trnH-psbA plant DNA     barcode. PLoSONE 2010, 5(7): e11533. DOI: https://doi.org/10.1371/journal.pone.0011533\n32.\n Degtjare\nva GV, Logacheva MD, Samigullin     TH, Terentieva EI,\nValiejo-Roman CM. Organization of chloroplast     psbA-trnHintergenic spacer in dicotyledonous angiosperms of the familyUmbelliferae. Biochemistry (Moscow) 2012, 77(9): 1056-1064.DOI: https://doi.org/10.1134/S0006297912090131\nReceived: 21 April 2021\nAccepted: 20 June 2021Hermila Belba D\u00edaz-Pillasca, Angel David Hern\u00e1ndez-Amasifuen, Miguel Machahua, Alexandra Jherina Pineda-L\u00e1zaro, Alexis Arg\u00fcelles-Curaca, Brayan Lugo\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2001\nRole of Candida glabrata  as nosocomial pathogen and its susceptibility to Fluconazole, Voriconazole, Caspofungin, Micafungin and Amphotericin B\nRole of Candida glabrata  as nosocomial pathogen and its susceptibility to \nFluconazole, Voriconazole, Caspofungin, Micafungin and Amphotericin B\nTeeba Hashim Mohammed1, Mohsen Hashim Risan1, Mohammed Kadhom2, Emad Yousif3* DOI. 10.21931/RB/2021.06.03.19\nAbstract: Candida has different types that could cause bloodstream infections. A total number of 150 samples were collected \nfrom candidemia patients and examined.  The Candida spp. Species isolated from blood samples were analysed. These were \nidentified by culturing the species using different media, namely the chromogenic agar test.  Then, the virulence factors of all samples were tested. The Candida glabrata isolates were tested with six commercial antifungal drugs. C. glabrata 67 (44.6%), C. albicans 34 (22.6%), C. krusei 18 (12%), C. tropicalis 17 (11.3%), and C. parasilosis 14 (9.3%). the production of phospholipaseranged between 0.63-0.99 mm. It was found that 96% of the species showed phospholipase activity in aerobic conditions. Theprotease activities of Candida spp. Isolates were experimentally tested by area of inhibition around the colonies, where 59.3% had the double (++) protease activity, 31.4% with (+) grade, and 9.3% had (\u2013) grade or clear zone around the colony. The hemolyticcapacity ranged from 0.69-0.89 in the optimum aerobic environments. Finally, 38.33% of the isolated Candida spp. were positive and 61.67% negative for biofilm formation. Out of the total positive Candida spp. for biofilm formation, 21.73% were strongbiofilm producers, and 78.27% were weak. Minimum fungicidal concentration (MFC) of Fluconazole for C. glabrata isolates wasnot appropriate (NA) due to the occurrence of low inhibition tested for species. Micafungin exhibited the lowest fungicidal activity against C. glabrata ranging from 0.03 - 0.125, while Fluconazole showed the highest.\nKey words: Candidemia, chromogenic agar, Candida glabrata, Antifungal.RESEARCH / INVESTIGACI\u00d3N\nIntroduction\nCandida is a significant genus of Ascomycete fungi, com-\nmonly called yeast, consisting of approximately 150 species, \nmore than 20 of them of clinical importance1.  Candida spp. be-\ncame the fourth most public reason for bloodstream infections (BSI) more than two decades ago\n2,3. The highest occurrence \nrate was described in the USA4, where candidemia signifies an \nessential danger for hospital patients5.  Hence, C. albicans and \nC. glabrata remain the primary cause of aggressive candidia-sis, responsible for 50% of all cases followed by other speciesof Candida, such as C. tropicalis and C. parapsilosis\n6,7.\nThe effect of Candida species is presented by interrup-\nting BSI incidents; their phospholipase and protease activity and the sensitivity towards the main antifungal agents were available\n8. Described mortality data comprised the age, period \nof hospitalization, skin infection, severe renal failure, preser-vation of the dominant venous line, and mechanical ventila-tion\n9,10. The germs become active at 37 \u00b0C, where protease \nand phospholipase are produced and facilitated adherence to the surfaces of host cell membranes; these were measured to be significant factors in starting the infection. Proteinase and phospholipase release can prime the membranes dysfunction or uniform rupture that assists the microbe to adhere to the host\n11. The communication in the pathogenesis of aggressi-\nve candidiasis, proliferation in fungal colonization is the best significant factor in the invasive candidiasis for pathogenesis. The density and colonized apparent area are responsible for the strength of the infection. Precise identification of Candida species helps control the hazards of candidemia infections and transmission from exogenous sources in certain patients\n12. Vi-\nrulence factors are also associated to a great degree with the antifungal resistance shown by the microorganisms.\nFurthermore, the capabilities of Candida species to produ-\nce drug-resistant virulence factors are significant in their de-velopment of human disease\n13. Recognition of Candida to the type's level is significant to improve the range of the antifungal agent to be prescribed. On the other hand, essential and deve-loping resistance to azoles characterizes a significant trial for experimental, therapeutic, and prophylactic approaches. The range of candidemia has altered with the appearance of C.gla-brata species, a strain with the hazard of increased transience and antifungal treatment of drug resistance, particularly in im-munocompromised and very ill patients. The situation is very significant to recognize Candida to the type's level to improve the range of the antifungal agent\n14.\nMaterials and methods \nCollection of samples\nSamples were collected from 150 patients with leukae-\nmia and dialysis who were hospitalized at Madinat Al-tib hos-pital. The collection continued over four months, from Sep-tember 2019 to January 2020. Processes of blood culturing and yeast segregation were conducted in the fungus labora-tory at the College of Biotechnology/ Al-Nahrain University. The blood samples were inoculated on an SDA medium with chloramphenicol. All plates were incubated at 37\u00b0C\u00b11 for 24, 48 hrs. Later, samples were examined and biochemical tests were performed to confirm the diagnosis of the species; the approval was obtained to take blood samples from the hospi-tal administration and the discharged patients.  \nIsolation of \nCandida spp\nSamples were inoculated on the appropriate culture me-\ndium containing sabouraud dextrose agar with chlorampheni-\ncol. All plates were incubated in aerobic conditions of 37 \u00b0C for 48 h\n15.\n1 College of Biotechnology, Al-Nahrain University, Baghdad, Iraq.  \n2 Department of Renewable Energy, College of Energy and Environmental Sciences, Alkarkh University of Science, Baghdad, Iraq.\n3 Department of Chemistry, College of Science, Al-Nahrain University, Baghdad, Iraq\nCorresponding author: emad_yousif@hotmail.com2002\nTeeba Hashim Mohammed, Mohsen Hashim Risan, Mohammed Kadhom, Emad Yousif\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nIdentification of Candida spp.  Isolates\nFirst, single colonies were separated from the prime posi-\ntive cultures; then, they were isolated according to published \nprotocols16 that involved the following examination. All isola-\ntes were grown on sabouraud dextrose agar and incubated at 37 \u00baC for 48 hrs. Pure isolates of Candida colonies were exami-ned to explore their form, size, color, and surface. Chromoge-nic agar plates were inoculated by streaking. Candida colonies using sterile loop then incubated at 37 C\u00ba\u00b11 for 48 hrs. The growth and color of colonies were observed.\nThe medium was prepared by dissolving 45.9 grams of the \nstandard medium in one liter of purified water, mixed well, and melted by heating with repeated agitation. The mixture was boiled for 2 minutes until the complete dissolution and was not autoclaved\n17.\nVirulence Factor Tests\nThe quick preliminary medical identification of Candida \nspp. usually depends on the detection of germ tubes from Candida cells, where their width or length is about three to four times the size of the cell. Candida spp. cells were added to 1000 \u03bcl of human serum with a sterilized loop, and incubated aerobically for three hours at 37 \u00baC. Then, cells were visualized under a microscope\n18.\nThe egg yolk agar technique is used to test the phospho-\nlipase activity19. The culture medium contained of 1 L of SDA \ncomprising (1M NaCl, 0.005 M CaCl2, and 10% egg yolk). From prepared yeast suspension, 10 microliters were taken to one McFarland (3\u00d710\n8 CFU/ml) inoculated at 37 C\u00ba for 48 hr. in the \npetri dish, 3 replicates per sample. After that, it was incuba-ted at 37 \u00b0C for 3 days in aerobic conditions; the significance of phospholipase action was calculated with this formula: (Pz value= Colony diameter/ (Colony diameter + zone of precipita-tion)\n20. To test the proteinase activity, bovine-serum albumin \nagar was used. The prepared agar consisted of 0.1% KH2PO4, \n0.05% MgSO4, 2% agar, and 1% bovine serum albumin at a final \npH of 4.5. Similar inoculation aerobic conditions as above were applied for 48 h. The existence of the proteinase activity test was determined by observing a clear zone around the Candi-da spp. colonies\n21. Regarding the structural haemolytic action, \nSDA consisted of 7 ml human blood, 3g glucose, and 90 ml of sterile media was prepared using an autoclave with a final pH of 5.6 \u00b1 0.2. 10 microliters were taken to one McFarland (3\u00d7108 CFU/ml) inoculated onto a dish; this was replicated 3 times per sample. Then, it was incubated at 37 \u00b0C for five days in aerobic conditions. After incubation, a clear/semi-clear zone around the yeast colony was detected as a positive haemolytic activity. The significance of hemolysis activity (Hz) was tested according to the equation:  Hz rate = Colony diameter / (Co-lony diameter + Zone of precipitation) Agreeing to this scheme, activity kinds were recognized allowing to the Hz catalogue: Hz<0.69= very strong (++++), Hz = 0.70- 0.79= strong (+++) , Hz = 0.80- 0.89= slight (++), Hz = 0.90- 0.99=frail (+), and Hz =1 that is to say \"Negative\" results\n22.  Biofilm production was \ntested using different recognition tests for Candida spp., which needs the use of a specifically prepared brain heart infusion broth (BHI), solid medium supplemented (agar) with glucose and Congo red indicator. The medium contained BHI (37 gm/L), agar no.1 (10 gm/L), glucose (80 gm/L), and Congo red stain (0.8 gm/L) as an indicator\n23.\nDetermination of minimum inhibitory concentration (MIC) \nof several antifungals for Candida glabrata\nThe MIC of Fluconazole, Voriconazole, Caspofungin, Mi-cafungin, Amphotericin B, and Flucytosine against Candida \nglabrata was determined broth microdilution method establi-shed on the Clinical and Laboratory Standards Institute (CLSI) natural resistance + base (bioMerieux, USA). Manufacturers' recommendations were strictly followed to obtain adequate measurements, which confirmed sterility and efficacy of the prepared media and used mixtures. Card type AST-YS07 of a barcode no. 287 (bioMerieuxm, USA) was used with an analysis time of 24 hours\n24.\nDetermination of MFC for Candida glabrata\nFor MFC determination, samples with different concentra-\ntions of MIC and C.  glabrata were subcultured in Petri dishes containing SDA and incubated at 37 \u00b0C for 48 hours. The MFC is the minimum product concentration that stops apparent growth; it is the minor concentration capable of killing the yeast\n25.  \nResults\nGroup\u2019s classification\nIn this study, 150 samples were taken from three groups.  \nThe first group comprised 50 infected patients (women and men), as illustrated in Table 1; the second group comprised 50 patients of children with leukemia (Table 2); the third group comprised 50 patients with dialysis (women and men), as lis-ted in Table 3.  The first and third groups were divided into five categories, while the second group contained three subcatego-ries.  Generally, it was found that the total number of infected patients with Candida present in the bloodstream were isola-\nted as follows: 67(44.6%) with C. glabrata, 34 (22.6%) with C. albicans, 18 (12%) with C. krusei, 17 (11.3%) with C. tropicalis, and 14 (9.3%) with C. parapsilosis.\nDetermination of \nCandida  species by Chromogenic agar \nMedium\nCandida spp was cultivated in a chromogenic agar me-\ndium plates and the characteristic dyed colonies were obtai-\nned after incubation; the medium supported the development of all isolates. C. albicans isolates produced green colonies \nwhen incubation for 48 h, while C. glabrata formed light pink \nsmooth colonies and C. krusei colonies were pink; the distribu-tion graduated from a light surrounding to a dark center. Also, C. tropicalis color was dark blue and C. parapsilosis formedpale colored colonies\n26 as shown in Figure 1.\nDetermination of Virulence Factors for Candida  Species\nThe development of germ tubes was achieved, as long tu-\nbes, within 2 hours, and positive results of Candida albicans isolates were observed, while no C. tropicalis production within that time was detected, as shown in Figure 2. \nThe germ tubes were grown in an incubator, and a par-\nticular diagnostic was used for distinguishing the C. albicans \nby separating it from other yeasts. Other species of yeasts, in general, did not produce germ tubes during this 2-hour incuba-tion period. The Pz value varied between 0.63\u20130.99 mm when species were measured. It was found that 144 (96%) Candida spp. isolates expressed phospholipase activity in aerobic con-ditions, whereas the rest did not. Candida spp. possibly vary depending on the species and basis of isolates; Figure 3 shows the phospholipase activity of different Candida types on egg yolk agar medium. \nThe protease activities of Candida spp. isolates were tes-2003\nted for 3 days after an inoculation loop on bovine-serum albu-\nmin agar by the inhibition area around the colony.  Eighty-nine \n(59.3%) isolates had the double (++) protease activity, while \nthe grade (+) of protease activity was for forty-seven (30%) \nof isolates and fourteen (9.3%) had the grade (\u2013) or clear zone \naround the colony as shown in Figure 4. \nCommonly, the hemolytic index is 0.69\u20130.89 in optimal ae-\nrobic environments. In this study, all experimental Candida spp \nisolations from blood samples had hemolysis activity when cul-\ntivated on SDA involving 7% human blood and 3% glucose.\nOut of all Candida spp. isolates, the biofilms were \n81(54.4%) negative, 28(18.6%) strong positive, and 41(27%) \nweak positive resulted from patients with leukemia and dialy-\nsis who are lying in hospital. The number of recovered Candida \nspp. from experimental samples was C. glabrata 34(49.2%), \nfollowed by C albicans (15.8%), C. krusei (12.5%), C.tropicalis \n(11.6%), and C. parapsilosis (10.9%). Among all Candida isola-\ntes, 46% were positive biofilm, and 54% cases were harmful \nbiofilm. However, within the positive Candida biofilm, 21.73 % \nwere strong biofilm producers, and 78.27% were weak; Figure \n5 shows the biofilms.\nDetermination of MICs for Candida glabrata\nThe results of the susceptibility analysis of Candida gla-\nbrata isolates are summarized in Table 7. In all examinations, the minimum inhibitory concentrations (MICs) of the control C.\nglabrata isolated yeast were within the recognized limits (data \nare not shown). However, the CLSI's wild-brand MIC distribu-\ntions were tested against six commercial antifungal drugs, \nnamely: Fluconazole, Voriconazole, Caspofungin, Micafungin, \nAmphotericin B, and Flucytosine. The results showed that Flu-\nconazole was the most active antifungal against Candida gla-\nbrata with different concentrations, whereas micafungin was \nthe lowest antifungal resistance against Candida glabrata.\nThe MFC ranges for the six drugs though significant chan-\nge for the different organisms. Fluconazole, Voriconazole, and \nFlucytosine showed fungicidal activity against C. glabrata \n(MFC50s where appropriate \u22651 g/mL). MFCs of Fluconazole \nfor this yeast was not appropriate (NA) due to the occurrence \nof small inhibitions tested number for species; table 8 illustra-\ntes this.\nDISCUSSION\nHospitalization (especially in cancer cases), location of \ncentral venous dialysis, and who preceding antimicrobial the-\nrapies control the number of candidemia infections. Candide-\nmia in this concept was related to the prolonged stay (more \nthan 15 days) of patients27. It is essential to mention that el-\nTable 1. Age group relationship with \nthe number (and percentage) of in -\nfected patients with Candida spp from \nblood samples for adults (women and \nmen).\nTable 2. Age group relationship with \nthe number (and percentage) of in -\nfected patients with Candida spp from \nblood samples for children.\nTable 3. Age group relationship with \nthe number (and percentage) of in -\nfected patients with Candida spp from \nblood samples of patients with dialysis \nfor women and men.Role of Candida glabrata  as nosocomial pathogen and its susceptibility to Fluconazole, Voriconazole, Caspofungin, Micafungin and Amphotericin B2004\nFigure 1. Observation of Candida spp. in Chromogenic agar media, (a) C. krusei, (b) C. albicans, (c) C. tropicalis, (d) C. glabrata, \nand (e) C. parapsilosis.\nFigure 2. Germ tube of C. albicans growth \non human serum at 37\u00b0C for 2hrs (40 X)..\nFigure 3. Phospholipase activity of (a) C. krusei, (b) C. albicans, (c) C. tropicalis, (d) C. glabrata, and (e) C. parapsilosis on egg yolk \nagar medium at 37 \u00b0C for (24-48) hrs.Teeba Hashim Mohammed, Mohsen Hashim Risan, Mohammed Kadhom, Emad Yousif\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2005\nTable 4. Phospholipase activity of \nCandida spp on egg yolk agar medium \nat 37 \u00b0C for (24-48) hrs.\nFigure 4. Protease activity from (a) C. krusei, (b) C. albicans, (c) C. tropicalis, (d) C. glabrata, and (e) C.parapsilosis on bovi -\nne-serum albumin agar at 37\u00b0C for (24-48) hrs.\nTable 5. Protease activity from Candida spp on bovine-serum albumin agar at 37\u00b0C for (24-48) hrs.Role of Candida glabrata  as nosocomial pathogen and its susceptibility to Fluconazole, Voriconazole, Caspofungin, Micafungin and Amphotericin B2006\nTable 6. Biofilm formation results of 150 Candida isolated by Congo red agar.\nFigure 5.  Biofilm formation resulted by (a) C. krusei, (b) C. albicans, (c) C. tropicalis, (d) C. glabrata and (e) C. parapsilosis on \nCongo red agar\nTable 7. Minimum Inhibitory Concentration (MIC) for C. glabrata isolates.Teeba Hashim Mohammed, Mohsen Hashim Risan, Mohammed Kadhom, Emad Yousif\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2007\nder patients were more likely to receive insufficient antifungal \ntherapy. Candidemia is connected with high mortality rates, increasing the hospitalization staying period, and raising thera-peutic care\n28. The production test of the germ-tube has the be-\nnefit of being simple, effective, inexpensive, and fast to identify the Candida spp\n29. The chromogenic agar media are different; \na selective medium was used to identify Candida spp fast. As a result, the capability to distinguish these species macrosco-pically was achieved\n30.\nThe impact of the phospholipase enzyme was presented \nby digesting the cells' membrane of the host, producing cell ly-sis, and altering the external structures that increase adheren-ce and result in infection. Therefore, phospholipase is possibly used as one of the limits to distinguish virulent hostile strains from non-hostile colonizers\n20. Mohandas and Ballal, (2008)31 \nwas referred that Candida spp. isolated from blood has more phospholipase activity. In two different studies from Turkey Candida isolates from blood culture, phospholipase activity resulted was (60.3% - 100%). The differences in results were retained because of distinctions in the sources of yeast isola-tes and the percentage of occurrence of isolates\n32.\nThe essential protease enzyme of Candida spp. evades the \nattack of host tissues. The majority of tested Candida spp. had \na positive protease activity. These conclusions propose that generating the protease may play a significant role in the pa-thogenesis of candidemia produced by Candida spp. It has been testified that more than 90% of Candida spp isolates proteina-se products\n33. Proteinase production was identified in 74.56% \nof Candida spp. It was also testified that 88% of Candida spp. \nisolated from blood-linked intense proteinase action.\nMoreover, Candida spp. atmospheric environments did not \ndamage isolates testifying strong proteinase action. The alte-rations between studies may include product from differences in the sources of incubation, isolates and times\n34.\nSachin et al. (2012)35 reported that 94.8% of C. albicans \nsamples presented hemolysis activity, whereas hemolysis ac-tivity of additional non-C.albicans extended from 7% to 60%; similarly, Sathiya et al. (2015)\n36 described 100% of Candida \nspp. isolates exhibited \u03b2-hemolytic.\nForm biofilms are associated with pathogenicity and \nshould be considered an important virulence determinant du-ring candidiasis. Biofilms may help fungi maintain the role of commensal and pathogen by evading host immune mechanis-ms, resisting antifungal treatment, and withstanding the com-petitive pressure from other organisms\n37.\nOur results are in good agreement with Khan's et al. re-\nsults (2012)38, where amphotericin B and Fluconazole showed \nvigorous antifungal activity against Candida due to their MIC standards of under 100 \u03bcg/ml. Also, the antifungal proved to be an active inhibitor against C. glabrata\n39. According to Ha-\nfidh et al. (2011)40, the MFC/MIC relation is used to identify the \ninfluence of the antifungal effect against a specific pathogen. When the percentage of MFC:MIC result is between 1:1 and 2:1, the biochemical analysis measured fungicidal. In addition, Mohamadi et al. (2014)\n41 also testified the fungicidal action \nof strain, using the destroy time technique in C. albicans and expending agar disc diffusion test, for example C. albicans, C.\ntropicalis, and C. glabrata. Fungicidal action is clinically more significant than fungistatic action. The prophylactic usage of fungistatic treatments has been related to an increased rate of innate or acquired immunity in clinical isolates\n24-44.\nConclusions\nCandida samples vary in their ability to form virulence \nfactors, such as the production of phospholipase, proteinase, biofilms, and hemolysis when taken from leukemia patients. Candida spp samples were more sensitive to Fluconazole fo-llowed by Flucytosine, Amphotericin B, Voriconazole, Caspo-fungin, and Micafungin.\nFunding\nNot applicable.\nAcknowledgments\nThe authors like to thank the Department of Molecular \nand Medical Biotechnology at the College of Biotechnology/\nAl-Nahrain University and the Department of Chemistry at the College of Science/Al-Nahrain University for partially suppor-ting this work.\nConflicts of Interest\nThe authors declare no conflict of interest.\nBibliographic references\n1. Saikk onen K. Forest structure and fungal endophytes. Fungal\nBiol. Rev. 2007; 21: 67\u201374. doi:10.1016/j.fbr.2007.05.001\n2.Risan M H. Molecular Identification of Y\neast Candida glabrata\nfrom Candidemia Patients in Iraq. Iraqi J. Sci. 2016; 808-813.\n3.Mei-\nYin  L, Jen-Fu H , Shih-Ming  C , Hsyuan W,  Hsuan-Rong H,\nMing-Chou C, Ren-Huei  F, Ming-Horng T. Risk Factors and Out-\ncomes of Recurrent Candidemia in Children: Relapse or Re-Infec-tion. J. Clin. Med. 2019; 8: 99. doi:10.3390/jcm8010099\n4.\n Cle\nveland  A  A, Harrison  L  H, Farley M  M, Hollick  R, Stein B,\nChiller  T  M , Lockhart S  R, Park B  J. Declining incidence ofcandidemia and the shifting epidemiology of Candida resistancein two US metropolitan areas 2008\u20132013: Results from Pop-ulation-Based Surveillance. Microb. Pathog 2018; 117: 128-13.https://doi.org/10.1371/journal.pone.0120452\n5.\n Blot S I, V\nandewoude K H,  Hoste E A. Colardyn F A. Effects of\nnosocomial candidemia on outcomes of critically ill patients. A.M.J. Med. 2002; 113: 480-485. doi: 10.1016/s0002-9343(02)01248-2\nTable 8. Minimum \nFungicidal Concen-\ntrations (MFC) for C.  \nglabrata.Role of Candida glabrata  as nosocomial pathogen and its susceptibility to Fluconazole, Voriconazole, Caspofungin, Micafungin and Amphotericin B2008\n6.Ruan  S  Y , Hsueh  P R. Invasive candidiasis: an overview from\nTaiwan. J. Formos. Med. Assoc.2009; 108: 443-451. doi: 10.1016/\nS0929-6646(09)60091-7\n7.Chih-Cheng  L, W\nang  C  Y, Wei-Lun Liu W  L, Huang, Y  T, Hsueh\nP  R. Time to positivity of blood cultures of different Candida spe-cies causing fungaemia. J. Med. Microbiol. 2012; 61: 701-704. DOI 10.1099/jmm.0.038166-0\n8.\n Mohandas \nV, Ballal  M. Proteinase and phospholipase activity as vir-\nulence factors in Candida species isolated from blood. Rev Iberoam Micol 2008; 25: 208-10. doi: 10.1016/s1130-1406(08)70050-0\n9.\n Zaoutis T E, Argon J\n, Chu J, Berlin J A, Waish,  T J,  Feudtner C. The\nepidemiology and attributable outcomes of candidemia in adultsand children, hospitalized in the United States: a propensity analy-sis. Clin. Infect. Dis. 2005; 41 (9): 1232-1239. doi: 10.1086/496922\n10.\n Labelle A  J\n, Micek  S T,  Roubinian  N, Koilef M  H . Treatment-re-\nlated risk factors for hospital mortality in Candida bloodstreaminfections. Crit.Care Med. 2008; 36 (11): 2967-2972. DOI: 10.1097/CCM.0b013e31818b3477\n11.\n Cos\nta  C  R, Passos  X  S, Hasimoto  L K,  Lucena F  O,  Silva M.\nDifferences in exoenzyme P. production and adherence ability ofCandida spp. isolates from catheter, blood and oral cavity. Rev.Inst. Med. Trop. Sao Paulo 2010; 52 (3): 139-143. http://dx.doi.org/10.1590/S0036-46652010000300005\n12.\n Sule\nyman G, Alangaden G J. Nosocomial fungal infections: epide-\nmiology, infection control, and prevention. Infect. Dis. Clin. NorthAm. 2016; 30: 1023-1052. doi: 10.1016/j.idc.2010.11.003\n13.\n R\nodrigues C F, Silva S, Henriques M.  Candida glabrata: A review\nof its features and resistance. Eur. J. Clin. Microbiol. Infect. Dis.2014; 33: 673\u2013688. doi: 10.1007/s10096-013-2009-3\n14.\n Garcia-Cues\nta C, Sarrion-Perez  M G,  Bagan J V. Current treat-\nment of oral candidiasis: A literature review. J. Clin. Exp. Dent.2014; 6: 576\u2013582. doi:10.4317/jced.51798\n15.\n Colle  J  G\n, Fraser A  G, Marmion  B  P, Simmons  A. Pactical med-\nical microbiology.14th ed. Curchill living stone 1996; USA.\n16.\n Emmons  C W\n, Binford C H, Uts J P, Kwonchung, K J. Medical\nMycology.  1977; 3rd Ed. Lea and Febiger. Philadelphia.\n17.\n Willinger  B, Hillo\nwoth  C,  Selitsch B,  Manafi  M. Performance of Can-\ndida ID, a new chromogenic medium for presumptive identification of Candida species, in comparison to CHROMagar Candida, J. Clin. Micro-biol 2001; 39: 3793-3795. DOI: 10.1128/JCM.39.10.3793\u20133795.2001\n18.\n Murr\nay  P R. Manual of Clinical Microbiolog. 9th Ed. American So-\nciety for Microbiology 2007; Washington, D.C.\n19.\n Janaina  C O\n,  Duque C, Fl\u00e1via  S, Iza  T  A, Jos\u00e9  F, Reginaldo\nB. Candida spp. in periodontal disease: a brief review. J. Oral Sci. 2010; 52 (2): 177-185. doi: 10.2334/josnusd.52.177\n20.\n Deepa  K, Jee\nvitha  T, Michael  A. In vitro evaluation of virulence fac-\ntors of Candida species isolated from oral cavity. J. Microbiol. An-timicrob 2015; 7(3):28-32. https://doi.org/10.5897/JMA2015.0337\n21.\n Mohandas \nV, and Ballal M, . Proteinase and phospholipase activity \nas virulence factors in Candida species isolated from blood. RevIberoam Micol., 2008;  25: 208-10.\n22.\n Ak\nca\u011flar  S, Ener  B, Tore  O. Acid proteinase enzyme activity in Can-\ndida albicans strains: a comparison of spectrophotometry and plate methods. Turk. J. Biol. 2001; 67-559:35. doi:10.3906/biy-1002-39\n23.\n Y\neni\u015fehirli G,   Bulut  Y, Tun\u00e7oglu  E, . Phospholipase proteinase\nand hemolytic activities of Candida albicans isolates obtainedfrom clinical specimens. Mikrobiyol Bul. 2010; 44: 71-7.\n24.\n G\u00fcl\ntekin  B, Eyig\u00f6r M, Tiryaki Y, K\u0131rdar S, Ayd\u0131n N, . Investigation of \nantifungal susceptibilities and some virulence factors of Candida strains isolated from blood cultures and genotyping by RAPD-PCR. Mikrobiyol Bul. 2011; 45: 306-17.\n25.\n Melek  I, Mus\ntafa  A A,  Ayse  N K,  Erkan Y, Omar  E, Suleiman D,  \nGonca D. Investigating virulence factors of clinical Candida iso-lates in relation to atmospheric conditions and genotype. Turk .J. Med. Sci. 2012; 42(2):1476-1483. doi:10.3906/sag-1204-119\n26.\n Na\nveen  S, Deepak  M,  Divya D,  Savita S. Evaluation of congo red \nagar for detection of biofilm production by various clinical Can-dida isolates. J. of Evolution of Med. and Dent. Sci 2014; 3 (59):2278-4748. DOI: 10.14260/jemds/2014/376127.\n  Andre w  M  B, Fraser M, Michael D  P, Szekely A, Houldsworth  M, \nPatterson  Z, Elizabeth M  J. MIC Distributions and Evaluation ofFungicidal Activity for Amphotericin B, Itraconazole, Voriconazole, Posaconazole and Caspofungin and 20 Species of Pathogenic Fil-amentous Fungi Determine Using the CLSI Broth MicrodilutionMethod. J. Fungi 2017; 3: 27. doi: 10.3390/jof3020027\n28.\n R\nex  J  H, Pfaller M A, Walsh  T J, Chaturvedi  V, Espinel-Ingroff\nA  et al. Antifungal susceptibility testing: Practical aspects andcurrent challenges. Clin. Microbiol. Rev. 2001; 14: 643-658. DOI:10.1128/CMR.14.4.643\u2013658.2001\n29.\n Ghelardi E,  Pichierri  G\n, Castagna  B,  Barnini S, Tavanti  A, Campa  \nM. Efficacy of Chromogenic Candida Agar for isolation and pre-sumptive identification of pathogenic yeast species. Clin Microbiol Infect. 2007; 1469-0691. doi: 10.1111/j.1469-0691.2007.01872.x\n30.\n Wisplinghoff H,  Bischoff  T\n, Tallent S  M,  Seifert H,  Wenzel  R  P,\nEdmond  M B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 2004; 39: 309-317. doi: 10.1086/421946\n31.\n Mot\nta-Silva A  C, Aleva  N  A, Chavasco,  J  K, Armond M  C, Fran\u00e7a  J  P,\nPereira L  J . Erythematous Oral Candidiasis in Patients with Controlled Type II Diabetes Mellitus and Complete Dentures, Mycopathologia.2010; 169: 215-223. https://doi.org/10.1007/s11046-009-9240-6\n32.\n Chakr\nabarti  A, Shivaprakash  M,  Ghosh A. Standard Operating\nprocedures, Mycology Laboratories. Indian Council of Medical Re-search 2016; 5-47.\n33.\n Baillie G  S, Douglas L  J\n.  Candida biofilm and their susceptibility \nto antifungal agents. Methods Enzymol 1999; 310: 644-56. doi:10.1016/s0076-6879(99)10050-8\n34.\n Sil\nva  J  O F  S,  Lavrador M A,  Candido  R C. Performance of selec-\ntive and differential media in the primary isolation of yeasts from different biological samples.Mycopathologia. 2004; 151(1):29-36. https://doi.org/10.1023/B:MYCO.0000012223.38967.7d\n35.\n Sachin C D\n, Ruchi K, Santosh  S. In vitro evaluation of proteinase, \nphospholipase and haemolysin activities of Candida species iso-lated from clinical specimens. Int. J. Med. Bio Res. 2012; 1(2):153-157. DOI: 10.14194/ijmbr.1211\n36.\n Sathiy\na T,  Arul Sheeba  M S, Moorthy  K,  Punitha T,  Vinodhini  R, \nSaranya, A S. Candida albicans non-albicans species: Astudy ofbiofilm production and putative virulence properties. J. Harmo.Res. Pham. 2015;  4(1): 64-75. DOI: 10.1007/s11046-013-9638-z\n37.\n Khan  S M A, Malik A, Ahmad I. Anti-candidal activit\ny of essential \noils alone and in combination with amphotericin B or Fluconazole against multi-drug resistant isolates of Candida albicans. MedMycol 2012; 50: 33 - 42. doi: 10.3109/13693786.2011.582890\n38.\n Espinel-Ingroff A,  Chatur\nvedi  V, Fothergill A, Rinaldi  M G. Opti-\nmal testing conditions for determining MICs and minimum fungi-cidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study. J. Clinic Microbiol 2002; 40: 3776 - 3781. DOI: 10.1128/JCM.40.10.3776\u20133781.2002\n39.\n Mohamadi  J\n, Motaghi  M,  Panahi J,  Havasian  M R,  Delpisheh\nA, Azizian M, Pakzad I. Anti-fungal resistance in candida isolatedfrom oral and diaper rash candidiasis in neonates. Bioinformation 2014; 10:667-70. DOI: 10.6026/97320630010667\n40.\n Hafidh \n  R  R, Abdulamir   A  S, Vern  L S, Bakar F A,  Abas  F, Jah-\nanshiri F, Sekawi   Z. Inhibition of growth of highly resistant bacte-rial and fungal pathogens by a natural product. Open Microbiol. J. 2011; 5: 96 -106. doi: 10.2174/1874285801105010096\n41.\n Monk B C\n, Goffeau A. Outwitting multidrug resistance to antifun-\ngals. Science 2008; 321: 367 - 369. DOI: 10.1126/science.1159746\n42.\n Luksamijarulkul P\n, Aiempradit N, Vatanasomboon P. Microbial con-\ntamination on used surgical masks among hospital personnel andmicrobial air quality in their working wards: A hospital in Bangkok.Oman Med J 2014; 29(5):346-350. DOI: 10.5001/omj.2014.92\n43.\n Mohammad T\n, Risan M, El-Hiti G, Ahmed D, Yousif E. Success-\nful in-vivo treatment of mice infected with Candida glabrata us-ing silver nanoparticles. Bionatura 2020, 5(4), 1340\u20131345. DOI.10.21931/RB/2020.05.04.10\nReceived: 4 April 2021\nAccepted: 25 June 2021Teeba Hashim Mohammed, Mohsen Hashim Risan, Mohammed Kadhom, Emad Yousif\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2009\nConjugation strategies on functionalized iron oxide nanoparticles as a malaria vaccine delivery system\nConjugation strategies on functionalized iron oxide nanoparticles as a malaria \nvaccine delivery system\nAswan Al-Abboodi1, Hussain A. Mhouse Alsaady1, Shaima R. Banoon1, Mohammed Al-Saady2 DOI. 10.21931/RB/2021.06.03.20\nAbstract: Vaccination has been used effectively to protect from infectious diseases and non-infectious diseases such as cancer \nand allergies. Different forms of particulate arrangements, including nanoparticles, virus-like particles (VLPs), and virosomes, \nhave been built recently depending on the type of pathogen to be targeted. The ability to conjugate the recombinant Plasmodium yoelii, 19-kDa C-terminal fragment of merozoite surface protein 1 (PyMSP1\n19) on the surface of superparamagnetic magnetite \nnanoparticles (SPIONs) was explored as a new technique of enhancing vaccination against malaria. Different conjugation strategies were performed to correlate the effects of nanoparticle chemistry surfaces to bind later with the malaria protein. (SPIONs) were prepared by chemical coprecipitation method and coated with 3-aminopropyltriethoxysilane (APTS) alone (as a surface coater), or with both APTS and polyethylene glycol (PEG) (as a shield to protect the malaria protein from proteolytic enzymes) by using a modified silanisation method.X-ray powder diffraction (XRD, Philips Model) patterns indicated that the SPIONs were of high purity with an inverse spinalstructure. Fourier Transform Infrared Spectroscopy (FTIR) was collected using PerkinElmer Spectrum 100 Series; spectra ofuncoated and coated magnetite nanoparticles confirmed that the silane layer had been coated on the surface Fe\n3O4. The SPIONs \nwere superparamagnetic as investigated by Vibrating Sample Magnetometry (VSM, Princeton Applied Research, model ISS) and relatively stable in aqueous phase at room temperature and could also be quickly recovered from suspension using an externalmagnet. Introduce the carboxyl groups onto the SPIONs surfaces, resulting in a relatively high protein binding capacity onto thenanoparticle surfaces.The bare particles had a mean size of around 20 nm with a relatively narrow size distribution. 82% of African Green Monkeyfibroblast (COS-7) were alive in nanoparticle suspension using the MTT assay method. The quantity of protein explicitly bound to particles was determined using Sodium Dodecyl Sulfate (SDS) - Polyacrylamide Gel Electrophoresis (PAGE). SDS\u2013PAGE. Whenthe conjugation blend was prepared in EDC, there was approximately 100% binding between PyMSP1\n19 and the Fe3O4-COOH\npar\nticles because no protein band was apparent at the expected molecular weight for PyMSP119 (45 kDa).\nThe current study investigates the theory that the gradual, persistent release of the malaria antigen may stimulate and maintain an elevated level of immune response for an extended period in vivo, which will be the scope of future work.\nKey words: Malaria vaccine, Superparamagnetic nanoparticles, protein functionalization.RESEARCH / INVESTIGACI\u00d3N\nIntroduction\nIron oxide nanoparticles such as magnetite Fe3O4 or ma-\nghemite \u03b3- Fe2O3 are promising materials for applications in \nbiomedicine and bioengineering areas1-3,30 These nanoparticles \nhave attracted great interest due to their unique properties4, 31 \nsuch as narrow size distribution, biocompatibility, non-toxicity, \nand ability to be detected and manipulated with an external magnetic field. Both are generally appropriate and safe for in vivo biomedical applications\n4. However, the utilization of these \nnanoparticles is still subject to many limitations, including sur-faces containing hydroxyl groups that cannot bond covalent-ly with biomolecules. Therefore, examining the best method to conjugate high protein binding capacity is an urgent issue because the most excellent technique for increasing vaccine efficiency still needs investigation since many diseases are still without effective vaccines, such as malaria disease.\nThe Coprecipitation technique is the most common me-\nthod to prepare iron oxide nanoparticles. Both sodium hydroxi-de (NaOH) and ammonium hydroxide (NH\n4OH) have been used \nto detect whether the basicity manipulates the crystallization process during particle formation\n8,32. Various surface modifi-\ncation techniques have been used to enhance nanoparticles' diagnosis and therapeutics potential in biomedicine applica-tions\n6. Successful conjugation of biomolecules to the surface \nof magnetic particles is critical to their applicability5. Therefo-re, a versatile method of surface functionalization of SPIONs is often required, which sensitively balances the intermolecular forces concerning biomolecules such as proteins and antibo-dies attached to the particles' outer layer. However, conjuga-tion of a desired functional group at the right orientation on the nanoparticle surface remains a significant challenge\n7,33,44. \nThe method of surface modification of iron oxide by using or-ganosilane reagent [amino-silane reagent (3-aminopropyltrie-thoxysilane, APTS)] is relatively robust, with many parameters such as silane concentration, temperature, time, and solvent type that can be optimized to create diffused functionalized magnetic particles for consequent tagging with biomolecules\n6.\nSome vaccines are still challenged and need effective \nstrategies to obtain good control for malaria vaccines. Pro-tein vaccine is one strategy that can generate both humoral and cellular immune responses, primarily when it supports by promoter injections\n12,34. Magnetofection is a suitable device for \nprotein delivery, gene therapy, and gene expression14,42,43; the-\nrefore, magnetic nanoparticles have been chosen for this study to prove its achievability as a proposed protein delivery carrier of malaria vaccine to use it later as a vaccine carrier for other some parasitic diseases that their vaccines are underdevelo-ped until now.  Substantial development in the malaria vaccine field has been presented in the current study; the key to this \n1 Department of Biology, College of Science, University of Misan, Misan, Iraq.  \n2 Department of Mechanical and Aerospace Engineering, Monash University, Clayton, Australia.\nCorresponding author: aswan.abboodi@uomisan.edu.iq2010\nAswan Al-Abboodi, Hussain A. Mhouse Alsaady, Shaima R. Banoon, Mohammed Al-Saady\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nsuccess is iron oxide nanoparticles' use to deliver malaria pro-\ntein (antigen) in an effectual technique to where it matters.\nMaterials \nAnalytical grade reagents for magnetite nanoparticles \nsynthesis included Fe (\u0399\u0399\u0399) chloride hexahydrate (FeCl3.6H2O \n>99%) from Ajax Finechem (NSW Australia), Fe (\u0399\u0399) sulfate(FeCl\n2.7H2O >99%) from Ajax Chemical (Sydney, Australia), so-\ndium hydroxide (NaOH), and trisodium citrate dihydrate (C6H-\n5Na3O7.2H2O) from Sigma Aldrich (Sydney, Australia). All ma-\nterials including 3-aminopropyltriethoxysilane (APTS, 95%),Polyethyleneglycol (PEG), absolute ethanol (C\n2H5OH, 99.5%)\nglutar\naldehyde (10%), succinic anhydride, phosphate buffered\nsaline (PBS, 0.01M, pH 7.4), and the conjugating agents N-hy-droxysulfosuccinimide (NHS), 1-ethyl-3-(3-dimethylaminopro-pyl) carbodiimide (EDC), N, N-dimethylformamide (DMF) weresupplied by Sigma Aldrich (Sydney, Australia). African greenmonkey kidney cells (COS-7 cell lines) were kindly providedby staff at Prof. Ross Coppel's laboratory (Department of Mi-crobiology, Monash University, Australia), Dimethylsulfoxude(DMSO), 3-(4,5-87-90% dimethyl-2-thiazol-2-yl-2, 5-diphen-yltetra-zolium bromide (MTT), penicillin/ streptomycin, foetalcalf serum and other related reagent grade chemicals wereacquired from Invtrogen (Carlsbad, California, USA) and usedto measure the toxicity of the as-synthesised nanoparticles.\nMethods\nSynthesis and coating of Magnetite nanoparticles\nMagnetite nanoparticles were prepared using the proce-\ndure reported in (8), in which a chemical coprecipitation me-thod was used with some modification. Trisodium citrate was used as an electrostatic stabilizer to create an electrostatic double layer and reduced the extent of agglomeration\n12,13,41. In \na typical experiment, ferric chloride (0.005 mol) and ferrous chloride (0.0025 mol) (molar ratio 2:1) were dissolved in deio-nized water (50 ml). To raise the pH value, sodium hydroxide solution (20 ml, 1.5 M, including 0.005 mol trisodium citrate) was added to a 100 ml three-necked flask. The precipitation was done by drop-by-drop addition of iron salts solution to the mixture of NaOH and trisodium citrate under vigorous stirring (homogenization string rate was 1500 rpm) for 1h at 80 \u00ba C in a nitrogen (N\n2) atmosphere. The color of the bulk solution \nimmediately turned from orange to black. The nanoparticles were then split from the solution by a permanent magnet and cleaned several times with ethanol and distilled water before re-suspended in water.\nAPTS is an amino-functional silane-coupling agent used \nto immobilize physiologically active molecules. The hydroxyl groups on the magnetite surface can be easily coupled with silanes by forming covalent bonds through condensation reac-tion to give a siloxane linkage, as Scheme 1 shows. In this work, ethanol was used to change the medium from water. 0.43g of Fe\n3O4 nanoparticles were dispersed in 9.7ml ethanol by sonica-\ntion for 10 min. 0.3ml of 3-aminopropyltriethoxysilane (APTS) was added, and the resulting solution was transferred into a round-bottomed flask to carry out the silanisation reaction at 25 \u00baC under N\n2 atmosphere overnight in a Schlenk system. The \nFe3O4 \u2013 APTS magnetic nanoparticles were recovered from the \nreaction mixture using a permanent magnet. The supernatant was removed, and the precipitates were washed several times with ethanol and then with water. The high molecular weight of PEG polymer was mixed with silane to possibly improve the biocompatibility and dispersibility of Fe\n3O4 nanoparticles15,16.\nSPIONs Characterisations\nPowder X-Ray diffraction (XRD)\nX-ray powder diffraction (XRD) measurements were used\nto identify the crystalline phase of the particles before and af-\nter coating. XRD was performed on a Philips PW 1140/90 di-ffractometer using monochromatized x-ray beams from CuK\u03b1, \u03bb = 1.54 \u01fa radiation at a scan rate of 1\u00b0 min\n-1 from 5\u00b0 to 60\u00b0 \nwith a step size of 0.02\u00b0. The scanning voltage was 50KV, and the scanning current was 20 mA.\nVibrating Sample Magnetometry (VSM)\nThe particular values for the inundation magnetization \nmeasurements were directly acquired on a predetermined \nweight of SPIONs before and after coating using Vibrating Sample Magnetometry (VSM, Princeton Applied Research, model ISS) working at room temperature. A recognized weight of the samples was placed into the VSM sample holder. A top magnetic field of approximately 15KOe was used. The satura-tion magnetization values were standardized to the mass of samples to yield specific magnetization, M\ns (emu g-1).\nFourier Transform Infrared Spectroscopy (FTIR)\nFTIR spectra of the nanoparticles were collected on an \nFTIR spectrophotometer using PerkinElmer Spectrum 100 Se-ries FT-IR spectrometer in a wave number varying from 4000 to 400 cm\n-1 with a resolution accuracy of 4 cm-1 under ambient \nconditions. Before compacting, all samples were dried at 70 \u00baC for 48h. A small amount of each sample dry powder was tho-roughly mixed and crushed with dried KBr using a mortar and pestle. The mixture was pressed into pellets using 8 tons/cm\n2 \nof pressure for 2 minutes to form discs for analysis.\nTransmission Electron Microscope (TEM)\nTEM was used to determine the size and morphology of \nthe nanoparticles. The nanoparticle suspension was diluted, \nand a few drops were put on a carbon-stabilized grid (200 meshes). The grids were left in the oven at 50\u00baC overnight. Sample grids were attached to the sample holder on a Hitachi H7500 TEM instrument at an accelerating voltage of 120 kV microscope. The mean diameter of the size distribution was determined by measuring more than 150 particles from TEM images using Image J\n9.\nMTT assay\nTo evaluate whether the particles could be used for bio-\nmedical applications, a non-radioactive colorimetric MTT as-say\n10 was performed to measure the cell cytotoxicity. African \nGreen Monkey Fibroblast (COS-7) cells were seeded on a 96-well microtiter plate at a concentration of 2* 10\n4 /well and \ncultured in a complete RPMI (C-RPMI) medium supplemented with 10% fetal calf serum (FCS). The plate was incubated at 37\u00baC and 5% CO\n2 overnight. Three different concentrations of \nbare and coated nanoparticles (0.1 mg/ml, 1 mg/ml and 10 mg/ml) were added for a further 24h incubation. The control well group was a culture medium with no particles. All sam-ples and the control were tested in triplicate, with the results conveyed as mean \u00b1 standard deviation shown as error bars in the MTT plots. 5\n\u03bc\nl of a solution of 5mg/ml MTT (3-(4,5- di-\nmethylthiazol-2-yl-2, 5-diphenyltetra-zolium bromide) dissol-2011\nved in PBS pH 7.4 was added to each well and incubated for \n4h at 37\u00baC in the 5% CO2 incubator. After incubation for 4h, \nthe medium was removed from the plate and rinsed with PBS. \nMTT is a yellow-colored, water-soluble, and tetrazolium salt. \nLiving cells can metabolize this salt in their mitochondria by \nactive mitochondrial reductase enzyme into a water-insoluble \nand dark blue ring, Formazan derivative. Dead cells can now \nreduce tetrazolium salt; thus, the conversion can be related to \nthe amount of Formazan crystals formed. Subsequently, ring \nFormazan crystals can be dispersed in an organic solvent such \nas dimethyl sulfur oxide (DMSO). Therefore, 100 \u03bcl of 5mg/ml \nof (DMSO) was added to each well in the plate to dissolve the \ncrystals, and the plate was incubated for 1h. The absorban-\nce of each well was read on a microplate reader (Magellan, \nTecan, Australia) at wavelengths of 570nm and 690nm. The \nnet absorbance was calculated by (A570-A690) (A refers to the \narea means absorbance). The relative cell viability (%) was cal-\nculated as ([Asample] / [Acontrol]*100%, with the resultant value \nrepresenting the number of living cells.\nSurface functionalization of Fe3O4 \u2013 APTS nanoparticles\nThe particles were modified to introduce aldehyde or car-boxylic functional groups. 20 ml of 10% glutaraldehyde was \nadded to the precipitate of silane-coated magnetic particles \n(Fe3O4 \u2013 APTS) prepared previously, and the reaction mixture \nwas left under gentle agitation for 3hrs at room temperature \n(25\u00baC) to introduce aldehyde functional groups. After 3hrs, the \nFe3O4 \u2013 CHO particles were steadied with a magnet and then \ncleaned several times with PBS via magnetic parting and then \nre-dispersed. To create the carboxyl functional groups, succi-\nnic anhydride was added to the Fe3O4 \u2013 APTS nanoparticles \n(1:20 wt/ wt) suspended in DMF. The mixture was agitated for \n3hrs under an N2 atmosphere. Subsequently, the Fe3O4 \u2013 COOH \nderivatized particles were washed two times with DMF fo-\nllowed by PBS. The washed particles were suspended in PBS \nand stored at 4\u00baC for further use.\nResults\nCharacterization of nanoparticles\nX-ray powder diffraction (XRD) was performed to cha-\nracterize the crystal phase of as-synthesized nanoparticles \nScheme 1.  Silane chemistry approa -\nches to functionalize Fe3O4 particles \nwith \u2212NH2, \u2212CHO, and \u2212COOH.Conjugation strategies on functionalized iron oxide nanoparticles as a malaria vaccine delivery system2012\n(Fig. 1). The different peaks of Fe3O4 marked by their indices: \n(220), (311), (400), (422), (511), and (440) at 2\u03b8 can be refe-\nrred to as the cubic structure of Fe3O4. Magnetic features of \nthe as-synthesized nanoparticles were investigated by VSM \nmeasurement at room temperature (Fig. 2). The bare Fe3O4 \ndisplayed relatively high magnetization (67 emu/g) at 15KOe. \nThe magnetization of silane-coated Fe3O4 \u2013 APTS nanoparti-\ncles was calculated to be 63.3 emu/g (Fig. 2b), slightly dimi-\nnished in comparison to bare Fe3O4 due to the non-magnetic \nsilane layer. In addition, Fe3O4 \u2013 APTS+PEG nanoparticles have \na magnetization of 58.9 emu/g, due to the thickness of the si-\nlane and PEG coating.\nTEM images of bare and silane-coated nanoparticles were \ntaken to investigate the particles' size, shape, and uniformity. \nThe bare particles had a mean size of around 20 nm with a \nrelatively good size distribution (Fig. 3a). Scanning electron \nmicrograph images for magnetic nanoparticles before and af-ter silanisation are shown in Fig. 3, confirming the size of bare \nFe3O4 of around 20nm. FTIR spectra of uncoated and coated \nmagnetite nanoparticles are shown in Fig. 4. The wide band \nof 3600 \u2013 3300 cm-1 paralleled the O-H stretching tremor of a \ntrace amount of water due to physisorbed water and surface \nhydroxyls. After silanisation, the characteristic bands of Si-O-C \nat 1086 and 1155 cm-1 appeared (Fig. 4b), confirming that sila-\nne layer had been coated on the surface of Fe3O4.\nIn vitro  cytotoxicity evaluation\nTo investigate the percentage of cell viability due to the \nintroduction to nanoparticles, the viabilities of African Green \nMonkey fibroblast (COS-7) cells in models with both bare and \ncoated magnetite were studied by the MTT assay method to \nevaluate whether these nanoparticles are suitable for biome-\ndical applications. This method measures the mitochondrial \ndehydrogenase activity of viable cells, with materials inducing \nFigure 1.  Indexed X-ray \ndiffractograms of (a) \nFe3O4, (b) Fe3O4 \u2013 APTS, \nand (c) Fe3O4 \u2013 APTS+PEG \nnanoparticles.\nFigure 2.  Magnetization curves of (a) Fe3O4, (b) Fe3O4 \u2013 APTS and (c) Fe3O4 \u2013 APTS+PEG nanoparticles.  (H) Applied magnetic \nfield (KOe); (M) Magnetization (emu/g).Aswan Al-Abboodi, Hussain A. Mhouse Alsaady, Shaima R. Banoon, Mohammed Al-Saady\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2013\n Figure 3. TEM images showing \nthe morphology of (a) Fe3O4; (b) \nFe3O4 \u2013 APTS, SEM images of (c) \nFe3O4; (d) Fe3O4 \u2013 APTS.\nFigure 4.  FTIR spectra of Fe3O4, Fe3O4 \u2013 APTS, and Fe3O4 \u2013 APTS+PEG.\ncell viability of more than 80%, often recognized as biocom-\npatible22. All the nanoparticles samples (three different con-\ncentrations for each sample) from a 24 h incubation led to a \ndecrease in the viability of COS-7 cell lines compared to the \ncontrol. As shown in Fig. 5, when the cells were incubated \nwith 0.1 mg/ml bare Fe3O4 solution, more than 82% of cells re-\nmained alive, whereas the cell viability decreased to 34% and \n12.5% with increasing concentrations to 1 mg/ml and 10 mg/\nml, respectively.Surface functionalization of Fe3O4 \u2013 APTS nanoparticles\nThe introduction of \u2013COOH and \u2013CHO groups on the mag-\nnetite surface was confirmed with FTIR spectroscopy (Fig. \n6). The spectrum of the functionalized SPIONs with \u2013COOH \nshowed the characteristic absorption peak at 1634 cm-1 co-\nrresponding to the symmetric COO- stretching. The characte-\nristic absorption peak \u2013C-O-C\u2013 at 2993.4 cm\u22121 was observed in \nthe spectrum of the \u2013COOH group activated on the silane-coa-\nted Fe3O4 nanoparticles.Conjugation strategies on functionalized iron oxide nanoparticles as a malaria vaccine delivery system2014\nDISCUSSION\nCharacterization of nanoparticles\nThe X-ray diffraction results showed in (Fig. 1) are in good \nagreement with the theoretical values (JCPDS  19-629) of the \nstandard XRD reference pattern of pure magnetite. A clean \nFe3O4 cubic spinel phase can be confirmed. Generally, the-\nre was no significant shift in the highest position due to the presence of amino silane. The broader peak that appeared at \nabout 23.4\u00ba in the coated particles Fe3O4 \u2013 APTS+PEG attri-\nbuted to the existence of an amorphous layer possibly due to \nthe presence of polymer. The magnetic properties presented \nin (Fig. 2), in all cases, the magnetization plots exhibited zero \nremanence and coercivity with no hysteresis loop, indicating \nthat these nanoparticles were superparamagnetic17,18,35, due to \ntheir sizes rendering single magnetic domains19. The TEM ima-\nges illustrated in (Fig 3) revealed a thin silane layer favorable \nFigure 5.  MTT assay of Fe3O4, Fe3O4 \u2013 APTS, and Fe3O4 \u2013 APTS+PEG.\nFigure 6.  FTIR spectra of functionalized Fe3O4 \u2013 COOH and Fe3O4 \u2013 CHO nanoparticles.Aswan Al-Abboodi, Hussain A. Mhouse Alsaady, Shaima R. Banoon, Mohammed Al-Saady\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2015\nto keep the high magnetization and stability, while it was also \nconvenient for modification on the nanoparticles surface29. In \nthe three presented samples in (Fig. 4), the presence of Fe3O4 \ncore could be seen by the strong assimilation bond 579 cm-1, corresponding to the Fe-O bond of Fe\n3O420,21,36. The strong \nC-O-C, CH2, and \u2013CH peaks indicated that PEG was bonded tothe surface through a reaction of PEG-silane with \u2013OH groupon the nanoparticle's surface\n11.\nIn vitro  cytotoxicity evaluation\nFig. 5 showed the results of the MTT assay. This result \nproved the biocompatibility of the synthesized magnetite na-noparticles at minimal concentrations (<0.1 mg/ml), compa-rable to the standard dosage for particulate vaccine typically measured in micrograms\n23. The toxicity of SPIONs may corre-\nlate to the capability of these nanoparticles to damage DNA via magnetite oxidation. Karlsson et al.\n24 indicated that magnetite \nnanoparticles could cause a minimal amount of toxicity (exa-mined with a comet assay) due to the effectiveness in causing oxidative DNA lesions in cultured A549 cells (the human lung epithelial cell line). A small adverse effect on cell viability at low concentrations suggested that citrate groups on the surfa-ce of Fe\n3O4 play an essential role in providing some protection \nagainst cell toxicity and reducing the toxic effect of magnetic solution\n25,26,37. The coated SPIONs with silane alone and silane \nwith PEG showed slightly reduced toxic effects at the highest concentrations. This may be due to the different properties and surface reactivity of their surfaces. The toxicity of silane has been well-reviewed by Iler et al.\n27. Addition of \u2013NH2 groups \n(Fig. 6) denote less accessible sites for biomolecules to attach in comparison to the uncoated SPIONs.  The reduced toxicity of the Fe\n3O4 \u2013 APTS+PEG nanoparticles may be attributed to \nthe high solubility of PEG in the cell membranes28,38. However, \nthere were still toxic effects on the soluble factors present in these nanoparticles, including detergents and monomers from the preparation procedure or the breakdown of products du-ring incubation.\nSurface functionalization of Fe\n3O4 \u2013 APTS nanoparticles\nThe peaks that appeared in (Fig.6) provide evidence that \n\u2013COOH groups were attached to the surface through a re-\naction of \u2013NH2 and succinic anhydride at a transmittance of119%\n29,39,40. As the amine-terminated surface was converted to \nthe aldehyde group, the characteristic band for HC=O vibration appeared at 1711 cm\n-1 and CH2-CHO at 1414 cm-1, and CHO at\n137\n4 cm-1 indicating that the aldehyde group had been intro-\nduced to the SPION surfaces. The findings illustrated in (Fig. 6) indicated that the size of Fe\n3O4 \u2013 APTS+PEG was the largest,\npossibly either due to the high molecular weight of the poly-mer or due to the agglomerate of these particles.\nConclusions\nMultifunctional magnetite nanoparticles have been suc-\ncessfully prepared by a co- precipitation method. By surface modification with APTS and subsequent functionalization with glutaraldehyde and succinic anhydride, these nanoparticles should have a high active binding to PyMSP1\n19 malaria protein \nmolecules (which is currently under study). XRD patterns indi-cated the high purity of the synthesized SPIONs, FTIR spectra confirmed that silane layer had been coated on the surface of Fe\n3O4. The SPIONs were superparamagnetic and were stable in \naqueous phase at room temperature. VSM displayed relatively high magnetization (67 emu/g) at 15Koe of the iron oxide na-noparticles. TEM images of bare and silane-coated nanoparti-cles were taken to investigate the size, shape and uniformity of the particles. The bare particles had a mean size of around 20 nm with relatively slim size distribution which also confirmed by Scanning Electron Micrograph (SEM). The fabricated nano-particles were non-toxic which indicated by MTT assay. The particles can potentially be used as a platform to conjugate with other proteins including those targeting specific parasi-tes. With the advantage of narrow size properties, relatively low toxicity, and ease of coupling with other biomolecules, we envision that these nanoparticles could be used as particulate vaccine in biomedical application.\nBibliographic references\n1. Hala vaara J, Tervahartiala P, Isoniemi H, H\u00f6ckerstedt K. Efficacy\nof sequential use of superparamagnetic iron oxide and gadolini-\num in liver MR imaging. Acta radiologica. 2002 Mar;43(2):180-5.\n2.Liber\nti PA, Rao CG, Terstappen LW. Optimization of ferrofluids\nand protocols for the enrichment of breast tumor cells in blood.Journal of magnetism and magnetic materials. 2001 1 Janu-ary;225(1-2):301-7.\n3.\n L\u00fcbbe A\nS, Alexiou C, Bergemann C. Clinical applications of magnetic\ndrug targeting. Journal of Surgical Research. 2001 Feb 1;95(2):200-6.\n4.\n Dormann JL, Fior\nani D, Tronc E. Advances in chemical physics. Vol.\nXCVII, Eds. I. Prigogine y Stuart A. Rice, John Wiley and Sons. 1997.\n5.T\nartaj P, Morales MP, Gonzalez-Carreno T, Veintemillas-Verdagu-\ner S, Serna CJ. Advances in magnetic nanoparticles for biotech-nology applications. Journal of Magnetism and Magnetic Materi-als. 2005 Apr 1;290:28-34.\n6.\n Li D\n, Teoh WY, Gooding JJ, Selomulya C, Amal R. Functionalization \nstrategies for protease immobilization on magnetic nanoparticles.Advanced Functional Materials. 2010 9 June;20(11):1767-77.\n7.\nCannon WR, Danfor\nth SC, Flint JH, Haggerty JS, Marra RA. Sin-\nterable Ceramic Powders from Laser-Driven Reactions: I, Process Description and Modeling. Journal of the American Ceramic Soci-ety. 1982 Jul;65(7):324-30.\n8.\n He R, Y\nou X, Shao J, Gao F, Pan B, Cui D. Core/shell fluorescent\nmagnetic silica-coated composite nanoparticles for bioconjuga-tion. Nanotechnology. 2007 6 July;18(31):315601.\n9.\nR\nasband WS. US National Institute of Health. http://rsb. info. nih.\ngov/ij. 2006.\n10.\n \n11.\n Gupta AK, W\nells S. Surface-modified superparamagnetic\nnanoparticles for drug delivery: preparation, characterization, and cytotoxicity studies. IEEE transactions on nanobioscience. 2004Mar 15;3(1):66-73.\n12.\n Liu X, Ma Z, Xing J\n, Liu H. Preparation and characterization of ami-\nno\u2013silane modified superparamagnetic silica nanospheres. Journal of Magnetism and magnetic Materials. 2004 Mar 1;270(1-2):1-6.\n13.\n Liu \nX, Xing J, Guan Y, Shan G, Liu H. Synthesis of amino-silane\nmodified superparamagnetic silica supports and their use forprotein immobilization. Colloids and Surfaces A: Physicochemical and Engineering Aspects. 2004 4 May;238(1-3):127-31.\n14.\n Sun J\n, Zhou S, Hou P, Yang Y, Weng J, Li X, Li M. Synthesis and\ncharacterization of biocompatible Fe3O4 nanoparticles. Journalof biomedical materials research Part A. 2007 Feb;80(2):333-41.\n15.\n Zaitse\nv VS, Filimonov DS, Presnyakov IA, Gambino RJ, Chu B.\nPhysical and chemical properties of magnetite and magne-tite-polymer nanoparticles and their colloidal dispersions. Jour-nal of Colloid and Interface Science. 1999 Apr 1;212(1):49-57.\n16.\n Harris L\nA, Goff JD, Carmichael AY, Riffle JS, Harburn JJ, St.\nPierre TG, Saunders M. Magnetite nanoparticle dispersions sta-bilized with triblock copolymers. Chemistry of Materials. 2003 25 March;15(6):1367-77.\n17.\n Sar\navanan P, Alam S, Mathur GN. Comparative study on the syn-\nthesis of \u03b3-Fe 2 O 3 and Fe 3 O 4 nanocrystals using high-tem-perature solution-phase technique. Journal of materials scienceletters. 2003 Sep;22(18):1283-5.Conjugation strategies on functionalized iron oxide nanoparticles as a malaria vaccine delivery system2016\n18. Kim DK, Zhang Y , Voit W, Rao KV, Muhammed M. Synthesis and\ncharacterization of surfactant-coated superparamagnetic mon-\nodispersed iron oxide nanoparticles. Journal of magnetism andMagnetic Materials. 2001 1 January;225(1-2):30-6.\n19.\n Montagne F\n, Mondain-Monval O, Pichot C, Mozzanega H, Ela\u0131ssari \nA. Preparation and characterization of narrow sized (o/w) mag-netic emulsion. Journal of magnetism and magnetic materials.2002 Sep 1;250:302-12.\n20.\n Cornell RM, Schw\nertmann U. The iron oxides: structure, proper-\nties, reactions, occurrences and uses. John Wiley & Sons; 200317 October.\n21.\n Y\namaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of\npoly (ethylene glycol) with different molecular weights after in-travenous administration to mice. Journal of pharmaceutical sci-ences. 1994 1 April;83(4):601-6.\n22.\n W\neissleder R, Bogdanov A, Neuwelt EA, Papisov M. Long-circulat-\ning iron oxides for MR imaging. Advanced Drug Delivery Reviews. 1995 Sep 1;16(2-3):321-34.\n23.\n K\narlsson HL, Cronholm P, Gustafsson J, Moller L. Copper oxide\nnanoparticles are highly toxic: a comparison between metal oxide nanoparticles and carbon nanotubes. Chemical research in toxi-cology. 2008 Sep 15;21(9):1726-32.\n24.\n Laca\nva ZG, Azevedo RB, Martins EV, Lacava LM, Freitas ML, Garcia \nVA, Rebula CA, Lemos AP, Sousa MH, Tourinho FA, Da Silva MF.Biological effects of magnetic fluids: toxicity studies. Journal ofmagnetism and magnetic materials. 1999 Jul 1;201(1-3):431-4.\n25.\n H\u00e4feli \nUO, Pauer GJ. In vitro and in vivo toxicity of magnetic mi-\ncrospheres. Journal of magnetism and magnetic materials. 1999 Apr 1;194(1-3):76-82.\n26.\n Iler KR. The chemis\ntry of silica. Solubility, polymerization, colloid\nand surface properties and biochemistry of silica. Wiley, NewYork.1979: 89.\n27.\n Jarrell BE, Williams SK, S\ntokes G, Hubbard FA, Carabasi RA,\nKoolpe E, Greener D, Pratt K, Moritz MJ, Radomski J. Use offreshly isolated capillary endothelial cells for the immediate es-tablishment of a monolayer on a vascular graft at surgery. Sur-gery. 1986 1 August;100(2):392-9.\n28.\n Liu C\n, Wu X, Klemmer T, Shukla N, Weller D, Roy AG, Tanase\nM, Laughlin D. Reduction of sintering during annealing of FePtnanoparticles coated with iron oxide. Chemistry of materials.2005 8 February;17(3):620-5.\n29.\n F\neng B, Hong RY, Wang LS, Guo L, Li HZ, Ding J, Zheng Y, Wei DG. \nSynthesis of Fe3O4/APTES/PEG diacid functionalized magneticnanoparticles for MR imaging. Colloids and Surfaces A: Physico-chemical and Engineering Aspects. 2008 Oct 1;328(1-3):52-9.\n30.\n Ajinky\na N, Yu X, Kaithal P, Luo H, Somani P, Ramakrishna S. Mag-\nnetic Iron Oxide Nanoparticle (IONP) Synthesis to Applications:Present and Future. Materials. 2020 Jan;13(20):4644.\n31.\n Cheah P\n, Cowan T, Zhang R, Fatemi-Ardekani A, Liu Y, Zheng\nJ, Han F, Li Y, Cao D, Zhao Y. Continuous growth phenomenonfor direct synthesis of monodisperse water-soluble iron oxidenanoparticles with extraordinarily high relaxivity. Nanoscale.2020;12(16):9272-83.\n32.\n V\nel\u00e1zquez-Herrera FD, Fetter G. Hydrotalcites with heteroge-\nneous anion distributions: a first approach to producing newmaterials to be used as vehicles for the successive delivery ofcompounds. Clay Minerals. 2020 Mar;55(1):31-9.\n33.\n Y\nong KW, Yuen D, Chen MZ, Porter CJ, Johnston AP. Pointing\nin the right direction: controlling the orientation of proteins onnanoparticles improves targeting efficiency. Nano letters. 2019Feb 18;19(3):1827-31.34.\n  Li X, Y ang Y, Yang F, Wang F, Li H, Tian H, Wang G. Chitosan hydro-\ngel loaded with recombinant protein containing epitope C fromHSP90 of Candida albicans induces protective immune respons-es against systemic candidiasis. International Journal of Biologi-cal Macromolecules. 2021 Mar 15;173:327-40.\n35.\n Nkurikiyimfur\na I, Wang Y, Safari B, Nshingabigwi E. Tempera-\nture-dependent magnetic properties of magnetite nanoparticlessynthesized via coprecipitation method. Journal of Alloys andCompounds. 2020 15 December;846:156344.\n36.\n Mos\ntafaei M, Hosseini SN, Khatami M, Javidanbardan A, Sepahy\nAA, Asadi E. Isolation of recombinant Hepatitis B surface antigen with antibody-conjugated superparamagnetic Fe3O4/SiO2 core-shell nanoparticles. Protein expression and purification. 2018 1May;145:1-6.\n37.\n Y\new YP, Shameli K, Miyake M, Khairudin NB, Mohamad SE, Naiki\nT, Lee KX. Green biosynthesis of superparamagnetic magnetiteFe3O4 nanoparticles and biomedical applications in targetedanticancer drug delivery system: A review. Arabian Journal ofChemistry. 2020 1 January;13(1):2287-308.\n38.\n Sharma A, Jy\noti K, Bansal V, Jain UK, Bhushan B, Madan J.\nSoluble telmisartan bearing poly (ethylene glycol) conjugatedchitosan nanoparticles augmented drug delivery, cytotoxicity,apoptosis and cellular uptake in human cervical cancer cells. Ma-terials Science and Engineering: C. 2017 1 March;72:69-76.\n39.\n Shagholani H, Ghoreishi SM, Sharifi SH. Conversion of aminegroups \non chitosan-coated SPIONs into carbocyclic acid and\ninvestigation of its interaction with BSA in drug delivery sys-tems. Journal of Drug Delivery Science and Technology. 2018 1June;45:373-7.\n40.\n Ik\nonen T, Kalidas N, Lahtinen K, Isoniemi T, Toppari JJ, V\u00e1zquez\nE, Herrero-Chamorro MA, Fierro JL, Kallio T, Lehto VP. Conjuga-tion with carbon nanotubes improves the performance of meso-porous silicon as Li-ion battery anode. Scientific reports. 2020 27 March;10(1):1-8.\n41.\n Filipczak P\n, Borkowski M, Chudobinski P, Bres S, Matusiak M,\nNowaczyk G, Kozanecki M. Sodium citrate stabilized Ag NPs un-der thermal treatment, electron-beam and laser irradiations. Ra-diation Physics and Chemistry. 2020 1 April;169:107948.\n42.\n Albukhat\ny S, Naderi-Manesh H, Tiraihi T, Sakhi Jabir M. Po-\nly-l-lysine-coated superparamagnetic nanoparticles: a novelmethod for the transfection of pro-BDNF into neural stem cells.Artificial cells, nanomedicine, and biotechnology. 2018 Nov12;46(sup3):S125-32.\n43.\n Albukhat\ny S, Al-Musawi S, Abdul Mahdi S, Sulaiman GM, Alwa-\nhibi MS, Dewir YH, Soliman DA, Rizwana H. Investigation of Dex-tran-Coated Superparamagnetic Nanoparticles for Targeted Vin-blastine Controlled Release, Delivery, Apoptosis Induction, andGene Expression in Pancreatic Cancer Cells. Molecules. 2020Jan;25(20):4721.\n44.\n Banoon SR, Ghasemian A. The Char\nacters of Graphene Oxide\nNanoparticles and Doxorubicin Against HCT-116 Colorectal Can-cer Cells In Vitro. Journal of Gastrointestinal Cancer. 2021 Mar19:1-5.\nReceived: 10  April 2021\nAccepted: 15 July 2021Aswan Al-Abboodi, Hussain A. Mhouse Alsaady, Shaima R. Banoon, Mohammed Al-Saady\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2017\nMolecular Exploring of Plasmid-mediated Ampc beta Lactamase Gene in Clinical Isolates of Proteus mirabilis\nMolecular Exploring of Plasmid-mediated Ampc beta Lactamase Gene in \nClinical Isolates of Proteus mirabilis\nIsraa Abdul Ameer Al-Kraety1, Sddiq Ghani Al-Muhanna1, Shaima R. Banoon2 DOI. 10.21931/RB/2021.06.03.21\nAbstract: Between September to December 2020, thirteen isolates of Proteus mirabilis were recovered among one hundred \nfifty; MacConkey agar was utilized to purify Gram-negative bacteria isolated from infections of the urinary tract. The primary \nidentification of Proteus mirabilis isolates was relied on \u201ccolonial morphology, microscopic examination, and biochemical \u201ctests; \nhowever, the confirmation of identification of antimicrobial susceptibility of isolates was conducted utilizing an automated \nVITEK-2 compact system. The result showed that Proteus mirabilis isolates were highly resistant to most antibiotics, making \nthem multi-drug resistant (MDR). Phenotype methods were used to detect AmpC beta-lactamase. Initial and confirmatory \nmethods showed that eight isolates were AmpC producers. Polymerase Chain Reaction (PCR) was employed to detect the \nblaampC gene.\nKey words: Proteus mirabilis, \u03b2-lactamase, blaampC, VITEK-2, PCR.RESEARCH / INVESTIGACI\u00d3N\nIntroduction\nUrinary tract infection (UTI) is a form of infection that \naffects the urinary tract. Microorganisms infecting or colo-\nnizing the urinary tract. The most common bacterial are pa-\nthogens in UTIs are P. aeruginosa, S. saprophyticus, E .coli, \nand P. mirabilis1. Infections of the urinary tract can take place \nthroughout the body. Urinary tract infections, such as cysti-\ntis, pyelonephritis, urethritis, prostatitis, and perinephritis2-5, \naffect people of all ages and are among the most widespread \ninfectious diseases. Proteus mirabilis represents a Gram-ne-\ngative bacterium famous for its ability to spread rapidly within \na pattern resembling bulls\u2019 eyes. This organism is most com-\nmonly a urinary tract pathogen in clinical settings, especially \nin long-term catheterization patients. P. mirabilis uses urease \nand stone formation, fimbriae and other adhesives, iron and \nzinc conquest, proteases and toxins such as hemolysin and its \nfunction in pore formation, biofilm formation, and pathogene-\nsis regulation to enter and colonize the host urinary tract6,7. \nThe continuous usage of antibiotics produces the spread of \nantibiotic impedance and, in particular, to the progress of anti-\nbiotic resistance genes in gram-negative organisms, which are \nconsidered the most severe medical problems. For P. mirabilis \nthe resistance to antimicrobials is growing8,9, including the re-\nsistance to expanded spectrum cephalosporin according to the \nproduction of expanded-spectrum \u03b2-lactamases (ESBLs)10. Al-\nthough antibiotics are so valuable for treating many bacterial \ndiseases, they are considered environmental contaminants in \ninfected animals and humans for a long time38. This study ai-\nmed to detect Plasmid-mediated Ampc beta Lactamase Gene \nin Clinical Isolates of Proteus mirabilis at the molecular level.\nMethods\nSample\u2019s collection and identification\nDuring the study period from September to December \n2020, the whole 150 midstream urine samples were obtained. \nThe samples were taken from patients in Al-Najaf province \nhospitals who had urinary tract infections. Suspected P. mira-\nbilis isolates were retrieved from clinical samples after purifi-cation on MacConkey agar and incubated aerobically overnight \nat 37\u00b0C and confirmed by biochemical tests. The definite iden-\ntification was carried out using Gram-Negative - Identification \n(GN-ID) cards and VITEK 2 compact devices.\nAntibiotic Susceptibility Testing\nUsing the automated VITEK-2 compact device and \nAST-N093 cards (bioM\u00e9rieux, France), the Minimum Inhibi-\ntory Concentration (MIC) technique was calculated. This card \ncomposed the following antibiotics: Amikacin, Aztreonam, \nCefepime, Ceftazidime, Ciprofloxacin, Colistin, Imipenem, Ise-\npamicin, Gentamicin, Meropenem, Minocycline, Pefloxacin, \nPiperacillin, Piperacillin-Tazobactam, Rifampicin, Ticarcillin, \nTicarcillin-Clavulanic acid, Tobramycin, Trimethoprim-Sulfa-\nmethoxazole.\nExploring AmpC \u03b2-Lactamase\nInitial Examination for AmpC \u03b2-Lactamase Production\nEmploying the standard disk diffusion process, all P. mi-\nrabilis isolates were checked for cefoxitin susceptibility using \ncefoxitin disk 30 \u03bcg/ml (CLSI, 2019)11. Initially 14mm inhibition \nzone diameter) were thought to be AmpC lactamase produ-\ncers12.\nConfirmatory Test for AmpC \u03b2-Lactamase Product\nTo detect plasmid-mediated AmpC B-lactamase, the \nAmpC disk test was used. The test involves permeabilizing a \nbacterial cell with Tris-EDTA and releasing \u03b2-lactamases into \nthe surrounding medium. AmpC disks (i.e., filter paper disks \nconsisting of Tris-EDTA) were made via immerse sterile filter \npaper disks with 20 \u03bcl of a 1:1 mixture of normal saline and \n100X Tris-EDTA, allowing the disks to dry, and storing them \nat 2 to 8 \u02daC. Using the typical disk diffusion process, a lawn \nof cefoxitin susceptible E. coli ATCC 25922 was spread on the \nsurface of a Mueller-Hinton agar plate (CLSI, 2019). AmpC dis-\nks were rehydrated with 20 \u03bcl of normal saline immediately \nbefore use, and several colonies of each research organism \nwere added to the disk. On the inoculated surface of the Mue-\n1 Department of Medical Laboratory Techniques, Faculty of Medical and Health Techniques, University of Alkafeel, Najaf, Iraq.  \n2 Department of Biology, College of Science, University of Misan, Maysan, Iraq.\nCorresponding author: sddiq.g@gmail.com2018\nIsraa Abdul Ameer Al-Kraety, Sddiq Ghani Al-Muhanna, Shaima R. Banoon\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nller-Hinton agar, a 30 g cefoxitin disk occurred. After that, the \ninoculated AmpC disk was mounted on top of the antibiotic \ndisk, with the inoculated disk face touching the agar base. Af-\nter that, the plate was switched over and left to incubate at \n37\u00b0C in ambient air overnight. After incubation, the plate was \ninspected, indicating the enzyme inactivation of cefoxitin or \nlack of distortion, indicating no apparent inactivation of cefoxi-\ntin (negative result) for indentation or flattening of the inhibi-\ntion zone (negative result)13.\nMolecular Identification\nThe blaampC gene for P.mirabilis was detected using a PCR \nassay, as shown in Table (2). As shown in Table (1), this primer \nwas developed by Alpha DNA Company in Canada. To estimate \nthe size of the PCR products, 1% agarose gel electrophoresis \nwas used to validate amplified products. The gel was stained \nwith 5 \u03bcL of 10 mg/mL ethidium bromide (Promega, USA) and \nrun for 1.5 hours at 85 volts. On an ultraviolet light transillumi-\nnator (Cleaver, UK), one band was viewed at the required pla-\nce; bands were produced employing a gel registration method \n\u201cCleaver, UK.\u201d The molecular weights of amplified items were \ncalculated using a 100bp ladder \u201cBioneer, South Korea\u201d14.\nResults and discussion\nInitial identification of bacterial isolates obtained from cli-\nnical samples was based on cultural morphology, microscopic \ncharacteristics, and biochemical examinations. The colonial \nmorphology was employed to define the cultural identity of P. \nmirabilis from those isolates. P. mirabilis colonies are grown on \nblood agar and nutrient agar swarm in waves, while colonies \ngrown on MacConkey agar15 do not swarm and form smooth \ncolorless colonies, suggesting that P. mirabilis cannot ferment \nlactose sugar. P. mirabilis was Gram-negative bacilli organized \nseparately, in couples, or short chains under microscopic exa-\nmination. Table (3) displays the results of biochemical tests \nused to perform the initial identification of P. mirabilis insula-\ntes. The isolates shared oxidase-negative and catalase-positi-\nve characteristics in common. They were motile, methyl red, \nand gelatin liquefication positive for urease, catalase, citrate, \nurease, and gelatin. The isolates could sour glucose on Kli-\nger iron agar, resulting in (Alkaline) red color on the slant and \nlower (acidic) yellow color with gas and H2S production16; oxi-\ndase, indole, and vogues-Proskauer were all negative17,18. \nThe automated VITEK-2 compact device was utilized to \ncomplete the identification, including 47 biochemical tests and one negative control well on GN-ID cards. The findings show \nthat only thirteen of 150 suspected isolates were emphasized \nas P.mirabilis, with ID message confidence levels varying from \nvery good to excellent (Eventually from 93% to 99%).\nAntibiogram Testing and Minimum Inhibitory Concentration\nThe automated VITEK-2 compact device was employed \nto test antibiograms. The analysis findings showed that all P. \nmirabilis isolates tested were resistant to at least three groups \nof antibiotics. As a result, all isolates were deemed multi-drug \nresistant (MDR). The findings showed that (100%) of isolates \nwere resistant to penicillins (piperacillin and ticarcillin), while \n(64.7%) were resistant to both. Resistance to \u03b2-lactam- \u03b2-lac-\ntamase inhibitor was found in 100% of piperacillin/tazobac-\ntam and (47%) of ticarcillin_clavulanic acid moreover resists \nto ceftazidime, cefepime, and cefoxitin\u201d were identified in \n(100%), (94.1%) and (64.7%), correspondingly, in the sample. \nAztreonam resistance was 100 percent in all isolates. Low re-\nsistance was observed in the carbapenem community, which \nincluded imipenem and meropenem (the efficient \u03b2-lactam \nantibiotics), with the resistance of (5.9%) for each. This finding \nwas confirmed by (19), who found that P.mirabilis is (97.2%)\nsensitive to this antimicrobial. Some Proteus mirabilis isola-\ntes have reduced resistance to imipenem for various reasons, \nincluding the lack of outer film porins, reduced expression of \nPBP1a, and decreased imipenem combining by PBP220. Becau-\nse of the lack of 24 kDa OMP, Proteus mirabilis has developed \nresistance to imipenem. Amikacin (70.5%), isepamicin (64.7%), \ntobramycin (53%), and gentamicin (23.5%) of the aminogly-\ncoside population all had a significant intermediate effect \non P.mirabilis insulates. These mechanisms of transmission \neffectively accelerate the spread of MDR bacteria causing \nnosocomial outbreaks worldwide21-23. Amikacin represents an \naminoglycoside antibiotic that can be used to combat several \nbacterial infections. It works by interacting with the 30s riboso-\nmal subunit of bacteria, triggering mRNA misreading and pre-\nventing the bacterium from synthesizing important proteins \nfor development. This finding agrees with (24), who found that \n(88.2%) of insulates were resistant to pefloxacin and (64.7%) \nof isolates were resistant to ciprofloxacin. (76.5%) of insula-\ntes were impedance to trimethoprim-sulfamethoxazole, while \n(94.1%) were impedance to minocycline, (25) observed that \nall insulates were impedance to both colistin and rifampicin. \nSusceptibility testing showed that none of the insulates were \ncompletely immune or susceptible to any of the antibiotics \nexamined.\nTable 1. Primers employed in the current investigation.\nTable 2. PCR program of ampC gene that applies in the thermocycler.2019\nExploring Phenotypic of Plasmid-Mediated AmpC \n\u03b2-Lactamase (PMABL)\nProducing insulates phenotypic detection cefoxitin impe-\ndance was an initial screening marker for AmpC \u03b2 -lactamase \nproducers. The basic Kirby-Bauer disk diffusion approach was employed to test P.mirabilis insulates for cefoxitin suscepti-bility. Cefoxitin zone diameter less than 14 mm yielded Such impedance insulates were classified as AmpC \u03b2-lactamase producers, due to the Clinical and Laboratory Standards Ins-titute\u2019s (2019) recommendation. According to the phenotypic data collected in this study, 10 (76.9%) insulates were resistant to cefoxitin, while 2 (15.3%) were intermediate, and 1 (7.6%) was susceptible. The development of AmpC \u03b2-lactamase was screened in all isolates using the AmpC disk test, that AmpC producer was found in five (38.4%) of the thirteen isolates with 5 (62.5%) isolates resistant to cefoxitin, 2 (25%) intermediate resistant isolates, and 1 (12.5%) isolate susceptible to cefoxitin (Figure 1). The detection of plasmid-mediated AmpC-lactama-ses was calculated employing the AmpC disk test. The AmpC disk examination had 100% responsively and 98% mainly for detecting plasmid-mediated AmpC \u03b2-lactamases.\nOn the other hand, the phenotypic data revealed that the \nwhole AmpC positive insulates had previously been identified as cefoxitin resistant\n26 However, this test was in cefoxitin sus-\nceptible, and intermediate resistant insulates not able to de-monstrate the possibility of AmpC development. This may be because the AmpC disk test relies on the permeabilization of the cell membrane and the release of \u03b2-lactamases into the system. This examination may not identify low-level expres-sion enzymes. According to (27) (22%) of AmpC producers, insulates were susceptible to cefoxitin. The development of amps in these insulates may be according to a mechanism close to that of ESBL production organisms susceptible to ceftazidime when tested using the disc diffusion approach. Ce-foxitin impedance in non-producers of AmpC may be following several mechanisms, including a lack of porin permeation (27). Occasionally, rather than AmpC enzyme activity, cefoxitin im-pedance results from producing several carbapenemases and a few forms of class A \u03b2-lactamases\n28.\nMolecular Exposure of Plasmid-Mediated AmpC \u03b2 -Lactamase \n(PMABL) Producing Insulates\nThe existence of the blaampC gene was investigated in thir-\nteen isolates of P.mirabilis, with the results indicating that only 5 (38.4%) isolates yielded blaampC gene amplification products \nusing specific primers (Table1). The identification of these iso-lates by PCR is depicted in (Figure 2). Several cellular func-tions\n29-32. Some Enterobacteriaceae family members such as \n\u201cEnterobacter, Shigella, Providencia, Citrobacterfreundii, Mor-ganellamorganii, Serratiamarcescens, and Escherichia coli\u201d\n33-35 \nhave AmpC \u03b2-lactamase genes on their chromosomes. As a consequence of this shift, plasmid-mediated ampC-lactama-ses have arisen. Plasmid-mediated AmpC-lactamases are a novel task since they impart carbapenem tolerance in strains missing outer membrane porins, have cephamycin impedance and are unaffected by commercially available -lactamase inhi-bitors. This mechanism of resistance has been discovered all over the world and has the potential to cause nosocomial out-breaks. It seems to be increasing, so more research is required to evaluate the best detection and treatment options\n37.\nTable 3. Conventional biochemical tests results of P.mirabilis \nsuspected isolates.\nFigure 1.  A positive result of a phenotypic confirmatory test for AmpC.\nConclusions\nAccording to our knowledge, the present study revealed \nthat chromosome ampC gene was detected on a plasmid of local Proteus mirabilis isolates. Show the result that Proteus \nmirabilis isolates were highly resistant to most antibiotics, ma-king them multi-drug resistant (MDR). Meropenem and imipe-nem were highly active against P.mirabilis isolates. The simul-taneous presence of ESBLs and AmpC \u03b2-lactamase was seen in several P.mirabilis isolates. The results indicating that only 5 (38.4%) isolates yielded blaAmpC gene amplification products.\nBibliographic references\n1. F oxman B. Urinary tract infection syndromes: occurrence, recur-\nrence, bacteriology, risk factors, and disease burden. Infectious\ndisease clinics of North America. 2013 Dec 8;28(1):1-3.\n2.O\u2019Har\na CM, Brenner FW, Miller JM. Classification, identification,\nand clinical significance of Proteus, Providencia, and Morganella.Clinical microbiology reviews. 2000 1 October;13(4):534-46.\n3.\nNicolle LE. Catheter-related urinar\ny tract infection. Drugs & ag-\ning. 2005 Aug;22(8):627-39.\n4.\n Jacobsen S\n\u00c1, Stickler DJ, Mobley HL, Shirtliff ME. Complicated\ncatheter-associated urinary tract infections due to Escherichiacoli and Proteus mirabilis. Clinical microbiology reviews. 2008 1January;21(1):26-59.Molecular Exploring of Plasmid-mediated Ampc beta Lactamase Gene in Clinical Isolates of Proteus mirabilis2020\n5.O\u2019Brien VP , Hannan TJ, Schaeffer AJ, Hultgren SJ. Are you expe-\nrienced? Understanding bladder innate immunity in the context\nof recurrent urinary tract infection. Current opinion in infectiousdiseases. 2015 Feb;28(1):97.\n6.\n Mas\nsad G, Bahrani FK, Mobley HL. Proteus mirabilis fimbriae: iden-\ntification, isolation, and characterization of a new ambient-tempera-ture fimbria. Infection and immunity. 1994 1 May;62(5):1989-94.\n7.\nZunino P\n, Geymonat L, Allen AG, Legnani-Fajardo C, Maskell\nDJ. Virulence of a Proteus mirabilis ATF isogenic mutant isnot impaired in a mouse model of ascending urinary tract in-fection. FEMS Immunology & Medical Microbiology. 2000 Oct1;29(2):137-43.\n8.\n P\naterson DL, Yu VL. Editorial response: extended-spectrum\n\u03b1\n-lactamases: a call for improved detection and control. Clinical \nInfectious Diseases. 1999 Dec 1;29(6):1419-22.\n9.Br\nadford PA. Extended-spectrum \n\u03b1\n-lactamases in the 21st cen-\ntury: characterization, epidemiology, and detection of this im-portant resistance threat. Clinical microbiology reviews. 2001 1October;14(4):933-51.\n10.\n Sohn \nKM, Kang CI, Joo EJ, Ha YE, Chung DR, Peck KR, Lee NY,\nSong JH. Epidemiology of ciprofloxacin resistance and its rela-tionship to extended-spectrum \n\u03b1\n-lactamase production in Prote-\nus mirabilis bacteremia. The Korean journal of internal medicine.2011 Mar;26(1):89.\n11.\n Nasim K, Elsa\nyed S, Pitout JD, Conly J, Church DL, Gregson DB.\nNew method for laboratory detection of AmpC \u03b1\n-lactamases in\nEscherichia coli and Klebsiella pneumoniae. Journal of clinicalmicrobiology. 2004 Oct 1;42(10):4799-802.\n12.\n Coudron \nPE, Hanson ND, Climo MW. Occurrence of extend-\ned-spectrum and AmpC beta-lactamases in bloodstream iso-lates of Klebsiella pneumoniae: isolates harbor plasmid-mediat-ed FOX-5 and ACT-1 AmpC beta-lactamases. Journal of ClinicalMicrobiology. 2003 Feb 1;41(2):772-7.\n13.\n Black J\nA, Moland ES, Thomson KS. AmpC disk test for detection \nof plasmid-mediated AmpC \n\u03b1\n-lactamases in Enterobacteriaceae \nlacking chromosomal AmpC \n\u03b1-lactamases. Journal of clinical\nmicrobiology\n. 2005 1 July;43(7):3110-3.\n14.\n Le\nvy H, Diallo S, Tennant SM, Livio S, Sow SO, Tapia M, Fields PI,\nMikoleit M, Tamboura B, Kotloff KL, Lagos R. PCR method to iden-tify Salmonella enterica serovars Typhi, Paratyphi A, and Para-typhi B among Salmonella isolates from the blood of patientswith clinical enteric fever. Journal of clinical microbiology. 20081 May;46(5):1861-6.\n15.\n Mahillon J\n, Chandler M. Insertion sequences. Microbiology and\nmolecular biology reviews. 1998 Sep 1;62(3):725-74.\n16.\n Matsen JM, Blaze\nvic DJ, Ryan JA, Ewing WH. Characterization\nof indole-positive Proteus mirabilis. Applied microbiology. 1972 1March;23(3):592-4.17.\n  Kishore J. Isolation, identification & characterization of Proteus\npenneri-a missed rare pathogen. The Indian journal of medicalresearch. 2012 Mar;135(3):341.\n18.\n  K\namga HL, Nsagha DS, Assob JC, Njunda AL, Tchape GN. Epide-\nmiological studies on proteeae isolates from clinical specimens in the Laquintinie Hospital in Douala, Cameroon. African Journal ofClinical and Experimental Microbiology. 2012;13(2):118-26.\n19.\n Al-Jumail\ny E, Zgaer SH. Multi-drug resistant Proteus mirabilis\nisolated from urinary tract infection from different hospitals inBaghdad City. Int. J. Curr. Microbiol. App. Sci. 2016;5(9):390-9.\n20.\n Girlich D\n, Dortet L, Poirel L, Nordmann P. Integration of the bla\nNDM-1 carbapenemase gene into Proteus genomic island 1(PGI1-Pm PEL) in a Proteus mirabilis clinical isolate. Journal ofAntimicrobial Chemotherapy. 2015 1 January;70(1):98-102.\n21.\n K\noehn FE, Carter GT. The evolving role of natural products in drug \ndiscovery. Nature reviews Drug discovery. 2005 Mar;4(3):206-20.\n22.\n Molinari G\n. Natural products in drug discovery: present status and \nperspectives. Pharmaceutical Biotechnology. 2009:13-27.\n23.\n Ha\nyashi MA, Bizerra FC, Da Silva Junior PI. Antimicrobial compounds \nfrom natural sources. Frontiers in microbiology. 2013 15 July;4:195.\n24.\n Al-Muhanna \nAS, Al-Muhanna S, Alzuhairi MA. Molecular investi-\ngation of extended-spectrum beta-lactamase genes and poten-tial drug resistance in clinical isolates of Morganella morganii.Annals of Saudi medicine. 2016 May;36(3):223-8.\n25.\n Al-Muhanna SG\n, Banoon SR, Al-Kraety IA. Molecular detection of \nintegron class 1 gene in proteus mirabilis isolated from diabeticfoot infections. Plant Archives. 2020 Apr; 20(1): 3101-3107.\n26.\n Black J\nA, Moland ES, Thomson KS. AmpC disk test for detection \nof plasmid-mediated AmpC \n\u03b1\n-lactamases in Enterobacteriaceae \nlacking chromosomal AmpC \n\u03b1-lactamases. Journal of clinical\nmicrobiology\n. 2005 1 July;43(7):3110-3.\n27.\n Mohamudha PR, Harish BN, P\narija SC. AmpC beta lactamas-\nes among Gram negative clinical isolates from a tertiary hos-pital, South India. Brazilian Journal of Microbiology. 2010Oct;41(3):596-602.\n28.\n Jacob\ny GA. AmpC \n\u03b1\n-lactamases. Clinical microbiology reviews.\n2009 1 January;22(1):161-82.\n29.\n Schmitzo\nva J, Klaudiny J, Albert \u0160, Schr\u00f6der W, Schreckengost\nW, Hanes J, Judova J, \u0160im\u00fath J. A family of major royal jelly pro-teins of the honeybee Apis mellifera L. Cellular and MolecularLife Sciences CMLS. 1998 Sep;54(9):1020-30.\n30.\n Alber\nt S, Bhattacharya D, Klaudiny J, Schmitzov\u00e1 J, Sim\u00fath J.\nThe family of major royal jelly proteins and its evolution. Journal of Molecular Evolution. 1999 1 August;49(2):290-7.\n31.\n K\nupke J, Spaethe J, Mueller MJ, R\u00f6ssler W, Albert \u0160. Molecular\nand biochemical characterization of the major royal jelly proteinin bumblebees suggest a non-nutritive function. Insect biochem-istry and molecular biology. 2012 Sep 1;42(9):647-54.\nFigure 2.  PCR production of P.mirabilis isolates dilated with blaampC primary genes, with a product size of 510 bp. (L): 100-bp \nladder; Lanes (2, 3, 4, 6, and 7): positive blaampC gene results; Lanes (1, 5, 8, and 9): negative blaampC gene results.Israa Abdul Ameer Al-Kraety, Sddiq Ghani Al-Muhanna, Shaima R. Banoon\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2021\n32. But tstedt A, Moritz RF, Erler S. Origin and function of the ma-\njor royal jelly proteins of the honeybee (Apis mellifera) as\nmembers of the yellow gene family. Biological Reviews. 2014May;89(2):255-69.\n33.\n Medeiros AA. E\nvolution and dissemination of \n\u03b1\n-lactamases ac-\ncelerated by generations of \n\u03b1\n-lactam antibiotics. Clinical Infec-\ntious Diseases. 1997 1 January;24(Supplement_1):S19-45.\n34.\n Subha A, Devi VR, Ananthan S. AmpC beta-lactamase producingmul\nti-drug resistant strains of Klebsiella spp. & Escherichia coli\nisolated from children under five in Chennai. Indian Journal ofMedical Research. 2003 1 January;117:13-8.\n35.\n Mohamudha PR, Harish BN, P\narija SC. AmpC beta lactamas-\nes among Gram negative clinical isolates from a tertiary hos-pital, South India. Brazilian Journal of Microbiology. 2010Oct;41(3):596-602.\n36.\n Mes\nsai Y, Benhassine T, Naim M, Paul G, Bakour R. Prevalence\nof \n\u03b1\n-lactams resistance among Escherichia coli clinical iso-\nlates from a hospital in Algiers. Rev Esp Quimioter. 2006 Jun1;19(2):144-51.\n37.\n T\nan TY, Ng LS, He J, Koh TH, Hsu LY. Evaluation of screening\nmethods to detect plasmid-mediated AmpC in Escherichia coli,Klebsiella pneumoniae, and Proteus mirabilis. Antimicrobialagents and chemotherapy. 2009 1 January;53(1):146-9.\n38.\n Banoon S, Ali Z, Salih T\n. Antibiotic resistance profile of local ther-\nmophilic Bacillus licheniformis isolated from Maysan provincesoil. Comunicata Scientiae. 2020 13 July;11:e3921-.\nReceived: 10 April 2021\nAccepted: 15 July 2021Molecular Exploring of Plasmid-mediated Ampc beta Lactamase Gene in Clinical Isolates of Proteus mirabilis2022\nEkremah K. Shaker, Fatima A. Chaloob\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nRisk factors in bacterial colonization of internal ureteral stent\nEkremah K. Shaker1, Fatima A. Chaloob2 DOI. 10.21931/RB/2021.06.03.22\nAbstract: A ureteral stent is most broadly used to manage upper urinary tract disorders such as obstruction and prevent post-\nendoscopic complications. However, the stent may become a niche for bacterial colonization. This study aimed to determine \nthe rate of bacterial colonization and type of bacteria in internal ureteral stents and the risk factors associated with bacterial \ncolonization. This prospective cross-sectional study included 100 consecutive adult patients who had temporary ureteral \nstenting as preparation for a secondary ureterorenoscopy at Al-Yarmook Hospital/ Baghdad. All included patients were negative \nfor bacterial culture before stenting.\nStent and urine culture were performed at the time of stent removal. The colonization rate and bacteriuria in patients with \ninternal ureteral stent were 19% and 9%, respectively. The most common bacteria in-stent and urine were E. coli accounting for \n31.58% and 33.33%. Pseudomonas aeruginosa was common in stent culture, representing 21.05%.  Positive bacterial culture \nwas confirmed in 19 stents and 9 urine samples. All cases with positive urine samples were also positive for culture. Thus, \nthe sensitivity and specificity of urine culture for detection of stent colonization were 47.37% and 100%, respectively.  Diabetes \nmellitus, chronic renal failure, and prolonged stenting were significantly associated with increased stent colonization. The \nureteral stent could be a source of urinary tract infection. The most pathogenic bacteria associated with the ureter stent are E. \ncoli and Pseudomonas aeruginosa. Risk factors associated with stent colonization are diabetes mellitus, chronic renal failure, \nand prolonged indwelling time.\nKey words: Ureteral stent colonization, urine culture, bacterial profile, urinary tract infection.RESEARCH / INVESTIGACI\u00d3N\nIntroduction\nUreteral Double-J (DJ) stents are broadly employed to \ntreat obstruction in upper urinary tract and avoid post-endos-\ncopic complications. Moreover, these stents are also used to \ndecrease the possible risk of obstruction resulting in stone \nfragmentation after extracorporeal shock-wave lithotripsy  \n(ESWL), especially in patients with relatively large stones1. On \nthe other hand, a ureteral stent is generally associated with \nseveral complications, including dysuria, hematuria, lumbar or \nsuprapubic pain2, stent migration, fragmentation, and encrus-\ntation. However, the most severe complication possibly invol-\nves the biofilm formation on the stent and infection, which may \nbe associated with bacteremia, renal worsening, pyelonephri-\ntis, or even mortality because of the development of sepsis3.\nThe biofilms that form on the ureteral stent can origina-\nte from urinary tract microbiota or contamination of the stent \nduring insertion of the device4. Moreover, the internal ureteral \nstents offer a perfect medium for bacterial adhesion, coloni-\nzation, and biofilm formation5. Regardless of its origin, biofilm \nformation on the stent indicates that even very small numbers \nof bacteria can rapidly benefit from the niche-altering non-self \nmaterial to grow and increase their population. Previous stu-\ndies in stented patients have indicated that 70% to 90% of tho-\nse patients developed bacterial colonization6.\nThe present study aimed to determine the rate of bac-\nterial colonization and type of bacteria in an internal ureteral \nstent and determine the risk factors associated with bacterial \ncolonization of these stents.\nMaterials and methods\nPatients\nThis is a single prospective center observational study in-cluding all consecutive adult patients who had ureteral sten-\nting as part of management for a secondary ureterorenoscopy \n(URS) due to urolithiasis during the period from April 2020 to \nMay 2021 in the department of Urology/ Al-Yarmook Teaching \nHospital, Baghdad, Iraq. Patients positive for urine bacterial \nculture, immune suppression, pregnant women, those with \nprevious surgery for lower urinary tract, and those who refu-\nsed to give consent were excluded from the study. Demogra-\nphic data, including age, gender, body mass index (BMI), the \npresence of comorbidities, and stent dwelling time, were ex-\ntracted through direct interviews or from patient records. The \nstudy was approved by the Institutional Review Board (IRB) of \nAl-Dewaniyah Technical Institute, Al-Furat Al-Awsat Technical \nUniversity. Written consent from each participant was obtai-\nned at the time of sample collection after explaining the aim of \nthe study. Each patient was given the complete unconditioned \nchoice to withdraw anytime. The patients were assured that \ndata will be used for research purposes only. Based on inclu-\nsion and exclusion criteria, the eligible patients who give the \nconsent form were 100 patients.\nBacterial Isolation from Stents and Urine\nAt the time of stent removal, Midstream urine from all \npatients was collected. The stents were removed under anti-\nseptic conditions with the aid of a cystoscope and foreign body \nforceps. All stent segments (inner and outer surface and the \nstent tip) were splashed with 1 mL sterile tryptic soy broth \nsolution. The resultant liquid was vortexed for 1 minute, then \ndiluted (1/100) with phosphate buffer saline. Both urine sam-\nples and diluted stent preparation were immediately transfe-\nrred to a Brain heart infusion (BHI) medium. The medium was \nincubated at 37\u00b0C overnight. The samples were then subcultu-\nred aerobically on MacConkey agar, while chocolate agar me-\n1 Medical Laboratory Technique, Al-Rasheed University College, Iraq.  \n2 Al-Dewaniyah Technical Institute, Al-Furat Al-Awsat Technical University, Iraq\nCorresponding author: aa98414@yahoo.com2023\nRisk factors in bacterial colonization of internal ureteral stent\ndia was used for incubation under CO2 conditions. The growth \nof microorganisms on the agar was evaluated quantitatively \n(growth of >1000 colony-forming units/mL was considered \npositive)7. Api20E system was used to identify Enterobacteria-\nceae, while Api Staph System was used to identify staphylo-\ncocci (bio-Merieux, France). These systems can detect bacteria \nto species level. For other bacteria, routine biochemical tests \nwere used for identification. These included the oxidase test, \ncatalase test, CAMP test, motility agar, and urease test.\nStatistical Analysis\nAll statistical analyses were performed using SPSS Sta-\ntistics Windows, Version 25.0 (Armonk, NY: IBM Corp.). Data \nwere expressed as mean and standard deviation (for quanti-\ntative variables) and frequency and percentage (for binomial \nvariables). Student t-test or Chi-square as required was used \nto compare the association between different factors and the \nstent colonization. The level of significance was set at p < 0.05.\nDemographic and Clinical Characteristics of the Patients\nThe mean age of the patients was 53.01\u00b19.67 years (ran-\nge 26-82 years). About three-quarters of the patients were males. The mean BMI was 26.44\u00b13.57 kg/m2. Most patients \n(60%) had no comorbidity, while 25% and 24% of them were \nsuffering from DM or hypertension, respectively. The mean \nstent indwelling time was 42.32\u00b19.9 days (range 24-66 days), \nas shown in table 1.\nMicrobiology\nOut of 100 stents, positive culture was confirmed in 19 \nstents (19%). On the other hand, only 9 urine samples had a \npositive culture. Interestingly, all positive urine samples were \npositive for stent culture. On the other hand, 10 positive stent \ncultures had negative urine cultures. Thus, urine culture's \nsensitivity and specificity for stent colonization detection are \n47.37% and 100%, respectively (Table 2).\nThe most common bacterium was E. coli encountered in \n31.58% and 33.33% of stent and urine cultures. P. aeruginosa \ncame next accounted for 21.05% of stent colonization but was \nnot detected in urine samples. Staphylococcus epidermidis and \nKlebsiella pneumoniae were detected in 10.53% and 11.11% \nof stent and urine culture, respectively (Table 3). None of the \nstent or urine cultures had mixed infection.\nTable 1. Patients' characteristics and demographic data (n=100).\nTable 2. Relationship of stent colonization with \nurine culture.2024\nAssociation of Demographic and Clinical Characteristics \nwith Stent Colonization\nTwo factors were significantly associated with stent co-\nlonization: comorbidities and stent indwelling. A 47.37% of \npatients in the bacterial colonization group had DM compared \nwith 19.75% among patients without colonization with a sig-\nnificant difference. Similarly, chronic renal failure was more \ncommon among patients than without colonization (15.79% \nvs. 3.7%), with a significant difference. The mean time for ind-\nwelling stent patients with colonization was 47.68\u00b19.63 days \ncompared with 41.06\u00b19.59 days in patients without coloniza-\ntion, with a highly significant difference (Table 4).\nDiscussion\nAccording to the result of the present study, 19% and 9% \nof internal ureteral stents and urine samples were positive for \nbacterial colonization. A speedy result was obtained by Ulkar \net al.8, in which bacterial colonies were demonstrated in 20%. \nAlso, Lojanapiwat9 reported that bacterial colonization and \ngrowth in-stent culture was detected in 7 of 35 patients (20%). \nA much higher rate was reported in other studies. Kehinde et \nal.10 reported that about 42 % of patients with indwelled stent \nhad their stent colonized, while 17% developed bacteriuria. Li-\nfschitz et al.11 reported that 45 of their patients had positive \nstent culture, and 15% suffered from bacteriuria. In Bangla-\ndesh, Rahman et al.6 investigated 100 adult patients who had ureteral stent placement for different urinary tract operations. \nBacterial colonies were found in 45% of the stent, while bacte-\nriuria was found only in 21% of patients. On the other extreme, \nas high as 90% of stent colonization was reported in an earlier \nseries of 30 patients12.\nThese discrepancies in the colonization rate may be attri-\nbuted to several factors, the most important of which are the \npolymer characteristic of the stent, indwelling times, different \npatient populations, and technical issues. The relatively low \nrate of colonization in the present study reflects the high stan-\ndard of hygiene followed by the operative team, and maybe \nsome prophylactic antibiotics were taken by the patients.\nIn the present study, the sensitivity and specificity of bac-\nteriuria in the detection of stent colonization were 47.37% and \n100%, respectively. In a similar study, Lifshitz et al.11 demons-\ntrated that the sensitivity and specificity of urine culture were \n31% and 97%, respectively. Thus, in most cases, urine culture \nhad low sensitivity and very high specificity because mostly \nurine gives negative results when there is no stent coloniza-\ntion, but not all stent colonization results in bacteriuria.\nAccording to the present study, E. coli and. P. aeruginosa \nwas the most predominant pathogen in-stent and urine cultu-\nre. In this regard, different studies disclosed different bacte-\nrial profiles of stent and urine colonization.  In many previous \nstudies, E. coli and Enterococci spp were found to be the most \nprevalent13-14. In a Turkish study, the most frequently isolated \nbacteria were Staphylococcus epidermidis, Escherichia coli, \nTable 3. Bacterial iso -\nlates from stent and \nurine samples.\nTable 4. Bacterial \nisolates from stent \nand urine samples.Ekremah K. Shaker, Fatima A. Chaloob\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2025\nand Enterococcus faecalis8. In Rahman's et al.'s study, E. coli \nwas the common organism isolated from both stent and uri-\nne6. Lojanapiwat et al.9 found that Staphylococcus epidermidis \nis the predominant bacteria responsible for stent colonization. Two other recent studies described gram-positive pathogens, particularly Staphylococcus, as predominant bacterium\n15-16. \nFarsi et al.13 reported that P. aeroginosa was most commonly \nisolated from both stents and urine. Paick et al.17 isolated  En-\nterococcus species from 6 stents out of 25, followed by E. coli (5 of 25). They indicated that Gram-positive and gram-negative bacteria were similarly distributed in-stent cultures; neverthe-less, only gram-negative bacteria were established in urine cultures. Another study demonstrated that Acinetobacter sp. and R. pickettii were the most common pathogens, followed \nby Staphylococci and Pseudomonas species in-stent culture\n7.\nTherefore, it seems that each study has its peculiar con-\nditions regarding antibiotic use, isolation, stent material, and study population that result in specific bacterial profiles.\nThere was almost complete agreement between stent \nand urine in the types of bacterial isolates. These data suggest that colonization in the stent is a crucial step of UTI and prece-des colonization in the urine.\nIn the present study, DM and chronic renal failure, as co-\nmorbidities, were significantly associated with an increased stent colonization rate. Furthermore, the meantime for indwe-lling stent patients with colonization was significantly longer than in patients without colonization. Following these results is the outcome of many previous studies worldwide. Akay et al.\n14 investigated risk factors for UTI and stent colonization in \n190 patients with ureteral stents. The independent risk factors for the development of UTI were DM, chronic renal failure, and pregnancy. Altuna et al.\n18 demonstrated that UTI was more \ncommon in patients with ureteral stents with DM and chronic renal failure.\nDiabetes is known to hurt the immune system. Besides, \nthe presence of sugar in the urinary tract enhances bacterial growth. On the other hand, chronic renal failure is associated with urinary stagnation, alkalization of urine, and absence of flushing action\n19. All these factors increase the likelihood of \nbacterial colonization.\nThe association of prolonged stent dwelling with stent \ncolonization is beyond dispute. Most studies in this regard demonstrated that stent dwelling periods were significantly correlated with stent colonization rates\n10. The longer the ind-\nwelling period, the higher rate of stents colonized. Rahman et al.\n6 disclosed that the colonization rate was 71.4% in stents \nthat exist for 6 weeks compared to 33.3% in those that exist for 4-6 weeks and 23.5% for stents removed before 4 weeks. In aprospective study, Farsi et al.\n13 investigated stent colonization\nin 266 patients for 2 weeks to 27 months. A linear correlationwas disclosed between the indwelling time and stent coloniza-tion rate. Coskun et al.\n20 emphasized that prompt removal of\nthe stent can significantly decrease the rate of UTI. Shabenaaet al.\n21 did not find bacterial colonization in the first two weeks\nof stent employment.\nAs dwelling time increases, there will be more chance for \ndifferent bacterial strains to adhere and colonize the stent re-gardless of the stent material. Eventually, a biofilm is formed, and most bacteria find their way to the urine.\nThe study has some limitations. Firstly, it was a sin-\ngle-center study with a limited number of patients, and the result cannot be generalized. Therefore, multicenter studies with a larger sample size are required for more solid conclu-sions. Secondly, the study did not link stent colonization with clinical symptoms and patients' quality of life. That is because the study was intended to be a microbiological rather than a clinical study. However, this study provides a clear insight into the risk of bacterial colonization of internal ureteral stent.\nConclusions\nThe study findings indicate the importance of internal ure-\nteral stent as a source for UTI. The most pathogenic bacteria associated with the ureter stent are E. coli and Pseudomonas aeruginosa. Risk factors associated with stent colonization are DM, chronic renal failure, and indwelling time. Thus, the use of ureter stents should be reduced to a short dwelling time. Otherwise, every measure should be taken to reduce the sent colonization, especially in diabetics and patients with chronic renal failure, such as regular urine analysis and prophylactic broad-spectrum antibiotics.\nConflict of interest\nThe authors declare no conflict of interest.\nAuthors' Declaration\nThe authors at this moment declare that the work presen-\nted in this article is original and that they will bear any liability \nfor claims relating to the content of this article.\nBibliographic references\n1. Shinde S, Al Balushi Y , Hossny M, Jose S, Al Busaidy S. Factors\nAffecting the      Outcome of Extracorporeal Shockwave Lithotripsy\nin Urinary Stone Treatment. Oman      Med J. 2018;33(3):209-217.\n2.Joshi HB, S\ntainthorpe A, Keeley FX, MacDonagh R, Timoney AG.\nIndwelling ureteral      stents: evaluation of quality of life to aidoutcome analysis. J Endourol.      2001;15:151-154.\n3.\n R\nanganathan M, Akbar M, Ilham MA, Chavez R, Kumar N, Asderakis \nA. Infective      complications associated with ureteral stents inrenal transplant      recipients. Transplant Proc. 2009;41(1):162-4.\n4.\n Bos\nsa L, Kline K, McDougald D, Lee BB, Rice SA. Urinary cathe-\nter-associated      microbiota changes in accordance with treat-ment and infection status, PLoS      One. 2017;12(6):e0177633.\n5.\nV\nalentin Z, Patrick B, Werner A, Matthias B, Qun R, Hans-Peter S, \nDominik A.      Biofilm formation on ureteral stents \u2013 incidence, clin-ical impact and      prevention. Swiss Med Wkly. 2017;147:w14408.\n6.\nR\nahman MA, Alam MM, Shamsuzzaman SM, Haque ME. Evalu-\nation of bacterial      colonization and bacteriuria secondary tointernal ureteral stent.      Mymensingh Med J. 2010;19, 366\u2013371.\n7.\nOzgur BC\n, Ek\u0131c\u0131 M, Yuceturk CN, Bayrak O. Bacterial colonization\nof double J      stents and bacteriuria frequency. Kaohsiung J Med Sci.      2013;29(12):658-61.\n8.\n Ulkar \nV, Yilmaz N, Agus N, Can E, Cakmak O, Yucel C, Celik O,\nLibey YO. Bacterial colonization of      ureteral double-J stentsin patients with negative urine culture. J      Urological Surg2019;2:125-129.\n9.\nLojanapiw\nat B. Colonization of internal ureteral stent and bacte-\nriuria. World J Urol.      2006;24(6):681-683.\n10.\n K\nehinde EO, Rotimi VO, Al-Hunayan A, Abdul-Halim H, Boland F,\nAl-Awadi KA. Bacteriology of urinary tract infection      associatedwith indwelling J ureteral stents. J. Endourol.      2004;18:891-896.\n11.\n Lifshitz D\nA, Winkler HZ, Gross M. Predictive value of urinary\ncultures in      assessment of microbial colonization of ureteralstents. J Endourol.      1999;13:735\u2013738.\n12.\n R\neid G, Denstedt JD, Kang YS, Lam D, Nause C. Microbial adhe-\nsion and biofilm      formation on ureteral stents in vitro and in vivo. J Urol.      1992;148:1592-1594.\n13.\n F\narsi HM, Mosli HA, Al-Zemaity MF, Bahnasy AA, Alvarez M. Bac-\nteriuria and      colonization of double-pigtail ureteral stents: long-term experience with      237 patients. J Endourol. 1995;9:469\u2013472 2.Risk factors in bacterial colonization of internal ureteral stent2026\n14. Aka y AF, Aflay U, Gedik A. Risk factors for lower urinary tract\ninfection and      bacterial stent colonization in patients with a\ndouble J ureteral stent.      Int Urol Nephrol. 2007;39:95-98.\n15.\n A\nydin HR, Irkilata H, Aydin M, Gorgun S, Demirel HC, Adanur S,\nKeles M, Atilla      A, Atilla MK. Incidence of bacterial colonisation after indwelling og      double-J ureteral stent. Arch Ital Urol An-drol. 2016;87:291-294.\n16.\n Ne\nvo A, Mano R, Schreter E, Lifshitz DA. Clinical implications of\nstent culture in patients with      indwelling ureteral stents prior to ureteroscopy. J Urol.      2017;198:116-121.\n17.\n P\naick SH, Park HK, Oh SJ, Kim HH. Characteristics of bacterial\ncolonization and      urinary tract infection after indwelling of dou-ble-J ureteral stent. Urol.      2003;62(2):214-217.\n18.\n Al\ntunal N, Willke A, Hamzao\u011flu O. Ureteral stent infections: a\nprospective study.      Braz J Infect Dis. 2017;21(3):361-364.\n19.\n Richa C\n, Bhushan CS, Kumar SP, Dev PN, Nabaraj P. Bacteriology \nof Urinary Tract      Infection of Chronic Renal Failure Patients Un-dergoing for Hemodialysis. J      Microbiol Exp. 2016;3(3): 00089.\n20.\n Coskun AK, Harlak A, Ozer T\n, Eyitilen T, Yigit T, Demirbas\u201a S. Is\nremoval of the      stent at the end of 2 weeks helpful to reduce in-fectious or urologic      complications after renal transplantation? Transplant Proc. 2011;43:813e5.\n21.\n Shabenaa \nKS, Bhargava R, Manzoor MAP, Mujeeburahiman M.\nCharacteristics of      bacterial colonization after indwelling dou-ble-J ureteral stents for different      time duration. Urol Ann.2018;10:71-75.\nReceived: 20 April 2021\nAccepted: 15 July 2021Ekremah K. Shaker, Fatima A. Chaloob\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2027\nInvestigation about contamination of some food items in local markets, Mosul, Iraq\nInvestigation about contamination of some food items in local markets, Mosul, Iraq\nAmmar Nafea Alnema, Mazin Nazar Fadhel DOI. 10.21931/RB/2021.06.03.23\nAbstract: Results of enzyme-linked immunoassay (ELISA), which was conducted on 58 samples of dried fruits and nuts \navailable in the local market in Mosul city that there were samples that are contaminated with aflatoxins with rates higher \nthan the tolerated level permitted by the European Union (4 parts per billion) in the human-consumed foodstuff products as \nthe percentages were 40%, 40, 70% and 10% for almond, cashew, pistachio, and walnut respectively, which are beyond the \npermitted level. At the same time, the percentages were 66% and 10% for dried apricot and figs, respectively, and more than the \npermitted level. The average quantity of aflatoxins in the nuts samples was (1.6, 3.8. 4.1 and 6.1 ppb) for walnut, cashew, almond, \nand pistachio, respectively, while in the dried fruits (3.3, 1.4, and 6.9 ppb) for raisin, figs, and apricot respectively.\nKey words: Aflatoxin pollution, (ELISA), Mycotoxins.RESEARCH / INVESTIGACI\u00d3N\nIntroduction\nAflatoxins are secondary metabolites with relatively low \nmolecular weights produced by genus Aspergillus that affect \nthe human-consumed foodstuff and animal fodders1. The Uni-\nted Nations Foods and Agriculture Organization (FAO) estima-\nted that about 25% of foodstuff and fodders worldwide are \npolluted with aflatoxins2.\nThe foodstuff that is more subject to aflatoxins is cereals, \nspices, rice, corn, nuts, and dried fruits3. The term was used \nfor the first time in 1952 when animal diseases were studied4.\nIn general, toxins affect the foods in various stages: trans-\nport, storage, or affecting the various crops in the growth stage \nbefore the harvest. The effect of these poisons is associated \nwith the quantities consumed, as having them for long periods \nwith small quantities in foods and fodder causes chronic disea-\nses to humans and animals, while having large quantities for \nshort periods leads to acute cases and might result in death in \nmost of the cases5.The most critical main aflatoxins types are (G2, G1, B2, \nand B1). Aspergillus flavus produces type B only, whereas the \nother two (Aspergillus parasiticus and Aspergillus nomius) pro-\nduce G and B. The two letters \"B\" and \"G\" refer to the two \ncolors, blue and green, produced when subjected to the ultra-\nviolet rays on the TLC plates, while the numbers 1 and 2 refer \nto the main ad the secondary compounds, respectively7.\nAflatoxin B1 is considered the most poisonous, and it was \nidentified as the most carcinogenic chemical that occurs natu-\nrally in the liver.\nThe International Agency classified AFB1 for Cancer Re-\nsearches as a first-class carcinogen, and several epidemics \nstudied demonstrated a relationship between aflatoxins and \nstomach, intestine, and liver tumors in Africa, the Philippines, \nand China9. Therefore, regulations were adopted by many \ncountries to control the concentrations of Aflatoxin in foods as \nthe concentration of Aflatoxins was restricted to the highest \nconcentration in nuts and dried fruits to be (4 \u03bcg/kg)10.\nThe primary purpose of this work is to test the level of AFs \nin samples of dried fruits and nuts which are available in the \nlocal markets in Mosul city, Iraq, that are consumed in huge \nquantities and on a wide range.\nMaterials and methods \nSampling\nSamples were collected in January 2021and they were 58 \nsamples (n=58). These samples included dried fruits and nuts \nIncluded: (6 samples of dried grapes, 6 samples of dried apri-\ncot, 6 samples of dried figs, 10 samples of walnut, 10 samples \nof almonds, 10 samples of cashews, and 10 samples of Alle-\npo pistachios), which were all bought from the local market in \nMosul city. Each sample was ground to a volume of 250 grams, \nput in plastic bags, taken to the laboratory, and analyzed im-\nmediately in search of AFs11.\nChemical and reagents\nThe number of Aflatoxins in the samples was measured \naccording to Ela science American company using Enzyme \n(ELISA).\n1 Department of Environmental Sciences, College of Environmental Sciences and Technology, Mosul University, Iraq.\nCorresponding author: ammer.abd.technology@gmail.com\nFigure 1.  Chemical structure of aflatoxin B (AFB1 and AFB2), \naflatoxin G  (AFG1 and AFG2)8.\nAflatoxins stand for a set of metabolites, which are seve-\nrely poisonous and produced by certain types of Aspergillus \nspecies, including Aspergillus flavus, Aspergillus parasitic us, \nand Aspergillus nomius during their growth on foods and fod-\nders6.2028\nAmmar Nafea Alnema, Mazin Nazar Fadhel\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nReagents: Methanol, N-hexane, were obtained from Merck \n(Darmstadt, Germany), Methanol (V): Deionized water (V) =7: 3\nThe extraction procedure\nSample uniformity using an electrical blender.  A quantity \nof  2 grams of the homogeneous sample was weighted, put \nin the 50 ml-capacity centrifuge tube. Then 8 ml of N-hexane \nand 10 ml of methanol 70% and they are shacked well for 5 \nminutes and then they are put in the centrifuge at 4000 round \nper minute for 10 minutes at the room temperature. The upper \nliquid is removed, and 0.5 ml of the lower liquid is taken to \nanother centrifuge tube. After that, 0.5 ml of deionized water \nis added and thoroughly mixed. A quantity of 50 \u03bcl is taken for \nanalysis and detection. The test is conducted.  All the reagents \nand samples are prepared at room temperature before using \nthem.\nSample's numbering: The samples are numbered in order, \nand records of standard well and wells samples are kept.  \nSample's addition: a volume of 50 microliters is added to \neach well, and then 50 \u03bcl of conjugated HRP is added to each \nwell, and then 50 \u03bcl of antibody action solution is added. After \nthat, the plate is sealed with a plate stopper; it is shacked for 5 \nseconds to get a good mixture and put in the incubator for 30 \nminutes at 25 C\u00ba.\nWash, examine carefully, and remove the liquid. Immedia-\ntely add 300 \u03bcl of wash buffer to each well, and the process is \nrepeated 5 times with intervals of 30 seconds. The plate is re-\nversed and fixed on a thick, clean, and absorbent paper (if there \nwere bubbles in the wells, clean tips are used to pierce them).\nColor development: 50 \u03bcl of substrate reagent A is added \nto each well, and then 50 \u03bcl of the substrate reagent B is ad-\nded and shake gently until a good mixture is obtained and after \nthat, it is incubated for 15 minutes in the slight shade (the time \nof the reaction can be extended according to the fundamental \nchange in the color). Suspension of the reaction: 50 \u03bcl of the \nsuspension solution is added to each well and shaken gently \nfor good mixing.\nOD measurement: Determining the optical density (OD \nvalue) for each well at 450 nanometers (the standard wave-\nlength is 630 nanometers) using the microplate reader. This \nstep should be completed within 10 minutes after the suspen-\nsion of the reaction12.\nResults\nThe Aflatoxins quantitative measurement of dried fruit \nand nuts samples in the local markets in Mosul city showed \nthat they are highly polluted with these poisons, and several \nsamples were polluted at a rate higher than the accepted limit \nstipulated by the European Union.Dried fruits\nResults of the test, as shown by table (1), that apricot con-\ntains the least quantity of Aflatoxin (1.948 per billion) and the \nhighest was (12.295 per billion) due to the long period of sto-\nrage of the samples and this is because the low demand on it \nduring January and this conforms with what was found by (13). \nin their study of 20 samples of dried apricot, as they found that \n4 sample was highly polluted. \nThe Results Shown that figs dried is polluted with the \nAflatoxin with the highest value (13.694 per billion) and the \nlowest value (0.296 per billion), and the average quantity of \nAflatoxin (3.354 per billion) as shown in figure 2. \nAs for raisin, the analysis results showed that the samples \nincluded concentrations of Aflatoxin at the accepted range as \nthe highest pollution with Aflatoxin was (3.096 per billion), \nwhile the lowest was (0.000 per billion). The average quantity \nof Aflatoxin was (1.456 per billion).\nNuts\nThe analysis showed that several samples of nuts excee-\nded the acceptable limit, as shown in Table 2. These results \ndemonstrated that the pollution was (40%) in the almonds \nsamples and the pollution levels between (1.838 to 8.726 per \nbillion) and the average quantities of Aflatoxin was (4.017 per \nbillion), as displayed in figure 3.\nResults of the walnuts test also revealed that one of the \nsamples exceeded the tolerated limit of the European Union (4 \nper billion) for the total AF in the foodstuff and its concentra-\ntion was (11.529 per billion) due to the lousy storage, high hu-\nmidity, and the long period of storage and the average quantity \nin the samples was (1.687 per billion).\nAFL concentrations in cashew samples ranged between \n(2.701 per billion), and this value lies within the tolerated limit. \nThe average quantities in the sample were (3.857 per billion).\nFor the AFL concentrations in measured pistachio sam-\nples, the highest values were (9.761 per billion) and the most \nnegligible value was (1.814 per billion), and the average quan-\ntity of Aflatoxin was (6.195 per billion) as shown in table 2 and \nfigure 3.\nDiscussion\nThrough the qualitative and quantitative detection of Afla-\ntoxins in the samples of the nuts and the dried fruits used in \nthe study that used the ELISA technique, results showed that \nsome samples were polluted with Aflatoxins11,12 found that the \npollution of nuts with Aflatoxin with a percentage of 43% with \nconcentrations that range between 0.58-15.2 \u03bcl per billion. The \nreason behind that was inadequate storage, extended storage, \nand humidity, which led to increased Aflatoxins in the samples.\nTable 1. Results of the occurrence of AFs in the analyzed dried fruit samples.2029\nTable 2. Results of the occurrence of AFs in the analyzed nuts samples.\nFigure 2.  Average concentrations of AFLA in dried fruit samples.\nFigure 3.  Average AFLA Concentrations in Nuts Samples.\nThe current research recommends that several actions \nshould be taken to limit the occurrence of mycotoxins in foods. \nFirst of all, storing the foods in good conditions and also con-\nducting coordinated studies with the Colleges of Medicine and \nother relevant specializations to diagnose the fungi and the \ndiseases they cause in an attempt to limit them and also sym-\nposiums should be held to raise the awareness of the society \nabout the risks of these poisons and the ways to avoid them.Conclusions\nIt is concluded that Aflatoxins highly pollute the samples \nof nuts and dried fruits in question, and this implies a high risk \nof cancers incidence, especially liver cancer.\nAcknowledgments\nWe, the authors, bear witness that what has been mentio-\nned in this research in terms of results and everything is our \nown, and we bear responsibility in the event of any problem.Investigation about contamination of some food items in local markets, Mosul, Iraq2030\nAuthor's conflict\nWe researchers acknowledge that there is no conflict with \nour interests.\nBibliographic references\n1. Calder ari, T.O., Iamanaka, B.T., Frisvad, J.C., Pitt, J.I., Sartori, D.,\nPereira, J.L., Fungaro, M.H.P., et al.,. The biodiversity of Aspergil-\nlus section Flavi in Brazil nuts: from rainforest to consumer. Int. J. Food Microbiol.2013; 160 (3), 267\u2013272.\n2.\nP\nark ,O.L.H. Niapau , E.Boutrif. Minimizing  risks posed by myco-\ntoxins  utilizing  the  HACCP  concept .2009; 17 November, Avail-able from .\n3.\nSmith, M. C\n., Madec, S., Coton, E., & Hymery, N. Natural co-oc-\ncurrence of mycotoxins in foods and feeds and their in vitro com-bined toxicological effects. Toxins,2016; 8(4), 94\n4.\n Dhanasekar\nan, D., Shanmugapriya, S., Thajuddin, N., & Panneer-\nselvam, A.Aflatoxins and aflatoxicosis in human and animals. Af-latoxins-Biochemistry and Molecular Biology,2011; 221-254 .\n5.\nChukwuka,O\n.K. ; Okoli ,I.C. ; Opara,M. N. ; Ogbuewu ,I.P . and Iheshi-\nulor, O.O.M.The growing proplems of mycotoxin in animal feed in-dustry .Asian.J.Poultry.Sci.,2010; 4:122-134\n6.\nK\numar, P., Mahato, D. K., Kamle, M., Mohanta, T. K., & Kang, S.\nG.Aflatoxins: a global concern for food safety, human health andtheir management. Frontiers in microbiology,2017; 7, 2170.\n\u03b1\n7.A Saadullah, A., & K Abdullah, S. Detection of Aspergillus species in dried fruits collected from Duhok mark\net and study their afla-\ntoxiginic properties. Rafidain journal of science,2014; 25(1), 12-18.            \n8.\n Zain, M. E. Impact of my\ncotoxins on humans and animals. Journal \nof Saudi chemical society,2011; 15(2), 129-144.\n9.Marchese, S., P\nolo, A., Ariano, A., Velotto, S., Costantini, S., & Sev-\nerino, L. Aflatoxin B1 and M1: Biological properties and their in-volvement in cancer development. Toxins, 2018; 10(6), 214.\n10.\n Commis\nsion Regulation (EC) n.1881/2006 of 19 December 2006\nSetting Maximum Levels for Certain Contaminants in Foodstuffs. Official Journal of the European Union,2006; 364, 5-24. \n\u03b1\u03b1\n11.\n Commis\nsion, E. Commission Regulation (EC) No 401/2006 of 23\nFebruary 2006 laying down the methods of sampling and analy-sis for the official control of the levels of mycotoxins in foodstuffs. Off. J. Eur. Union.2006; 12\u201334.\n12.\n Commis\nsion, E. Commission Regulation (EC) No 165/2010 of 26\nFebruary 2010 amending Regulation (EC) No 1881/2006 settingmaximum levels for certain contaminants in foodstuffs as re-gards aflatoxins. Off. J. Eur. Union.2010; 8\u201312 .\n13.\n Lut\ntfullah, G., & Hussain, A. Studies on contamination level of\naflatoxins in some dried fruits and nuts of Pakistan. Food Con-trol,2011; 22(3-4), 426-429 .\nReceived: 11 May 2021\nAccepted: 25 June 2021Ammar Nafea Alnema, Mazin Nazar Fadhel\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2031\nModelo de regresi\u00f3n de Cox para an\u00e1lisis de supervivencia en pacientes con c\u00e1ncer de mama en la provincia de Manab\u00ed, Ecuador\nCox regression model for survival analysis in patients with breast cancer in the province of Manab\u00ed, Ecuador\nModelo de regresi\u00f3n de Cox para an\u00e1lisis de supervivencia en pacientes \ncon c\u00e1ncer de mama en la provincia de Manab\u00ed, Ecuador\nCox regression model for survival analysis in patients with breast cancer in the province of \nManab\u00ed, Ecuador\nCecilia Bucheli Giler1, Daniel Fabricio Alarc\u00f3n Cano2, Karime Montes Escobar3 DOI. 10.21931/RB/2021.06.03.24\nResumen: El c\u00e1ncer de mama es un problema de salud p\u00fablica, que ha venido increment\u00e1ndose, ubic\u00e1ndose como el c\u00e1ncer de \nmayor incidencia en las mujeres, su repercusi\u00f3n en la poblaci\u00f3n en general ocupaba el segundo lugar a nivel mundial, siendo la \nneoplasia maligna m\u00e1s frecuente en la poblaci\u00f3n femenina y en relaci\u00f3n a los decesos por c\u00e1ncer y afecta con m\u00e1s frecuencia \na los pa\u00edses del primer mundo y en v\u00edas de desarrollo. Estudio observacional, descriptivo y retrospectivo realizado a pacientes \ndiagnosticados con c\u00e1ncer de mama en el Hospital Oncol\u00f3gico de Manab\u00ed, Ecuador.  La supervivencia global y libre de enfermedad \na seis a\u00f1os se estableci\u00f3 a partir del tiempo trascurrido desde el diagn\u00f3stico hasta la ocurrencia de un evento o fecha del \u00faltimo \ncontacto, con l\u00edmite a diciembre de 2015. De los 403 pacientes, los l\u00edmites de edad fueron 15 y 90 a\u00f1os, con media de 56.08 a\u00f1os. \nSe considero el tama\u00f1o del tumor, donde (T1) representa el 26.55%, (T2) representaron 45.66%, la supervivencia global fue de \n80% a 6 a\u00f1os. Los pacientes en etapas avanzadas tuvieron menores probabilidades de supervivir con un porcentaje del 43%. Con \nel modelo de regresi\u00f3n de Cox, fue posible demostrar asociaci\u00f3n estad\u00edsticamente significativa entre el tama\u00f1o del tumor y la \nsupervivencia. El estudio demuestra que los pacientes en etapas avanzadas tienen menores probabilidades de supervivir, por lo \nque es imperativo que se contin\u00faen esfuerzos en promoci\u00f3n de la salud hasta conseguir que la detecci\u00f3n sea en etapas curables.\nPalabras clave: Modelo de Riesgos Proporcionales de Cox, supervivencia, c\u00e1ncer de mama, Ecuador.\nAbstract: Breast cancer is a public health problem, which has been increasing, ranking as cancer with the highest incidence in women, \nits impact on the general population ranked second worldwide, being the most frequent malignant neoplasm in the female population \nand concerning deaths from cancer and affects more frequently the first world and developing countries. Observational, descriptive, \nand retrospective study carried out in patients diagnosed with breast cancer at the Oncological Hospital of Manab\u00ed, Ecuador. The six-\nyear global and disease-free survival was established from the time elapsed from the diagnosis to the occurrence of an event or the \ndate of the last contact, with a limit to December 2015. Of the 403 patients, the age limits were 15 and 90 years, with a mean of 56.08 \nyears. The tumor size was considered, where (T1) represents 26.55%, (T2) represented 45.66%, the overall survival was 80% at 6 \nyears. Patients in advanced stages were less likely to survive with a percentage of 43%. With the Cox regression model, it was possible \nto demonstrate a statistically significant association between tumor size and survival. The study shows that patients in advanced \nstages are less likely to survive, so efforts in health promotion must continue until detection is in curable stages.\nKey words: Cox Proportional Hazards Model, survival, breast cancer, Ecuador.RESEARCH / INVESTIGACI\u00d3N\nIntroducci\u00f3n\nSeg\u00fan cifras de Globocan, el c\u00e1ncer de mama es un pro-\nblema de salud p\u00fablica, que desde el a\u00f1o 2012 ha venido incre-\nment\u00e1ndose, ubic\u00e1ndose como el c\u00e1ncer de mayor incidencia \nen las mujeres1; para el a\u00f1o 2018 su repercusi\u00f3n en la pobla-\nci\u00f3n en general ocupaba el segundo lugar a nivel mundial, al-\ncanzando el 11.6%; siendo la neoplasia maligna m\u00e1s frecuente \nen la poblaci\u00f3n femenina y en relaci\u00f3n a los decesos por c\u00e1n-\ncer, ocupa el cuarto lugar con un 6.6%.  El c\u00e1ncer de mama \nafecta con m\u00e1s frecuencia a los pa\u00edses del primer mundo y en \nv\u00edas de desarrollo, la edad con m\u00e1s recurrencia a la mortalidad \nes en mujeres de 60 a 74 a\u00f1os2.\nPara la Organizaci\u00f3n mundial de la salud, el desaf\u00edo de la \nproblem\u00e1tica de esta enfermedad es detectarla a tiempo. En \nEcuador, seg\u00fan registros del Ministerio de Salud P\u00fablica, hasta \njunio de 2018 se realizaron 1.287 nuevas atenciones con diag-\nn\u00f3stico de c\u00e1ncer de mama, de las cuales 1.254, corresponden \na mujeres representando el 97,6% de los casos presentados \npor esta patolog\u00eda, de acuerdo a datos obtenidos del Registro Diario Automatizado de Consultas y Atenciones Ambulatorias \n(RDACAA 2018) Y Plataforma de Registro de Atenci\u00f3n en Sa-\nlud (PRAS 2018)3.\nSeguidamente el Instituto de Estad\u00edsticas y Censos (INEC), \nen el a\u00f1o 2015, Manab\u00ed era la provincia que ocupaba el cuarto \npuesto a nivel nacional en decesos provocados por el c\u00e1ncer \nde mama y el tercer puesto a nivel nacional en tasa de mortali-\ndad por la misma enfermedad4.  En Manab\u00ed el c\u00e1ncer de mama \nocupa el primer lugar entre los diferentes tipos de c\u00e1ncer que \nexisten; siendo esta una de las principales provincias de nues-\ntro pa\u00eds, donde se encuentran estad\u00edsticas que punt\u00faan al c\u00e1n-\ncer de mama como la principal causa de mortalidad femenina. \nEn total, 235 casos en el 2018, que representan el 14,28%, se-\ng\u00fan estad\u00edstica emitida por Solca (Sociedad de Lucha contra \nel C\u00e1ncer)5.\nCon base en lo anterior se han desarrollado Modelos de \nRiesgos Proporcionales de Cox, para predecir la supervivencia \nde c\u00e1ncer de mama, que han conllevado a estimar la super-\n1 Maestr\u00eda en Estad\u00edstica, Instituto de Posgrado, Universidad t\u00e9cnica de Manab\u00ed, Portoviejo, Ecuador.  \n2 Docencia e investigaci\u00f3n, Solca Manab\u00ed, Ecuador.\n3 Departamento de Matem\u00e1ticas y Estad\u00edstica. Instituto de Ciencias B\u00e1sicas. Universidad T\u00e9cnica de Manab\u00ed, Portoviejo, Ecuador y Departamento de Estad\u00edstica. \nUniversidad de Salamanca, Salamanca, Espa\u00f1a. \nCorresponding author: karime.montes@gmail.com2032\nCecilia Bucheli Giler, Daniel Fabricio Alarc\u00f3n Cano, Karime Montes Escobar\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nvivencia personalizada a largo plazo en funci\u00f3n de las carac-\nter\u00edsticas demogr\u00e1ficas del paciente, los factores tumorales \ny tratamiento entregado6; este modelo permite identificar los \nfactores cl\u00ednicamente significativos asociados con el c\u00e1ncer de \nmama y esto puede ayudar a predecir el riesgo de enfermedad, \npor lo tanto sirve para obtener una evaluaci\u00f3n adecuada de los \nfactores cl\u00ednicos relevantes para el pron\u00f3stico del c\u00e1ncer, lo \nque contribuye particularmente en la selecci\u00f3n de eficientes \nestrategias terap\u00e9uticas7.\nEs por ello que el presente estudio tiene como objetivo \nrealizar un an\u00e1lisis de supervivencia en pacientes con c\u00e1ncer \nde mama de la Provincia de Manab\u00ed, mediante el Modelo de \nRiesgos proporcionales de Cox que permita determinar la su-\npervivencia a los 6 a\u00f1os de los pacientes diagnosticados con \nla enfermedad y su relaci\u00f3n con las variables como edad, g\u00e9-\nnero y estadio del tumor, sobrevida y meses de tratamiento, \nque proporcionen informaci\u00f3n \u00fatil a la toma de decisiones del \nm\u00e9dico con el paciente.\nM\u00e9todos\nEl presente trabajo es un estudio Transversal, Retros-\npectivo, Descriptivo, Anal\u00edtico y observacional; comprendido \ndurante el periodo 2010 hasta 2015 en el Hospital Oncol\u00f3gi-\nco \u201cDr. Julio Villacreses Colmont\u201d; de la Sociedad de Lucha \ncontra el c\u00e1ncer SOLCA Manab\u00ed, Ecuador.  Los pacientes con \nc\u00e1ncer de mama en este periodo ascendieron a 403, que fue-\nron objetos del an\u00e1lisis de supervivencia.  El estudio se realiz\u00f3 \nutilizando una matriz de informaci\u00f3n sobre los pacientes con \nc\u00e1ncer de mama, obtenida del departamento de estad\u00edstica, \nde SOLCA, Manab\u00ed, donde se elabor\u00f3 una tabla de an\u00e1lisis \ndescriptivo para un examen lo m\u00e1s completo posible sobre \nel c\u00e1ncer de mama, sin buscar ni causas ni consecuencias de \n\u00e9ste.  Se midi\u00f3 las caracter\u00edsticas de manera porcentual y se \nobserv\u00f3 la configuraci\u00f3n y los procesos que componen esta \nenfermedad, sin detenerse a valorarlos.\nSe realiz\u00f3 un an\u00e1lisis de la matriz de informaci\u00f3n, sobre \nlas variables o caracter\u00edsticas de los pacientes con c\u00e1ncer de \nmama, consiguiendo priorizarlas en los pacientes que reunie-\nron las caracter\u00edsticas como: g\u00e9nero, edad, estadio del tumor \nen relaci\u00f3n al tama\u00f1o del mismo, la sobrevida y meses de tra-\ntamiento constituyendo esta \u00faltima en la variable respuesta, \nen sentido de dar una mejor utilidad para el an\u00e1lisis de su-\npervivencia; en ellas se analiz\u00f3 la relaci\u00f3n con caracter\u00edsticas \ncl\u00ednicas o covariables que intervienen en el tiempo hasta la \nocurrencia del evento o no, es decir el tiempo de censura. Este \nan\u00e1lisis de supervivencia general se efectu\u00f3 mediante el pro-\ngrama RStudio versi\u00f3n 3.2.2.8.\nSeguidamente se efectu\u00f3 un an\u00e1lisis de supervivencia \nmediante el Modelo de Riesgos Proporcionales de Cox, donde \nse desarroll\u00f3 el concepto de probabilidad marginal, una fun-\nci\u00f3n de probabilidad que se caracteriza por los coeficientes de \n\u03b2, que miden los efectos de las covariables en la funci\u00f3n de \ntasa de falla9.\nEl modelo de Riesgos Proporcionales de Cox, constitu-\nye un modelo multivariado que puede ponderar el efecto de \nuna serie de covariables, variables explicativas, predictores, factores de riesgo, variables de confusi\u00f3n10, como tambi\u00e9n de \nvariables cualitativas o cuantitativas sobre un desenlace dico-\nt\u00f3mico en funci\u00f3n del tiempo y que puede definir al individuo \nen estudio mediante la ecuaci\u00f3n11: \nLa finalidad del Modelo de Riesgos Proporcionales de Cox \nes facilitar un m\u00e9todo de an\u00e1lisis de supervivencia sin nece-\nsidad de especificar o estimar una funci\u00f3n de riesgo basal, \nmediante el desarrollo del concepto de probabilidad marginal, \nuna funci\u00f3n de probabilidad que solo depende de los coeficien-\ntes del modelo; al usar este modelo, el resultado se expresa \npor medio de una estad\u00edstica llamada hazard ratio (HR), que \nes una divisi\u00f3n de riesgo (h) entre grupos y se define como la \nprobabilidad de tener el desenlace en un periodo de tiempo \ndeterminado, donde hay la posibilidad de que uno de los gru-\npos llegue antes al evento de inter\u00e9s al compararlo con otro \ngrupo11. \nEl Modelo de Riesgos Proporcionales de Cox se basa en \nconsiderar la prueba de significaci\u00f3n que ser\u00e1 la variable de \nagrupaci\u00f3n o de tratamiento, la misma cuyo efecto se probar\u00e1 \ncon la prueba de Wald, que proporciona un valor de p; ade-\nm\u00e1s se considera la obtenci\u00f3n del estimador del efecto, que \nes el Hazard ratio, y la obtenci\u00f3n del intervalo de confianza de \n95% para el Hazard ratio, que permite evaluar la significan-\ncia estad\u00edstica de la relaci\u00f3n de las variables del estudio y sus \nefectos en el desenlace del  evento de inter\u00e9s; en este sentido \nel primer supuesto que debe cumplirse ser\u00e1 sobre los datos \ncensurados que no est\u00e1n relacionados con la probabilidad que \nocurra el evento, es decir, que los individuos que no llegan al \nevento, no abandonaron el estudio por razones relacionadas a \nla variable de agrupaci\u00f3n, este supuesto se corrobora investi-\ngando las posibles razones por las que abandonaron el estudio, \ny el segundo supuesto seria  que las curvas de supervivencia \npara cada uno de los estratos deben tener funciones de ries-\ngos que sean proporcionales en el tiempo entre las etapas del \nproblema estudiado, aplic\u00e1ndose a las variables cuantitativas \ny ordinales, en donde se logre evidenciar los riesgos con in-\ncrementos constantes de un valor a otro y que siga la misma \ndirecci\u00f3n11. Este an\u00e1lisis de supervivencia se efectu\u00f3 mediante \nel programa SPSS versi\u00f3n 2512.\nEsta investigaci\u00f3n no busc\u00f3 lograr un estudio profundo so-\nbre el C\u00e1ncer de mama en el aspecto de la medicina cient\u00edfica; \nlo que se pretendi\u00f3 fue lograr un an\u00e1lisis de supervivencia a la \nenfermedad de acuerdo con las variables intervinientes en el \nestudio en funci\u00f3n a la tasa de muerte.\nResultados\nDe los 403 pacientes analizados, se observ\u00f3 que el \n98.76%, son mujeres y el 1.24% son hombres, los l\u00edmites \nde edad fueron 15 y 90 a\u00f1os, con media de 56.08 a\u00f1os.  El \n45.66%, presentan un tama\u00f1o del tumor T2 y el 16.63%, en T4.  \nEl 30.27%, tienen menos de un a\u00f1o padeciendo la enfermedad \ny el 4.96% m\u00e1s de cinco a\u00f1os.  El 87.10%, estaban vivos y el \n12.90% fallecieron (Tabla 1).2033\nSe procedi\u00f3 a realizar el an\u00e1lisis de supervivencia gene-\nral, considerando el tiempo de censura y el tiempo de fallas, \nubic\u00e1ndose a la variable meses de tratamiento como la varia-ble respuesta del presente estudio, la misma que se mide en meses considerando la fecha del primer diagn\u00f3stico hasta la fecha del fin del estudio o la ocurrencia del evento de inter\u00e9s que ser\u00eda la muerte del paciente con c\u00e1ncer de mama.  El ma-yor tiempo de supervivencia de los 52 pacientes que llegaron al evento, es de 40 meses para 15 pacientes (Figura 1).\nEn el estudio del tiempo de supervivencia en los pacientes \ncon c\u00e1ncer de mama se evidenciaron observaciones incom-pletas o parciales, es decir censuras m\u00faltiples de tipo I a la derecha (tiempo censurado); en donde el inicio del tiempo de supervivencia se realiz\u00f3 en diferentes fechas y a la fecha fin de estudio no se observ\u00f3 el evento de inter\u00e9s (muerte) en 351 pacientes; los mismos que no abandonaron el estudio por ra-zones relacionadas con el tratamiento o la variable de agrupa-ci\u00f3n, ya que algunos pacientes fallecieron despu\u00e9s de la fecha fin de estudio.  Entre 0 a 20 meses existe la mayor cantidad de pacientes que no llegaron al evento de inter\u00e9s (muerte) (Figura 2).\nLa Tabla 2, indica los valores de beta (B) que se encuentran \nasociados al hazard ratio y resultan positivos para los estadios del tumor (T3 y T4), estos estadios seg\u00fan los resultados re-presentan los principales factores de riesgo de la enfermedad, esto significa, que los pacientes con estadio del tumor (T3), con un 95% de confianza (IC95%:2.841-56.051) tienen 12.6 ve-ces el riesgo de haber fallecido en el mes 72 de seguimiento, en relaci\u00f3n con el estadio del tumor T1, y los pacientes con es-tadio del tumor T4 (IC95%:2.902-52.900), tienen 12.4 veces el riesgo de haber fallecido en el mes 72 de seguimiento en rela-ci\u00f3n con el estadio del tumor T1. Seguidamente el estad\u00edstico chi cuadrado modificado de Wald es significativo con valores p> 0.001, para los tama\u00f1os del tumor T3 y T4 respectivamen-te, el resto de covariables como edad y g\u00e9nero  resultan conun valor  no significativo en cuanto al riesgo de la enfermedad,por lo tanto no contribuyen con la ocurrencia del evento deinter\u00e9s; lo que significa que los pacientes que llegan con untama\u00f1o del tumor en categor\u00eda T3 y T4 tienen menor tiempode supervivencia al c\u00e1ncer de mama sin incidir el g\u00e9nero y laedad del paciente.\nLa curva de supervivencia global (Figura 3), en la que se \nrepresenta gr\u00e1ficamente c\u00f3mo van llegando al desenlace los 403 casos analizados conforme pasa el tiempo.  La probabili-dad de supervivencia global a 6 a\u00f1os fue de 80%, esto significa que para el mes 72 de seguimiento, el 80% de los pacientes contin\u00faa con vida. El tiempo medio de supervivencia est\u00e1 cerca a los 54 meses.\nLas curvas de supervivencia ajustadas por edad y g\u00e9nero \npara cada uno de los estadios de la enfermedad reflejan c\u00f3mo va incrementando la mortalidad en los pacientes en los tama-\u00f1os del tumor (T1, T2, T3 y T4) de la enfermedad.  Es claro que los pacientes en tama\u00f1o (T3 y T4) viven menos que los pacientes en estadios menos avanzados.  Para el mes 72 cer-ca del 57% de los pacientes en estadio 3 y 4 habr\u00e1n fallecido mientras que m\u00e1s del 90% de los pacientes con estadio I con-tin\u00faan con vida (Figura 4).\nLa figura 5, muestra la curva para los estadios del tumor \nT1, T2, T3 Y T4, donde puede verse que los estadios T3 y T4 se incrementan con mayor proporci\u00f3n en los intervalos del tiempo de manera que a mayor tama\u00f1o del estadio del tumor, mayor es el riesgo de supervivencia al c\u00e1ncer de mama.\nDiscusi\u00f3n\nEn relaci\u00f3n a los hallazgos encontrados, el Modelo de \nRiesgos Proporcionales de Cox ha  sido de gran importancia para el presente estudio, ya que genera una descripci\u00f3n pre-cisa y clara sobre la incidencia de las variables en el an\u00e1lisis de supervivencia del c\u00e1ncer mama, considerando la variable respuesta al tiempo transcurrido desde la fecha del primer diagn\u00f3stico del paciente, hasta la fecha fin de estudio u ocu-rrencia del evento del inter\u00e9s (muerte), frente a covariables como sobrevida, estadio del tumor, edad y g\u00e9nero; estos resul-tados guardan relaci\u00f3n con lo que se\u00f1ala (11) que el modelo multivariante de Riesgos Proporcionales de Cox, es muy \u00fatil en el campo de la salud, cuando se trata de enfermedades graves como el c\u00e1ncer, ya que el exponente de Beta o hazard ratio proporciona la significancia de la covariable m\u00e1s representa-tiva en el an\u00e1lisis de supervivencia y as\u00ed se obtiene un an\u00e1lisis que ayuda a la toma de decisiones sobre el tratamiento de la enfermedad entre el m\u00e9dico tratante con el paciente que la padece.\nAs\u00ed mismo los resultados del presente estudio guardan \nrelaci\u00f3n con lo que manifiesta (7), que el modelo de Riesgos Proporcionales de Cox genera una evaluaci\u00f3n adecuada de los factores cl\u00ednicos relevantes para el pron\u00f3stico del c\u00e1ncer, lo que contribuye particularmente en la selecci\u00f3n de eficientes \nTabla 1. Descripci\u00f3n de las Variables.Modelo de regresi\u00f3n de Cox para an\u00e1lisis de supervivencia en pacientes con c\u00e1ncer de mama en la provincia de Manab\u00ed, Ecuador\nCox regression model for survival analysis in patients with breast cancer in the province of Manab\u00ed, Ecuador2034\nestrategias terap\u00e9uticas; pero este no concuerda con (2) ya \nque los pacientes con menor edad presentaran una mejor su-\npervivencia global al c\u00e1ncer de mama.\nPor lo tanto en lo que se refiere a la variable edad no se \npudo demostrar relaci\u00f3n con la supervivencia, lo que tampo-\nco coincide con estudios realizados (13), a 1113 pacientes con \nc\u00e1ncer de mama en un periodo de estudio de cinco y diez a\u00f1os \ndonde el aumento de la edad en el momento del diagn\u00f3sti-\nco se asoci\u00f3 con un mayor riesgo de muerte en los pacientes, \nas\u00ed mismo en la investigaci\u00f3n hecha por (14), a 767 pacien-\ntes con c\u00e1ncer de mama, en donde se analiz\u00f3 la edad con la supervivencia, este encontr\u00f3 que los pacientes m\u00e1s j\u00f3venes y \nmayores parecen tener una supervivencia m\u00e1s corta al c\u00e1ncer \nde mama, sin embargo en este estudio no hay significancia en \nesta covariable edad, y por consiguiente el riesgo de que ocurra \nel evento no discrimina la edad del paciente.\nLa supervivencia global encontrada en el presente trabajo, \nen 6 a\u00f1os fue del 80%, semejante a la reportada en el estudio \nde (15),  que se efectu\u00f3 a 119 pacientes con c\u00e1ncer de mama \natendidas durante el 2010 al 2015 en el Hospital Militar de \nEspecialidades de la Mujer y Neonatolog\u00eda en la Ciudad de M\u00e9-\nxico, donde la supervivencia global se situ\u00f3 en 81%. En lo que \nFigura 1. Tiempo de supervivencia.\nFigura 2. Tiempo censurado.Cecilia Bucheli Giler, Daniel Fabricio Alarc\u00f3n Cano, Karime Montes Escobar\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2035\nno concuerda con la investigaci\u00f3n citada, es que en esta no se \npudo demostrar que la supervivencia se relaciona con otras va-\nriables como estadio del tumor (tama\u00f1o), ya que precisamente \nes la variable significativa relacionada con la supervivencia en \nlos pacientes con c\u00e1ncer de la presente investigaci\u00f3n, donde \ntama\u00f1o del tumor T1 y T2, demostraron que a menor tama\u00f1o \ndel tumor, mayor supervivencia a la enfermedad.\nConclusiones\nEn Ecuador los reportes de supervivencia son pocos, por \nello se realiza esta investigaci\u00f3n la cual significa un gran logro \ny esfuerzo entre instituciones, teniendo en cuenta los reportes \nde supervivencia a 6 a\u00f1os.   Se demostr\u00f3 en este estudio, que los pacientes diagnosticados en etapas avanzadas son aque-\nllos que su probabilidad de sobrevida es mucho menor, con \nbase en lo anterior cabe resaltar que es de gran importancia \nseguir investigando en pro de la salud, esto con el fin de detec-\ntar a tiempo y en etapas curables a los pacientes.\nAgradecimientos\nEste estudio fue apoyado por el Departamento de Mate-\nm\u00e1ticas y Estad\u00edstica. Instituto de Ciencias B\u00e1sicas. Los au-\ntores desean agradecer a SOLCA Portoviejo por su apoyo y \nfacilitar los datos.\nTabla 2. Factores predictores \nde supervivencia de los pa -\ncientes con c\u00e1ncer de mama.\nFigura 3. Curva de supervivencia ajustada por los cofactores.Modelo de regresi\u00f3n de Cox para an\u00e1lisis de supervivencia en pacientes con c\u00e1ncer de mama en la provincia de Manab\u00ed, Ecuador\nCox regression model for survival analysis in patients with breast cancer in the province of Manab\u00ed, Ecuador2036\nFigura 4. Curva de supervivencia por estadio de la enfermedad.\nFigura 5. Evaluaci\u00f3n de la funci\u00f3n de riesgos proporcionales.Cecilia Bucheli Giler, Daniel Fabricio Alarc\u00f3n Cano, Karime Montes Escobar\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2037\nReferencias bibliogr\u00e1ficas\n1. Minis terio de Salud P\u00fablica. Estrategia Nacional para la atenci\u00f3n\nintegral del c\u00e1ncer en el Ecuador. (2017).\n2.Ulloa, P\n., Ronquillo, S. & S\u00e1nchez, K. Sobrevida en pacientes con\nc\u00e1ncer de mama seg\u00fan su inmunohistoqu\u00edmica experiencia del\nInstituto Oncol\u00f3gico Nacional - Sociedad de Lucha Contra elC\u00e1ncer, Guayaquil Ecuador. Rev. Medica Sinerg. 5, e542 (2020).\n3.\nMinis\nterio de Salud Publica del Ecuador. Instructivo para el llena-\ndo del Automatizado de Consultas y Atenciones Ambulatorias(RDACAA). Minist. Salud P\u00fablica Ecuador 10\u201360 (2013).\n4.\n Arreaga, A. & T\norres, L. Visualizaci\u00f3n geogr\u00e1fica de la tasa de\nmortalidad por c\u00e1ncer de mama, c\u00e9rvix y de pr\u00f3stata en el Ec-uador. (2017).\n5.\nRisco, J\n. Nosotros \u2013 REVISTA DE MANAB\u00cd.. Se dieron \u2018un toque\u2019\npara prevenir el c\u00e1ncer de mama. (2019).\n6.Asare, E. A. et al. De\nvelopment of a model to predict breast can-\ncer survival using data from the National Cancer Data Base. Surg. (United States) 159, 495\u2013502 (2016).\n7.\nT\nang, W. et al. Screening of Clinical Factors Related to Prognosis \nof Breast Cancer Based on the Cox Proportional Risk Model. J.Comput. Biol. 27, 1\u201310 (2020).\n8.\n T\neam, R. r studio - Google Acad\u00e9mico. RStudio: integrated devel-\nopment for R. RStudio, Inc. Boston, MA (2018).\n9.R\nebaza, D. \u201cMODELOS SEMIPARAM\u00c9TRICOS DE EVENTOS RE-\nCURRENTES: CASO APLICACI\u00d3N A PACIENTES CON CANCERDE MAMA\u201d. 67 (2017).10.\n Boj del V\nal, E. El modelo de regresi\u00f3n de Cox. El modelo de re-\ngresi\u00f3n de Cox (2017).\n11. P\u00e9rez-Rodr\u00edguez, M., Rivas-Ruiz, R., Palacios-Cruz, L. & Talavera,\nJ. O. XXII. Del juicio cl\u00ednico al modelo de riesgos proporcionales de Cox. Rev Med Inst Mex Seguro Soc 52, 430\u2013435 (2014).\n12.\n Sps\ns, I. spss - Google Acad\u00e9mico. IBM SPSS Statistics for Win-\ndows, version 25 Armonk, NY: IBM SPSS CORP. (2017).\n13.\n Caleffi, M. et al. Breas\nt cancer survival in Brazil: How much health \ncare access impact on cancer outcomes? Breast 54, 155\u2013159(2020).\n14.\n Balabr\nam, D. Asociaci\u00f3n entre edad y supervivencia en una co-\nhorte de pacientes brasile\u00f1as con c\u00e1ncer de mama operable Aso-ciaci\u00f3n entre edad y supervivencia en una cohorte de pacientesbrasile\u00f1as con c\u00e1ncer de mama operable Asociaci\u00f3n entre edad y supervivencia en una. 31, 1732\u20131742 (2015).\n15.\n Heredia, \nA. & Palacios, G. Supervivencia a 5 a\u00f1os pos tratamien-\nto de c\u00e1ncer de mama: experiencia institucional. Ginecol. Obstet.Mex. 86, 575\u2013583 (2018).\nReceived: 18 marzo 2021\nAccepted: 15 julio 2021Modelo de regresi\u00f3n de Cox para an\u00e1lisis de supervivencia en pacientes con c\u00e1ncer de mama en la provincia de Manab\u00ed, Ecuador\nCox regression model for survival analysis in patients with breast cancer in the province of Manab\u00ed, Ecuador2038\nLaura Taylor, Carlos S. Mamani-Garc\u00eda, Alexandra Guti\u00e9rrez-Pingo, Jerry K. Benites-Meza, Diego Chambergo-Michilot, Norma del Carmen G\u00e1lvez-D\u00edaz, \nJoshuan J. Barboza\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nInfecci\u00f3n metast\u00e1sica por Staphylococcus aureus  en neonatos: a prop\u00f3sito \nde un caso\nMetastatic infection by Staphylococcus aureus  in neonates: about a case\nLaura Taylor1, Carlos S. Mamani-Garc\u00eda2, Alexandra Guti\u00e9rrez-Pingo3, Jerry K. Benites-Meza4, Diego Chambergo-Michilot5, Norma del Carmen \nG\u00e1lvez-D\u00edaz6, Joshuan J. Barboza7DOI. 10.21931/RB/2021.06.03.25\nResumen: La infecci\u00f3n metast\u00e1sica como complicaci\u00f3n infrecuente de bacteriemia por Staphylococcus aureus en neonatos \nes de dif\u00edcil manejo por la limitada bibliograf\u00eda. Comunicar el caso cl\u00ednico de un neonato prematuro que desarroll\u00f3 infecci\u00f3n \nmetast\u00e1sica como complicaci\u00f3n de bacteriemia por S. aureus. Presentamos el caso de un neonato prematuro que ingres\u00f3 a \nUnidad de cuidados intensivos neonatal, diagnosticado de sepsis bacteriana, s\u00edndrome de dificultad respiratoria neonatal y \nafectaci\u00f3n por ruptura prematura de membrana. Le insertaron cat\u00e9ter epicut\u00e1neo y fue tratado para bacteriemia por E. coli \ncon \u00e9xito. Reingres\u00f3 por sepsis tard\u00eda debido a infecci\u00f3n de S. aureus multisensible en cat\u00e9ter epicut\u00e1neo. Aparece un absceso \nen la cara anterior del t\u00f3rax por S. aureus, confirmando infecci\u00f3n metast\u00e1sica. Se realiz\u00f3 el drenaje del absceso con resoluci\u00f3n \nfavorable del cuadro cl\u00ednico. En neonatos sometidos a procedimientos invasivos es importante vigilar la evoluci\u00f3n cl\u00ednica e \nidentificaci\u00f3n temprana de infecci\u00f3n metast\u00e1sica post-bacteriemia por Staphylococcus aureus y brindar tratamiento temprano \npara evitar secuelas.\nPalabras clave: Bacteriemia, infecci\u00f3n metast\u00e1sica, infecci\u00f3n relacionada a cat\u00e9ter, reci\u00e9n nacido, Staphylococcus aureus.\nAbstract: Metastatic infection as an infrequent complication of Staphylococcus aureus bacteremia in neonates is challenging due \nto the limited literature. To report the clinical case of a premature neonate who developed a metastatic infection as a complication \nof S. aureus bacteremia. We present the case of a premature neonate admitted to the Neonatal Intensive Care Unit, diagnosed with \nbacterial sepsis, neonatal respiratory distress syndrome, and involvement by premature rupture of the membrane. A patch catheter \nwas inserted, and he was successfully treated for E. coli bacteremia. He was re-admitted for late sepsis due to infection with multi-\nsensitive S. aureus in a patch catheter. An abscess appears on the front of the chest due to S. aureus, confirming metastatic infection. \nThe abscess was drained with a favorable resolution of the clinical picture. In neonates submitted to invasive procedures, it is essential \nto monitor the clinical evolution and early identification of metastatic infection after Staphylococcus aureus bacteremia and provide \nearly treatment to avoid sequelae.\nKey words: Bacteremia, catheter-related infections, metastatic infection, newborn, Staphylococcus aureus.CASE REPORTS / REPORTE DE CASO\nIntroducci\u00f3n\nLa bacteriemia es la presencia de bacterias en la sangre1. \nAl ser una infecci\u00f3n grave, puede conducir a una morbilidad y \nmortalidad significativa si no se maneja adecuadamente2. La \nincidencia es variable por pa\u00edses y grupos de edad. En pobla-\nci\u00f3n pedi\u00e1trica; el diagn\u00f3stico cl\u00ednico puede ser un desaf\u00edo de-\nbido a la presentaci\u00f3n variable dependiendo de la edad, el sitio \nde infecci\u00f3n y el organismo causal3; e incluso la bacteriemia \npor Staphylococcus aureus tiene variedad de presentaciones4.\nLa bacteriemia por S. aureus provoca infecciones que in-\ncluyen infecciones de piel, tejidos blandos y neumon\u00eda. \u00c9sta \npuede dar lugar a complicaciones como endocarditis infeccio-\nsa, complicaciones pulmonares e infecciones metast\u00e1sicas5. \nLa infecci\u00f3n metast\u00e1sica se define como la extensi\u00f3n de la in-\nfecci\u00f3n que no presenta relaci\u00f3n alguna con la infecci\u00f3n del si-\ntio primario6. Puede ser del tipo endocarditis infecciosa, osteo-\nmielitis vertebral, abscesos de tejidos blandos, artritis s\u00e9ptica, infecci\u00f3n ocular, embolismo pulmonar s\u00e9ptico, entre otros7,8.\nLa prevalencia de infecci\u00f3n metast\u00e1sica por S. aureus en \nreci\u00e9n nacidos es incierta, sin embargo, un estudio report\u00f3 la \ndiseminaci\u00f3n metast\u00e1sica en el 13,4%  de 112 episodios de \nbacteriemias por S. aureus relacionadas a cat\u00e9ter en pacientes \npedi\u00e1tricos9.\nSeg\u00fan las gu\u00edas, la duraci\u00f3n del tratamiento en pacientes \npedi\u00e1tricos con bacteriemia puede variar de 2 a 6 semanas se-\ng\u00fan diversos factores10. Por ello, es importante identificar una \ninfecci\u00f3n metast\u00e1sica en neonatos debido a que el tratamiento \nes diferente al de una bacteriemia no complicada, adem\u00e1s de \nque un tratamiento insuficiente (por ejemplo, por una identifi-\ncaci\u00f3n tard\u00eda) para estas complicaciones graves se asocia con \nmal pron\u00f3stico, discapacidad y reca\u00edda.\nNuestro objetivo es reportar el caso de un neonato que \ndesarroll\u00f3 infecci\u00f3n metast\u00e1sica como complicaci\u00f3n de bac-\n1 M\u00e9dico Epidemi\u00f3logo, Cl\u00ednica Palermo de Bogot\u00e1, Colombia. \n2 Estudiante de medicina, Facultad de Medicina, Universidad Nacional de San Agust\u00edn, Arequipa, Per\u00fa y Sociedad Cient\u00edfica de Estudiantes de Medicina Agustinos \n(SOCIEMA), Universidad Nacional de San Agust\u00edn, Arequipa, Per\u00fa.\n3 Estudiante de medicina, Escuela de Medicina, Universidad Nacional del Santa, Nuevo Chimbote-Ancash, Per\u00fa y Sociedad Cient\u00edfica de Estudiantes de Medicina de \nla Universidad Nacional del Santa (SOCEMUNS), Universidad Nacional del Santa, Nuevo Chimbote-Ancash, Per\u00fa.\n4 Estudiante de medicina, Facultad de Medicina, Universidad Nacional de Trujillo, Trujillo, Per\u00fa y Sociedad Cient\u00edfica de Estudiantes de Medicina de la Universidad \nNacional de Trujillo (SOCEMUNT), Universidad Nacional de Trujillo, Trujillo, Per\u00fa. \n5 Estudiante de medicina, Facultad de Medicina, Universidad Cient\u00edfica del Sur, Lima, Per\u00fa y Tau-Relaped Group, Trujillo, Per\u00fa. \n6 Doctora en Enfermer\u00eda, Escuela de Enfermer\u00eda, Universidad Se\u00f1or de Sip\u00e1n, Chiclayo, Per\u00fa. \n7 Maestr\u00eda en Investigaci\u00f3n Cl\u00ednica, Especialista en Cuidados Intensivos Neonatales, Tau-Relaped Group, Trujillo, Per\u00fa y Escuela de Medicina, Universidad Se\u00f1or de \nSip\u00e1n, Chiclayo, Per\u00fa.  \nCorresponding author: jbarbozameca@relaped.com.2039\nInfecci\u00f3n metast\u00e1sica por Staphylococcus aureus  en neonatos: a prop\u00f3sito de un caso\nMetastatic infection by Staphylococcus aureus  in neonates: about a case\nteriemia por Staphylococcus aureus; abordar aspectos diag-\nn\u00f3sticos y terap\u00e9uticos m\u00e1s importantes y revisar la literatura \ndisponible.\nCaso cl\u00ednico\nNeonato masculino, nacido a las 29,4 semanas por ce-\ns\u00e1rea debido a ruptura prematura de membrana prolongada. \nComo antecedente se destaca: madre de 30 a\u00f1os, sin antece-\ndentes patol\u00f3gicos, con 6 controles en la gestaci\u00f3n y pruebas \nde infecci\u00f3n cong\u00e9nitas negativas.\nSe realiz\u00f3 maduraci\u00f3n pulmonar y reanimaci\u00f3n con pre-\nsi\u00f3n positiva continua en v\u00eda a\u00e9rea (CPAP). Present\u00f3 presi\u00f3n \narterial de 56/25, Silverman 4/0, frecuencia cardiaca de 138 \nlatidos por minuto, frecuencia respiratoria de 60 respiraciones \npor minuto, SaO2 de 94%, FiO2 de 35% y ventilaci\u00f3n mediante \ntubo orotraqueal. Naci\u00f3 con bajo peso (1 540 g), talla adecuada \n(43 cm), per\u00edmetro cef\u00e1lico de 29 cm, sin contacto piel con piel \ny no se inici\u00f3 lactancia materna en la primera hora. Ingres\u00f3 a \nUnidad de cuidados intensivos neonatales (UCIN) con diagn\u00f3s-\ntico de sepsis bacteriana y s\u00edndrome de dificultad respiratoria \n(SDR) neonatal.\nEn su 2\u00b0 d\u00eda de vida se inserta cat\u00e9ter epicut\u00e1neo, inicia \nventilaci\u00f3n no invasiva (VNI) y posteriormente, por c\u00e1nula na-\nsal. Se administr\u00f3 1 dosis de surfactante ex\u00f3geno y fue retira-do el tubo orotraqueal. Se inici\u00f3 antibioticoterapia. Luego del \ncultivo se reporta Escherichia coli, leucopenia y PCR positiva \n(Tabla 1); asimismo, por ictericia acentuada, se inici\u00f3 fotote-\nrapia, acompa\u00f1ado de nutrici\u00f3n parenteral y segunda dosis de \nsurfactante ex\u00f3geno. Al 6\u00b0 d\u00eda, amerit\u00f3 paso de ox\u00edgeno por \nc\u00e1nula nasal a VNI, pero fue retomado al d\u00eda siguiente, adem\u00e1s \nno present\u00f3 distermias y la PCR fue en descenso. Al 10\u00b0 d\u00eda, \nfue trasladado a cuidados intermedios, finaliz\u00f3 antibioticotera-\npia y los hemocultivos y PCR fueron negativos. \nEl 15\u00b0 d\u00eda, present\u00f3 polipnea y edemas perif\u00e9ricos, au-\nmento del requerimiento respiratorio y tendencia a la taqui-\ncardia. Se retir\u00f3 cat\u00e9ter epicut\u00e1neo y se orden\u00f3 cultivo de la \npunta y ex\u00e1menes auxiliares (Tabla 1). Se inici\u00f3 tratamiento \npor sospecha de sepsis tard\u00eda (Tabla 2). El 16\u00b0 d\u00eda, los resul-\ntados de hemocultivo y punta de cat\u00e9ter fueron positivos, la \ncausa de la sepsis tard\u00eda por Staphylococcus aureus, present\u00f3 \nlesi\u00f3n de tipo absceso en la cara anterior del t\u00f3rax. El 17\u00b0 d\u00eda, \npresent\u00f3 hipotensi\u00f3n, taquicardia, llenado capilar lento, gasto \nurinario aumentado. Se pas\u00f3 bolo de soluci\u00f3n salina y reingre-\ns\u00f3 a UCIN. Posteriormente fue trasladado a cuidados b\u00e1sicos, \ncon absceso del t\u00f3rax limitado de 1 x 2 cm con calor local, cuya \nsecreci\u00f3n report\u00f3 S. aureus multisensible, por lo que se inicia-\nron 10 d\u00edas de antibioticoterapia (Tabla 2). Egres\u00f3 el d\u00eda 29 de \nvida con ox\u00edgeno domiciliario, plan canguro, absceso resuelto y \ncon dosis de palivizumab.\nTabla 1. Resultados de \nex\u00e1menes diagn\u00f3sticos y \nauxiliares.2040\nDiscusi\u00f3n\nPresentamos el caso de un neonato pret\u00e9rmino, recupe-\nrado de una bacteriemia inicial por E. coli, con diagn\u00f3stico de \nbacteriemia por S. aureus, sospechada por signos y s\u00edntomas hemodin\u00e1micos inespec\u00edficos y confirmada por hemocultivos, complicada por sepsis e infecci\u00f3n metast\u00e1sica (absceso) la cual se comprob\u00f3 al identificar el origen en el cat\u00e9ter peri-f\u00e9rico.  La bibliograf\u00eda acerca de la infecci\u00f3n metast\u00e1sica en neonatos es escasa, por lo que reportamos este caso con el objetivo de ampliar los conocimientos sobre el tema.\nSe realiz\u00f3 una b\u00fasqueda sistem\u00e1tica en dos bases de \ndatos (Pubmed y Scopus). No se aplicaron restricciones de idioma o fecha de publicaci\u00f3n. Las palabras clave usadas para formular las estrategias de b\u00fasqueda fueron \u201cStaphylococcus aureus\u201d, \u201cMetastatic infection\u201d, \u201cBacteremia\u201d, \u201cCatheter-Rela-ted Infections\u201d y \u201cNewborn infant\u201d.\nEn este caso, el primer microorganismo aislado fue E. coli, \nel cual probablemente provino del tracto genitourinario de la madre considerando los 5 d\u00edas de evoluci\u00f3n de la ruptura pre-matura de membrana; pues la bacteria Escherichia coli, luego de S. aureus, es uno de los microorganismos m\u00e1s frecuente-\nmente transferidos madre-hijo en pacientes con ruptura pre-matura de membrana y suele ocurrir antes de las 37 semanas de gestaci\u00f3n\n11.\nLa ruptura prematura de membrana es factor de riesgo \nmaterno para infecci\u00f3n de aparici\u00f3n temprana por Escherichia coli. As\u00ed mismo la prematuridad y bajo peso predisponen a una infecci\u00f3n que puede resultar en sepsis\n12. Una vez superada esa \ninfecci\u00f3n, hubo un episodio de inestabilidad hemodin\u00e1mica con hemocultivos positivos para S. aureus, confirm\u00e1ndose la infec-ci\u00f3n tard\u00eda. Esto dado que el acceso venoso central por cat\u00e9-ter epicut\u00e1neo es factor de riesgo para infecci\u00f3n de aparici\u00f3n tard\u00eda (despu\u00e9s de los 3 a 7 d\u00edas de vida) por Staphylococcus aureus\n12.\nConsiderando que el paciente hab\u00eda sido sometido a pro-\ncedimiento invasivo (colocaci\u00f3n de un cat\u00e9ter epicut\u00e1neo) y haber descartado otro proceso infeccioso simult\u00e1neo, se con-sidera como diagn\u00f3stico una infecci\u00f3n del torrente sangu\u00edneo asociada a cat\u00e9ter (ITS-AC). Con la ITS-AC de m\u00ednimo 6 d\u00edas de evoluci\u00f3n (periodo de suspensi\u00f3n de antibioticoterapia para la infecci\u00f3n anterior) se procedi\u00f3 a retirar el cat\u00e9ter (lo recomen-dado en las gu\u00edas de manejo)\n13 e insertar uno nuevo. Los estu-\ndios recomiendan que se retire de manera inmediata, evitando una infecci\u00f3n en sangre\n14 dentro de las dos primeras semanas. \nEstas recomendaciones se basan en estudios observacionales, por los escasos o nulos ECA respecto a este tema\n15. Por ejem-\nplo, un estudio realizado en la cl\u00ednica privada de Sao Paulo16, \nentre el 2010 y 2011 demostr\u00f3 que la ITS-AC es una compli-caci\u00f3n en neonatos que requiere la extracci\u00f3n no selectiva del cat\u00e9ter. Otro estudio, realizado por Beard, Lauren MD et al.\n17, \nen el a\u00f1o 2019, demostr\u00f3 un valor significativo entre el tiempo de permanencia del cat\u00e9ter y el retiro no selectivo del mismo (p< 0.0001), siendo observado en menor frecuencia entre los 8 y 59 d\u00edas de permanencia del cat\u00e9ter. As\u00ed se concluy\u00f3 en el estudio que durante la primera semana y pasado los 59 d\u00edas el retiro no selectivo del cat\u00e9ter conlleva mayores riesgos de complicaciones como la ITS-AC, acompa\u00f1ados de un periodo de estabilidad. Una particularidad en nuestro caso, es que se hace visible un absceso en la cara anterior del t\u00f3rax, sin lesio-nes previas, en donde se a\u00edsla el mismo microorganismo. Esto confirma una infecci\u00f3n metast\u00e1sica a tejidos blandos por S. aureus, lo cual constituye una de las pocas met\u00e1stasis repor-tadas\n18. En neonatos, la infecci\u00f3n metast\u00e1sica de origen en el \ncat\u00e9ter perif\u00e9rico ha sido poco estudiada9,19. De acuerdo a Mur-\ndoch F, et al.20, en el 2017, en una poblaci\u00f3n pedi\u00e1trica menores \nde 15 a\u00f1os (mediana = 1 a\u00f1o) se reportaron un 4,8% (N=126) de casos que desarrollaron un absceso profundo. Asimismo, un reciente estudio de Falup-Pecurariu O, et al.\n21, report\u00f3 un \ncaso de un reci\u00e9n nacido de 3 semanas present\u00f3 un absceso profundo, pero fue en la regi\u00f3n izquierda del cuello.\nAnte la sospecha de sepsis tard\u00eda por bacteriemia, se \nadministr\u00f3 tratamiento emp\u00edrico (abarcando a S. aureus me-ticilino-resistente[SAMR]). Este consisti\u00f3 en vancomicina y piperacilina - tazobactam. Diferentes estudios muestran la eficacia mayor de administrar vancomicina junto a un beta-lact\u00e1mico, comparado con tan s\u00f3lo vancomicina. El betalac-t\u00e1mico m\u00e1s usado para estas combinaciones fue piperacilina - tazobactam, similar a nuestro caso\n22. El desescalamiento\nde piper\nacilina - tazobactam es a menudo a ceftriaxona pero\ntambi\u00e9n es aceptable otro betalact\u00e1mico22. En este caso, el\ndesescalamiento fue a cefepime, una cefalosporina de cuartageneraci\u00f3n. Algunos otros estudios han demostrado la efecti-vidad de reg\u00edmenes basados en daptomicina u otros basadosen vancomicina; y en caso de que los reg\u00edmenes basados envancomicina y daptomicina no reviertan la bacteriemia, otrosf\u00e1rmacos como ceftarolina sola, ceftarolina con trimetoprim- sulfametoxazol (TMP-SMX), linezolid, telavancina, fosfomici-na con imipenem y quinupristina-dalfopristina, han mostradoeficacia\n22. Sin embargo, la IDSA recomienda usar vancomicina\nIV como tratamiento primario para las infecciones graves porSAMR en el per\u00edodo neonatal, a su vez; la decisi\u00f3n de combinar f\u00e1rmacos debe ser individualizada y que TMP-SMX no se usedurante el per\u00edodo neonatal inmediato debido al mayor riesgode kern\u00edcterus\n10.\nLa duraci\u00f3n del tratamiento desde la confirmaci\u00f3n de S. \nTabla 2. Cambios en el tratamiento.Laura Taylor, Carlos S. Mamani-Garc\u00eda, Alexandra Guti\u00e9rrez-Pingo, Jerry K. Benites-Meza, Diego Chambergo-Michilot, Norma del Carmen G\u00e1lvez-D\u00edaz, \nJoshuan J. Barboza\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2041\naureus como causa de la sepsis tard\u00eda (un d\u00eda despu\u00e9s del \ninicio del tratamiento emp\u00edrico con vancomicina y piperacili-na - tazobactam) hasta la resoluci\u00f3n del absceso fue de 12 d\u00edas. La Sociedad Americana de Enfermedades Infecciosas (en ingl\u00e9s, IDSA) recomienda que el tratamiento en bacteriemias complicadas dure entre 2-6 semanas dependiendo del caso\n10. \nExisten estudios que indican cu\u00e1nto debe durar el tratamiento en caso de infecci\u00f3n metast\u00e1sica tipo endocarditis infecciosa, osteomielitis vertebral, artritis s\u00e9ptica, entre otros\n7; pero no \nexisten en el caso de infecci\u00f3n de tejidos blandos, probable-mente debido a que este debe ser tratado de manera similar a una infecci\u00f3n de tejidos blandos primaria (es decir, no infecci\u00f3n metast\u00e1sica). La IDSA recomienda vancomicina IV si se sospe-cha de SAMR\n10. En este caso, el absceso en los dos primeros \nd\u00edas fue tratado con la misma combinaci\u00f3n para la bacteriemia (vancomicina y cefepime) y una vez identificado que el S. au-reus era multisensible, se suspendi\u00f3 la vancomicina y se inici\u00f3 oxacilina, por diez d\u00edas, hasta resoluci\u00f3n del absceso.\nConclusiones\nEs importante la vigilancia de la evoluci\u00f3n cl\u00ednica, la sos-\npecha e identificaci\u00f3n temprana de una infecci\u00f3n metast\u00e1sica como complicaci\u00f3n de una bacteriemia por Staphylococcus aureus en neonatos sometidos a procedimientos invasivos con el fin de iniciar un tratamiento adecuado y temprano para evi-tar las posibles secuelas.\nAgradecimientos\nEste estudio fue apoyado por el Departamento de Mate-\nm\u00e1ticas y Estad\u00edstica. Instituto de Ciencias B\u00e1sicas. Los au-\ntores desean agradecer a SOLCA Portoviejo por su apoyo y facilitar los datos.\nContribuciones de autores\nLaura Taylor y Joshuan J. Barboza: Revisi\u00f3n cr\u00edtica del \nart\u00edculo, aprobaci\u00f3n de la versi\u00f3n final, aporte de pacientes o \nmaterial de estudio, garante.\nCarlos S. Mamani-Garc\u00eda, Alexandra Guti\u00e9rrez-Pingo, Je-\nrry K. Benites-Meza: Redacci\u00f3n, revisi\u00f3n cr\u00edtica y aprobaci\u00f3n de la versi\u00f3n final.\nDiego Chambergo-Michilot y Norma del Carmen G\u00e1l-\nvez-D\u00edaz: Revisi\u00f3n cr\u00edtica del art\u00edculo, aprobaci\u00f3n de la versi\u00f3n final\nInformaci\u00f3n de financiaci\u00f3n\nEl reporte ha sido autofinanciado.\nConflictos de inter\u00e9s\nLos autores declaran que no tienen conflicto de intereses \ncontrapuestos.\nReferencias bibliogr\u00e1ficas\n1. Geier R, Liu S, Tille y P, Roberts A, Rassekh SR, Ting J, et al.\nEpidemiology of Antibiotic Resistant Gram-negative Bacte-\nremia in a Hospital-Based Pediatric Population. Pediatrics2018;142:567\u2013567. https://doi.org/10.1542/PEDS.142.1_MEET -\nINGABSTRACT.567.\n2.\nCoon ER, Sriv\nastava R, Stoddard G, Wilkes J, Pavia AT, Shah SS.\nShortened IV antibiotic course for uncomplicated, late-onsetgroup b streptococcal bacteremia. Pediatrics 2018;142. https://doi.org/10.1542/peds.2018-0345.3.\nP\nai S, Enoch DA, Aliyu SH. Bacteremia in children: Epidemiology,\nclinical diagnosis and antibiotic treatment. Expert Rev Anti Infect Ther 2015;13:1073\u201388. https://doi.org/10.1586/14787210.2015.1063418.\n4.\n McMullan BJ\n, Bowen A, Blyth CC, Van Hal S, Korman TM, But-\ntery J, et al. Epidemiology and mortality of staphylococcus au-reus Bacteremia in Australian and New Zealand children. JAMAPediatr 2016;170:979\u201386. https://doi.org/10.1001/jamapediat-rics.2016.1477.\n5.\nK\neynan Y, Rubinstein E. Staphylococcus aureus Bacteremia,\nRisk Factors, Complications, and Management. Crit Care Clin2013;29:547\u201362. https://doi.org/10.1016/j.ccc.2013.03.008.\n6.\nKhatib R, Riederer K, Saeed S, Johnson LB, F\nakih MG, Sharma\nM, et al. Time to Positivity in Staphylococcus aureus Bacteremia: Possible Correlation with the Source and Outcome of Infection.Clin Infect Dis 2005;41:594\u20138. https://doi.org/10.1086/432472.\n7.\nHorino T\n, Hori S. Metastatic infection during Staphylococcus au-\nreus bacteremia. J Infect Chemother 2020;26:162\u20139. https://doi.org/10.1016/j.jiac.2019.10.003.\n8.\n F\nowler VG, Justice A, Moore C, Benjamin DK, Woods CW, Camp-\nbell S, et al. Risk Factors For Hematogenous Complicationsof Intravascular Catheter--Associated Staphylococcus au-reus Bacteremia. Clin Infect Dis 2005;40:695\u2013703. https://doi.org/10.1086/427806.\n9.\nCarrillo-Marquez \nMA, Hulten KG, Mason EO, Kaplan SL. Clin-\nical and Molecular Epidemiology of Staphylococcus aureusCatheter-Related Bacteremia in Children. Pediatr Infect Dis J2010;29:410\u20134. https://doi.org/10.1097/INF.0b013e3181c767b6.\n10.\n Catherine Liu 1, Arnold Ba\nyer, Sara E Cosgrove, Robert S Daum,\nScott K Fridkin, Rachel J Gorwitz, Sheldon L Kaplan, Adolf WKarchmer, Donald P Levine, Barbara E Murray, Michael J Rybak,David A Talan HFC. Clinical Practice Guidelines by the InfectiousDiseases Society of America for the Treatment of Methicillin-Re-sistant Staphylococcus aureus Infections in Adults and Children| Clinical Infectious Diseases | Oxford Academic. Clin Infect Dis2011;52:e18\u20139. https://doi.org/10.1097/INF.0b013e3181c767b6.\n11.\n Z\neng L nan, Zhang L li, Shi J, Gu L ling, Grogan W, Gargano MM, et \nal. The primary microbial pathogens associated with prematurerupture of the membranes in China: A systematic review. TaiwanJ Obstet Gynecol 2014;53:443\u201351. https://doi.org/10.1016/j.tjog.2014.02.003.\n12.\n Shane AL, S\u00e1nchez P\nJ, Stoll BJ. Neonatal sepsis. Lan-\ncet 2017;390:1770\u201380. https://doi.org/10.1016/S0140-6736(17)31002-4.\n13.\n Bous\nsamet L, Launay E, Thomas E, Leguen CG, Lepelletier D.\nShould central venous catheters be rapidly removed to treatStaphylococcus aureus related-catheter bloodstream infection(CR-BSI) in neonates and children? An 8-year period (2010\u20132017) retrospective analysis in a French University Hospital. J Hosp In-fect 2019;103:97\u2013100. https://doi.org/10.1016/j.jhin.2019.03.015.\n14.\n Ser\nane T, Kothendaraman B. Incidence and risk factors of infections \nassociated with peripheral intravenous catheters. J Infect Prev2015;17:115\u201320. https://doi.org/10.1177/1757177416631415.\n15.\n Gordon A, Greenhalgh M, Mcguire W\n. Early planned removal\nversus expectant management of peripherally inserted centralcatheters to prevent infection in newborn infants. Cochrane Da-tabase Syst Rev 2018;2018. https://doi.org/10.1002/14651858.CD012141.pub2.\n16.\n P\naiva ED, Costa P, Kimura AF, de Castro TE. Reasons for\nnon-elective removal of epicutaneous catheters in neonates.Rev Da Esc Enferm 2013;47:1279\u201384. https://doi.org/10.1590/S0080-623420130000600004.\n17.\n Beard L, Le\nvek C, Hwang S, Grover T. Prediction of Nonelective\nCentral Venous Catheter Removal in Medically Complex Neo-nates. Pediatr Qual Saf 2019;4:e179. https://doi.org/10.1097/pq9.0000000000000179.\n18.\n Chuang YY\n, Huang YC, Lee CY, Lin TY, Lien R, Chou YH. Meth-\nicillin-resistant Staphylococcus aureus bacteraemia inneonatal intensive care units: An analysis of 90 episodes.Acta Paediatr Int J Paediatr 2004;93:786\u201390. https://doi.org/10.1080/08035250410028084.Infecci\u00f3n metast\u00e1sica por Staphylococcus aureus  en neonatos: a prop\u00f3sito de un caso\nMetastatic infection by Staphylococcus aureus  in neonates: about a case2042\n19. Hakim H, Mylot te JM, Faden H. Morbidity and mortality of\nStaphylococcal bacteremia in children. Am J Infect Control\n2007;35:102\u20135. https://doi.org/10.1016/j.ajic.2006.09.016.\n20.\n Murdoch F\n, Danial J, Morris AK, Czarniak E, Bishop JL, Glass\nE, et al. The Scottish enhanced Staphylococcus aureus bacte-raemia surveillance programme: the first 18 months of data inchildren. J Hosp Infect 2017;97:127\u201332. https://doi.org/10.1016/j.jhin.2017.06.017.\n21.\n F\nalup-Pecurariu O, Leibovitz E, Pascu C, Falup-Pecurariu C.\nBacteremic methicillin-resistant Staphylococcus aureus deepneck abscess in a newborn-Case report and review of litera-ture. Int J Pediatr Otorhinolaryngol 2009;73:1824\u20137. https://doi.org/10.1016/j.ijporl.2009.09.008.\n22.\n Le\nwis PO, Heil EL, Covert KL, Cluck DB. Treatment strategies for \npersistent methicillin-resistant Staphylococcus aureus bacterae-mia. J Clin Pharm Ther 2018;43:614\u201325. https://doi.org/10.1111/jcpt.12743.\nReceived: 10 February 2021\nAccepted: 10 May 2021Laura Taylor, Carlos S. Mamani-Garc\u00eda, Alexandra Guti\u00e9rrez-Pingo, Jerry K. Benites-Meza, Diego Chambergo-Michilot, Norma del Carmen G\u00e1lvez-D\u00edaz, \nJoshuan J. Barboza\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2043\nCommon Peroneal Nerve Injury in a Patient with COVID-19 Infection\nZeynab Bossaghzadeh1, Firoozeh Niazvand2*, Medi Saneie3, Shahram Rahimi-Dehgolan4, Hooshan Sahariati Ghadikolaei5,  Sara Mobarak6\nDOI. 10.21931/RB/2021.06.03.26\nAbstract: This report described a 46-year man with the characteristic Computerized Tomography (CT) scan findings of Corona \nVirus Disease Infection 19 (COVID-19) who presented to the hospital with right ankle weakness three weeks after the pneumonitis. \nHe had been initially hospitalized, complaining of fever, myalgia, cough, and dyspnea. Electromyogram (EMG) revealed obvious evidence of increased insertional activity (IA) and significant denervation potentials, including positive sharp waves (PSW) and fibrillation potentials, particularly in ankle dorsiflexor muscles. Moreover, no voluntary motor unit action potential (MUAP) was observed. Eventually, the patient was diagnosed with severe axonal mononeuropathy of the right CPN, which could be considered a rare complication of COVID-19.\nKey words: Nerve injury, Electromyography, Coronavirus, COVID-19.CASE REPORTS / REPORTE DE CASO\nIntroduction\nA new beta coronavirus named COVID-19 was detected \nin December 2019 in Wuhan City, China, and shortly became a \npandemic1. COVID-19 is fused with the angiotensin-converting \nenzyme II (ACE-II) receptor and enters the cells2. This new co-\nronavirus can cause several systemic infections, among which respiratory complications are the most prevalent, quite similar to what earlier happened in severe acute respiratory syndrome coronavirus called SARS-CoV\n3.\nIt has been previously proved that around one-third of pa-\ntients with COVID-19 had neurological symptoms. Although several specific neurological presentations such as anosmia, other non-specific ones, including reduced consciousness le-vel, dizziness, and headache, have also been detected\n4. In one \nstudy, 214 patients with COVID-19 were evaluated in terms of neurological symptoms\n5. According to their findings, 36.4% of \nthe hospitalized patients showed nervous system manifesta-tions such as hyposmia, hypogeusia, headache, muscle injury, dizziness, ischemic, and hemorrhage stroke. However, it is still unknown whether the neurological symptoms are associated with the virus's direct damage, an abnormal immune response, or secondary mechanisms, including systemic inflammation or multi-organ dysfunction.\nIt has been hypothesized that SARS-CoV-2 can be consi-\ndered as a new neuropathogen. However, it has not yet been proven by solid evidence\n6. Before COVID-19, it had been we-\nll-defined that infectious peripheral neuropathy could happen secondary to other viruses, including varicella-zoster, hepatitis C and human immunodeficiency virus (HIV)\n7. Similarly, during \na viral infection, immune-mediated neuropathies such as chro-nic inflammatory demyelinating polyneuropathy (CIDP), as well as Guillain-Barre syndrome (GBS), might occur\n8. Also, an \nextended stay in the hospital can cause peripheral nerves.\nDamage resulting from prolonged pressure effect or even \ncritical illness polyneuropathy9. Recently, in some case re-\nports, a potential relationship between peripheral nerve injury and the SARS-CoV-2 infection preceding the onset of dama-ge by up to 4 weeks. Thus, the most probable reason would be a SARS-CoV2-triggered dysregulation of the immune sys-tem10-12. This case report described a male patient infected \nwith COVID-19 who showed a common peroneal nerve (CPN) injury as a rare complication.\nCase presentation\nOn 2 December, 2020, a 46-year-old man complained of \ninability to dorsiflex the right ankle from 3 weeks ago. The pa-tient has referred to the emergency ward about 6 weeks ago under the probable diagnosis of COVID-19 and symptoms in-cluding fever, body aches, cough, and shortness of breath. Du-ring hospitalization, the polymerase chain reaction (PCR) and computerized chest tomography (CT) scan were performed and confirmed the diagnosis (Figure 1). \nThe patient had been admitted for 2 weeks resulting in \n20 kg weight loss during this period. One week after the pa-tient came back home, he noticed paresthesia on the right foot's dorsum and the sudden weakness of the right ankle dor-siflexion while walking and during the affected limb's swing phase.\nHe was referred to the clinic of physical medicine and re-\nhabilitation (PM&R) to perform electromyography (EMG) and nerve conduction studies (NCS). As a result, sensory nerve action potential (SNAP) of the right superficial peroneal ner-ve (SPN) was not present, and the compound muscle action potential (CMAP) of the deep peroneal nerve (DPN) nerve was absent at the right side. In the EMG analysis, some evidence of increased insertional activity (IA) and denervation potentials, including PSW and fibrillation potentials, were detected in Ti-bialis Anterior (TA), Peroneus Longus (PL), Extensor Hallucis Longus (EHL), and Extensor Digitorum Brevis (EDB) muscles. Moreover, no voluntary motor unit action potential (MUAP) was observed in these muscles. Therefore, he was diagnosed with severe acute mono-neuropathy of the right CPN. Lum-bosacral spine magnetic resonance imaging (MRI) was perfor-med to assess discopathy, which was reported to be expected.Common Peroneal Nerve Injury in a Patient with COVID-19 Infection\n1 Assistant professor of Physical Medicine , Rehabilitat ion and Elect rodiagnosis D epartment, Scho ol of Medicine Ab adan Faculty o f Medical S ciences, Abadan , Iran. \n2 Assistant Professor of Anatomical Science, School of Medicine, Abadan Faculty of Medical Sciences, Abadan, Iran.\n3 Department of Orthopedics, School of Medicine, Abadan Faculty of Medical Sciences.\n4 PM&R Department, Tehran University of Medical Sciences, Tehran, Iran.\n5 Department of Neurosurgery, School of Medicine, Abadan Faculty of Medical Sciences, Abadan, Iran.\n6 Assistant Professor of Infectious Disease, School of Medicine, Abadan Faculty of Medical Sciences, Abadan, Iran. 2044\nZeynab Bossaghzadeh, Firoozeh Niazvand, Medi Saneie, Shahram Rahimi-Dehgolan, Hooshan Sahariati Ghadikolaei,  Sara Mobarak\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nDiscussion\nAs we mentioned, as a post-infectious inflammatory res-\nponse after SARS-CoV-2 infection, peripheral nerve injury can \noccur during the acute phase of resolution. This might be either the result of an abnormal hyper-immune response or treat-ment complications for COVID-19, such as nerve entrapment secondary to hematoma in the anticoagulation consumption setting or prolonged hospitalization that could be positional or critical illness-related polyneuropathy.\nIn the presented case, the patient was diagnosed with \nsevere mononeuropathy of the right CPN after 3 weeks of developing symptoms such as fever, body aches, cough, and shortness of breath; compatible with COVID-19 pneumonia. The possibility of a direct neuropathic effect or an abnormal hyper-immune response in COVID-19 patients requires further research. There have been existed several case reports about GBS incidence among COVID-19 sufferers\n10,13,16.\nThis case has been reported even though all neurological \nmanifestations in severe COVID-19 are not fully understood yet; then, the peripheral neuropathic damage cannot be posi-tively attributed to COVID-19 due to the lack of nerve biopsy. However, the EMG findings, along with the clinical neural image, indicated peripheral neuropathy. There are two main probabilities in this regard: 1) direct involvement of nerve by the virus and the following inflammatory response; 2) nerve compression after severe weight loss has also been reported in bariatric surgery and so on\n17,18.\nOn the other hand, it has not clearly been understood how \nweight loss contributes to peroneal neuropathy. It is assumed that changes in metabolism followed by weight loss and me-chanical compression of the peroneal nerve can play a signifi-cant role in this regard\n17,21. The adipose tissue depletion (inside \nand surrounding the nerve) results from weight loss; thus, the peroneal nerve's sensitivity to compression caused by the PL tendon on the lateral side and the adjacent fibular head medial side increases\n22.\nThe ACE-II receptor is where COVID-19 and SARS have in common19. The receptor is found in the cell membrane of \nvarious organs in humans, such as the liver, kidney, lung, skele-tal muscle, and nervous system\n5. However, the mechanisms \ninvolved in peripheral nerve injury incidence after COVID-19 in-fection have not yet been precisely studied. COVID-19 stimula-tes inflammatory cells, and different cytokines are generated, resulting in immune-mediated processes\n19. Therefore, peri-\npheral nerve injury after SARS-CoV-2 infection is a theoretical consideration, and some COVID-19 patients have been repor-ted to present with peripheral neuropathy and GBS\n13,20. Then, \nthe cases of immune-mediated nerve injuries should be con-sidered during this pandemic. According to the global pande-mic of the SARS-COVID-1923-26, additional surveys should be conducted to find all epidemiological properties of disease\n27.\nConclusions\nTo summarize, peripheral nerve injury should always be \nconsidered as a neurological complication that might occur in COVID-19. Probable post-infection peripheral nerve injury mechanisms include autoimmune response, direct neuro-in-vasion by the virus, and systemic disease complications. Fur-ther investigations are necessary to shed light on the exact pathophysiology of peripheral nerve involvement and high-risk patient determination. Given that, clinicians must be aware of these relationships to prevent delayed diagnosis from promo-ting treatment initiation at early stages and supportive care. This fact will be elucidated by further identified cases as well as longer time results.\nAcknowledgments\nThe authors would like to thank the School of Medicine, \nAbadan Faculty of Medical Sciences, Abadan, Iran, for the cli-\nnical supports.\nAuthor contributions\nFN designed the study and carried out the case identifica-\ntion. ZB, MS, and SRD carried out the CT-Scan and PCR. HSG \nand SM carried out the history taking and electromyography. FN wrote and drafted the manuscript. All authors read and confirm the final manuscript.\nCompeting interests\nThe authors declared that they have no conflict of inte-\nrest.Data and materials availability\nAll data are available in the main text or supplementary \nmaterials.Ethics statement\nAs noted on the journal's author guidelines page, the au-\nthors confirm that the journal's ethical policies have been ad-\nhered to. All identifying information of the patient presented in this study was kept secret.\nBibliographic references\n1. Zhu N, Zhang D , Wang W. China Novel Coronavirus Investigat-\ning and Research Team. A novel coronavirus from patients with\npneumonia in China, 2019 [published 24 January, 2020]. N EnglJ Med.\nFigure 1. Findings of the CT scan of COVID-19 patient. Bilate -\nral  peripheral  ground-glass  opacities  in a patient with cough \nand dy\nspnea.2045\n2.W an Y, Shang J, Graham R, Baric RS, Li F. Information: read & look \nat all below. 2020.\n3.Zhou P\n, Lou YX, Wang X, Hu B, Zhang L, Zhang W. A pneumonia\noutbreak associated with a new coronavirus of probable bat ori-\ngin. Nature [Internet]. 2020; 579 (7798): 270\u20133.\n4.\n Zito A, Al\nfonsi E, Franciotta D, Todisco M, Gastaldi M, Cotta Ra-\nmusino M, et al. COVID-19 and Guillain-Barr\u00e9 Syndrome: A CaseReport and Review of Literature. Front Neurol. 2020;11:909-.\n5.\nMao L, Jin H, W\nang M, Hu Y, Chen S, He Q, et al. Neurologic man-\nifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA neurology. 2020;77:683-90.\n6.\nF\nernandez CE, Franz CK, Ko JH, Walter JM, Koralnik IJ, Ahlawat\nS, et al. Imaging Review of Peripheral Nerve Injuries in Patientswith COVID-19. Radiology. 2020:203116.\n7.\nSindic CJ\n. Infectious neuropathies. Current opinion in neurology.\n2013;26:510-5.\n8.\n K\natona I, Weis J. Diseases of the peripheral nerves.  Handbook of \nclinical Neurology: Elsevier; 2018. p. 453-74.\n9.T\nsivgoulis G, Palaiodimou L, Katsanos AH, Caso V, K\u00f6hrmann M,\nMolina C, et al. <? covid19?> Neurological manifestations and im-plications of COVID-19 pandemic. Therapeutic Advances in Neu-rological Disorders. 2020;13:1756286420932036.\n10.\n T\noscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni\nMG, et al. Guillain\u2013Barr\u00e9 syndrome associated with SARS-CoV-2. New England Journal of Medicine. 2020.\n11.\n Bigaut K, Mallaret M, Baloglu S, Nemoz B, Mor\nand P, Baicry F,\net al. Guillain-Barr\u00e9 syndrome related to SARS-CoV-2 infection.Neurology-Neuroimmunology Neuroinflammation. 2020;7.\n12.\n F\narzi MA, Ayromlou H, Jahanbakhsh N, Bavil PH, Janzadeh\nA, Shayan FK. Guillain-Barr\u00e9 syndrome in a patient infectedwith SARS-CoV-2, a case report. Journal of neuroimmunology.2020;346:577294.\n13.\n Zhao H, Shen D\n, Zhou H, Liu J, Chen S. Guillain-Barr\u00e9 syndrome\nassociated with SARS-CoV-2 infection: causality or coincidence?The Lancet Neurology. 2020;19:383-4.\n14.\n Sedaghat Z, K\narimi N. Guillain Barre syndrome associated with\nCOVID-19 infection: a case report. Journal of Clinical Neurosci-ence. 2020.\n15.\n Vir\nani A, Rabold E, Hanson T, Haag A, Elrufay R, Cheema T, et al.\nGuillain-Barr\u00e9 syndrome associated with SARS-CoV-2 infection.IDCases. 2020:e00771.\n16.\n W\nebb S, Wallace VC, Martin-Lopez D, Yogarajah M. Guillain-Barr\u00e9 \nsyndrome following COVID-19: a newly emerging post-infectiouscomplication. BMJ Case Reports CP. 2020;13:e236182.17.\n  Thaiset thawatkul P, Collazo-Clavell M, Sarr M, Norell J, Dyck\nPJB. A controlled study of peripheral neuropathy after bariatricsurgery. Neurology. 2004;63:1462-70.\n18.\n Clark N. Neuropathy follo\nwing bariatric surgery.  Seminars in\nneurology: \u00a9 Thieme Medical Publishers; 2010. p. 433-5.\n19.\n Huang C\n, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features \nof patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395:497-506.\n20.\n Abdelnour L, Abdalla ME, Babik\ner S. COVID 19 infection present-\ning as motor peripheral neuropathy. Journal of the FormosanMedical Association. 2020.\n21.\n Sernik RA, Abicalaf C\nA, Pimentel BF, Braga-Baiak A, Braga L, Cer-\nri GG. Ultrasound features of carpal tunnel syndrome: a prospec-tive case-control study. Skeletal radiology. 2008;37:49-53.\n22.\n Me\nylaerts L, Cardinaels E, Vandevenne J, Velghe B, Gelin G, Va-\nnormelingen L, et al. Peroneal neuropathy after weight loss: ahigh-resolution ultrasonographic characterization of the common peroneal nerve. Skeletal radiology. 2011;40:1557-62.\n23.\n R\nanjbar R, Mahmoodzadeh Hosseini H, Safarpoor Dehkordi F. A\nReview on Biochemical and Immunological Biomarkers used forLaboratory Diagnosis of SARS-CoV-2 (COVID-19). The Open Mi-crobiology Journal. 2020;14(1).\n24.\n Mirzaie \nA, Halaji M, Dehkordi FS, Ranjbar R, Noorbazargan H. A\nnarrative literature review on traditional medicine options fortreatment of corona virus disease 2019 (COVID-19). Complemen-tary Therapies in Clinical Practice. 2020:101214.\n25.\n Halaji M, F\narahani A, Ranjbar R, Heiat M, Dehkordi FS. Emerging\ncoronaviruses: first SARS, second MERS and third SARS-CoV-2:epidemiological updates of COVID-19. Infez Med. 2020;28(suppl1):6-17.\n26.\n Sheikhshahrokh A, R\nanjbar R, Saeidi E, Dehkordi FS, Heiat M,\nGhasemi-Dehkordi P, Goodarzi H. Frontier therapeutics and vac-cine strategies for sars-cov-2 (COVID-19): A review. Iranian Jour-nal of Public Health. 2020;49:18-29.\n27.\n Dehk\nordi FS, Valizadeh Y, Birgani TA, Dehkordi KG. Prevalence\nstudy of Brucella melitensis and Brucella abortus in cow's milkusing dot enzyme linked immuno sorbent assay and duplex poly-merase chain reaction. J Pure Appl Microbiol. 2014;8(2):1065-9.\nReceived: 20 April 2021\nAccepted: 10 June 2021Common Peroneal Nerve Injury in a Patient with COVID-19 Infection2046\nRicardo Rubio-S\u00e1nchez, Esperanza Lepe-Balsalobre\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nStrongyloides stercoralis  infestation in a pediatric patient\nRicardo Rubio-S\u00e1nchez1, Esperanza Lepe-Balsalobre2 DOI. 10.21931/RB/2021.06.03.27\nAbstract: Strongyloidiasis is a parasitic disease, very rare in countries like Spain, caused by the Strongyloides stercoralis \nnematode. We present a case of a 5-year-old patient from Ecuador who came to the Emergency Department due to fever, \ncolicky abdominal pain, watery diarrhea, and occasional vomiting of several days of evolution. In laboratory studies, a marked leukocytosis with eosinophilia stands out, for which reason a microscopic study of the stool was carried out where larval forms compatible with Strongyloides stercoralis were observed. The diagnostic strategy of parasitic infection in developed countries is highly influenced by the low prevalence and diversity of the parasitic species, causing the diagnosis, on many occasions, to be a challenge. In the presence of eosinophilia and abdominal symptoms, it is recommended to orient the diagnosis towards a possible infection of parasitic origin to make an early diagnosis of the infection and avoid possible serious complications.\nKey words: Diarrhea, eosinophilia, larva, microscopy, parasite, Strongyloides stercoralis.CASE REPORTS / REPORTE DE CASO\nBackground\nStrongyloidiasis is a parasitic disease caused by the Stron-\ngyloides stercoralis nematode that usually occurs asympto-\nmatically but can manifest as a severe disseminated infection1. \nThe necessary forms for the diagnosis of this parasitosis are the rhabditiform larvae present in the intestinal mucosa, cha-racterized by a prominent esophageal bulb, and the filariform larvae present in the feces, which are the infecting forms, me-asuring about 600 \u03bcm in length and having elongated fusiform esophagus\n1,2.\nThe biological cycle of Strongyloides stercoralis is unique \nand unusual since the females are parthenogenetic; that is, they can give rise to a progeny without being fertilized. Due to this, there can be two types of cycles, the free life cycle that occurs in the external environment without the need for a mammalian host and the parasitic cycle inside a mammalian host. The invasion of this parasite occurs by penetration throu-gh the skin of filariform larvae present in the soil or the water\n3.Clinical case\nA 5-year-old male patient from Ecuador with no relevant \nmedical history came to the Emergency Department due to fever, colicky abdominal pain, watery diarrhea, and occasional vomiting of several days of evolution that intensified in the last two days. On physical examination, the abdomen was tender and painful on palpation, without masses or megaly, and in-creased peristalsis. The following complimentary tests were urgently requested: complete blood count, basic biochemis-try with inflammatory markers (C-reactive protein), and uri-nary study. Laboratory results showed marked leukocytosis (24,000 leukocytes/\n\u03bc\nL) at the expense of 27% eosinophilia. \nThe biochemistry and the study of the urinary sediment did not show alterations. Given the patient\u00b4s symptoms and origin, a microscopic study of parasites in feces was indicated, where larval forms compatible with Strongyloides stercoralis were observed (Figure 1). \nGiven this finding, treatment with oral ivermectin (200 \nmg/kg of body weight) was prescribed for two days, progressi-vely decreasing diarrheal episodes and abdominal pain.\nDiscussion\nThe diagnosis of this disease is epidemiological, clinical, \nand laboratory, and it is based on the microscopic visualization of the larvae of Strongyloides stercoralis in feces but, except in cases of hyperinfestation, the elimination is usually scarce and sporadic; therefore, the sensitivity of standard concentration procedures is very low\n4. This, together with the fact that the \ndiagnostic strategy of parasitic infection in countries such as Spain is highly influenced by the low prevalence and diversity of parasitic species, makes the diagnosis, on many occasions, a challenge\n5,6.\nBased on the above, many laboratories are replacing diag-\nnostic methods based on conventional microscopy with enzy-me immunoassay or molecular methods, which are techni-ques with higher sensitivity and specificity and less dependent on the observer. Thus, with more sensitive methods, work time is significantly reduced, and it is unnecessary to obtain the three classic fecal samples for parasitological examination. This approach would be similar to that already established for \n1 UGC de An\u00e1lisis Cl\u00ednicos, Hospital Universitario Virgen de Valme, Sevilla, Espa\u00f1a. \n2 Laboratorio de An\u00e1lisis Cl\u00ednicos, Hospital Universitario Virgen del Roc\u00edo, Sevilla, Espa\u00f1a.\nCorresponding author: ricrubsan@gmail.com\nFigure 1. Strongyloides stercoralis larva in the stool.2047\nStrongyloides stercoralis  infestation in a pediatric patient\ndetecting microorganisms that cause bacterial and viral diarr-\nhea (molecular stool culture), giving an entirely new dimension to the differential laboratory diagnosis of diarrheal diseases\n6,7.\nConclusions\nCurrently, there are initiatives to organize quality as-\nsessment schemes for the molecular diagnosis of intestinal parasites. However, these systems have not yet been widely adopted due to the high cost of traditional microscopy and the uncertainty regarding the clinical importance of the molecular detection of each of the parasites included in the panels. The-refore, its impact on clinical practice has yet to be assessed.\nIn short, in the presence of eosinophilia and abdominal \nsymptoms, it is recommended to orient the diagnosis towards a possible infection of parasitic origin to make an early diagno-sis of the infection and avoid possible serious complications.\nBibliographic references\n1. Grea ves D, Coggle S, Pollard C, Aliyu SH, Moore EM. Strongyloi-\ndes stercoralis infection. BMJ 2013;347:f4610.\n2.Buonfr\nate D, Gobbi F, Angheben A, Bisoffi Z. Strongyloides ster-\ncoralis: the need for accurate information. Lancet 2018;391:2322-\n23.\n3.Mor\nales ML, L\u00f3pez M, Ly P, Anjum S, Fern\u00e1ndez-Baca MV, Valdiv-\nia-Rodr\u00edguez AM, et at. Strongyloides stercoralis infection at dif-ferent altitudes of the Cusco region in Peru. Am J Trop Med Hyg2019;101:422-27.\n4.\n Barroso M, \nSalvador F, S\u00e1nchez-Montalv\u00e1 A, Bosch-Nicolau P, Mo-\nlina I. Strongyloides stercoralis infection: A systematic review ofendemic cases in Spain. PLoS Negl Trop Dis 2019;13:e0007230.\n5.\nMeningher T\n, Boleslavsky D, Barshack I, Tabibian-Keissar H,\nKohen R, Gur-Wahnon D, et al. Giardia lamblia miRNAs as anew diagnostic tool for human giardiasis. PLoS Negl Trop Dis.2019;13(6): e0007398.\n6.\nDe \nBoer RF, Ott A, Kesztyus B, Kooistra-Smid AM. Improved de-\ntection of five major gastrointestinal pathogens by use of a mo-lecular screening approach. Clin Microbiol. 2010; 48: 4140-6.\n7.\nV\nerweij JJ, Stensvold CR. Molecular testing for clinical diagnosis \nand epidemiological investigations of intestinal parasitic infec-tions. Clin Microbiol. 2014; 27: 371-418.\nReceived: 1 April 2021\nAccepted: 10 June 20212048\nClara Gualotu\u00f1a y Thelvia I. Ramos\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nReporte de caso de postcirug\u00eda de ligamento cruzado anterior\nCase report of post-surgery anterior cruciate ligament surgery\nClara Gualotu\u00f1a1 y Thelvia I. Ramos2DOI. 10.21931/RB/2021.06.03.28\nResumen: El ligamento cruzado anterior (LCA) es la lesi\u00f3n de la rodilla con mayor prevalencia en los atletas. Los avances en la \nt\u00e9cnica quir\u00fargica y la fijaci\u00f3n de injertos han permitido a los pacientes participar en una rehabilitaci\u00f3n funcional postoperatoria temprana. Este tratamiento est\u00e1 dirigido a lograr un mayor rango de movimiento, progresando hacia la movilizaci\u00f3n, fortalecimiento y control neuromuscular propioceptivo de la articulaci\u00f3n. Existen varios protocolos de rehabilitaci\u00f3n con variaciones en ejercicios espec\u00edficos, progresi\u00f3n a trav\u00e9s de fases y componentes claves que permiten la recuperaci\u00f3n funcional. El objetivo final de la fisioterapia es devolver al paciente al nivel de rendimiento anterior a la lesi\u00f3n, incluidos el movimiento y la fuerza, sin da\u00f1ar ni alargar el injerto. Presentamos el reporte de un caso con una lesi\u00f3n de LCA compleja, que recupero la funcionalidad de la articulaci\u00f3n por aplicaci\u00f3n de plan de tratamiento fisioterap\u00e9utico de forma inmediata a su intervenci\u00f3n quir\u00fargica.\nPalabras clave: Ligamento cruzado anterior, rehabilitaci\u00f3n funcional, propiocepci\u00f3n, injerto, fuerza muscular y movimiento.Abstract: An anterior cruciate ligament (ACL) is the most prevalent knee injury in athletes. Advances in surgical technique and graft \nfixation have allowed patients to participate in early postoperative functional rehabilitation. This treatment focuses on achieving a \nmore excellent range of motion, progressing toward mobilization, strengthening, and proprioceptive neuromuscular control of the joint. Several rehabilitation protocols have variations in specific exercises, progression through phases, and critical components that allow functional recovery. The ultimate goal of physical therapy is to return the patient to the pre-injury level of performance, including motion and strength, without damaging or lengthening the graft. We present a case report of a patient with a complex ACL injury who recovered joint function by applying a physiotherapy treatment plan immediately after surgery.\nKey words: Anterior cruciate ligament, functional rehabilitation, proprioception, grafting, muscle strength, and movement.CASE REPORTS / REPORTE DE CASO\nIntroducci\u00f3n\nLa articulaci\u00f3n de la rodilla es propensa a lesionarse \ndebido a su complejidad y funci\u00f3n de soporte de peso1. Est\u00e1 \nformado por la tibia, el f\u00e9mur y la r\u00f3tula, que est\u00e1n estabili-\nzados por el ligamento colateral medial (LCM), el ligamento colateral lateral (LCL), el ligamento cruzado posterior (LCP) y el LCA\n1. Los meniscos medial y lateral act\u00faan como amorti-\nguadores, distribuyendo el peso uniformemente con cada paso o giro\n1. El LCA tiene una funci\u00f3n importante en la estabilidad\nde la rodilla2. Esta estructura articular presenta dos porciones\nuna antero medial y otra postero lateral, adem\u00e1s sostiene el90% del peso corporal\n3. Las fibras tendinosas del LCA tienen\nforma helicoidal dirigi\u00e9ndose desde el \u00e1rea pre-espinal de latibia hasta la superficie interna del c\u00f3ndilo externo f\u00e9mur\n2.\nEs\nt\u00e9 ligamento se considera la principal restricci\u00f3n pasiva de\nla traslaci\u00f3n anterior de la tibia en el f\u00e9mur4,5 proporcionan-\ndo estabilidad rotacional a la rodilla tanto en el plano frontalcomo en el transversal\n1.\nLas lesiones ligamentosas de la rodilla son frecuentes en \nlas poblaciones j\u00f3venes f\u00edsicamente activas3,5,6. Se reporta una \nincidencia de estas lesiones de 1 por cada 3.000 personas en los Estados Unidos\n7. Solo en Norteam\u00e9rica 250.000 personas \nsufren una ruptura de LCA cada a\u00f1o6,8. En un estudio de Li y \ncolaboradores demostraron que la incidencia de lesiones por LCA ocurr\u00eda de cuatro a cinco veces m\u00e1s entre los militares en referencia a la poblaci\u00f3n general\n9. En un meta-an\u00e1lisis que \nreuni\u00f3 25 estudios epidemiol\u00f3gicos encontraron una tasa de desgarro del LCA del 5% en mujeres que jugaban f\u00fatbol y ba-loncesto durante todo el a\u00f1o\n10. En esta investigaci\u00f3n las muje-\nres ten\u00edan un riesgo tres veces mayor de desgarro del LCA que los hombres que practicaban el mismo deporte, report\u00e1ndose un 42,3% cifra m\u00e1s alta reportada en la literatura para cual-quier tipo de deporte\n5,11.\nAlgunas actividades deportivas se han asociado a la rup-\ntura de LCA ocasionados  por la pr\u00e1ctica de deportes profe-sionales como: baloncesto\n12, f\u00fatbol13 alpinismo10, balonmano14, \nf\u00fatbol americano15, voleibol y lucha16. Estas lesiones tienen una \nmayor predisposici\u00f3n en los deportistas de fin semana, en el adulto mayor y en mujeres que presenta un valgo fisiol\u00f3gico\n17.\nExisten tres mecanismos principales de lesi\u00f3n del LCA: \ncontacto directo, contacto indirecto y sin contacto18. Por con-\ntacto directo la lesi\u00f3n se ocasiona cuando una persona u ob-jeto golpea directamente la rodilla; en el contacto indirecto la lesi\u00f3n aparece en las regiones no propias de la rodilla transfi-ri\u00e9ndose una fuerza excesivas hacia la articulaci\u00f3n y las lesio-nes sin contacto se producen cuando se aplica una fuerza de desaceleraci\u00f3n o de cambio de direcci\u00f3n (pivote) sobre la ro-dilla\n19. Otros mecanismos asociados a LCA menos frecuentes  \nson: los movimientos combinados de  flexi\u00f3n de la articulaci\u00f3n de la rodilla con valgo forzado, rotaci\u00f3n medial excesiva de la espina tibial\n20 y varo con rotaci\u00f3n lateral16.\nEn la evaluaci\u00f3n cl\u00ednica de una lesi\u00f3n por LCA los s\u00ednto-\nmas iniciales son: dolor intenso, crepitaci\u00f3n, inflamaci\u00f3n, tu-mefacci\u00f3n y p\u00e9rdida de la movilidad\n21. La lesi\u00f3n en si suele pro-\nvocar derrames articulares, alteraciones en la cinem\u00e1tica de la rodilla, afectaciones de la marcha, debilidad muscular y reduc-ci\u00f3n del rendimiento funcional\n6.Tambi\u00e9n las personas afecta-\ndas manifiestan sensaci\u00f3n de inestabilidad de las rodillas22,6. \nOtros autores fundamentan que existe ruptura de ligamento cruzado anterior en actividades de torsi\u00f3n-recorte-desacele-raci\u00f3n aceleraci\u00f3n en combinaci\u00f3n con una carga en el valgo \n1 Sistema Integrado de Salud, \u00c1rea de Fisioterapia Universidad de las Fuerzas Armadas ESPE, Sangolqu\u00ed, Ecuador. \n2 Departamento Ciencias de la Vida y de la Agricultura, Universidad de las Fuerzas Armadas ESPE, Sangolqu\u00ed, Ecuador.\nCorresponding author: tiramos@espe.edu.ec2049\nReporte de caso de postcirug\u00eda de ligamento cruzado anterior\nCase report of post-surgery anterior cruciate ligament surgery\nde rodilla6,8. Algunos pacientes manifiestan que escuchan  o \nsienten un \"estallido\" en el momento de la lesi\u00f3n, acompa\u00f1ado \nen ocasiones de hemartrosis durante  las dos primeras horas \nposteriores al da\u00f1o6.\nEn la exploraci\u00f3n f\u00edsica se detecta la laxitud articular \nanteroposterior y antero externa, siendo las maniobras m\u00e1s \nimportantes  el   test de subluxaci\u00f3n exc\u00e9ntrica con un 98% \nde especificidad, considerada como la \u00fanica prueba cl\u00ednica y \ndin\u00e1mica m\u00e1s espec\u00edfica para determinar la lesi\u00f3n  de LCA4,8,22. \nExisten otras pruebas como  el test de Lachman y la prueba \nde caj\u00f3n anterior para determinar  la ruptura del LCA6, y para \nel diagn\u00f3stico definitivo se realiza ex\u00e1menes de imagenolog\u00eda \ncomo la Resonancia Magn\u00e9tica Nuclear (RMN)22,23.\nEl principal tratamiento para esta lesi\u00f3n es el quir\u00fargico \ndirigido a la reconstruir el LCA y considerando aspectos como: \nla edad, tipo de deporte que la ocasion\u00f3 y el injerto, con el fin \nde evitar lesiones secundarias a la articulaci\u00f3n24. Actualmen-\nte hay dos opciones para injertos del LCA: los autoinjertos y \nlos aloinjertos22. El primero requiere la sustituci\u00f3n del LCA \ncon tejido obtenido de otra parte del cuerpo25, como cuando \nse utiliza un autoinjerto de tendones semitendinosos, cu\u00e1dri-\nceps y el gracilis25. El aloinjerto se obtiene a partir de donantes \ncadav\u00e9ricos y tiene la ventaja de que no presenta morbilidad \nen el sitio donante, no es necesario tomar precauciones en el \nproceso de rehabilitaci\u00f3n  y presenta la misma fuerza que los \nautoinjertos26. Pero la curaci\u00f3n del aloinjerto se retrasa con \nrespecto a la incorporaci\u00f3n y remodelaci\u00f3n y puede transmi-\ntir enfermedades que no tienen la resistencia biomec\u00e1nica de \nla intervenci\u00f3n27. La literatura reciente sugiere el uso de au-\ntoinjertos biol\u00f3gicos, sobre todo en pacientes j\u00f3venes, debido \na su potencial para la remodelaci\u00f3n, la curaci\u00f3n del tend\u00f3n al \nhueso4.\nDespu\u00e9s de la cirug\u00eda de una lesi\u00f3n por LCA se requie-\nre tratamiento fisioterap\u00e9utico que permita recuperar la fun-\ncionalidad de la articulaci\u00f3n. En estas lesiones por lo general \ntambi\u00e9n se presentan secuelas cl\u00ednicas a largo plazo asocia-\ndos con desgarro del menisco medial, lesiones condrales y \ndesarrollo de osteoartritis postraum\u00e1tica6. Otros factores a \nconsiderar es fallo articular, con subluxaci\u00f3n femorotibial28. \nAumento del grado de laxitud articular condicionando a un \ndeterioro articular progresivo  objetivable en los estudios ra-\ndiogr\u00e1ficos (aplanamiento del c\u00f3ndilo, esclerosis subcondral, \npinzamiento articular y formaci\u00f3n de osteofitos)29.\nEs relevante presentar un programa de rehabilitaci\u00f3n que \nse debe desarrollar en forma inmediata despu\u00e9s de la cirug\u00eda \ndel LCA, respetando todos los procesos fisiol\u00f3gicos de repara-\nci\u00f3n de los tejidos afectados30. Los procedimientos fisiotera-\np\u00e9uticos deben ir encaminados a restaurar la condici\u00f3n loco-\nmotora e identificar  factores prexistente para prevenir futuras \nlesiones del LCA31. La locomoci\u00f3n normal depende, entre otros \nfactores, de la estabilidad de la estructura ligamento capsular, \nel rango de movimiento de la articulaci\u00f3n de la rodilla y un \nnivel de fuerza apropiado de los m\u00fasculos as\u00ed como de la pro-\npiocepci\u00f3n de esta articulaci\u00f3n tan compleja32. El prop\u00f3sito en \nel programa de rehabilitaci\u00f3n es restaurar la funci\u00f3n completa \nsin restricciones y ayudar al paciente a regresar al 100% del \nnivel anterior a la lesi\u00f3n mientras logra excelentes resultados \na largo plazo33.\nPresentamos un reporte de un paciente con una compleja \nruptura del LCA, el cual tuvo una rehabilitaci\u00f3n en el servi-\ncio de fisioterapia de la Universidad de las Fuerzas Armadas \nESPE. Los resultados alcanzados son debidos a la combina-\nci\u00f3n de t\u00e9cnicas de rehabilitaci\u00f3n orientadas a una acelerada \nrecuperaci\u00f3n funcional, reflejada en el aumento de la movili-\ndad articular y fuerza de los m\u00fasculos extensores y flexores, as\u00ed como de la restituci\u00f3n de la propiocepci\u00f3n de la rodilla y de \ntodo el miembro inferior, permitiendo que pudiera incorporase \na todas sus actividades de la vida diaria con normalidad.\nReporte de caso\nPaciente de 33 a\u00f1os de edad, obrero, que tuvo un acciden-\nte en el a\u00f1o 2017 al levantar una puerta met\u00e1lica, que trau-\nmatiz\u00f3 la cara anterior de la rodilla izquierda, presentando un \ndolor grado 4 en escala de EVA (Escala Visual Anal\u00f3gica) (Gon-\nzales, Ana ;Ramos, Adriana; Rojas, 2018). El dolor persisti\u00f3 por \n8 semanas y acudi\u00f3 a consulta m\u00e9dica de la empresa donde \nlabora. El examen f\u00edsico revel\u00f3 un diagn\u00f3stico de sinovitis y ho-\nffitis (inflamaci\u00f3n de la grasa de la Hoffa)35 y el tratamiento fue \nmedicaci\u00f3n con antiinflamatorios y 10 sesiones de fisioterapia, \nmejorando su sintomatolog\u00eda.\nDos a\u00f1os despu\u00e9s, practicando f\u00fatbol (septiembre 2019) \nel paciente presenta nuevamente dolor en la cara anterior de \nla rodilla izquierda grado 5 en escala de EVA manifestando \nfatiga muscular durante el trote, limitando de manera parcial \nla funcionalidad biomec\u00e1nica de la marcha. Al finalizar ese \nmismo a\u00f1o tiene un segundo accidente de trabajo armando \nuna columna de 11 cajas pl\u00e1sticas con un peso de 1,5 kg, por \ncada caja. Un compa\u00f1ero provoca una colisi\u00f3n de una columna \nconformadas por 11 cajas que se impactaron sobre el cuerpo \ndel paciente. Realiza una flexi\u00f3n de hombros con extensi\u00f3n de \ncodos y mu\u00f1eca quedando la cara palmar apoyada en las ca-\njas y al mismo tiempo efectu\u00f3 una flexi\u00f3n de cadera y rodilla \nderecha simult\u00e1neamente sobre la estructura para soportar el \npeso de 126 kg, el miembro inferior izquierdo se mantuvo apo-\nyado en el piso provocando un movimiento de desplazamiento \nmedial.\nInmediatamente inicio un dolor agudo intenso en la rodilla \ncon un grado 8 en la escala de EVA, con limitaci\u00f3n funcional al \ncaminar e inestabilidad de la rodilla. Es valorado por el m\u00e9dico \nde la empresa quien diagn\u00f3stica una lesi\u00f3n de LCA e indica un \ntratamiento con antinflamatorios y reposo. El dolor persiste \nsin alivio durante un mes y es evaluado por fisioterapia, apli-\nc\u00e1ndose la prueba de caj\u00f3n anterior y la prueba de Lachman, \nsiendo ambas positivas, remiti\u00e9ndose a evaluaci\u00f3n por trau-\nmatolog\u00eda3,4.\nEl diagn\u00f3stico por el especialista se apoy\u00f3 en la valoraci\u00f3n \ncl\u00ednica y una RMN de rodilla que revel\u00f3 cambios en la intensi-\ndad del ligamento cruzado anterior, signos de ruptura intrasus-\ntancial 50%, desgarro a nivel de la base del menisco lateral y \ncambios de la intensidad de se\u00f1al a nivel de cart\u00edlago articular \ny el tejido \u00f3seo subcondral hacia el borde lateral de la meseta \ntibial, edema \u00f3seo a este nivel e incremento de l\u00edquido articular \n(ver figura1. 2, 3 y 4). \nSe practica la cirug\u00eda reparadora con la t\u00e9cnica de inter-\nvenci\u00f3n hueso tend\u00f3n hueso (HTH) cirug\u00edas m\u00e1s autoinjerto \npor representar un menor riesgo por la edad del paciente y la \nactividad laboral4,25. El autoinjerto fue extra\u00eddo del tend\u00f3n del \nm\u00fasculo semitendinoso de la rodilla teniendo \u00e9xito la cirug\u00eda36. \nEste tipo de cirug\u00eda realizada permiti\u00f3 comenzar la fisioterapia \nde forma precoz, evitando la debilidad de la musculatura de \nlos isquiotibiales, perdida de arcos de movimiento y perdida de \nla propiocepci\u00f3n, como describe la literatura5.\nTratamiento fisioterap\u00e9utico\nLa rehabilitaci\u00f3n estuvo dirigida a recuperar el rango de \nmovimiento articular, la fuerza de los m\u00fasculos flexores y ex-\ntensores de la articulaci\u00f3n de la rodilla (sartorio, gr\u00e1ciles, se-\nmitendinoso, semimembranoso, b\u00edceps femoral, gastrocnemio 2050\nFigura 1. Corte sa -\ngital de resonancia \nmagn\u00e9tica (RM), en \nT2 se puede visua -\nlizar que existe un \nproceso inflama -\ntorio a la altura del \nligamento cruzado \nanterior.\nFigura 3. Corte sagital de resonancia magn\u00e9tica (RM) poten -\nciado de T1 se puede visualizar que existe un proceso inflama -\ntorio a la altura del ligamento cruzado anterior.Figura 2. Corte coronal de RM potenciado de T1 se observa \nproceso inflamatorio.Clara Gualotu\u00f1a y Thelvia I. Ramos\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2051\nFigura 4. Corte sagital de RM potenciado en T1 se observa un leve incremento l\u00edquido articular, y proceso inicial de esclerosis.\nA nivel de la meseta tibial lesiones osteocondrales borde lateral y a nivel del c\u00f3ndilo femoral lateral.\ny el cu\u00e1driceps) tanto en condiciones est\u00e1ticas como la din\u00e1-\nmica articular, recuperar la amplitud y la propiocepci\u00f3n para \nlograr una adecuada funcionabilidad de la rodilla23.   \nSe consider\u00f3 adem\u00e1s la selecci\u00f3n de los ejercicios, la \nmagnitud y el tiempo de aplicaci\u00f3n de la carga, el proceso gra-\ndual de angiog\u00e9nesis del autoinjerto en el nuevo ligamento5. \nLos procedimientos fisioterap\u00e9uticos se establecieron en dife-\nrentes etapas apoyados en los datos cl\u00ednicos.\nDiagn\u00f3stico fisioterap\u00e9utico\nPostcirug\u00eda de ligamento cruzado anterior, con dolor en la \ncara posterior de los isquiotibiales, y cara anterior. Puntos de \ngatillo en el m\u00fasculo tensor de la fascia lata y semitendinoso.\nSintomatolog\u00eda Cl\u00ednica\nEl paciente acude con los puntos de sutura y presenta una \nmarcha claudicante, apoyado con muletas. Presenta inflama-\nci\u00f3n en todo el contorno de la rodilla, derrame en absorci\u00f3n en \nla parte anterior, equimosis en la parte posterior, piel brillante \ntersa, temperatura normal, atrofia de la masa muscular. Mani-\nfiesta dolor al flexionar la rodilla a partir de los 60 grados y al \ncaminar en terreno irregular, en la cara anterolateral interna \nde la rodilla grado 5 de EVA y en la cara postero externa del \nmuslo grado 7 de EVA, lugar de donde se extrajo el tend\u00f3n para \nel autoinjerto.\nExamen f\u00edsico\nDolor a la palpaci\u00f3n en la cara posterior un grado 8 en \nescala de EVA. Sensibilidad superficial alterada en la parte an-\nterior de la rodilla (en la intervenci\u00f3n quir\u00fargica). Sensibilidad \nprofunda normal. Puntos de gatillo en el musculo semitendi-\nnoso y tensor de la fascia lata.\nValoraci\u00f3n funcional\nGoniometr\u00eda\nPlan de tratamiento de rehabilitaci\u00f3n consta de cuatro \nfases\nPrimera fase inflamatoria de 1 a 2 semanas\nEn esta fase se realizar\u00e1 el control del dolor e inflamaci\u00f3n. \nSe aplicaron compresas fr\u00edas a nivel local en la parte anterior \nde la rodilla durante la primera semana. Se emplearon bolsas \nde hielo, reemplazadas con crioterapia local. Se indican movi-\nmientos pasivos continuos20. Estimulaci\u00f3n con electroestimu-\nlaci\u00f3n percut\u00e1nea (o transcut\u00e1nea) de los nervios en la cara \nanterior de la rodilla, cu\u00e1driceps y en los m\u00fasculos isquioti-\nbiales del muslo. Utilizamos ultrasonido en la cara anterior de \nla rodilla con 1 w/cm2, al 20 % y 1 hz para obtener un efecto \nmec\u00e1nico y alineamiento de las fibras de col\u00e1geno, evitando la \nformaci\u00f3n de adherencias en el sitio de intervenci\u00f3n quir\u00fargi-\nca. Ejercicios de activaci\u00f3n muscular mediante movilidad acti-\nva asistida de la rodilla y ejercicios de fortalecimiento del otro \nmiembro inferior. Se recurri\u00f3 a la t\u00e9cnica Kinesio Tape (KT) o \nvendaje neuromuscular sobre los m\u00fasculos isquiotibiales para \nmejorar la oxigenaci\u00f3n y aporte de nutrientes disminuyendo de \nesta forma el dolor y acelerando el proceso de cicatrizaci\u00f3n, el \nuso del vendaje tambi\u00e9n se puede utilizar como estabilizador \nde la rodilla despu\u00e9s de la poscirug\u00eda de LCA.\nSegunda fase proliferativa de 3 a 6 semanas\nEn esta fase es importante realizar la movilidad y carga \nprogresiva, por tal motivo se realizara movilizaci\u00f3n de la r\u00f3tula \nen sentido c\u00e9falo caudal, transversal y oblicuo, electroestimu-\nlaci\u00f3n para fortalecimiento del vasto medial37. Ejercicios de \nfortalecimiento progresivo de flexi\u00f3n y extensi\u00f3n de la rodilla \ncon aumento gradual del rango de movimiento, en posici\u00f3n \nsupina y con deslizamiento del tal\u00f3n sobre la camilla38. Se \npractic\u00f3 al paciente t\u00e9cnicas de inducci\u00f3n miofascial, como: la \nt\u00e9cnica longitudinal y transversal para los isquiotibiales y para \nlos cu\u00e1driceps.\nTercera fase de remodelaci\u00f3n de 7 a 12 semanas\nEn esta fase se inicia el programa de entrenamiento de \nfuerza, coordinaci\u00f3n y propiocepci\u00f3n en combinaci\u00f3n con ejer-\ncicios en cadena cinem\u00e1tica cerrada en terreno plano, con ojos Reporte de caso de postcirug\u00eda de ligamento cruzado anterior\nCase report of post-surgery anterior cruciate ligament surgery2052\nFigura 5. Corte coronal potenciado a T2, se visualiza ruptura intrasustancial de ligamento cruzado anterior aproximadamente \nun 50%, presencia de l\u00edquido inflamatorio.\nabiertos y posteriormente con inhibici\u00f3n de ojos, pero en terre-\nno plano. Es necesario trabajar ejercicios exc\u00e9ntricos, aer\u00f3bi-\ncos, equilibrio y control postural39.\nSe realizaron ejercicios del puente (paciente en posici\u00f3n \nsupina con rodillas flexionadas y las plantas de los pies apo-\nyadas en balanc\u00edn.\nSe efectuaron ejercicios de subir y bajar un solo escal\u00f3n y \nsentadillas logrando aumentar gradualmente la fuerza de los \nm\u00fasculos isquiotibiales  y cu\u00e1driceps de la pierna operada en \nel plano sagital20.Fase final de 13 a 15 semanas\nDirigida a la recuperaci\u00f3n total de la coordinaci\u00f3n, fuerza \ny gestos deportivos, para lo cual se trabaja a nivel muscular \nmediante la t\u00e9cnica de facilitaci\u00f3n neuromuscular para los \nmiembros inferiores partiendo de extensi\u00f3n, abducci\u00f3n y ro-\ntaci\u00f3n interna de cadera  retornando con flexi\u00f3n, aducci\u00f3n y \nrotaci\u00f3n externa  de cadera con flexi\u00f3n de rodilla, tambi\u00e9n se \nejecut\u00f3 ejercicios de propiocepci\u00f3n con inhibici\u00f3n de ojos y en \n\u00e1rea inestable utilizando elementos externos de perturbaci\u00f3n \ncomo ligas y bal\u00f3n medicinal.. Para finalizar est\u00e1 fase se aplic\u00f3 \nejercicios polim\u00e9tricos, trote con desplazamientos en diferen-Clara Gualotu\u00f1a y Thelvia I. Ramos\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2053\ntes direcciones y por \u00faltimo se practic\u00f3 diferentes gestos de-\nportivos (f\u00fatbol).\nDiscusi\u00f3n\nEl objetivo de la reconstrucci\u00f3n del LCA es restaurar las \npropiedades anat\u00f3micas y biomec\u00e1nicas de este ligamento40. \nAlgunos autores mencionan que para este tipo de lesi\u00f3n es ne-\ncesario mantener la estabilidad de la articulaci\u00f3n de la rodilla \nanteroposterior, anteromedial y recuperar la cinem\u00e1tica de la \narticulaci\u00f3n41.\nLa rehabilitaci\u00f3n rigurosa despu\u00e9s de la reconstrucci\u00f3n \ndel ligamento cruzado anterior (LCA) es necesaria para un re-\nsultado quir\u00fargico exitoso33, el fortalecimiento muscular ace-\nlerado42, la rehabilitaci\u00f3n en el hogar43, la propiocepci\u00f3n con \nentrenamiento neuromuscular37, pero sin excluir el rango de \nmovimiento y los ejercicios funcionales44. Otro autor mencio-\nna que es importante recuperar la locomoci\u00f3n normal, entre \notros factores, la estabilidad de la estructura ligamento cap-\nsular, el rango de movimiento y un nivel de fuerza apropiado \nde los m\u00fasculos de la articulaci\u00f3n de la rodilla y la propiocep-\nci\u00f3n45. En nuestro trabajo consideramos la importancia de re-\ncuperar la estabilidad de la rodilla en conjunto con la fuerza, el \narco de movimiento, la propiocepci\u00f3n y con el fin de integrarlo \na la actividad laboral o deportiva.\nLa terapia de crio compresi\u00f3n se ha propuesto como un \nm\u00e9todo para reducir el dolor y la respuesta inflamatoria en el \nper\u00edodo postoperatorio temprano despu\u00e9s de la cirug\u00eda de re-\nconstrucci\u00f3n de la articulaci\u00f3n46. Otro estudio menciona que \nla aplicaci\u00f3n de compresas fr\u00edas sobre la lesi\u00f3n disminuye el \ndolor32. De acuerdo con la pr\u00e1ctica cuando se aplic\u00f3 las com-\npresas qu\u00edmicas fr\u00edas en la etapa inicial de la poscirug\u00eda de \nLCA, se determin\u00f3 la disminuci\u00f3n considerable del dolor y la \ninflamaci\u00f3n permitiendo mejores rangos de movimientos con \nlo cual se confirma lo mencionado por Nabiyev V. N. y colabo-\nradores (2018)47.\nLa incorporaci\u00f3n de estrategias efectivas para aliviar el \ndolor durante la rehabilitaci\u00f3n de la cirug\u00eda de RLCA conduce \na una mejor condici\u00f3n en la recuperaci\u00f3n del rango de movi-\nmiento y la funci\u00f3n de la rodilla. Al aplicar electroestimulaci\u00f3n \ntranscut\u00e1nea se ocasiona una inhibici\u00f3n pre-sin\u00e1ptica con dis-\nminuci\u00f3n del dolor, en combinaci\u00f3n con ejercicios controlados \nen las cuatro primeras semanas que permitieron resultados \npositivos en la recuperaci\u00f3n. Esto se corrobora tambi\u00e9n con el \nestudio de Forogh y colaboradores que aplica electroestimu-\nlaci\u00f3n transcut\u00e1nea sobre 70 deportistas en combinaci\u00f3n con \nejercicios controlados reportando disminuci\u00f3n de los niveles \nde dolor en todos los individuos del estudio48. En otro estudio \nla utilizaci\u00f3n de electroestimulaci\u00f3n transcut\u00e1neo manifiesta \nque sus efectos son relativos, obteniendo mejores resultados \na nivel de cu\u00e1driceps con la aplicaci\u00f3n de electroestimulaci\u00f3n \nel\u00e9ctrica  funcional a partir de la cuarta semana49.\nEl uso de KT tiene un efecto positivo sobre la propiocep-\nci\u00f3n en pacientes con rotura del LCA. Por lo tanto, la aplicaci\u00f3n \npuede mejorar el patr\u00f3n de la marcha, as\u00ed como la funci\u00f3n sub-\njetiva de la articulaci\u00f3n de la rodilla afectada50. Liu menciona \nque el KT puede tener efectos beneficiosos sobre la propiocep-\nci\u00f3n, el equilibrio y el rendimiento funcional en personas con \nruptura LCA, pero no puede compensar por completo la p\u00e9r-\ndida de propiocepci\u00f3n51. En la pr\u00e1ctica actual se aplic\u00f3 el KT \npara disminuir la contractura que presentaban los m\u00fasculos \nisquiotibiales y tambi\u00e9n se utiliz\u00f3 en la fase final del programa \nde fisioterapia como t\u00e9cnica para estabilizar la rodilla, solo du-\nrante la primera semana cuando retorno a la actividad laboral y deportiva, es decir, que el KT se puede utilizar como medio de \napoyo temporal para estimular la propiocepci\u00f3n pero no como \ntratamiento permanente.\nSe debe lograr la extensi\u00f3n completa de rodilla sobre las \ndos primeras semanas de rehabilitaci\u00f3n y para esto se requie-\nren t\u00e9cnicas de estiramiento de larga duraci\u00f3n con poca car-\nga52. La literatura cient\u00edfica indica la importancia de la marcha \ncon extensi\u00f3n completa de la rodilla, para obtener una buena \nfuncionabilidad de la articulaci\u00f3n44. En la experiencia profe-\nsional es importante alcanzar durante las primeras semanas \nla extensi\u00f3n completa de la rodilla con el fin de recuperar la \nbiomec\u00e1nica funcional en forma correcta despu\u00e9s de la postci-\nrug\u00eda de LCA. Aplicando al paciente la rehabilitaci\u00f3n con ejer-\ncicios selectivos, se obtiene la extensi\u00f3n completa de rodilla en \nel periodo inicial del tratamiento acompa\u00f1ado con movilizaci\u00f3n \nde la articulaci\u00f3n patelofemoral el cual permite ganar rangos \nde movimiento durante el programa de fisioterapia estableci-\nda. La aplicaci\u00f3n de masaje en la banda iliotibial y de la parte \nlateral del cu\u00e1driceps ayuda a mejorar la movilidad articular, \ncon lo cual aumentan los arcos de movilidad y disminuyen las \ncontracturas  mejorando el proceso de oxigenaci\u00f3n y aportes \nde nutrientes para obtener el proceso de cicatrizaci\u00f3n de ma-\nnera \u00f3ptima32. Tambi\u00e9n contribuye la movilizaci\u00f3n de rotula \ncon movimientos fisiol\u00f3gicos durante la primera semana y el \nmasaje profundo en el muslo, para mejorar los rangos de mo-\nvimientos y la irrigaci\u00f3n sangu\u00ednea a nivel de la rodilla.\nLa rehabilitaci\u00f3n acelerada y bien programada no ha \nmostrado efectos perjudiciales, iniciando con  activaci\u00f3n de \ncu\u00e1driceps mediante ejercicios isom\u00e9tricos, posteriormente \nejercicios con carga progresiva, luego utilizando el propio peso, \nejercicios de cadena cin\u00e9tica abierta y cerrada53. En la fase \ninicial de rehabilitaci\u00f3n es seguro para los pacientes empezar \ninmediatamente despu\u00e9s del postoperatorio con ejercicios \nisom\u00e9tricos, conforme va mejorando se incrementa en forma \nprogresiva el peso para el fortalecimiento de los m\u00fasculos que \nintervienen en la funci\u00f3n de la rodilla, es necesario  trabajar  \nejercicios de cadena cin\u00e9tica cerrada y abierta para ganar fuer-\nza tanto en los m\u00fasculos proximales y distales de miembros \ninferiores los mismos que se requieren para una buena reedu-\ncaci\u00f3n de la marcha.\nCimino y colaboradores (2010) explican que al realizar el \nentrenamiento neuromuscular propioceptivo mejora la res-\npuesta refleja de la articulaci\u00f3n y la reacci\u00f3n voluntaria de los \nm\u00fasculos que tiende a ser r\u00e1pida para contrarrestar las fuer-\nzas que act\u00faan sobre la rodilla1. En otro estudio de  Basar y \ncolaboradores determina que el mecanismo propioceptivo de \nla rodilla da informaci\u00f3n sobre la posici\u00f3n y el movimiento de \nlas articulaciones evitando de esa manera una segunda lesi\u00f3n \nde LCA54. Es necesario trabajar en la fase final de la  fisiote-\nrapia el programa de entrenamiento neuromuscular propio-\nceptivo para un aprendizaje motor mediante la utilizaci\u00f3n de \nmovimientos de perturbaci\u00f3n en combinaci\u00f3n con acciones \nvisomotoras en lesi\u00f3n de LCA55. Al aplicar el programa de pro-\npiocepci\u00f3n en el paciente con lesi\u00f3n de LCA se pudo observar \nun cambio importante en la funcionalidad estabilidad con me-\njor coordinaci\u00f3n en las reacciones motoras y articulares de la \nrodilla, permitiendo integrar al paciente de forma \u00f3ptima en \nla actividad deportiva y laboral. El trabajo de entrenamiento \nmuscular propioceptivo permite constituir los factores senso-\nriales, visuales y motores con el fin de minimizar los riesgos \nacelerados de secuelas y reduciendo el riesgo de una segunda \nlesi\u00f3n de LCA.\nEn la fase final de la rehabilitaci\u00f3n se deben realizar prue-\nbas de salto despu\u00e9s de completar los seis meses de  trata-\nmiento para el retorno a la actividad deportiva52. Otro estudio Reporte de caso de postcirug\u00eda de ligamento cruzado anterior\nCase report of post-surgery anterior cruciate ligament surgery2054\nmenciona que todos los atletas a menudo son autorizados \npara regresar a las actividades cuando pueden realizar saltos en un solo pie sin dolor (periodo 6 meses) despu\u00e9s de la re-construcci\u00f3n del LCA\n56. Actualmente para autorizar el retorno \na la actividad deportiva se ejecut\u00f3 los ejercicios de saltos con los dos pies y con un pie es decir ejercicios polim\u00e9tricos de baja y alta intensidad, tambi\u00e9n es importante que pueda correr y subir escaleras sin molestias para el retorno de la actividad laboral y deportiva.\nConclusiones\nLos estudios presentados en este documento se centra-\nron en mejorar la rehabilitaci\u00f3n despu\u00e9s de la reconstrucci\u00f3n del LCA, con el objetivo de retornar en forma segura con una fuerza muscular \u00f3ptima para darle mayor estabilidad a la rodi-lla y evitar la aparici\u00f3n acelerada de la osteotritis con el fin de evitar limitaciones en la vida diaria.\nUn programa de rehabilitaci\u00f3n tradicional despu\u00e9s de la \ncirug\u00eda es eficaz para mejorar la fuerza muscular de los m\u00fas-culos flexores de la rodilla. Esta intervenci\u00f3n temprana puede incorporarse a la rehabilitaci\u00f3n actual para facilitar la recupe-raci\u00f3n r\u00e1pida de la fuerza en los pacientes con ruptura de LCA.\nReferencias bibliogr\u00e1ficas\n1. Cimino, F ., Naval Hospital, U., Bradford Scott Volk, J. & Setter, D.\nAnterior Cruciate Ligament Injury: Diagnosis, Management, and\nPrevention. American Family Physician vol. 82 (2010).\n2.Amis, A. A. The functions of the fibre bundles of the anterior cru\n-\nciate ligament in anterior drawer, rotational laxity and the pivotshift. Knee Surgery, Sports Traumatology, Arthroscopy vol. 20613\u2013620 (2012).\n3.\nSeco, J\n. Afecciones medicoquirurgicas para fisioterapia. in\n297,298,299,300,301 (2017).\n4.\n Biz, C\n., Cigolotti, A., Zonta, F., Belluzzi, E. & Ruggieri, P. ACL recon-\nstruction using a bone patellar tendon bone (BPTB) allograft or a hamstring tendon autograft (GST): A single-center comparativestudy. Acta Biomed. 90, 109\u2013117 (2019).\n5.\nKr\nause, M. et al. Operative versus conservative treatment of an-\nterior cruciate ligament rupture a systematic review of functional improvement in adults. Dtsch. Arztebl. Int. 115, 855\u2013862 (2018).\n6.\nFilba\ny, S. R. & Grindem, H. Evidence-based recommendations for \nthe management of anterior cruciate ligament (ACL) rupture.Best Practice and Research: Clinical Rheumatology vol. 33 33\u201347 (2019).\n7.\nHerzog, \nM. M. et al. Trends in Incidence of ACL Reconstruction\nand Concomitant Procedures Among Commercially Insured In-dividuals in the United States, 2002-2014. Sports Health 10,523\u2013531 (2018).\n8.\n A\nyala,J; Gracia ,G;Alcocer, L. Lesi\u00f3n de ligamneto cruzado anteri-\nor. Acta Ortop\u00e9dica Mexicana 1,21 (2014).\n9.Li, W\n. et al. Biomechanical Evaluation of Preoperative Rehabili-\ntation in Patients of Anterior Cruciate Ligament Injury. Orthop.Surg. 12, 421 (2020).\n10.\n W\nestin, M., Harringe, M. L., Engstr\u00f6m, B., Alricsson, M. & Werner,\nS. Risk Factors for Anterior Cruciate Ligament Injury in Compet-itive Adolescent Alpine Skiers. Orthop. J. Sport. Med. 6, (2018).\n11.\n Anderson, M. J\n., Browning, W. M., Urband, C. E., Kluczynski, M. A.\n& Bisson, L. J. A Systematic Summary of Systematic Reviewson the Topic of the Anterior Cruciate Ligament. Orthop. J. Sport.Med. 4, 1\u201323 (2016).\n12.\n Ok\noroha, K. R. et al. Amount of minutes played does not contrib-\nute to anterior cruciate ligament injury in national basketball as-sociation athletes. Orthopedics 40, e658\u2013e662 (2017).13.\n Bisciot\nti, G. N. et al. Anterior cruciate ligament injury risk factors\nin football. Journal of Sports Medicine and Physical Fitness vol.59 1724\u20131738 (2019).\n14.\n K\noga, H. et al. Mechanisms for noncontact anterior cruciate lig-\nament injuries: Knee joint kinematics in 10 injury situations fromfemale team handball and basketball. Am. J. Sports Med. 38,2218\u20132225 (2010).\n15.\n Niederer\n, D., Engeroff, T., Wilke, J., Vogt, L. & Banzer, W. Return\nto play, performance, and career duration after anterior cruciateligament rupture: A case\u2013control study in the five biggest foot-ball nations in Europe. Scand. J. Med. Sci. Sport. 28, 2226\u20132233(2018).\n16.\n Garin, D\n. R. E. A. Lesi\u00f3n de ligamneto cruzado anterior. Medi-\ngraphic 88,89,90,91,92,93,94,95 (2016).\n17.\n W\nald\u00e9n, M., H\u00e4gglund, M., Magnusson, H. & Ekstrand, J. Anterior\ncruciate ligament injury in elite football: A prospective three-co-hort study. Knee Surgery, Sport. Traumatol. Arthrosc. 19, 11\u201319(2011).\n18.\n T\nood, Benjam\u00ed; Nacleiro, Emily;Seth, S. Management of Anterior\nCruciate Ligament Injury. Oliver J Edited by Araujo K 1,2,3 (2017).\n19.\n P\nadua, D. A. et al. National athletic trainers\u2019 association position\nstatement: Prevention of anterior cruciate ligament injury. J. Athl. Train. 53, 5\u201319 (2018).\n20.\n Czamar\na, A. & Kr\u00f3likowska, A. Two-plane assessment of knee\nmuscles isometric and isokinetic torques after anterior cruciateligament reconstruction. Med. Sci. Monit. 24, 4882\u20134893 (2018).\n21.\n Huang, W\n., Zhang, Y., Yao, Z. & Ma, L. Clinical examination of an-\nterior cruciate ligament rupture: A systematic review and me-ta-analysis. Acta Orthop. Traumatol. Turc. 50, 22\u201331 (2016).\n22.\n Hughes, \nJ. D., Rauer, T., Gibbs, C. M. & Musahl, V. Diagnosis and\ntreatment of rotatory knee instability. Journal of ExperimentalOrthopaedics vol. 6 (2019).\n23.\n Zicaro, J\n. P., Garcia, I., Yacuzzi, C. & Costa, M. Reparaci\u00f3n del Liga-\nmento Cruzado Anterior con Utilizaci\u00f3n de Tutor Interno\n : T\n\u00e9cnica \nQuir\u00fargica y Revisi\u00f3n de la Literatura. vol. 26 56\u201362 (2019).\n24.\n Seco, J\n. Fisioterapia en especialidades cl\u00ednicas. in Panamericana\n247,248 (2016).\n25.\n Cris\ntiani, R., Engstr\u00f6m, B., Edman, G., Forssblad, M. & St\u00e5lman,\nA. Revision anterior cruciate ligament reconstruction restoresknee laxity but shows inferior functional knee outcome compared with primary reconstruction. Knee Surgery, Sport. Traumatol. Ar-throsc. 27, 137\u2013145 (2019).\n26.\n Shumborski, S. et al. Allogr\naft Donor Characteristics Significantly \nInfluence Graft Rupture After Anterior Cruciate Ligament Recon-struction in a Young Active Population. Am. J. Sports Med. 48,2401\u20132407 (2020).\n27.\n Y\nang, X. gang et al. Network meta-analysis of knee outcomes\nfollowing anterior cruciate ligament reconstruction with varioustypes of tendon grafts. International Orthopaedics vol. 44 365\u2013380 (2020).\n28.\n W\nebster, K. E., Feller, J. A., Kimp, A. J. & Whitehead, T. S. Revision \nAnterior Cruciate Ligament Reconstruction Outcomes in Younger Patients: Medial Meniscal Pathology and High Rates of Return to Sport Are Associated With Third ACL Injuries. Am. J. Sports Med. 46, 1137\u20131142 (2018).\n29.\n Shelbourne, K. D\n., Benner, R. W. & Gray, T. Results of Anterior Cru-\nciate Ligament Reconstruction with Patellar Tendon Autografts:Objective Factors Associated with the Development of Osteoar-thritis at 20 to 33 Years after Surgery. Am. J. Sports Med. 45,2730\u20132738 (2017).\n30.\n Pius\nsi, R. et al. Recovery of preoperative absolute knee extension \nand flexion strength after ACL reconstruction. BMC Sports Sci.Med. Rehabil. 12, (2020).\n31.\n Cris\ntiani, R. et al. Increased knee laxity with hamstring tendon\nautograft compared to patellar tendon autograft: a cohort studyof 5462 patients with primary anterior cruciate ligament recon-struction. Knee Surgery, Sport. Traumatol. Arthrosc. 27, 381\u2013388 (2019).Clara Gualotu\u00f1a y Thelvia I. Ramos\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2055\n32. Andrzej Czamara, Def, W. T. & Cde, T. B. The effect of physiother-\napy on knee joint extensor and flexor muscle strength after an-\nterior cruciate ligament reconstruction using hamstring tendon.17, 33\u201341 (2011).\n33.\n Wilk, K. E. & Arrigo, C\n. A. Rehabilitation Principles of the Anterior \nCruciate Ligament Reconstructed Knee: Twelve Steps for Suc-cessful Progression and Return to Play. Clinics in Sports Medicine vol. 36 189\u2013232 (2017).\n34.\n Gonzales, Ana;R\namos, Adriana;Rojas, E. Correlaci\u00f3n entre las es-\ncalas unidimensionales utilizadas en la medici\u00f3n del dolor post-operatoriole. Revista Mexicana de Anestesiolog\u00eda 8 (2018).\n35.\n F\nelson, D. T. et al. Synovitis and the risk of knee osteoarthritis:\nThe MOST Study. Osteoarthr. Cartil. 24, 458\u2013464 (2016).\n36.\n Zhao, L. et al. Outcome of bone-patellar tendon-bone v\ns ham-\nstring tendon autograft for anterior cruciate ligament recon-struction: A meta-analysis of randomized controlled trials witha 5-year minimum follow-up. Medicine (Baltimore). 99, e23476(2020).\n37.\n Buck\nthorpe, M., La Rosa, G. & Villa, F. Della. RESTORING KNEE\nEXTENSOR STRENGTH AFTER ANTERIOR CRUCIATE LIGA -\nMENT RECONSTRUCTION: A CLINICAL COMMENTARY. Int. J.Sports Phys. Ther. 14, 159\u2013172 (2019).\n38.\n F\nukuda, T. Y. et al. Open kinetic chain exercises in a restricted\nrange of motion after anterior cruciate ligament reconstruction:A randomized controlled clinical trial. Am. J. Sports Med. 41,788\u2013794 (2013).\n39.\n Capin, J\n. J. & Snyder-Mackler, L. The current management of\npatients with patellofemoral pain from the physical therapist\u2019sperspective. Ann. Jt. 3, 40\u201340 (2018).\n40.\n Zampeli, F\n. et al. Restoring tibiofemoral alignment during ACL re-\nconstruction results in better knee biomechanics. Knee Surgery,Sport. Traumatol. Arthrosc. 26, 1367\u20131374 (2018).\n41.\n F\nu, F. H., van Eck, C. F., Tashman, S., Irrgang, J. J. & Moreland, M. \nS. Anatomic anterior cruciate ligament reconstruction: a chang-ing paradigm. Knee Surgery, Sport. Traumatol. Arthrosc. 23,640\u2013648 (2015).\n42.\n Lim, J\n. M., Cho, J. J., Kim, T. Y. & Yoon, B. C. Isokinetic knee\nstrength and proprioception before and after anterior cruciateligament reconstruction: A comparison between home-basedand supervised rehabilitation. J. Back Musculoskelet. Rehabil. 32, 421\u2013429 (2019).\n43.\n Bre\nwer, B. W., Cornelius, A. E., Van Raalte, J. L., Tennen, H. & Ar-\nmeli, S. Predictors of adherence to home rehabilitation exercisesfollowing anterior cruciate ligament reconstruction. Rehabil. Psy-chol. 58, 64\u201372 (2013).\n44.\n Kruse, L. M., Gr\nay, B. & Wright, R. W. Rehabilitation after anterior\ncruciate ligament reconstruction: A systematic review. Journalof Bone and Joint Surgery - Series A vol. 94 1737\u20131748 (2012).\n45.\n v\nan Grinsven, S., van Cingel, R. E. H., Holla, C. J. M. & van Loon,\nC. J. M. Evidence-based rehabilitation following anterior cruciateligament reconstruction. Knee Surgery, Sport. Traumatol. Ar-throsc. 18, 1128\u20131144 (2010).46.\n  Nab\u0131y ev, V. N. et al. Cryo-compression therapy after elective spi-\nnal surgery for pain management: A cross-sectional study withhistorical control. Neurospine 15, 348\u2013352 (2018).\n47.\n Czamar\naabcdefg, A., Tomaszewskidef, W., Bobercde, T. & Lubar-\nskib, B. The effect of physiotherapy on knee joint extensor andflexor muscle strength after anterior cruciate ligament recon-struction using hamstring tendon.\n48.\n F\norogh, B., Aslanpour, H., Fallah, E., Babaei-Ghazani, A. & Eba-\ndi, S. Adding high-frequency transcutaneous electrical nervestimulation to the first phase of post anterior cruciate ligamentreconstruction rehabilitation does not improve pain and functionin young male athletes more than exercise alone: a randomizedsingle-b. Disabil. Rehabil. 41, 514\u2013522 (2019).\n49.\n Mor\nan, U., Gottlieb, U., Gam, A. & Springer, S. Functional electri-\ncal stimulation following anterior cruciate ligament reconstruc-tion: A randomized controlled pilot study. J. Neuroeng. Rehabil.16, (2019).\n50.\n Bischoff\n, L. et al. Effects on proprioception by Kinesio taping of\nthe knee after anterior cruciate ligament rupture. Eur. J. Orthop.Surg. Traumatol. 28, 1157\u20131164 (2018).\n51.\n Liu, \nK., Qian, J., Gao, Q. & Ruan, B. Effects of Kinesio taping of the \nknee on proprioception, balance, and functional performance inpatients with anterior cruciate ligament rupture: A retrospectivecase series. Med. (United States) 98, (2019).\n52.\n Adams, \nD., Logerstedt, D., Hunter-Giordano, A., Axe, M. J. & Sny-\nder-Mackler, L. Current concepts for anterior cruciate ligamentreconstruction: A criterion-based rehabilitation progression. J.Orthop. Sports Phys. Ther. 42, 601\u2013614 (2012).\n53.\n Z\nebis, M. K. et al. Electromyography Evaluation of Bodyweight\nExercise Progression in a Validated Anterior Cruciate LigamentInjury Rehabilitation Program: A Cross-Sectional Study. Am. J.Phys. Med. Rehabil. 98, 998\u20131004 (2019).\n54.\n Ba\u015far\n, B., Ba\u015far, G., Aybar, A., Kurtan, A. & Ba\u015far, H. The effects\nof partial meniscectomy and meniscal repair on the knee proprio-ception and function. J. Orthop. Surg. 28, (2020).\n55.\n Gok\neler, A., Neuhaus, D., Benjaminse, A., Grooms, D. R. & Bau-\nmeister, J. Principles of Motor Learning to Support Neuroplas-ticity After ACL Injury: Implications for Optimizing Performanceand Reducing Risk of Second ACL Injury. Sports Medicine vol. 49853\u2013865 (2019).\n56.\n Y\nang, X. gang, Feng, J. tao, He, X., Wang, F. & Hu, Y. cheng. The\neffect of knee bracing on the knee function and stability following anterior cruciate ligament reconstruction: A systematic reviewand meta-analysis of randomized controlled trials. Orthopaedicsand Traumatology: Surgery and Research vol. 105 1107\u20131114(2019).\nReceived: 20 Febrero 2021\nAccepted: 20 Mayo 2021Reporte de caso de postcirug\u00eda de ligamento cruzado anterior\nCase report of post-surgery anterior cruciate ligament surgery2056\nJulio G\u00f3mez-Assan, Rosa Ajila-Freire\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nExperiencias en el uso de energ\u00eda renovable en la Rep\u00fablica del Ecuador\nExperiencies in the use of renewable energies in the Republic of Ecuador\nJulio G\u00f3mez-Assan, Rosa Ajila-Freire DOI. 10.21931/RB/2021.06.03.29\nResumen: La tendencia a nivel mundial es utilizar energ\u00eda renovable para depender menos de los combustibles f\u00f3siles y a su vez \nminimizar la contaminaci\u00f3n ambiental, el Ecuador y sus gobiernos han realizado esfuerzos para generar este tipo de energ\u00eda para \ncontribuir a la matriz productiva del mismo.  El objetivo de este estudio es determinar los proyectos y cambios que ha tenido la \nproducci\u00f3n tanto de energ\u00eda primaria como de energ\u00eda renovable durante los a\u00f1os 2008 y 2018.  El estudio se lo realiz\u00f3 a nivel \nmundial y de pa\u00eds; en lo que respecta al pa\u00eds se identific\u00f3 experiencias del uso de energ\u00edas renovables, se recopilaron datos para \nsu respectivo an\u00e1lisis a nivel internacional y nacional, nos centramos en las principales obras de energ\u00eda renovable funcionando \ny en proyectos dentro del proceso transformador de la matriz productiva energ\u00e9tica del Ecuador. Para la elaboraci\u00f3n de esta \nrevisi\u00f3n bibliogr\u00e1fica se recopilaron art\u00edculos, folletos, libros pertinentes y relevantes publicados en los \u00faltimos 10 a\u00f1os. Se \neligieron fuentes con datos originales y se descart\u00f3 las que depend\u00edan de \u00e9stas. En el \u00e1mbito ecuatoriano, se determin\u00f3 el \nvalor del kilovatio instalado seg\u00fan la fuente de energ\u00eda, su capacidad instalada y la energ\u00eda producida.  No hemos avanzado en \nproyectos de energ\u00eda maremotriz y geot\u00e9rmica.\nPalabras clave: Centrales, energ\u00eda, e\u00f3lica, fotovoltaica, geot\u00e9rmica, renovable.\nAbstract: The global trend is to use renewable energy to rely less on fossil fuels and minimize environmental pollution; Ecuador \nand its governments have made efforts to generate this energy to contribute to its productive matrix. This study aims to determine \nthe projects and changes that production of both primary energy and renewable energy has had during 2008 and 2018. The study \nwas conducted globally and as a country; regarding the country, experiences of the use of renewable energies were identified, data \nwere collected for their respective analysis at the international and national levels, we focused on the leading renewable energy \nworks in operation and on projects within the transformative process of Ecuador's energy production matrix. Articles, brochures, \nrelevant and relevant books published over the past 10 years.  Sources with unique information were picked, and those that relied \nupon them were wrecked. In the Ecuadorian ambit, the estimation of the kilowatt introduced by the source and fuel, its introduced \nlimit, and the energy created is resolved. We have not progressed on geothermal flowing energy projects.\nKey words: Power plants, energy, wind, photovoltaic, geothermal, renewable.REVIEW / ART\u00cdCULO DE REVISI\u00d3N\nIntroducci\u00f3n\nA nivel mundial, el consumo de energ\u00eda provenientes de \ncombustibles f\u00f3siles en el 2005 era del 80,7%, en el 2015 hubo \nun ligero descenso llegando a 79,6%. El uso de combustibles \nrenovables y residuos combustibles en el 2005 estaba en el \n8,1% de la demanda total de energ\u00eda y ha experimentado un \ndescenso, llegando al 3,9% en el 20151. En el Ecuador, la ex-\nplotaci\u00f3n petrolera empez\u00f3 en el a\u00f1o 1970 lo que provoc\u00f3 la \nmodernizaci\u00f3n de su econom\u00eda y un mayor crecimiento eco-\nn\u00f3mico, por lo tanto, una creciente demanda de energ\u00eda.  En \nel a\u00f1o 2008, se produjeron 185000 kBEP mientras que en el \n2018 fue de 189000 kBEP2.  Seg\u00fan un informe del 2015 de \nla Fundaci\u00f3n Empresa & Clima ubicada en Espa\u00f1a, se indica \nque las emisiones totales en el mundo en el a\u00f1o 2014 fueron \nde 32.000 millones de toneladas de CO2, con un aumento del \n0.8% respecto al a\u00f1o anterior.  La principal actividad emisora \nes la generaci\u00f3n de electricidad y calor, con el 42%, seguida de \nindustrias manufactureras y de construcci\u00f3n con el 19% y del \ntransporte por carretera con el 17%3. El objetivo de esta inves-\ntigaci\u00f3n es dar a conocer la producci\u00f3n de energ\u00eda renovable \na nivel mundial y a nivel local en los \u00faltimos a\u00f1os, as\u00ed como \nlos principales proyectos, su capacidad instalada. A nivel pa\u00eds, \nlos principales proyectos ejecutados, sus costos de ejecuci\u00f3n y \nuna comparaci\u00f3n del valor de la inversi\u00f3n por kW instalado to-\nmando como ejemplos cuatro proyectos de diferente energ\u00eda.  \nAdicionalmente determinar proyectos de energ\u00eda hidr\u00e1ulica \nque est\u00e1n en fase de estudio o construcci\u00f3n.Panorama Mundial\nLa producci\u00f3n de energ\u00eda primaria entre el 2008 y 2018 \nha aumentado, salvo el caso de la energ\u00eda nuclear.  Ver tabla 1, \ncuyas unidades est\u00e1n en mega toneladas de petr\u00f3leo (Mtoe)4.  \nSiendo la energ\u00eda el\u00e9ctrica un elemento de suma importancia \nen la sociedad actual, puesto que es una de las variables nece-\nsarias para el desarrollo industrial de los pa\u00edses, as\u00ed como para \nel bienestar de los pueblos, por lo que se hace conveniente \nmantener la continuidad en la prestaci\u00f3n del servicio el\u00e9ctrico. \nCarrera de Tecnolog\u00eda Superior en Ensamblaje y Mantenimiento de Equipos de C\u00f3mputo, Instituto T\u00e9cnico Superior Vicente Rocafuerte-Guayaquil, Ecuador. \nCorresponding author: jgomez@istvr.edu.ec\nTabla 1. Producci\u00f3n de energ\u00eda primaria mundial de los a\u00f1os \n2008 y 2018. Fuente: tomado de la p\u00e1gina web de Internatio -\nnal Energy Agency, Datos y Estad\u00edsticas (4)\nLa producci\u00f3n de energ\u00eda el\u00e9ctrica a partir de las dife-\nrentes fuentes de energ\u00eda ha aumentado del 2008 al 2018, a \nexcepci\u00f3n de la producida por energ\u00eda nuclear y petr\u00f3leo.  Ver \ntabla 24.\nLa energ\u00eda renovable se ha establecido como la fuente 2057\nExperiencias en el uso de energ\u00eda renovable en la Rep\u00fablica del Ecuador\nExperiencies in the use of renewable energies in the Republic of Ecuador\nprincipal de generaci\u00f3n de electricidad y entre ellas, la que \npredomina es la hidroel\u00e9ctrica, se ha mantenido estable su \nparticipaci\u00f3n, siendo del 16% en el 2008 como en el 2018, del \ntotal de producci\u00f3n de electricidad4. S\u00ed de esta informaci\u00f3n, \ns\u00f3lo analizamos la producci\u00f3n de energ\u00eda el\u00e9ctrica, sin incluir \na las centrales hidroel\u00e9ctricas, entre esos mismos a\u00f1os, ob-\ntenemos un incremento del 433%1 en unidades de TWh, sien-\ndo las de mayor crecimiento las energ\u00eda e\u00f3lica y fotovoltaica.  \nEsta producci\u00f3n de energ\u00eda va de la mano con la capacidad \ninstalada que en el 2008 fue de 280 GW y en el 2018 de 1246 \nGW, lo que representa un aumento del 345%5,6. Del total de la \ncapacidad de la energ\u00eda renovable, la hidr\u00e1ulica represent\u00f3 en \nel 2018 el 47,6%.\nLos pa\u00edses con mayor potencia instalada son China, Brasil \ny Canad\u00e17.  China cuenta con una capacidad de 322 GW y po-\nsee tres centrales hidroel\u00e9ctricas entre las diez m\u00e1s grandes \ndel mundo por potencia instalada, en primer lugar, est\u00e1 la de \nTres Gargantas que posee 22,5 GW8.  Le sigue Brasil.  \nLa energ\u00eda e\u00f3lica terrestre (proyectos ubicados en el \ncontinente) ha crecido a pasos agigantados en los \u00faltimos 20 \na\u00f1os, convirti\u00e9ndose en una fuente principal de energ\u00eda limpia \ny competitiva en todo el mundo, la capacidad total de energ\u00eda \ne\u00f3lica a nivel mundial ahora supera los 651 GW en el 2019.  En \nt\u00e9rminos de capacidad instalada, los tres principales merca-\ndos a finales de 2019 son: China, Estados Unidos y Alemania9.  \nEl parque e\u00f3lico de Gansu, es el m\u00e1s grande del mundo, ubica-\ndo en China con una capacidad de 8 GW9.  \nLa e\u00f3lica marina (proyectos ubicados en la superficie del \nmar), est\u00e1 desempe\u00f1ando un papel cada vez m\u00e1s importante \nen la conducci\u00f3n de instalaciones e\u00f3licas mundiales9, al mo-\nmento cuenta con una capacidad instalada de 29,1 GW10.  El \nparque Walney Extension tiene una capacidad de 659 MW, est\u00e1 \nsituado en el mar de Irlanda, a unos 19 kil\u00f3metros de la costa \nde la isla de Walney (Reino Unido), posee 189 turbinas11.\nEn el 2017, la electricidad generada a partir de la bioma-\nsa, es la tercera despu\u00e9s de la hidr\u00e1ulica y e\u00f3lica12. Los ma-\nyores productores a partir de los biocombustibles y residuos \nen el 2017 fueron: China con 92923 GWh, Estados Unidos con \n70656 GWh y Brasil con 52255 GWh sin embargo; por capaci-\ndad instalada, en primer lugar, est\u00e1 Brasil con 14,5 GW, Esta-\ndos Unidos con 12,86 GW y tercero est\u00e1 China con 11,2 GW13.  \nLa tecnolog\u00eda solar fotovoltaica es una de las principales alternativas para afrontar decididamente la problem\u00e1tica ener-\ng\u00e9tica global14.  En el 2018, la capacidad instalada en el mun-\ndo fue de 485 GW y los pa\u00edses que tienen la mayor capacidad \ninstalada son: China con 175 GW, le sigue Jap\u00f3n con 55 GW y \nen tercer lugar aparece Estados Unidos con 51 GW.  En la India \nse ubica el m\u00e1s grande parque solar llamado Bhadla con 2,2 \nGW, le sigue el proyecto Pavagada Solar Park de 2 GW, tambi\u00e9n \nubicado en la India y en tercer lugar est\u00e1 el parque solar en el \ndesierto de Tengger en China, con una capacidad de 1,5 GW15.\nPor \u00faltimo, nombraremos a la electricidad cuyo origen sea \ndel tipo geot\u00e9rmica, la capacidad instalada en el mundo, en el \n2019 fue de 13,9 GW, donde los principales pa\u00edses con capaci-\ndad instalada son: Estados Unidos con 2,5 GW, Indonesia con \n2,1 GW y Filipinas con 1,9 GW.   Llama la atenci\u00f3n que est\u00e9n \nestos dos pa\u00edses,  Indonesia a\u00f1o a a\u00f1o, ha venido incrementan-\ndo su capacidad, considerando que poseen el 40% del poten-\ncial geot\u00e9rmico del mundo, pero no se ha desarrollado del todo \nbien, alcanzando s\u00f3lo el 6%16.\nEnerg\u00eda en Ecuador\nEn el 2010, las centrales termoel\u00e9ctricas representaban \n(generan energ\u00eda a base de combustibles f\u00f3siles) el 54% de la \npotencia efectiva en MW, mientras que las centrales hidr\u00e1uli-\ncas/renovables era del 46%17, ver figura 1.\nEste panorama cambia y en el 2019, las termoel\u00e9ctricas \ncaen al 35.01% y las hidr\u00e1ulicas/renovables suben al 64.99%.\nEcuador tiene como recurso energ\u00e9tico primario principal \nlos combustibles f\u00f3siles, el petr\u00f3leo con sus derivados y gas \nnatural llegando al 83,8% y s\u00f3lo el 16,2% proviene de energ\u00edas \nrenovables.  A continuaci\u00f3n, se indica el de participaci\u00f3n de \ncentrales el\u00e9ctricas de acuerdo a su tipo en el 201018.\nProyectos de energ\u00eda e\u00f3lica\nEn el a\u00f1o 2007, se inaugur\u00f3 el primer parque e\u00f3lico en la \nisla San Crist\u00f3bal del Archipi\u00e9lago de Gal\u00e1pagos, con una po-\ntencia instalada de 2.4 MW19. En el 2019, la producci\u00f3n total de \nenerg\u00eda fue de 86 GWh.  En la provincia de Loja se encuentra el \nparque e\u00f3lico m\u00e1s alto del mundo, Villonaco, que abastece el \n25% de la energ\u00eda que demanda la provincia20.  En la tabla 3, se \npuede apreciar los principales parques e\u00f3licos que se encuen-\ntran operando y en construcci\u00f3n, dando como resultado una \ncapacidad instalada de 21.15 MW. Dos parques est\u00e1n ubicados \nen las Islas Gal\u00e1pagos y uno en la provincia de Loja.\nTabla 2. Generaci\u00f3n mundial de electricidad por fuente. Fuen -\nte: tomado de la p\u00e1gina web de International Energy Agency, \nDatos y Estad\u00edsticas (4)\nTabla 3. Principales parques E\u00f3licos del Ecuador.\nProyectos de energ\u00eda solar\nEcuador debido a su ubicaci\u00f3n geogr\u00e1fica puede utilizar \nla energ\u00eda solar durante todo el a\u00f1o.   La energ\u00eda solar se utili-\nza principalmente para usos t\u00e9rmicos como calentamiento de \nagua y climatizaci\u00f3n de edificios y para la generaci\u00f3n de elec-\ntricidad a base de paneles fotovoltaicos.\nLa radiaci\u00f3n solar global promedio en su territorio fluc-\nt\u00faa entre 4.1 y 4.9 kWh/m2/d\u00eda21.  La energ\u00eda fotovoltaica dio \nsus primeros aportes en el a\u00f1o 2005 fluctuando entre 10 y 30 \nMWh hasta el a\u00f1o 2006, luego hubo un aumento a 60 MWh en \nel a\u00f1o 2011, llegando a 38 GWh en el 2019.  En el a\u00f1o 2011, \nel Conelec por medio de la regulaci\u00f3n 004/11, determin\u00f3 el \ntratamiento para la energ\u00eda producida con recursos energ\u00e9ti-\ncos renovables no convencionales para centrales menores a 2058\n50 MW.  Bajo esta regulaci\u00f3n, a las generadoras fotovoltaicas \nse les cancelar\u00e1 40.03 c USD/KWh en el territorio nacional y \n44.03 c USD/KWh en la regi\u00f3n insular22.  Actualmente, este \ntipo de energ\u00eda tiene una potencia efectiva de 26.74 MW.  Los \nprincipales proyectos de energ\u00eda solar a base de paneles foto-\nvoltaicos se indican en la tabla 4.Proyectos de energ\u00eda hidr\u00e1ulica\nEcuador es el pa\u00eds con la m\u00e1s alta concentraci\u00f3n de r\u00edos \npor kil\u00f3metro cuadrado en el hidroel\u00e9ctrica, que es la base del \ncambio de matriz energ\u00e9tica iniciado en el gobierno anterior. La \ncordillera andina es la l\u00ednea divisoria de aguas entre la cuenca \nhidrogr\u00e1fica del r\u00edo Amazonas, que discurre hacia el este, y del \noc\u00e9ano Pac\u00edfico, que incluye los r\u00edos Mataje, Santiago, Coca, \nEsmeraldas, Chone, Guayas y Jubones, entre otros20. Este tipo \nde energ\u00eda primaria increment\u00f3 su participaci\u00f3n, pasando del \n1% en 1970 a casi el 4% en la actualidad. En el 2006, la capa-\ncidad instalada era de 3300 MW, alcanzando los 5073 MW en \nel 2018.  La producci\u00f3n de este tipo de energ\u00eda es 24.665 GWh. \nEn la tabla 6 se observa la potencia nominal de cada fuente \nrenovable. \nLas principales centrales hidroel\u00e9ctricas que est\u00e1n fun-\ncionando se muestran en la siguiente tabla (Tabla 7) con su \nrespectiva potencia en MW. \nEntre los principales proyectos que se encuentran en \nconstrucci\u00f3n est\u00e1n el Zamora-Santiago que aprovechar\u00e1 las \naguas del r\u00edo Zamora, se estima una potencia superior a los \n3000 MW; el Paute-Cardenillo que constituye el pelda\u00f1o final \ndel desarrollo integral de la cuenca del r\u00edo Paute, tendr\u00e1 una \ncapacidad instalada de 595 MW; el Mazar-Dudas que captar\u00e1 \nlas aguas del r\u00edo Mazar, se espera obtener una potencia ins-\ntalada del 20,82 MW, se encuentra en la provincia de Ca\u00f1ar \ny Quijos que tendr\u00e1 una potencia instalada de 50 MW, apro-\nvechar\u00e1 las agua del mismo nombre en la provincia de Napo, \nFigura 1. Consumo de energ\u00eda por sector en el 2010 en Ecuador. Figura 2. Porcentaje de participaci\u00f3n de centrales el\u00e9ctricas \nde acuerdo a su tipo en el 2010.\nTabla 4. Principales proyectos fotovoltaicos en el Ecuador.\nFigura 3. Parque e\u00f3lico de Villonaco \nubicado en la provincia de Loja, foto to -\nmada de la p\u00e1gina web de Celec Gensur, \ngaler\u00eda.\nProyectos de energ\u00eda de la biomasa-biog\u00e1s\nEl proyecto San Carlos de cogeneraci\u00f3n entr\u00f3 en funcio-\nnamiento en el 2005, se convirti\u00f3 en el primer proyecto de este \ntipo del pa\u00eds, en lograr un registro internacional, en la Organi-\nzaci\u00f3n de las Naciones Unidad, como proyecto de mecanismo \nde desarrollo limpio23.  En el a\u00f1o 2019, la potencia efectiva de \neste tipo de energ\u00eda fue de 142.90 MW y la producci\u00f3n de ener-\ng\u00eda llega a 455 GWh.  Los principales proyectos de este tipo de \nenerg\u00eda se muestran en la tabla 5.Julio G\u00f3mez-Assan, Rosa Ajila-Freire\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2059\ngeot\u00e9rmico se limita a balnearios y piscinas termales. Se han \nrealizado estudios de prefactibilidad en cinco proyectos.   Los \nan\u00e1lisis definieron un potencial en cuatro zonas espec\u00edficas: \nTufi\u00f1o-Chiles (frontera Ecuador-Colombia), Chalupas (Coto-\npaxi), Cachimbiro (Imbabura) y Chacana (Pichincha).   En la si-\nguiente tabla se indica la potencia estimada de cada proyecto. \nEl valor promedio de los estudios, perforaci\u00f3n y entrada \nde operaciones oscila entre 15 millones y 25 millones USD.  \nTambi\u00e9n se necesitan tres a\u00f1os para que la perforaci\u00f3n de \nprueba proporcione los suficientes datos que permitan prose-\nguir con el desarrollo del proyecto26.\nProyectos de energ\u00eda del mar\nEn el Ecuador a\u00fan no se ha aplicado a gran escala la ge-\nneraci\u00f3n de electricidad a trav\u00e9s de este tipo de energ\u00eda debido \na la falta de inter\u00e9s de las entidades p\u00fablicas27.  El perfil costa-\nnero de Ecuador por su extensi\u00f3n de 640 km motiva la b\u00fasque-\nda de un recurso energ\u00e9tico en el Oc\u00e9ano Pac\u00edfico.   Seg\u00fan una \ninvestigaci\u00f3n realizada por Juan S. Guam\u00e1n, donde se indica \nque por la existencia de la corriente Sub-Superficial Ecuato-\nrial del Pac\u00edfico se puede aprovechar la energ\u00eda existente en \nesta corriente marina debido a su velocidad de 1.5 m/s, que es \nmayor al requerimiento m\u00ednimo de 1.0 m/s.  Luego indica que, \npara reemplazar a una central termoel\u00e9ctrica, se necesita una \ninversi\u00f3n de 85 millones USD28.\nSe ha realizado un sencillo c\u00e1lculo, considerando valores \nde la inversi\u00f3n por proyecto terminado y la potencia instalada, \nse obtuvo la siguiente tabla, en donde se indica el costo de la \ninversi\u00f3n para obtener un kilovatio (kW) de potencia.  Se toma-\nron como ejemplo cuatro proyectos.\nConclusiones\nPara la producci\u00f3n de energ\u00eda dependemos indiscutible-\nmente del petr\u00f3leo y ese panorama no ha cambiado desde el \nauge petrolero del a\u00f1o 2000.  El objetivo del gobierno anterior \nde cambiar la matriz energ\u00e9tica del Ecuador, dio paso a la inau-\nguraci\u00f3n de m\u00e1s centrales hidroel\u00e9ctricas, como la Coca Codo \nSinclair de 1500 MW.  Debido al subsidio al gas y a la gasolina \nno se avizora cambio para utilizar fuentes de energ\u00eda renova-\nTabla 5. Principales plan -\ntas de energ\u00eda de bioma -\nsa-biog\u00e1s en Ecuador\nTabla 6. Potencia nominal ins -\ntalada seg\u00fan tipo de energ\u00eda en \nEcuador.\nTabla 7. Centrales hidroel\u00e9ctricas en funcionamiento en \nEcuador.\nTabla 8. Proyectos hidroel\u00e9ctricos (no terminados) del Ecuador.la obra tiene un 46% de avance24. En la tabla 8 se muestran \nalgunos de los proyectos que todav\u00eda no entran en operaci\u00f3n, \ncon la potencia y energ\u00eda estimada.\nProyectos de energ\u00eda geot\u00e9rmica\nLa exploraci\u00f3n geot\u00e9rmica se inici\u00f3 en el Ecuador hace \nm\u00e1s de 30 a\u00f1os con el Instituto Ecuatoriano de Electrificaci\u00f3n \n(INECEL), sin embargo, fue cerrada en 1993, debido principal-\nmente a los bajos precios del petr\u00f3leo, a la falta de un marco \nregulatorio y a la no disponibilidad de un capital inicial de ries-\ngo25.  El Ecuador al estar ubicado en el cintur\u00f3n de fuego del \nPac\u00edfico posee un potencial t\u00e9rmico estimado de 1700 MW, es \ndecir, un poco m\u00e1s que la potencia de la central hidroel\u00e9ctrica \nCoca Codo Sinclair.  En la pr\u00e1ctica, la utilizaci\u00f3n del recurso \nTabla 9. Principales proyectos geot\u00e9rmicos del Ecuador.\nTabla 10. Inversi\u00f3n en d\u00f3lares por kW instalado seg\u00fan el tipo \nde energ\u00eda.Experiencias en el uso de energ\u00eda renovable en la Rep\u00fablica del Ecuador\nExperiencies in the use of renewable energies in the Republic of Ecuador2060\nbles, especialmente en el sector del transporte y residencial.  \nEl aumento de la potencia nominal de la energ\u00eda renovable se debe al financiamiento del Estado.\nEstamos viviendo una \u00e9poca en que las empresas el\u00e9c-\ntricas garantizan la entrega de la energ\u00eda debido a que no te-nemos problemas de estiaje o sequ\u00eda en las zonas donde se ubican las centrales, por lo tanto, la poblaci\u00f3n urbana no sien-te la necesidad de adquirir otras fuentes de energ\u00eda el\u00e9ctrica. Finalmente, los esfuerzos estatales deben apuntar a aprove-char la energ\u00eda geot\u00e9rmica debido a su gran potencial t\u00e9rmi-co, as\u00ed tendr\u00edamos otra fuente de energ\u00eda sin depender de las hidroel\u00e9ctricas.\nDespu\u00e9s de la energ\u00eda hidr\u00e1ulica, sigue la producida por \nbiomasa, luego la e\u00f3lica.  La primera y la tercera son inversio-nes y proyectos estatales, mientras que la segunda proviene de inversiones privadas.  Parecer\u00eda que la inversi\u00f3n estatal no apunta a los proyectos de celdas fotovoltaicas.\nEn la comparaci\u00f3n de la inversi\u00f3n necesaria para instalar \nun kilovatio de potencia, no se obtuvo el valor del proyecto del Ingenio San Carlos, despu\u00e9s de realizar las respectivas consul-tas en su p\u00e1gina web.\nAgradecimientos\nLos autores agradecen a la docente investigadora Lissenia \nSornoza Quijije por sus valiosos aportes y ayuda incondicional \npara la culminar con \u00e9xito de este trabajo de revisi\u00f3n biblio-gr\u00e1fica.\nReferencias bibliogr\u00e1ficas\n1. W orld Bank Group [online].  Disponible en: https://data.world-\nbank.org/topic/energy-and- mining.\n2.IIGE, \u201cBalance Energ\u00e9tico Nacional 2018\u201d, [on line].  Disponible\nen: ht\ntps://www.recursosyenergia.gob.ec/5900-2\n3.A. \nde la Heras Ab\u00e1s, Informe de situaci\u00f3n de las emisiones de\nCO2 en el mundo. A\u00f1o 2014, Catalu\u00f1a, Fundaci\u00f3n   UniversitariaIberoamericana, 2016, pp. 35.\n4.\n International Energy Agenc\ny, Datos y Estad\u00edsticas, [on line].  Dis-\nponible en: https://www.iea.org/data-and-statistics\n5.REN21, \n\"Renewables Global Status Report: 2009\" [on line]. Dis-\nponible en: https://www.ren21.net/wp-content/uploads/2019/05/GSR2009_Full-Report_English.pdf\n6.\nREN21, \"R\nenewables 2019 Global Status Report\" [on line].  Dis-\nponible en: https://www.ren21.net/wp-content/uploads/2019/05/gsr_2019_full_report_en.pdf , ISBN 978-3-9818911-7-1\n7.\nSe\nvilla, B. \u201cRanking mundial de los pa\u00edses con mayor potencia\nhidr\u00e1ulica instalada en 2018\u201d [on line].  Disponible en: https://es.statista.com/estadisticas/641232/potencia-hidraulica-instala-da-por-paises/#statisticContainer\n8.\n El Peri\u00f3dico de la Energ\u00eda, \u201cLas 10        hidroel\u00e9ctricas m\u00e1sgr\nandes del mundo\u201d [on line].  Disponible en: https://elpe-\nriodicodelaenergia.com/las-10-centrales-hidroelectri-cas-mas-grandes-del-mundo/\n9.\nGlobal Wind Energy Council [on line].  Disponible en: ht\ntps://\ngwec.net/global-wind-report-2019/\n10.\n Global Wind Energy Council, \"Global Wind R\neport 2019\", Rue Bel-\nliard 51-53 1000 Brussels, Belgium, 2020, pp. 41\n11.\n R\nevista Muy Interesante, [on line].  Disponible en: https://www.\nmuyinteresante.es/tecnologia/video/ \u00bfCu\u00e1l es el mayor parquee\u00f3lico marino del mundo? (muyinteresante.es)12.\n W\norld Bioenergy Association, \"Global Bioenergy Statistics 2019\"\n[on line], pp. 15.    Disponible en:    https://worldbioenergy.org/uploads/191129%20WBA%20GBS%202019_HQ.pdf\n13.\n International R\nenewable Energy Agency IRENA [on line].  Dis-\nponible en: https://www.irena.org/bioenergy\n14.\n P\nower Technology, \u201cLas plantas de energ\u00eda solar m\u00e1s grandes del \nmundo\u201d, [on line].  Disponible en: https://www.power-technology.com/features/the-worlds-biggest-solar-power-plants/\n15.\n Our W\norld In Data, \u201cCapacidad instalada de energ\u00eda solar, 2018\u201d,\n[on line].  Disponible en: https://ourworldindata.org/renew-able-energy\n16.\n Piensa en Geotermia, \u201cInv\nersi\u00f3n geot\u00e9rmica en Indonesia para lle-\ngar a $1,7 billones en 2018\u201d [on line].  Disponible en: https://www.piensageotermia.com/inversion-geotermica-en-indonesia-pa-ra-llegar-a-1-7-billones-en-2018/\n17.\n Olade, \n\u201cPanorama energ\u00e9tico de Am\u00e9rica Latina y el Caribe\n2020\u201d, 1ra. ed. Ecuador, 2020, pp. 137\n18.\n Conelec, \n\u201cBolet\u00edn estad\u00edstico sector el\u00e9ctrico ecuatoriano 2010\u201d\n[on line]. Disponible en: https://www.regulacionelectrica.gob.ec/wp-content/uploads/downloads/2015/12/Estad\u00edstica-Sec-tor-El\u00e9ctrico-Ecuatoriano-2010.pdf\n19.\n R\neve, \u201cLa energ\u00eda e\u00f3lica en Ecuador\u201d [online].  Disponible en:\nhttps://www.evwind.com/2010/08/11/la-energia-e\u00f3lica-en-ec-uador/\n20.\n el\ntel\u00e9grafo, \u201cel parque e\u00f3lico m\u00e1s alto del mundo en Ecuador\u201d\n[online].  Disponible en: https://www.eltelegrafo.com.ec/noticias/economia/4/parque-eolico-mas-alto-del-mundo-en-ecuador\n21.\n Corpor\naci\u00f3n  para  la  investigaci\u00f3n energ\u00e9tica,  \u201cAtlas  solar  solar  \ndel  Ecuador con  fines  de  generaci\u00f3n  el\u00e9ctrica\u201d,  Quito, 2008,pp. 10-46.\n22.\n Conelec, \u201cRegulaci\u00f3n No. Conelec-004-11\u201d [online].  Disponibleen: ht\ntps://regulacionelectrica.gob.ec/wp-content/uploads/\ndownloads/2015/10/conelec_004_11_ernc.pdf\n23.\n San Carlos, p\u00e1gina W\neb, http://www.sancarlos.com.ec/mod-\nelo-de-produccion-sostenible/cogeneracion-de-energia-electri-ca/\n24.\n  Celec, [online].  Disponible en:ht\ntps://www.celec.gob.ec\n25.\n R\neve, \u201cLa energ\u00eda geot\u00e9rmica en Ecuador\u201d [online].  Disponible\nen: https://www.evwind.com/2012/06/26/la-energia-geotermi-ca-en-ecuador/\n26.\n A. Garc\u00eda, \u201cEl uso de energ\u00eda geot\u00e9rmica se extiende por todo elplaneta\n\u201d [online]. Disponible en: https://www.elcomercio.com/\ntendencias/ener giageotermica-planeta-cop20-lima.html.\n27.R.     R\nodr\u00edguez,    M.     Chimbo. \u201cAprovechamiento de la energ\u00eda\nundimotriz en el      Ecuador\u201d.   Ingenius No.17, (Enero- Junio), pp. 24.\n28.\n J\n.   Guam\u00e1n,  J.   Espinoza,  E.   Ribeiro. \u201cEnerg\u00eda del mar para su\nintegraci\u00f3n en la matriz energ\u00e9tica del Ecuador\u201d.   Revista Mas-kana, pp. 314-317.\nReceived: 25 marzo 2021\nAccepted: 10 julio 2021Julio G\u00f3mez-Assan, Rosa Ajila-Freire\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2061\nTecnolog\u00eda IgY: Estrategia en el tratamiento de enfermedades infecciosas \nhumanas\nIgY Technology: Strategy in the treatment of human infectious diseases\nNathaly Cruz Tipantiza1 and Marbel Torres Arias2 DOI. 10.21931/RB/2021.06.03.30\nResumen: La aparici\u00f3n de microorganismos resistentes a antibi\u00f3ticos, el descubrimiento de nuevos agentes pat\u00f3genos con \npotencial pand\u00e9mico y el aumento de una poblaci\u00f3n inmunocomprometida han dejado casi obsoleta la terapia antimicrobiana, terapia com\u00fanmente usada para tratar enfermedades infecciosas. Por otro lado, las investigaciones acerca del uso del anticuerpo IgY para desarrollar inmunidad pasiva han demostrado el potencial que tiene la tecnolog\u00eda IgY para tratar enfermedades infecciosas v\u00edricas y bacterianas. Donde los anticuerpos IgY de aves se destacan por su alta especificidad, rendimiento y escalabilidad de producci\u00f3n a menor costo, con relaci\u00f3n a los anticuerpos IgG de mam\u00edferos. El objetivo de esta revisi\u00f3n es determinar la importancia del uso de los anticuerpos IgY como tratamiento terap\u00e9utico y profil\u00e1ctico frente a los pat\u00f3genos causantes de infecciones virales y bacterianas en humanos, mediante la recopilaci\u00f3n de ensayos cl\u00ednicos, productos comerciales y patentes registradas en el per\u00edodo de 2010-2021. Finalmente, con este estudio se estableci\u00f3 que la tecnolog\u00eda IgY es una herramienta biotecnol\u00f3gica vers\u00e1til y eficaz para tratar y prevenir enfermedades infecciosas, al reducir los s\u00edntomas y la carga del pat\u00f3geno.\nPalabras clave: Anticuerpo IgY, bacteria, terapia pasiva, virus.Abstract: The emergence of antibiotic-resistant microorganisms, the discovery of new pathogens with pandemic potential, and \nthe rise of an immunocompromised population have rendered antimicrobial therapy, a commonly used therapy to treat infectious \ndiseases, almost obsolete. On the other hand, research into the use of IgY antibodies to develop passive immunity has demonstrated the potential of IgY technology to treat viral and bacterial infectious diseases. Avian IgY antibodies stand out for their high specificity, performance, and scalability at a lower cost relative to mammalian IgG antibodies. This review aims to compile information on the use of IgY antibodies as therapeutic and prophylactic treatment against pathogens causing viral and bacterial infections in humans by collecting clinical trials, commercial products, and patents registered in 2010-2021. Finally, this study established that IgY technology is a versatile and effective biotechnological tool to treat and prevent infectious diseases by reducing symptoms and pathogen burden.\nKey words: IgY antibody, bacteria, passive therapy, virus.REVIEW / ART\u00cdCULO DE REVISI\u00d3N\nIntroducci\u00f3n\nCuando un hospedero se encuentra en desequilibrio dis-\nminuye la capacidad de protecci\u00f3n del sistema inmunol\u00f3gico \npermitiendo la entrada de microorganismos. Estos pat\u00f3genos desencadenan  una infecci\u00f3n, que se define como \u201cla presencia y multiplicaci\u00f3n de un microorganismo en los tejidos, fluidos o cavidades de un hu\u00e9sped\u201d\n1. La colonizaci\u00f3n de los pat\u00f3genos \nen conjunto con otros factores ambientales permiten la inva-si\u00f3n del hu\u00e9sped generando da\u00f1os a nivel local o sist\u00e9mico, causando un infeccion\n2.\nDurante el siglo XIX era com\u00fan el uso de sueros de origen \nanimal (sueros heter\u00f3logos) para tratar enfermedades infec-ciosas, sin embargo la idea fue abandonada por la toxicidad asociada a su administraci\u00f3n y la introducci\u00f3n de la quimiote-rapia antimicrobiana en 1909\n3. A pesar de todo, las infeccio-\nnes virales y bacterianas siguen siendo las principales causas de mortalidad y morbilidad en el mundo, representando a\u00fan un desaf\u00edo en la salud humana\n4. La p\u00e9rdida de eficacia de la \nquimioterapia antimicrobiana se atribuye al aumento de indi-viduos inmunodeprimidos, la reaparici\u00f3n de enfermedades que se consideraban ya erradicadas (sarampi\u00f3n, viruela), nuevos agentes infecciosos (SARS COV-2) y el desarrollo de resisten-cia a los antimicrobianos (RAM)\n5,6. Por esta raz\u00f3n, se busca un tratamiento capaz de reconocer ep\u00edtopos espec\u00edficos, y as\u00ed evitar la entrada, propagaci\u00f3n, y neutralizaci\u00f3n de factores de virulencia sin da\u00f1ar las c\u00e9lulas hu\u00e9sped. Permitiendo que el sistema inmunol\u00f3gico elimine los pat\u00f3genos y evite desarro-llar una infecci\u00f3n cr\u00f3nica.\nPor otro lado surge el inter\u00e9s por el uso de sueros de ori-\ngen animal, generado por el sistema inmune de aves, dada su capacidad para generar anticuerpos que brindan inmunidad pasiva a su descendencia\n7,8. Existen tres isotipos de inmuno-\nglobulinas aviares: IgA e IgM presentes en la clara, e IgY pre-sente en la yema; siendo este, el de principal inter\u00e9s terape\u00fati-co por su alta especificidad contra ant\u00edgenos de mam\u00edferos altamente conservados\n9. Fue as\u00ed que desde 1995 se asigna el \nt\u00e9rmino \u201ctecnolog\u00eda IgY\u201d al proceso de producci\u00f3n y aplicaci\u00f3n de anticuerpos IgY aviares\n10, reportandose aplicaciones  en el \n\u00e1rea veterinaria, inmuno-diagn\u00f3stica y de investigaci\u00f3n11.\nEn el a\u00f1o 2010 empieza el apogeo de esta tecnolog\u00eda en la \nmedicina humana como alternativa al uso de antibi\u00f3ticos y por su bajo costo de producci\u00f3n\n12. Se ha documentado la eficacia \ndel uso de IgY para tratar y prevenir infecciones bacterianas y v\u00edricas causantes de patolog\u00edas como caries dental, periodonti-tis, gastritis, diarrea, entre otras\n13. De forma general se ha visto \n1 Departamento de Ciencias de la Vida y la Agricultura, Carrera de Ingenier\u00eda en Biotecnolog\u00eda, Universidad de las Fuerzas Armadas ESPE, Ecuador. \n2 Departamento de Ciencias de la Vida y la Agricultura, Carrera de Ingenier\u00eda en Biotecnolog\u00eda, Universidad de las Fuerzas Armadas ESPE, Ecuador y Laboratorio de \nInmunolog\u00eda y Virolog\u00eda, CENCINAT, GISAH, Universidad de las Fuerzas Armadas, ESPE, Ecuador.\nCorresponding author: mmtorres@espe.edu.ecTecnolog\u00eda IgY: Estrategia en el tratamiento de enfermedades infecciosas humanas\nIgY Technology: Strategy in the treatment of human infectious diseases2062\nNathaly Cruz Tipantiza and Marbel Torres Arias\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nque IgY facilita la eliminaci\u00f3n del pat\u00f3geno a trav\u00e9s del intes-\ntino, evitando la replicaci\u00f3n y propagaci\u00f3n del mismo9. Se ha \nevaluado la administraci\u00f3n sist\u00e9mica del anticuerpo IgY aviar \nen comparaci\u00f3n con IgG de mamiferos, evidenci\u00e1ndose una ac-\nci\u00f3n m\u00e1s r\u00e1pida y local14. Asimismo, la inmunoterapia oral con \nIgY demostr\u00f3 su versatilidad y seguridad de uso al poder ser \naplicada como f\u00e1rmaco y nutrac\u00e9utico en un rango amplio de \npacientes, desde reci\u00e9n nacidos, adultos, embarazadas hasta \npacientes con inmunodeficientes e infecciones activas15.\nTras una breve descripci\u00f3n de la tecnolog\u00eda IgY, sus ven-\ntajas y aplicaciones, esta revisi\u00f3n resume el uso potencial de \nIgY aviar como inmunoterapia contra infecciones bacterianas \ny virales en humanos. Para ello se recopil\u00f3 mediante p\u00e1ginas \nweb oficiales y  bases de datos cient\u00edficas los principales ensa-\nyos cl\u00ednicos, patentes y productos comerciales disponibles en \nel per\u00edodo de 2010-2021.\nTecnolog\u00eda IgY\nEn 1893 el cient\u00edfico Felix Klemperer reporta el primer uso \nde IgY aviar (IgY antitoxina tet\u00e1nica) para generar inmunidad \npasiva en ratones, permitiendo que estos sobrevivan a dosis \nconsideradas letales de esta toxina16. Sin embargo, fue has-\nta el a\u00f1o 1959 donde el bienestar animal se convierte en una \npreocupaci\u00f3n \u00e9tica para la comunidad cient\u00edfica, lo que atrae \nnuevamente el inter\u00e9s por el experimento de Klemperer17. Fue \nentonces, que desde la d\u00e9cada de 1980 se empieza a desarro-\nllar una amplia gama de aplicaciones para IgY,  principalmente \nen investigaci\u00f3n, diagn\u00f3stico e inmunoterapia en medicina ve-\nterinaria12,18.\nEn 1995, el Doctor Claus Staak, asigna el t\u00e9rmino \u201ctec-\nnolog\u00eda IgY\u201d al proceso de producci\u00f3n y aplicaci\u00f3n de anti-\ncuerpos IgY aviares10. De forma paralela en 1996, el Centro \nEuropeo para la Validaci\u00f3n de M\u00e9todos Alternativos (CEVMA) \nrecomienda el uso de IgY como alternativa al uso de IgG de \nmam\u00edfero, convirtiendo la tecnolog\u00eda IgY en una pr\u00e1ctica inter-\nnacionalmente aceptada19. Por \u00faltimo, a partir del a\u00f1o 2010 y \nhasta la actualidad se ha evidenciado un incremento del uso de \nIgY en la medicina humana como herramienta de diagn\u00f3stico \ne inmunoterapia11,15.\nInmunoglobulina IgY vs Inmunoglobulina IgG\nIgY es un isotipo de inmunoglobulina secretada por aves, \nanfibios, reptiles y peces pulmonados20, es considerado el pre-\ncursor evolutivo de IgG e IgE de mam\u00edferos por su similitud \nfuncional con ambos anticuerpos y a nivel estructural con \nIgE21. A nivel inmunol\u00f3gico IgY es el equivalente de IgG de ma-\nm\u00edferos, sin embargo, difieren en aspectos funcionales y es-\ntructurales. Por ejemplo, IgY posee una masa molecular (~180 \nkDa) en comparaci\u00f3n a IgG (~160 kDa)22 ya que posee cuatro \ndominios constantes en la cadena pesada (CH1-CH4) mientras \nque IgG solo posee tres (CH1-CH3). Asimismo, IgY carece de \nla regi\u00f3n bisagra entre el dominio CH1 y CH2 al igual que IgE \nde mam\u00edfero10. Esta ausencia otorga a IgY una flexibilidad res-\ntringida en comparaci\u00f3n a IgG afectando su capacidad de pre-\ncipitar ant\u00edgenos multivalentes23,24. No obstante, su limitada \nflexibilidad le ha permitido reconocer mejor los ant\u00edgenos, es \ndecir tener una alta especificidad, y adem\u00e1s le ha otorgado una \nmayor resistencia a la degradaci\u00f3n y fragmentaci\u00f3n proteol\u00edti-\nca, manteni\u00e9ndose estable a temperaturas de entre 30-70\u00b0C y \nun pH de 3,5-1125.\nEstas diferencias estructurales y funcionales entre los an-\nticuerpos IgY aviar y su hom\u00f3logo IgG de mam\u00edfero le han con-\ncedido ciertas ventajas, como (1) generar una mayor respuesta \ninmune contra ep\u00edtopos de prote\u00ednas conservadas y prote\u00ednas que evaden el sistema inmune de mam\u00edferos26, (2) disminuir la \nreactividad cruzada27, (3) no activa el sistema complemento \nhumano, y por \u00faltimo, (4) IgY reduce los falsos positivos en \npruebas cl\u00ednicas al carecer de los sitios de uni\u00f3n en la regi\u00f3n \nFc, por ejemplo, no reacciona con el factor reumatoide (RF)28, \ntampoco con los receptores Fc bacterianos (prote\u00edna A y G)29 ni \ncon los aglutin\u00f3genos eritrocitarios A y B30.\nModo de acci\u00f3n de IgY\nEn la actualidad, a\u00fan se desconocen los mecanismos es-\npec\u00edficos que emplea la inmunoglobulina IgY para proteger al \nhu\u00e9sped contra los pat\u00f3genos31, pero se sabe de forma general \nque combina las funciones de IgG: opsonizar y fijar ant\u00edgenos \ne IgE: mediar reacciones anafil\u00e1cticas, espec\u00edficamente las \nde hipersensibilidad de tipo I o inmediato32; por lo que se han \npropuesto mecanismos de acci\u00f3n generales para explicar las \nfunciones efectoras que permiten la protecci\u00f3n al hu\u00e9sped (Fi-\ngura 1), como:\nAglutinaci\u00f3n\nIgY act\u00faa como un \u201cpegamento biol\u00f3gico\u201d, al aglutinar e \ninmovilizar los pat\u00f3genos y facilitar su eliminaci\u00f3n por el in-\ntestino11. Esto se afirma con el estudio de Tsubokura et al.33 al \ndesarrollar IgY-anti Campylobacter jejuni y registrar una dis-\nminuci\u00f3n del 99% de bacterias en el intestino, y un aumento \ndel  80-95% de bacterias en los recuentos bacterianos fecales.\nBloqueo de adherencia\nMecanismo principal de IgY, aprovecha su alta especifici-\ndad y permite unirse a ep\u00edtopos particulares del pat\u00f3geno, inhi-\nbiendo la adherencia de este a la superficie celular y previnien-\ndo la propagaci\u00f3n intercelular (mecanismo com\u00fan en virus)34. \nPor ejemplo, Xu et al.9 propone que si IgY se une a un ant\u00edgeno \nde superficie (prote\u00ednas de la membrana, fimbrias o flagelos) \nque sea crucial para la colonizaci\u00f3n bacteriana, se lograr\u00eda \nafectar las funciones normales de crecimiento, producci\u00f3n y \nliberaci\u00f3n de toxinas.\nNeutralizaci\u00f3n de toxinas\nIgY puede evitar el desarrollo de una infecci\u00f3n sin inhibir \ndirectamente al pat\u00f3geno, al neutralizar las toxinas secretadas \npor los mismos y evitar el desarrollo de efectos fisiopatol\u00f3gi-\ncos que estos podr\u00edan desencadenar35. Por ejemplo, la patente \nWO2013009843 describe las composiciones de IgY anti-LPS \ncontra bacterias gastrointestinales en animales, demostrando \nser eficaces en la disminuci\u00f3n de toxinas y pat\u00f3genos del trac-\nto digestivo, adem\u00e1s de registrar actividad antiinflamatoria36.\nOpsonizaci\u00f3n\nLa uni\u00f3n IgY-pat\u00f3geno, genera alteraciones estructura-\nles en el pat\u00f3geno torn\u00e1ndolo m\u00e1s suceptible a fagocitarse. \nPor ejemplo, en el estudio in vitro de Lee et al.37 se encontr\u00f3 \nque IgY- anti Salmonella typhimurium se un\u00eda a un ant\u00edgeno \nde superficie de la membrana celular, generando alteraciones \nestructurales en la superficie bacteriana. Por otro lado se pro-\npone que IgY puede mejorar la capacidad fag\u00f3citica de las c\u00e9-\nlulas inmunes del hospedero, pese a carecer del sitio de uni\u00f3n \nde la regi\u00f3n Fc. Esto se evidencio en el estudio de  Zhen et al.38  \ndonde la IgY- anti Escherichia coli mejor\u00f3 la actividad fagocitica \nde macr\u00f3fagos y neutr\u00f3filos.\nProductividad de IgY de la yema del huevo\nIgY es el \u00fanico anticuerpo aviar capaz de transferirse de \nla sangre de su progenitora a los oocitos maduros, otorgando 2063\nprotecci\u00f3n al embri\u00f3n de posibles infecciones patog\u00e9nicas39. \nEn base a este principio inmunol\u00f3gico y considerando que la \nyema de huevo es una fuente econ\u00f3mica y accesible para obte-\nner anticuerpos, la tecnolog\u00eda IgY desarrolla una metodolog\u00eda \npr\u00e1ctica, repetible, segura y de bajo costo para la producci\u00f3n de \nIgY30. Se comienza por inmunizar a las gallinas (por v\u00eda subcu-\nt\u00e1nea, intramuscular o intrad\u00e9rmica), con el fin de desarrollar \nuna respuesta inmunol\u00f3gica adaptativa humoral40. Para ello se \npueden utilizar diferentes tipos de ant\u00edgenos como pat\u00f3genos \ninactivados, prote\u00ednas recombinantes o prote\u00ednas obtenidas de \nADN plasm\u00eddico41. Una vez inmunizada el ave, el ant\u00edgeno se \nprocesa y genera los anticuerpos IgY que por inmunidad pasiva \nse transfieren del plasma sangu\u00edneo a la yema del huevo, este \ntraspaso se da a partir del quinto o sexto d\u00eda post inoculaci\u00f3n42. \nTras obtener el huevo, se separa la yema de la clara y se proce-\nde a remover la fracci\u00f3n lip\u00eddica por delipidaci\u00f3n43. Se recupera \nla fracci\u00f3n acuosa y se precipita con polietilenglicol o sales de \namonio o sodio, obteniendo un pellet de prote\u00ednas totales en \ndonde se encuentran las IgY44. Por \u00faltimo se realiza una puri-\nficaci\u00f3n por t\u00e9cnicas cromatogr\u00e1ficas o de ultrafiltraci\u00f3n, y se \ncuantifica la concentraci\u00f3n de anticuerpo IgY obtenido45.\nLa eficiencia de producci\u00f3n de la tecnolog\u00eda IgY para \nobtener un anticuerpo con alto rendimiento, pureza y activi-dad depende de varios aspectos como (1) la raza y dieta de \nlas aves, siendo las mejores razas de gallinas ponedoras ISA \nBrown y Lohmann Selected Leghorn. Por otro lado Villaguala \net al.46 propone evaluar la relaci\u00f3n yema:alb\u00famina, indepen-\ndientemente de la raza al considerar una relaci\u00f3n directa para \nobtener una concentraci\u00f3n mayor de IgY. (2)La modulaci\u00f3n de \nla respuesta humoral donde se vio que la v\u00eda intramuscular \nproduce niveles m\u00e1s altos que la subcut\u00e1nea47. (3) El uso o no \nde inmunoestimulantes o adyuvantes, donde los adyuvantes a \nbase de aceite, como el adyuvante completo de Freund (FCA) \ny el incompleto (FIA) siguen siendo los adyuvantes de elecci\u00f3n \nen producci\u00f3n48, sin embargo, se sabe que estos desencadenan \nefectos secundarios en el ave. L\u00e9vesque et al.49 ha propuesto \nla adici\u00f3n de inmunoestimulantes CpG ODN en conjunto con \nel adyuvante FIA, al conseguir aumentar la producci\u00f3n de IgY \nespec\u00edfica hasta en un 480%. (4) El tiempo y refuerzo del ant\u00ed-\ngeno, considerando que la concentraci\u00f3n en la yema es direc-\ntamente proporcional al tiempo de exposici\u00f3n del ant\u00edgeno en \nel ave50. Y por \u00faltimo, (5) el m\u00e9todo de purificaci\u00f3n aplicado, \nlas t\u00e9cnicas de cromatograf\u00eda y UF son \u00fatiles a nivel de labo-\nratorio, sin embargo, la aplicaci\u00f3n de estos m\u00e9todos para la \nproducci\u00f3n de IgY a gran escala se limita por problemas rela-\ncionados con la seguridad alimentaria y los altos costos51. A ni-\nFigura 1. Mecanismos de acci\u00f3n de anticuerpos IgY.Tecnolog\u00eda IgY: Estrategia en el tratamiento de enfermedades infecciosas humanas\nIgY Technology: Strategy in the treatment of human infectious diseases2064\nvel industrial se emplean coagulantes polisac\u00e1ridos naturales \ncomo pectina, alginato de sodio, goma xantana, carboximetil-\ncelulosa y carragenina, obteni\u00e9ndose una precipitaci\u00f3n de m\u00e1s \ndel 90% de las lipoprote\u00ednas de la yema48. De esta forma, la \nTecnolog\u00eda IgY ha reportado altos rendimientos de producci\u00f3n, \nobteniendo 300-325 huevos al a\u00f1o por gallina inmunizada de \nlos que se extraen de 100-150 mg de IgY por yema con una \nespecificidad del 5 al 10% contra el ant\u00edgeno inoculado31,52.\nPor otro lado, IgY se puede conservar por hasta 6 meses a \ntemperatura ambiente, por hasta 3 meses a temperaturas de \nhasta 50\u00b0C, y de 5-10 a\u00f1os a 4\u00b0C11. A largo plazo se recomien-\nda conservarlas a un m\u00e1ximo de -20\u00b0C53 o liofilizadas44. En la \nindustria farmac\u00e9utica y alimenticia es com\u00fan almacenar las \nIgY en forma pulverizada, tras aplicar un secado por atomiza-\nci\u00f3n54; adem\u00e1s, se suelen adicionar estabilizadores como car-\nbohidratos, az\u00facares, polioles y otros complejos, para aumen-\ntar la estabilidad t\u00e9rmica y de pH de IgY55.\nAplicaciones de IgY\nLa tecnolog\u00eda IgY ha evolucionado dr\u00e1sticamente en los \n\u00faltimos a\u00f1os, y es gracias a su estructura, propiedades y ca-\nracter\u00edsticas lo que la han convertido en uno de los principales \nanticuerpos terap\u00e9uticos y profil\u00e1cticos contra enfermedades \nen animales y humanos24. Ha logrado abarcar una gran varie-\ndad de campos, desde el \u00e1rea de diagn\u00f3stico e investigaci\u00f3n, \nhasta la de producci\u00f3n alimenticia y farmacol\u00f3gica13. A conti-\nnuaci\u00f3n, se abordar\u00e1 de forma r\u00e1pida algunas aplicaciones po-\ntenciales del anticuerpo IgY (Figura 2), para una revisi\u00f3n m\u00e1s \ndetallada, v\u00e9anse las ref. 10, 13 y 48. \nIgY para inmunoensayos\nLa alta sensibilidad, especificidad y avidez de IgY la han \nconvertido en un componente esencial para inmunoensayos \ncuantitativos y cualitativos18. Se ha utilizado IgY como biomar-\ncador de calidad ambiental y seguridad alimentaria56, permi-\ntiendo detectar sustancias como: f\u00e1rmacos residuales, al\u00e9rge-\nnos, hormonas, toxinas, ant\u00edgenos (de origen viral, bacteriano, \nparasitario, vegetal o animal)57\u201359, entre otros. Tambi\u00e9n se ha \nutilizado como reactivo inmunodiagn\u00f3stico, donde la avidez de \nIgY con prote\u00ednas conservadas de mam\u00edferos la han conver-\ntido en el sustituto de IgG en pruebas cl\u00ednicas al eliminar fal-\nsos positivos y disminuir interferencias10, incluso se ha usado \nen la detecci\u00f3n y cuantificaci\u00f3n de biomarcadores de c\u00e1ncer \ng\u00e1strico60, c\u00e1ncer de mama y ovario61. Adem\u00e1s, Zhang et al.62 \ndemostr\u00f3 que IgY se puede utilizar como un anticuerpo secun-\ndario, al ser capaz de conjugarse con las enzimas (peroxidasa \ne isotiocianato), reaccionar con el anticuerpo primario (IgG de \nrat\u00f3n) y amplificar las se\u00f1ales ant\u00edgeno-anticuerpo.\nEn consecuencia, IgY ya se aplica a varios formatos de \ninmunoensayos, tales como: ELISA63, Western blot45, croma-\ntograf\u00eda64, ensayos inmunoenzim\u00e1ticos65, ensayos de fluores-\ncencia66, entre otros.\nIgY como suplemento\nEl inter\u00e9s del consumidor por llevar un estilo de vida m\u00e1s \nsano, ha permitido que durante los \u00faltimos 20 a\u00f1os se produzca y \nutilice de forma masiva anticuerpos IgY en forma de suplemento \nfuncional13. Se han desarrollado suplementos nutricionales, cos-\nm\u00e9ticos y farmac\u00e9uticos que se pueden ingerir de forma segura, \nmejoran la calidad de vida de humanos y animales dom\u00e9sticos67.\nIgY como agente antitoxinas\nLa administraci\u00f3n sistem\u00e1tica de IgY ha reportado una \nnula inflamaci\u00f3n inespec\u00edfica y un bajo \u00edndice de efectos se-cundarios68, que en combinaci\u00f3n con su funci\u00f3n efectora de \nneutralizaci\u00f3n de toxinas la han convertido en una estrategia \nperfecta para el desarrollo de ant\u00eddotos69. Por ejemplo, en \npa\u00edses tropicales y subtropicales la mordedura de serpientes \nvenenosas, escorpiones y ara\u00f1as representan a\u00fan un peligro \npara la salud p\u00fablica70, com\u00fanmente se utilizan inyecciones \ncon sueros producidos en caballos, cabras y ovejas, pero estos \ninducen efectos secundarios como la enfermedad del suero o \nshock anafil\u00e1ctico71. Thalley et al.72 demostr\u00f3 a nivel in vivo el \nuso de IgY como antitoxina contra serpientes cascabel y escor-\npiones, siendo esta capaz de neutralizar los efectos letales y \nactuar como ant\u00eddoto de amplio espectro. De igual forma, LeC-\nlaire et al.73 report\u00f3 el desarrollo y uso de IgY anti-enterotoxina \nB estafiloc\u00f3cica (SEB), un agente microbiano letal utilizado en \nguerras biol\u00f3gicas, donde IgY actu\u00f3 como agente anti bioterro-\nrista al reducir la cantidad de citotoxinas inflamatorias y pro-\nteger a ratones y simios de dosis letales de SEB administradas \nen forma de aerosol.\nIgY como agente antitumoral\nLa supresi\u00f3n de la respuesta del sistema apopt\u00f3tico en con-\njunto con la auto-renovaci\u00f3n y supervivencia de las c\u00e9lulas tumo-\nrales, generan resistencia a la quimioterapia, tratamiento com\u00fan \npara tumores74. Es aqu\u00ed donde IgY se muestra como un potencial \nagente antitumoral al inducir la apoptosis en c\u00e9lulas cancerosas. \nPor ejemplo, Xiao et al.75 demostr\u00f3 que IgY anti- HER2 conjugadas \ncon nanotubos de carbono permiten la destrucci\u00f3n selectiva de \nc\u00e9lulas de c\u00e1ncer de mama. Por otro lado, Ch\u00e1vez et al.76 eviden-\nci\u00f3 que IgY-anti-abrina ejercia actividad citot\u00f3xica contra el bio-\nmarcador de c\u00e9lulas (CD133) en glioblastoma.\nIgY como agente antiobesidad\nLa obesidad es una enfermedad grave de la sociedad ac-\ntual, considerada como un trastorno metab\u00f3lico de l\u00edpidos y \nenzimas; por ello se han propuesto desarrollar f\u00e1rmacos con \ninhibidores de lipasa pancre\u00e1tica, tanto naturales como sint\u00e9-\nticos77. Hace poco Hirose et al.78 desarroll\u00f3 una IgY anti-lipasa, \nque tras probarse a nivel in vivo e in vitro, reduj\u00f3 el tejido adi-\nposo y el nivel de grasa hep\u00e1tica en sangre. IgY actu\u00f3 como \nagente antiobesidad, al inhibir y reducir la absorci\u00f3n intestinal \nde lipasa, y aumentar la excreci\u00f3n fecal de triglic\u00e9ridos.\nIgY como agente antiinfeccioso\nLa prevenci\u00f3n y tratamiento temprano de enfermedades \ninfecciosas es indispensable para combatir la morbilidad y la \nmortalidad asociada a pat\u00f3genos como: virus, bacterias, par\u00e1-\nsitos y hongos3. La capacidad de IgY para neutralizar y elimi-\nnar pat\u00f3genos a trav\u00e9s del intestino lo han convertido en un \npotencial agente antiinfeccioso. Por ejemplo, la inmunoterapia \nantimic\u00f3tica con IgY se ha vuelto atractiva como complemen-\nto a los f\u00e1rmacos antimic\u00f3ticos existentes, asociada a micosis \ninvasiva79. Se han desarrollado preparaciones a base de IgY \nque inhiben la adhesi\u00f3n y disminuyen la colonizaci\u00f3n del hongo \nCandida albicans80, un gel de uso oral desarrollado por Takeu-\nchi et al.81. Asimismo se ha reportado el uso de IgY en parasi-\ntolog\u00eda, como m\u00e9todo de diagn\u00f3stico temprano82,83. Thirumalai \net al.31 demostr\u00f3 que las preparaciones de IgY policlonal son \nla forma m\u00e1s experimentada y adecuada de inmunoterapia, \npuesto que se pueden aislar grandes cantidades con una alta \nespecificidad. Por ejemplo, Sampaio et al.82 y Grando et al.84 \nevaluaron el potencial terap\u00e9utico de IgY- anti Trypanosoma, \na nivel in vitro e in vivo, reportando un aumento en la viabilidad \nde las c\u00e9lulas y la supervivencia de los animales infectados. \nAsimismo  Esp\u00edn et al.85 desarroll\u00f3 una IgY anti- Leishmania Nathaly Cruz Tipantiza and Marbel Torres Arias\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2065\nmexicana, que permite detectar concentraciones m\u00ednimas (5-\n50 \u03bcg/mL) del par\u00e1sito.\nIgY para contrarrestar respuestas autoinmunes\nIgY ha demostrado un potencial para disminuir las respues-\ntas autoinmunes asociadas a enfermedades y al\u00e9rgenos. Husby \net al.86 desarroll\u00f3 una IgY anti-gliadina (glicoprote\u00edna presente \nen cereales) para tratar la enfermedad cel\u00edaca, enfermedad \ngenerada por la intolerancia al gl\u00faten, consiguiendo inhibir la \nabsorci\u00f3n de gliadina y evitar la respuesta inflamatoria. Worle-\ndge et al.87 report\u00f3 el uso de IgY anti- TNF\u03b1  (factor de necrosis \ntumoral) para tratar la enfermedad de Crohn y la colitis ulce-\nrosa, consiguiendo un efecto preventivo y m\u00e1s eficaz que los \nf\u00e1rmacos antiinflamatorios. Incluso se ha desarrollado una IgY \n(IgY- anti \u03b1 Gal) que evita el rechazo de xenotrasplantes en pri-\nmates, al impedir que los anticuerpos naturales xenoreactivos \ninteract\u00faan con el tejido porcino trasplantado88. Por \u00faltimo, se \nha empleado IgY como agente anti-alerg\u00e9nico (Figura 2), Wei-\nxu et al.89 evalu\u00f3 el efecto de IgY- anti IL-\u03b2 1/TNF-\u03b1  en cobayas \ncon rinitis al\u00e9rgica, donde observ\u00f3 una reducci\u00f3n del n\u00famero de \neosin\u00f3filos, neutr\u00f3filos y linfocitos en los pulmones.\nIgY como terapia de infecciones humanas\nEn la actualidad se exige una constante demanda de tera-\npias que desarrollen inmunidad inmediata y a largo plazo, con \nuna producci\u00f3n continua y escalable, que garantice pureza y \nsuministro constante90. Los anticuerpos IgY se muestran como \nuna inmunoterapia pasiva prometedora y eficaz en el trata-\nmiento de muchas infecciones91, principalmente del sistema respiratorio, digestivo y oral92. A continuaci\u00f3n, se abordar\u00e1 el \nuso de IgY para la prevenci\u00f3n y terapia de infecciones bacteria-\nnas y virales, mediante la recopilaci\u00f3n de ensayos cl\u00ednicos re-\ngistrados (Tabla 1), patentes (Tabla 2) y productos comerciales \n(Tabla 3) desarrolladas en el periodo de 2010-2021.\nInfecciones bacterianas\nLos pat\u00f3genos bacterianos se caracterizan por su capaci-\ndad de replicarse de forma aut\u00f3noma y por secretar factores \nde virulencia f\u00e1cilmente propagables como: toxinas, pigmentos, \nprote\u00ednas y mol\u00e9culas de se\u00f1alizaci\u00f3n93. Que en conjunto con la \naparici\u00f3n de bacterias multirresistentes, por el uso indiscrimina-\ndo de antibi\u00f3ticos, ha convertido las infecciones bacterianas en \nuna amenaza para la salud p\u00fablica en todo el mundo94. Como \nalternativa al uso de antibi\u00f3ticos se propone utilizar anticuerpos \nIgY, puesto que su capacidad de adhesi\u00f3n disminuye y previene \nla colonizaci\u00f3n bacteriana, sobre todo en la etapa inicial, impi-\ndiendo que se transformen en infecciones cr\u00f3nicas10.\nSe ha evaluado el uso de IgY contra pat\u00f3genos de la ca-\nvidad oral, tales como Prevotella intermedia95, Fusobacterium \nnucleatum42, Streptococcus mutans96, Porphyromonas gingi-\nvalis97, entre otras. Tras la administraci\u00f3n oral de IgY en pasti-\nllas, sprays y enjuagues bucales (Tabla 1) se evit\u00f3 desarrollar \ncaries, acumular placa dental y posibles reinfecciones, incluso \ntrataron la periodontitis y gingivitis98. Tamb\u00ed\u00e9n, se ha admi-\nnistrado IgY de forma intranasal contra pat\u00f3genos del tracto \nrespiratorio, tales como Mycobacterium tuberculosis99, Sta-\nphylococcus aureus100 y Pseudomona aeruginosa101. Donde IgY \nneutraliz\u00f3 los pat\u00f3genos en el tracto respiratorio y pulmones, \nFigura 2. Aplicaciones del anticuerpo IgY.Tecnolog\u00eda IgY: Estrategia en el tratamiento de enfermedades infecciosas humanas\nIgY Technology: Strategy in the treatment of human infectious diseases2066\nadem\u00e1s se vio que al utilizar IgY como adyuvante de antibi\u00f3-\nticos este permite reducir la colonizaci\u00f3n en los pulmones102.\nPor otro lado, los principales pat\u00f3genos asociados a in-\ntoxicaciones alimentarias y gastritis son las bacterias gas-\ntrointestinales Escherichia coli, Salmonella spp.103, Clostridium \ndifficile104, Helicobacter pylori105,106, Vibrio cholerae107, entre \notras. Es necesario eliminar pat\u00f3genos del est\u00f3mago para evi-\ntar que se desarrollen afecciones m\u00e1s severas como \u00falceras y \nc\u00e1ncer de est\u00f3mago108. Se han realizado ensayos cl\u00ednicos para \ninvestigar el efecto de IgY por administraci\u00f3n oral, en f\u00e1rmacos \n(GastimunHP y GastimunHp Plus) y suplementos diet\u00e9ticos \n(IM-01) (Tabla1), donde se evidencia de forma general que es-\ntos brindan protecci\u00f3n contra enterobacterias y mejoran los \ns\u00edntomas cl\u00ednicos como la diarrea109. Asimismo, se ha evaluado \nel uso de IgY contra bacterias asociadas al desarrollo de acn\u00e9 \n(Propionibacterium acnes) y dermatitis at\u00f3pica (Staphylococ-\ncus aureus)110, donde IgY ha permitido controlar la secreci\u00f3n \nde enterotoxinas y mejorar la barrera cut\u00e1nea100.\nFinalmente, se ha evaluado el uso de IgY contra bacterias \nresistentes a antibi\u00f3ticos betalact\u00e1micos como Acinetobacter \nbaumannii111, Klebsiella pneumoniae y Escherichia coli (Tabla \n1), logrando erradicar el transporte intestinal de las enzimas \nBLEE (betalactamasas de expectro extendido) responsables \nde generar resistencia a este tipo de antibi\u00f3ticos12.\nInfecciones Virales\nLos virus son organismos contagiosos con una alta capa-\ncidad de adaptabilidad y potencial pand\u00e9mico, que se caracte-\nrizan por utilizar las v\u00edas del propio hu\u00e9sped para replicarse y \npropagarse112. Pese a que ya se disponen de vacunas para algu-\nnas enfermedades virales, estas generan incertidumbre acerca \nde su eficacia, capacidad de producci\u00f3n y entrega  masiva113. Es \nas\u00ed, que en 1990 el desarrollo de IgY anti-rotavirus114 v\u00e1lida el \nuso de la tecnolog\u00eda IgY como tratamiento de infecciones vira-\nles, puesto que, responde a la necesidad urgente de producir \nanticuerpos contra componentes virales espec\u00edficos en un cor-\nto tiempo, un bajo costo y sin da\u00f1ar las c\u00e9lulas hu\u00e9sped92.\nSe ha propuesto el uso de IgY para tratar infecciones cau-\nsadas por virus altamente contagiosos y mortales como el \u00e9bo-\nla115, hepatitis116, dengue117,118, zika119, entre otros; donde la IgY ha \npermitido neutralizar la replicaci\u00f3n viral, atenuar la infecci\u00f3n y \ndisminuir la letalidad en infecciones leves y asintom\u00e1ticas.\nAdemas la administraci\u00f3n oral de IgY para tratar infeccio-\nnes gastrointestinales asociadas a rotavirus y norovirus. En el \nensayo cl\u00ednico del producto PTM202 con IgY- anti rotavirus que \nse prob\u00f3 en ni\u00f1os con diarrea, tras su aplicaci\u00f3n se mejoraron \nlos s\u00edntomas asociados como la diarrea y fiebre (Tabla 1)120. \nPor otro lado, Dai et al.114 eval\u00fao la producci\u00f3n a gran escala de \nIgY anti-norovirus, obteni\u00e9ndose en tan solo 3 meses concen-\ntraciones de 4,7-9,2 mg/mL de yema de huevo, demostrando \nel potencial antiviral y diagn\u00f3stico de IgY.\nEn infecciones respiratorias virales los primeros informes \nde utilizaci\u00f3n de la tecnolog\u00eda IgY fue hace 20 a\u00f1os, al aplicar \nIgY por administraci\u00f3n intranasal en modelos animales y tener \n\u00e9xito en virus como: virus sincitial respiratorio, virus de la gripe, \nvirus de Sendai, entre otros9. Posteriormente se logr\u00f3 llegar \na ensayos cl\u00ednicos en humanos para los virus de la influenza \nA (H1N1121 y H5N1122), influenza B123, Hantavirus124,125, SARS54, \nentre otros. Donde IgY consigui\u00f3 neutralizar la infectividad y \nreducir la replicaci\u00f3n de estos virus en los pulmones, previ-\nniendo s\u00edndromes respiratorios agudos y graves.\nIgY como potencial inmunoterapia para el COVID-19\nEn diciembre de 2019 en Wuhan-China se report\u00f3 un gru-po de pacientes con neumon\u00eda asociada al coronavirus del s\u00edn-\ndrome respiratorio agudo severo 2 (SARS-CoV-2)126, virus que \nha mostrado una alta letalidad infecciosa y significativa mor-\ntalidad. Esta infecci\u00f3n respiratoria se caracteriza por su alto \ngrado de propagaci\u00f3n y adaptabilidad, que en conjunto con las \nmalas pr\u00e1cticas de bioseguridad ejecutadas por la poblaci\u00f3n \nhan permitido que se desarrolle la actual pandemia del CO-\nVID-1992. En consecuencia ha sido de suma urgencia el desa-\nrrollo de terapias y profil\u00e1cticos efectivos127. En base a la ex-\nperiencia con el tratamiento del SARS, Fu et al.54 propone una \ncombinaci\u00f3n de vacuna, inmunizaci\u00f3n pasiva y f\u00e1rmacos, para \ncontrolar de forma eficaz este tipo de infecciones.\nLa prote\u00edna pico (S) del SARS est\u00e1 compuesta por dos su-\nbunidades, la subunidad S1 que contiene el dominio de uni\u00f3n al \nreceptor (RBD) y la subunidad S2 que media la fusi\u00f3n entre el \nvirus y la c\u00e9lula hu\u00e9sped128. Por esta raz\u00f3n la prote\u00edna S se ha \nconvertido en el principal ep\u00edtopo para desarrollar medicamen-\ntos antivirales, vacunas y anticuerpos129. Tomando en cuenta \nesta noci\u00f3n, la tecnolog\u00eda IgY se muestra como un potencial \nmaterial cl\u00ednico antiinfeccioso. Lu et al.130 desarroll\u00f3 IgY-S es-\npec\u00edfica para el ep\u00edtopo SIIAYTMSL de la prote\u00edna S, ep\u00edtopo \nque se superpone a la regi\u00f3n de escisi\u00f3n de las subunidades \nS1 y S2. IgY-S exhibi\u00f3 una alta inmunorreactividad en ensayos \nELISA y su uso permitir\u00eda prevenir la infecci\u00f3n de las c\u00e9lulas \nmediante un bloqueo f\u00edsico. Es decir, IgY- S evita el acceso de \nlas enzimas proteol\u00edticas al sitio de escisi\u00f3n S1/S2 y se  evade \nla fusi\u00f3n de la membrana de las c\u00e9lulas y el virus. Somasunda-\nram et al.131 propone desarrollar un anticuerpo recombinante \nde fragmento variable de cadena \u00fanica (scFv) contra la  subu-\nnidad S1, puesto que, IgY monoclonal ha demostrado ser m\u00e1s \nespec\u00edfica en comparaci\u00f3n con IgY policlonal al reconocer un \n\u00fanico ep\u00edtopo. Se propone obtener esta IgY monoclonal anti S1 \nmediante tecnolog\u00eda de presentaci\u00f3n de fagos ya que esta tec-\nnolog\u00eda es m\u00e1s estandarizada, reproducible y adecuada para \nla producci\u00f3n a gran escala. Asimismo, a nivel precl\u00ednico se ha \ndesarrollado el aerosol nasal IGY-110 que busca neutralizar el \nSARS-CoV-2 en la cavidad nasal, \u00e1rea primaria de infecci\u00f3n132. \nPor otro lado, se ha empezado a reclutar pacientes para probar \nla seguridad y tolerabilidad de IgY anti-SARS-CoV-2 (Tabla 1) \nadministrada por v\u00eda intranasal en participantes sanos, con el \nfin de prevenir la infecci\u00f3n.\nPatentes de IgY\nIgY ha demostrado a lo largo de la historia tener un amplio \npotencial para desarrollar aplicaciones a base de inmunizaci\u00f3n \npasiva, a partir del a\u00f1o 2000 el aumento de investigaciones y \npublicaciones12. Leiva et al.143 menciona que a partir del 2010 \nse empiezan a generar patentes de IgY asociadas al diagn\u00f3s-\ntico, terapia y profilaxis en medicina humana, principalmente \nen patolog\u00edas como periodontitis, gingivitis, \u00falceras g\u00e1stricas, \ninfecciones asociadas al virus del papiloma humano, disbiosis, \nproblemas nutricionales y metab\u00f3licos.\nHay que considerar que la estructura de la inmunoglobuli-\nna IgY no es patentable, no obstante, es posible patentar el m\u00e9-\ntodo de preparaci\u00f3n de IgY (obtenci\u00f3n, purificaci\u00f3n y conserva-\nci\u00f3n), su forma de producci\u00f3n  y el producto a base de IgY18. Por \nejemplo, la solicitud de patente WO2016191389 establece un \nnuevo m\u00e9todo para preparar IgY contra las bacterias causan-\ntes de periodontitis (Porphyromonas gingivalis / Streptococcus \nmutans/ Aggregatibacter actinomycetemcomitans) median-\nte la inmunizaci\u00f3n de gallinas con polip\u00e9ptidos sint\u00e9ticos144. \nAsimismo, la solicitud de patente WO2014011853 describe \nel m\u00e9todo para la producci\u00f3n a gran escala de IgY-anti-NoV \nP (prote\u00edna de la c\u00e1pside de norovirus) mediante la inmuniza-Nathaly Cruz Tipantiza and Marbel Torres Arias\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2067\nci\u00f3n de las gallinas con part\u00edculas recombinantes de norovirus, \nadem\u00e1s estandariza las condiciones en las que IgY se logra \nmantener estable (70 \u00b0C durante 30 minutos o a un pH de 4-9 \npor 3 h145). En el caso de productos patentados a base de IgY \ntenemos la solicitud de patente CN104739719,  una f\u00f3rmula \nde una pasta de dientes a base de IgY anti-S. mutans con com-\npuestos como lisozima y extractos de plantas.\nEn la tabla 2 se presentan m\u00e1s patentes de IgY como in-\nmunoterapia de  infecciones virales y bacterianas en humanos, \npara ello, se revisaron las patentes registradas entre 2010-\n2021 en la base de datos Patentscope. \nProductos comerciales de IgY\nDesde hace m\u00e1s de 20 a\u00f1os se ha registrado un incremen-\nto en la comercializaci\u00f3n de IgY a nivel mundial buscando pro-\nmover la salud de los seres humanos y animales155, donde se ha visto que los fundadores, l\u00edderes y expertos en tecnolog\u00eda \nIgY son los pa\u00edses asi\u00e1ticos tales como Corea del Sur, Jap\u00f3n, \nChina y Vietnam. Este incremento en la comercializaci\u00f3n de \nIgY se refleja con la variedad de ensayos cl\u00ednicos con resulta-\ndos alentadores que se han logrado patentar y llevar al merca-\ndo como f\u00e1rmacos y suplementos nutrac\u00e9uticos, basados   en \nformulaciones monoespec\u00edficas o mixtas de IgY (Tabla 3)67,68. \nLa administraci\u00f3n parenteral de IgY mediante formulaciones \norales e intranasales son las m\u00e1s comunes, ya que permiten \nmantener estable IgY a temperatura ambiente por m\u00e1s tiem-\npo. Adem\u00e1s, cuentan con un registro de perfil de seguridad al \nusar IgY en forma de huevo entero en polvo, la yema entera en \npolvo o \u00fanicamente la IgY purificada13.\nEn el \u00e1mbito veterinario se ha utilizado IgY en animales do-\nm\u00e9sticos para mejorar la eficiencia de su alimentaci\u00f3n, la tasa \nde crecimiento y de forma general la salud del animal156. Aqu\u00ed \nTabla 1. Principales \nensayos cl\u00ednicos de \nanticuerpos IgY como  \ntratamiento terap\u00e9u -\ntico y profil\u00e1ctico de  \ninfecciosas v\u00edricas y \nbacterianas en huma -\nnos. Se incluy\u00f3 \u00fanica -\nmente ensayos cl\u00edni -\ncos registrados en las \nbases de datos guber -\nnamentales de  Clini -\ncal Trials de  EEUU, \nEuropa y Jap\u00f3n du -\nrante el peri\u00f3do de \n2010-2021. Esta lista \nincluye ensayos cl\u00ed -\nnicos registrados en \nbases de datos de or -\nganizaciones guber -\nnamentales de EEUU \n( https://clinicaltrials.\ngov/),  Jap\u00f3n (https://\nwww.umin.ac.jp/ctr/ \n) y Europa (https:// \nwww.clinicaltrialsre -\ngister.eu/ ), las bases \nde datos se accedie -\nron por \u00faltima vez el \n15 de enero de 2021.Tecnolog\u00eda IgY: Estrategia en el tratamiento de enfermedades infecciosas humanas\nIgY Technology: Strategy in the treatment of human infectious diseases2068\nTabla 2. Patentes de IgY como inmunoterapia de infecciones bacterianas y v\u00edricas en humanos. Abreviaturas NoV P: prote\u00edna \nde la c\u00e1pside de norovirus; VPH: virus del papiloma humano ; L1: prote\u00edna de la c\u00e1pside del virus del papiloma humano ; E6/E7: \noncoprote\u00ednas del virus del papiloma humano.Nathaly Cruz Tipantiza and Marbel Torres Arias\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2069\nencontramos empresas como Aova Technologies que ofrece \nla l\u00ednea de productos BIG\u2122 para ganado y peces utilizados en acuicultura\n157. PRN Pharmacal con el suplemento alimenticio \nGastroMate\u00ae que apoya la salud digestiva de perros y cacho-rros\n158. BIOINNOVO con el polvo IgY DNT que se incorpora a \nla dieta l\u00e1ctea de terneros para controlar agentes como ro-tavirus A, coronavirus, Escherichia coli y Salmonella\n159. Trouw \nNutrition con la l\u00ednea Protimax\u00ae para ganado con productos como: Protimax\u00ae-T Forte para aumentar el peso y prevenir infecciones por pat\u00f3genos ent\u00e9ricos como Escherichia coli, Salmonella, Clostridium perfringens, rotavirus, coronavirus y \nCryptosporidium; y EggMotion como suplemento alimenticio para la salud intestinal de mascotas\n160.\nIgualmente, en el \u00e1mbito de la salud humana se han desa-\nrrollado una variedad de productos de consumo diario que van desde l\u00e1cteos y pastillas hasta cremas, jabones y mascarillas (Tabla 3). B\u00e1sicamente estos productos fortalecen el sistema inmune y previenen la adhesi\u00f3n de pat\u00f3genos en la boca, tracto gastrointestinal y rostro\n67,161. Existen empresas que han desa-\nrrollado productos para uso humano y animal. Pharma Foods International Co. Ltd con el ingrediente funcional Ovopron IgY para el tratamiento y prevenci\u00f3n de infecciones asociadas a Helicobacter pylori en humanos (Tabla 3). Arkion Life Sciences con su la l\u00ednea i26\u00ae Companion para mascotas que ayuda en la salud bucal y sensibilidad digestiva, mejorando la salud de articulaciones, piel y pelaje. Suplementos para humanos como i26\u00ae un suplemento probi\u00f3tico y Muno-IgY \u2122 como suplemento diet\u00e9tico\n162 (Tabla 3). Tambi\u00e9n tenemos a EW Nutrition con la \nl\u00ednea Globigen\u00ae para mejorar la nutrici\u00f3n y el estado de salud intestinal de rumiantes y porcinos j\u00f3venes durante el per\u00edodo de destete. Dentro de esta l\u00ednea encontramos productos como: Globigen Jump Start , Globigen Sow y Globigen Life Start. Por otro lado, desarroll\u00f3 el suplemento alimenticio y cosm\u00e9tico Ovalgen\u00ae para el cuidado de la salud humana. Se ha utilizado Ovalgen\u00ae como ingrediente funcional de la serie de productos IgYGate\u00ae:  GastimunHP y GastimunHP Plus para el tratamien-to de gastritis y \u00falceras g\u00e1stricas, IgYGate\u00ae-F contra gripes estacionales ,y como herramienta de apoyo al tratamiento de caries y gingivitis IgYGate\u00ae DC-PG\n163 (Tabla 3). Por \u00faltimo, Dan \nBiotech Inc. con su l\u00ednea Ig-Lock\u00ae permite prevenir y controlar infecciones intestinales asociadas a Escherichia coli, parvovi-rus, coronavirus y adenovirus en animales dom\u00e9sticos como perros, aves de corral, ganado vacuno y porcino. Por otro lado, para humanos desarrollo la l\u00ednea Cleanato\u00ae para el cuidado de la piel y Ulcer lock\u00ae / Gasto lock\u00ae para el fortalecimiento gastrointestinal\n164 (Tabla 3).\nVentajas de la Tecnolog\u00eda IgY\nComo se ha visto el uso de tecnolog\u00eda IgY en relaci\u00f3n a \nanticuerpos convencionales traen un serie de ventajas como: (1) reemplaza el sangrado de los animales por la recolecci\u00f3nde huevos, promoviendo el bienestar animal y disminuyendoel sufrimiento asociado a manipulaciones dolorosas\n155, (2) se\nnecesita una baja  carga de ant\u00edgeno para inducir una res-puesta inmune espec\u00edfica\n156, (3) tiene una alta escalabilidad\nde producci\u00f3n a un menor costo y tiempo, aproximadamentecinco semanas desde el per\u00edodo de inmunizaci\u00f3n\n44, (4) gracias\na su especificidad y acci\u00f3n in situ, no inducen resistencia bac-teriana o alteraciones en la flora microbiana normal\n67, (5) no\ngener\na efectos secundarios t\u00f3xicos ya que al estar purificada\nno contiene alb\u00famina, por lo que, puede incluso utilizarse enpacientes con alergia al huevo\n34, (6) al ser una tecnolog\u00eda de\ninmunizaci\u00f3n pasiv\na es aplicable en un rango de edad amplio\nde pacientes, desde reci\u00e9n nacidos hasta adultos incluidos pa-cientes inmunodeficientes y embarazadas92, (7) posee una ma-\nyor estabilidad en comparaci\u00f3n a anticuerpos mam\u00edferos, esto gracias a su composici\u00f3n gen\u00e9tica m\u00e1s sencilla\n171, (8) tiene una \namplia versatilidad permitiendo utilizarse como anticuerpo po-liclonal, monoclonal, fragmentado o quim\u00e9rico\n172, y por \u00faltimo \n(9) ejerce un efecto antimicrobiano e inmunoestimulante adi-cional gracias a la presencia de prote\u00ednas bioactivas encontra-das en las preparaciones de IgY en forma de huevo entero enpolvo o  yema entera en polvo, tales como fosfoprote\u00edna fosvi-tina\n173 y derivados del \u00e1cido si\u00e1lico (propiedades antivirales)174.\nConclusiones\nComo se ha visto desde los a\u00f1os 80 hasta la actualidad la \ntecnolog\u00eda IgY se ha empleado como una herramienta diagn\u00f3s-tica, terap\u00e9utica y profil\u00e1ctica, logrando posicionarse a nivel in-dustrial y comercial en todo el mundo. El uso de huevos como fuente de anticuerpos IgY ha permitido desarrollar una meto-dolog\u00eda de producci\u00f3n pr\u00e1ctica, escalable y de bajo costo. Es-tos anticuerpos IgY aviar han atra\u00eddo cada vez m\u00e1s la atenci\u00f3n de la comunidad cient\u00edfica para reemplazar a los anticuerpos IgG de mam\u00edferos, puesto que, sus particularidades estructu-rales y funcionales le han otorgado una mayor especificidad, baja reactividad cruzada y alta vida media circulante. En cuan-to a su modo de acci\u00f3n se han descubierto los mecanismos de acci\u00f3n general, donde si bien IgY no ejerce una erradicaci\u00f3n microbiana total permite reducir significativamente la carga de pat\u00f3genos hasta el punto en el que la propia inmunidad del paciente puede erradicarlos. Se han propuesto que las funcio-nes efectoras de IgY son: el bloqueo de adherencia del pat\u00f3-geno, neutralizaci\u00f3n de ep\u00edtopos espec\u00edficos incluidos toxinas, opsonizaci\u00f3n del pat\u00f3geno y formaci\u00f3n de aglutinados de ant\u00ed-genos-anticuerpos para eliminarlos a trav\u00e9s del intestino.\nDesde  2010 se registra una mayor acogida de la tecno-\nlog\u00eda IgY en la medicina humana gracias a sus propiedades antiinfecciosas, antitumorales, antitoxinas, antiinflamatorias y antiobesidad. Afirmando que el uso de anticuerpos IgY permite tratar y prevenir infecciones v\u00edricas y bacterianas. Este hecho se evidencia con el incremento de ensayos cl\u00ednicos, patentes y productos a base de IgY, por ejemplo, ya se comercializan una gran variedad de productos de consumo diario, tales como: f\u00e1rmacos, cosm\u00e9ticos, filtros de mascarilla, suplementos y nutrac\u00e9uticos. Adem\u00e1s el uso de IgY en lugar de antibi\u00f3ticos para tratar este tipo de infecciones responde a la grave pro-blem\u00e1tica de salud que representa el desarrollo de pat\u00f3genos resistentes a antimicrobianos.\nPor \u00faltimo, como hemos visto el mundo se enfrenta a uno \nde los mayores desaf\u00edos sanitarios con la actual pandemia del COVID-19, evidenciando la necesidad urgente de nuevas o me-joradas terapias. Y como alternativa del uso de la tecnolog\u00eda IgY como herramienta biotecnol\u00f3gica segura, eficaz, econ\u00f3mi-ca y vers\u00e1til para disminuir la incidencia, prevalencia y severi-dad de varias enfermedades infecciosas.\nReferencias bibliogr\u00e1ficas\n1. Garc\u00eda P alomo JD, Ag\u00fcero Balb\u00edn J, Parra Blanco JA, Santos\nBenito MF. Enfermedades infecciosas. Concepto. Clasificaci\u00f3n.\nAspectos generales y espec\u00edficos de las infecciones. Criterios desospecha de enfermedad infecciosa. Pruebas diagn\u00f3sticas com-plementarias. Criterios de indicaci\u00f3n. Medicine (Baltimore) 2010;10: 3251\u20133264.Tecnolog\u00eda IgY: Estrategia en el tratamiento de enfermedades infecciosas humanas\nIgY Technology: Strategy in the treatment of human infectious diseases2070\nTabla 3. Productos suplementados con IgY para uso humano. Datos tomados de la base de datos Patentscope.Nathaly Cruz Tipantiza and Marbel Torres Arias\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2071\n2.Dobson AP , Carper ER. Infectious Diseases and Human Popula-\ntion History: Throughout history the establishment of disease has \nbeen a side effect of the growth of civilization. BioScience 1996;46: 115\u2013126.\n3.\nCasade\nvall A. Antibody-based therapies for emerging infectious\ndiseases. Emerg Infect Dis 1996; 2: 200\u2013208.\n4.\n K\naufmann SHE, Dorhoi A, Hotchkiss RS, Bartenschlager R.\nHost-directed therapies for bacterial and viral infections. Nat Rev Drug Discov 2018; 17: 35\u201356.\n5.\nNii-\nTrebi NI. Emerging and Neglected Infectious Diseases: In-\nsights, Advances, and Challenges. BioMed Res Int 2017; 2017:5245021.\n6.\nOr\nal HB, Ozakin C, Akdi\u015f CA. Back to the future: antibody-based\nstrategies for the treatment of infectious diseases. Mol Biotech-nol 2002; 21: 225\u2013239.\n7.\nP\natterson R, Youngner JS, Weigle WO, Dixon FJ. Antibody Pro-\nduction and Transfer to Egg Yolk in Chickens. J Immunol 1962;89: 272\u2013278.\n8.\n Thomsen K, Chris\ntophersen L, Bjarnsholt T, Jensen P\u00d8, Moser C, \nH\u00f8iby N. Anti-Pseudomonas aeruginosa IgY antibodies augmentbacterial clearance in a murine pneumonia model. J Cyst FibrosOff J Eur Cyst Fibros Soc 2016; 15: 171\u2013178.\n9.\nXu Y\n, Li X, Jin L, Zhen Y, Lu Y, Li S et al. Application of chicken egg \nyolk immunoglobulins in the control of terrestrial and aquatic an-imal diseases: a review. Biotechnol Adv 2011; 29: 860\u2013868.\n10.\n Schade R, Calzado E\nG, Sarmiento R, Chacana PA, Porank-\niewicz-Asplund J, Terzolo HR. Chicken egg yolk antibodies(IgY-technology): a review of progress in production and use inresearch and human and veterinary medicine. Altern Lab AnimATLA 2005; 33: 129\u2013154.\n11.\n Thu HM, My\nat TW, Win MM, Thant KZ, Rahman S, Umeda K et al. \nChicken Egg Yolk Antibodies (IgY) for Prophylaxis and Treatmentof Rotavirus Diarrhea in Human and Animal Neonates: A Concise Review. Korean J Food Sci Anim Resour 2017; 37: 1\u20139.\n12.\n Leiv\na CL, Gallardo MJ, Casanova N, Terzolo H, Chacana P. IgY-tech-\nnology (egg yolk antibodies) in human medicine: A review of pat-ents and clinical trials. Int Immunopharmacol 2020; 81: 106269.\n13.\n Hat\nta H, Horimoto Y. Chapter 16: Applications of Egg Yolk Anti-\nbody (IgY) in Diagnosis Reagents and in Prevention of Diseases. In: Eggs as Functional Foods and Nutraceuticals for Human Health.2019, pp 305\u2013328.\n14.\n R\nahman S, Van Nguyen S, Icatlo Jr. FC, Umeda K, Kodama Y. Oral \npassive IgY-based immunotherapeutics. Hum Vaccines Immuno-ther 2013; 9: 1039\u20131048.\n15.\n Muller S, Schuber\nt A, Dyck T, Oelkrug C. IgY antibodies in human \nnutrition for disease prevention. Nutr J 2015; 14: 109.\n16.\n Klemperer F\n. Ueber nat\u00fcrliche Immunit\u00e4t und ihre Verwerthung\nf\u00fcr die Immunisirungstherapie. Arch F\u00fcr Exp Pathol Pharmakol1893; 31: 356\u2013382.\n17.\n Schade R, Hlinak A. E\ngg Yolk Antibodies, State of the Art and Fu-\nture Prospects. ALTEX 1996; 13: 5\u20139.\n18.\n Schade R, T\nerzolo H. IgY-technology: application and trends.\n[Internet]. 2006. Available from: https://www.researchgate.net/publication/267702265_IgY-technology_application_and_trends\n19.\n Schade R, S\ntaak C, Hendriksen C, Erhard M, Hugl H, Koch G et\nal. La producci\u00f3n de anticuerpos aviares (yema de huevo): IgY:Informe y recomendaciones del taller ECVAM 21 1,2. Altern LabAnim 1996; 24: 925\u2013934.\n20.\n W\narr G, Magor K, Higgins D. IgY: clues to the origins of modern\nantibodies. Immunol Today 1995; 16: 392\u2013398.\n21.\n P\nereira EPV, Van Tilburg MF, Florean EOPT, Guedes MIF. Egg yolk \nantibodies (IgY) and their applications in human and veterinaryhealth: A review. Int Immunopharmacol 2019; 73: 293\u2013303.\n22.\n Sun S, Mo W\n, Ji Y, Liu S. Preparation and mass spectrometric\nstudy of egg yolk antibody (IgY) against rabies virus. Rapid Com-mun Mass Spectrom RCM 2001; 15: 708\u2013712.\n23.\n F\naith RE, Clem LW. Passive cutaneous anaphylaxis in the chicken. \nImmunology 1973; 25: 151\u2013164.\n24.\n Spillner E, Br\naren I, Greunke K, Seismann H, Blank S, du Plessis\nD. Avian IgY antibodies and their recombinant equivalents in re-search, diagnostics and therapy. Biologicals 2012; 40: 313\u2013322.25.\n  Hern\u00e1ndez Cas tillo LM, Duque Restrepo AM, Mart\u00ednez Delgado\nCM. Tecnolog\u00eda IgY para el control de enfermedades infecciosascomo la caries dental. Tesis [Internet]. Universidad CES. 2015.Available from: https://repository.ces.edu.co/handle/10946/390\n26.\n Sesarman A, Mihai S, Chiriac MT\n, Olaru F, Sitaru AG, Thurman JM \net al. Binding of avian IgY to type VII collagen does not activatecomplement and leucocytes and fails to induce subepidermalblistering in mice. Br J Dermatol 2008; 158: 463\u2013471.\n27.\n Chacana P\n, Terzolo H, Gutierrez E. Tecnolog\u00eda IgY o aplicaciones\nde los anticuerpos de yema de huevo de gallina. Rev Med Vet2004; 85: 179\u2013189.\n28.\n Nguy\nen HH, Tumpey TM, Park H-J, Byun Y-H, Tran LD, Nguyen VD \net al. Prophylactic and Therapeutic Efficacy of Avian AntibodiesAgainst Influenza Virus H5N1 and H1N1 in Mice. PLoS ONE 2010; 5. doi:10.1371/journal.pone.0010152.\n29.\n Carlander D\n, St\u00e5lberg J, Larsson A. Chicken Antibodies: A Clinical \nChemistry Perspective. Ups J Med Sci 1999; 104: 179\u2013189.\n30.\n Contrer\nas VT, Lima ARD, Navarro MC, Arteaga RY, Graterol D,\nCabello L et al. Producci\u00f3n y purificaci\u00f3n de anticuerpos (IgY) apartir de huevos de gallinas inmunizadas con epimastigotas deTrypanosoma cruzi. Salus 2005; 9: 21\u201327.\n31.\n Thirumalai D\n, Visaga Ambi S, Vieira-Pires RS, Xiaoying Z, Sekaran \nS, Krishnan U. Chicken egg yolk antibody (IgY) as diagnostics and therapeutics in parasitic infections - A review. Int J Biol Macromol 2019; 136: 755\u2013763.\n32.\n Lundqvis\nt ML, Middleton DL, Radford C, Warr GW, Magor KE. Im-\nmunoglobulins of the non-galliform birds: Antibody expressionand repertoire in the duck. Dev Comp Immunol 2006; 30: 93\u2013100.\n33.\n T\nsubokura K, Berndtson E, Bodgstedt A, Kaijser B, Kim M, Ozeki\nM et al. Oral administration of antibodies as prophylaxis and ther-apy in Campylobacter jejuni-infected chickens. Clin Exp Immunol 1997; 108: 451\u2013455.\n34.\n Abbas A\nT, El-Kafrawy SA, Sohrab SS, Azhar EIA. IgY antibodies\nfor the immunoprophylaxis and therapy of respiratory infections.Hum Vaccines Immunother 2018; 15: 264\u2013275.\n35.\n Arimitsu H, Sasaki K, K\nohda T, Shimizu T, Tsuji T. Evaluation of\nShiga toxin 2e-specific chicken egg yolk immunoglobulin: Pro-duction and neutralization activity. Microbiol Immunol 2014; 58:643\u2013648.\n36.\n Mit\nteness BM, Phillips C., Inventors; Camas Incorporated, assign-\nee: Compositions Against Bacterial Toxins. World IntellectualProperty Organization patent WO 2013009843. 2013 Jan 7.\n37.\n Lee EN, Sunw\noo HH, Menninen K, Sim JS. In vitro studies of chick-\nen egg yolk antibody (IgY) against Salmonella enteritidis and Sal-monella typhimurium. Poult Sci 2002; 81: 632\u2013641.\n38.\n Zhen Y\n-H, Jin L-J, Guo J, Li X-Y, Lu Y-N, Chen J et al. Charac-\nterization of specific egg yolk immunoglobulin (IgY) against mas-titis-causing Escherichia coli. Vet Microbiol 2008; 130: 126\u2013133.\n39.\n Mur\nai A. Maternal Transfer of Immunoglobulins into Egg Yolks of \nBirds. J Poult Sci 2013; 50: 185\u2013193.\n40.\n F\nerreira \u00c1, Santos JP, Sousa L de O, Martin I, Alves EGL, Rosa-\ndo IR. Gallus gallus domesticus: immune system and its poten-tial for generation of immunobiologics. Ci\u00eanc Rural 2018; 48.doi:10.1590/0103-8478cr20180250.\n41.\n Nakamur\na R, Pedrosa-Gerasmio IR, Alenton RRR, Nozaki R, Kon-\ndo H, Hirono I. Anti-PirA-like toxin immunoglobulin (IgY) in feedspassively immunizes shrimp against acute hepatopancreatic ne-crosis disease. J Fish Dis 2019; 42: 1125\u20131132.\n42.\n Xu FX, Xu YP\n, Jin LJ, Liu H, Wang LH, You JS et al. Effective-\nness of egg yolk immunoglobulin (IgY) against periodontal dis-ease-causing Fusobacterium nucleatum. J Appl Microbiol 2012;113: 983\u2013991.\n43.\n Barroso P\n, Murcia H, Vega N, P\u00e9rez G. Purification of IgY against\nSalvia bogotensis lectin. Biom\u00e9dica 2005; 25: 496\u2013510.\n44.\n P\nauly D, Chacana PA, Calzado EG, Brembs B, Schade R. IgY\nTechnology: Extraction of Chicken Antibodies from Egg Yolk byPolyethylene Glycol (PEG) Precipitation. J Vis Exp JoVE 2011.doi:10.3791/3084.Tecnolog\u00eda IgY: Estrategia en el tratamiento de enfermedades infecciosas humanas\nIgY Technology: Strategy in the treatment of human infectious diseases2072\n45. T ong C, Geng F, He Z, Cai Z, Ma M. A simple method for isolat-\ning chicken egg yolk immunoglobulin using effective delipidation\nsolution and ammonium sulfate. Poult Sci 2015; 94: 104\u2013110.\n46.\n Villaguala C\n, Gonz\u00e1lez C, Pastene E, Far\u00edas C, S\u00e1ez K, Re-\ntamal-D\u00edaz A et al. Obtenci\u00f3n de inmunoglobulinas de yema dehuevo contra Helicobacter pylori producidos en gallinas arauca-nas. Arch Med Vet 2016; 48: 79\u201388.\n47.\n Chang HM, Ou-\nYang RF, Chen YT, Chen CC. Productivity and some \nproperties of immunoglobulin specific against Streptococcusmutans serotype c in chicken egg yolk (IgY). J Agric Food Chem1999; 47: 61\u201366.\n48.\n K\novacs-Nolan J, Mine Y. 17 - Using egg IgY antibodies for health,\ndiagnostic and other industrial applications. In: Van Immerseel F,Nys Y, Bain M (eds). Improving the Safety and Quality of Eggs and Egg Products. Woodhead Publishing, 2011, pp 346\u2013373.\n49.\n L\u00e9\nvesque S, Martinez G, Fairbrother JM. Improvement of adju-\nvant systems to obtain a cost-effective production of high levelsof specific IgY. Poult Sci 2007; 86: 630\u2013635.\n50.\n Agr\nawal R, Hirpurkar SD, Sannat C, Gupta AK. Comparative study \non immunoglobulin Y transfer from breeding hens to egg yolk and progeny chicks in different breeds of poultry. Vet World 2016; 9:425\u2013431.\n51.\n Hat\nta H, Kapoor MP, Juneja LR. Bioactive Components in Egg\nYolk. In: Egg Bioscience and Biotechnology. John Wiley & Sons,Ltd, 2008, pp 185\u2013237.\n52.\n Amro W\nA, Al-Qaisi W, Al-Razem F. Production and purification\nof IgY antibodies from chicken egg yolk. J Genet Eng Biotechnol2018; 16: 99\u2013103.\n53.\n R\nose ME, Orlans E, Buttress N. Immunoglobulin classes in the\nhen\u2019s egg: Their segregation in yolk and white. Eur J Immunol1974; 4: 521\u2013523.\n54.\n F\nu C-Y, Huang H, Wang X-M, Liu Y-G, Wang Z-G, Cui S-J et al.\nPreparation and evaluation of anti-SARS coronavirus IgY fromyolks of immunized SPF chickens. J Virol Methods 2006; 133:112\u2013115.\n55.\n Y\nokoyama H, Peralta RC, Diaz R, Sendo S, Ikemori Y, Kodama Y.\nPassive protective effect of chicken egg yolk immunoglobulinsagainst experimental enterotoxigenic Escherichia coli infection in neonatal piglets. Infect Immun 1992; 60: 998\u20131007.\n56.\n Mudili V\n, Makam SS, Sundararaj N, Siddaiah C, Gupta VK, Rao\nPVL. A novel IgY-Aptamer hybrid system for cost-effective de-tection of SEB and its evaluation on food and clinical samples. Sci Rep 2015; 5: 15151.\n57.\n Caza J\n, Fernandez R, Torres M, Mu\u00f1oz D, Ortiz Tirado J, Bangep-\npagari M et al. The development, purification and characteriza-tion of anti- vitellogenin antibodies raised in hens (gallus gallusdomesticus) against tilapia (oreochromis niloticus) vitellogen-in protein. J Microbiol Biotechnol Food Sci 2018. doi:10.15414/jmbfs.2019.8.5.1165-1168.\n58.\n He J\n, Hu J, Thirumalai D, Schade R, Du E, Zhang X. Development \nof indirect competitive ELISA using egg yolk-derived immuno-globulin (IgY) for the detection of Gentamicin residues. J EnvironSci Health B 2016; 51: 8\u201313.\n59.\n Li C\n, Zhang Y, Eremin SA, Yakup O, Yao G, Zhang X. Detection of\nkanamycin and gentamicin residues in animal-derived food usingIgY antibody based ic-ELISA and FPIA. Food Chem 2017; 227:48\u201354.\n60.\n Noack F\n, Helmecke D, Rosenberg R, Thorban S, Nekarda H, Fink\nU et al. CD87-positive tumor cells in bone marrow aspirates iden-tified by confocal laser scanning fluorescence microscopy. Int JOncol 1999; 15: 617\u2013623.\n61.\n P\nan Z-L, Ji X-Y, Shi Y-M, Zhou J, He E, Skog S. Serum thymidine\nkinase 1 concentration as a prognostic factor of chemothera-py-treated non-Hodgkin\u2019s lymphoma patients. J Cancer Res ClinOncol 2010; 136: 1193\u20131199.\n62.\n Zhang Q, He D\n, Xu L, Ge S, Wang J, Zhang X. Generation and eval-\nuation of anti-mouse IgG IgY as secondary antibody. Prep Bio-chem Biotechnol 2020; 50: 788\u2013793.\n63.\n F\nerreira J\u00fanior A, Santos JP, Bassi PB, F.F.Bittar J, Bittar ER.\nIgY-Technology Applied to Studies of Toxoplasma gondii Infection. Toxoplasmosis 2017. doi:10.5772/67997.64.\n  Nagar aj S, Ramlal S, Kingston J, Batra HV. Development of IgY\nbased sandwich ELISA for the detection of staphylococcal entero-toxin G (SEG), an egc toxin. Int J Food Microbiol 2016; 237: 136\u2013141.\n65.\n He J\n, Wang Y, Sun S, Zhang X. Evaluation of Chicken IgY Gen-\nerated Against Canine Parvovirus Viral-Like Particles and Devel-opment of Enzyme-Linked Immunosorbent Assay and Immuno-chromatographic Assay for Canine Parvovirus Detection. ViralImmunol 2015; 28: 489\u2013494.\n66.\n Sil\nva A dos S da, Vasconcelos GALBM de, Kappel LA, Pinto MA,\nPaula VS de. An immunoenzymatic assay for the diagnosis ofhepatitis A utilising immunoglobulin Y. Mem Inst Oswaldo Cruz2012; 107: 960\u2013963.\n67.\n R\nahman S, Nguyen S, Icatlo F, Umeda K, Kodama Y. Oral pas-\nsive IgY-based immunotherapeutics. Hum Vaccines Immunother2013; 9. doi:10.4161/hv.23383.\n68.\n K\novacs-Nolan J, Phillips M, Mine Y. Advances in the value of eggs \nand egg components for human health. J Agric Food Chem 2005; 53: 8421\u20138431.\n69.\n Ar\na\u00fajo AS, Lobato ZIP, Ch\u00e1vez-Ol\u00f3rtegui C, Velarde DT. Brazilian\nIgY-Bothrops antivenom: Studies on the development of a process in chicken egg yolk. Toxicon Off J Int Soc Toxinology 2010; 55: 739\u2013744.\n70.\n Guti\u00e9rrez JM, Theaks\nton RDG, Warrell DA. Confronting the ne-\nglected problem of snake bite envenoming: the need for a globalpartnership. PLoS Med 2006; 3: e150.\n71.\n Al\nvarez A, Montero Y, Jimenez E, Zerpa N, Parrilla P, Malav\u00e9 C. IgY \nantibodies anti-Tityus caripitensis venom: purification and neutral-ization efficacy. Toxicon Off J Int Soc Toxinology 2013; 74: 208\u2013214.\n72.\n Thalle\ny BS, Carroll SB. Rattlesnake and scorpion antivenoms\nfrom the egg yolks of immunized hens. Biotechnol Nat Publ Co1990; 8: 934\u2013938.\n73.\n LeClaire RD\n, Hunt RE, Bavari S. Protection against Bacterial Su-\nperantigen Staphylococcal Enterotoxin B by Passive Vaccination.Infect Immun 2002; 70: 2278\u20132281.\n74.\n Y\nang J, Jin Z, Yu Q, Yang T, Wang H, Liu L. The selective recogni-\ntion of antibody IgY for digestive system cancers. Chin J Biotech-nol 1997; 13: 85\u201390.\n75.\n Xiao Y\n, Gao X, Taratula O, Treado S, Urbas A, Holbrook RD et al.\nAnti-HER2 IgY antibody-functionalized single-walled carbonnanotubes for detection and selective destruction of breast can-cer cells. BMC Cancer 2009; 9: 351.\n76.\n Cha\nvez Cortez E-G, Vargas Felix G, Rangel L\u00f3pez E, Sotelo J,\nMart\u00ednez-Canseco C, P\u00e9rez-de la Cruz V et al. Production andEvaluation of an Avian IgY Immunotoxin against CD133+ forTreatment of Carcinogenic Stem Cells in Malignant Glioma: IgYImmunotoxin for the Treatment of Glioblastoma. J Oncol 2019.doi:10.1155/2019/2563092.\n77.\n Rb B, \nKk B. Pancreatic lipase inhibitors from natural sources: un-\nexplored potential. Drug Discov Today 2007; 12: 879\u2013889.\n78.\n Hirose M, Ando T\n, Shofiqur R, Umeda K, Kodama Y, Nguyen SV\net al. Anti-obesity activity of hen egg anti-lipase immunoglobulin yolk, a novel pancreatic lipase inhibitor. Nutr Metab 2013; 10: 70.\n79.\n Dat\nta K, Hamad M. Immunotherapy of Fungal Infections. Immu-\nnol Invest 2015; 44: 738\u2013776.\n80.\n K\namikawa Y, Fujisaki J, Nagayama T, Kawasaki K, Hirabayashi D,\nHamada T et al. Use of Candida-specific chicken egg yolk antibodies to inhibit the adhering of Candida to denture base materials: preven-tion of denture stomatitis. Gerodontology 2016; 33: 342\u2013347.\n81.\n T\nakeuchi S, Motohashi J, Kimori H, Nakagawa Y, Tsurumoto A. Ef-\nfects of oral moisturising gel containing egg yolk antibodies againstCandida albicans in older people. Gerodontology 2016; 33: 128\u2013134.\n82.\n Sampaio L\nCL, Baldissera MD, Grando TH, Gressler LT, Capeleto\nD de M, de Sa MF et al. Production, purification and therapeuticpotential of egg yolk antibodies for treating Trypanosoma evansiinfection. Vet Parasitol 2014; 204: 96\u2013103.\n83.\n W\nolf Nassif P, DE Mello TFP, Navasconi TR, Mota CA, Demarchi\nIG, Aristides SMA et al. Safety and efficacy of current alternatives in the topical treatment of cutaneous leishmaniasis: a systematic review. Parasitology 2017; 144: 995\u20131004.\n84.\n Gr\nando TH, Baldissera MD, de S\u00e1 MF, do Carmo GM, Porto BCZ, Aguirre \nGSV et al. Avian antibodies (IgY) against Trypanosoma cruzi: Purificationand characterization studies. J Immunol Methods 2017; 449: 56\u201361.Nathaly Cruz Tipantiza and Marbel Torres Arias\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2073\n85. Esp\u00edn Arroba S, A yala L, Ort\u00edz M, Seqqat R, Torres Arias M. Char-\nacterization and Immunologic Response of IgY Against Leishma-\nnia Mexicana. Appl Med Res 2021; 8: 86\u201389.\n86.\n Husb\ny S, Koletzko S, Korponay-Szab\u00f3 IR, Mearin ML, Phillips A,\nShamir R et al. European Society for Pediatric Gastroenterology,Hepatology, and Nutrition guidelines for the diagnosis of coeliacdisease. J Pediatr Gastroenterol Nutr 2012; 54: 136\u2013160.\n87.\n W\norledge KL, Godiska R, Barrett TA, Kink JA. Oral administration \nof avian tumor necrosis factor antibodies effectively treats exper-imental colitis in rats. Dig Dis Sci 2000; 45: 2298\u20132305.\n88.\n F\nryer J, Firca J, Leventhal J, Blondie B, Malcolm A, Ivancic D et al. IgY \nantiporcine endothelial cell antibodies effectively block human anti-porcine xenoantibody binding. Xenotransplantation 1999; 6: 98\u2013109.\n89.\n W\nei-xu H, Wen-yun Z, Xi-ling Z, Zhu W, Li-hua W, Xiao-mu W\net al. Anti-Interleukin-1 Beta/Tumor Necrosis Factor-AlphaIgY Antibodies Reduce Pathological Allergic Responses inGuinea Pigs with Allergic Rhinitis. Mediators Inflamm 2016.doi:10.1155/2016/3128182.\n90.\n Bentes G\nA, Lanzarini NM, Lima LRP, Manso PP de A, da Silva A\ndos S, Mouta S da S e et al. Using immunoglobulin Y as an alter-native antibody for the detection of hepatitis A virus in frozen liver sections. Mem Inst Oswaldo Cruz 2015; 110: 577\u2013579.\n91.\n Casade\nvall A, Scharff MD. Return to the past: the case for an-\ntibody-based therapies in infectious diseases. Clin Infect Dis OffPubl Infect Dis Soc Am 1995; 21: 150\u2013161.\n92.\n Cons\ntantin C, Neagu M, Diana Supeanu T, Chiurciu V, A. Span-\ndidos D. IgY - turning the page toward passive immunization inCOVID-19 infection (Review). Exp Ther Med 2020; 20: 151\u2013158.\n93.\n Bebbington C\n, Yarranton G. Antibodies for the treatment of bacte-\nrial infections: current experience and future prospects. Curr Opin Biotechnol 2008; 19: 613\u2013619.\n94.\n Munita \nJM, Arias CA. Mechanisms of Antibiotic Resistance. Micro-\nbiol Spectr 2016; 4. doi:10.1128/microbiolspec.VMBF-0016-2015.\n95.\n Hou Y\n-Y, Zhen Y-H, Wang D, Zhu J, Sun D-X, Liu X-T et al. Protective ef-\nfect of an egg yolk-derived immunoglobulin (IgY) against Prevotella in-termedia-mediated gingivitis. J Appl Microbiol 2014; 116: 1020\u20131027.\n96.\n Bachtiar \nEW, Bachtiar BM, Soejoedono RD, Wibawan IW, Afdhal\nA. Biological and Immunogenicity Property of IgY Anti S. mutansComD. Open Dent J 2016; 10: 308\u2013314.\n97.\n Sando\nval R. Inmunoterapia sint\u00e9tica para infecciones por bacte-\nrias gram-positivas y gram-negativas. Ecuad ES Calid Rev Cient\u00ed-fica Ecuat 2020; 7. doi:10.36331/revista.v7i1.93.\n98.\n Schade R, Zhang X-\nY, Terzolo HR. Use of IgY Antibodies in Human \nand Veterinary Medicine. In: Huopalahti R, L\u00f3pez-Fandi\u00f1o R, An-ton M, Schade R (eds). Bioactive Egg Compounds. Springer: Ber-lin, Heidelberg, 2007, pp 213\u2013222.\n99.\n Sudjar\nwo SA, Eraiko K, Sudjarwo GW, Koerniasari. The Activity of \nImmunoglobulin Y Anti-Mycobacterium tuberculosis on Prolifer-ation and Cytokine Expression of Rat Peripheral Blood Mononu-clear Cells. Pharmacogn Res 2017; 9: S5\u2013S8.\n100.\n Guimar\n\u00e3es MCC, Amaral LG, Rangel LBA, Silva IV, Matta\nCGF, Matta MF de R. Growth inhibition of Staphylococcus aureusby chicken egg yolk antibodies. Arch Immunol Ther Exp (Warsz)2009; 57: 377\u2013382.\n101.\n Norouzi F\n, Behrouz B, Ranjbar M, Mousavi Gargari SL. Im-\nmunotherapy with IgY Antibodies toward Outer Membrane Pro-tein F Protects Burned Mice against Pseudomonas aeruginosaInfection. J Immunol Res 2020; 2020: 7840631.\n102.\n Sugita-K\nonishi Y, Shibata K, Yun SS, Hara-Kudo Y, Yamagu-\nchi K, Kumagai S. Immune Functions of Immunoglobulin Y Iso-lated from Egg Yolk of Hens Immunized with Various InfectiousBacteria. Biosci Biotechnol Biochem 1996; 60: 886\u2013888.\n103.\nEsmailnejad \nA, Abdi-Hachesoo B, Hosseini Nasab E, Sha-\nkoori M. Production, purification, and evaluation of quail immu-noglobulin Y against Salmonella typhimurium and Salmonellaenteritidis. Mol Immunol 2019; 107: 79\u201383.\n104.\n Marjorie Pizarro-Guajardo, D\u00edaz-Gonz\u00e1lez F\n, \u00c1lvarez-Lobos\nM, Paredes-Sabja D. Characterization of Chicken IgY Specific toClostridium difficile R20291 Spores and the Effect of Oral Ad-ministration in Mouse Models of Initiation and Recurrent Disease. Front Cell Infect Microbiol 2017; 7. doi:10.3389/fcimb.2017.00365.105.\nHong KS, Ki M-R, Ullah HMA, Lee E-J, Kim YD, Chung M-J et \nal. Preventive effect of anti-VacA egg yolk immunoglobulin (IgY)on Helicobacter pylori-infected mice. Vaccine 2018; 36: 371\u2013380.\n106.\nMalekshahi ZV\n, Gargari SLM, Rasooli I, Ebrahimizadeh W.\nTreatment of Helicobacter pylori infection in mice with oral ad-ministration of egg yolk-driven anti-UreC immunoglobulin. Mi-crob Pathog 2011; 51: 366\u2013372.\n107.\n Pu M. Gener\nation and Characterization of specific Chicken\nEgg Yolk Antibodies (IgY) against Microbial Bio-terroristic Agent(Vibrio cholerae). Res J Anim Vet Fish Sci 2014; 2: 2320\u20136535.\n108.\n Uemur\na N, Okamoto S, Yamamoto S, Matsumura N, Yama-\nguchi S, Yamakido M et al. Helicobacter pylori infection and thedevelopment of gastric cancer. N Engl J Med 2001; 345: 784\u2013789.\n109.\n Gordon G\n, Mor\u00e1n G, Ayala L, Seqqat R, Fern\u00e1ndez R, Tor-\nres M. Generation and Characterization of IgY antibodies fromLohmann Brown Hens Immunized with Salmonella spp. for theirSubsequent Application in Nanotherapy. Biol Med 2016; 80.doi:10.4172/0974-8369.1000284.\n110.\n R\nevathy J, Karthika S, Sentila R, Michael A. In vitro evalua-\ntion of the efficacy of chicken egg yolk antibodies (IgY) generat-ed against Propionibacterium acnes. Int J Cosmet Sci 2014; 36:68\u201373.\n111.\n Shi \nH, Zhu J, Zou B, Shi L, Du L, Long Y et al. Effects of\nspecific egg yolk immunoglobulin on pan-drug-resistant Acine-tobacter baumannii. Biomed Pharmacother 2017; 95: 1734\u20131742.\n112.\n Shahani L, Heredia E\nJ, Chemaly RF. Antiviral therapy for re-\nspiratory viral infections in immunocompromised patients. Expert Rev Anti Infect Ther 2017; 15: 401\u2013415.\n113.\nDub\u00e9 E, Laberge \nC, Guay M, Bramadat P, Roy R, Bettinger J. \nVaccine hesitancy: an overview. Hum Vaccines Immunother 2013; 9: 1763\u20131773.\n114.\n Dai Y\n-C, Zhang X-F, Tan M, Huang P, Lei W, Fang H et al. A\nDual Chicken IgY Against Rotavirus and Norovirus. Antiviral Res2013; 97: 293\u2013300.\n115.\nZhang Y\n, Wei Y, Li Y, Wang X, Liu Y, Tian D et al. IgY an-\ntibodies against Ebola virus possess post-exposure pro-tection and excellent thermostability. bioRxiv 2020.doi:10.1101/2020.05.21.108159.\n116.\n Chen DCP\n.,  Inventor; Asia Hepato Gene Co., assignee: Compo-\nsitions and Methods for Treating Hepatitis Virus Infection. World Intel-lectual Property Organization patent WO 2012016429. 2012 Feb 9.\n117.\n Fink AL, Williams KL, Harris E, Al\nvine TD, Henderson T,\nSchiltz J et al. Dengue virus specific IgY provides protection fol-lowing lethal dengue virus challenge and is neutralizing in the ab-\nsence of inducing antibody dependent enhancement. PLoS Negl\nTrop Dis 2017; 11. doi:10.1371/journal.pntd.0005721.\n118.\n O\u2019Donnell KL, Fink A, Nilles ML, Br\nadley DS. Dengue\nNS1-specific IgY antibodies neutralizes dengue infection withoutinducing antibody dependent enhancement. J Immunol 2017;198: 225.3-225.3.\n119.\n O\u2019Donnell KL, Meberg B, Schil\ntz J, Nilles ML, Bradley DS.\nZika Virus-Specific IgY Results Are Therapeutic Following a Le-thal Zika Virus Challenge without Inducing Antibody-DependentEnhancement. Viruses 2019; 11. doi:10.3390/v11030301.\n120.\n W\nang X, Song L, Tan W, Zhao W. Clinical efficacy of oral im-\nmunoglobulin Y in infant rotavirus enteritis. Medicine (Baltimore)2019; 98. doi:10.1097/MD.0000000000016100.\n121.\n Y\nang Y, Wen J, Zhao S, Zhang K, Zhou Y. Prophylaxis and\ntherapy of pandemic H1N1 virus infection using egg yolk antibody. J Virol Methods 2014; 206: 19\u201326.\n122.\nW\nallach MG, Webby RJ, Islam F, Walkden-Brown S, Emmoth \nE, Feinstein R et al. Cross-Protection of Chicken ImmunoglobulinY Antibodies against H5N1 and H1N1 Viruses Passively Adminis-tered in Mice\n\u03b1\n. Clin Vaccine Immunol CVI 2011; 18: 1083\u20131090.\n123. W\nen J, Zhao S, He D, Yang Y, Li Y, Zhu S. Preparation and\ncharacterization of egg yolk immunoglobulin Y specific to influen-za B virus. Antiviral Res 2012; 93: 154\u2013159.\n124.\n Brocato \nR, Josleyn M, Ballantyne J, Vial P, Hooper JW. DNA \nVaccine-Generated Duck Polyclonal Antibodies as a Postexpo-sure Prophylactic to Prevent Hantavirus Pulmonary Syndrome(HPS). PLoS ONE 2012; 7. doi:10.1371/journal.pone.0035996.Tecnolog\u00eda IgY: Estrategia en el tratamiento de enfermedades infecciosas humanas\nIgY Technology: Strategy in the treatment of human infectious diseases2074\n125. Haese N, Brocato RL, Henderson T , Nilles ML, Kwilas SA,\nJosleyn MD et al. Antiviral Biologic Produced in DNA Vaccine/\nGoose Platform Protects Hamsters Against Hantavirus Pulmo-nary Syndrome When Administered Post-exposure. PLoS NeglTrop Dis 2015; 9. doi:10.1371/journal.pntd.0003803.\n126.\nZhu N, Zhang D\n, Wang W, Li X, Yang B, Song J et al. A Novel \nCoronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020; 382: 727\u2013733.\n127.\nF\norni G, Mantovani A. COVID-19 vaccines: where we stand\nand challenges ahead. Cell Death Differ 2021; : 1\u201314.\n128.\n Du L, He Y\n, Zhou Y, Liu S, Zheng B-J, Jiang S. The spike\nprotein of SARS-CoV--a target for vaccine and therapeutic devel-opment. Nat Rev Microbiol 2009; 7: 226\u2013236.\n129.\nS\nternberg A, Naujokat C. Structural features of coronavirus \nSARS-CoV-2 spike protein: Targets for vaccination. Life Sci 2020; 257: 118056.\n130.\nLu Y\n, Wang Y, Zhang Z, Huang J, Yao M, Huang G et al. Gen-\neration of Chicken IgY against SARS-COV-2 Spike Protein and Epi-tope Mapping. J Immunol Res 2020. doi:10.1155/2020/9465398.\n131.\nSomasundar\nam R, Choraria A, Antonysamy M. An approach \ntowards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review. Int Immunopharmacol 2020. doi: 85: 106654.\n132.\nIgY Antibody Agains\nt Covid-19. Protheragen Inc. [Internet].\n2020. Available from: https://www.protheragen.com/pdf-down/igy-antibody-against-covid-19/\n133.\nClinicalT\nrials.gov [Internet]. Stanford University. 2020 Sep\n28. Identifier NCT04567810, A Phase 1 Study in Healthy Partici-pants to Evaluate the Safety, Tolerability, and Pharmacokineticsof Single -Ascending and Multiple Doses of an Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken EggAntibody (IgY)(cited 2 Dec2020). Available from:https://clinical-trials.gov/ct2/show/study/NCT04567810\n134.\n ClinicalT\nrials.gov [Internet]. University of Colorado, Den-\nver. 2017 Jan 4. Identifier NCT02385773, A Double Blind, Ran-domized, Placebo-Controlled Trial to Assess the Impact of theNutritional Product PTM202 on Acute and Long-Term RecoveryFrom Childhood Diarrheal Disease (cited 16 Dec2020). Availablefrom:https://clinicaltrials.gov/ct2/show/NCT02385773\n135.\nClinicalT\nrials.gov [Internet]. ImmuniMed Inc. 2019 Oct 8.\nIdentifier NCT04121169, Clinical Effectiveness of Egg-derivedPolyclonal Antibodies (IM-01) for the Treatment of Mild-moder-ate Clostridium Difficile Infection (CDI) (cited 16 Dec2020). Avail-able from: https://clinicaltrials.gov/ct2/show/NCT04121169\n136.\nClinicalT\nrials.gov [Internet]. Immunology Research Insti-\ntute in Gifu. 2016 Mar 7. Identifier NCT02705885, Evaluation ofIgY Antibody Effectiveness in Supportive Therapy of Periodontitis Patients (cited 13 May2021). Available from: https://clinicaltrials.gov/ct2/show/NCT02705885\n137.\nClinicalT\nrials.gov [Internet]. Chen X.. 2015 Jan 13. Identifier \nNCT02341352, Study on Children\u2019s Dental Caries Prevention and Mechanism (cited 16 Dec2020). Available from: https://clinicaltri-als.gov/ct2/show/NCT02341352\n138.\n ClinicalT\nrials.gov [Internet]. Immunology Research Insti-\ntute in Gifu. 2016 Aug 29. Identifier NCT02721355, Evaluation ofa Health Food Supplement Containing Anti-Helicobacter PyloriUrease IgY Antibody on Patients With Chronic Gastritis in Hanoi,Vietnam (cited 16 Dec2020). Available from:https://clinicaltrials.gov/ct2/show/NCT02721355\n139.\nClinicalT\nrials.gov [Internet]. Institute of Gastroenterology\nand Hepatology, Vietnam. 2020 Jul 27. Identifier NCT04025983,Effectiveness of GastimunHp Plus in Supporting the Treatmentof Peptic Ulcer Disease With Helicobacter Pylori Infection (cited16 Dec2020). Available from: https://clinicaltrials.gov/ct2/show/NCT04025983\n140.\n ClinicalT\nrials.gov [Internet]. Immunsystem AB. 2016 Aug\n31. Identifier NCT00633191, Post Marketing Study of Anti-pseu-domonas IgY in Prevention of Recurrence of Pseudomonas Aeru-ginosa Infections Infections in Cystic Fibrosis (CF) Patients  (cited 2 Dec2020). Available from: https://clinicaltrials.gov/ct2/show/study/NCT00633191141.\n  ClinicalT rials.gov [Internet]. Mukoviszidose Institut gGmbH. \n2017 Jul 3. Identifier NCT01455675, Phase III Study to EvaluateClinical Efficacy and Safety of Avian Polyclonal Anti-Pseudo-monas Antibodies (IgY) in Prevention of Recurrence of Pseudo-monas Aeruginosa Infection in Cystic Fibrosis Patients (cited 2Dec2020). Available from: https://clinicaltrials.gov/ct2/show/study/NCT01455675\n142.\n ClinicalT\nrials.gov [Internet]. Uppsala University. 2011 Jul\n4. Identifier EUCTR2009-011446-26-SE, Chicken antibodies (IgY) for the eradication of ESBL-Klebsiella pneumoniae and E coliin carriers (cited 18 Dec2020). Available from: https://www.co-chranelibrary.com/central/doi/10.1002/central/CN-01802509/full?highlightAbstract=igy%7Cigi\n143.\n Leiv\na CL, Gallardo MJ, Casanova N, Terzolo H, Chacana P. Data \nfor: IgY-technology (egg yolk antibodies) in human medicine: a review of patents and clinical trials. 2020; 2. doi:10.17632/9ryvhgm3d2.2.\n144.\n Nordgren R, Dias Figueiredo M., Inv\nentors; Merial, Inc., assign-\nee:Compositions Containing Antimicrobial Igy Antibodies, forTreatment and Prevention of Disorders and Diseases Caused byOral Health Compromising (ohc) Microorganisms. World Intellec-tual Property Organization patent WO 2016191389. 2016 Dec 1.\n145.\n Dai Y\n-C, Jiang X., Inventors;  Children's Hospital Medical\nCenter Dai, assignee: Igy from Norovirus P Particles and TheirDerivatives. World Intellectual Property Organization patent WO2014011853. 2014 Jan 16.\n146.\n Pr\nadip K M., Inventor; Immunimed Inc., assignee: Polyclonal \nantibodies against Clostridium difficile and uses thereof. UnitedStates patent US 154008029. 2015 Dec 24.\n147.\n W\nei S, Yiqiang A, Qing G., Inventors; Xuzhou Biotechnology\nCo., Ltd., assignee: Preparation method of egg yolk antibody con-taining helicobacter pylori resisting IgY and application. Chinesepatent CN 198343666. 2017 May 10.\n148.\n Le\nvin M, Vani E., Inventors; Karunya Institute Of Technology \nAnd Sciences, assignee: Chicken antibody generation against mi-crobial pathogen bacillus cereus from human nail. Indian patentIN 283165535. 2019 Nov 28.\n149.\n Zhong Q, W\nang B, Pu J, Fang X, Liao Z., Inventors; South\nChina Agricultural University, assignee: Anti-vibrio parahaemo-lyticus chicken yolk antibody, preparation method and application thereof. Chinese patent CN 83537470. 2012 Jun 27.\n150.\nHui Z, Bai Z, Bao H, Ming H., Inv\nentors; Jilin Modern Tra-\nditional Chinese Medicine Engineering Research Center Co., Ltd,assignee: Toothpaste capable of quickly relieving pain, diminish-ing inflammation, inhibiting bacteria, preventing dental caries and freshening breath. Chinese patent CN 145093694. 2015 Jul 1.\n151.\nJianfen C\n., Inventor; Shanghai Maxam Daily Chemical\nCo.,Ltd., assignee: Gingivitis and gingivitis ozostomia preventingmouthwash prepared by anti-porphyromonas gingivalis and IgYantibody with fusobacterium nucleatum specificity. Chinese pat-ent CN 85796831. 2014 May 2014.\n152.\nAiguo B, T\nongsen L, Cheng L., Inventors; Hangzhou Yasheng \nBiotechnology co., Ltd., assignee: Preparation method of compos-ite IgY against periodontal disease pathogenic bacteria. Chinesepatent CN 124076022. 2015 Oct 29.\n153.\n Xiong Y\n., Inventor; Guangzhou Annel Biotechnology Co., Ltd.\n, Ltd, assignee: New anti-human papilloma virus (HPV) and endo-metritis preparation. Chinese patent CN 123483343. 2014 Sep 24.\n154.\n Bao S, Y\nang R, Wang C, Cao T, Gong Q., Inventors; Shenzhen \nYachen Intelligent Biological Engineering Co. , assignee: Broadspectrum anti-HPV-L1 and E6/E7-IgY, small molecule antibodyand application thereof. Chinese patent CN 250122865. 2019 Jul 26.\n155.\nT\nerzolo H. Aplicaciones de tecnolog\u00eda de las inmunoglob-\nulinas de yema de huevo (IgY) de gallina. ResearchGate 2010; :173\u2013183.\n156.\nLi X, W\nang L, Zhen Y, Li S, Xu Y. Chicken egg yolk antibodies \n(IgY) as non-antibiotic production enhancers for use in swine pro-duction: a review. J Anim Sci Biotechnol 2015; 6: 40.\n157.\nK\novacs-Nolan J, Mine Y. Egg Yolk Antibodies for Passive Im-\nmunity. Annu Rev Food Sci Technol 2012; 3: 163\u2013182.Nathaly Cruz Tipantiza and Marbel Torres Arias\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2075\n158. GastroMate. PRN Pharmacal. [Internet]. 2021. Available \nfrom: https://www.prnpharmacal.com/products/critical-care/\ngastromate/\n159. Bioinnovo IgY DNT Terneros. Vetanco[Internet]. 2017. \nAvailable from: https://www.vetanco.com/es/produto/bioinno-\nvo-igy-dnt/\n160. Products & Services as Pet Food. Trouw Nutrition [Inter-\nnet]. Available from: 2020.https://www.trouwnutritionusa.com/\nen/products/\n161. Horie K, Horie N, Abdou AM, Yang J-O, Yun S-S, Chun H-N  \net al. Suppressive effect of functional drinking yogurt containing  \nspecific egg yolk immunoglobulin on Helicobacter pylori in hu-\nmans. J Dairy Sci 2004; 87: 4073\u20134079.\n162. About i26. I26--Health. Arkion Life Sciences [Internet]. \n2016. Available from: https://www.i26forhealth.com/i26-com-\npanion\n163. Health Food Products.EW Nutrition [Internet]. 2020. Avail-\nable from: https://ew-nutrition.com/healthfood/health-food-\nproducts/\n164. Dan Biotech [Internet]. 2016. Available from: http://\nwww.danbio.com/en/sub.php?menucode=0401\n165. Ovopron \u00ae. Pharma Foods International Co., Ltd. [Internet]. \n2019. Available from: https://www.pharmafoods.co.jp/en/prod-\nucts/ovopron\n166. Muno-IgYTM .IGY Life Sciences [Internet]. 2021. Avail-\nable from: https://www.ulprospector.com/es/na/Food/De-\ntail/18617/524018/Muno-IgY\n167. Ovalgen Products. EW Nutrition [Internet]. 2020. Available \nfrom: https://ew-nutrition.com/healthfood/health-food-products/\novalgen/168.  Ulcer-Lock Product. Dan Biotech [Internet]. 2016. Av ailable \nfrom: http://www.danbio.com/en/sub.php?menucode=0402&-\ncategory=0201&idx=17\n169. Gasto-Lock Product. Dan Biotech [Internet]. 2016. A\nvailable \nfrom: http://www.danbio.com/en/sub.php?menucode=0402&-category=0201&idx=20\n170.\n AtoIB (Cosmetic effectiv\ne for atopic dermatitis). Dan Bio-\ntech [Internet]. 2016. Available from: http://www.danbio.com/en/sub.php?menucode=0402&category=0201&idx=19\n171.\n Jensenius JC, Andersen I, Hau J\n, Crone M, Koch C. Eggs:\nconveniently packaged antibodies. Methods for purification ofyolk IgG. J Immunol Methods 1981; 46: 63\u201368.\n172.\nHarley C\n, Vieira-Pires RS. Antibody fragment technology\nand avian IgY antibodies: a powerful combination. 2016; 3: 62\u201366.\n173. Brady D\n, Gaines S, Fenelon L, Mcpartlin J, O\u2019Farrelly C. A\nLipoprotein-derived Antimicrobial Factor from Hen-egg Yolkis Active Against Streptococcus Species. J Food Sci 2002; 67:3096\u20133103.\n174.\n Zhang H, \nMine Y. CHAPTER 11:Antiviral Properties of Egg\nComponents. In: Eggs as Functional Foods and Nutraceuticals for Human Health. Royal Society of Chemistry: Reino Unido, 2019,pp 198\u2013210.\nReceived: 23 Febrero 2021\nAccepted: 15 Junio 2021Tecnolog\u00eda IgY: Estrategia en el tratamiento de enfermedades infecciosas humanas\nIgY Technology: Strategy in the treatment of human infectious diseases2076\nC.P.Ortega, D.A Corredor, M.E Santill\u00e1n, W.S Ger, J.M Noceda, J.M Pais-Chanfrau, L.E Trujillo\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nAbstract: Lab on a Chip (LoC) as part of Microbioreactors (MBRs) constitute an emergent technology to carry out micro-\nbioprocesses based on microfluidics research. In this review, the usefulness of LoCs is exposed since its inception, demonstrating \nthat it is a multidisciplinary research field, gathering different science branches to develop this technology. As a result, a beneficial \npoint of advancement is reached, producing useful consumables for humanity. Some of the described LoCs throughout this work \nare also used to detect infectious diseases caused by bacteria or viruses, allowing accelerated studies on emerging or high-\nimpact diseases, such as COVID-19. Here are also displayed with an updated panorama, different strategies to improve the use, \napplications in the biomedical field, and spread of these devices aimed at their availability to solve social problems.  \nKey words: Bioprocesses, COVID-19, micro bioreactors, Organ on a Chip, plasmonic, Point of Care.\nIntroduction\nThe emergence of micro-bioreactors (MBRs) comes from \ntwo main fields: microfluidic technology and molecular bio-\nlogy. In the early 1950s, photolithography development gave \nrise to microfabrication, which allowed scientists to develop \nthe first microdevices, known as micro-size transistors. Over \nthe years, microtechnology began to gain new approaches and \napplications, so chemical tests start to miniaturize. The appea-\nrance of these techniques allowed to get high precision data \nwith a high-resolution level using small sample amounts1.\nA growing interest in MBRs development, which typically \nworks at the milliliter (mL) and microliter (\u03bcl) scale, is thought \nto be more convenient to collect chemical and biological infor-\nmation related to bioprocesses or diagnosis tests2,3. Apart from \nworking on a micrometric scale4, the MBRs operation mode \nincludes conventional bioreactors, discontinuous (batch), fed-\nbatch, or continuous systems2. However, differently from con-\nventional reactors, MRBs mainly use two modalities: those \nthat consist of microwells and those based on microfluids1.\nMBRs development was carried out to parallelize an inte-\ngrative high-performance and quickly experimental design in \nseveral studies. The acceleration of quantitative microbial phe-\nnotyping stands out over conventional cultivation techniques \nand turns out to be economical, competitive, and effective for \nbioprocesses in the pharmaceutical and industrial sectors5. It \nseeks to miniaturize conventional cultivation to achieve MBRs \nthat provide rapid data output, as they can be adapted by fa-\nbricating different types, sizes, and shapes. They also allow a \nreduction in experimentation expenses, require fewer installa-\ntions and less time, and give the possibility of automation6.\nBioreactors miniaturization leads to obtaining bioproces-\nses or diagnosis tests just reduced to chips so-called Lab on \na chip (LoC), which integrate and miniaturize some laboratory \nfunctions in a single device7. Its development is interdiscipli-\nnary since it involves biology, chemistry, physics, software \nsciences, and material engineering. LoCs main characteristics \nconsist in the arrangement of multiple components integrated \ninto a single artifact. Additionally, they can be automated; each \nbioprocess can be independently treated as an individual expe-\nriment in multiple microsystems8, thus increasing sensitivity, decreasing reagent consumption, and having efficient sterili-\nzation, sample detection, and product separation9.\nPortable LoC platforms are used in Severe Acute Respi-\nratory Syndrome coronavirus studies detected in 2019 (SARS-\nCoV-2), constituting an emerging research area with signi-\nficant potential for diagnosis. SARS-CoV-2 is responsible for \nthe COVID-19 disease, which was classified as a pandemic on \nMarch 11 2020. The countries with the highest number of in-\nfections are United States, India, Brazil, Russia, and the United \nKingdom, but worldwide gathered data reveals that there are \na total of ninety-three million infections and more than two \nmillion confirmed deaths until January 17, 202110.\nThis work aims to provide an updated panorama to natio-\nnal researchers on the use and powerful potential applications \nof miniaturized systems based on Lab on a Chip, its applica-\ntions in the biomedical field, and the advances that this tech-\nnology offers in the study of SARS-CoV-2.\nMICRO BIOREACTORS\nTable 1 summarizes some of the most used MBRs models \nto date. The diversity of MBR designs gives the possibility to \nadapt the purposes of the equipment according to the user's \nneeds and requirements. Currently, MBRs have been used in \nhigh-throughput screening techniques to evaluate the biologi-\ncal activity of different molecules of interest11. \nAdditionally, in industry, MBRs are widely used to manu-\nfacture pharmaceuticals, chemicals, enzymes, and food from \ncell factories6,12.\nAn indispensable requirement in developing a bioprocess is \nselecting ideal conditions, such as optimal growth of microor-\nganisms and adequate growth medium, and a strategy that \nguarantees the final product with the required quality. However, \nthe productive parameters and the operational characteristics \nof a bioprocess can change and affect the environment's phy-\nsiological and molecular cell response. Therefore, it is essential \nto know and study the main biochemical, microbiological, and \nphysical factors that influence obtaining high concentrations of \nbiotechnological products and guarantee the control of the cul-\nture and its conditions throughout the bioprocess13,14.Lab on a Chip: Bioreactors miniaturization for rapid optimization of biomedi-\ncal processes and its impact on SARS-CoV-2 diagnosis\nC.P.Ortega1, D.A Corredor1, M.E Santill\u00e1n1, W.S Ger1, J.M Noceda1,2, J.M Pais-Chanfrau2,3, L.E Trujillo1,2REVIEW / ART\u00cdCULO DE REVISI\u00d3N\nDOI. 10.21931/RB/2021.06.03.31 \n1 Departamento de Ciencias de la Vida y la Agricultura, Laboratorio Multidisciplinario, Universidad de las Fuerzas Armadas \u2013 ESPE, Sangolqu\u00ed, Ecuador. \n2 Grupo de Investigaci\u00f3n de Biotecnolog\u00eda Industrial y Bioproductos Centro de Nanociencia y Nanotecnolog\u00eda \u2013 CENCINAT, Universidad de las Fuerzas Armadas \nESPE, Sangolqu\u00ed, Ecuador.\n3 FICAYA, Universidad T\u00e9cnica del Norte (UTN), Ibarra, Imbabura, Ecuador.\nCorresponding author: letrujillo3@espe.edu.ec2077\nLab on a Chip: Bioreactors miniaturization for rapid optimization of biomedical processes and its impact on SARS-CoV-2 diagnosis\nAn appropriate MBR will retain the functionality of con-\nventional bioreactors in a miniaturized form and allow the \nintegration of additional sensors. Therefore, the following cri-\nteria should be met in an MBR: i) biocompatibility of the cho-\nsen material, ii) adequate aeration, iii) temperature control, iv) \nbiomass measurement, v) dissolved oxygen detection, and vi) \npH measurement15. These characteristics allow bioprocess \nexperiments to be carried out under dynamic and flexible con-\nditions1.\nLAB ON A CHIP (LoCs)\nAs an exciting branch of MBRs, LoCs can integrate optic \n(for luminescence or absorbance measurements), magnetic, \nelectrical, and micro-resonator sensors. They allow the appli-\ncation of fast and effective biomarker detection protocols wi-\nthout being physically linked to a specialized laboratory or hos-\npital. Thus, micro bioreactors are compacted-size devices that \nconfer versatility to control and monitor chronic or epidemic \noutbreak-related diseases since they facilitate the collection, \ntransport, extraction, and sample analysis, thus increasing the \npopulation coverage16.\nThe production and manufacture of LoCs follow a logical \nand orderly process that improves their development, which is \ndetailed in Figure 1. The primary materials for their manufac-\nture are silica and polymers like poly dimethyl siloxane (PDMS) \nand polytetrafluoroethylene (PTFE)7. Its main manufacturing \nmethods are engraving and lithography17,18.\nThe transition from large laboratories to simple chips has \nbeen due to microfabrication techniques, facilitating the use of LoCs such as Point of Care (POC) tests, which are laboratory \ntests that are applied near the patient's location and can be \napplied even by the same patient because no prior training is \nneeded with these tests19.\nLoCs has predominantly become a valuable tool for the \nfuture of medicine. For example, LoCs such as Point of Care \n(POC) tests constitute laboratory tests applied near the pa-\ntient's location and can be applied even by the same patient \nsince prior training is needed19. However, due to several limita-\ntions, a transition from LoCs was made to a device with a few \nsquare centimeters capable of emulating conditions of expe-\nrimentation, screening, and in vitro personalized medicine of \nbiopsies or derived cells for a multiplatform system of a tissue, \nwhich was called Organ-on-a-Chip (OoC)20.\nOoC systems are instruments whose main objective is to \nimitate the tissue-tissue interface of living organisms of the \nanimal kingdom, focusing mainly on the most relevant proces-\nses of the organism, which include: adsorption, distribution, \nmetabolism, and elimination21.\nOoCs are microfluidic-based devices designed for the cul-\ntivation of live cells in continuously perfused micrometer-sized \nchambers. Generally, these micrometric chambers are compo-\nsed of 3D polymeric microchannels, which are transparent and \nlined by living cells, which are responsible for replicating three \ncritical aspects of intact organs: the 3D microarchitecture de-\nfined by the spatial distribution of multiple types of tissues; \ntissue-tissue functional interfaces; and complex organ-specific \nbiochemical and mechanical microenvironments22.\nOoC systems can be used as specialized in vitro models \nTable 1. Microbioreactor \nmodels and examples of \ntheir uses.2078\nAnupam Saha, Arijit Das, Subhasish Dutta, Suprodip Mandal\nVolumen 6 / N\u00famero 2     \u2022     http://www.revistabionatura.com\nthat allow the simulation of microenvironments, investigation \nof physical stimuli, and pharmacological modulation of com-\nplex biological processes22. Several systems can be designed, \nsuch as i) Simple systems, which have a single perfused mi-\ncrofluidic chamber containing a type of cultured cells that \nexhibit tissue functions, for example, hepatocyte systems or \nkidney epithelial cells. ii) Complex systems, which have two or \nmore microchannels connected by porous membranes, lined \non opposite sides by different types of cells, recreate interfa-\nces between tissues, such as a pulmonary alveolar-capillary \ninterface or even a blood-brain barrier23.\nLOCS APPLICATIONS IN BIOMEDICAL RESEARCH\nMBRs development in the health sector focuses on stud-\nying the new drugs' effects24, the development of culture \nsystems25, production, and manufacturing of diagnostic equi-\npment26. The main advantages in the medical sector are the \ncultivation of cells in three dimensions, the use of OoC, high \nyield, and the production of biomass and personalized medici-\nne applications27.\nCytotoxicity studies\nOoCs are instruments that provide a variety of appli-\ncations in the field of pharmacology, they stand out for their \nability to imitate different environments of the animal orga-\nnism to evaluate toxicity. In the study by Coppeta et al.(2017), \na cross-platform design based on reconfigurable human cells \nthat supports the function of individual organs is presented18.\nHeart on a Chip (HoC) has shown the potential to facilita-\nte and shorten drug development. In the study by Mandenius \n(2018), a prototype of HoC is designed based on cardiomyo-\ncytes obtained from the development of induced pluripotent \nstem cells (iPSC)11,28. This and other OoC studies can be seen \nin Figure 2.\nDisease\u2019s study and diagnosis\nOoCs can simulate intracellular environments and broad \nscreening for drugs and cell responses, whereas LoCs allow \nrapid diagnosis of diseases that can be detected using human \nfluid samples7,29. This section will provide examples of the ad-\nvancement of this technology and the integration of miniaturi-zed conventional tests.\nLoC-based platforms have been increasingly developed \nfor the analysis and detection of biomarkers. They allow better \nsample preparation, handling, high throughput, and portability. \nAlso, provide attractive features such as marker-free detec-\ntion, higher sensitivity, and the integration of novel detection \ntechniques that reduce testing time and simplify processes30. \nThe comparison between LoC-based platforms and conventio-\nnal tests is shown in Figure 3. \nMalaria is a disease that requires quick and easy ways of \ndiagnosis, so LoCs have been beneficial for developing rapid \ntests31. The main LoC diagnostic techniques to detect mala-\nria are based on real-time capillary PCR (q-PCR), which has \na sensitivity of 97.4% and a specificity of 93.8% compared to \nconventional q-PCR32. Other LoC-based diagnostic techni-\nques for malaria include microfluidic chips that perform En-\nzyme-Linked ImmunoSorbent Assay (ELISA) to detect histidi-\nne-rich protein 2 (HRP-2). Besides, chips were developed for \nstudies of individual cells, in which cells infected with malaria \nare identified for their properties in microfluidics31.\nThe study has extensively developed in LoC for its diag-\nnosis and OoC for its culture in viruses. In a dual microchannel \ndesign with human liver cells separated by a porous membra-\nne (liver-sinusoid-on-a-chip), an optimal replication rate of the \nHepatitis B Virus (HBV) was achieved, measured by the pre-\nsence of viral DNA secreted by the cells and the expression \nof the central antigen of hepatitis B (HBcAg) was determined. \nDifferentiation and functions of the hepatocytes were maintai-\nned during the trial; approximately 73.3% of the hepatocytes \nexpressed HBcAg33.\nResearch on SARS-COV-2\nThe Severe Acute Respiratory Syndrome (SARS-CoV) \ncaused an epidemic between 2002-2004; this misfortune \nallowed the development of a microfluidic system manufac-\ntured using the photolithography technique. The chip had been \ntested to detect the coronavirus SARS-CoV; this system had \na laser fluorescence detection, capable of giving a positive \nrate of SARS clinical samples up to 94.44%. The research had \nshown a higher positive rate than a conventional PCR, with \nshorter test times and lower costs34.\nFigure 1. The process to develop a Lab on a Chip (LoC). In the case of inconveniences at any stage, the process must be repea -\nted. Adapted from: Shanti, Teo, and Stefanini (2018)41. Created with Canva.com.2079\nA Competitive Analysis Of Top Ten Pharmaceutical Companies In India\nIn the COVID-19 pandemic, LoCs were developed as \ndiagnostic tools based on qRT-PCR; these provide significant \nadvantages such as using a small sample volume, rapid de-\ntection, and the incorporation of the Gold Standard test to \ndiagnose SARS-CoV-2 in a miniature portable form35,36.\nAnother application of LoC is to detect the RNA transduc-\ntion of SARS-CoV-2 without the need for qRT-PCR. Instead, \nthe genetic material is detected by hybridization with probes; \na diode laser allows quantifying the viral RNA by excitation of \nthe probe hybrid with the RdRp-COVID, ORF1ab-COVID SARS-\nCoV-2 and E protein genes. This technique significantly impro-\nved the stability, sensitivity, and reliability of the chip37.\nA novel method for detecting SARS-CoV-2 is plasmonic, \nwhich is the excitation of a metal-dielectric target molecule \nthat generates a signal when catching an RNA target. It has \nshown high sensitivity and detects samples with low concen-\ntrations of nucleic acids. These advantages allow the use of \nLoCs in versatile ways to detect viruses38.\nSARS-CoV-2 diagnosis by qRT-PCR test didn't cover the \npresented demands, so some LoCs had an emergency use \nauthorization to solve this trouble. These authorizations were \ngiven by the Food and Drug Administration (FDA) in the United \nStates39. The SARS-CoV-2 detection LoCs on the market can \nbe seen in Table 2. \nComplementing the use of LoCs for diagnosis, the Appli-\nkon\u00ae company has researched the use of MBR Micro-matrix \nfor possible vaccines against COVID-19 by the Virology Labora-\ntory and the Bioprocess Engineering group of Wageningen Uni-\nversity. The MBR is being applied to optimize cell growth pa-\nrameters for the production of the Spike protein in Sf9 cells40.\nFUTURE PERSPECTIVES\nThere are many possibilities for future exploration and te-\nchnical issues that need to be addressed to turn MBRs emer-\nging technologies into valuable tools. The innovation of detec-\ntion methods and the miniaturization of instruments need to \nbe improved, which requires collaboration between scientists with experience in different fields. Among the improvements \nthat must be made, the material used to manufacture the \nmicrofluidic device must not influence the cellular response \nbehavior. Currently, PDMS is the standard material used for \nmanufacturing; however, it is highly lipophilic to bind to mole-\ncules in the perfusion medium or bind to introduced drugs41.\nAn essential requirement for commercialization and a \nchallenge for complex microfluidic structures is scalability. As \na result, scalability considerations must drive the materials, \nthe design, and the fabrication methods used for such devices. \nAdvances in 3D printing technology will likely start to bridge \nthat gap shortly to build plastic-based MBRs42.\nBased on the variety of diagnostic chips capable of detec-\nting COVID-19, portability, sensitivity, and performance are the \nruling guideline to implement a virus-specific diagnostic stra-\ntegy. The SARS-CoV-2 biomarkers enable plasmonic and colo-\nrimetry for developing chip tests that ensure correct diagnosis, \nopening the possibility of an integrated POC system38,43. Given \nthis potential for rapid results, plasmonic-based sensors can \nreduce the total analytical time from hours or days to minutes, \nwhich would allow patients to receive their diagnosis in less \ntime, reducing nosocomial transmission and minimizing the \nburden on clinical laboratories38.\nAlthough rapid diagnostic LoCs can bring benefits for \nthose affected, in the future, these devices should have an in-\ntegrated internet communication system with real-time data \ntransmission capacity and updated monitoring (integrated \ntransmitting antenna), which allows data acquisition to enter \ninto a health network, this would have a significant impact on \nthe management of current or future pandemics44.\nA new method of detection and analysis of samples is \nthrough the use of smartphones (SP), thanks to their sophis-\nticated technological characteristics, such as high-quality \ncameras, great computational power, and easy connectivity; \nthese have facilitated its integration as an analytical detection \ntool. SP-based tests measure optical variables such as bright \nfield, colorimetry, luminescence, and fluorescence42.\nFigure 2. Main Organ on a Chip (OoC) devices, \nbased on impermeable and microfluidic mem -\nbranes to mimic the tissue-tissue interface of \nliving organisms, Heart on a chip: a three-di -\nmensional cell microstructure is generally \nused for toxicology tests in cardiomyocytes. \nLymph node on a chip: used in research si -\nmulating microstructures of the paracortical \nregion of the lymph node to examine the dyna -\nmics of interaction between dendritic cells and \nT cells. Skin on a chip: they are preferentially \nbased on mimicking the active immune cells \nof the skin and physiological research adding \nvascularization in skin models with endothe -\nlial cells. Spleen on a chip: system consisting \nof two channels, the first one with a fast liquid \nflow and the other with a slow liquid flow to \nbalance hydrodynamic forces and imitate the \nfilter function in the spleen. Liver on a Chip: for \nits therapeutic research on functions, metabo -\nlism, detoxification, and response to drugs, an \nOoC of interest developed from hepatocytes \nand endothelial cells. Gut on a chip: usually \nused for phase I drug development and is hel -\npful to examine the small intestine functions. \nBased on Shanti et al.(2018).2080\nAnupam Saha, Arijit Das, Subhasish Dutta, Suprodip Mandal\nVolumen 6 / N\u00famero 2     \u2022     http://www.revistabionatura.com\nThe identification of viruses using SP has been proved on \ndifferent systems such as detection of Ebola virus-specific \nantibodies, RT-LAMP tests for detecting the human immuno-deficiency virus (HIV) and Zika virus, and diagnosing influen-za with gold nanoparticles test\n39. Sun et al.(2020) study the \ndetection from LAMP of 5 bacterial and viral pathogens that cause respiratory infections in equines, using the SP Motoro-la Nexus 6 to measure fluorescence. The system managed to differentiate positive and negative controls and detect one or more pathogens simultaneously in an hour (ideal for co-infec-tion diagnosis). Furthermore, the large capacity of SPs to be used as analytical equipment makes them an excellent option for designing rapid tests for SARS-CoV-2 without the need to invest in expensive equipment\n45.\nMicrofluidic chips provide favorable support for OoC deve-\nlopment that capture the attention of global research due to the breakthroughs that have been made in this field. The ulti-mate goal of OoC is to integrate numerous organs on a single chip and build a more complex multi-organ chip model, ultima-tely achieving a \"Human on a chip\"\n46.\nConclusions\nThis work gave an overview of the applications of LoCs de-\nvices, highlighting their value in cytotoxicity studies and their importance as diagnostic tools, their advances in disease stu-dies make great successes in biomedicine concerning health care.  Besides, LoCs and OoCs have demonstrated the fantas-tic performance of this technology, with the most avant-garde research on LoCs focused on SARS-CoV-2, plasmonic-based chips, integration of communication systems between the tests with medical data-network and the use of SmartPhones as analytical devices. The LoCs were positioned as POC tests, which would open the door to a faster diagnosis without the need for biomedical or hospital equipment and better manage different diseases thanks to Lab on a Chips.\nAcknowledgements\nThe authors thank the Universidad de las Fuerzas Arma-\ndas, ESPE and the Industrial Biotechnology and Bioproducts \nResearch Group, CENCINAT, due to the opportunity provided to us as their invaluable help and guidance during the develo-pment of this work.\nCompeting interests\nThe authors declare that they have no conflicting inte-\nrests.\nBibliographic references\n1. Pr ado, R. C. & Borges, E. R. Microbioreactors as engineering tools \nfor bioprocess development. Brazilian J. Chem. Eng. 35, 1163\u2013\n1182 (2018).\n2.P\nasirayi, G. et al. Microfluidic Bioreactors for Cell Culturing: A Re-\nview. 3, (2011).\nFigure 3. Comparison of Lab on a Chip \n(LoC) versus conventional tests. a) The \ntime required for diagnoses in LoC is more minor than conventional tests. b) Your usa -\nge costs decrease due to lower reagent consumption. \nc)The risk of possible infec-\ntions or nosocomial transmission decrea -\nses because patients obtain their results in a shor\nter time. d) A smaller laboratory staff \nis needed. e) Required training is simpler. f) The reach or coverage of the population is greater. g) Due to their portability, they faci -\nlitate handling and mobilization.2081\nA Competitive Analysis Of Top Ten Pharmaceutical Companies In India\n3.Marques, M. P. C. & Szita, N. Bioprocess microfluidics: applying\nmicrofluidic devices for bioprocessing. Curr. Opin. Chem. Eng. 18,\n61\u201368 (2017).\n4.\n Lat\ntermann, C. & B\u00fcchs, J. 2 Design and Operation of Microbiore-\nactor Systems for Screening and Process Development. (2016).\n5.Hemmerich, J\n., Noack, S., Wiechert, W. & Oldiges, M. Microbio-\nreactor Systems for Accelerated Bioprocess Development. Bio-technology Journal 13, (2018).\n6.\nNagr\naik, T., Salcedo, A. G., Solle, D. & Scheper, T. Process Opti-\nmization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation. JoVE (Journal Vis. Exp.e60577 (2020).\n7.\nHerold, K. E. & R\nasooly, A. Lab-on-a-Chip Technology (Vol. 1) Fab-\nrication and Microfluidics. (2009).\n8.\n Mohammed, M. I., Hasw\nell, S. & Gibson, I. Lab-on-a-chip or Chip-\nin-a-lab: Challenges of Commercialization Lost in Translation.Procedia Technol. 20, 54\u201359 (2015).\n9.\nGiannitsis, A. T\n. Biomeditsiiniliste kiiplaborite valmistamine. Est.\nJ. Eng. 17, 109\u2013139 (2011).\n10.\n WHO\n. WHO Coronavirus Disease (COVID-19) Dashboard. https://\ncovid19.who.int/table (2020). Available at: https://covid19.who.int/table. (Accessed: December 16 2020)\n11.\n Mandenius, C\n. F. Conceptual design of micro-bioreactors and or-\ngan-on-chips for studies of cell cultures. Bioengineering 5, (2018).\n12.\n R\navindran, S. et al. Microbioreactors and Perfusion Bioreactors for \nMicrobial and Mammalian Cell Culture. in Biotechnology and Bio-engineering (IntechOpen, 2019). doi:10.5772/intechopen.83825\n13.\n Z\nepeda, A. B., Pessoa Jr, A. & Far\u00edas, J. G. Carbon metabolism\ninfluenced for promoters and temperature used in the heterol-ogous protein production using Pichia pastoris yeast. brazilian J.Microbiol. 49, 119\u2013127 (2018).\n14.\n P\narekh, M. et al. Microbioreactor for lower cost and faster opti-\nmisation of protein production. Analyst 145, 6148\u20136161 (2020).15.  Zanzot to, A. Integrated Microbioreactors for Rapid Screening and \nAnalysis of Bioprocesses. (2005).\n16.\n R\nomao, V. C. et al. Lab-on-Chip Devices: Gaining Ground Losing\nSize. ACS Nano 11, 10659\u201310664 (2017).\n17.\n S\ntoytcheva, M. & Zlatev, R. Lab-on-a-chip fabrication and applica-\ntion. (BoD\u2013Books on Demand, 2016).\n18.\n Coppeta, J\n. R. et al. A portable and reconfigurable multi-organ\nplatform for drug development with onboard microfluidic flowcontrol. Lab Chip 17, 134\u2013144 (2017).\n19.\n Goble, J\n. A. & Rocafort, P. T. Point-of-care testing: Future of\nchronic disease state management? Journal of Pharmacy Prac-tice 30, 229\u2013237 (2017).\n20.\n Azizipour\n, N., Avazpour, R., Rosenzweig, D. H., Sawan, M. & Ajji, A. \nEvolution of biochip technology: A review from lab-on-a-chip toorgan-on-a-chip. Micromachines 11, 1\u201315 (2020).\n21.\n Khalid, N., K\nobayashi, I. & Nakajima, M. Recent lab-on-chip de-\nvelopments for novel drug discovery. Wiley Interdiscip. Rev. Syst.Biol. Med. 9, 1\u201317 (2017).\n22.\n Esch, E. W\n., Bahinski, A. & Huh, D. Organs-on-chips at the fron-\ntiers of drug discovery. Nature Reviews Drug Discovery 14, 248\u2013260 (2015).\n23.\n Bhatia, S. N. & Ingber\n, D. E. Microfluidic organs-on-chips. Nature\nBiotechnology 32, 760\u2013772 (2014).\n24.\n Chris\ntoffersson, J. & Mandenius, C. F. Using a microfluidic device \nfor culture and drug toxicity testing of 3D cells. in Methods in Mo-lecular Biology 1994, 235\u2013241 (Humana Press Inc., 2019).\n25.\n V\nelugula-Yellela, S. R. et al. Use of high-throughput automated\nmicrobioreactor system for production of model igG1 in CHOcells. J. Vis. Exp. 2018, 58231 (2018).\n26.\n Barisam, M., Saidi, M. S., K\nashaninejad, N. & Nguyen, N. T. Predic-\ntion of necrotic core and hypoxic zone of multicellular spheroidsin a microbioreactor with a U-shaped barrier. Micromachines 9,(2018).\nTable 2. Products based on Lab on a Chip (LoC) are in the market for the diagnosis of SARS-CoV-2. Adapted from Zhuang et al.(2020).2082\nAnupam Saha, Arijit Das, Subhasish Dutta, Suprodip Mandal\nVolumen 6 / N\u00famero 2     \u2022     http://www.revistabionatura.com\n27. Got twald, E. & Altmann, B. Advanced 3D-Cell Culture Techniques \nin Micro-Bioreactors. (2020).\n28.\n Marsano, A. et al. Beating hear\nt on a chip: A novel microfluid-\nic platform to generate functional 3D cardiac microtissues. Lab\nChip 16, 599\u2013610 (2016).\n29.\n Hemmerich, J\n. et al. Less Sacrifice, More Insight: Repeated\nLow-Volume Sampling of Microbioreactor Cultivations EnablesAccelerated Deep Phenotyping of Microbial Strain Libraries. Bio-technol. J. 14, 1\u201326 (2019).\n30.\n W\nu, J. et al. Lab-on-a-chip platforms for detection of cardiovas-\ncular disease and cancer biomarkers. Sensors (Switzerland) 17,(2017).\n31.\n K\nolluri, N., Klapperich, C. M. & Cabodi, M. Towards lab-on-a-chip\ndiagnostics for malaria elimination. Lab Chip 18, 75\u201394 (2018).\n32.\n T\naylor, S. C. & Mrkusich, E. M. The state of RT-quantitative PCR:\nfirsthand observations of implementation of  minimum informa-tion for the publication of quantitative real-time PCR experiments (MIQE). J. Mol. Microbiol. Biotechnol. 24, 46\u201352 (2014).\n33.\n K\nang, Y. B., Rawat, S., Duchemin, N., Bouchard, M. & Noh, M. Hu-\nman liver sinusoid on a chip for hepatitis B virus replication study. Micromachines 8, 1\u201313 (2017).\n34.\n Zhou, \nX. et al. Determination of SARS-coronavirus by a microflu-\nidic chip system. Electrophoresis 25, 3032\u20133039 (2004).\n35.\n Sharma, S., K\numar, V., Chawla, A. & Logani, A. Rapid detection of \nSARS-CoV-2 in saliva: can an endodontist take the lead in point-of-care COVID-19 testing? International Endodontic Journal 53,1017\u20131019 (2020).\n36.\n Udugama, B. et al. Diagnosing CO\nVID-19: The Disease and Tools\nfor Detection. ACS Nano 14, 3822\u201338Udugama, B., Kadhiresan, P., Kozlowski, H. (2020).\n37.\n Qiu, G\n. et al. Dual-Functional Plasmonic Photothermal Biosen-\nsors for Highly Accurate Severe Acute Respiratory SyndromeCoronavirus 2 Detection. ACS Nano 14, 5268\u20135277 (2020).\n38.\n T\nymm, C., Zhou, J., Tadimety, A., Burklund, A. & Zhang, J. X. J.\nScalable COVID-19 Detection Enabled by Lab-on-Chip Biosen-sors. Cell. Mol. Bioeng. 13, 313\u2013329 (2020).\n39.\n Zhuang, J\n., Yin, J., Lv, S., Wang, B. & Mu, Y. Advanced \"lab-on-a-\nchip\" to detect viruses \u2013 Current challenges and future perspec-tives. Biosensors and Bioelectronics 163, (2020).40.\n  Applik on. Applikon bioreactors used in search for COVID-19\nvaccine. (2020). Available at: https://www.applikon-biotechnol-ogy.com/en/about-applikon/news-events/applikon-bioreactors-used-in-search-for-covid-19-vaccine/. (Accessed: December 162020)\n41.\n Shanti, \nA., Teo, J. & Stefanini, C. In vitro immune organs-on-chip\nfor drug development: A review. Pharmaceutics 10, (2018).\n42.\n Arsha\nvsky-Graham, S. & Segal, E. Lab-on-a-Chip Devices for Point-\nof-Care Medical Diagnostics. in (2020). doi:10.1007/10_2020_127\n43.\n Zhu, H., F\nohlerov\u00e1, Z., Pek\u00e1rek, J., Basova, E. & Neu\u017eil, P. Recent\nadvances in lab-on-a-chip technologies for viral diagnosis. Bios-ens. Bioelectron. 153, 112041 (2020).\n44.\n Zhu, H., F\nohlerov\u00e1, Z., Pek\u00e1rek, J., Basova, E. & Neu\u017eil, P. Recent\nadvances in lab-on-a-chip technologies for viral diagnosis. Bios-ens. Bioelectron. 153, 112041 (2020).\n45.\n Sun, F\n. et al. Smartphone-based multiplex 30-minute nucleic acid \ntest of live virus from nasal swab extract. Lab Chip 20, 1621\u20131627 (2020).\n46.\n W\nu, Q. et al. Organ-on-a-chip: Recent breakthroughs and future\nprospects. BioMedical Engineering Online 19, (2020).\n47.\n T\nan, C. K. et al. Electromagnetic stirring in a microbioreactor with \nnon-conventional chamber morphology and implementation ofmultiplexed mixing. J. Chem. Technol. Biotechnol. 90, 1927\u20131936 (2015).\n48.\n Jonczyk, R. et al. Living Cell Microarr\nays: An Overview of Con-\ncepts. Microarrays 5, 11 (2016).\n49.\n Vit, F\n. F. et al. Perfusion microbioreactor system with permeable\nmembranes to monitor bacterial growth. J. Chem. Technol. Bio-technol. 94, 712\u2013720 (2019).\n50.\n Figallo, E. et al. Micro-bioreactor arr\nay for controlling cellular mi-\ncroenvironments. Lab Chip 7, 710\u2013719 (2007).\n51.\n Titmarsh, D\n. M. et al. Induction of human iPSC-derived cardio-\nmyocyte proliferation revealed by combinatorial screening in high density microbioreactor arrays. Sci. Rep. 6, 1\u201315 (2016).\nReceived: 2 March 2021\nAccepted: 12 July 20212083\nMetachromatic Leukodystrophy: Diagnosis and Treatment Challenges\nAbstract: Metachromatic leukodystrophy is a neurological disease of the lysosomal deposit that has a significant impact given \nthe implications for the neurodegenerative deterioration of the patient. Currently, there is no treatment available that reverses \nthe development of characteristic neurological and systemic symptoms. Objective. Carry out an updated bibliographic search on \nthe most critical advances in the treatment and diagnosis for LDM. A retrospective topic review published in English and Spanish \nin the Orphanet and Pubmed databases. Current treatment options, such as enzyme replacement therapy and hematopoietic \nstem cell transplantation aimed at decreasing the rapid progression of the disease, improving patient survival; however, these \nare costly. The pathophysiological events of intracellular signaling related to the deficiency of the enzyme Arylsulfatase A and \nsubsequent accumulation of sulphatides and glycosylated ceramides have not yet been established. Recently, the accumulation \nof C16 sulphatides has been shown to inhibit glycolysis and insulin secretion in pancreatic cells. The significant advance in \ntechnology has allowed timely diagnosis in patients suffering from LDM; however, they still do not have an effective treatment.\nKey words: Metachromatic leukodystrophy, treatment, diagnosis, prevalence.\nIntroduction\nMetachromatic leukodystrophy (LDM) is a neurodegene-\nrative lysosomal deposition disease caused by a deficiency in \nthe enzyme Arylsulfatase A (ARSA), which leads to an accu-\nmulation of sulfates in lysosomes, lipids of great importance in \nthe structure of myelin. The lysosomal deposition of sulphati-\ndes in neurons and myelinating cells produces severe demyeli-\nnation and neurodegeneration of central (CNS) and peripheral \nnervous systems (PNS)1,2.\nAccording to the progress of the disease and the onset of \nsymptoms, it is classified into three stages: late infantile, juve-\nnile, and adult3. Although there is still no effective treatment \nto reverse the symptoms, different therapeutic strategies are \nin the research and deepening phase3.\nThere are no pathological mechanisms by which the ac-\ncumulation of sulfates leads to lamyelination in CNS and PNS \ncells. However, in in vitro and in vivo models of pancreatic B \ncells, the accumulation of sulphatides can inhibit insulin secre-\ntion and therefore disable the glycolytic function of the cells4\u20136. \nThe main objective of this review is to carry out an updated \nbibliographic search on the most critical advances in the treat-\nment and diagnosis of LDM.\nMethods\nRetrospective review article consisted of searching for \narticles published in English and Spanish in the Orphanet \nand Pubmed databases with the keywords, Medical Subject \nHeadings (MeSH): Metachromatic leukodystrophy, treatment, \ndiagnosis, prevalence.\nReview articles, meta-analyses, systematic reviews, and \nstudies that preferably had descriptions of cellular mechanis-\nms in LDM were included; 80 relevant references are inclu-\nded due to their historical antecedents considered valuable \nto complement the information and have LDM criteria. Other \nreferences support the descriptions of essential mechanisms \nin this pathology.Results\n3086 articles containing MeSH were found: When spe-\ncifying \"Metachromatic leukodystrophy\", 1,650 articles were \nfound, 410 with the words \"Metachromatic leukodystrophy, \ntreatment,\" 932 with \"Metachromatic leukodystrophy, diag-\nnosis\" and 94 \"Metachromatic leukodystrophy, prevalence\". \nOf all the articles, 80 references were located considering \nthat metachromatic leukodystrophy is the infantile stage and \nstudies in which new diagnostic technologies and treatments \nwere mentioned, Figure 1.\nLEUKODYSTROPHIES\nAccording to the National Institute of Health of the United \nStates (NIH) and the Neurological Disorders Unit, leukodystro-\nphies or leukoencephalopathies7 are a group of rare diseases \ncaused by genetic defects, leading to the presence of chemical \ndeposits within cells of both the CNS and the PNS, resulting in \nthe deterioration of the myelin sheath8,9.\nThis pathology is characterized by demyelinating proces-\nses that primarily affect the CNS and later the PNS10,11. Leu-\nkodystrophies have an incidence of 1 in 7,500 live births; howe-\nver, only half of the patients receive a specific diagnosis7,12.\nThe European Association of Leukodystrophies (ELA) \nclassification includes those caused by peroxisomal content, \nlysosome, vacuolation, undetermined atypical hypomyelina-\ntion. All of these leukodystrophies target myelin; in some ca-\nses, its degradation occurs, and in others, there is no formation \nof it13,14.\nSpecific leukodystrophies include metachromatic leu-\nkodystrophy, Krabb\u00e9 disease, adrenoleukodystrophy, Peli-\nzaeus-Merzbacher disease, Canavan disease, and childhood \nataxia hypomyelination of the central nervous system (also \nknown as substance disappearance disease or white matter), \nAlexander's disease, Refsum's disease, and cerebrotendinous \nxanthomatosis15.\nThe progress of the disease is rapid and devastating. It can \noccur at any age, both in childhood and in adults12. Currently, Metachromatic Leukodystrophy: Diagnosis and Treatment Challenges\nNayibe Tatiana Sanchez-Alvarez1,2,3, Paula Katherine Bautista-Ni\u00f1o2, Juanita Trejos-Su\u00e1rez3, Norma Cecilia Serrano-Diaz2REVIEW / ART\u00cdCULO DE REVISI\u00d3N\nDOI. 10.21931/RB/2021.06.03.32 \n1 Universidad del Valle, Faculty of Health, Biomedical Sciences Doctorate Program, Colombia. \n2 Universidad del Valle, Faculty of Health, Biomedical Sciences Doctorate Program,Colombia.\n3 Universidad de Santander, Faculty of Health Sciences, CliniUDES Research Group, Bucaramanga, Santander, Colombia.\nCorresponding author: tatianasanchezalvarez@hotmail.com2084\nNayibe Tatiana Sanchez-Alvarez, Paula Katherine Bautista-Ni\u00f1o, Juanita Trejos-Su\u00e1rez, Norma Cecilia Serrano-Diaz\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nfew reports are generated on diagnostic tests, treatment, and \nthe course of this disease.  The current diagnosis is based on \nclinical history, examinations, radiological and laboratory fin-\ndings, including genetic tests12,15. This review summarizes the \nknowledge about the epidemiology, pathophysiology, diagno-\nsis, and treatment of Metachromatic Leukodystrophy.\nMetachromatic Leukodystrophy (MLD)\nMLD was first described in 1910 by Perisini and Alzhei-\nmer's in adult patients3,16. In 1925, Scholz published a pa-\nthological clinical study of juvenile MLD, and 34 years later, \nPeiffer showed that the neural tissues in Scholz's study had \nmetachromatically stained sections. In 1958, independently, \nJatzkewitz discovered that the metachromatic sections resul-\nted from the accumulation of sulphatides. On the other hand, \nAustin and his colleagues were the ones who discovered the \ndefect in the activity of the enzyme arylsulfatase A. Greenfield \nmade the first report of infantile MLD in 1933, and the term \n\"metachromatic leukodystrophy\" (metachromatischen Leu-\nkodystrophien) was first used by Peiffer in 1959 to describe \nwhat was previously known as \"diffuse cerebral sclerosis\"16,17.\nMLD (OMIM # 250100) is a lysosomal storage disorder \nwith an autosomal recessive pattern of inheritance, so carriers \nof one copy of the abnormal gene are not affected by the disea-\nse18,19. MLD is caused by mutations in the ARSA gene, located \non chromosome 22q13.3320, that encodes the lysosomal en-\nzyme Arylsulfatase A (ARSA) (ARSA; OMIM 607574, GenBank \naccession number, NG_009260)21,22.\nAmong the types of mutations that have been reported in \nARSA are amino acid substitutions, nonsense mutations, dele-\ntions, and sense-change mutation. ARSA is a crucial enzyme \nin the catabolism of sphingolipids, an abundant component of \nmyelin, Figure 2. The progressive accumulation of sulphatides \nin the lysosomes of neurons and myelinating cells (Schwann \ncells in the PNS, oligodendrocytes in the CNS) causes severe \ndemyelination and neurodegeneration progressive neurologi-\ncal deficits, and premature death in childhood form23.\nMLD has three clinical subtypes: late-infantile, juveni-\nle, and adult17. Each of the subtypes has characteristics that \nmake them different from each other.Late childhood MLD\nThe start occurs before 30 months. Typical findings are \nweakness, hypotonia, clumsiness, frequent falls, difficulty \nwalking, and dysarthria. As the disease progresses, motor, \ncognitive, and language skills deteriorate. Later signs include \nspasticity, pain, seizures, impaired vision, and hearing. Of the \ncases of MLD, 50 to 60% are of late childhood presentation24. \nIn the final stages, children have tonic spasms, mindless pos-\nture, and general ignorance of their environment17.\nJuvenile MLD\nThe clinical signs of this pathology appear between 30 \nmonths and 16 years of age. This clinical form of the disease \nrepresents 20 to 30% of MLD cases25. Initial manifestations in-\nclude decreased school performance and the appearance of \nbehavioral problems, followed by gait disturbances. Progres-\nsion is similar but slower than in the late-infant form17.\nAdult MLD\nSymptom presentation occurs after 16, sometimes up \nto the fourth or fifth decade, and represents 10 - 20% of the \nMLD cases25. Initial signs include problems with school or work \nperformance, personality changes, emotional lability, or psy-\nchosis; in other patients, neurological symptoms (weakness \nand loss of coordination that progresses to spasticity and in-\ncontinence) or seizures predominate. Peripheral neuropathy is \ncommon. The course of the disease is variable, with periods of \nstability interspersed with periods of decline. The final stage is \nsimilar to the juvenile and infantile forms17.\nEpidemiology - Prevalence\nCurrently, there are no relevant reports of prevalence \nworldwide, since there is talk of a set of orphan llama diseases, \nconsidered in the countries of the European Union as one that \naffects one in 2,000 people; less than 200,000 people affect \nthe United States, less than 50,000 people in Japan, less than \none in 10,000 in Taiwan and one in 5,000 in Colombia26.\nHowever, in the Orphanet database that describes the \nMLD, an estimated prevalence of 1 case in 625,000, with an \nincidence of 0.5 and 1 in 50,00025,27\u201330.\nFigure 1. List of findings and selection of references for this review article.2085\nIn Latin America, the reports generated so far are focused \non describing cases and mutations in the ARSA gene31\u201337.\nPATHOPHYSIOLOGICAL MECHANISMS OF THE DISEASE\nMLD is a neurodegenerative disease characterized by the \naccumulation of sulfates (sulfated glycosphingolipids, espe-\ncially sulfogalactocerebrosides or sulfogalactosylceramides) \nin the central nervous system, kidneys, and in other organs \nsuch as the retina, liver, testes, pancreas, sweat glands, adre-\nnal cortex, and tissue. rectal38. The PNS is systematically \naffected, causing a decrease in nerve conduction velocities. \nThis disorder progresses to a state of decerebration after a \nfew years, resulting in death within 5 years after the onset of \nsymptoms39.\nGalactosylceramide (GalC) and its sulfated form, the sul-\nphatides, are two glycosphingolipids found in high concentra-\ntions in the CNS and PNS cell membranes. GalC and sulpha-tides comprise 23% and 4% of the total mass of myelin lipids, \nrespectively, and together account for about a third of the \ncontent of the myelin sheath40,41. Among the primary myeli-\nnating cells, oligodendrocytes and sulfate-producing Schwann \ncells42. In the nervous system, sulphatides are related to inter-\ncellular recognition, cell differentiation, the interaction of the \nmyelinating cell with the axon, the maintenance of the axonal \nstructure, and nerve conduction39-42.\nThe myelin sheath is an extended membrane, which spi-\nrally wraps around a portion of the axon. Each myelin sheath is \nextended by modifying the cell membrane of oligodendrocytes \nand Schwann cells, forming a structure with several myelin \nsegments surrounding the axon (Figure 3)40.\nEach oligodendrocyte can contribute to the protection of \naround 50 different axons. In addition to its importance in driving \nthe nerve impulse, myelin may have a symbiotic relationship \nwith the axon45. Other publications suggest that the develop-\nFigure 2. Synthetic sulfatide route.\nFigure 3. Structure of the myelin sheath. Source: Figure adapted from Poitelon Y. et al., 202026. Diagram of the structure of the \nmyelin sheath, (I) myelinated axon, (II) myelin sheath, (III) Bilayer membrane, and (IV) Lipid classes. Myelin is formed by the opposition \nof the external surfaces and the internal surfaces of the myelin bilayer that constitute the intraperiodic line and the dense main line, \nrespectively (II, III). The myelin bilayer has an asymmetric lipid composition (III, IV). The myelin protein is also distributed asymmetrica -\nlly, such as PLP (Proteolipid Protein) and P0 in the intraperiodic line and the dense mainline, the PMP2 protein in the dense main line \n(III), as well as the composition of cholesterol, phospholipids (e.g., Plasmogen, lecithin, sphingomyelin), glycolipids (eg, Galactosylce -\nramide) and other phospholipids. Proteins P0, PMP2, and enrichment of sphingomyelin in myelin are specific for myelin PNS.Metachromatic Leukodystrophy: Diagnosis and Treatment Challenges2086\nment of myelin occurs synergistically with the axon and that \nthe axonal cytoskeleton does not form correctly in the absence of myelin\n46. Myelin is usually synthesized in MLD. However, the \nprogressive accumulation of sulfatides induces instability of the myelin membrane, leading to final demyelination.\nMyelin formation occurs in two ways. In the CNS, widely \nbranched oligodendrocytes form myelin around multiple axons at the same time, allowing for higher neuronal density in the brain. On the other hand, in the PNS, Schwann cells circulari-ze an axon with several layers of myelin, forming a multilayer structure. Although the primary function of myelin is the same in the CNS and PNS, the molecular requirements for myelin formation differ. In general terms, myelination is a complex process during which a set of proteins and lipids are synthe-sized in a coordinated way by glial cells (Schwann cells and Oligodendrocytes). i) the pluripotent precursors of Schwann and Oligodendrocyte cells must differentiate; for this, a set of transcription factors is involved in the cell's potential de-velopment and its myelinating function. ii) the precursor cells must migrate to the myelination site; this step is believed to require communication between the migrant cells and the axons. iii) when the cell contacts the axon, transcriptional and post-transcriptional changes force the exit of the cell cycle and the differentiation of the cell into a mature Oligodendro-cyte or Schwann cell. iv) Myelin synthesis is carried out around the axon to form a compact and functional structure to finally v) ensure that the structure and function of myelin are preser-ved through the continuous expression and synthesis of eachof the components of myelin\n46.\nAlthough many of the myelin components have been rela-\nted to the assembly and maintenance of the structure of this47, \nGalactolipids and sulfatides, the main components of myelin, have received significant attention. The synthesis and matura-tion of most of these compounds begin in the endoplasmic re-ticulum and rapidly spreads to the extracellular space through the early secretion system\n48,49.\nAs already mentioned, this myelination process is continuous, \nestablishing a balance in the amount of each of its compounds.\nDiverse studies50\u201352 have shown that mitochondria and \nlysosomes are critical organelles for the maintenance of ho-meostasis in myelinating cells; likewise, there is a close rela-tionship between these two and the interaction directly with cellular stress\n50, In this way, communication between mito-\nchondria and lysosomes can lead to mitophagy, processes in which damaged mitochondria target autophagosomes for lysis. Autophagosomes subsequently fuse with lysosomes / late endosomes to generate autolysosomes that mediate the degradation of mitochondria, or in contrast, mitochondria and lysosomes can also interact directly through nondegradable processes through the dynamic formation of sites of Membra-ne contact between organelles in healthy mammalian cells, leading to transfer of lipid, calcium, and iron metabolites, re-gulation of organelle dynamics, such as mitochondrial division and endosomal division\n50.\nHowever, the misregulation of mitochondria or contacts \nwith lysosomes can simultaneously lead to the dysfunction of both organelles in various lysosomal storage disorders (LSD) such as MLD, which has been genetically and functionally re-lated to mitochondrial and lysosomal defects\n53.\nDIAGNOSIS\nDiagnosis of MLD requires a high level of complexity; \nhowever, Technological development is allowing the evolu-tion of new diagnostic strategies aimed not only at identifying ARSA enzyme deficiency but also at the presence of findings such as progressive neurological dysfunction or evidence of typical lesions on magnetic resonance imaging, characteristic of the disease.\nFor the diagnosis of MLD, one of the following events must \nbe present: \n\u2022\nIdentification of biallelic ARS\nA pathogenic variants in\nmolecular genetic tests (see Table 1).\n\u2022 Identification of increased urinar\ny excretion of sulfa-\ntides.\n\u2022 Identification of metachromatic lipid deposits in aner\nve or brain biopsy.\nTHERAPIES - TREATMENT\nDue to the lack of information on this disease, few treat-\nments aimed at safeguarding the lives of patients, mainly be-cause the barrier between the blood and the brain limits the access of the recombinant product to the nervous tissues\n54,55.\nCurrently, there is no treatment available to reverse the \nfatal outcome of this devastating disease; therapy is only su-pportive, disease severity and lack of effective therapies des-cribe the need for innovative therapeutic approaches\n54, howe -\nver, according to the database of clinicaltrials.gov, To date, 36 clinical trials have been registered, of which 6 are in an active state, focused on determining the natural history of the di-sease, efficacy, and safety of HGT-1110 (recombinant human arylsulfatase A), gene therapy based on lentiviral vectors, bio-marker search, Human placental-derived stem cell transplan-tation in participants with MLD.\nSymptom treatment and support\nAt the beginning of the disease, the patient is treated with \nremedies for epilepsy, muscle relaxants for contractures, phy-\nsical therapy to improve nerve and muscle function, stimula-tion to maximize the intellect, and finally support to the fa-milies of those affected so that the parents and/or caregivers can anticipate decisions about wheelchairs, feeding tubes, and other care\n9,36,56.\nEnzyme replacement therapy\nEnzyme replacement therapy has become the most pro-\nmising therapeutic option for various lysosomal diseases due to its potential to compensate for the deficiency; it is current-ly available as a treatment for some disorders such as Fabry, Gaucher, Pompe, mucopolysaccharidosis I, II, VI and it's under development for others like MLD\n54. However, this type of the-\nrapy remains challenging because the blood-brain barrier is impervious to lysosomal enzymes\n57,58.\nCurrently, there are three-phase I and II studies reporting \nthe safety, efficacy, and pharmacodynamics of this type of therapy in patients with MLD\n59\u201361. In this therapy, recombinant \nhuman arylsulfatase A (rhASA) has been used, which has ge-nerated changes in the concentrations of sulfates in CSF and urine of the patients from the beginning to the end of the study, demonstrating an excellent therapeutic start\n61,62.\nGene therapy\nTherapy based on the overexpression of wild-type ARSA \nin different cell types. This type of therapy has been success-ful when autologous hematopoietic stem cells obtained from patients with MLD are used, in which the ARSA gene is ove-rexpressed by gene transfer using retroviral or lentiviral vec-tors\n63. The wild-type synthesized ARSA secreted by these ge-\nnetically engineered autologous hematopoietic stem cells are Nayibe Tatiana Sanchez-Alvarez, Paula Katherine Bautista-Ni\u00f1o, Juanita Trejos-Su\u00e1rez, Norma Cecilia Serrano-Diaz\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2087\nMetachromatic Leukodystrophy: Diagnosis and Treatment Challenges\nTable 1. Diagnostic methods for the identification of MLD.\nabsorbed by adjacent ARSA-deficient cells through the man-\nnose-6-phosphate receptor system64.\nToday, there are complete and ongoing clinical trials in which \ngene therapy has been used as an adjunct in patients with MLD65.\nHematopoietic stem cell therapy\nWith this type of therapy, it is possible to reach the \nblood-brain barrier by using hematopoietic stem cells that di-fferentiate into microglial cells66. In principle, once the donor's \nmicroglial cells cross the blood-brain barrier, they can secrete \nthe wild-type ARSA enzyme, taken up by ARSA-deficient re-\nceptor neuronal cells. This uptake is performed by the man-\nnose-6-phosphate receptor system, which carries the enzyme \ndirectly to the lysosomes, where the sulfatides accumulate in \nthe ARSA receptor-deficient neural cells63,67.2088\nDespite being a promising therapy in clinical trials, it has \nbeen shown that the main complication that can occur in trea-\nted patients is the presence of graft-versus-host disease. The drugs used for this type of therapy have been busulfan, cyclo-phosphamide, anti-thymocyte globulin (ATG), tested on both children and adults\n67,68.\nBrain gene therapy with adeno-associated virus (AAV) \nvectors\nThis type of therapy is ideal for treating MLD patients \nsince the genetic message for the ARSA gene could be sent \ndirectly to the SNC. This therapy has the use of AAV vectors that have low immunogenicity, low oncogenic potential throu-gh insertion mutagenesis, and in addition to this, three main characteristics that make it unique:\n- Because it is safe, it can be administered directly in\nthe CNS to Through the intraparenchymal, intracerebroven-tricular, and intracisternal routes where the ARSA protein is expressed persistently and permanently in a single dose.\n- Once this therapy is administered at the site of action, \nit has the ability to prevent the symptoms of the disease\n69\u201371. \n- The ARSA protein when expressed in healthy cells is\ncapable of cross-correcting neighboring cells, therefore cells that are corrected will secrete the protein that is endocitated through the mannose-6-phosphate receptor (M6P) pathway\n72.\nAAVs that have been used so far for the treatment of MLD \nhave been AAV5, and then with the discovery of serotypes deri-ved from non-human primates, studies with AAVrh were conduc-ted\n71,73\u201375.\nCRISPR Cas9\nThis technique has become a novel and widely used research \ntool with which rapid, easy and efficient genetic modification is achieved\n76, with which alleles that cause disease are repaired by \nchanging the DNA sequence at the exact location of the chromo-some\n10. The acronym CRISPR Cas9 comes from Clustered Re-\ngularly Interspaced Short Palindromic Repeats, in Spanish \"Short Palindromic Repeats Grouped and Regularly interspaced\".\nThis technology has enabled two-stage genome editing. In \nthe first, guide RNA, which is specific to a DNA sequence, is asso-ciated with the enzyme Cas9 endonuclease, which works by cut-ting DNA. In the second stage, natural repair mechanisms of the cut DNA are activated. In which indel (insertion-deletion) can be generated or, moreover, a specific sequence is incorporated exact-ly at the original cut site. For this, the sequence of interest is su-pplied to the cell in such a way that it is integrated into the DNA\n77.\nThis technology brings hope of a cure not only for MLD but \nfor many other genetic diseases such as Alzheimer's, Cancer, AIDS, Cystic Fibrosis, etc., for many genetic diseases. It should be noted that to date it has not been used as a treatment for patients with this type of disease\n78.\nConclusions\nDespite great research efforts to find an effective treat-\nment for MLD, these approaches have not been effective not only because of the low efficiency of gene editing but becau-se gene therapies must cross the blood-brain barrier. which becomes a challenge. Therefore, patients with MLD continue without any treatment and, above all, there are still gaps in knowledge about the management of this disease.\nGiven the limitations presented by existing therapies in the \ntreatment of MLD, it is necessary to investigate new therapies to increase the effectiveness of the treatment.\nConsidering the panorama in MLD, it is essential to conti-\nnue in the constant search that points to the understanding of epidemiology and diagnostic tools for the disease.\nFinancial support\nThis project was funded by the project entitled \"Metabo-\nlism of sulfatides, glycolysis and mitochondrial function in me-\ntachromatic leukodystrophy\" in the call for research projects in basic sciences 712-2015, of Minciencias. Whose principal investigator is Dr. Norma C. Serrano.\nConflict of interests\nNone\nAbbreviations\nMLD: Metachromatic Leukodystrophy\nCNS: Central Nervous SystemPNS: Peripheral Nervous SystemCRISPR Cas9: Short Palindromic Repetitions Grouped and \nRegularly Spaced\nATP: Adenosine triphosphateGalC: GalactosylceramiderhASA: Recombinant Human Arylsulfatase AATG: Anti-thymocyte Globulin\nBibliographic references\n1. T akahashi T, Suzuki T. Role of sulfatide in normal and pathologi-\ncal cells and tissues. J Lipid Res. 2012;53(8):1437-50.\n2.T\nan M, Fuller M, Zabidi-Hussin Z, Hopwood JJ, Meikle PJ. Bio-\nchemical profiling to predict disease severity in metachromatic\nleukodystrophy. Mol Genet Metab. 2010;99(2):142-8.\n3.OMIM - Herencia mendeliana en l\u00ednea en el hombre [Internet].[Updated April 16, 2021, cited 13 of Jul\ny de 2019]. available in:\nhttps://www.omim.org/\n4.\n Blomqvis\nt M, Carrier M, Andrews T, Pettersson K, Mansson JE,\nRynmark BM, et al. In vivo administration of the C16:0 fatty acidisoform of sulfatide increases pancreatic sulfatide and enhancesglucose-stimulated insulin secretion in Zucker fatty (fa/fa) rats.Diabetes Metab Res Rev. 2005;21(2):158-66.\n5.\nBoslem E, Meikle P\nJ, Biden TJ. Roles of ceramide and sphin-\ngolipids in pancreatic \n\u03b1\n-cell function and dysfunction. Islets.\n2012;4(3):177-87.\n6.Buschard K, Blomqvis\nt M, M\u00e5nsson J-E, Fredman P, Juhl K, Gro-\nmada J. C16:0 Sulfatide Inhibits Insulin Secretion in Rat \u03b1-Cells\nb\ny Reducing the Sensitivity of KATP Channels to ATP Inhibition.\nDiabetes. 2006;55(10):2826.\n7.Gulati S, Jain P\n, Chakrabarty B, Kumar A, Gupta N, Kabra M.\nThe spectrum of leukodystrophies in children: Experience at atertiary care centre from North India. Ann Indian Acad Neurol.2016;19(3):332-8.\n8.\n Leucodis\ntrofia\n : National Ins\ntitute of Neurological Disorders and\nStroke (NINDS) [Internet]. [Updated December 21, 2016, cited 12 de November of 2019]. available in: https://espanol.ninds.nih.gov/trastornos/leucodistrofia.htm\n9.\n Leucodis\ntrofia metacrom\u00e1tica | Genetic and Rare Diseases Infor-\nmation Center (GARD) \u2013 an NCATS Program [Internet]. [updated10/6/2015, cited 31 de December of 2018]. available in: https://raredis-eases.info.nih.gov/espanol/12627/leucodistrofia-metacromaticaNayibe Tatiana Sanchez-Alvarez, Paula Katherine Bautista-Ni\u00f1o, Juanita Trejos-Su\u00e1rez, Norma Cecilia Serrano-Diaz\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2089\n10. V an der Knaap MS, Wolf NI, Heine VM. Leukodystrophies: Five\nnew things. Neurol Clin Pract. 2016;6(6):506-14.\n11.\n Beerepoot S, Nierk\nens S, Boelens JJ, Lindemans C, Bugiani M,\nWolf NI. Peripheral neuropathy in metachromatic leukodystrophy: \ncurrent status and future perspective. Orphanet J Rare Dis. 2019\n12.\n Gordon H, Letsou A, Bonk\nowsky J. The Leukodystrophies. Semin\nNeurol. 2014;34(03):312-20.\n13.\n As\nsociation Europ\u00e9enne Contre les Leucodystrophies. Accueil -\n[Internet]. [cited 15 of November of 2019]. available in: https://ela-asso.com/\n14.\n Brignone MS, Lanciot\nti A, Camerini S, De Nuccio C, Petrucci TC, Vis-\nentin S, et al. MLC1 protein: a likely link between leukodystrophies and brain channelopathies. Front Cell Neurosci. 2015;9:66-66.\n15.\n Gordon-Lipkin E, F\natemi A. Current Therapeutic Approaches in\nLeukodystrophies: A Review. J Child Neurol. 2018;33(13):861-8.\n16.\n Nyhan WL, Barshop B\nA, Ozand PT. Atlas of Metabolic Diseases\nSecond edition. CRC Press; 2005.\n17.\n Gomez-Ospina N. Ar\nylsulfatase A Deficiency. En: Adam MP, Ar-\ndinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al.,editores. GeneReviews((R)). Seattle WA: University of Washing-ton, Seattle. GeneReviews is a registered trademark of the Uni-versity of Washington, Seattle; 1993.\n18.\n Almarzooqi S, Quadri A, Alba\nwardi A. Gallbladder Polyps in Meta-\nchromatic Leukodystrophy. Fetal Pediatr Pathol. 2018;37(2):102-8.\n19.\n V\nan den Broek BTA, Page K, Paviglianiti A, Hol J, Allewelt H, Volt F, et al.\nEarly and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies. Blood Adv. 2018;2(1):49-60.\n20.\n Golchin N, Hajjari M, Malamiri RA, Aminzadeh M, Mohammadi-asl J\n, Golchin N, et al. Identification of a novel mutation in ARSA gene \nin three patients of an Iranian family with metachromatic leuko-dystrophy disorder. Genet Mol Biol. 2017;40(4):759-62.\n21.\n Belli G\n, Bartolini E, Bianchi A, Mascalchi M, Stagi S. Central Pre-\ncocious Puberty in a Child With Metachromatic Leukodystrophy.Front Endocrinol. 2018;9.\n22.\n Bindu P\n, Mahadevan A, Taly A, Christopher R, Gayathri N, Shan-\nkar S. Peripheral neuropathy in metachromatic leucodystrophy. A study of 40 cases from south India. J Neurol Neurosurg Psychia-try. 2005;76(12):1698-701.\n23.\n Calbi V\n, Fumagalli F, Consiglieri G, Penati R, Acquati S, Redaelli D, \net al. Use of Defibrotide to help prevent post-transplant endothe-lial injury in a genetically predisposed infant with metachromatic leukodystrophy undergoing hematopoietic stem cell gene thera-py. Bone Marrow Transpl. 2018.\n24.\n W\nang RY, Bodamer OA, Watson MS, Wilcox WR. Lysosomal stor-\nage diseases: Diagnostic confirmation and management of pre-symptomatic individuals. Genet Med. 2011;13(5):457-84.\n25.\n Dehghan Manshadi M, K\namalidehghan B, Aryani O, Khalili E,\nDadgar S, Tondar M, et al. Four novel ARSA gene mutations withpathogenic impacts on metachromatic leukodystrophy: a bioin-\nformatics approach to predict pathogenic mutations. Ther Clin\nRisk Manag. 2017;13:725-31.\n26.\n Minis\nterio de Salud y Protecci\u00f3n Social, Consuelo Pinz\u00f3n Guti\u00e9r-\nrez, Fredy Orlando Mendivelso Duarte, Sandra Patricia MisnazaCastrill\u00f3n. HU\u00c9RFANAS-RARAS code: 342 [Internet]. p. 19. avail-able in: https://www.ins.gov.co/buscador-eventos/Lineamientos/PRO%20Enfermedades%20hu%C3%A9rfanas%20y%20raras.pdf#search=enfermedades%20raras\n27.\n Pre\nvalence of rare diseases: Bibliographic data [Internet]. [cited\n28 of November of 2018]. available in: http://online.fliphtml5.com/trmf/ktss/#p=10\n28.\n K\nehrer C, Groeschel S, Kustermann-Kuhn B, Burger F, Kohler W,\nKohlschutter A, et al. Language and cognition in children withmetachromatic leukodystrophy: onset and natural course in anationwide cohort. Orphanet J Rare Dis. 2014;9(18):1750-1172.\n29.\n Kr\n\u00e4geloh-Mann I, Groeschel S, Kehrer C, Opherk K, N\u00e4gele T,\nHandgretinger R, et al. Juvenile metachromatic leukodystrophy10 years post transplant compared with a non-transplanted co-hort. Bone Marrow Transplant. 2012;48:369.\n30.\n Doher\nty K, Frazier SB, Clark M, Childers A, Pruthi S, Wenger DA,\net al. A closer look at ARSA activity in a patient with metachro-matic leukodystrophy. Mol Genet Metab Rep. 2019;19.31.\n  Ar tigal\u00e1s O, Lagranha VL, Saraiva-Pereira ML, Burin MG, Lou-\nren\u00e7o CM, van der Linden H, et al. Clinical and biochemical study of 29 Brazilian patients with metachromatic leukodystrophy. JInherit Metab Dis.  2010;33(S3):257-62.\n32.\n Virgens MYF\n, Siebert M, Bock H, Burin M, Giugliani R, Sarai-\nva-Pereira ML. Genotypic characterization of Brazilian patientswith infantile and juvenile forms of metachromatic leukodystro-phy. Gene. 2015;568(1):69-75.\n33.\n Saute J\nAM, Souza CFM de, Poswar F de O, Donis KC, Campos LG, \nDeyl AVS, et al. Neurological outcomes after hematopoietic stem cell transplantation for cerebral X-linked adrenoleukodystrophy,late onset metachromatic leukodystrophy and Hurler syndrome.Arq Neuropsiquiatr. 2016;74(12):953-66.\n34.\n Al\nvarez-Leal M, Contreras-Hern\u00e1ndez D, Ch\u00e1vez A, Diaz-Contre-\nras JA, Careaga-Olivares J, Z\u00fa\u00f1iga-Charles MA, et al. Leukocytearylsulfatase A activity in patients with alcohol-related cirrhosis: Arylsulfatase A in Chronic Alcoholic Cirrhosis. Am J Hum Biol.2001;13(3):297-300.\n35.\n E\ncheverri Olga Y, Salazar Diego A, Rodriguez-Lopez A, Janneth\nG, Almeciga-Diaz Carlos J, Barrera Luis A. Understanding theMetabolic Consequences of Human Arylsulfatase A Deficiencythrough a Computational Systems Biology Study. Cent Nerv Syst Agents Med Chem. 2016.\n36.\n Espejo LM, de la Espriella R, Hern\u00e1ndez JF\n. Leucodistrofia metacro-\nm\u00e1tica. Presentaci\u00f3n de caso. Rev Colomb Psiquiatr. 2017;46(1):44-9.\n37.\n \u00c1l\nvarez-Pab\u00f3n Yelitza. Leucodistrofia metacrom\u00e1tica infantil tar-\nd\u00eda: Presentaci\u00f3n de un caso. Arch Argent Pediatr. 2019;117(1).\n38.\n F\numagalli DF, Fumagalli AI, Biffi A, Cesani M, Corea F, Sessa M,\net al. Leucodistrofia metacrom\u00e1tica: del diagn\u00f3stico a la terapiag\u00e9nica como perspectiva terap\u00e9utica. 1982;6.\n39.\n ht\ntps://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=ES&-\nExpert=512. Orphanet: Leucodistrofia metacrom\u00e1tica [Internet].[cited 31 of December de 2018]. available in: https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=ES&Expert=512\n40.\n Ozgen H, Baron W\n, Hoekstra D, Kahya N. Oligodendroglial mem-\nbrane dynamics in relation to myelin biogenesis. Cell Mol Life Sci. 2016;73:3291-310.\n41.\n V\nos JP, Lopes-Cardozo M, Gadella BM. Metabolic and functional\naspects of sulfogalactolipids. Biochim Biophys Acta BBA - LipidsLipid Metab. 1994;1211(2):125-49.\n42.\n Sherman DL, Brophy P\nJ. Mechanisms of axon ensheathment and \nmyelin growth. Nat Rev Neurosci. 2005;6(9):683-90.\n43.\n Berntson Z, Hans\nson E, Ronnback L, Fredman P. Intracellular\nsulfatide expression in a subpopulation of astrocytes in primarycultures. J Neurosci Res. 1998;52(5):559-68.\n44.\n F\nullerton PM. Peripheral nerve conduction in metachromatic leu-\ncodystrophy (sulphatide lipidosis). J Neurol Neurosurg Psychia-try. 1964;27(2):100-5.\n45.\n P\nopovich PG, Jakeman LB, McTigue DM. Glial Responses to In-\njury. En: Encyclopedia of Neuroscience [Internet]. Elsevier; 2009[cited 26 July 2020]. p. 853-9. Available at: https://linkinghub.elsevier.com/retrieve/pii/B9780080450469000188\n46.\n Br\nady ST, Witt AS, Kirkpatrick LL, de Waegh SM, Readhead C, Tu\nP-H, et al. Formation of Compact Myelin Is Required for Maturationof the Axonal Cytoskeleton. J Neurosci. 1999;19(17):7278-88.\n47.\n Mik\noshiba K, Okano H, Tamura TA, Ikenaka K. Structure and Function \nof Myelin Protein Genes. Annu Rev Neurosci. 1991;14(1):201-17.\n48.\n Kr\n\u00e4mer E-M, Koch T, Niehaus A, Trotter J. Oligodendrocytes Di-\nrect Glycosyl Phosphatidylinositol-anchored Proteins to the My-elin Sheath in Glycosphingolipid-rich Complexes. J Biol Chem.1997;272(14):8937-45.\n49.\n T\naylor CM, Coetzee T, Pfeiffer SE. Detergent\n\u03b1\ninsoluble glyco-\nsphingolipid/cholesterol microdomains of the myelin membrane.J Neurochem. 2002;81(5):993-1004.\n50.\n W\nong YC, Kim S, Peng W, Krainc D. Regulation and Function of\nMitochondria\u2013Lysosome Membrane Contact Sites in Cellular Ho-meostasis. Trends Cell Biol. 2019;29(6):500-13.\n51.\n Plotegher N, Duchen MR. Cros\nstalk between Lysosomes and Mi-\ntochondria in Parkinson's Disease. Front Cell Dev Biol. 2017 [cited 11 April 2020];5. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732996/Metachromatic Leukodystrophy: Diagnosis and Treatment Challenges2090\n52. Deus CM, Y ambire KF, Oliveira PJ, Raimundo N. Mitochondria\u2013\nLysosome Crosstalk: From Physiology to Neurodegeneration.\nTrends Mol Med. enero de 2020;26(1):71-88.\n53.\n Plat\nt FM, d\u2019Azzo A, Davidson BL, Neufeld EF, Tifft CJ. Lysosomal \nstorage diseases. Nat Rev Dis Primer.  2018;4(1):27.\n54.\n Biffi A, Lucchini G\n, Rovelli A, Sessa M. Metachromatic leukodys-\ntrophy: an overview of current and prospective treatments. BoneMarrow Transpl. 2008;42(2):275.\n55.\n Lagr\nanha VL, Baldo G, de Carvalho TG, Burin M, Saraiva-Pereira\nML, Matte U, et al. In vitro correction of ARSA deficiency in human skin fibroblasts from metachromatic leukodystrophy patients af-ter treatment with microencapsulated recombinant cells. MetabBrain Dis. 2008;23(4):469-84.\n56.\n Eichler F\nS, Cox TM, Crombez E, Dali C\u00cd, Kohlsch\u00fctter A. Meta-\nchromatic Leukodystrophy: An Assessment of Disease Burden. J Child Neurol. 2016;31(13):1457-63.\n57.\n Bock\nenhoff A, Cramer S, Wolte P, Knieling S, Wohlenberg C,\nGieselmann V, et al. Comparison of Five Peptide Vectors for Im-proved Brain Delivery of the Lysosomal Enzyme Arylsulfatase A. J Neurosci. 2014;34(9):3122-9.\n58.\n Desnick RJ\n, Schuchman EH. Enzyme Replacement Therapy\nfor Lysosomal Diseases: Lessons from 20 Years of Experienceand Remaining Challenges. Annu Rev Genomics Hum Genet.2012;13(1):307-35.\n59.\n Biffi A, Montini E, Lorioli L, Cesani M, F\numagalli F, Plati T, et al.\nLentiviral Hematopoietic Stem Cell Gene Therapy Benefits Meta-chromatic Leukodystrophy. Science. 2013;341(6148). Availableat: http://science.sciencemag.org/content/341/6148/1233158.abstract\n60.\n K\nehrer C, Blumenstock G, Gieselmann V, Kr\u00e4geloh-Mann I, GER-\nMAN LEUKONET. The natural course of gross motor deteriora-tion in metachromatic leukodystrophy. Dev Med Child Neurol.2011;53(9):850-5.\n61.\n Efficac\ny METAZYM for the Treatment Metachromatic Leukodys-\ntrophy Treated With Hematopoietic Stem Cell Transplantation- No Study Results Posted - ClinicalTrials.gov [Internet]. [cited10 April 2020]. Available in: https://clinicaltrials.gov/ct2/show/results/NCT01303146\n62.\n Shire. A Single Center\n, Open-label, Non-randomized, Uncon-\ntrolled, Multiple-dose, Dose Escalation Study of the Safety, Phar-macokinetics and Efficacy of Metazym for the Treatment of Pa-tients With Late Infantile Metachromatic Leukodystrophy (MLD)[Internet]. clinicaltrials.gov; 2018 dic [citado 24 de julio de 2020]. Report No.: results/NCT00418561. Disponible en: https://clinical-trials.gov/ct2/show/results/NCT00418561\n63.\n P\natil SA, Maegawa GH. Developing therapeutic approach-\nes for metachromatic leukodystrophy. Drug Des Devel Ther.2013;7:729-45.\n64.\n Saftig P\n, Klumperman J. Lysosome biogenesis and lysosomal\nmembrane proteins: trafficking meets function. Nat Rev Mol CellBiol. 2009;10:623.\n65.\n Intr\nacerebral Gene Therapy for Children With Early Onset Forms\nof Metachromatic Leukodystrophy - Full Text View - ClinicalTri-als.gov [Internet]. [cited 27 January 2019]. Available at: https://clinicaltrials.gov/ct2/show/NCT01801709\n66.\n Asheuer M, Pflumio F\n, Benhamida S, Dubart-Kupperschmitt A,\nFouquet F, Imai Y, et al. Human CD34+ cells differentiate into mi-croglia and express recombinant therapeutic protein. Proc NatlAcad Sci U S A. 2004;101(10):3557-62.67.\n  S tem Cell Transplant for Inborn Errors of Metabolism - Full Text\nView - ClinicalTrials.gov [Internet]. [cited 27 January 2019].Available at: https://clinicaltrials.gov/ct2/show/NCT00176904\n68.\n Masonic Cancer Center\n, University of Minnesota. Treatment of\nLysosomal and Peroxisomal Inborn Errors of Metabolism by Bone Marrow Transplantation [Internet]. clinicaltrials.gov; 2017 dic[cited 24 July 2020]. Report No.: study/NCT00176904. Available at: https://clinicaltrials.gov/ct2/show/study/NCT00176904\n69.\n R\nauschka H, Colsch B, Baumann N, Wevers R, Schmidbauer\nM, Krammer M, et al. Late-onset metachromatic leukodys-trophy: Genotype strongly influences phenotype. Neurology.2006;67(5):859-63.\n70.\n Golebio\nwski D, Bradbury AM, Kwon C-S, van der Bom IMJ, Stoica \nL, Johnson AK, et al. AAV Gene Therapy Strategies for Lysosomal Storage Disorders with Central Nervous System Involvement. En: Bo X, Verhaagen J, editores. Gene Delivery and Therapy for Neu-rological Disorders [Internet]. New York, NY: Springer New York;2015 [cited 27 January 2019]. p. 265-95. (Neuromethods). Avail-able at: https://doi.org/10.1007/978-1-4939-2306-9_11\n71.\n R\nosenberg JB, Sondhi D, Rubin DG, Monette S, Chen A, Cram S,\net al. Comparative Efficacy and Safety of Multiple Routes of Di-rect CNS Administration of Adeno-Associated Virus Gene Trans-fer Vector Serotype rh.10 Expressing the Human ArylsulfataseA cDNA to Nonhuman Primates. Hum Gene Ther Clin Dev. 1 deseptiembre de 2014;25(3):164-77.\n72.\n R\nosenberg JB, Kaminsky SM, Aubourg P, Crystal RG, Sondhi D.\nGene Therapy for Metachromatic Leukodystrophy. J NeurosciRes. 2016;94(11):1169-79.\n73.\n Piguet F\n, Sondhi D, Piraud M, Fouquet F, Hackett NR, Ahouansou\nO, et al. Correction of Brain Oligodendrocytes by AAVrh.10 Intra-cerebral Gene Therapy in Metachromatic Leukodystrophy Mice.Hum Gene Ther. 2012;23(8):903-14.\n74.\n Sondhi D\n, Hackett NR, Peterson DA, Stratton J, Baad M, Travis\nKM, et al. Enhanced Survival of the LINCL Mouse Following CLN2 Gene Transfer Using the rh.10 Rhesus Macaque-derived Ade-no-associated Virus Vector. Mol Ther. 2007;15(3):481-91.\n75.\n Sondhi D\n, Johnson L, Purpura K, Monette S, Souweidane MM,\nKaplitt MG, et al. Long-Term Expression and Safety of Adminis-tration of AAVrh.10hCLN2 to the Brain of Rats and NonhumanPrimates for the Treatment of Late Infantile Neuronal Ceroid Li-pofuscinosis. Hum Gene Ther Methods. 2012;23(5):324-35.\n76.\n Ormond \nKE, Mortlock DP, Scholes DT, Bombard Y, Brody LC, Fau-\ncett WA, et al. Human Germline Genome Editing. Am J Hum Gen-et. 2017;101(2):167-76.\n77.\n Thur\ntle\n\u03b1\nSchmidt DM, Lo T. Molecular biology at the cutting\nedge: A review on CRISPR/CAS9 gene editing for undergraduates. Biochem Mol Biol Educ. 2018;46(2):195-205.\n78.\n Ashr\nafi MR, Amanat M, Garshasbi M, Kameli R, Nilipour Y, Heidari \nM, et al. An update on clinical, pathological, diagnostic, and ther-apeutic perspectives of childhood leukodystrophies. Expert RevNeurother. 2020;20(1):65-84.\n79.\n Manual de Pruebas Diagnos\nticas de Laboratorio Clinico. Alejan-\ndro Almarza; 130 p.\n80.\n Winzeler \nAM, Mandemakers WJ, Sun MZ, Stafford M, Phillips CT, \nBarres BA. The Lipid Sulfatide Is a Novel Myelin-Associated In-hibitor of CNS Axon Outgrowth. J Neurosci. 2011;31(17):6481-92.\nReceived: 15 march 2021\nAccepted: 10 July 2021Nayibe Tatiana Sanchez-Alvarez, Paula Katherine Bautista-Ni\u00f1o, Juanita Trejos-Su\u00e1rez, Norma Cecilia Serrano-Diaz\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2091\nTecnolog\u00eda IgY: Estrategia en el tratamiento de enfermedades infecciosas \nhumanas\nBiotechnological tools in the diagnosis, prevention, and treatment of pandemics\nPamela Molina1 and Marbel Torres Arias2 DOI. 10.21931/RB/2021.06.03.33\nResumen: Las pandemias son consideradas como un problema emergente de salud p\u00fablica a nivel mundial, las cuales adem\u00e1s \nde caracterizarse por tasas altas de morbilidad y mortalidad, ocasionan conflictos en los aspectos sociales, econ\u00f3micos y pol\u00edticos. Las herramientas biotecnol\u00f3gicas, por su parte, han ido evolucionando conforme al avance tecnol\u00f3gico-cient\u00edfico, lo que ha permitido optimizar m\u00e9todos de diagn\u00f3stico con alta sensibilidad y especificidad, adem\u00e1s de mejorar el desarrollo de productos biol\u00f3gicos para la prevenci\u00f3n y terapia de enfermedades. El objetivo de esta revisi\u00f3n es identificar la actualizaci\u00f3n de las herramientas biotecnol\u00f3gicas en el diagn\u00f3stico, tratamiento terap\u00e9utico y profil\u00e1ctico frente a los pat\u00f3genos causantes de las enfermedades pand\u00e9micas a lo largo de la historia, mediante la recopilaci\u00f3n de informaci\u00f3n cient\u00edfica. Con este estudio se logr\u00f3 establecer que las herramientas y productos de origen biotecnol\u00f3gico han constituido un papel fundamental en el control de pandemias a trav\u00e9s de la innovaci\u00f3n constante que ha permitido alcanzar resultados eficientes tanto en diagn\u00f3stico como en el tratamiento.\nPalabras clave: Diagn\u00f3stico, herramientas biotecnol\u00f3gicas, pandemias, productos biol\u00f3gicos, vacunas.Abstract: Pandemics are considered as an emerging public health problem worldwide, which in addition to being characterized \nby high rates of morbidity and mortality cause conflicts in social, economic and political aspects. Biotechnological tools, for \ntheir part, have evolved according to technological-scientific advance, which has allowed optimizing diagnostic methods with high sensitivity and specificity; in addition to improving the development of biological products for the prevention and therapy of diseases. The objective of this review is to identify the performance of biotechnological tools in the diagnosis, therapeutic and prophylactic treatment against pathogens that cause pandemic diseases throughout history, through the collection of scientific information. Finally, with this study it was possible to establish that tools and products of biotechnological origin have constituted an fundamental role in the control of pandemics through constant innovation that has allowed achieving efficient results in both diagnosis and treatment.\nKey words: Diagnostics, biotechnological tools, pandemics, biological products, vaccines.REVIEW / ART\u00cdCULO DE REVISI\u00d3N\nIntroducci\u00f3n\nLa manifestaci\u00f3n de enfermedades infecciosas a lo lar-\ngo de la historia de la humanidad adem\u00e1s de ser una de las \nprincipales causas de mortalidad y morbilidad1,2, han dejado \nsecuelas letales y duraderas en el \u00e1mbito social, econ\u00f3mico y pol\u00edtico, siendo las de mayor proporci\u00f3n las enfermedades que han sido capaces de provocar pandemias\n3\u20135. Es as\u00ed que una de \nlas cat\u00e1strofes m\u00e1s devastadoras que ha golpeado al mundo es la peste negra, en el siglo XIV, ocasionando el fallecimiento del 30-50% de la poblaci\u00f3n europea de la \u00e9poca, en un corto periodo de tiempo (1347-1351)\n6.\nEl desarrollo de enfermedades infecciosas emergentes \npuede ocurrir por tres eventos claves: 1) el cruce de barreras geogr\u00e1ficas debido a la invasi\u00f3n de espacios silvestres, 2) el cruce de barreras por compatibilidad gracias a la evoluci\u00f3n y 3) el levantamiento de barreras por el cambio de condicionesambientales que favorecen la formaci\u00f3n del nicho ecol\u00f3gicoadecuado, siendo la primera la que define la situaci\u00f3n\n7. Jones\net \nal.8 concluyeron en su investigaci\u00f3n que el 60,3% de enfer-\nmedades infecciosas son originadas por pat\u00f3genos zoon\u00f3ticosy el 71.8% de estas son de origen silvestre, lo que indica queestos microorganismos figuran una amenaza potencial para lasalud mundial, con perspectiva a la manifestaci\u00f3n de epide-mias y posibles pandemias, en caso de no tomar las medidas precautelares.\nDurante el origen de una epidemia y/o pandemia, el diag-\nn\u00f3stico temprano, el tratamiento, el seguimiento epidemiol\u00f3-gico y la prevenci\u00f3n de futuras infecciones han sido procesos fundamentales para el manejo cl\u00ednico, control y mitigaci\u00f3n de la enfermedad\n9,10. Aqu\u00ed la biotecnolog\u00eda juega un papel \nfundamental, por lo que en este estudio se consideran las herramientas biotecnol\u00f3gicas modernas empleadas en el de-sarrollo de pruebas de diagn\u00f3stico, producci\u00f3n de mol\u00e9culas biotecnol\u00f3gicas para el tratamiento y en el dise\u00f1o de vacunas. Con el objetivo de identificar la evoluci\u00f3n y optimizaci\u00f3n a tra-v\u00e9s del tiempo de las herramientas biotecnol\u00f3gicas  cuando nos enfrentamos a infecciones a nivel pand\u00e9mico, mediante la comparaci\u00f3n de sensibilidad y especificidad de los diferentes enfoques establecidos para el diagn\u00f3stico, y la recopilaci\u00f3n de los resultados de los principales productos biotecnol\u00f3gicos llevados a ensayos cl\u00ednicos en cada enfermedad.\nPara la redacci\u00f3n del art\u00edculo se llev\u00f3 a cabo una revisi\u00f3n \nbibliogr\u00e1fica exhaustiva en revistas de alto impacto, en las que se tom\u00f3 en cuenta: art\u00edculos originales, revisiones, res\u00famenes de conferencias y dem\u00e1s. Obteni\u00e9ndose datos actualizados de \n1 Departamento de Ciencias de la Vida y la Agricultura, Carrera de Ingenier\u00eda en Biotecnolog\u00eda, Universidad de las Fuerzas Armadas ESPE, Ecuador. \n2 Departamento de Ciencias de la Vida y la Agricultura, Carrera de Ingenier\u00eda en Biotecnolog\u00eda, Universidad de las Fuerzas Armadas ESPE, Ecuador y Laboratorio de \nInmunolog\u00eda y Virolog\u00eda, CENCINAT, GISAH, Universidad de las Fuerzas Armadas, ESPE, Ecuador.\nCorresponding author: mmtorres@espe.edu.ecHerramientas biotecnol\u00f3gicas en el diagn\u00f3stico, prevenci\u00f3n y tratamiento frente a pandemias\nBiotechnological tools in the diagnosis, prevention, and treatment of pandemics2092\nPamela Molina and Marbel Torres Arias\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nnueva tecnolog\u00eda desarrollada para diagn\u00f3stico,  tratamientos \nbiol\u00f3gicos, desarrollo de vacunas  y su influencia en el manejo \nde epidemias y pandemias para apoyar al control de la Salud \nPublica.\nEpidemias y pandemias importantes a partir de 1950\nEl t\u00e9rmino epidemia se refiere a \u201cun brote de una enfer-\nmedad (especialmente una enfermedad infecciosa) que afec-\nta a un gran n\u00famero de personas dentro de una poblaci\u00f3n al \nmismo tiempo\u201d11. Por otro lado, pandemia se define como \u201cuna \nepidemia que ocurre en un \u00e1rea muy amplia, cruzas fronteras \ninternacionales y generalmente afecta a un gran n\u00famero de \npersonas\u201d12.\nExisten condiciones imprescindibles para la aparici\u00f3n de \nuna epidemia, entre las caracter\u00edsticas se hallan: transmisi\u00f3n \neficiente entre humanos, un \u00edndice significativo de letalidad, fal-\nta de un tratamiento m\u00e9dico efectivo, una poblaci\u00f3n inmunol\u00f3gi-\ncamente deprimida y una forma de diseminaci\u00f3n r\u00e1pida13.\nEs asi que, una pandemia se entiende como una enferme-\ndad que ha alcanzado los cinco continentes, mientras que una \nepidemia es una enfermedad se esparce localmente11,12.\nA continuaci\u00f3n, se abordar\u00e1n el diagn\u00f3stico (Tabla 1), tra-\ntamientos biol\u00f3gicos (Tabla 2) y vacunas (Tabla 3) de las pan-\ndemias y epidemias m\u00e1s importantes en \u00e9poca cronol\u00f3gica, a \npartir del inicio de la biotecnolog\u00eda moderna (Figura 1).\nH1N1 (1918-1919)\nLa pandemia de influenza m\u00e1s grave de la historia fue \nla gripe espa\u00f1ola H1N1 en 191814, cubri\u00f3 el mundo en cuatro \nmeses cobrando aproximadamente de 50 a 100 millones de vidas15. La falta de recursos limit\u00f3 la identificaci\u00f3n del origen \nde la gripe con lo que se hizo imposible el hallazgo de vacunas, \nadem\u00e1s, no se logr\u00f3 controlar las infecciones secundarias con \nneumon\u00eda bacteriana debido a que la penicilina no se descubri\u00f3 \nhasta 1928. A pesar del esfuerzo de las compa\u00f1\u00edas farmac\u00e9u-\nticas el virus desapareci\u00f3 antes de conseguir aislarlo14.\nH2N2 (1957-1960)\nSegunda gran pandemia de influenza registrada, la gripe \nasi\u00e1tica surgi\u00f3 en Singapur a finales de febrero de 1957 y dur\u00f3 \nhasta 1960, fue provocada por un subtipo de virus de la in-\nfluenza A, denominado H2N216,17. A nivel mundial se registra-\nron 1,1 millones de fallecimientos18.\nEl diagn\u00f3stico de la enfermedad se ejecut\u00f3 mediante prue-\nbas serol\u00f3gicas de laboratorio. La identificaci\u00f3n de anticuerpos \ncontra el ant\u00edgeno viral del subtipo H2N2 a partir de suero de \npersonas afectadas se realiz\u00f3 con la t\u00e9cnica de fijaci\u00f3n del \ncomplemento (FC) y la prueba de inhibici\u00f3n de la hemagluti-\nnaci\u00f3n (HAI) con el uso de tripsina y periodato de potasio para \nla inactivaci\u00f3n de inhibidores espec\u00edficos19,20. Los estudios y la \nexperiencia de campo demostraron que la FC present\u00f3 mayor \nsensibilidad, sin embargo, existieron casos en los que se requi-\nrieron de las dos t\u00e9cnicas para un diagn\u00f3stico confirmatorio20.\nTratamiento terap\u00e9utico y profil\u00e1ctico\nLa mortalidad de la pandemia de  gripe asi\u00e1tica se redujo \naproximadamente un 97% en comparaci\u00f3n con la pandemia de \ngripe espa\u00f1ola15. Una de las aportaciones fundamentales en \nel control de la propagaci\u00f3n de la influenza asi\u00e1tica fue el r\u00e1-\npido proceso de preparaci\u00f3n y distribuci\u00f3n de la vacuna frente \nFigura 1. Las principales pandemias a partir de 1950. Origen y n\u00famero de muertes a nivel mundial.2093\nal virus H2N2, se estima que en julio de 1957 inici\u00f3 el primer \nestudio cl\u00ednico21,22.\nExistieron varias vacunas inactivadas de influenza en en-\nsayos en humanos, desarrolladas a partir de l\u00edquido alantoideo \nde embriones de pollo infectados con diferentes cepas de in-\nfluenza23,24. Entre las que se encontraron vacunas monovalen-\ntes21\u201323,25 y polivalentes, en el caso de las polivalentes en algu-\nnas se incluy\u00f3 el virus H2N225. Para la inactivaci\u00f3n del virus se \nmanejaron t\u00e9cnicas como irradiaci\u00f3n ultravioleta21 y el empleo \nde formalina22,23,25.\nLas vacunas fueron probadas con diversas concentracio-\nnes de unidades de aglutinaci\u00f3n de c\u00e9lulas de pollo (CCA) por \nmililitro, oscilando entre 200 CCA a 750 CCA24, los resulta-\ndos evidenciaron un porcentaje de eficacia estimado de 42% \na 77%24. Asimismo, se observ\u00f3 que la protecci\u00f3n inducida era \ndirectamente proporcional a la dosis administrada de vacuna \nante la presencia de una cepa de H2N2, estos datos se evalua-\nron mediante FC e HAI, en los que se determinaron el aumento \nde los niveles de anticuerpos contra el virus de la influenza \nasi\u00e1tica posterior a la vacunaci\u00f3n en pacientes participan-\ntes21,23,25.  \nDebido a que Centro Am\u00e9rica y Sudam\u00e9rica no contaban \ncon los recursos ni la tecnolog\u00eda para el desarrollo de una va-\ncuna, y sumando los problemas serios en la salud p\u00fablica, los \nsistemas de control no fueron efectivos como en Norteam\u00e9ri-\nca. Por lo que, solo grupos selectos de personas en Chile, Bra-\nsil y Argentina accedieron al medicamento26.H3N2 (1968-1970)     \nLa siguiente pandemia provocada por un virus de la in-\nfluenza A surgi\u00f3 en julio de 1968 al sureste de China, con el \nsubtipo H3N2, extendi\u00e9ndose hasta 1970. La enfermedad \nse denomin\u00f3 gripe de Hong Kong, la cual provoc\u00f3 entre 1 y \n4 millones de muertes a nivel mundial27,28. El diagn\u00f3stico se \nbas\u00f3 en la identificaci\u00f3n de s\u00edntomas combinado con ensayos \nserol\u00f3gicos. Para la detecci\u00f3n de anticuerpos contra el virus \nH3N2 se emple\u00f3 HAI y FC, con el uso de ant\u00edgenos obtenidos \ndel l\u00edquido alantoideo de huevo de las variantes aisladas de las \ndiferentes propagaciones. Dando mejores resultados la HAI, \nsin embargo, fue recomendable realizar los dos m\u00e9todos para \nobtener una m\u00e1xima eficiencia en el serodiagn\u00f3stico29.\nTratamiento terap\u00e9utico y profil\u00e1ctico\nPosterior al aislamiento viral y la confirmaci\u00f3n de la apari-\nci\u00f3n de H3N2, una variante antig\u00e9nica del virus de la influenza \ncon potencial epid\u00e9mico, la cepa aislada fue distribuida a los \nlaboratorios para la investigaci\u00f3n y producci\u00f3n de vacunas27,30. \nEn EE. UU., en noviembre del mismo a\u00f1o estuvo disponible \nel primer lote de producci\u00f3n con 110 000 dosis, se trat\u00f3 de \nuna vacuna inactivada monovalente de 400 CCA, desarrollada \nen huevos f\u00e9rtiles de gallina con la cepa Aichi de la influenza \nH3N2. A diferencia de la anterior pandemia, en esta ocasi\u00f3n \nexisti\u00f3 un mayor n\u00famero de vacunados, principalmente perso-\nnas pertenecientes al grupo prioritario. Las semanas siguien-\ntes al lanzamiento del primer lote se produjeron y comerciali-\nTabla 1. Especificidad y sensibilidad de las herramientas biotecnol\u00f3gicas frente al diagn\u00f3stico de pandemias.Herramientas biotecnol\u00f3gicas en el diagn\u00f3stico, prevenci\u00f3n y tratamiento frente a pandemias\nBiotechnological tools in the diagnosis, prevention, and treatment of pandemics2094\nTabla 2. Principales ensayos cl\u00ednicos de herramientas biotecnol\u00f3gicas usadas como tratamiento terap\u00e9utico y profil\u00e1ctico de pandemias.Pamela Molina and Marbel Torres Arias\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2095\nzaron alrededor de 123 millones de dosis30.\nMaassab et al.31 dise\u00f1aron y probaron una vacuna de in-\nfluenza viva atenuada desarrollada en huevos de gallina. La \natenuaci\u00f3n de una l\u00ednea del virus de Hong Kong se llev\u00f3 a cabo \nmediante cambios abruptos en la temperatura de incubaci\u00f3n \nde la cepa viral, esta t\u00e9cnica acort\u00f3 el proceso a 3 meses, en \ncomparaci\u00f3n con m\u00e9todos anteriores que empleaban cambios \ndecrecientes de temperatura de forma gradual, las cuales du-\nraban de 6 a 8 meses. Los ensayos cl\u00ednicos de esta vacuna de-\nmostraron aceptabilidad e inmunogenicidad de la cepa atenua-\nda, por lo que este proceso se consider\u00f3 prometedor para el \ndesarrollo futuro de vacunas contra la influenza. Por otro lado, \nse aprob\u00f3 la aplicaci\u00f3n de vacunas de virus fraccionados, me-\ndiante \u00e9ter32 o desoxicolato de sodio33, que se conformaron de \nfragmentos espec\u00edficos del virus capaces activar la inmunidad \nde forma m\u00e1s segura. Las respuestas inmunol\u00f3gicas inducidas \npor dichas vacunas fueron tan eficientes como las desarrolla-\ndas por las vacunas convencionales, constituidas por el virus \ncompleto, adem\u00e1s se observ\u00f3 menos efectos secundarios des-\npu\u00e9s de la vacunaci\u00f3n32,33.\nOtra de las investigaciones que marc\u00f3 el control de fu-\nturas epidemias y pandemias, fue el uso de recombinaci\u00f3n \ngen\u00e9tica para la facricaci\u00f3n de una vacuna34,35. Este avance \nmostr\u00f3 que la producci\u00f3n de variantes gen\u00e9ticas adecuadas \npara la construcci\u00f3n de una vacuna, fue posible desarrollarlas \nde forma deliberada34, sustituyendo a m\u00e9todos de selecci\u00f3n \ntradicionales30. La construcci\u00f3n del virus recombinante de alto \nrendimiento (X-31) se realiz\u00f3 mediante el reordenamiento ge-\nn\u00e9tico de una cepa est\u00e1ndar de laboratorio de alto rendimiento \n(A0 / PR / 8), la cual proporcion\u00f3 los genes de adaptaci\u00f3n y \ncrecimiento; con la cepa Aichi del virus de Hong Kong, con-\nsiderada como una cepa de bajo rendimiento, la cual aport\u00f3 \nlos genes que codificar\u00edan el nuevo ant\u00edgeno de inter\u00e9s34. Los \nensayos cl\u00ednicos de una vacuna inactivada recombinante con el virus X-31 mostraron ausencia de toxicidad, alta antigenicidad \ny protecci\u00f3n frente a la influenza35.\nSARS-CoV-1 (epidemia 2002-2003)\nEl s\u00edndrome respiratorio agudo severo (SARS), provocado \npor el coronavirus del SARS (SARS-CoV) fue la primera gran \nepidemia del siglo XXI, apareci\u00f3 en Guangdong-China en no-\nviembre de 2002 y finaliz\u00f3 en julio de 2003, hasta donde se \nregistraron 8437 infectados y 813 muertes a nivel mundial36,37.\nPara el diagn\u00f3stico de la infecci\u00f3n por SARS-CoV la Or-\nganizaci\u00f3n Mundial de la Salud (OMS) estableci\u00f3 tres ensayos \nde laboratorio, entre los que se encontraron: pruebas mole-\nculares, pruebas de anticuerpos y cultivo celular38, a partir de \ndiferentes muestras cl\u00ednicas como esputo, aspirado o lavado \nnasofar\u00edngeo, hisopos nasofar\u00edngeos y orofar\u00edngeos, lavado \nbronquio alveolar, heces, orina y suero o plasma39\u201341.\nUna de las t\u00e9cnicas modernas fue la detecci\u00f3n de ARN \ndel coronavirus mediante RT-PCR dirigida al gen de la nucleo-\nc\u00e1pside (N) o al marco abierto de lectura (ORF) 1b, con la que \nse consigui\u00f3 alta especificidad; sin embargo, la sensibilidad fue \ninferior a la necesaria en los primeros d\u00edas del desarrollo de \nla infecci\u00f3n. Esta prueba se optimiz\u00f3 con el an\u00e1lisis de m\u00e1s \nde una muestra originaria del mismo paciente, o con la doble \nejecuci\u00f3n del ensayo, logrando el aumento de la sensibilidad \ndel diagn\u00f3stico39,40. Otra forma de mejorar la sensibilidad y \nprecisi\u00f3n del examen molecular fue el perfeccionamiento de \nlos m\u00e9todos de extracci\u00f3n de ARN previo a la qRT-PCR, faci-\nlitando la cuantificaci\u00f3n de la carga viral y el reconocimiento \nprecoz del SARS, por lo que se convirti\u00f3 en el ensayo pilar para \nel diagn\u00f3stico prematuro de la enfermedad41.\nEn el aislamiento viral a partir de cultivo celular se em-\nplearon muestras cl\u00ednicas para infectar c\u00e9lulas c\u00f3mo c\u00e9lulas \nde ri\u00f1\u00f3n fetal de mono rhesus (FRhK-4) o c\u00e9lulas Vero E6, en \nlas que se analiz\u00f3 el efecto citop\u00e1tico y se realiz\u00f3 tinci\u00f3n por \nTabla 2. Principales ensayos cl\u00ednicos de herramientas biotecnol\u00f3gicas usadas como tratamiento terap\u00e9utico y profil\u00e1ctico de pandemias.Herramientas biotecnol\u00f3gicas en el diagn\u00f3stico, prevenci\u00f3n y tratamiento frente a pandemias\nBiotechnological tools in the diagnosis, prevention, and treatment of pandemics2096\nTabla 3. Desarrollo de vacunas frente a pandemias.Pamela Molina and Marbel Torres Arias\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\n2097\nTabla 3. Desarrollo de vacunas frente a pandemias.Herramientas biotecnol\u00f3gicas en el diagn\u00f3stico, prevenci\u00f3n y tratamiento frente a pandemias\nBiotechnological tools in the diagnosis, prevention, and treatment of pandemics\n2098\ninmunofluorescencia. Los resultados indicaron un rendimiento \nmenor en comparaci\u00f3n con los ensayos moleculares, debido a \nque \u00fanicamente muestran la presencia del virus vivo39,42. Final-\nmente, la detecci\u00f3n de seroconversi\u00f3n fue la prueba est\u00e1ndar \npara la confirmaci\u00f3n virol\u00f3gica retrospectiva de la infecci\u00f3n \npor SARS-CoV, se manej\u00f3 ELISA e IFI para la identificaci\u00f3n de \nanticuerpos IgG, los cuales se reconocieron despu\u00e9s de la pri-\nmera semana de infecci\u00f3n39,43,44.\nTratamiento terap\u00e9utico y profil\u00e1ctico\nDebido a que no existi\u00f3 un tratamiento espec\u00edfico para \nel SARS, se probaron varios agentes inmunomoduladores y \ncompuestos con potencial antiv\u00edrico45,46. La terapia con plas-\nma convaleciente fue una de las alternativas de tratamiento \ny prevenci\u00f3n. La administraci\u00f3n antes de los 14 d\u00edas desde el \ninicio de la infecci\u00f3n o durante la fase vir\u00e9mica y seronegativa, \npresent\u00f3 una tasa de alta m\u00e9dica m\u00e1s temprana y una tasa \nde mortalidad menor en comparaci\u00f3n con los pacientes que \nrecibieron el plasma posterior a los 14 d\u00edas. Adem\u00e1s, no se \nevidenci\u00f3 efectos secundarios inmediatos despu\u00e9s de la apli-\ncaci\u00f3n del plasma46. Por otro lado, la pentaglobulina se admi-\nnistr\u00f3 como una soluci\u00f3n enriquecida en IgM a 12 pacientes en \netapa grave de SARS. Diez personas tuvieron una recuperaci\u00f3n \nfavorable sin eventos adversos, posterior al tratamiento. Como \nevidencia se estableci\u00f3 el progreso relevante en las puntuacio-\nnes radiogr\u00e1ficas y en el requerimiento de ox\u00edgeno47.\nEn el caso del tratamiento profil\u00e1ctico, se produjeron \nvarias vacunas candidatas contra el SARS-CoV. Zhou et al.48 \nllevaron a cabo estudios precl\u00ednicos de una vacuna inactivada \ncon formaldeh\u00eddo, en monos Rhesus. Los resultados expusie-\nron que a una dosis de 50 \u03bcg, la vacuna fue capaz de inducir \ninmunidad humoral espec\u00edfica 7 d\u00edas despu\u00e9s de la primera \ninmunizaci\u00f3n y el t\u00edtulo de anticuerpos IgG se elev\u00f3 posterior a \nla segunda inmunizaci\u00f3n; mientras que con la administraci\u00f3n \nde dosis de 0.5 y 5 \u03bcg se observ\u00f3 inmunidad parcial. Adem\u00e1s, \nno se presenci\u00f3 efectos adversos significativos en los animales \ninmunizados hasta con una dosis de 5000 \u03bcg y en el 41.7% de \nlos monos que recibieron la vacuna se determin\u00f3 anticuerpos \nIgA anti-SARS-V en las mucosas nasofar\u00edngeas.\nYang et al.49 experimentaron una vacuna de ADN que \ntradujo la glicoprote\u00edna Spike (S) del SARS-CoV, en modelos \nanimales, la cual estimul\u00f3 respuestas de c\u00e9lulas T, produc-\nci\u00f3n de anticuerpos neutralizantes e inmunidad protectora. La \nreplicaci\u00f3n viral se redujo seis veces en los pulmones de los \nratones inmunizados despu\u00e9s de la infecci\u00f3n por el coronavi-\nrus. Las vacunas de vectores virales fueron otra opci\u00f3n, Gao \net al.50, desarrollaron tres vectores basados en adenovirus, los \nque expresaron prote\u00ednas antig\u00e9nicas de estructura del SARS-\nCoV con codones optimizados, entre las que se encontraron el fragmento S1 de la prote\u00edna S, la prote\u00edna de membrana (M) y \nla prote\u00edna N. La inmunizaci\u00f3n se realiz\u00f3 con una combinaci\u00f3n \nde los tres vectores en macacos Rhesus al d\u00eda 0, y una vacu-\nna de refuerzo con el mismo r\u00e9gimen a los 28 d\u00edas. En todos \nlos animales tratados se encontr\u00f3 anticuerpos neutralizantes \nespec\u00edficos contra el fragmento S1 y respuesta de c\u00e9lulas T \ncontra la prote\u00edna N, al mismo tiempo, todas las muestras de \nsuero de los animales vacunados mostraron una gran capaci-\ndad neutralizante contra el virus SARS-CoV.\nA pesar de que no se logr\u00f3 llegar a ensayos cl\u00ednicos duran-\nte esta pandemia, en a\u00f1os posteriores dos vacunas lograron \ndesarrollar estudios cl\u00ednicos fase 1 (Tabla 3).\nH1N1 (2009-2010)\nEl virus de la influenza A H1N1 de origen porcino apareci\u00f3 \npor primera vez en abril de 2009 en los Estados Unidos y en \nM\u00e9xico51, la pandemia finaliz\u00f3 en agosto de 2010, sin embargo, \nel virus contin\u00faa circulando y provocando la gripe estacional52. \nSe estima que la pandemia dej\u00f3 151 700 - 575 500 muertes a \nnivel mundial53.\nLa OMS54 estableci\u00f3 varias pruebas de laboratorio para la \nconfirmaci\u00f3n de la infecci\u00f3n causada por el virus de influenza \nde origen porcino (S-OIV) H1N1. Entre las que se encontraron:  \ndiagn\u00f3stico molecular con ensayos de RT-PCR y qRT-PCR;  \naislamiento y la tipificaci\u00f3n viral, detecci\u00f3n de ant\u00edgenos para \nlo que se recomendaron pruebas r\u00e1pidas de flujo lateral e IFD, \ny  finalmente ensayos serol\u00f3gicos como HAI y micro-neutra-\nlizaci\u00f3n para la evaluaci\u00f3n de t\u00edtulos de anticuerpos contra \nS-OIV. Las muestras de v\u00edas respiratorias superiores fueron las \nm\u00e1s recomendadas, como aspirados e hisopos nasofar\u00edngeos, \nhisopos nasales o de garganta; adem\u00e1s se emple\u00f3 muestras \nde suero en pacientes convalecientes para el reconocimiento \nde t\u00edtulos de anticuerpos55.  \nLa qRT-PCR fue la prueba de referencia para el diagn\u00f3s-\ntico de la influenza A (H1N1), la identificaci\u00f3n de diferentes \ngenes diana fue apropiado para el diagn\u00f3stico preciso54,56. La \nprimera prueba de este tipo aprobada por la Administraci\u00f3n \nde Alimentos y Medicamentos (FDA) con una autorizaci\u00f3n de \nuso de emergencia (EAU), fue realizada por los Centros para el \nControl y Prevenci\u00f3n de Enfermedades (CDC) y fue dirigida al \ngen de la prote\u00edna M, la cual mostr\u00f3 una sensibilidad 99.3% y \nuna especificidad del 92.3%, se trat\u00f3 de un ensayo singleplex \npara la tipificaci\u00f3n y subtipificaci\u00f3n viral57\u201359. Para el diagn\u00f3sti-\nco mediante cultivo viral, la OMS recomend\u00f3 aislar el virus en \nc\u00e9lulas de ri\u00f1\u00f3n canino Madin-Darby (MDCK) en presencia de \ntripsina o en huevos embrionados54. Entre las desventajas de \nesta t\u00e9cnica se establecieron el tiempo tard\u00edo para la obten-\nci\u00f3n de resultados (3-14 d\u00edas) y la baja sensibilidad58.\nLas pruebas r\u00e1pidas de diagn\u00f3stico de influenza (RIDTS) Pamela Molina and Marbel Torres Arias\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nTabla 3. Desarrollo de vacunas frente a pandemias.2099\nmostraron una sensibilidad variable y menor que las pruebas \nmoleculares y el cultivo viral, por lo que un resultado nega-\ntivo no descart\u00f3 la infecci\u00f3n por el virus de la influenza A \n(H1N1)57,60. Vasoo et al.61 evaluaron tres RIDTS para el virus de \nla influenza pand\u00e9mica A/H1N1 en muestras positivas  confir-\nmadas con RT-PCR. Las sensibilidades halladas estuvieron en \nun nivel de bajo a moderado (46.7%, 38.3% y 53.3%) y presen-\ntaron una excelente especificidad, sin reactividad cruzada con \notros virus estacionales. El ensayo de IFD, otra de las pruebas \npara la detecci\u00f3n de ant\u00edgenos mostr\u00f3 amplia disponibilidad y \nun tiempo de procesamiento promedio de 2-4 horas, sin em-\nbargo, al igual que las RIDTS no fueron capaces de distinguir la \ninfluenza H1N1 2009 de otros virus de la influenza A62. \nTratamiento terap\u00e9utico y profil\u00e1ctico\nUn porcentaje de la poblaci\u00f3n mayor a los 65 a\u00f1os pose\u00edan \nanticuerpos contra el nuevo virus de esta influenza pand\u00e9mica, \nesto pudo ser posible por la exposici\u00f3n anterior al virus H1N1 \nen 191852. Debido a la aparici\u00f3n del S-OIV H1N1 en humanos \ncon una composici\u00f3n gen\u00e9tica previamente no conocida, dife-\nrente al virus de la influenza A estacional63; adem\u00e1s de la f\u00e1cil \ntransmisibilidad entre humanos64, el sistema de salud mundial \ninici\u00f3 r\u00e1pidamente el desarrollo de antivirales y de una nueva \nvacuna para el tratamiento y prevenci\u00f3n de la infecci\u00f3n.  \nLa terapia con inmunoglobulina intravenosa hiperinmune \n(H-IVIG) obtenida a partir de plasma convaleciente de perso-\nnas recuperadas fue probado como una alternativa antiviral \nen pacientes con infecci\u00f3n por la influenza pand\u00e9mica, los re-\nsultados mostraron que la administraci\u00f3n de H-IVIG dentro de \nlos 5 d\u00edas posteriores al inicio de los s\u00edntomas se asoci\u00f3 a una \ndisminuci\u00f3n de la carga viral y reducci\u00f3n de mortalidad65. De \nigual manera, la administraci\u00f3n de plasma convaleciente con \nun t\u00edtulo de  anticuerpos neutralizantes \u2265 1:160 en pacientes \nafectados, disminuy\u00f3 la carga  viral, las respuestas de citoci-\nnas s\u00e9ricas y la mortalidad66.\nPara el control de esta pandemia se autorizaron dos tipos \nde vacunas monovalentes, un grupo de vacunas inactivadas di-\nvididas de administraci\u00f3n intramuscular y otro grupo de vacu-\nnas atenuadas en aerosol de administraci\u00f3n intranasal67.\nEn septiembre de 2009, la FDA aprob\u00f3 las primeras va-\ncunas para el tratamiento contra la gripe porcina con la cepa \nA / California / 7/2009 (H1N1)68,69, entre las que se encontra-\nron tres vacunas monovalentes, inactivadas y sin adyuvante, \nfabricadas por Sanofi Pasteur70, Novartis Vaccines and Diag-\nnostics Limited68 y CSL Limited71, con 15 \u03bcg de hemaglutinina \n(HA), y la cuarta fue una vacuna, monovalente, viva atenuada \ny sin adyuvante elaborada por MedImmune LLC72. En Europa \nla Agencia Europea de Medicamentos (EMA) aprob\u00f3 vacunas \ncon adyuvantes en una emulsi\u00f3n aceite-agua, una de ellas con \nMF59 y 7.5 \u03bcg de HA desarrollada por Novartis Vaccines73, y \notra con AS03 y 3.75 \u03bcg de HA fabricada por GlaxoSmithKline \n(GSK) Biologicals74. Una revisi\u00f3n sistem\u00e1tica identific\u00f3 que las \nvacunas inactivadas monovalentes A (H1N1) pdm09 fueron \nefectivas para prevenir la influenza pand\u00e9mica. En los ni\u00f1os, \nlas vacunas con adyuvante fueron m\u00e1s efectivas en compa-\nraci\u00f3n con las vacunas sin adyuvante 75. Por otro lado, otro \nestudio que analiz\u00f3 la efectividad de una vacuna inactivada \ncon adyuvante y una atenuada, mostr\u00f3 que las vacunas fueron \neficaces para prevenir la infecci\u00f3n confirmada por la influenza \npand\u00e9mica A (H1N1) 2009 a a partir de una semana despu\u00e9s \nde la vacunaci\u00f3n74.\nMERS-CoV (epidemia 2012-2021)\nLa epidemia S\u00edndrome Respiratorio de Medio Oriente (MERS) fue causada por el coronavirus del MERS (MERS-CoV), \ndescrito por primera vez en Arabia Saudita en junio de 201276, \ncontin\u00faa vigente hasta la fecha. La mayor\u00eda de casos apare-\ncen en el Medio Oriente debido a la exposici\u00f3n directa de sus \nhabitantes a fuentes zoon\u00f3ticas. Hasta la actualidad se han \nnotificado 2566 casos confirmados y 882 muertes77.\nEntre las pruebas de laboratorio empleadas para la detec-\nci\u00f3n de MERS se encuentran las moleculares y las serol\u00f3gicas. \nLos ensayos moleculares se utilizan para el diagn\u00f3stico de la \ninfecci\u00f3n viral activa en personas con s\u00edntomas cl\u00ednicos o que \nhan estado en contacto con casos confirmados con MERS-CoV. \nPor otra parte, los estudios serol\u00f3gicos llevados a cabo por la \ndetecci\u00f3n de anticuerpos, se aplican con fines de vigilancia e \ninvestigaci\u00f3n, y no de diagn\u00f3stico78.\nEl ensayo de qRT-PCR a partir de muestras respiratorias \ninferiores, superiores, suero y heces, ha sido la t\u00e9cnica tradi-\ncional en el diagn\u00f3stico de MERS-CoV. Para la confirmaci\u00f3n \nde la infecci\u00f3n se requiere un resultado positivo de qRT-PCR \npara dos regiones gen\u00f3micas \u00fanicas y espec\u00edficas del virus, o \nun resultado positivo para una sola diana y la secuenciaci\u00f3n de \notra78,79. Entre las dianas gen\u00e9ticas recomendadas para la de-\ntecci\u00f3n primaria del MERS se encuentran las regiones aguas \narriba del gen de la prote\u00edna E (UpE) y el gen N79,80, mientras \nque las pruebas confirmatorias se orientaron al ORF1a, ORF1b \no al gen N79,81.\nSe han investigado otras posibles t\u00e9cnicas moleculares \napropiadas para el diagn\u00f3stico. Por ejemplo, la RT-RPA mostr\u00f3 \nuna especificidad comparable a la de la RT-PCR, con benefi-\ncios adicionales como el corto tiempo de determinaci\u00f3n (3-7 \nminutos) y la facilidad de movilidad82. La RT-LAMP fue posible \nllevarla a cabo en menos de una hora, con una alta especifi-\ncidad y sin reacciones cruzadas83. Huang et al.84 optimizaron \ndicha t\u00e9cnica, y establecieron un ensayo de visualizaci\u00f3n de \n\u00e1cidos nucleicos con la combinaci\u00f3n del ensayo RT-LAMP y \nuna tira de visualizaci\u00f3n de flujo vertical (RT-LAMP-VF), con el \nfin de detectar el gen N del MERS-CoV, con alta especificidad, \nen un tiempo estimado de 35 minutos y sin el empleo de equi-\npos de alto costo.\nTratamiento terap\u00e9utico y profil\u00e1ctico\nLa atenci\u00f3n de apoyo y la prevenci\u00f3n de complicaciones, \ncomo el s\u00edndrome de dificultad respiratoria y las infecciones \nnosocomiales son las principales estrategias para prevenir la \nepidemia del MERS. Hasta el momento, se han registrado va-\ncunas y antivirales en fase de desarrollo85\u201387.\nVarias de las opciones de tratamiento, se han basado en \nanticuerpos neutralizantes88,89. En  el brote de Corea en el \n2015, se evalu\u00f3 la infusi\u00f3n de plasma convaleciente en  3 de 13 \npacientes con insuficiencia respiratoria producto del MERS. El \nempleo  de plasma con un t\u00edtulo en la prueba de neutralizaci\u00f3n \npor reducci\u00f3n de placa  (PRNT) de 1:80 revel\u00f3 una respues-\nta serol\u00f3gica significativa en comparaci\u00f3n  con el de un t\u00edtulo \nPRNT de 1:40. Los autores recomendaron el uso de plasma  \nconvaleciente de donantes con una actividad neutralizante \nPRNT \u22651: 80 para  conseguir resultados eficaces90.  Por otro \nlado, de Wit et al.91 evaluaron la eficacia terap\u00e9utica y profi-\nl\u00e1ctica de dos anticuerpos monoclonales (mAb) neutralizantes \ncompletamente humanos (REGN3048 y REGN3051) que se di-\nrigen al dominio de uni\u00f3n al receptor (RBD) de la prote\u00edna S del \nMERS-CoV en primates no humano, los resultados mostraron \nniveles altos de actividad neutralizante y reducci\u00f3n de la carga \nviral en los pulmones de los animales, sin embargo, se observ\u00f3 \nuna mejor respuesta como r\u00e9gimen profil\u00e1ctico. Adem\u00e1s, se \nllev\u00f3 a cabo un ensayo de seguridad, tolerabilidad, farmaco-Herramientas biotecnol\u00f3gicas en el diagn\u00f3stico, prevenci\u00f3n y tratamiento frente a pandemias\nBiotechnological tools in the diagnosis, prevention, and treatment of pandemics2100\ncin\u00e9tica e inmunogenicidad de la combinaci\u00f3n de REGN3048 \ny REGN3051, administrado por v\u00eda intravenosa en voluntarios \nsanos, este estudio ha completado su fase 1 (NCT03301090).\nLos anticuerpos policlonales son otra opci\u00f3n terap\u00e9utica, \nLuke et al.92 produjeron inmunoglobulina G (IgG) policlonal \ncompletamente humana contra la prote\u00edna de pico del MERS-\nCoV, a partir de la inmunizaci\u00f3n de ganado transcromos\u00f3mico. \nEn modelos murinos, estos anticuerpos (SAB-301) tuvieron la \ncapacidad de reducir los t\u00edtulos virales con la aplicaci\u00f3n de una \n\u00fanica dosis a las 24 o 48 horas, despu\u00e9s de la exposici\u00f3n del \ncoronavirus. Un estudio cl\u00ednico de fase 1, en el que se evalu\u00f3 \nla seguridad, tolerabilidad y farmacocin\u00e9tica de SAB-301 en \nadultos sanos, interpret\u00f3 que las infusiones \u00fanicas de SAB-\n301 con una concentraci\u00f3n de hasta 50 mg / kg parecen ser \nseguras y bien toleradas93.\nLa combinaci\u00f3n de antivirales e interferones ha sido la \nbase de varios tratamientos ensayados. Un estudio cl\u00ednico fase \n2/3 en el que se prob\u00f3 la combinaci\u00f3n de interfer\u00f3n \u03b2-1b re-\ncombinante m\u00e1s lopinavir-ritonavir, durante 14 d\u00edas, concluy\u00f3 \nque el tratamiento produjo menor mortalidad en comparaci\u00f3n \ncon el placebo en pacientes confirmados con MERS y produjo \nefectos adversos graves en el 9% de la poblaci\u00f3n. Existieron \nmejores resultados cuando este se aplic\u00f3 entre los 7 d\u00edas pos-\nteriores a la aparici\u00f3n de s\u00edntomas87.\nDesde el inicio de la epidemia provocada por el MERS-\nCoV, se plante\u00f3 el objetivo de desarrollar una vacuna contra \nel virus, por lo que diferentes grupos de investigadores alre-\ndedor del mundo se han unido al proceso. La vacuna GLS-\n5300 basada en pl\u00e1smido de ADN que expresa la prote\u00edna S \ndel MERS-CoV94, en el ensayo fase 1 revel\u00f3 que las respuestas \ninmunitarias fueron independientes de la concentraci\u00f3n de la \ndosis, adem\u00e1s se observ\u00f3 seroconversi\u00f3n en 86% de los parti-\ncipantes y respuestas de c\u00e9lulas T en el 71% despu\u00e9s de dos \ndosis, mientras que en el grupo que se administr\u00f3 tres dosis se \npresenci\u00f3 seroconversi\u00f3n en el 94% de los participantes y res-\npuestas de c\u00e9lulas T en el 76%, asimismo se observaron anti-\ncuerpos neutralizantes en el 50% de la poblaci\u00f3n estudiada94. \nAdem\u00e1s, se est\u00e1n llevando a cabo dos ensayos cl\u00ednicos fase \n1/2 en los que se est\u00e1 evaluando la inmunogenicidad y la segu-\nridad de las vacunas de vectores virales BVRS-GamVac-Combi \n(NCT04128059) y BVRS-GamVac (NCT04130594).\nLas otras dos vacunas que publicaron sus ensayos fase \n1 se basaron en vectores virales de replicaci\u00f3n incompetente, \nen las que se evalu\u00f3 la seguridad, tolerabilidad e inmunoge-\nnicidad. La vacuna MVA-MERS-S, basada en la Vacuna Modi-\nficada de Ankara (MVA) que expresa la glicoprote\u00edna S86; y la \nvacuna ChAdOx1 MERS vectorizada de adenovirus de chim-\npanc\u00e9 (ChAdOx1) que de igual forma expresa la prote\u00edna S de \nlongitud completa95. En los resultados, los dos ensayos mos-\ntraron seguridad con ausencia de efectos secundarios graves, \nadem\u00e1s de respuestas humorales y celulares contra el MERS-\nCoV86,95. En el caso de la vacuna MVA-MERS-S en el 75% de los \nparticipantes se observ\u00f3 seroconversi\u00f3n despu\u00e9s de la segun-\nda inmunizaci\u00f3n con dosis baja y en el 100% con la dosis alta. \nSe detectaron respuestas de c\u00e9lulas T en el 83% y en el 91% \nde la poblaci\u00f3n dependiendo del tipo de dosis administrada86.\n\u00c9BOV (epidemia 2013-2016)\nLa enfermedad del virus del \u00e9bola (EVE), es una infecci\u00f3n \ngrave y letal provocada por el virus del \u00e9bola de Zaire (EBOV), \nque apareci\u00f3 por primera vez en Rep\u00fablica Democr\u00e1tica del \nCongo en 197696. Sin embargo, el brote m\u00e1s grande reportado \nen la historia surgi\u00f3 en diciembre de 2013 en \u00c1frica Occiden-\ntal y dur\u00f3 hasta 2016, periodo en el que se registraron 18 616 casos y 11 310 muertes97. Los brotes de EBOV del 2013-2016 \ny los \u00faltimos brotes registrados en Rep\u00fablica Democr\u00e1tica del \nCongo98, han permitido mejorar la comprensi\u00f3n de la enferme-\ndad y optimizar las estrategias para la prevenci\u00f3n, el diagn\u00f3s-\ntico, la atenci\u00f3n cl\u00ednica y el tratamiento de EVE, debido a la \naplicaci\u00f3n de t\u00e9cnicas moleculares modernas en la caracteri-\nzaci\u00f3n del virus99,100.\nLas pruebas de diagn\u00f3stico para el EVE recomendadas \npor la OMS son las pruebas de \u00e1cido nucleico automatizadas o \nsemiautomatizadas para la detecci\u00f3n de ARN viral y las prue-\nbas r\u00e1pidas de detecci\u00f3n de ant\u00edgenos como test de vigilan-\ncia101. En general, la sangre es la muestra de preferencia para \nel diagn\u00f3stico en pacientes y los hisopos orofar\u00edngeos son de \nutilidad para el diagn\u00f3stico post mortem101,102.\nLa qRT-PCR es la prueba est\u00e1ndar para el diagn\u00f3stico, ca-\npaz de detectar el virus de 3-6 d\u00edas despu\u00e9s del inicio de los \ns\u00edntomas102,103.  Uno de los ensayos importantes desarrollados \ny con EUA por la FDA y la OMS, en el brote del 2013-2016,  fue \nla prueba molecular automatizada Gene Xpert Ebola (Cepheid) \nbasada en qRT-PCR con se\u00f1al fluorescente de sondas para \ncontrol de calidad, que amplifica dos genes del EBOV, el gen \nN y el de la glicoprote\u00edna (GP), el doble objetivo de esta prue-\nba permiti\u00f3 disminuir falsos negativos cuando se analizaron \nmuestras con nuevas variantes de virus, los resultados mos-\ntraron una alta sensibilidad anal\u00edtica (100%) y especificidad \n(99.5-100%), con un tiempo corto de respuestas, en compa-\nraci\u00f3n con la RT-PCR com\u00fan104; este ensayo fue empleado en \nsu mayor\u00eda en el \u00faltimo brote de Rep\u00fablica del Congo (2018-\n2020)99.\nAdem\u00e1s, se han dise\u00f1ado varias pruebas port\u00e1tiles de \nflujo lateral para la detecci\u00f3n r\u00e1pida de ant\u00edgenos105. La pri-\nmera prueba de este tipo aprobada por la FDA en el 2019 fue \nOraQuick Ebola Rapid Antigen Test de OraSure Technologies, \nun ensayo inmunocromatogr\u00e1fico dirigido a la prote\u00edna viral 40 \n(VP40) o de la matriz proteica con una sensibilidad de 97.1-\n100% y una especificidad del 98-100%106,107.\nTratamiento terap\u00e9utico y profil\u00e1ctico\nDurante el gran brote de EVE del 2013-2016 varios f\u00e1rma-\ncos biotecnol\u00f3gicos con actividad antiviral o como inmunotera-\npia contra EBOV fueron llevados a ensayos cl\u00ednicos, entre los \nque estuvieron: administraci\u00f3n de plasma convaleciente108; un \nc\u00f3ctel de tres anticuerpos monoclonales neutralizantes (ZMa-\npp) dirigidos hacia la GP de superficie del EBOV109; interfer\u00f3n \nIFN\u03b2-1a110; y un producto de nanopart\u00edculas lip\u00eddicas de ARNip \nque inhibe la producci\u00f3n de dos prote\u00ednas virales fundamenta-\nles, la L-polimerasa, la cual interviene en la transcripci\u00f3n y re-\nplicaci\u00f3n del EVE, y la prote\u00edna viral 35 (VP35), comprometida \ncon la destrucci\u00f3n de la respuesta inmune del hu\u00e9sped111. Sin \nembargo, estas terapias no cumplieron con los criterios esta-\nblecidos para ser aprobadas para su uso masivo99,103.\nDurante el brote de Rep\u00fablica del Congo de 2018 inici\u00f3 \nel ensayo Pamoja Tulinde Maisha (PALM) que significa \u201cJun-\ntos salvamos vidas\u201d, un ensayo controlado, aleatorio, abierto \ny multic\u00e9ntrico, en el que se estudi\u00f3 las terapias experimenta-\nles m\u00e1s prometedoras. Esta investigaci\u00f3n compar\u00f3 a Zmapp \ncontra tres nuevos agentes: remdesivir, mAb114 y REGN-EB3 \n(NCT03719586)112. Inmazeb (REGN-EB3 ) fue el primer f\u00e1rma-\nco aprobado por la FDA para tratar el EVE (14 de octubre de \n2020) con una \u00fanica perfusi\u00f3n intravenosa de 150 mg por kg113. \nSe trata de un c\u00f3ctel de tres anticuerpos IgG1 humanizados \nen una proporci\u00f3n 1:1:1 dirigidos a la tres ep\u00edtopes no super-\npuestos de la GP del EBOV, los tres anticuerpos pueden unirse \nsimult\u00e1neamente bloqueando la uni\u00f3n y entrada del virus a Pamela Molina and Marbel Torres Arias\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2101\nla c\u00e9lula hu\u00e9sped114. El segundo tratamiento aprobado por la \nFDA, en diciembre de 2020, fue Ebanga (mAb114), un \u00fanico \nanticuerpo monoclonal IgG1 dirigido a un ep\u00edtope altamen-\nte conservado del dominio de uni\u00f3n al receptor de la GP del \nEBOV, este es administrado por v\u00eda intravenosa con una sola \ndosis de 50 mg/kg115. Ebanga  previene la interacci\u00f3n de GP del \nEBOV con el receptor NPC1, bloqueando la infecci\u00f3n del virus \na la c\u00e9lula hu\u00e9sped116.\nDebido a que la GP del EBOV es el inmun\u00f3geno m\u00e1s \nimportante detectado117, la mayor\u00eda de las vacunas en desa-\nrrollo durante el brote de \u00e9bola 2013-2016 fueron dise\u00f1adas \npara activar la respuesta inmune del hu\u00e9sped frente a este \nant\u00edgeno118. Entre las vacunas candidatas llevadas a ensayos \ncl\u00ednicos se encontr\u00f3 rVSV-ZEBOV, una vacuna de vector viral \ncompetente para la replicaci\u00f3n basada en el virus de estoma-\ntitis vesicular recombinante que expresa la GP de superficie \ndel EBOV del Zaire119. El ensayo Ebola \u00e7a Suffit (\u201c\u00c9bola esto \nes suficiente\u201d) de fase 3 llevado a cabo en Guinea en el 2015, \nevalu\u00f3 la eficacia y efectividad de una sola dosis intramuscu-\nlar de la vacuna rVSV-ZEBOV con una estrategia de vacuna-\nci\u00f3n en anillo abierta y aleatorizada por grupos, mediante la \ncual se administra la vacuna a individuos con conexi\u00f3n social \no geogr\u00e1fica a un caso confirmado119. La eficacia de la vacuna \nfue del 100%, con alta tolerancia en los seres humanos,  una \nactivaci\u00f3n r\u00e1pida de la respuesta inmune despu\u00e9s de una \u00fanica \ndosis y sin casos confirmados entre las personas vacunadas \ndespu\u00e9s de los 10 d\u00edas de inmunizaci\u00f3n120. En 2019 esta va-\ncuna denominada Ervebo desarrollada por Merck Inc., fue la \nprimera vacuna aprobada por la EMA y por la FDA para su uso \nm\u00e9dico121,122, con una eficacia estimada de 95.7% evaluada por \nla OMS en 90 000 personas asociadas al brote del 2018 de \nRep\u00fablica Democr\u00e1tica del Congo123.\nOtra de las vacunas empleadas para la prevenci\u00f3n del \nEVE es la vacuna fabricada por Johnson & Johnson,  autoriza-\nda para su comercializaci\u00f3n en circunstancias excepcionales \npor la EMA en julio de 2020124. Esta vacuna fue desarrollada \nen el brote de 2013- 2016 y ha alcanzado ensayos cl\u00ednicos de \nfase 1, los que demostraron seguridad, tolerabilidad e inmu-\nnogenicidad125. El r\u00e9gimen de vacunaci\u00f3n consta de dos dosis \nconformado por vacunas diferentes: Zabeno (Ad26.ZEBOV), \nuna vacuna de adenovirus humano serotipo 26 no replicante \nque codifica la GP del EBOV de Zaire, y una vacuna de refuerzo \nadministrada ocho semanas despu\u00e9s, denominada Mvabea \u00ae \n(MVA-BN-Filo), constituida por MVA de replicaci\u00f3n incompe-\ntente que expresa tres GP y una nucleoprote\u00edna de diferentes \nvariantes del virus del \u00c9bola125,126.\nSARS-CoV-2 (2019-2021)\nLa pandemia en curso de la enfermedad por coronavirus \n2019 (COVID-19), provocada por el Coronavirus del S\u00edndrome \nRespiratorio Agudo Severo 2 (SARS-CoV-2), inici\u00f3 en diciembre \nde 2019 en un mercado de animales en Wuhan, provincia de \nHubei, China127. Hasta inicios de marzo de 2021, la OMS ha re-\nportado 113.6 millones de casos confirmados, 2.5 millones de \nmuertes en todo el mundo y 223 pa\u00edses afectados128.\nEn el caso de esta pandemia, la FDA recomend\u00f3 tres tipos \nde pruebas: las pruebas de diagn\u00f3stico que identifican una in-\nfecci\u00f3n activa por presencia del virus, las pruebas serol\u00f3gicas \no de anticuerpos y las pruebas de manejo de pacientes con \nCOVID-19 para detectar biomarcadores relacionados con la \ninflamaci\u00f3n129,130.\nLa prueba est\u00e1ndar para el diagn\u00f3stico de COVID-19 es la \nqRT-PCR131, esta t\u00e9cnica molecular va dirigida a regiones alta-\nmente conservados o que se expresan con abundancia como el gen E, N, S y el gen de la ARN polimerasa dependiente de ARN \n(RdRp) del ORF1ab132,133. Sin embargo, a pesar de la alta es-\npecificidad de la prueba ha demostrado sensibilidad inestable, \ncomparada con otras t\u00e9cnicas como la tomograf\u00eda computari-\nzada (TC) de t\u00f3rax, esto puede depender varios factores como: \nla carga viral del paciente, la forma de muestreo, el procesa-\nmiento y el transporte de la muestra, la tasa de detecci\u00f3n de \nlos diferentes fabricantes, entre otras133,134.\nCon los antecedentes antes mencionados el objetivo de \nvarios grupos de investigaci\u00f3n se han centrado en dise\u00f1ar \npruebas de diagn\u00f3stico alternativas, entre ellas se halla la RT-\nLAMP, una tecnolog\u00eda de amplificaci\u00f3n de ADN, que se emplea \npara detectar ARN del SARS-CoV-2, los resultados se logran \nobtener en aproximadamente 45 minutos en muestras con \nuna baja concentraci\u00f3n viral, sin el empleo de equipamiento \ncostoso debido a que la reacci\u00f3n final se puede observar a \nsimple vista por un cambio colorim\u00e9trico; adem\u00e1s el dise\u00f1o de \nlos cebadores ha sido dirigido a regiones conservadas con baja \nfrecuencia de mutaci\u00f3n como el gen S, gen ORF1ab y el gen N, \nlo que garantiza la especificidad135,136. Huang et al.137 probaron \nel ensayo RT-LAMP en un solo paso, es decir sin la extracci\u00f3n \nde ARN, el resultado fue la amplificaci\u00f3n de ARN directamente \nde una muestra; por lo que aseguraron que la meta final es de-\nsarrollar un dispositivo capaz de extraer, purificar, retro trans-\ncribir ARN, y llevar a cabo la amplificaci\u00f3n isot\u00e9rmica mediada \npor bucle (LAMP) para la detecci\u00f3n de SARS-CoV-2.\nLa tecnolog\u00eda Crispr-Cas es una nueva herramienta bio-\ntecnol\u00f3gica que ha revolucionado el diagn\u00f3stico molecular de \nr\u00e1pida detecci\u00f3n, alta precisi\u00f3n y sensibilidad, gran versatili-\ndad y portabilidad sin la intervenci\u00f3n de equipos sofisticados \nde laboratorio138. En mayo de 2020 la FDA otorg\u00f3 una EUA a \nla primera prueba de CRISPR combinada con RT-LAMP para el \ndiagn\u00f3stico de la infecci\u00f3n activa por SARS-CoV-2 en el punto \nde atenci\u00f3n, denominada SHERLOCK, desarrollada por Sher-\nlock BioSciences139. Este protocolo se basa en la enzima Ca-\ns13a guiada por el ARN Crispr (ARNcr) para reconocer un ARN \nde cadena simple o un ARN mensajero viral, cuando el comple-\njo Crispr -Cas se une a su diana, la actividad nucleasa colateral \nde la enzima conduce a la escisi\u00f3n inespec\u00edfica de una mol\u00e9cu-\nla marcada con fluorescencia, tras este proceso la se\u00f1al ser\u00e1 \ndetectada mediante fluorescencia o tiras de flujo lateral140. \nSeg\u00fan Joung et al.141 SHERLOCK proporciona una sensibilidad \ncomparable con la qRT-PCR y posee un l\u00edmite de detecci\u00f3n \nde 100 copias del genoma viral; en muestras de hisopados de \nnariz, boca o garganta, adem\u00e1s de fluido pulmonar141.\nOtro de los kits de diagn\u00f3stico frente a COVID-19 dispo-\nnible comercialmente y basado en los mismos principios es \nDETECTR, dise\u00f1ado por Mammoth Biosciences138. Este sis-\ntema por su parte usa la enzima Cas12a para dirigirse a una \nsecuencia de ADN de doble cadena (dsADN) del SARS-CoV-2, \nuna vez hallada la diana gen\u00e9tica la enzima escinde indiscrimi-\nnadamente mol\u00e9culas indicadoras de ADN de cadena simple \n(ssADN) marcadas con el flour\u00f3foro y ocurre el mismo proce-\nso antes mencionado140,142. DETECTR muestra una alternativa \nvisual y m\u00e1s r\u00e1pida que la t\u00e9cnica est\u00e1ndar para la tipificaci\u00f3n \nde secuencias moleculares del SARS-CoV-2, con una sensibili-\ndad del 95% y una especificidad del 100%142.\nLas pruebas r\u00e1pidas de detecci\u00f3n de ant\u00edgenos son otra \nopci\u00f3n para el diagn\u00f3stico de COVID-19, estos inmunoensa-\nyos est\u00e1n esquematizados para localizar part\u00edculas virales en \nmuestras nasofar\u00edngeas o de frotis nasal. Las ventajas de las \npruebas de ant\u00edgenos es la rapidez de detecci\u00f3n, aproximada-\nmente 15 minutos, a un bajo costo y alta especificidad143,144. \nHasta la fecha la FDA ha otorgado la EUA a quince test comer-\nciales con este principio129.Herramientas biotecnol\u00f3gicas en el diagn\u00f3stico, prevenci\u00f3n y tratamiento frente a pandemias\nBiotechnological tools in the diagnosis, prevention, and treatment of pandemics2102\nLa pandemia por COVID-19 sigue vigente y cada d\u00eda que \npasa contin\u00faa la I + D en pruebas de diagn\u00f3stico m\u00e1s r\u00e1pidas, \nsimples, baratas, escalables y precisas en comparaci\u00f3n con \nlas existentes145. Como el desarrollo de biosensores fotot\u00e9rmi-\ncos plasm\u00f3nicos de doble funci\u00f3n con una alta precisi\u00f3n146, o \nun ensayo de CRISPR potencializado y ultrasensible con la po-\nsibilidad de ser integrado en un chip de microfluidos que pueda \nser le\u00eddo por un tel\u00e9fono celular inteligente147,148.\nTratamiento terap\u00e9utico y profil\u00e1ctico\nExiste una gran variedad de tratamientos en investigaci\u00f3n \npara el COVID-19 por ejemplo antivirales, terapias celulares y \ngen\u00e9ticas, inmunomoduladores, anticuerpos neutralizantes y \ntratamientos combinadas; de los cuales, varios se encuentran \nen ensayos en etapa temprana donde se eval\u00faan la seguridad \ny dosificaci\u00f3n, mientras que otros se hallan en etapa tard\u00eda en \nlos que se prueba la seguridad y la efectividad149. Por otro lado, \nse han empleado m\u00faltiples plataformas biotecnol\u00f3gicas tanto \ntradicionales como modernas para el desarrollo de vacunas \ncontra el COVID-19150,151 (Figura 3).\nLas terapias basadas en anticuerpos neutralizantes se \nhan mostrado efectivas en las primeras etapas de la infecci\u00f3n \npor SARS-CoV-2, cuando el virus empieza su proceso de repli-\ncaci\u00f3n y el hu\u00e9sped a\u00fan no reacciona con una respuesta inmu-\nne eficaz152. La FDA ha concedido la EUA a ciertos anticuerpos \nmonoclonales neutralizantes anti-SARS-COV-2 dirigidos al \nRBD de la prote\u00edna S como tratamiento para pacientes ambu-\nlatorios con COVID-19 de leve a moderado, la funci\u00f3n de estos \nanticuerpos es bloquear la uni\u00f3n del RBD a la c\u00e9lula hu\u00e9sped \ny neutralizar el virus153,154.\nBamlanivimab, ha alcanzado estudios cl\u00ednicos fase 2, los \nresultados obtenidos en un an\u00e1lisis intermedio sugirieron que \nuna \u00fanica infusi\u00f3n intravenosa de este mAb con una dosis de \n2800 mg aceler\u00f3 la disminuci\u00f3n de la carga viral, adem\u00e1s \nlos pacientes no hospitalizados que recibieron el tratamiento \nmostraron s\u00edntomas m\u00e1s leves y una tasa de hospitalizaci\u00f3n \nmenor que el grupo placebo. Sin embargo, no es posible sacar \nconclusiones finales, por lo que se necesitan datos de ensayos \ncl\u00ednicos m\u00e1s amplios155. Al mismo tiempo se est\u00e1 llevando a \ncabo un ensayo fase 2/3 para determinar el efecto de la mono-\nterapia de bamlanivimab y la terapia combinada de bamlanivi-\nmab con etesevimab. El estudio concluy\u00f3 que el tratamiento \ncombinado se asoci\u00f3 con una reducci\u00f3n de la carga viral esta-\nd\u00edsticamente significativa al d\u00eda 11, en contraste con la mono-\nterapia y el grupo placebo156.\nFinalmente, el an\u00e1lisis intermedio del estudio cl\u00ednico fase \n1/3 del c\u00f3ctel de anticuerpos humanos neutralizantes REGN-\nCOV2 (casirivimab y imdevimab), inform\u00f3 que una sola dosis de \nREGN-COV2 de 2,4 g o 8,0 g fue capaz de reducir la carga viral \nal d\u00eda 7 con un efecto mayor en pacientes con anticuerpos s\u00e9ri-\ncos negativos (anticuerpos end\u00f3genos) contra el SARS-CoV-2. \nAsimismo, el porcentaje de participantes con visitas m\u00e9dicas \nfue menor en el grupo que recibi\u00f3 el c\u00f3ctel de anticuerpos que \nen el grupo placebo157.\nUna  tecnolog\u00eda tradicional, el plasma convaleciente de \nt\u00edtulo alto, es decir con  la relaci\u00f3n se\u00f1al/corte (s/c) de \u226512.0 \na \u22659.5 en la prueba Ortho VITROS  Anti-SARS-CoV-2 IgG, es \notro de los productos biol\u00f3gicos aprobados como EUA  por la \nFDA153. Los resultados de los diferentes estudios var\u00edan, en pa-\ncientes con COVID-19 grave o potencialmente mortal no pre-\nsenta una mejora cl\u00ednica estad\u00edsticamente significativa158,159, \nmientras que otros proporcionan datos s\u00f3lidos de que la trans-\nfusi\u00f3n de plasma convaleciente en pacientes hospitalizados \nes segura con una administraci\u00f3n temprana dentro del curso cl\u00ednico160\u2013162.\nActualmente, existen 182 vacunas en desarrollo precl\u00edni-\nco y 74 en desarrollo cl\u00ednico de las cuales 3 han obtenido la \nEUA por parte de la FDA, pertenecientes a Moderna Therapeu-\ntics, Pfizer-BioNTech y Johnson & Johnson150.\nModerna Therapeutics junto con Instituto Nacional de \nAlergias y Enfermedades Infecciosas (NIAID) produjeron la \nprimera vacuna en ser llevada a ensayos cl\u00ednicos, se trata de \nmRNA-1273, una vacuna de ARN encapsulada en nanopart\u00ed-\nculas lip\u00eddicas que contiene la informaci\u00f3n de la prote\u00edna de \nS de longitud completa estabilizada previa a la fusi\u00f3n, un en-\nsayo fase 3 determin\u00f3 una eficacia del 94.1% con dos dosis \nde 100 \u03bcg de esta vacuna163. La vacuna producida por John-\nson & Johnson, Ad26.COV2.S, es una vacuna de dosis \u00fanica \n(5\u00d71010 part\u00edculas virales) basada en un adenovirus serotipo \n26 incompetente para la replicaci\u00f3n que expresa la prote\u00edna \nS del SARS-CoV-2, los ensayos cl\u00ednicos muestran diferentes \neficacias de la vacuna frente al virus; 72% en EE.UU., 66% en \nLatino Am\u00e9rica y 57% en Sud\u00e1frica150,164,165.\nPor otro lado, la primera vacuna para la prevenci\u00f3n de CO-\nVID-19 que recibi\u00f3 un EUA fue BNT162b2 de Pfizer-BioNTech, \nel 2 de diciembre por la  Agencia Reguladora de Medicamentos \ny Productos Sanitarios (MHRA) del Reino Unido166 y el 11 de \ndiciembre de 2020 por la FDA167.\nEn Ecuador esta vacuna desarrollada por Pfizer-BioN-\nTech, fue la primera en ser aprobada para uso de emergencia \npor la Agencia Nacional de Regulaci\u00f3n, Control y Vigilancia Sa-\nnitaria (ARCSA)168. BNT162b2 es una vacuna de ARNm modifi-\ncado con nucle\u00f3sidos y formulada con part\u00edculas lip\u00eddicas que \ncodifica la prote\u00edna S transmembrana de longitud completa. \nUn ensayo global fase 2/3 manifest\u00f3 que la administraci\u00f3n de \ndos dosis (30 \u03bcg de vacuna por dosis) de BNT162b2  con 21 \nd\u00edas de diferencia alcanza 95% de eficacia en la prevenci\u00f3n de \nCOVID-19 y un perfil de seguridad caracterizado por dolor leve \nen el lugar de la inyecci\u00f3n, dolor de cabeza y fatiga, con una \nbaja incidencia de efectos secundarios graves169.\nLa segunda vacuna aprobada por el ARCSA es ChAdOx1 \nnCoV-19 (AZD1222)170, una vacuna de vector no replicante \nChAdOx1 que contiene el gen de la prote\u00edna S del virus, dise-\n\u00f1ada por AstraZeneca y la Universidad de Oxford. Un an\u00e1lisis \nde cuatro ensayos con una administraci\u00f3n de dos dosis (dosis \nest\u00e1ndar 5 \u00d7 1010 part\u00edculas virales) demostr\u00f3 que en aquellos \nparticipantes que recibieron dos dosis est\u00e1ndar la eficacia de \nla vacuna fue del 62%, mientras que en el grupo que adopt\u00f3 \nmedia dosis est\u00e1ndar seguida de una dosis completa la efica-\ncia fue de 90%, obteniendo una eficacia global de la vacuna del \n70,4% contra el COVID-19 sintom\u00e1tico con un perfil de seguri-\ndad aceptable171.\nA continuaci\u00f3n se describir\u00e1n las herramientas de la bio-\ntecnolog\u00eda y sus m\u00faltiples aplicaciones, adem\u00e1s se mencio-\nnar\u00e1n sus caracter\u00edsticas m\u00e1s importantes empleadas en el \ncontrol, manejo y prevenci\u00f3n de las diferentes pandemias.\nHerramientas biotecnol\u00f3gicas\nEn 1919, el ministro de alimentos h\u00fangaro, Kark Ereky, \nmencion\u00f3 por primera vez la palabra biotecnolog\u00eda refiri\u00e9ndo-\nse a todas las \u00e1reas de trabajo en las cuales los productos \nson obtenidos a partir de materia prima org\u00e1nica mediante la \nintervenci\u00f3n de organismos vivos172. Sobre esta base la biotec-\nnolog\u00eda ha ido evolucionando y ha sido dividida en tres periodos \nen funci\u00f3n del tiempo: la biotecnolog\u00eda antigua, la biotecnolo-\ng\u00eda cl\u00e1sica y la biotecnolog\u00eda moderna173,174. El \u00faltimo periodo \ninici\u00f3 con la revelaci\u00f3n del modelo de doble h\u00e9lice del \u00e1cido \ndesoxirribonucleico (ADN) en 1953, desde este evento, la bio-Pamela Molina and Marbel Torres Arias\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2103\ntecnolog\u00eda fue considerada como una ciencia moderna capaz \nde desarrollar sus propias aplicaciones175, basadas en t\u00e9cnicas \nmodernas como las t\u00e9cnicas de ADN recombinante176 o la t\u00e9c-\nnica de la hibridoma177.\nEn la actualidad se puede definir a la biotecnolog\u00eda como \nuna ciencia multidisciplinaria e interdisciplinaria que emplea \norganismos vivos, c\u00e9lulas o sus derivados para el desarrollo \nde productos y procesos orientados al bienestar humano em-\npleando diversos tipos de herramientas y tecnolog\u00edas173,178. \nOtra de las clasificaciones de esta ciencia se basa en un c\u00f3digo \nde colores que diferencia las principales \u00e1reas179. Un \u00e1rea de \nla biotecnolog\u00eda de inter\u00e9s en esta revisi\u00f3n es la biotecnolog\u00eda \nroja, m\u00e9dica o farmac\u00e9utica, que se relaciona con la producci\u00f3n \ny desarrollo de m\u00e9todos de diagn\u00f3stico y productos biofarma-\nce\u00faticos como biof\u00e1rmacos recombinantes, productos de in-\ngenier\u00eda de tejidos, productos de ingenier\u00eda de prote\u00ednas, anti-\ncuerpos monoclonales, vacunas, medicamentos regenerativos \n(terapia de c\u00e9lulas madre y g\u00e9nica), nanopart\u00edculas y biosen-\nsores173,178,179. Las herramientas biotecnol\u00f3gicas han permitido \nla obtenci\u00f3n de estos productos a escala industrial, incluyendo \nagentes novedosos y tradicionales los cuales eran producidos \nen minor\u00eda, para lo que se emplean bioprocesamientos conoci-\ndos como biotecnolog\u00eda blanca o industrial178,179.\nEra de las \u201cOMICAS\u201d para el desarrollo de herramientas \nbiotecnol\u00f3gicas\nLas tecnolog\u00edas \u201comicas\u201d inspiradas en el proceso natural \nde producci\u00f3n de biomol\u00e9culas en las c\u00e9lulas, han aportado \nsignificativamente en el avance del diagn\u00f3stico, manejo y pro-\nn\u00f3stico de varias enfermedades, siendo elementales para el \nperfeccionamiento de la medicina personalizada de pr\u00f3xima \ngeneraci\u00f3n180,181, debido a que permiten una mejor compren-\nsi\u00f3n de los mecanismos moleculares y celulares que interfie-\nren en la progresi\u00f3n de una enfermedad en humanos180. Entre las \u201c\u00f3micas\u201d con mayor avance est\u00e1n la gen\u00f3mica, transcrip-\nt\u00f3mica, prote\u00f3mica y metabol\u00f3mica181, siendo la gen\u00f3mica y \nprote\u00f3mica las \u201comicas\u201d, con un protagonismo superior en la \ninvestigaci\u00f3n de diagn\u00f3stico y tratamiento en enfermedades \ninfecciosas182. La gen\u00f3mica trata de la estructura, funci\u00f3n, \nevoluci\u00f3n y mapeo de genomas, con el objetivo de cuantificar \ny caracterizar genes180. La obtenci\u00f3n y an\u00e1lisis de secuencias \ncompletas de los genomas de pat\u00f3genos causantes de enfer-\nmedades emergentes ha sido valioso para el an\u00e1lisis filogen\u00e9-\ntico de estos microorganismos, conocer su origen, caracterizar \nlos patrones de transmisi\u00f3n, el desarrollo acelerado de prue-\nbas de diagn\u00f3stico eficientes, adem\u00e1s, ha sido la base para el \ndise\u00f1o de nuevas tecnolog\u00edas terap\u00e9uticas, incluidos biotecno-\nl\u00f3gicos y ha permitido la identificaci\u00f3n de ep\u00edtopes claves para \nla construcci\u00f3n de vacunas. Asimismo, ha influido en el segui-\nmiento epidemiol\u00f3gico de las pandemias y en la detecci\u00f3n de \nnuevas variantes virales76,183\u2013186.\nLa prote\u00f3mica, por otro lado, estudia todas las prote\u00ednas \npresentes en una c\u00e9lula, tejido u organismo, centr\u00e1ndose en \nlas propiedades bioqu\u00edmicas, roles funcionales y sus cambios \nfrente al crecimiento o a est\u00edmulos internos y externos182,187,188. \nLa prote\u00f3mica a trav\u00e9s de espectrometr\u00eda de masas facilita los \nan\u00e1lisis de precisi\u00f3n, sensibles y de alto rendimiento de prote\u00ed-\nnas a gran escala187. Adem\u00e1s, es posible comprender y descu-\nbrir interacciones claves prote\u00edna-prote\u00edna, redes de se\u00f1aliza-\nci\u00f3n, interacciones complejas hu\u00e9sped-pat\u00f3geno, respuestas \ndel hu\u00e9sped al invasor y los mecanismos de aprovechamien-\nto del microorganismo, lo que ha proporcionado informaci\u00f3n \nsobre la patog\u00e9nesis de una enfermedad, caracterizaci\u00f3n de \nbiomarcadores para m\u00e9todos de diagn\u00f3stico y f\u00e1rmacos anti-\nvirales durante una epidemia182,188. Al mismo tiempo el proto-\ntipado por espectrometr\u00eda de masas puede ser un m\u00e9todo de \ndiagn\u00f3stico alternativo188.\nFigura 2. Herramientas biotecnol\u00f3gicas para el diagn\u00f3stico de enfermedades pand\u00e9micas - Ventajas y desventajas.Herramientas biotecnol\u00f3gicas en el diagn\u00f3stico, prevenci\u00f3n y tratamiento frente a pandemias\nBiotechnological tools in the diagnosis, prevention, and treatment of pandemics2104\nHerramientas biotecnol\u00f3gicas en el diagn\u00f3stico\nLas herramientas biotecnol\u00f3gicas modernas aplicadas \npara el diagn\u00f3stico se han optimizado a lo largo de la apari-\nci\u00f3n de las diferentes pandemias, gracias a la investigaci\u00f3n y \nel avance tecnol\u00f3gico, con el fin de producir pruebas sencillas, \nde bajo costo, que requieran menor tiempo de detecci\u00f3n, con \nsensibilidad y especificidad alta58,148,189. Los m\u00e9todos para la \nidentificaci\u00f3n de pat\u00f3genos se han basado principalmente en \ncultivo viral58, detecci\u00f3n de ant\u00edgenos61,105, identificaci\u00f3n indi-\nrecta de anticuerpos20,29 y detecci\u00f3n de \u00e1cidos nucleicos42,130,132 \n(Figura 2). Debido a la necesidad de pruebas de diagn\u00f3stico \nen el punto de atenci\u00f3n (POCT) se est\u00e1n efectuando estudios \ntrascendentales para convertir las t\u00e9cnicas conocidas en he-\nrramientas POCT r\u00e1pidas, eficientes y ultrasensibles, sin la \nnecesidad de mano de obra experimentada y laboratorios so-\nfisticados84,130,189,190.\nT\u00e9cnicas de diagn\u00f3stico molecular \nLos test moleculares son las pruebas de diagn\u00f3stico \ncon mayor demanda en los \u00faltimos a\u00f1os, debido a su elevada \nsensibilidad y precisi\u00f3n133,189. Estas tecnolog\u00edas mecanizadas \ndetectan y amplifican secuencias espec\u00edficas y conservadas \ndel genoma del pat\u00f3geno en muestras de pacientes infecta-\ndos41,133. Las cuales se describen a continuaci\u00f3n:\nReacci\u00f3n en cadena de la polimerasa (PCR)\nEs una t\u00e9cnica que se emplea para amplificar exponencial-\nmente peque\u00f1os fragmentos de ADN diana. El principio de la PCR \nse fundamenta en el ciclo repetitivo de tres reacciones: desnatu-\nralizaci\u00f3n, alineaci\u00f3n y extensi\u00f3n, el proceso se repite de 30 a 40 veces, con el doble de la cantidad de material gen\u00e9tico objetivo \nen cada ciclo. Al final se producen millones de fragmentos de la \nsecuencia de ADN diana, en un per\u00edodo corto de tiempo191.\nExisten algunas variaciones de la PCR. PCR de transcrip-\nci\u00f3n inversa (RT-PCR) inicia con la obtenci\u00f3n de ADNc a partir \nde ARN mediante transcripci\u00f3n inversa, seguido por la amplifi-\ncaci\u00f3n del ADNc. Esta t\u00e9cnica se usa para la detecci\u00f3n de virus \nde ARN80. PCR cuantitativa en tiempo real (qPCR) se basa en \nel empleo de sondas marcadas con fluorescencia que permi-\nten cuantificar los productos de PCR a medida que se generan, \nen esta t\u00e9cnica el ciclo de temperatura ocurre m\u00e1s r\u00e1pido que \nen los ensayos de PCR est\u00e1ndar, la hibridaci\u00f3n de sondas se \nproduce continuamente durante la reacci\u00f3n de amplificaci\u00f3n y \nel tinte fluorescente acoplado a la sonda emite una se\u00f1al solo \ncuando tiene lugar la hibridaci\u00f3n192. Por otro lado, PCR m\u00falti-\nple es utilizada para la identificaci\u00f3n simult\u00e1nea de varias se-\ncuencias de genes que pertenecen al mismo pat\u00f3geno o a una \nmezcla de diferentes pat\u00f3genos. Esta t\u00e9cnica permite ahorrar \ntiempo y reactivos al dirigirse a m\u00faltiples dianas a la vez193. \nOtro tipo de PCR es la PCR anidada, este ensayo implica dos \nreacciones de amplificaci\u00f3n secuenciales con un par de ceba-\ndores diferentes en cada una, el segundo conjunto de cebado-\nres amplifica un objetivo secundario dentro del producto de la \nprimera reacci\u00f3n. Esto proporciona ejecutar un mayor n\u00famero \nde ciclos mientras se reducen los productos no espec\u00edficos, \naumentando la especificidad y sensibilidad de detecci\u00f3n194,195.\nT\u00e9cnicas de diagn\u00f3stico molecular en desarrollo\nA lo largo del tiempo se han ido desarrollando t\u00e9cnicas \nmoleculares modernas para el diagn\u00f3stico (Figura 2).\nFigura 3. Productos biol\u00f3gicos usados en el control de pandemias (Creado en BioRender).Pamela Molina and Marbel Torres Arias\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2105\nLa amplificaci\u00f3n isot\u00e9rmica mediada por LOOP (LAMP) \namplifica secuencias espec\u00edficas de ADN empleando un conjun-\nto de cuatro o seis cebadores \u00fanicos, la mezcla de reacci\u00f3n se \nincuba en una sola temperatura y el producto de amplificaci\u00f3n \npuede detectarse por la presencia de precipitado de pirofosfato \nde magnesio como subproducto del proceso de amplificaci\u00f3n \no por fluorescencia bajo luz UV, adem\u00e1s es posible monitorear \nla reacci\u00f3n en tiempo real midiendo la turbidez del pirofostato. \nEste ensayo se caracteriza por su simplicidad y alta sensibili-\ndad83,135,196. La t\u00e9cnica LAMP se combina con una transcripci\u00f3n \ninversa para la identificaci\u00f3n de ARN (RT-LAMP)83,137.\nPor otro lado, las Repeticiones Palindr\u00f3micas Cortas \nagrupadas y Regularmente Espaciadas (CRISPR), secuencias \nasociadas con las nucleasas Cas son la base de la tecnolog\u00eda \nCRISPR/Cas. CRISPR son una familia de secuencias de ADN \npropias de organismos procariota y Cas son un grupo de en-\ndonucleasas que precisan de un ARN gu\u00eda para reconocer y \ncortar una secuencia complementaria de ADN. Estas enzimas \npueden ser programadas para ser dirigidas a ARN viral142,197. La \namplificaci\u00f3n mediada por transcripci\u00f3n (TMA) es un ensayo \nde amplificaci\u00f3n isot\u00e9rmica de un \u00fanico tubo que emplea una \ntranscriptasa inversa y una polimerasa de ARN para amplifi-\ncar segmentos espec\u00edficos de ADN o ARN con mayor eficiencia \nque la RT-PCR198. Mientras que una alternativa isot\u00e9rmica de la \nPCR, es la amplificaci\u00f3n isot\u00e9rmica de recombinasa y polime-\nrasa (RPA), un ensayo r\u00e1pido, port\u00e1til y de detecci\u00f3n m\u00faltiple189.\nInmunoensayos en el diagn\u00f3stico\nLas pruebas de anticuerpos identifican el aumento de \nestas prote\u00ednas en el suero de pacientes, los anticuerpos son \nproducto de la activaci\u00f3n de una respuesta inmune humoral \npos infecci\u00f3n de microorganismos pat\u00f3genos44. Estos ensayos \nsuelen estar dise\u00f1ados para detectar anticuerpos humanos \nIgA, IgM o/y IgG, usualmente, los anticuerpos IgM son hallados \npocos d\u00edas despu\u00e9s de la infecci\u00f3n, y los anticuerpos IgG apa-\nrecen m\u00e1s tarde199. Los estudios de cuantificaci\u00f3n de anticuer-\npos permiten determinar infecciones recientes o pasadas200,201, \nsin embargo, estas pruebas no se las utiliza para diagnosticar \npacientes infectados debido a problemas de mutaciones de c\u00e9-\nlulas B202 y deficiencia en la producci\u00f3n de anticuerpos203, por \nlo que son aprovechadas como una herramienta de estudios \nserol\u00f3gicos para conocer el estado de la respuesta inmune204  y \npara evaluar la din\u00e1mica de las respuestas humorales activa-\ndas por vacunas70,95,125 (Figura 2).\nOtro tipo de inmunoensayo son las pruebas de detecci\u00f3n \nde ant\u00edgenos (Figura 2), que se encargan de identificar direc-\ntamente part\u00edculas de pat\u00f3genos en muestras biol\u00f3gicas, es \ndecir son capaces de detectar la infecci\u00f3n activa en personas \nafectadas. Las m\u00e1s comunes son las pruebas r\u00e1pidas de de-\ntecci\u00f3n de ant\u00edgenos (RAP) que se basan en inmunoensayos \nde flujo lateral (LFIA)61, estas realizan una determinaci\u00f3n cua-\nlitativa del ant\u00edgeno mediante un anticuerpo espec\u00edfico inmo-\nvilizado en el dispositivo205. Las RAP son ideales en pacientes \nque se encuentran en la etapa inicial de la enfermedad, cuando \nla carga viral es com\u00fanmente elevada; adem\u00e1s en sujetos con \nexposici\u00f3n a casos confirmados. La sensibilidad de las RAP es \nmenor en comparaci\u00f3n con las pruebas moleculares y el culti-\nvo viral206,207. En consecuencia, los resultados negativos de las \npruebas basadas en este m\u00e9todo no son capaces de descartar \ninfecciones.\nProductos biotecnol\u00f3gicos\nLos productos de origen biol\u00f3gico son mol\u00e9culas grandes \ny complejas, compuestos de az\u00facares, prote\u00ednas o \u00e1cidos nu-cleicos o combinaciones de estas sustancias, tambi\u00e9n pueden \nser entidades vivas como c\u00e9lulas y tejidos que se emplean \npara diagnosticar, prevenir, tratar o curar enfermedades. Estos \nproductos se obtienen de fuentes naturales (humanos, anima-\nles, microorganismos, c\u00e9lulas animales o vegetales), y se pro-\nducen mediante m\u00e9todos biotecnol\u00f3gicos y otras tecnolog\u00edas \nde vanguardia como la nanotecnolog\u00eda208,209.\nLos productos biol\u00f3gicos constituyen un producto crecien-\nte en el mercado farmac\u00e9utico, a nivel mundial los gastos en \nproductos biol\u00f3gicos sumaron $277 mil millones durante el \n2017 y se predice que en el 2022 aumenten a $452 mil millo-\nnes210. Estos biof\u00e1rmacos se encuentran protegidos por una \nmayor cantidad de patentes que los f\u00e1rmacos de origen qu\u00edmi-\nco puesto que la fabricaci\u00f3n biol\u00f3gica posee mayor compleji-\ndad, por lo que es necesario conservar la propiedad intelectual \nno s\u00f3lo sobre las composiciones de materia, sino tambi\u00e9n sobre \nlos procesos de fabricaci\u00f3n211,212. El gran n\u00famero de patentes \nexistentes representan un desaf\u00edo al momento de identificar \nlos procesos que deben ser eludidos para evitar litigios, por lo \nque el proyecto de Ley de Transparencia de Patentes Biol\u00f3gi-\ncas propuesto en el Congreso de los EE. UU. en 2019, busca \nsolucionar este conflicto estableciendo una lista de b\u00fasqueda \nimperativa de patentes que resguarda los productos biol\u00f3gicos, \nla cual se incorporar\u00e1 en el Libro P\u00farpura de la FDA211,213.  \nPor otro lado, a diferencia de los f\u00e1rmacos de mol\u00e9cula \npeque\u00f1a la mayor\u00eda de biol\u00f3gicos son composiciones comple-\njas y heterog\u00e9neas que requieren principios as\u00e9pticos en todo \nel proceso de fabricaci\u00f3n208. Es as\u00ed que la licencia de comercia-\nlizaci\u00f3n de un producto biol\u00f3gico es otorgada por organismos \nreguladores como la FDA y la EMA, que cumplen con los re-\nquisitos que garantizan seguridad, pureza y potencia continua \ndel producto214.\nLos principales productos biotecnol\u00f3gicos dirigidos a enfer-\nmedades causantes de pandemias se observan en la Figura 3. \nLos anticuerpos monoclonales (mAb) neutralizantes se \na\u00edslan de personas recuperadas de la infecci\u00f3n o de modelos \nanimales inmunizados y se  pueden administrar en pacientes \nantes o despu\u00e9s de una infecci\u00f3n viral para aplicaciones tera-\np\u00e9uticas o profil\u00e1cticas, los cuales van dirigidos a una diana \nespec\u00edfica del pat\u00f3geno evitando la infecci\u00f3n de este a la c\u00e9lu-\nla hu\u00e9sped93,114,155. Por otro lado, los interferones (IFN) son pro-\nte\u00ednas se\u00f1alizadoras de origen natural producidas por c\u00e9lulas \ndel sistema inmunol\u00f3gico, que poseen propiedades antivirales \ne inmunomoduladoras no espec\u00edficas87,110. Son estimulados \npor infecciones virales, estos se secretan y se unen a la c\u00e9lula \nafectada o a sus c\u00e9lulas vecinas y activa la expresi\u00f3n de genes \ncon funci\u00f3n antiviral215. Existen tres clases principales de inter-\nferones empleados en farmacoterapia los alfa (IFN-\u03b1), los beta \n(IFN-\u03b2) y los gamma (INF-\u03b3)216. Com\u00fanmente los interferones \nson estudiados en combinaci\u00f3n con otros agentes antivirales, \nribavirina o lopinavir / ritonavir87,217. Otro de los tratamientos \nvalorados en la aparici\u00f3n de pandemias es el empleo de ARN \nde interferencia, como ARN de interferencia peque\u00f1os (siRNA) \ny micro ARN (miARN), la funci\u00f3n de estas mol\u00e9culas es la su-\npresi\u00f3n de la expresi\u00f3n de genes claves de los pat\u00f3genos me-\ndiante interferencia por ARN111,218,219.\nVacunas\nLas plataformas empleadas para el dise\u00f1o de vacunas \nhan evolucionado conforme las necesidades de la humanidad \ny la disponibilidad de tecnolog\u00eda (Figura 3).\nVacunas de virus (inactivadas y atenuadas)\nEn las vacunas inactivadas se aplican enfoques qu\u00edmicos Herramientas biotecnol\u00f3gicas en el diagn\u00f3stico, prevenci\u00f3n y tratamiento frente a pandemias\nBiotechnological tools in the diagnosis, prevention, and treatment of pandemics2106\no f\u00edsicos para eliminar las propiedades infecciosas del pat\u00f3-\ngeno21,23. Las ventajas de estas vacunas son la facilidad de \nproducci\u00f3n, adem\u00e1s de su seguridad y eficacia en el recono-\ncimiento inmunol\u00f3gico, sin embargo, el rendimiento podr\u00eda ser \nlimitado debido a la baja producci\u00f3n del virus y la necesidad de \ninstalaciones de altos niveles de bioseguridad48,71.\nLas vacunas vivas atenuadas constan de una versi\u00f3n de-\nbilitada del pat\u00f3geno que se replica limitadamente con el fin \nde no causar la enfermedad y al mismo tiempo activar las res-\npuestas inmunes de manera similar a una infecci\u00f3n natural. \nAlgunas de las desventajas son los problemas de seguridad y \nel desaf\u00edo en el proceso de atenuaci\u00f3n31,72.\nVacunas basadas en prote\u00ednas (subunidad proteica y \npart\u00edculas similares a virus)\nEn el caso de las vacunas de subunidades se administran \nprote\u00ednas altamente antig\u00e9nicas del pat\u00f3geno en el individuo, \ndebido a su baja complejidad antig\u00e9nica su eficacia protectora \npuede ser limitada, adem\u00e1s de provocar respuestas inmunes \nno regulares220,221. Las vacunas de part\u00edculas similares al virus \nconstan de prote\u00ednas de la c\u00e1pside viral, que generan una alta \nactivaci\u00f3n del sistema inmune debido a la repetici\u00f3n de sus \nestructuras, adem\u00e1s confieren seguridad debido a la ausencia \nde material gen\u00e9tico del pat\u00f3geno, sin embargo, existen com-\nplicaciones en el proceso dise\u00f1o de la plataforma222.\nVacunas de vectores virales (replicantes y no \nreplicantes)\nLas vacunas de vectores virales se basan en un virus mo-\ndificado con un gen que exprese una prote\u00edna de inter\u00e9s del \npat\u00f3geno en cuesti\u00f3n. Los vectores virales de replicaci\u00f3n in-\ncompetente son virus inhabilitados para la replicaci\u00f3n median-\nte la eliminaci\u00f3n de partes de su genoma, entre las ventajas de \nesta plataforma es que no es necesario manipular el pat\u00f3geno \nin vivo, estos vectores son capaces de activar respuestas in-\nmunitarias celulares y humorales, y existe gran experiencia en \nla producci\u00f3n de este tipo de vacunas95,125. Por otro lado, para \nel empleo de vectores de replicaci\u00f3n competente se considera \na virus que no se replican de manera eficiente o virus de ani-\nmales que no causan enfermedades en humanos, la ventaja \nde esta plataforma es que tiene la capacidad de promover una \ninmunidad robusta debido a que existe una infecci\u00f3n real119.\nVacunas g\u00e9nicas (ADN o ARN)\nEn este tipo de vacunas la informaci\u00f3n gen\u00e9tica del pat\u00f3-\ngeno, ADN o ARN, es administrada para luego dirigirse a las \nc\u00e9lulas del individuo vacunado y expresar una prote\u00edna de in-\nter\u00e9s capaz de activar efectivamente el sistema inmunitario y \nlograr defender al hu\u00e9sped en caso en una futura infecci\u00f3n. La \ntecnolog\u00eda de ADN se puede producir a gran escala, sin embar-\ngo, muestran baja inmunogenicidad y necesitan de dispositivos \neficientes para su administraci\u00f3n94,223,224. Mientras que, las va-\ncunas de ARNm poseen capacidad de desarrollo breve, ele-\nvada potencia y fabricaci\u00f3n rentable, pero requiere almacena-\nmiento a bajas temperaturas para su estabilidad, sin embargo, \ncon los \u00faltimos desarrollos referentes a ARNm encapsulado \nen nanopart\u00edculas se podr\u00eda almacenar este tipo de vacunas a \ntemperaturas de 4\u00b0C169,225.\nDiscusi\u00f3n y conclusiones \nEn cuanto a las herramientas de diagn\u00f3stico, se debe te-\nner en cuenta que ninguna prueba biol\u00f3gica puede alcanzar \nuna especificidad del 100% y una sensibilidad del 100%130. Por su parte, la sensibilidad se define como la capacidad de una \nprueba de arrojar un resultado positivo en una persona enfer-\nma, mientras que la especificidad es la capacidad de la prueba \nde obtener un resultado negativo en un sujeto libre de la en-\nfermedad226,227. Como se muestra en la comparaci\u00f3n de resul-\ntados de la Tabla 1, la sensibilidad y especificidad de cada una \nde las t\u00e9cnicas no son 100%, sin embargo, las herramientas \nmoleculares presentan la mejor alternativa para el diagn\u00f3stico \nde enfermedades pand\u00e9micas, reduciendo en gran medida los \nfalsos positivos y falsos negativos, elevando as\u00ed la eficiencia de \nlas pruebas. Seg\u00fan Yuan et al.148 los resultados del diagn\u00f3stico \ndependen de varias condiciones como las caracter\u00edsticas del \nkit de detecci\u00f3n, sus controles, su especificidad, sensibilidad \ny calidad de la muestra, como se demuestra en la Figura 2, \nnuevamente las t\u00e9cnicas moleculares alcanzan un porcentaje \nsuperior en comparaci\u00f3n con el cultivo celular que presenta di-\nficultades en el tiempo de ejecuci\u00f3n, baja sensibilidad; y los in-\nmunoensayos para la detecci\u00f3n de ant\u00edgenos, los cuales no se \nrecomiendan como un diagn\u00f3stico confirmatorio debido al alto \n\u00edndice de falsos negativos. No obstante, las pruebas de ant\u00edge-\nnos debido a que permiten la obtenci\u00f3n resultados acelerados \na un menor costo, se pueden aplicar masivamente teniendo un \nmayor impacto en la salud p\u00fablica.\nLa qRT-PCR ha sido la t\u00e9cnica m\u00e1s empleada como es-\nt\u00e1ndar de oro para el diagn\u00f3stico de pandemias, sin embargo, \na pesar de los altos \u00edndices de especificidad y sensibilidad, han \nsurgido algunos problemas como costos elevados, tiempo de \nprocesamiento, requerimiento de personal capacitado y altos \nest\u00e1ndares de bioseguridad, por lo que se est\u00e1n desarrollando \nvarias alternativas con resultados prometedores como LAMP, \nCRISPR-Cas y biosensores con el fin de minimizar las desven-\ntajas y optimizar el diagn\u00f3stico de enfermedades pand\u00e9mi-\ncas148,189.\nPor otro lado, el gran avance en el desarrollo de los pro-\nductos biotecnol\u00f3gicos se debe a varias ventajas como su alta \neficiencia, efectos secundarios m\u00e1s seguros y reducidos en \ncontraste con los f\u00e1rmacos de mol\u00e9culas peque\u00f1as, adem\u00e1s \nde los costos relativamente bajos que presentan en compa-\nraci\u00f3n con sus beneficios y terapias completamente inno-\nvadoras. En el caso de la fabricaci\u00f3n de vacunas fue posible \nobservar una diferencia significativa en esta pandemia del \nSARS-CoV-2 en contraposici\u00f3n con brotes anteriores, gracias \nal nivel cient\u00edfico actual, debido que a pesar de la capacidad \nde investigaci\u00f3n, de los avances biom\u00e9dicos y biotecnol\u00f3gicos, \ny del desarrollo de la tecnolog\u00eda, las vacunas podr\u00edan tardar \na\u00f1os, hasta d\u00e9cadas en ser llevadas al mercado para el bene-\nficio de la humanidad, como es el caso de la primera vacuna \ncontra el EBOV aprobada en el 2019 por la FDA y la EMA122. En \nla actualidad, la situaci\u00f3n ha sido diferente frente a la pande-\nmia de COVID-19, a un a\u00f1o y tres meses del inicio del brote del \nSARS-CoV-2 existen 3 vacunas aprobadas por la FDA, 4 vacu-\nnas candidatas en fase 4 y 12 vacunas en estudios cl\u00ednicos fase \n3150, los expertos afirman que todo el proceso de fabricaci\u00f3n y \nexperimentaci\u00f3n se han dado en un tiempo r\u00e9cord gracias a la \ngran inversi\u00f3n tanto p\u00fablica como privada que se ha llevado a \ncabo y al sobrelapamiento de las fases precl\u00ednicas y cl\u00ednicas en \nlos diferentes estudios.\nLas perspectivas futuras sobre las herramientas y pro-\nductos biotecnol\u00f3gicos son prometedoras, con t\u00e9cnicas de \ndiagn\u00f3stico eficientes con caracter\u00edsticas ultrasensibles con \nrequerimientos de concentraciones a escala  nano  y tecno-\nlog\u00eda basadas en inteligencia artificial o biolog\u00eda sint\u00e9tica148,228, \nlas cuales permitir\u00e1n brindar un apoyo intensivo en el diagnos-\ntico y seguimiento en la propagaci\u00f3n de la enfermedad y trans-\nmisi\u00f3n del pat\u00f3geno. Los biof\u00e1rmacos, por su parte, constitu-Pamela Molina and Marbel Torres Arias\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2107\nyen la vanguardia de la investigaci\u00f3n biom\u00e9dica, por lo que se \naspira que en el futuro representen una opci\u00f3n m\u00e1s eficiente en el control de enfermedades infecciosas que en la actualidad carecen de tratamiento o poseen muy pocas alternativas\n208, \nadem\u00e1s de terapias personalizadas optimizando dr\u00e1sticamen-te la seguridad y eficacia de los medicamentos\n178.\nFinalmente, podemos concluir que el desarrollo y uso de \nlas herramientas biotecnol\u00f3gicas actuales han revolucionado el campo de la medicina en este caso el control de enferme-dades emergentes con potencial pand\u00e9mico. Con todos los conocimientos y lecciones adquiridas a lo largo de las diferen-tes pandemias y epidemias ocurridas a trav\u00e9s de la historia, en posteriores brotes se poseer\u00e1 la capacidad de un mejor mane-jo y contenci\u00f3n de las enfermedades.\nReferencias bibliogr\u00e1ficas\n1. Dobson AP , Carper ER. Infectious diseases and human population \nhistory. Bioscience 1996; 46: 115\u2013126.\n2.W\norld Health Organization. Disease burden and mortality esti-\nmates: Cause-specific mortality, 2000\u20132016. 2017.http://www.\nwho.int/healthinfo/global_burden_disease/estimates/en/ (ac-cessed 27 Feb2021).\n3.\nSmith KM, Machalaba CC\n, Seifman R, Feferholtz Y, Karesh WB.\nInfectious disease and economics: The case for consideringmulti-sectoral impacts. One Heal 2019; 7: 100080.\n4.\n Nicola M, Alsafi Z, Sohr\nabi C, Kerwan A, Al-Jabir A, Iosifidis C et\nal. The socio-economic implications of the coronavirus pandemic (COVID-19): A review. Int J Surg 2020; 78: 185\u2013193.\n5.\nK\noplan JP, McPheeters M. Plagues, public health, and politics.\nEmerg Infect Dis 2004; 10: 2039\u20132043.\n6.DeWit\nte SN. Mortality risk and survival in the aftermath of the\nmedieval Black Death. PLoS One 2014; 9: e96513.\n7.Ogden \nNH, Wilson JRU, Richardson M, Hui C, Davies SJ, Kum-\nschick S et al. Emerging infectious diseases and biological inva-sions\n : a call for a One Heal\nth collaboration in science and man-\nagement. R Soc Open Sci 2019; 6. doi:https://doi.org/10.1098/rsos.181577.\n8.\n Jones KE, P\natel NG, Levy MA, Storeygard A, Balk D, Gittleman JL \net al. Global trends in emerging infectious diseases. Nature 2008; 451: 990\u2013994.\n9.\nSun Q, Qiu H, Huang M, Y\nang Y. Lower mortality of COVID-19\nby early recognition and intervention: experience from JiangsuProvince. Ann Intensive Care 2020; 10. doi:10.1186/s13613-020-00650-2.\n10.\n R\nauch S, Jasny E, Schmidt KE, Petsch B. New vaccine technol-\nogies to combat outbreak situations. Front Immunol 2018; 9.doi:10.3389/fimmu.2018.01963.\n11.\n Hine R. A Dictionar\ny of Biology. 2019 doi:10.1093/\nacref/9780198821489.001.0001.\n12.\n P\norta M. A Dictionary of Epidemiology. 2016 doi:10.1093/\nacref/9780199976720.001.0001.\n13.\n Adalja AA, W\natson M, Toner ES, Cicero A, Inglesby T V.\nThe characteristics of pandemic pathogens. 2018https://www.centerforhealthsecurity.org/our-work/pubs_archive/pubs-pdfs/2018/180510-pandemic-pathogens-report.pdf.\n14.\n Taubenberger JK, Morens DM. 1918 Influenza: The mother of allpandemics. Emerg. Infect. Dis. 2006; 12: 15\u201322.\n15.\n Johnson N, Muelle J\n. Updating the accounts: global mortality\nof the 1918 \u2013 1920 \u2018spanish\u2019 influenza pandemic. Bull Hist Med2002; 76: 105\u2013115.\n16.\n Dunn FL. P\nandemic influenza in 1957: Review of international\nspread of new asian strain. J Am Med Assoc 1958; 166: 1140\u20131148.\n17.\n Glezen WP. Emerging infections: pandemic influenza. EpidemiolR\nev 1996; 18: 64\u201376.\n18.\n Viboud C\n, Simonsen L, Fuentes R, Flores J, Miller MA, Chowell G. \nGlobal mortality impact of the 1957 \u2013 1959 influenza pandemic.J Infect Dis 2016; 213: 738\u2013745.19.\n Blumenfeld \nH, Kilbourne E, Louria D, Rogers D. Studies on influ-\nenza in the pandemic of 1957-1958. I. An epidemiologic, clinicaland serologic investigation of an intrahospital epidemic, with anote on vaccination efficacy. J Clin Invest 1958; 38: 199\u2013212.\n20.\n Jensen \nKE, Hogan RB. Laboratory diagnosis of asian influenza.\nPublic Health Rep 1958; 73: 140\u2013144.\n21.\n Gundel\nfinger BF, Stille WT, Bell JA. Effectiveness of influenza\nvaccines during an epidemic of asian influenza. N Engl J Med1958; 259: 1005\u20131009.\n22.\n Cul\nver JO, Nitz RE, Lennette EH. The protective effect of mon-\novalent asian-strain vaccine against asian influenza. J Am MedAssoc 1957; 165: 2174\u20132177.\n23.\n Dull BH, Jensen KE, R\nakich JH, Cohen A, Henderson DA, Pirkle CI. \nMonovalent asian influenza vaccine: evaluation of its use duringtwo waves of epidemic asian influenza in partly immunized peni-tentiary population. J Am Med Assoc 1960; 172: 87\u201393.\n24.\n Da\nvenport FM. Role of the commission on influenza. Public\nHealth Rep 1958; 73: 133\u2013139.\n25.\n Meiklejohn G\n, Morris AJ. Influenza vaccination. Ann Intern Med\n1958; 49: 529\u2013535.\n26. Langmuir A. Epidemiology of Asian influenza. With special em-\nphasis on the United States. Am Rev Respir Dis 1961; 83: 2\u201314.\n27.\n Cockburn \nWC, Delon PJ, Ferreira W. Origin and progress of the\n1968-69 Hong Kong influenza epidemic. Bull World Health Organ 1969; 41: 345\u2013348.\n28.\n R\nogers K. 1968 Flu pandemic. Encycl. Br. 2020.https://www.bri-\ntannica.com/event/1968-flu-pandemic (accessed 21 Sep2020).\n29.\n Coleman MT\n, Dowdle WR. Properties of the Hong Kong influenza \nvirus. I. General characteristics of the Hong Kong virus. Bull World Health Organ 1969; 41: 415\u2013418.\n30.\n Murr\nay R. Production and testing in the USA of influenza virus\nvaccine made from the Hong Kong variant in 1968-69. Bull World Health Organ 1969; 41: 495\u2013496.\n31.\n Maas\nsab HF, Francis T, Davenport FM, Hennessy A V, Minuse E,\nAnderson G. Laboratory and clinical characteristics of attenuat-ed strains of influenza virus. Bull World Health Organ 1969; 41:589\u2013594.\n32.\n Br\nandon FB, Cox F, Quinn E, Timm EA, Mclean IW. Influenza im-\nmunization: clinical studies with ether-split subunit vaccines. Bull World Health Organ 1969; 41: 629\u2013637.\n33.\n W\narburton MF. Desoxycholate-split influenza vaccines. Bull\nWorld Health Organ 1969; 41: 639\u2013641.\n34.\n Kilbourne ED\n. Future influenza vaccines and the use of genetic\nrecombinants. Bull World Health Organ 1969; 41: 643\u2013645.\n35.\n Couch RB, Douglas RG\n, Fedson DS, Kasel JA. Correlated studies\nof a recombinant influenza-virus vaccine. III. Protection againstexperimental influenza in man. J Infect Dis 1971; 124: 473\u2013480.\n36.\n K\nsiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S\net al. A novel coronavirus associated with severe acute respirato-ry syndrome. N Engl J Med 2003; 348: 1953\u20131966.\n37.\n W\norld Health Organization. Cumulative number of reported prob-\nable cases of SARS. 2015.https://www.who.int/csr/sars/coun-try/2003_07_11/en/ (accessed 25 Jan2021).\n38.\n W\norld Health Organization. Alert, verification and public health\nmanagement of SARS in the post-outbreak period. 2003.https://www.who.int/csr/sars/postoutbreak/en/ (accessed 30 Dec2020).\n39.\n Chan KH, P\noon LLLM, Cheng VCC, Guan Y, Hung IFN, Kong J et al. \nDetection of SARS coronavirus in patients with suspected SARS.Emerg Infect Dis 2004; 10: 294\u2013299.\n40.\n Y\nam WC, Chan KH, Poon LLM, Guan Y, Yuen KY, Seto WH et al.\nEvaluation of reverse transcription-PCR assays for rapid diagno-sis of severe acute respiratory syndrome associated with a novel coronavirus. J Clin Microbiol 2003; 41: 4521\u20134524.\n41.\n P\noon LLM, Chan KH, Wong OK, Yam WC, Yuen KY, Guan Y et al.\nEarly diagnosis of SARS Coronavirus infection by real time RT-PCR. J Clin Virol 2003; 28: 233\u2013238.\n42.\n Chan PK\nS, To WK, Ng KC, Lam RKY, Ng TK, Chan RCW et al. Lab-\noratory diagnosis of SARS. Emerg Infect Dis 2004; 10: 825\u2013831.\n43.\n P\neiris JSM, Lai ST, Poon LLM, Guan Y, Yam LYC, Lim W et al. Coro-\nnavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003; 361: 1319\u20131325.Herramientas biotecnol\u00f3gicas en el diagn\u00f3stico, prevenci\u00f3n y tratamiento frente a pandemias\nBiotechnological tools in the diagnosis, prevention, and treatment of pandemics2108\n44. Shi Y , Yi Y, Li P, Kuang T, Li L, Dong M et al. Diagnosis of Severe\nAcute Respiratory Syndrome (SARS) by Detection of SARS\ncoronavirus nucleocapsid antibodies in an antigen-capturing en-zyme-linked immunosorbent assay. J Clin Microbiol 2003; 41:5781\u20135782.\n45.\n Lu A, Zhang H, Zhang X, W\nang H, Hu Q, Shen L et al. Attenuation\nof SARS coronavirus by a short hairpin RNA expression plasmidtargeting RNA-dependent RNA polymerase. Virology 2004; 324:84\u201389.\n46.\n Cheng Y\n, Wong R, Soo YOY, Wong WS, Lee CK, Ng MHL et al. Use \nof convalescent plasma therapy in SARS patients in Hong Kong.Eur J Clin Microbiol Infect Dis 2005; 24: 44\u201346.\n47.\n Ho JC\n, Wu AY, Lam B, Ooi GC, Khong P-L, Ho PL et al. Pentaglo-\nbin in steroid-resistant severe acute respiratory syndrome. Int JTuberc Lung Dis 2004; 8: 1173\u20131179.\n48.\n Zhou \nJ, Wang W, Zhong Q, Hou W, Yang Z, Xiao SY et al. Im-\nmunogenicity, safety, and protective efficacy of an inactivatedSARS-associated coronavirus vaccine in rhesus monkeys. Vac-cine 2005; 23: 3202\u20133209.\n49.\n Y\nang ZY, Kong WP, Huang Y, Roberts A, Murphy BR, Subbarao K\net al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 2004; 428: 561\u2013564.\n50.\n Gao W\n, Tamin A, Soloff A, D\u2019Aiuto L, Nwanegbo E, Robbins PD et\nal. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 2003; 362: 1895\u20131896.\n51.\n Centers for Disease Control and Pre\nvention. Update: novel influ-\nenza A (H1N1) virus infections - worldwide, May 6, 2009. MMWRMorb Mortal Wkly Rep 2009; 58: 453\u2013458.\n52.\n Centers for Disease Control \nand Prevention. 2009 H1N1 Pandem-\nic (H1N1pdm09 virus). 2019.https://www.cdc.gov/flu/pandem-ic-resources/2009-h1n1-pandemic.html (accessed 25 Jan2021).\n53.\n Da\nwood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng PY\net al. Estimated global mortality associated with the first 12months of 2009 pandemic influenza A H1N1 virus circulation: amodelling study. Lancet Infect Dis 2012; 12: 687\u2013695.\n54.\n W\norld Health Organization. WHO information for laboratory di-\nagnosis of pandemic ( H1N1 ) 2009 virus in humans \n\u03b1\nrevised.\n2009https://www.who.int/csr/resources/publications/swineflu/WHO_Diagnostic_RecommendationsH1N1_20090521.pdf.\n55.\n P\neiris JM, Poon LLM, Guan Y. Emergence of a novel swine-origin\ninfluenza A virus (S-OIV) H1N1 virus in humans. J Clin Virol 2009; 45: 169\u2013173.\n56.\n Centers for Disease Control and Pre\nvention. Interim guidance\non specimen collection, processing, and testing for patients withsuspected novel influenza A (H1N1) virus infection. 2009.https://www.cdc.gov/h1n1flu/specimencollection.htm (accessed 20Jan2021).\n57.\n Balish A, W\narnes C, Wu K, Barnes N, Emery S, Berman L et al.\nEvaluation of rapid influenza diagnostic tests for detection of nov-el influenza A (H1N1) virus - United States, 2009. Morb MortalWkly Rep 2009; 58: 826\u2013829.\n58.\n K\numar S, Henrickson KJ. Update on influenza diagnostics: les-\nsons from the novel H1N1 influenza A pandemic. Clin MicrobiolRev 2012; 25: 344\u2013361.\n59.\n W\norld Health Organization. CDC protocol of realtime RTPCR for\ninfluenza A (H1N1). Atlanta, 2009.\n60.\n Kim D\n, Poudel B. Tools to Detect Influenza Virus. Yosei Med J\n2013; 54: 560\u2013566.\n61.\n V\nasoo S, Stevens J, Singh K. Rapid antigen tests for diagnosis\nof pandemic (Swine) influenza A/H1N1. Clin Infect Dis 2009; 49:1090\u20131093.\n62.\n Centers for Disease Control and Pre\nvention. Interim Recommen-\ndations for Clinical Use of Influenza Diagnostic Tests During the2009-10 Influenza Season. 2009.https://www.cdc.gov/h1n1flu/guidance/diagnostic_tests.htm#_ftn1 (accessed 4 Feb2021).\n63.\n Gar\nten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A et \nal. Antigenic and Genetic Characteristics of the Early Isolates ofSwine-Origin 2009 A(H1N1) Influenza Viruses Circulating in Hu-mans. Science 2009; 325: 197\u2013201.\n64.\n Y\nang Y, Sugimoto JD, Halloran ME, Basta NE, Chao DL, Matrajt\nL et al. The transmissibility and control of pandemic influenza A(H1N1) virus. Science 2009; 326: 729\u2013733.\n65.\n Hung IFN, T\no KKW, Lee CK, Lee KL, Yan WW, Chan K et al. Hy-\nperimmune IV immunoglobulin treatment: A multicenter dou-ble-blind randomized controlled trial for patients with severe2009 influenza A(H1N1) infection. Chest 2013; 144: 464\u2013473.\n66.\n Hung IFN, T\no KKW, Lee CK, Lee KL, Chan K, Yan WW et al. Con-\nvalescent plasma treatment reduced mortality in patients withsevere pandemic influenza A (H1N1) 2009 virus infection. ClinInfect Dis 2011; 52: 447\u2013456.\n67.\n Pre\nvention C for DC and. Key Facts About 2009 H1N1 Flu Vac-\ncine. 2010.https://www.cdc.gov/h1n1flu/vaccination/vaccine_keyfacts.htm (accessed 5 Feb2021).\n68.\n Centers \nfor Disease Control and Prevention. Update on Influenza \nA (H1N1) 2009 Monovalent Vaccines. MMWR Morb Mortal WklyRep 2009; 58: 1100\u20131101.\n69.\n Neumann G\n, Kawaoka Y. The first influenza pandemic of the new \nmillennium. Influenza Other Respi Viruses 2011; 5: 157\u2013166.\n70.\n Plenne\nvaux E, Sheldon E, Blatter M, Reeves-Hoch\u00e9 MK, Denis\nM. Immune response after a single vaccination against 2009 in-fluenza A H1N1 in USA: a preliminary report of two randomisedcontrolled phase 2 trials. Lancet 2010; 375: 41\u201348.\n71.\n Greenberg ME, Lai MH, Har\ntel GF, Wichems CH, Gittleson C, Ben-\nnet J et al. Response to a monovalent 2009 influenza A (H1N1)vaccine. New Engl J Med 2009; 361: 2405\u20132413.\n72.\n Mallor\ny RM, Malkin E, Ambrose CS, Bellamy T, Shi L, Yi T et al.\nSafety and immunogenicity following administration of a live, at-tenuated monovalent 2009 H1N1 influenza vaccine to childrenand adults in two randomized controlled trials. PLoS One 2010;5: e13755.\n73.\n Clark TW\n, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N\net al. Trial of 2009 influenza A (H1N1) monovalent MF59-adju-vanted vaccine. N Engl J Med 2009; 361: 2424\u20132435.\n74.\n Hardelid P\n, Fleming DM, Mcmenamin J, Andrews N, Robertson C, \nSebastianPillai P et al. Effectiveness of pandemic and seasonalinfluenza vaccine in preventing pandemic influenza A(H1N1)2009 infection in England and Scotland 2009-2010. Eurosurveillance2011; 16: 19763.\n75.\n Lansbur\ny LE, Smith S, Beyer W, Karamehic E, Pasic-Juhas E,\nSikira H et al. Effectiveness of 2009 pandemic influenza A(H1N1) vaccines: A systematic review and meta-analysis. Vaccine 2017;35: 1996\u20132006.\n76.\n Zaki AM, V\nan Boheemen S, Bestebroer TM, Osterhaus ADME,\nFouchier RAM. Isolation of a novel coronavirus from a man withpneumonia in Saudi Arabia. N Engl J Med 2012; 367: 1814\u20131820.\n77.\n W\norld Health Organization. Middle East respiratory syndrome\ncoronavirus (MERS-CoV) \u2013 The Kingdom of Saudi Arabia. 2021.http://www.who.int/csr/don/01-february-2021-mers-saudi-ara-bia/en/ (accessed 16 Feb2021).\n78.\n Centers for Disease Control and Pre\nvention. Laboratory Testing\nfor MERS-CoV. 2019.https://www.cdc.gov/coronavirus/mers/lab/lab-testing.html#molecular (accessed 21 Dec2020).\n79.\n W\norld Health Organization. Laboratory testing for Middle East\nRespiratory Syndrome Coronavirus- Interim guidance (revised).2018https://www.who.int/csr/disease/coronavirus_infections/mers-laboratory-testing/en/ (accessed 18 Dec2020).\n80.\n Corman VM, E\nckerle I, Bleicker T, Zaki A, Landt O, Es-\nchbach-Bludau M et al. Detection of a novel human coronavirusby real-time reverse-transcription polymerase chain reaction. Eu-rosurveillance 2012; 17. doi:10.2807/ese.17.39.20285-en.\n81.\n Corman \nVM, M\u00fcller MA, Costabel U, Timm J, Binger T, Meyer B\net al. Assays for laboratory confirmation of novel human corona-virus (hCoV-EMC) infections. Eurosurveillance 2012; 17: 20334.\n82.\n Abd El W\nahed A, Patel P, Heidenreich D, Hufert FT, Weidmann\nM. Reverse transcription recombinase polymerase amplificationassay for the detection of middle east respiratory syndrome coro-navirus. PLoS Curr 2013; 5. doi:10.1371/currents.outbreaks.62df-1c7c75ffc96cd59034531e2e8364.\n83.\n Shir\nato K, Yano T, Senba S, Akachi S, Kobayashi T, Nishinaka T et al. De-\ntection of Middle East respiratory syndrome coronavirus using reversetranscription loop-mediated isothermal amplification (RT-LAMP). Vi-rol J 2014; 11. doi:https://doi.org/10.1186/1743-422X-11-139.Pamela Molina and Marbel Torres Arias\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2109\n84. Huang P , Wang H, Cao Z, Jin H, Chi H, Zhao J et al. A rapid and\nspecific assay for the detection of MERS-CoV. Front Microbiol\n2018; 9. doi:10.3389/fmicb.2018.01101.\n85.\n Memish \nZA, Perlman S, Van Kerkhove MD, Zumla A. Middle East\nrespiratory syndrome. Lancet 2020; 395: 1063\u20131077.\n86.\n K\noch T, Dahlke C, Fathi A, Kupke A, Kr\u00e4hling V, Okba NMA et al.\nSafety and immunogenicity of a modified vaccinia virus Ankaravector vaccine candidate for Middle East respiratory syndrome:an open-label, phase 1 trial. Lancet Infect Dis 2020; 20: 827\u2013838.\n87.\n Ar\nabi YM, Asiri AY, Assiri AM, Balkhy HH, Al Bshabshe A, Al Jerai-\nsy M et al. Interferon beta-1b and lopinavir\u2013ritonavir for middleeast respiratory syndrome. N Engl J Med 2020; 383: 1645\u20131656.\n88.\n Widjaja I, W\nang C, van Haperen R, Guti\u00e9rrez-\u00c1lvarez J, van Die-\nren B, Okba NMA et al. Towards a solution to MERS: protectivehuman monoclonal antibodies targeting different domains andfunctions of the MERS-coronavirus spike glycoprotein. Emerg Mi-crobes Infect 2019; 8: 516\u2013530.\n89.\n R\naj VS, Okba NMA, Gutierrez-Alvarez J, Drabek D, van Dieren B,\nWidagdo W et al. Chimeric camel / human heavy-chain antibodies protect against MERS-CoV infection. Sci Adv 2018; 4: eaas9667.\n90.\n K\no JH, Seok H, Cho SY, Ha YE, Baek JY, Kim SH et al. Challenges \nof convalescent plasma infusion therapy in Middle East respirato-ry coronavirus infection: A single centre experience|. Antivir Ther 2018; 23: 617\u2013622.\n91.\n de Wit E, F\neldmann F, Okumura A, Horne E, Haddock E, Saturday \nG et al. Prophylactic and therapeutic efficacy of mAb treatmentagainst MERS-CoV in common marmosets. Antiviral Res 2018;156: 64\u201371.\n92.\n Luk\ne T, Wu H, Zhao J, Channappanavar R, Coleman CM, Jiao J-A \net al. Human polyclonal immunoglobulin G from transchromo-somic bovines inhibits MERS-CoV in vivo. Sci Transl Med 2016;8: 326ra21.\n93.\n Beigel JH, V\noell J, Kumar P, Raviprakash K, Wu H, Jiao JA et al.\nSafety and tolerability of a novel, polyclonal human anti-MERScoronavirus antibody produced from transchromosomic cattle: aphase 1 randomised, double-blind, single-dose-escalation study.Lancet Infect Dis 2018; 18: 410\u2013418.\n94.\n Modjarr\nad K, Roberts CC, Mills KT, Castellano AR, Paolino K,\nMuthumani K et al. Safety and immunogenicity of an anti-MiddleEast respiratory syndrome coronavirus DNA vaccine: a phase 1,open-label, single-arm, dose-escalation trial. Lancet 2019; 19:1013\u20131022.\n95.\n F\nolegatti PM, Bittaye M, Flaxman A, Lopez FR, Bellamy D, Kup-\nke A et al. Safety and immunogenicity of a candidate MiddleEast respiratory syndrome coronavirus viral-vectored vaccine:a dose-escalation, open-label, non-randomised, uncontrolled,phase 1 trial. Lancet Infect Dis 2020; 20: 816\u2013826.\n96.\n P\nattyn S, van der Groen G, Jacob W, Piot P, Courteille G. Isolation \nof Marburg-like virus from a case of h\u00e6morrhagic fever in Zaire.Lancet 1977; 309: 573\u2013574.\n97.\n W\norld Health Organization. Ebola outbreak 2014-2016. 2016.\nhttp://www.who.int/csr/disease/ebola/en/ (accessed 23 Oct2020).\n98.\n Centers for Disease Control and Pre\nvention. 2020 Democratic\nRepublic of the Congo, Equateur Province. 2020.https://www.cdc.gov/vhf/ebola/outbreaks/drc/2020-june.html (accessed 6Feb2021).\n99.\n Jacob S\nT, Crozier I, Fischer WA, Hewlett A, Kraft CS, Vega MA de \nLa et al. Ebola virus disease. Nat Rev Dis Prim 2020; 6. doi:https://doi.org/10.1038/s41572-020-0147-3.\n100.\n Dudas G\n, Carvalho LM, Bedford T, Tatem AJ, Baele G, Faria \nNR et al. Virus genomes reveal factors that spread and sustained the Ebola epidemic. Nature 2017; 544: 309\u2013315.\n101.\n W\norld Health Organization. Ebola virus disease. 2020.\nhttps://www.who.int/news-room/fact-sheets/detail/ebola-vi-rus-disease (accessed 6 Feb2021).\n102.\n Erickson BR, Seal\ny TK, Flietstra T, Morgan L, Kargbo B,\nMatt-Lebby VE et al. Ebola virus disease diagnostics, Sierra Le-one: analysis of real time RT-PCR values in clinical blood and oral swab specimens. J Infect Dis 2016; 214: S258\u2013S262.\n103.\nMal\nvy D, McElroy AK, de Clerck H, G\u00fcnther S, van Griensven \nJ. Ebola virus disease. Lancet 2019; 393: 936\u2013948.104.  Pinsky B A, Sahoo MK, Sandlund J, Kleman M, Kulkarni M,\nGrufman P et al. Analytical performance characteristics of thecepheid GeneXpert Ebola Assay for the detection of Ebola virus.PLoS One 2015; 10: e0142216.\n105.\nCnops \nL, De Smet B, Mbala-Kingebeni P, van Griensven J,\nAhuka-Mundeke S, Ari\u00ebn KK. Where are the Ebola diagnosticsfrom last time? Nature 2019; 565: 419\u2013421.\n106.\nOr\naSure Technologies I. OraQuick \u00ae Ebola rapid antigen\ntest customer letter. Bethlehem, 2019https://www.orasure.com/documents/products/ebola/Ebola_Instruction_PI-ENG.pdf (ac-cessed 6 Feb2021).\n107.\n U.S. F\nood and Drug Administration. FDA allows marketing\nof first rapid diagnostic test for detecting Ebola virus antigens.2019.https://www.fda.gov/news-events/press-announcements/fda-allows-marketing-first-rapid-diagnostic-test-detecting-ebo-la-virus-antigens (accessed 6 Feb2021).\n108.\n v\nan Griensven J, De Weiggheleire A, Delamou A, Smith PG,\nEdwards T, Vandekerckhove P et al. The use of ebola convales-cent plasma to treat ebola virus disease in resource-constrainedsettings: a perspective from the field. Clin Infect Dis 2016; 62:69\u201374.\n109.\n The PREV\nAIL II Writing Group for the Multi-National PRE-\nVAIL II Study Team. A randomized, controlled trial of ZMapp forebola virus infection. N Engl J Med 2016; 375: 1448\u20131456.\n110.\n K\nonde MK, Baker DP, Traore FA, Sow MS, Camara A, Barry\nAA et al. Interferon \n\u03b1\n-1a for the treatment of Ebola virus disease: \nA historically controlled, single-arm proof-of-concept trial. PLoSOne 2017; 12: e0169255.\n111.\n Dunning J\n, Sahr F, Rojek A, Gannon F, Carson G, Idriss B et al. \nExperimental treatment of Ebola virus disease with TKM-130803:A single-arm phase 2 clinical trial. PLoS Med 2016; 13: e1001997.\n112.\n Mulangu S, Dodd LE, Da\nvey RT, Tshiani Mbaya O, Proschan\nM, Mukadi D et al. A randomized, controlled trial of ebola virusdisease therapeutics. N Engl J Med 2019; 381: 2293\u20132303.\n113.\nU.S. F\nood and Drug Administration. FDA Approves First\nTreatment for Ebola Virus. 2020.https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-eb-ola-virus (accessed 9 Feb2021).\n114.\n Siv\napalasingam S, Kamal M, Slim R, Hosain R, Shao W,\nStoltz R et al. Safety, pharmacokinetics, and immunogenicity ofa co-formulated cocktail of three human monoclonal antibod-ies targeting Ebola virus glycoprotein in healthy adults: a ran-domised, first-in-human phase 1 study. Lancet Infect Dis 2018;18: 884\u2013893.\n115.\nU.S. F\nood and Drug Administration. FDA Approves\nTreatment for Ebola Virus. 2020.https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-treatment-ebola-vi-rus (accessed 9 Feb2021).\n116.\n Gaudinski \nMR, Coates EE, Novik L, Widge A, Houser K V.,\nBurch E et al. Safety, tolerability, pharmacokinetics, and immu-nogenicity of the therapeutic monoclonal antibody mAb114 tar-geting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet 2019; 393: 889\u2013898.\n117.\n P\nark DJ, Dudas G, Wohl S, Goba A, Whitmer SLM, Andersen \nKG et al. Ebola virus epidemiology, transmission, and evolutionduring seven months in Sierra Leone. Cell 2015; 161: 1516\u20131526.\n118.\n Henao R\nestrepo AM. Update on candidate Ebola vac-\ncines: available data on immunogenicity, efficacy and safety.2018https://www.who.int/immunization/sage/meetings/2018/october/SAGE_october_2018_ebola_Henaorestrepo.pdf (ac-cessed 9 Feb2021).\n119.\n Henao-R\nestrepo AM, Longini IM, Egger M, Dean NE, Ed-\nmunds WJ, Camacho A et al. Efficacy and effectiveness of anrVSV-vectored vaccine expressing Ebola surface glycoprotein:interim results from the Guinea ring vaccination cluster-ran-domised trial. Lancet 2015; 386: 857\u2013866.\n120.\n Henao-R\nestrepo AM, Camacho A, Longini IM, Watson CH,\nEdmunds WJ, Egger M et al. Efficacy and effectiveness of anrVSV-vectored vaccine in preventing Ebola virus disease: finalresults from the Guinea ring vaccination, open-label, cluster-ran-domised trial (Ebola \u00c7a Suffit!). Lancet 2017; 389: 505\u2013518.Herramientas biotecnol\u00f3gicas en el diagn\u00f3stico, prevenci\u00f3n y tratamiento frente a pandemias\nBiotechnological tools in the diagnosis, prevention, and treatment of pandemics2110\n121. European Commission. Vaccine against Ebola: Commission \ngrants market authorisation. 2019.https://ec.europa.eu/commis-\nsion/presscorner/detail/en/IP_19_6246 (accessed 21 Dec2020).\n122. US Food and Drug Administration. First FDA-approved \nvaccine for the prevention of Ebola virus disease, marking a \ncritical milestone in public health preparedness and response. \n2019.https://www.fda.gov/news-events/press-announce-\nments/first-fda-approved-vaccine-prevention-ebola-virus-dis-\nease-marking-critical-milestone-public-health (accessed 21 \nAug2020).\n123. World Health Organization. Preliminary results on the effi-\ncacy of rVSV-ZEBOV-GP Ebola vaccine using the ring vaccination \nstrategy in the control of an Ebola outbreak in the Democratic \nRepublic of the Congo: an example of integration of research into \nepidemic response. 2019https://www.who.int/csr/resources/\npublications/ebola/ebola-ring-vaccination-results-12-april-2019.\npdf (accessed 10 Feb2021).\n124. Johnson & Johnson. Johnson & Johnson Announces Eu-\nropean Commission Approval for Janssen\u2019s Preventive Ebola \nVaccine . 2020.https://www.jnj.com/johnson-johnson-announc-\nes-european-commission-approval-for-janssens-preventive-ebo-\nla-vaccine#_ednref6 (accessed 10 Feb2021).\n125. Milligan ID, Gibani MM, Sewell R, Clutterbuck EA, Campbell \nD, Plested E et al. Safety and immunogenicity of novel adenovirus \ntype 26-and modified vaccinia Ankara-vectored Ebola vaccines: A \nrandomized clinical trial. JAMA 2016; 315: 1610\u20131623.\n126. Winslow RL, Milligan ID, Voysey M, Luhn K, Shukarev G, \nDouoguih M et al. Immune responses to novel adenovirus type 26 \nand modified vaccinia virus Ankara-vectored ebola vaccines at 1 \nyear. JAMA 2017; 317: 1075\u20131077.\n127. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J et al. A novel \ncoronavirus from patients with pneumonia in China, 2019. N Engl \nJ Med 2020; 382: 727\u2013733.\n128. World Health Organization.  WHO Coronavirus Disease \n(COVID-19) Dashboard. 2021.https://covid19.who.int/ (accessed \n1 Mar2021).\n129. U.S. Food & Drug Administration. In vitro diagnostics EUAs. \n2021.https://n9.cl/wxx8 (accessed 1 Mar2021).\n130. Vandenberg O, Martiny D, Rochas O, van Belkum A, Ko-\nzlakidis Z. Considerations for diagnostic COVID-19 tests. Nat Rev \nMicrobiol 2020; 19: 171\u2013183.\n131. Liu R, Han H, Liu F, Lv Z, Wu K, Liu Y et al. Positive rate of \nRT-PCR detection of SARS-CoV-2 infection in 4880 cases from \none hospital in Wuhan, China, from Jan to Feb 2020. Clin Chim \nActa 2020; 505: 172\u2013175.\n132. Chu DKW, Pan Y, Cheng SMS, Hui KPY, Krishnan P, Liu Y et \nal. Molecular diagnosis of a novel coronavirus (2019-nCoV) caus-\ning an outbreak of pneumonia. Clin Chem 2020; 66: 549\u2013555.\n133. Touma M. COVID-19: molecular diagnostics overview. J Mol \nMed 2020; 98: 947\u2013954.\n134. Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P et al. Sensitiv-\nity of Chest CT for COVID-19: Comparison to RT-PCR. Radiology \n2020; 296: E115\u2013E117.\n135. Yan C, Cui J, Huang L, Du B, Chen L, Xue G et al. Rapid and \nvisual detection of 2019 novel coronavirus ( SARS-CoV-2 ) by a \nreverse transcription loop-mediated isothermal amplification as-\nsay. Clin Microbiol Infect 2020; 26: 773\u2013779.\n136. Park G, Ku K, Baek S, Kim S, Kim S Il, Kim B et al. Devel-\nopment of reverse transcription loop-mediated isothermal am-\nplification assays targeting Severe Acute Respiratory Syndrome \nCoronavirus 2 (SARS-CoV-2). J Mol Diagnostics 2020; 22: 729\u2013\n735.\n137. Huang WE, Lim B, Hsu C-C, Xiong D, Wu W, Yu Y et al. RT-\nLAMP for rapid diagnosis of coronavirus SARS-CoV-2. Microb Bio-\ntechnol 2020; 13: 950\u2013961.\n138. Rahimi H, Salehiabar M, Barsbay M, Ghaffarlou M, Ka-\nvetskyy T, Sharafi A et al. CRISPR Systems for COVID-19 Diagno-\nsis. ACS Sensors 2021; 6: 1430\u20131445.\n139. U.S. Food and Drug Administration. Sherlock CRISPR SARS-\nCoV-2 Kit. Cambridge, 2020https://www.fda.gov/media/137747/\ndownload.140. Jolany Vangah S, Katalani C, Booneh HA, Hajizade A, Sijer-\ncic A, Ahmadian G. CRISPR-Based Diagnosis of Infectious and \nNoninfectious Diseases. Biol Proced Online 2020; 22. doi:10.1186/\ns12575-020-00135-3.\n141. Joung J, Ladha A, Saito M, Segel M, Bruneau R, Huang MLW \net al. Point-of-care testing for COVID-19 using SHERLOCK diag-\nnostics. medRxiv 2020. doi:10.1101/2020.05.04.20091231.\n142. Broughton JP, Deng X, Yu G, Fasching CL, Servellita V, Singh \nJ et al. CRISPR \u2013 Cas12-based detection of SARS-CoV-2. Nat Bio-\ntechnol 2020; 38: 870\u2013874.\n143. Centers for Disease Control and Prevention. Interim Guid-\nance for Antigen Testing for SARS-CoV-2. 2020.https://www.cdc.\ngov/coronavirus/2019-ncov/lab/resources/antigen-tests-guide-\nlines.html (accessed 1 Mar2021).\n144. Dinnes J, Deeks JJ, Adriano A, Berhane S, Davenport C, \nDittrich S et al. Rapid, point-of-care antigen and molecular-based \ntests for diagnosis of SARS-CoV-2 infection. Cochrane Database \nSyst Rev 2020; 8: CD013705.\n145. Sheridan C. COVID-19 spurs wave of innovative diagnostics. \nNat Biotechnol 2020; 38: 769\u2013772.\n146. Qiu G, Gai Z, Tao Y, Schmitt J, Kullak-Ublick GA, Wang J. \nDual-Functional Plasmonic Photothermal Biosensors for Highly \nAccurate Severe Acute Respiratory Syndrome Coronavirus 2 De-\ntection. ACS Nano 2020; 14: 5268\u20135277.\n147. Huang Z, Tian D, Liu Y, Lin Z, Lyon CJ, Lai W et al. Ultra-sen-\nsitive and high-throughput CRISPR-p owered COVID-19 diagno-\nsis. Biosens Bioelectron 2020; 164: 112316.\n148. Yuan X, Yang C, He Q, Chen J, Yu D, Li J et al. Current and \nperspective diagnostic techniques for COVID-19. ACS Infect Dis \n2020; 6: 1998\u20132016.\n149. U.S Food & Drug Administration. Coronavirus Treatment \nAcceleration Program (CTAP). 2021.https://www.fda.gov/drugs/\ncoronavirus-covid-19-drugs/coronavirus-treatment-accelera -\ntion-program-ctap (accessed 26 Feb2020).\n150. World Health Organization. Draft landscape and tracker of \nCOVID-19 candidate vaccines. 2021.https://www.who.int/publi-\ncations/m/item/draft-landscape-of-covid-19-candidate-vaccines \n(accessed 1 Mar2021).\n151. Kyriakidis NC, L\u00f3pez-Cort\u00e9s A, Gonz\u00e1lez EV, Grimaldos AB, \nPrado EO. SARS-CoV-2 vaccines strategies: a comprehensive re-\nview of phase 3 candidates. NPJ Vaccines 2021; 6. doi:10.1038/\ns41541-021-00292-w.\n152. Jiang S, Zhang X, Yang Y, Hotez PJ, Du L. Neutralizing anti-\nbodies for the treatment of COVID-19. Nat Biomed Eng 2020; 4: \n1134\u20131139.\n153. U.S. Food and Drug Administration. Emergency Use Au-\nthorization. 2021.https://www.fda.gov/emergency-prepared-\nness-and-response/mcm-legal-regulatory-and-policy-framework/\nemergency-use-authorization#coviddrugs (accessed 13 Feb2021).\n154. National Institutes of Health. Anti-SARS-CoV-2 monoclonal \nantibodies. 2021.https://www.covid19treatmentguidelines.nih.\ngov/anti-sars-cov-2-antibody-products/anti-sars-cov-2-mono-\nclonal-antibodies/ (accessed 13 Feb2021).\n155. Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J et \nal. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients \nwith Covid-19. N Engl J Med 2021; 384: 229\u2013237.\n156. Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J \net al. Effect of bamlanivimab as monotherapy or in combination \nwith etesevimab on viral load in patients with mild to moderate \nCOVID-19. JAMA 2021; 325: 632\u2013644.\n157. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, \nBhore R et al. REGN-COV2, a neutralizing antibody cocktail, in \noutpatients with Covid-19. N Engl J Med 2021; 384: 238\u2013251.\n158. Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J et al. Effect of \nconvalescent plasma therapy on time to clinical improvement in \npatients with severe and Life-threatening COVID-19: a random-\nized clinical trial. JAMA 2020; 324: 460\u2013470.\n159. Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar \nT, Malhotra P. Convalescent plasma in the management of moder-\nate covid-19 in adults in India: Open label phase II multicentre ran-\ndomised controlled trial (PLACID Trial). BMJ 2020; 371: m3939.Pamela Molina and Marbel Torres Arias\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2111\n160. Jo yner MJ, Bruno KA, Klassen SA, Kunze KL, Johnson PW,\nLesser ER et al. Safety update: COVID-19 convalescent plasma\nin 20,000 hospitalized patients. Mayo Clin Proc 2020; 95: 1888\u20131897.\n161.\n Libs\nter R, P\u00e9rez Marc G, Wappner D, Coviello S, Bianchi A,\nBraem V et al. Early high-titer plasma therapy to prevent severeCovid-19 in older adults. N Engl J Med 2021; 384: 610\u2013618.\n162.\nLiu S\nTH, Lin HM, Baine I, Wajnberg A, Gumprecht JP, Rah-\nman F et al. Convalescent plasma treatment of severe COVID-19: a propensity score\u2013matched control study. Nat Med 2020; 26:1708\u20131713.\n163.\nBaden \nLR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R \net al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384: 403\u2013416.\n164.\n Sadoff J\n, Le Gars M, Shukarev G, Heerwegh D, Truyers C,\nde Groot AM et al. Interim results of a phase 1\u20132a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med 2021. doi:10.1056/NEJ-Moa2034201.\n165.\nJohnson & Johnson. Johnson & Johnson announces sin\n-\ngle-shot Janssen COVID-19 vaccines candidate met primary end-points in interim analysis of its phase 3 ENSEMBLE trial . 2021.https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial (accessed 15Feb2021).\n166.\nLedford \nH, Cyranoski D, Van Noorden R. The UK has ap-\nproved a COVID vaccine - here\u2019s what scientists now want toknow. Nature 2020; 588: 205\u2013206.\n167.\nU.S. F\nood & Drug Administration. Pfizer-BioNTech\nCOVID-19 Vaccine. 2020.https://www.fda.gov/emergency-pre-paredness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine (accessed 1 Mar2021).\n168.\n Minis\nterio de Salud P\u00fablica. Inici\u00f3 la vacunaci\u00f3n contra la\nCOVID-19 en Ecuador. 2021.https://www.salud.gob.ec/en-ec-uador-inicio-la-vacunacion-contra-la-covid-19/ (accessed 14Feb2021).\n169.\nP\nolack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A,\nLockhart S et al. Safety and efficacy of the BNT162b2 mRNACovid-19 vaccine. N Engl J Med 2020; 383: 2603\u20132615.\n170.\n Minis\nterio de Salud P\u00fablica. Vacuna de AstraZeneca contra\nla COVID-19 se aplicar\u00e1 en Ecuador. 2021.https://www.salud.gob.ec/vacuna-de-astrazeneca-contra-la-covid-19-se-aplicara-en-ecuador/ (accessed 14 Feb2021).\n171.\n V\noysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, \nAley PK et al. Safety and efficacy of the ChAdOx1 nCoV-19 vac-cine (AZD1222) against SARS-CoV-2: an interim analysis of fourrandomised controlled trials in Brazil, South Africa, and the UK.Lancet 2021; 397: 99\u2013111.\n172.\nBud R. His\ntory of \u2019 biotechnology \u2019. Nature 1989; 337: 10.\n173. Amar\nakoon II, Hamilton C, Mitchell SA, Tennant PF, Roye\nME. Biotechnology. In: Pharmacognosy: Fundamentals, Applica-tions and Strategies. Elsevier Inc., 2017, pp 549\u2013563.\n174.\n V\nerma A, Agrahari S, Rastogi S, Singh A. Biotechnology in\nthe realm of history. J Pharm Bioallied Sci 2011; 3: 321\u2013324.\n175. Bud R. Biotechnology in the t\nwentieth century. Soc Stud Sci \n1991; 21: 415\u2013457.\n176. W\nright S. Recombinant DNA technology and its social\ntransformation, 1972-1982. Osiris 1986; 2: 303\u2013360.\n177. K\n\u00f6hler G, Milstein C. Continuous cultures of fused cells\nsecreting antibody of predefined specificity. Nature 1975; 256:495\u2013497.\n178.\n Gupta V\n, Sengupta M, Prakash J, Tripathy BC. An Introduc-\ntion to Biotechnology. In: Basic and Applied Aspects of Biotech-nology. Springer Singapore: Singapore, 2017, pp 1\u201321.\n179.\n DaSil\nva EJ. The colours of biotechnology: science, devel-\nopment and humankind. Electron J Biotechnol 2004; 7.http://www.ejbiotechnology.info/index.php/ejbiotechnology/article/view/1114 (accessed 15 Dec2020).\n180.\n Olivier \nM, Asmis R, Hawkins GA, Howard TD, Cox LA. The\nneed for multi-omics biomarker signatures in precision medicine. Int J Mol Sci 2019; 20: 4781.181.\n  E ckhardt M, Hultquist JF, Kaake RM, H\u00fcttenhain R, Krogan\nNJ. A systems approach to infectious disease. Nat Rev Genet2020; 21: 339\u2013354.\n182.\n Sperk M, V\nan Domselaar R, Rodriguez JE, Mikaeloff F, S\u00e1\nVinhas B, Saccon E et al. Utility of proteomics in emerging andre-emerging infectious diseases caused by RNA viruses. J Pro-teome Res 2020; 19: 4259\u20134274.\n183.\n Cherr\ny JD, Krogstad P. SARS: The first pandem-\nic of the 21st century. Pediatr Res 2004; 56. doi:10.1203/01.PDR.0000129184.87042.FC.\n184.\n Zumla A, Chan JFW\n, Azhar EI, Hui DSC, Yuen KY. Coronavi-\nruses-drug discovery and therapeutic options. Nat Rev Drug Dis-cov 2016; 15: 327\u2013347.\n185.\n Gire \nSK, Goba A, Andersen KG, Sealfon RSG, Park DJ, Kanneh L \net al. Genomic surveillance elucidates Ebola virus origin and transmis-sion during the 2014 outbreak. Science (80- ) 2014; 345: 1369\u20131372.\n186.\n R\nahimi A, Mirzazadeh A, Tavakolpour S. Genetics and ge-\nnomics of SARS-CoV-2: A review of the literature with the special focus on genetic diversity and SARS-CoV-2 genome detection.Genomics 2021; 113: 1221\u20131232.\n187.\n Schuber\nt OT, R\u00f6st HL, Collins BC, Rosenberger G, Aeber-\nsold R. Quantitative proteomics: challenges and opportunities inbasic and applied research. Nat Protoc 2017; 12: 1289\u20131294.\n188.\n Grenga L, Armengaud J\n. Proteomics in the COVID-19 bat-\ntlefield: first semester check-up. Proteomics 2020; 21: e2000198.\n189.\n Sriv\nastava S, Upadhyay DJ, Srivastava A. Next-Generation\nmolecular diagnostics development by CRISPR/Cas tool: rapiddetection and surveillance of viral disease outbreaks. Front MolBiosci 2020; 7. doi:10.3389/fmolb.2020.582499.\n190.\n W\norld Health Organization. Urgently needed: rapid, sensi-\ntive, safe and simple Ebola diagnostic tests. 2014.https://www.who.int/mediacentre/news/ebola/18-november-2014-diagnos-tics/en/ (accessed 19 Nov2020).\n191.\n National Human Genome R\nesearch Institute. Polymerase\nChain Reaction (PCR) fact sheet. 2020.https://www.genome.gov/about-genomics/fact-sheets/Polymerase-Chain-Reaction-Fact-Sheet (accessed 27 Jan2021).\n192.\nV\nanGuilder HD, Vrana KE, Freeman WM. Twenty-five years\nof quantitative PCR for gene expression analysis. Biotechniques2008; 44: 619\u2013626.\n193.\nP\noritz MA, Lingenfelter B. Multiplex PCR for detection and\nidentification of microbial pathogens. In: Springer C (ed). Ad-vanced Techniques in Diagnostic Microbiology. Springer, Cham,2018, pp 475\u2013493.\n194.\n Zhang Y\n, Dai C, Wang H, Gao Y, Li T, Fang Y et al. Analysis\nand validation of a highly sensitive one-step nested quantitativereal-time polymerase chain reaction assay for specific detectionof severe acute respiratory syndrome coronavirus 2. Virol J 2020; 17. doi:10.1186/s12985-020-01467-y.\n195.\nGreen MR, Sambrook J\n. Nested polymerase chain reaction\n(PCR). Cold Spring Harb Protoc 2019; 2019. doi:10.1101/pdb.prot095182.\n196.\nMori Y\n, Nagamine K, Tomita N, Notomi T. Detection of\nloop-mediated isothermal amplification reaction by turbidity de-rived from magnesium pyrophosphate formation. Biochem Bio-phys Res Commun 2001; 289: 150\u2013154.\n197.\n The McGo\nvern Institute for Brain Research. What is CRIS-\nPR? Ask the Brain. Massachusetts Inst. Technol. 2019.https://mcgovern.mit.edu/2019/01/01/crispr-in-a-nutshell/ (accessed27 Jan2021).\n198.\n Car\nter LJ, Garner L V., Smoot JW, Li Y, Zhou Q, Saveson\nCJ et al. Assay techniques and test development for COVID-19diagnosis. ACS Cent Sci 2020; 6: 591\u2013605.\n199.\n R\nacine R, Winslow GM. IgM in microbial infections: Taken for \ngranted? Immunol Lett 2009; 125: 79\u201385.\n200.\n W\nang H, Li X, Li T, Zhang S, Wang L, Wu X et al. The genetic \nsequence, origin, and diagnosis of SARS-CoV-2. Eur J Clin Micro-biol Infect Dis 2020; 39: 1629\u20131635.\n201.\n Li Z, Yi Y\n, Luo X, Xiong N, Liu Y, Li S et al. Development and\nclinical application of a rapid IgM-IgG combined antibody test forSARS-CoV-2 infection diagnosis. J Med Virol 2020; 92: 1518\u20131524.Herramientas biotecnol\u00f3gicas en el diagn\u00f3stico, prevenci\u00f3n y tratamiento frente a pandemias\nBiotechnological tools in the diagnosis, prevention, and treatment of pandemics2112\n202. Davis CW, Jackson KJL, McElroy AK, Halfmann P, Huang J, \nChennareddy C et al. Longitudinal analysis of the human B cell \nresponse to ebola virus infection. Cell 2019; 177: 1566-1582.e17.\n203. Okba NMA, Stalin Raj V, Widjaja I, GeurtsvanKessel CH, \nDe Bruin E, Chandler FD et al. Sensitive and specific detection \nof low-level antibody responses in mild Middle East respirato-\nry syndrome coronavirus infections. Emerg Infect Dis 2019; 25: \n1868\u20131877.\n204. Augustine R, Das S, Hasan A, S A, Abdul Salam S, Augustine \nP et al. Rapid antibody-based COVID-19 mass surveillance: rele-\nvance, challenges, and prospects in a pandemic and post-pan-\ndemic world. J Clin Med 2020; 9: 3372.\n205. Broadhurst MJ, Kelly JD, Miller A, Semper A, Bailey D, \nGroppelli E et al. ReEBOV Antigen Rapid Test kit for point-of-care \nand laboratory-based testing for Ebola virus disease: a field vali-\ndation study. Lancet 2015; 386: 867\u2013874.\n206. Centers for Disease Control and Prevention. Interim Guid-\nance for Rapid Antigen Testing for SARS-CoV-2. 2020.https://\nwww.cdc.gov/coronavirus/2019-ncov/lab/resources/anti-\ngen-tests-guidelines.html#table2 (accessed 24 Nov2020).\n207. Chen Y, Chan KH, Kang Y, Chen H, Luk HKH, Poon RWS et al. A \nsensitive and specific antigen detection assay for Middle East respi-\nratory syndrome coronavirus. Emerg Microbes Infect 2015; 4: e26.\n208. U.S. Food & Drug Administration. What Are \u2018Biologics\u2019 \nQuestions and Answers. 2018.https://www.fda.gov/about-fda/\ncenter-biologics-evaluation-and-research-cber/what-are-biolog-\nics-questions-and-answers (accessed 28 Jan2021).\n209. U.S. Food & Drug Administration. Licensed Biological Prod-\nucts with Supporting Documents. 2021.https://www.fda.gov/\nvaccines-blood-biologics/licensed-biological-products-support-\ning-documents (accessed 1 Mar2021).\n210. Instituto IQVIA. Advancing Biosimilar Sustainability in Eu-\nrope. 2018.https://www.iqvia.com/insights/the-iqvia-institute/\nreports/advancing-biosimilar-sustainability-in-europe (accessed \n25 Apr2021).\n211. Druedahl LC, Almarsd\u00f3ttir AB, K\u00e4lvemark Sporrong S, De \nBruin ML, Hoogland H, Minssen T et al. A qualitative study of bi-\nosimilar manufacturer and regulator perceptions on intellectu-\nal property and abbreviated approval pathways. Nat Biotechnol \n2020; 38: 1253\u20131256.\n212. Price WN, Rai AK. How logically impossible patents block \nbiosimilars. Nat Biotechnol 2019; 37: 862\u2013863.\n213. Collins S. Biologic Patent Transparency Act (S. 659). In: \n116th Congress (2019-2020). 2019https://www.congress.gov/\nbill/116th-congress/senate-bill/659/text (accessed 25 Apr2021).\n214. U.S. Food and Drug Administration. Frequently Asked Ques-\ntions About Therapeutic Biological Products. 2015.https://www.\nfda.gov/drugs/therapeutic-biologics-applications-bla/frequent-\nly-asked-questions-about-therapeutic-biological-products (ac-\ncessed 25 Apr2021).\n215. Steel J, Staeheli P, Mubareka S, Garc\u00eda-sastre A, Palese P, \nLowen AC. Transmission of pandemic H1N1 influenza virus and \nimpact of prior exposure to seasonal strains or interferon treat-\nment. J Virol 2010; 84: 21\u201326.\n216. Samuel CE. Antiviral actions of interferons. Clin Microbiol \nRev 2001; 14: 778\u2013809.\n217. Falzarano D, de Wit E, Rasmussen AL, Feldmann F, Okumu-\nra A, Scott DP et al. Treatment with interferon-\u03b12b and ribavirin \nimproves outcome in MERS-CoV-infected rhesus macaques. Nat \nMed 2013; 19: 1313\u20131317.\n218. Li BJ, Tang Q, Cheng D, Qin C, Xie FY, Wei Q et al. Using \nsiRNA in prophylactic and therapeutic regimens against SARS \ncoronavirus in Rhesus macaque. Nat Med 2005; 11: 944\u2013951.\n219. Gallicano GI, Casey JL, Fu J, Mahapatra S. Molecular tar-\ngeting of vulnerable RNA sequences in SARS CoV-2: identifying \nclinical feasibility. Gene Ther 2020. doi:10.1038/s41434-020-\n00210-0.\n220. Tang J, Zhang N, Tao X, Zhao G, Guo Y, Tseng C-TK et al. Op-\ntimization of antigen dose for a receptor-binding domain-based \nsubunit vaccine against MERS coronavirus. Hum Vaccin Immuno-\nther 2015; 11: 1244\u20131250.221. Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S et \nal. Phase 1\u20132 trial of a SARS-CoV-2 recombinant spike protein \nnanoparticle vaccine. N Engl J Med 2020; 383: 2320\u20132332.\n222. Fuenmayor J, G\u00f2dia F, Cervera L. Production of virus-like \nparticles for vaccines. N Biotechnol 2017; 39: 174\u2013180.\n223. Tebas P, Kraynyak KA, Patel A, Maslow JN, Morrow MP, \nSylvester AJ et al. Intradermal SynCon\u00ae Ebola GP DNA vaccine \nis temperature stable and safely demonstrates cellular and hu-\nmoral immunogenicity advantages in healthy volunteers. J Infect \nDis 2019; 220: 400\u2013410.\n224. Martin JE, Louder MK, Holman LSA, Gordon IJ, Enama ME, \nLarkin BD et al. A SARS DNA vaccine induces neutralizing anti-\nbody and cellular immune responses in healthy adults in a Phase \nI clinical trial. Vaccine 2008; 26: 6338\u20136343.\n225. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines \n\u2014 a new era in vaccinology. Nat Rev Drug Discov 2018; 17: 261\u2013279.\n226. Glaros AG, Kline RB. Understanding the accuracy of tests \nwith cutting scores: The sensitivity, specificity, and predictive val-\nue model. J Clin Psychol 1988; 44: 1013\u20131023.\n227. Shreffler J, Huecker MR. Diagnostic Testing Accuracy: Sen-\nsitivity, Specificity, Predictive Values and Likelihood Ratios. Stat-\nPearls. 2021.http://www.ncbi.nlm.nih.gov/pubmed/32491423 \n(accessed 25 Apr2021).\n228.  Pereira R, Oliveira J, Sousa M. Bioinformatics and compu-\ntational tools for next-generation sequencing analysis in clinical \ngenetics. J Clin Med 2020; 9: 132.\n229. Pas SD, Patel P, Reusken C, Domingo C, Corman VM, Dro-\nsten C et al. First international external quality assessment of \nmolecular diagnostics for Mers-CoV. J Clin Virol 2015; 69: 81\u201385.\n230. B\u00f6ger B, Fachi MM, Vilhena RO, Cobre AF, Tonin FS, Pon-\ntarolo R. Systematic review with meta-analysis of the accuracy \nof diagnostic tests for COVID-19. Am J Infect Control 2021; 49: \n21\u201329.\n231. Joyner MJ, Senefeld JW, Klassen SA, Mills JR, Johnson \nPW, Theel ES et al. Effect of convalescent plasma on mortality \namong hospitalized patients with COVID-19: Initial three-month \nexperience. medRxiv 2020. doi:10.1101/2020.08.12.20169359.\n232. Lin JT, Zhang JS, Su N, Xu JG, Wang N, Chen JT et al. Safe-\nty and immunogenicity from a Phase I trial of inactivated severe \nacute respiratory syndrome coronavirus vaccine. Antivir Ther \n2007; 12: 1107\u20131113.\n233. Li Y Der, Chi WY, Su JH, Ferrall L, Hung CF, Wu TC. Corona-\nvirus vaccine development: from SARS and MERS to COVID-19. J. \nBiomed. Sci. 2020; 27. doi:10.1186/s12929-020-00695-2.\n234. Dolzhikova I V., Zubkova O V., Tukhvatulin AI, Dzharullae-\nva AS, Tukhvatulina NM, Shcheblyakov D V. et al. Safety and \nimmunogenicity of GamEvac-Combi, a heterologous VSV- and \nAd5-vectored Ebola vaccine: An open phase I/II trial in healthy \nadults in Russia. Hum Vaccines Immunother 2017; 13: 613\u2013620.\n235. Zhu FC, Wurie AH, Hou LH, Liang Q, Li YH, Russell JBW et \nal. Safety and immunogenicity of a recombinant adenovirus type-\n5 vector-based Ebola vaccine in healthy adults in Sierra Leone: \na single-centre, randomised, double-blind, placebo-controlled, \nphase 2 trial. Lancet 2017; 389: 621\u2013628.\n236. Tapia MD, Sow SO, Mbaye KD, Thiongane A, Ndiaye BP, \nNdour CT et al. Safety, reactogenicity, and immunogenicity of a \nchimpanzee adenovirus vectored Ebola vaccine in children in Af-\nrica: a randomised, observer-blind, placebo-controlled, phase 2 \ntrial. Lancet Infect Dis 2020; 20: 719\u2013730.\n237. Tapia MD, Sow SO, Ndiaye BP, Mbaye KD, Thiongane A, \nNdour CT et al. Safety, reactogenicity, and immunogenicity of a \nchimpanzee adenovirus vectored Ebola vaccine in adults in Africa: \na randomised, observer-blind, placebo-controlled, phase 2 trial. \nLancet Infect Dis 2020; 20: 707\u2013718.\n238. Mallapaty S. China COVID vaccine reports mixed re-\nsults \u2014 what does that mean for the pandemic? Nature 2021. \ndoi:10.1038/d41586-021-00094-z.\n239. Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z et al. Effect \nof an inactivated vaccine against SARS-CoV-2 on safety and im-\nmunogenicity outcomes: interim analysis of 2 randomized clinical \ntrials. JAMA 2020; 324: 951\u2013960.Pamela Molina and Marbel Torres Arias\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2113\n240. Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF et al. Safe-\nty and immunogenicity of an inactivated SARS-CoV-2 vaccine, \nBBIBP-CorV: a randomised, double-blind, placebo-controlled, \nphase 1/2 trial. Lancet Infect Dis 2021; 21: 39\u201351.\n241. Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi \nV et al. Safety and immunogenicity of an inactivated SARS-CoV-2 \nvaccine, BBV152: a double-blind, randomised, phase 1 trial. Lan-\ncet Infect Dis 2021. doi:10.1016/s1473-3099(20)30942-7.\n242. Pu J, Yu Q, Yin Z, Zhang Y, Li X, Li D et al. An in-depth in-\nvestigation of the safety and immunogenicity of an inactivated \nSARS-CoV-2 vaccine. medRxiv 2020. doi:10.1101/2020.09.27.20\n189548.\n243. Logunov DY, Dolzhikova I V, Shcheblyakov D V, Tukhvatu-\nlin AI, Zubkova O V, Dzharullaeva AS et al. Safety and efficacy \nof an rAd26 and rAd5 vector-based heterologous prime-boost \nCOVID-19 vaccine: an interim analysis of a randomised con-\ntrolled phase 3 trial in Russia. Lancet 2021. doi:10.1016/s0140-\n6736(21)00234-8.\n244. Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH et al. \nImmunogenicity and safety of a recombinant adenovirus type-\n5-vectored COVID-19 vaccine in healthy adults aged 18 years or \nolder: a randomised, double-blind, placebo-controlled, phase 2 \ntrial. Lancet 2020; 396: 479\u2013488.\n245. Novavax. Novavax COVID-19 vaccine demonstrates 89.3% \nefficacy in UK phase 3 trial . 2021.https://ir.novavax.com/\nnews-releases/news-release-details/novavax-covid-19-vaccine-\ndemonstrates-893-efficacy-uk-phase-3 (accessed 15 Feb2021).\n246. Kremsner P, Mann P, Bosch J, Fendel R, Gabor JJ, Kreiden-\nweiss A et al. Phase 1 assessment of the safety and immunoge-\nnicity of an mRNA- lipid nanoparticle vaccine candidate against \nSARS-CoV-2 in human volunteers. medRxiv 2020. doi:10.1101/2\n020.11.09.20228551.\nReceived: 10 Marzo 2021\nAccepted: 20 Julio 2021Herramientas biotecnol\u00f3gicas en el diagn\u00f3stico, prevenci\u00f3n y tratamiento frente a pandemias\nBiotechnological tools in the diagnosis, prevention, and treatment of pandemics2114\nAbstract: The worldwide spread of the virus has claimed multiple lives, especially in vulnerable groups. Therefore, an investigation \nwas carried out to present a viable solution for health personnel using the \u201cJES\u201d algorithm. The present study used the research \nto determine the possible complications presented by the sick individual, providing a viable and accessible healthcare personnel \nsolution through the proposed \u201cJES\u201d algorithm. A non-experimental, descriptive, correlational, and explanatory research is \npresented. According to pathologies of interest, the articles were taken virtually from scientific journals present in Google \nScholar and PubMed.  The excluded publications were: articles that do not detail the established protocol for detecting SARS-\nCoV-2, studies that do not present a significant number of people with Covid-19 disease, articles that the person has the covid-19 \ndisease but no underlying diseases of nutritional origin. It focused on the vulnerable or higher risk population group, including \nscientific information from children (over five years old), adults (over 18 years old), and older adults (over 65 years old) found in \ncountries of the Asian and American continents. The R program analyzed the scientific articles using the ggplot2 package with \na pie and bar diagram. A higher prevalence in men than women (56% vs. 44%) stood out. Likewise, arterial hypertension was \npresented in the first place with 40.82%, followed by diabetes with 30.61%, obesity with 12.24%, overweight and dyslipidemia \nwith 6.12%, malnutrition with 4.08%. There was a higher prevalence of stable individuals (29%) within the health facility than \nthose admitted to the ICU  (20%). Adults with 69.39%, followed by older adults with 16.33%, and mixed ages with 14.29%. \nComorbidities stand out as risk factors in people infected with SARS-CoV-2, regardless of age. A more significant contagion was \nobserved in the male versus female population; since men do not develop a rapid immune response and have a high content of \ncytokines that at the time of infection are released more quickly and can cause more significant damage\nKey words: Chronic diseases, vulnerable population, SARS-CoV-2, nutrition.  \nIntroduction\nThe World Health Organization defines chronic diseases as \nlong-term chronic diseases and progressively slower1. Among \nthem are heart diseases, high blood pressure (40.82%), dia-\nbetes mellitus 2 (30.61%), severe obesity (BMI> 40) (12.24%), \nand dyslipidaemias(6.12%)2.\nThe virus is known as SARS-CoV-23, whose disease is \ncaused by COVID-194. It is considered a new type of infectious \nand highly contagious coronavirus in a latency state5. Its me-\nchanism of action consists of the host organism\u2019s infection \nthrough the ACE2 receptor6, distributed to various organs and \ntissues such as lungs, heart, kidneys, intestine, and endothe-\nlial cells7. Clinical practice has determined that a population is \nconsidered vulnerable or at higher risk of contagion8, such as \nthe elderly and people at any stage of life with chronic disea-\nses9,10. Those people who have at least one of these chronic \nconditions mentioned above and are not under medical su-\npervision should pay more attention and health care against \nSARS-CoV-28. The Pan American Health Organization empha-\nsizes more outstanding care in vulnerable groups since 1 in 4 \npeople show a greater risk of obtaining unfavorable results due \nto underlying diseases11. Therefore, a search for information \nwas carried out to relate the diseases of nutritional origin men-\ntioned above with those who present the SARS-CoV-2 condi-\ntion allowing us to know the relationship between them and \nthe severity of complications12.Methods\nExhaustive bibliographic research was carried out, com-\npiling 40 articles at the international level, adding nine more \npublications found within the previously selected articles, ex-\ncluding those not indexed, for subsequent analysis focused on \nhealth professionals. These articles, \u201coriginal articles,\u201d were \ncarried out in China, the United States, Italy, Mexico, France, \nand at a multicenter level from January 2020 to July 2020. It \nis considered non-experimental, descriptive, and explanatory \nresearch by searching bibliographic materials published from \n2018 to 2020, taken virtually through search engines such as \nPubMed[A9] [A10]  and Google Scholar. Pathologies of nutri-\ntional origin of interest categorized these scientific articles, \nas shown in figures 1 and 2. The excluded publications were \nselected as follows: articles that do not detail an established \nprotocol for detecting SARS-CoV-2. These studies do not pre-\nsent a significant number of people with Covid-19 disease (less \nthan 50 people), articles that the person has the covid-19 di-\nsease but not underlying diseases of nutritional origin. The in-\nformation found with limited access, prepaid, and documents \nin development stands out regarding the restrictions. The \nkeywords used for this search are SARS-CoV-2, Coronavirus, \narterial hypertension, type 2 diabetes, dyslipidemia, and mal-\nnutrition, the latter being divided into malnutrition, overweight, \nand obesity. It was compiled through scientific studies carried \nout in China (26), United States (10), Italy (8), France (3), and Relationship of SARS-CoV-2 and chronic diseases of nutritional origin\nJohanna Pilay Baja\u00f1a1, Evelyn Ram\u00edrez Carguacundo1, Mar\u00eda Jos\u00e9 Vizcaino Tumbaco2, Daniel Silva-Ochoa1,2, Davide Di Grumo3, Luis Dora-\ndo-Sanchez4, Silvia Orellana-Manzano3, Patricia Manzano1,5, Andrea Orellana-Manzano1,2,3*REVIEW / ART\u00cdCULO DE REVISI\u00d3N\nDOI. 10.21931/RB/2021.06.03.34 \n1 ESPOL Polytechnic University, Facultad de Ciencias de la Vida (FCV), Campus Gustavo Galindo, Km. 30.5 v\u00eda Perimetral, Guayaquil, Ecuador. \n2 ESPOL Polytechnic University, Laboratory for Biomedical Research, Facultad de Ciencias de la Vida (FCV), Guayaquil, Ecuador.\n3 Escuela de Odontolog\u00eda, Universidad Esp\u00edritu Santo,  Ecuador\n4 Hospital General Monte Sinat\u00ed, Guayaquil, Ecuador.\n5 ESPOL Polytechnic University, Centro de Investigaciones Biotecnol\u00f3gicas del Ecuador (CIBE), Guayaquil, Ecuador.\nCorresponding author: akorella@espol.edu.ecJohanna Pilay Baja\u00f1a, Evelyn Ram\u00edrez Carguacundo, Mar\u00eda Jos\u00e9 Vizcaino Tumbaco, Daniel Silva-Ochoa, Davide Di Grumo, Luis Dorado-Sanchez, Silvia Orellana-Manzano, \nPatricia Manzano, Andrea Orellana-Manzano\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2115\nRelationship of SARS-CoV-2 and chronic diseases of nutritional origin\nFigure 1. Productos biol\u00f3gicos usados en el control de pande -\nmias (Creado en BioRender).\nFigure 2. General steps for obtaining information from this document.Mexico (1). The choice of these countries was made according \nto the number of relevant articles found up to the moment \nof the analysis, which provided outstanding information on \nthe relationship between SARS-CoV-2 and the pathologies of \ninterest, a protocol established for obtaining results, as well \nas variables of interest, highlighting the different age groups, \nsex, country of study, detection method of the SARS-CoV-2, \nsample size, nutritional parameters, and the results obtained \nin said scientific studies. \nThe algorithm was carried out using the web-based dia-\ngramming tool called Lucidchart in its entirety due to the \nease of implementation it presents and the different options it \noffers the user. It was based on the ten practical recommenda-\ntions published by the European Society for Clinical Nutrition \nand Metabolism (ESPEN) in 2020, which presents an indicated \nguide for the nutritional management of patients with CO-VID-19. It contains relevant information about adequate nutri-\ntional management to treat patients with chronic diseases and \nSARS-CoV-2 simultaneously, highlighting the use of screening. \nLikewise, it indicates essential nutritional parameters to consi-\nder in the sick patient, such as BMI, ascites, folds, and brachial \ncircumference.\nFor those patients with unfavorable results and a higher \nprobability of mortality after contracting the SARS-COV-2 in-\nfection (older adults and people with multiple comorbidities), it \nis recommended to control the presence of malnutrition throu-\ngh screening tests for later timely evaluation using the NRS \ncriteria. 2002 was established for hospitalized patients.\nLikewise, it is recommended to maintain a good nutritional \nstatus for the prevention or treatment of malnutrition since \nit reduces complications and subsequent negative results in \npatients with nutritional risk due to the presence of nausea, \nvomiting, and diarrhea (typical of SARS-CoV-2 ), affecting the \naverage intake and absorption of food in the body.\nOptimal maintenance of nutritional status is prioritized \nthrough dietary advice from experienced professionals (Regis-\ntered Dietitians, Experienced Nutrition Scientists, Clinical Nu-\ntritionists, and Specialty Physicians).\nA daily intake of 27 kcal per kg of body weight is suggested \nin patients with multiple comorbidities over 65 years and 30 \nkcal per kg of body weight/day in patients with a much lower \naverage weight and multiple comorbidities. However, these va-\nlues   are indicative and must be adjusted according to the ener-\ngy intake in older people, nutritional status, physical activity, \ndisease status, and food tolerance.\nIn patients with severe underweight, the goal of 30 kcal/\nkg of body weight should be gradually due to the refeeding sy-\nndrome.\nIt is estimated using already established formulas (1 g of \nprotein per kg of body weight in older people) regarding protein \nneeds. However, it must be adjusted according to nutritional \nstatus, physical activity, disease status, and food tolerance. \nThe fat and carbohydrate needs are adapted according to the \npatient\u2019s energy needs in a ratio of 30:70 (people without res-\npiratory deficiency) and 50:50 (ventilated patients).\nThe use of oral nutritional supplements is recommended \nto achieve optimal nutritional goals through individualized die-\ntary advice with at least 400 kcal/day, including 30 g or more 2116\nprotein per day and its continuation for at least one month.\nPatients with type II diabetes mellitus, arterial hyperten-\nsion, and malnutrition should be treated according to nutritio-\nnal guidelines already established for each pathology, taking \ninto account glucose levels, blood pressure, and caloric intake, \nrespectively.\nResults\nChronic diseases of nutritional origin such as diabetes \nmellitus, hypertension, dyslipidemia, undernourishment, and \nobesity were observed in patients with SARS-CoV-2. These \ncomorbidities help a better accommodation and progression \nof this virus in organs such as lungs, intestine, heart, and even \nbrain conditions. Therefore, a general distribution was made \nwith all previously selected articles, obtaining the following \npercentages (Figure 3): arterial hypertension (40.82%), diabe-\ntes mellitus (30.61%), obesity (12.24%), overweight (6.12%), \ndyslipidemia (6.12%) and undernourishment (4.08%), conside-\nring the risk factors in this vulnerable population, as we can \nsee in table 1. \nAdditionally, information was obtained according to the \ncountry of origin (Figure 4), obtaining the following results or-\ndered from highest to lowest respectively: China 26 articles \n(53.06%), followed by the United States with 10 (20.41%), Italy \nwith 8 (16.33%), France with 3 (6.12%) and articles on par be-\ntween Mexico and multicenter level with 1 (2.04%) respecti-\nvely. Likewise, the presence of a higher prevalence in men with \nSARS-CoV-2 compared to the women analyzed (56% vs. 44%) \nstands out. The presence of deceased people was not given in \nall the scientific articles reviewed. However, it can range from \ntwo to more than five thousand people (up to 23%). It should \nbe noted that the variable number of deceased persons was \nlater discarded from this analysis due to the little information \npresented following all the documents chosen.According to Table II, presented in the supplementary ma-\nterial section, a higher prevalence of individuals who remained \nstable within the health facility was observed than those ad-\nmitted to the ICU (29 vs. 20). In the age ranges, the presence \nof adults stood out, obtaining a total of 34 articles (69.39%), \nfollowed by older adults with 8 (16.33%) and finally mixed ages \nwith 7 (14.29%). For its part, the average age was a minimum \nof 21 years and a maximum of 79 years. \nThe algorithm presented in Figure 5 is composed of nutri-\ntional parameters and nutritional monitoring for the pathology \nof interest according to the presence of SARS-CoV-2 in the in-\ndividual. Likewise, it presents a general approach by the nutri-\ntionist through the Score according to NRS2002, dividing it into \na score less than three and a score greater than 3, highlighting \nthe intake of proteins and carbohydrates in the first case and a \nrapid nutritional intervention through supplementation for the \nsecond. In general, specific monitoring is suggested every 48 \nto 72 hours maximum, adjusting your energy requirements if \nnecessary.\nDiscussion\nThis article was developed with Open Access research \nthat had no economic cost at the time of its preparation sin-\nce all the information was obtained free of charge through hi-\ngh-impact scientific journals.\nHowever, in public health, the generation of additional \ncosts due to the stay in the ICU of public hospitals is estima-\nted, with values ranging between $ 1,000 to $ 3,000 per day, \ndepending on the complications that the patient\u2019s health sta-\ntus presents13. While in hospitals and private clinics, the prices \nvary between $ 1,000 to $ 5,000 per day, depending on the \nestablishment, health status, and the care required for their \nimprovement during the first wave in Ecuador14. For this rea-\nson, the consolidated information present in this document is \nFigure 3. Chronic diseases identified in patients infected by SARS-CoV-2.Johanna Pilay Baja\u00f1a, Evelyn Ram\u00edrez Carguacundo, Mar\u00eda Jos\u00e9 Vizcaino Tumbaco, Daniel Silva-Ochoa, Davide Di Grumo, Luis Dorado-Sanchez, Silvia Orellana-Manzano, \nPatricia Manzano, Andrea Orellana-Manzano\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2117\nRelationship of SARS-CoV-2 and chronic diseases of nutritional origin\nTable 1. Classification of articles according to variables of interest.2118\nessential, since it is expected to reduce costs in these areas, \nas well as a greater understanding about the pathologies of \nnutritional origin present in cases with the SARS-Cov-2 virus, \npreventing conditions critical health measures in the sick in-\ndividual and turn, generating an economically viable solution \nfor society.\nTable I highlights the strengths and weaknesses found in \nthe previous systematic review obtained from reliable scienti-\nfic articles such as gender, current information from countries \nthat reported more extensive clinical trials on confirmed coro-\nnavirus cases, pathology, number of infected, among others.\nAmong the weaknesses is the small variety of countries \nanalyzed due to clinical trials not found until the end of this \ndocument\u2019s research period and a null contribution by the se-\nlected documents about the treatment given to each patient \ndiagnosed with comorbidities SARS-CoV-2.\nThe indications and guidelines for future research lie in expanding the sample size of scientific articles analyzed, the \naddition of other comorbidities of nutritional origin as the ob-\nject of study, and a more generous selection of documents \nthat present the number of people who died SARS-CoV-2 and \ncomorbidities. The percentage of countries analyzed was ob-\ntained using the R program version 1.3.1056 using the ggplot2 \npackage with a sector and bar diagram, highlighting China, fo-\nllowed by the United States and Italy. Regarding the age ran-\nge, the presence of adults (69.39%) and older adults (16.33%) \nstood out, which were obtained through the previously des-\ncribed program.\nAccording to reviews and subsequent updates in the hi-\ngh-impact literature, it is known that suffering from chronic \nnon-communicable diseases and COVID-19 disease is still high \nrisk, as the CDC mentions the number of times of risk that the \nperson has when suffering one or more NCDs varying between \n3 and 5 times the risk of severity15.\nFigure 4. Scientific articles by country of origin.\nTable 2. Deaths according to sex and age.Johanna Pilay Baja\u00f1a, Evelyn Ram\u00edrez Carguacundo, Mar\u00eda Jos\u00e9 Vizcaino Tumbaco, Daniel Silva-Ochoa, Davide Di Grumo, Luis Dorado-Sanchez, Silvia Orellana-Manzano, \nPatricia Manzano, Andrea Orellana-Manzano\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2119\nRelationship of SARS-CoV-2 and chronic diseases of nutritional origin\nConclusions\nComorbidities are considered risk factors in sick indi-\nviduals with SARS-CoV-2, highlighting hypertension with \n40.82%, diabetes with 30.61%, and obesity with 12.24% con-\ncerning the total articles analyzed. SARS-CoV-2 affects any \nage group, highlighting the presence of adults with 69.39%, \nfollowed by older adults with 16.33%, according to studies ca-\nrried out in health centers internationally. Men\u2019s presence was \n56% compared to women with 44%, denoting more significant \ncontagion in the male population. The individuals found in the \nICU department were 40.82% compared to 59.19% who did \nnot require it due to the timely intervention. Comorbidities can \nbe significantly aggravated if not controlled and under timely \nmedical supervision. Among the weaknesses, incorporating \nnutritional treatments for each comorbidity and/or specific \npathology and the majority incorporation of individuals in the \nchildhood stage stands out for a more significant expansion \nof the study field. It is recommended to carry out nutritional \ntreatments with other pathologies and with more significant \nexpansion in age ranges, as well as the incorporation of infor-\nmation that it deems appropriate for a better analysis of the \nsituation.\nAcknowledgments\nThe authors wish to acknowledge the support of ESPOL, \nFCV-60-2020, for letting the study be part of the COVID-19 \nresearch.\nBibliographic references\n1. Organizacion Mundial de la Salud O. OMS | Enfermedades cr\u00f3ni-\ncas. World Health Organization; 2017.\n2. OPS. Las ENT de un vistazo: Mortalidad por enfermedades no \ntransmisibles y prevalencia de sus factores de riesgo en la Regi\u00f3n \nde las Am\u00e9ricas. Organizaci\u00f3n Panamericana de la salud, Wash-\nington, D.C. OPS; 2019 Dec.3. Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Vol. 395, \nThe Lancet. Lancet Publishing Group; 2020. p. 1225\u20138.\n4. Schwartz DA. An Analysis of 38 Pregnant Women with COVID-19, \nTheir Newborn Infants, and Maternal-Fetal Transmission of \nSARS-CoV-2: Maternal Coronavirus Infections and Pregnancy \nOutcomes. Arch Pathol Lab Med. 2020 Mar;\n5. Fifield K. C\u00f3mo la enfermedad COVID-19 afecta los \u00f3rganos del \ncuerpo. 2020.\n6. South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the car-\ndiovascular consequences. Am J Physiol Circ Physiol. 2020 \nMay;318(5):H1084\u201390.\n7. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, \nZinkernagel AS, et al. Endothelial cell infection and endothelii-\ntis in COVID-19. Vol. 395, The Lancet. Lancet Publishing Group; \n2020. p. 1417\u20138.\n8. Acosta G, Escobar G, Bernaola G, Alfaro J, Taype W, Marcos C, et al. \nOriginal Breve Caracterizaci\u00f3n De Pacientes Con Covid-19 Grave \nAtendidos En Un Hospital Treated in a National Referral Hospital \nin Peru. Rev Peru Med Exp Salud Publica. 2020;2019(2):253\u20138.\n9. Enviroment D of H and. Enfermedades cr\u00f3nicas y COVID-19: lo \nque necesita saber. 2020.\n10. Gandhi RT, Lynch JB, del Rio C. Mild or Moderate Covid-19. N Engl \nJ Med. 2020 Apr.\n11. OPS/OMS. Directora de la OPS dice que la lucha contra la pan-\ndemia COVID-19 debe incluir atenci\u00f3n de enfermedades cr\u00f3nicas \n- OPS/OMS | Organizaci\u00f3n Panamericana de la Salud. Organi-\nzaci\u00f3n Panamericana de la la Salud. 2020.\n12. Thais M, -Urizarri P, Ra\u00fal, Aguilera-Rodr\u00edguez, Luis E, Mederos A-. \nhipertensi\u00f3n, diabetes y enfermedad renal cr\u00f3nica como factores \nde riesgo para covid-19 grave. I Congreso Virtual de Ciencias B\u00e1si-\ncas Biom\u00e9dicas de Granma. 2020.\n13. Rodriguez A. El Tel\u00e9grafo - Noticias del Ecuador y del mundo - Un \nd\u00eda en cuidados intensivos cuesta m\u00e1s de $ 1.500. El Tel\u00e9grafo. \n2020.\n14. Heredia V, Rosero M. IESS no est\u00e1 derivando a pacientes con \ncovid-19 a cl\u00ednicas privadas. 2020.\n15. Morej\u00f3n A. Enfermedades Cr\u00f3nicas No Transmisibles Y Covid-19: \nLa Convergencia De Dos Crisis Globales. Scielo. 2020;\n16. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Charac-\nteristics of 138 Hospitalized Patients with 2019 Novel Corona-\nvirus-Infected Pneumonia in Wuhan, China. JAMA - J Am Med \nAssoc. 2020 Mar;323(11):1061\u20139.\nFigure 5. Nutritional Algorithm.2120\nJohanna Pilay Baja\u00f1a, Evelyn Ram\u00edrez Carguacundo, Mar\u00eda Jos\u00e9 Vizcaino Tumbaco, Daniel Silva-Ochoa, Davide Di Grumo, Luis Dorado-Sanchez, Silvia Orellana-Manzano, \nPatricia Manzano, Andrea Orellana-Manzano\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\n17. Cappuccio FP, Siani A. Covid-19 and cardiovascular risk: Sus-\nceptibility to infection to SARS-CoV-2, severity and prognosis of \nCovid-19 and blockade of the renin-angiotensin-aldosterone sys-\ntem. An evidence-based viewpoint. Nutr Metab Cardiovasc Dis. \n2020;30:1227\u201335.\n18. Piva S, Filippini M, Turla F, Cattaneo S, Margola A, De Fulviis S, et al. \nClinical presentation and initial management critically ill patients \nwith severe acute respiratory syndrome coronavirus 2 (SARS-\nCoV-2) infection in Brescia, Italy. J Crit Care. 2020;58:29\u201333.\n19. Li J, Wang X, Chen J, Zhang H, Deng A. Association of Renin-An-\ngiotensin System Inhibitors with Severity or Risk of Death in Pa-\ntients with Hypertension Hospitalized for Coronavirus Disease \n2019 (COVID-19) Infection in Wuhan, China. JAMA Cardiol. 2020;\n20. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular \nDisease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. \n2020 Jun;382(25):e102.\n21. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and \noutcomes of critically ill patients with SARS-CoV-2 pneumonia \nin Wuhan, China: a single-centered, retrospective, observational \nstudy. Lancet Respir Med. 2020 May;8(5):475\u201381.\n22. Zhang J, Dong X, Cao Y, Yuan Y, Yang Y, Yan Y, et al. Clinical char-\nacteristics of 140 patients infected with SARS\u03b1CoV\u03b12 in Wuhan, \nChina. Allergy. 2020 Jul;75(7):1730\u201341.\n23. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and \nrisk factors for mortality of adult inpatients with COVID-19 \nin Wuhan, China: a retrospective cohort study. Lancet. 2020 \nMar;395(10229):1054\u201362.\n24. de Lusignan S, Dorward J, Correa A, Jones N, Akinyemi O, Amir-\nthalingam G, et al. Risk factors for SARS-CoV-2 among patients \nin the Oxford Royal College of General Practitioners Research \nand Surveillance Centre primary care network: a cross-sectional \nstudy. Lancet Infect Dis. 2020 Sep;20(9):1034\u201342.\n25. Singh AK, Gupta R, Misra A. Comorbidities in COVID-19: Out-\ncomes in hypertensive cohort and controversies with renin an-\ngiotensin system blockers. Diabetes Metab Syndr Clin Res Rev. \n2020 Jul;14(4):283\u20137.\n26. Bajgain KT, Badal S, Bajgain BB, Santana MJ. Prevalence of co-\nmorbidities among individuals with COVID-19: A rapid review of \ncurrent literature. American Journal of Infection Control. Mosby \nInc.; 2020.\n27. Zachariah P, Johnson CL, Halabi KC, Ahn D, Sen AI, Fischer A, \net al. Epidemiology, Clinical Features, and Disease Severity in \nPatients with Coronavirus Disease 2019 (COVID-19) in a Chil-\ndren\u2019s Hospital in New York City, New York. JAMA Pediatr. 2020 \nOct;174(10):202430.\n28. Garg S, Kim L, Whitaker M, O\u2019Halloran A, Cummings C, Holstein \nR, et al. Hospitalization rates and characteristics of patients hos-\npitalized with laboratory-confirmed coronavirus disease 2019 \u2014 \nCovid-net, 14 states, March 1\u201330, 2020. Vol. 69, Morbidity and \nMortality Weekly Report. Department of Health and Human Ser-\nvices; 2020. p. 458\u201364.\n29. Tedeschi S, Giannella M, Bartoletti M, Trapani F, Tadolini M, \nBorghi C, et al. Clinical Impact of Renin-angiotensin System In-\nhibitors on In-hospital Mortality of Patients With Hypertension \nHospitalized for Coronavirus Disease 2019. Clin Infect Dis. 2020 \nJul;71(15):899\u2013901.\n30. Yao Q, Wang P, Wang X, Qie G, Meng M, Tong X, et al. A retrospec-\ntive study of risk factors for severe acute respiratory syndrome \ncoronavirus 2 infections in hospitalized adult patients. Polish Arch \nIntern Med. 2020 May;130(5):390\u20139.\n31. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. prevalence \nof comorbidities and its effects in coronavirus disease 2019 pa-\ntients: A systematic review and meta-analysis. Int J Infect Dis. \n2020 May;94:91\u20135.\n32. Petrova D, Salamanca-Fern\u00e1ndez E, Barranco MR, P\u00e9rez PN, \nJuan Jim\u00e9nez Mole\u00f3n J, S\u00e1nchez M-J. La obesidad como factor \nde riesgo en personas con COVID-19: Posibles mecanismos e im-\nplicaciones. Atenci\u00f3n Primaria. 2020 May;\n33. Huang Z, Cao J, Yao Y, Jin X, Luo Z, Xue Y, et al. The effect of RAS \nblockers on the clinical characteristics of COVID-19 patients with \nhypertension. Ann Transl Med. 2020 Apr;8(7):430\u2013430.34. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. prevalence and \nimpact of cardiovascular metabolic diseases on COVID-19 in China. \nVol. 109, Clinical Research in Cardiology. Springer; 2020. p. 531\u20138.\n35. Suleyman G, Fadel RA, Malette KM, Hammond C, Abdulla H, Entz \nA, et al. Clinical Characteristics and Morbidity Associated With \nCoronavirus Disease 2019 in a Series of Patients in Metropoli-\ntan Detroit. Vol. 3, JAMA network open. NLM (Medline); 2020. p. \ne2012270.\n36. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors As-\nsociated With Acute Respiratory Distress Syndrome and Death \nin Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, \nChina. JAMA Intern Med. 2020 Jul;180(7):934.\n37. Roxby AC, Greninger AL, Hatfield KM, Lynch JB, Dellit TH, James \nA, et al. Outbreak investigation of COVID-19 among residents \nand staff of an independent and assisted living community for \nolder adults in Seattle, Washington. JAMA Intern Med. 2020 \nAug;180(8):1101\u20135.\n38. Zheng KI, Gao F, Wang XB, Sun QF, Pan KH, Wang TY, et al. Let-\nter to the Editor: Obesity as a risk factor for greater severity of \nCOVID-19 in patients with metabolic associated fatty liver dis-\nease. Metabolism. 2020 Jul;108:154244.\n39. Wei X, Zeng W, Su J, Wan H, Yu X, Cao X, et al. Hypolipidemia \nis associated with the severity of COVID-19. J Clin Lipidol. 2020 \nMay;14(3):297\u2013304.\n40. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli \nA, et al. Baseline Characteristics and Outcomes of 1591 Patients \nInfected with SARS-CoV-2 Admitted to ICUs of the Lombardy Re-\ngion, Italy. JAMA - J Am Med Assoc. 2020 Apr;323(16):1574\u201381.\n41. Doglietto F, Vezzoli M, Gheza F, Lussardi GL, Domenicucci M, Vec-\nchiarelli L, et al. Factors Associated with Surgical Mortality and \nComplications among Patients with and without Coronavirus Dis-\nease 2019 (COVID-19) in Italy. JAMA Surg. 2020 Aug;155(8):691\u2013\n702.\n42. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Du-\nhamel A, et al. High Prevalence of Obesity in Severe Acute Re-\nspiratory Syndrome Coronavirus\u03b12 (SARS\u03b1CoV\u03b12) Requiring \nInvasive Mechanical Ventilation. Obesity. 2020 Jul;28(7):1195\u20139.\n43. Bello-Chavolla OY, Bahena-L\u00f3pez JP, Antonio-Villa NE, Var-\ngas-V\u00e1zquez A, Gonz\u00e1lez-D\u00edaz A, M\u00e1rquez-Salinas A, et al. Pre-\ndicting Mortality Due to SARS-CoV-2: A Mechanistic Score Relat-\ning Obesity and Diabetes to COVID-19 Outcomes in Mexico. J Clin \nEndocrinol Metab. 2020 Aug;105(8):2752\u201361.\n44. Moriconi D, Masi S, Rebelos E, Virdis A, Manca ML, De Marco S, \net al. obesity prolongs the hospital stay in patients affected by \nCOVID-19, and may impact on SARS-COV-2 shedding. Obes Res \nClin Pract. 2020 May;14(3):205\u20139.\n45. Engin AB, Engin ED, Engin A. Two important controversial risk \nfactors in SARS-CoV-2 infection: Obesity and smoking. Vol. 78, \nEnvironmental Toxicology and Pharmacology. Elsevier B.V.; 2020. \np. 103411.\n46. Finer N, Garnett SP, Bruun JM. COVID\u03b119 and obesity. Clin Obes. \n2020 Jun;10(3):e12365.\n47. Watanabe M, Risi R, Tuccinardi D, Baquero CJ, Manfrini S, Gnessi \nL. Obesity and SARS-CoV-2: a population to safeguard. Diabetes/\nMetabolism Research and Reviews. John Wiley and Sons Ltd; \n2020.\n48. Li T, Zhang Y, Gong C, Wang J, Liu B, Shi L, et al. prevalence \nof malnutrition and analysis of related factors in elderly pa-\ntients with COVID-19 in Wuhan, China. Eur J Clin Nutr. 2020 \nJun;74(6):871\u20135.\n49. Devaux CA, Rolain JM, Raoult D. ACE2 receptor polymorphism: \nSusceptibility to SARS-CoV-2, hypertension, multi-organ failure, \nand COVID-19 disease outcome. Vol. 53, Journal of Microbiology, \nImmunology and Infection. Elsevier Ltd; 2020. p. 425\u201335.\n50. Tsioufis C, Dimitriadis K, Tousoulis D. The interplay of hyperten-\nsion, ACE-2 and SARS-CoV-2: Emerging data as the \u201cAriadne\u2019s \nthread\u201d for the \u201clabyrinth\u201d of COVID-19. Vol. 61, Hellenic Journal \nof Cardiology. Hellenic Cardiological Society; 2020. p. 31\u20133.\n51. Brojakowska A, Narula J, Shimony R, Bander J. Clinical Implica-\ntions of SARS-CoV-2 Interaction With Renin Angiotensin System. \nJ Am Coll Cardiol. 2020 Jun;75(24):3085\u201395.2121\nRelationship of SARS-CoV-2 and chronic diseases of nutritional origin\n52. Iaccarino G, Borghi C, Cicero AFG, Ferri C, Minuz P, Muiesan ML, \net al. Renin-Angiotensin System Inhibition in Cardiovascular Pa-\ntients at the Time of COVID19: Much Ado for Nothing? A State-\nment of Activity from the Directors of the Board and the Scientific \nDirectors of the Italian Society of Hypertension. High Blood Press \nCardiovasc Prev. 2020 Apr;27(2):105\u20138.\n53. Kalligeros M, Shehadeh F, Mylona EK, Benitez G, Beckwith CG, \nChan PA, et al. Association of Obesity with Disease Severity \nAmong Patients with Coronavirus Disease 2019. Obesity. 2020 \nJul;28(7):1200\u20134.\nReceived: 16 April 2021\nAccepted: 10 July 20212122\nJohanna Pilay Baja\u00f1a, Evelyn Ram\u00edrez Carguacundo, Mar\u00eda Jos\u00e9 Vizcaino Tumbaco, Daniel Silva-Ochoa, Davide Di Grumo, Luis Dorado-Sanchez, Silvia Orellana-Manzano, \nPatricia Manzano, Andrea Orellana-Manzano\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nAbstract: The worldwide spread of the virus has claimed multiple lives, especially in vulnerable groups. Therefore, an investigation \nwas carried out to present a viable solution for health personnel using the \u201cJES\u201d algorithm. The present study used the research \nto determine the possible complications presented by the sick individual, providing a viable and accessible healthcare personnel \nsolution through the proposed \u201cJES\u201d algorithm. A non-experimental, descriptive, correlational, and explanatory research is \npresented. According to pathologies of interest, the articles were taken virtually from scientific journals present in Google \nScholar and PubMed.  The excluded publications were: articles that do not detail the established protocol for detecting SARS-\nCoV-2, studies that do not present a significant number of people with Covid-19 disease, articles that the person has the covid-19 \ndisease but no underlying diseases of nutritional origin. It focused on the vulnerable or higher risk population group, including \nscientific information from children (over five years old), adults (over 18 years old), and older adults (over 65 years old) found in \ncountries of the Asian and American continents. The R program analyzed the scientific articles using the ggplot2 package with \na pie and bar diagram. A higher prevalence in men than women (56% vs. 44%) stood out. Likewise, arterial hypertension was \npresented in the first place with 40.82%, followed by diabetes with 30.61%, obesity with 12.24%, overweight and dyslipidemia \nwith 6.12%, malnutrition with 4.08%. There was a higher prevalence of stable individuals (29%) within the health facility than \nthose admitted to the ICU  (20%). Adults with 69.39%, followed by older adults with 16.33%, and mixed ages with 14.29%. \nComorbidities stand out as risk factors in people infected with SARS-CoV-2, regardless of age. A more significant contagion was \nobserved in the male versus female population; since men do not develop a rapid immune response and have a high content of \ncytokines that at the time of infection are released more quickly and can cause more significant damage\nKey words: Hormonal control, neuroendocrine, reproductive function, teleost fish, aquaculture.  \nIntroduction\nAquaculture is the fastest-growing food production sector \nglobally and plays an essential role in meeting the food de-\nmand of populations. In this stage, incorporating new techno-\nlogies that allow increasing the number of cultivable species \nis crucial1,2. For several years, the aquaculture sector has fo-\ncused mainly on establishing the minimum requirements for \nthe development, growth, and reproductive success of the \ndifferent species3,4. The study of endocrinology in teleost fish \nhas been fundamental for understanding the functional roles \nof hormones in biological systems. In recent years, the existen-\nce of a complex and infinite number of interactions between \nhormones and nerve structures has been demonstrated5-9. Re-\nproduction is one of the most important biological processes \nof organisms since the survival and perpetuation of the spe-\ncies depend on it1,10. The control of reproductive events allows \nthe application of selection programs to improve the growth \nrate, the survival of the species, reduce the problems asso-\nciated with sexual maturation and generate monosex popula-\ntions11,12. The quality of spawning depends on environmental \nfactors such as photoperiod, temperature, salinity, tank volu-\nme, substrate vegetation, etc1,13. The initiation of reproduction \nis affected by the number of energy reserves in the body and is \nsensitive to various metabolic factors.\nThe neuroendocrine mechanisms responsible for the as-\nsociation between energy balance and fertility are represen-\nted by metabolic hormones and neuropeptides that affect \nthe hypothalamic center. In teleosts, as in other vertebrates, \nreproduction is coordinated by the hypothalamic-pituitary-go-\nnad (HPG) axis14-16. However, there is very little research on reproductive biology and these species' molecular and cellular \nmechanisms12,17,18. This review presents a general bibliographic \ncompilation of the main hormonal and neuroendocrine aspects \nof the control of reproductive function in teleost fish. There-\nfore, it will try to provide an overview of the most significant \nfindings in recent years.\nHormonal control of reproduction in teleost fish\nThe control of reproduction in fish is a multifactorial pro-\ncess involving environmental, social, neuronal, endocrine, and \nmetabolic agents. a cascade of hormones regulates19,20 repro-\nduction. The mechanisms involved in this process depend on \nthe HPG axis (Figure 1)15,16. Hormones and neuropeptides are \nproduced in specific neuronal regions of the brain, mainly in \nthe hypothalamus. These can directly inhibit or stimulate go-\nnadotropins (GtH) release into the bloodstream or indirectly \nthrough their functions on gonadotropin-releasing hormone \n(GnRH)21,19. The beginning of sexual maturation in fish pre-\nsents two simultaneous events: the release of gonadotro-\npin-releasing hormone (GnRH)22-25 and the activation of GtH \nreceptors in the gonads26. The activation of these receptors \nstimulates the production of germ cells, the synthesis of sex \nsteroids and growth factors, and the effectors of gonadal de-\nvelopment12,27,19. At the level of the pituitary gland, different \nmolecules are secreted, such as: luteinizing hormone (LH), \nfollicle-stimulating hormone (FSH), growth hormone (GH), \nprolactin (PRL), thyroid-stimulating hormone (TSH), among \nothers21. These hormones participate in osmoregulation pro-\ncesses, growth, gonadal steroid production, the onset of pu-Hormonal and neuroendocrine control of reproductive function in teleost fish\nAdrian Rodr\u00edguez Gabilondo, Liz Hern\u00e1ndez P\u00e9rez, Rebeca Mart\u00ednez Rodr\u00edguez*REVIEW / ART\u00cdCULO DE REVISI\u00d3N\nDOI. 10.21931/RB/2021.06.03.35 \nMetabolic Modifiers for Aquaculture, Agricultural Biotechnology Department, Center for Genetic Engineering and Biotechnology, Havana, Cuba. \nCorresponding author: rebeca.martinez@cigb.edu.cu2123\nHormonal and neuroendocrine control of reproductive function in teleost fish\nberty, and reproductive behavior of fish7,12,28-30. In addition, a \nseries of neuroendocrine factors and hypothalamic neuropep-\ntides have been identified that regulate behavior, eating, and \nenergy balance. Their physiological and metabolic functions \nguarantee survival and growth during the reproductive stage16. \nWithin these neuropeptides, we can mention the GH relea-\nsing hormone (GHRH), pituitary adenylate cyclase-activating \npolypeptide (PACAP), Somatostatin (SS), the thyrotropin-re-\nleasing hormone (TRH), Dopamine, Neuropeptide-Y ( NPY), \ngamma-aminobutyric acid (GABA), neurokinin B (NKB) and go-\nnadotropin inhibiting hormone (GnIH)18,31-36. In addition, among \nthese neuropeptides is also included Kisspeptin (Kiss)37, which \nconstitutes an important regulator of the synthesis and relea-\nse of GnRH38,39,40,41. Another very novel neuropeptide is Phoe-\nnixin (PNX), which regulates physiological processes such as \nfood consumption, proliferation, and cell differentiation42,43. \nMoreover, it has been reported to be involved in reproductive \nfunction; due to its role in gene expression regulation in the \nhypothalamus and pituitary44,45. High concentrations of phoe-\nnixin in the central and peripheral nervous systems suggest \nthat the peptide may serve as a multi site-directed signaling \nmolecule44,46,47. In general, these brain factors, in addition to \nbeing involved in the secretion of pituitary hormones, regulate \nother physiological systems, but they greatly influence repro-\nduction12,30,36,48. At each level of the axis, a limited number of \ntarget cells are under the influence of many factors. The final \ncellular response is the overall effects of these mediators on \nthe components of intracellular signal transduction49. Mature \ngonads secrete sex steroids (estrogens and androgens), which negatively regulate hormonal secretions in the hypothalamus \nand pituitary gland. This closed-loop system maintains the ho-\nmeostasis of the reproductive system12. In general, according \nto their functions on the reproductive cycle, FSH has a vitello-\ngenin function and LH a maturational function50-53.\nGonadotropin-releasing hormone (GnRH)\nIn fish, as in all vertebrates, reproduction is regulated by \nthe hypothalamus through gonadotropin-releasing hormone \n(GnRH)16,54. This hormone constitutes the critical element of \nthe neuroendocrine control of reproduction16,55-58. The (GnRHs) \nconstitute a family of peptide molecules whose nature and di-\nversity have been evidenced in teleost fish59. Three structural \nvariants of GnRH have been identified in various vertebrate \nspecies: GnRH1, GnRH2, and GnRH356,57,58,60,61. However, the \nmolecular mechanisms that link the 3 isoforms of GnRH with \nreproduction in fish are not well clarified62.Mammals only pos-\nsess GnRH1 and GnRH2, while teleost fish have two or all three \ntypes of GnRH41. Most teleost fish, including Perciformes and \nPleuronectiformes, present all three GnRH isoforms36,55,57,63. \nOther fish species such as salmon (Salmoninae), zebrafish \n(Danio rerio) and goldfish (Carassius auratus) possess only \ntwo forms of GnRH (GnRH2 and GnRH3)14,36,64,65 GnRH1 is ex-\npressed mainly in the olfactory bulb, ventral telencephalon, \nand the pre-optic zone. GnRH2, a conserved form from fish to \nmammals, is expressed mainly in the midbrain36.\nGnRH3 constitutes the specific form of GnRH in fish66,67 \nand has a similar distribution to GnRH1. The three structu-\nral variants of GnRH have different physiological functions. \nFigure 1. Hypothalamic-Pituitary-Gonads (HPG) axis. Gonadotropin-Releasing Hormone (GnRH); follicle-stimulating hormone \n(FSH); luteinizing hormone (LH); prolactin (PRL); growth hormone (GH); Kisspeptin (Kiss2); Gonadotropin inhibitory hormone \n(GnIH); Growth factors (IGF); Thyroid-stimulating hormone (TSH); Triiodothyronine (T3); Tetraiodothyronine (T4). GnRH secre -\ntion acts on a population of gonadotropic cells of the pituitary, which release LH and FSH. In addition, the pituitary is the site \nof synthesis, storage, and release of GH, TSH, and PRL; it is considered a transducer that, through its secretions, regulates \nendocrine functions, such as reproduction, osmoregulation, growth, and metabolism.2124\nJohanna Pilay Baja\u00f1a, Evelyn Ram\u00edrez Carguacundo, Mar\u00eda Jos\u00e9 Vizcaino Tumbaco, Daniel Silva-Ochoa, Davide Di Grumo, Luis Dorado-Sanchez, Silvia Orellana-Manzano, \nPatricia Manzano, Andrea Orellana-Manzano\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\nGnRH1 is considered the hypothalamic variant capable of \nstimulating gonadotropin secretion and constitutes the fun-\ndamental regulator of the pituitary in mammals56,58. In teleost \nfish, GnRH1 has its physiological importance in the regulation \nof gonadotropin secretion and gametogenesis14. GnRH2 is in-\nvolved in regulating eating behavior58,68,69,70,71 and probably has \nan intermediary role between food intake and reproduction72,73. \nIt is highly probable that both GnRH2 and other GnRH isoforms \nexpressed in the olfactory region play a role in the perception \nof social and pheromonal signals36,74. GnRH3 participates in \nthe control of reproductive behaviors in several fish species14 \n.For example, this isoform stimulates the nesting behavior of \nmale dwarf Gourami (Trichogaster lalius)14. In adult zebrafish \nlacking GnRH3 neurons, there was evidence of an arrest in oo-\ncyte development and also a reduction in the mean diameter \nof the oocytes. These findings suggest that hypophysiotropic \nGnRH3 neurons are critical for normal oocyte development \nand reproduction75. Both this study and those carried out by \nPalevitch et al. 200776, suggest that GnRH3 is the hypophy-\nsiotropic GnRH capable of regulating the HPG axis in species \nlacking GnRH1, such as zebrafish. The action of GnRHs on tar-\nget cells is mediated by specific binding to their membrane re-\nceptors (GnRHR)36. Corresponding to the primary role of GnRH \nin controlling reproduction, GnRHRs are mainly localized in \nthe brain to mediate the neuromodulatory actions of GnRH in \nother neuronal systems and in gonadotropic cells of the pitui-\ntary to regulate gonadotropin secretion. Furthermore, GnR-\nHRs, like GnRHs, are found in the gonads and other peripheral \ntissues, exerting multiple physiological actions36,77. In general, \nthe primary function attributed to GnRH is the stimulation of \nthe synthesis and release of GtH in teleost fish36,55,77-81 Besides, \nit can regulate the gonadal maturation, the development of \ngerm cells (oogenesis and spermatogenesis), gonadal steroid \nproduction, ovulation, spermiation, and spawning36,57 In addi-\ntion, it is involved in the control of the release and expression of \ngrowth hormone, somatolactin, and prolactin82,83. Considering \nthe published results in the literature, the effects of GnRHs \non the control of reproductive function depend on the species, \nsex, and reproductive status, as well as the complex endocrine \ninteractions along the HPG axis57,83.  \nKisspeptin\nKisspeptin regulates the HPG axis34,84,85,86, and in the ini-\ntiation of sexual maturation84,87. Kisspeptin expression is more \nabundant in the brain, particularly in the hypothalamus84,88. \nIt originates from neuronal populations in the hypothalamus \nand projects into the median eminence (EM) and preoptic \narea (POA) regions, where GnRH neurons are also found89,90,91. \nHowever, its expression has been evidenced in peripheral tis-\nsues such as the intestine, kidney, liver, pancreas, adipose tis-\nsue, and gonads92. In mammals, only (kiss1) coding for kisspep-\ntin and (kiss1r) coding for the receptor have been identified93. \nHowever, in some teleost species due to a third duplication of \nthe genome, two genes coding for kisspeptin (kiss1 and kiss2) \nhave been identified86,93 Some of these species are medaka \n(Oryzias latipes)84, zebrafish84,94, sea bass (Lateolabrax japoni-\ncus), and redfish (Sciaenops ocellatus)95. Other species, such as \nthe puffer fish (Takifugu niphobles)87 and Senegalese sole (So-\nlea senegalensis) contain only the kiss2 gene96. The kisspep-\ntin receptor (kiss-R) in fish is expressed in tissues such as the \nbrain, pituitary, gonads, heart, kidney, liver, and muscle84,87,97-99.\nDifferent teleosts species have two or even three genes en-\ncoding for kisspeptin receptors (kiss1r, kiss2r, kiss3r)93,100. For \nexample, kiss1r and kiss2r have been identified in medaka, ze-brafish, goldfish, striped bass (Morone saxatilis), and European \nbass (Dicentrarchus labrax). However, kiss2r has only been \nidentified in Nile tilapia (Oreochromis niloticus), cobia (Rachy-\ncentron canadum), gray mullet (Mullus barbatus), spotted \ngrouper (Epinephelus fuscoguttatus), Senegalese sole, among \nothers101. Kiss3r, the expression demonstrated in zebrafish97, \ngoldfish102, medaka103, striped bass (Zmora et al., 2012), and \nEuropean eel (Anguilla anguilla)104. There is evidence in fish of \nthe participation of kisspeptins and their receptors in the feed-\nback mechanisms of sex steroids40. The role of kisspeptin in re-\nproduction is based mainly on the stimulation of GnRH release, \nindirectly modulating the release of LH and FSH93,105. In mam-\nmalian models, kisspeptin regulates the release of LH through \nprojections on GnRH neurons. However, in the case of teleosts, \nthese functions are not clear62. Zhao et al. 2014106 provided \ninteresting data on the modulatory effects of kiss1 and kiss2 \non neuronal GnRH subpopulations. First, they reported that \ntreatment with kiss1 or kiss2 during the first day after ferti-\nlization stimulated the proliferation of GnRH3 neurons in the \nperipheral nervous system. However, only kiss1 stimulated the \nproliferation of terminal and hypothalamic nerve populations \nof GnRH3 neurons106. In zebrafish (GnRH3) and striped bass \n(GnRH1), few preoptic GnRH neurons appear to be innervated \nby kisspeptin94,107,108. However, European seabass (Dicentrar-\nchus labrax) and medaka hypothalamic GnRH3 neurons are \nnot associated with kisspeptin fibers88,109. Zmora et al. 2015110, \nfound kiss1 immunoreactive nerve endings that reach LH cells, \nsuggesting the existence of a direct pituitary site of action of \nkisspeptin These results are similar to those published by \nShahjahan et al. in 201414 where the expression of kisspeptin \nis evidenced in the pituitary gland of goldfish and puffer fish \n(Takifugu rubripes). Studies in goldfish37,99 and sea bass111 have \nconfirmed a direct stimulation in the secretion of LH and FSH \nin pituitary cells in response to kisspeptin administration. On \nthe other hand, in goldfish, kiss1 significantly increased LH-\u03b2, \nGH and PRL mRNA levels through in vitro studies99. Interestin-\ngly, both kiss1 and kiss2 regulate FSH-\u03b2 expression levels in \npituitary cell cultures in striped bass (Morone saxatilis). Howe-\nver, only Kiss1 can regulate LH-\u03b2 mRNA levels in seabass ne-\ngatively110. In sexually mature female zebrafish, administration \nof Kiss2 by intraperitoneal injection significantly increased FSH \nand LH mRNA levels. On the other hand, the administration \nof kiss1 by the same route did not have significant differen-\nces in GtH gene expression levels84,112. The stronger effect of \nkiss2 compared to kiss1 was also observed in the release of \nFSH and LH in sea bass95,112. A similar trend was observed for \nthe effects of kisspeptins on the stimulating effect on gonadal \nmaturation in seabass and striped bass113. In contrast, intra-\nperitoneal injections of kiss2 stimulated mRNA expression of \nFSH rather than LH in female spotted grouper114. Furthermore, \nin goldfish, intraperitoneal injections of kiss1, but not kiss2, sti-\nmulated the release of LH in sexually mature females102. Also, \nit has been reported that kiss2 may have effects on food intake \nand growth function88,96,115. Furthermore, it can act as a link be-\ntween food intake, energy homeostasis, and reproduction116-118. \nIn general, these findings indicate the role of kiss1 and kiss2 \nin gonadotropin regulation is species-specific. Collectively, the \ndifferences between the species derive from their reproductive \nbehavior and the stages of reproduction.\nGonadotropin inhibitory hormone (GnIH)\nMultifactorial control of reproduction also involves other \nneurohormones such as gonadotropin inhibitory hormone \n(GnIH)20. In fish, GnIH is expressed mainly in the brain and pi-2125\nHormonal and neuroendocrine control of reproductive function in teleost fish\ntuitary, although its expression has also been evidenced in the \nspleen, gonads, muscle, eyes, and kidney119-122. GnIH acts by \nbinding to GnIH receptors (GnIH-R) that belong to the fami-\nly of G protein-coupled receptors. Two GnIH-Rs (GPR147 and \nGPR74) have been identified in vertebrates, but only GPR147 \nappears to be present in fish122-124. GPR147 have been identified \nin fish's central and peripheral tissues, including the brain, pi-\ntuitary, eyes, heart, intestine, kidney, liver, spleen, muscle, and \ngonads125-127. As its name suggests, the main function of GnIH \nis the inhibition of gonadotropin release through the inhibition \nof GnRH and kisspeptin128,129, an action that has been described \nin many vertebrates. However, the physiological functions of \nGnIH in fish are not precise yet. Contradictory effects have \nbeen observed in fish, both in vivo130 and in vitro131 For example, \nadministration of GnIH to pituitary cell cultures of mature fe-\nmale Nile tilapia increased LH and FSH mRNA levels18,130. It has \nbeen shown that in goldfish, GnIH inhibits both the synthesis \nand the release of gonadotropins in the early stages of gona-\ndal maturation but not in spawning132. Administration of GnIH \nto zebrafish by intraperitoneal injection decreases plasma LH \nlevels in adult goldfish125,132. However, the inhibitory effect of \nGnIH injections was not observed in juvenile stages132. In vitro \nstudies showed that the administration of GnIH from goldfish \nstimulates the expression of gonadotropins in pufferfish with \napparent seasonal differences in reproduction132,133. These fin-\ndings indicate that, in teleosts, the physiological effect of GnIH \non the HPG axis differs between gonadotropin synthesis and \nrelease and depends on the reproductive stage. Even though \nresearchers have shown that GnIH exerts both stimulatory \nand inhibitory actions, depending on the season and species, \nboth GnRH and GnIH are considered essential components of \nthe multifactorial control of reproduction20.\nGonadotropins (GtHs)\nIn teleosts, as in all vertebrates, the functions of the \ngonads are maintained thanks to the actions of the gona-\ndotropins. They have a central role in the regulation of ga-\nmetogenesis134 and the steroidogenesis necessary for the \ndevelopment of sexual behavior and secondary sexual charac-\nteristics1,78,80,135. Gonadotrops are cells specialized in producing \ngonadotropins such as follicle-stimulating hormone (FSH) and \nluteinizing hormone (LH). Both are glycoproteins made up of \ntwo non-covalently associated subunits (\u03b1 and \u03b2). The \u03b1 subu-\nnit has 92 amino acids (aa) and is common in both gonadotro-\npins. The \u03b2 subunit has 121 aa for LH and 118 aa for FSH. This \nsubunit is specific for recognition by their cellular receptor \nand also confers biological activity15,53,134,136. These hormones \nexert their effects by binding to G protein-coupled surface re-\nceptors, called the LH receptor (LH-R) and the FSH receptor \n(FSH-R)134,137,138. Both receptors are mainly expressed in the \ngonads139. In the ovary, LH-R is expressed in theca cells, lu-\nteal cells, and interstitial cells, regulating actions such as the \nsynthesis of steroid hormones, ovulation, and the formation \nof the corpus luteum139. In the testicle, LH-R is expressed in \nLeydig cells, where it stimulates the synthesis of testosterone \n(T), a precursor hormone of testicular maturation via sperma-\ntogenesis.139 LH is related to the manifestation of secondary \nsexual characteristics in males, and its highest plasma levels \nare in the spermiation stage. In addition, it intervenes in the \ncapture and incorporation of blood vitellogenin to the oocyte. \nIn the final phase of oocyte maturation, LH levels increase, \nleading to the production of dihydroxyprogesterone (17\u03b1-20\u03b2). \nThe 17\u03b1-20\u03b2 is involved in the haploid processes before ovula-\ntion and in sodium and potassium transport control139. For its part, FSH-R is expressed in the ovary, exclusively in granulosa \ncells. Its activation by the action of FSH contributes to follicu-\nlar development and stimulates the synthesis of 17\u03b2 estradiol. \nThe 17\u03b2 estradiol acts on the liver to initiate and maintain vi-\ntellogenin synthesis in oocytes and is involved in gonadal ma-\nturation processes.\nFurthermore, FSH induces aromatase expression and \nthus modulates ovarian estrogen synthesis. On the other hand, \nin the testis, FSH-R is expressed in Sertoli cells139. In trout, \nplasma FSH increased at the beginning of oogenesis and in the \ninitial phases of spermatogenesis140. Also, in Pacific salmon \n(Oncorhynchus tshawytscha), the levels of FSH remained high \nand declined immediately before ovulation and spermiation. In \nphysiological studies carried out in this same species, FSH-\u03b2 \nexpression levels increased during the initiation of gonadal \ngrowth and decreased in spawning141. These results coincide \nwith Schulz et al. in 2001142, where they state that FSH is in-\nvolved in the initial phases of gametogenesis, and LH mainly \nregulated the last stages of gonadal maturation. Previous stu-\ndies have reported that FSH mRNA levels increased while LH \nmRNA decreased during the transition from female to male \nin Epinephelus merra. This was associated with testicular de-\nvelopment and suggests that FSH could trigger sex change in \nthis species143. In recent studies, the expression of LH-\u03b2 mRNA \nin the pituitary of carp (Cyprinus carpio) increased significant-\nly during the maturation of the male; however, FSH-\u03b2 mRNA \nexpression did not change significantly during development136. \nAs published by Yaron et al. in 200329, LH-<UNK> and FSH-\n<UNK> gene expression levels of LH-\u03b2 and FSH-\u03b2 were very \nlow in the juvenile stage of carp, while they increased during \nthe ovulation period. In general terms, FSH mainly controls the \nfirst stages of spermatogenesis, and LH regulates testicular \nmaturation, ovulation, and spermiation16,50-52.\nGrowth hormone (GH)\nThe growth hormone of teleost fish is a 21-23 kDa protein \nmade up of a single polypeptide chain. Similar to what happens \nin mammals, GH in fish is produced by somatotropic cells in \nthe anterior region of the pituitary gland144. Furthermore, its \nexpression has been confirmed in other fish tissues, including \nthe brain, liver, spleen, and gonads145,146. GH is an essential \nendocrine regulator in many physiological processes in verte-\nbrates. In fish, it is involved in events such as somatic growth, \nenergy metabolism, reproduction, appetite, the function of the \nimmune system, and the regulation of ionic and osmotic ba-\nlance147,148. In addition, it influences aspects of behavior such \nas aggressiveness and the ability to avoid predators149. This \nhormone is released from the pituitary in response to hypo-\nthalamic signals and exerts its effects on target tissues148,150 \nbinding to the GHR-I and GHRII receptors (hormone receptor \ngrowth I and II, respectively)148,149. Growth hormone receptors \n(GHRs) are members of the type I cytokine receptor family151. \nThey have been identified in several fish species, such as turbot \n(Scopthalmus maximus)146, salmon (Oncorhynchus masou)152, \nand Mozambique tilapia (Oreochromis mossambicus)153. These \nreceptors are expressed in a wide variety of tissues, including \nthe brain, pituitary, skin, heart, liver, gallbladder, intestine, adi-\npose tissue, kidney, spleen, gonads, and muscle152-154. However, \nthe primary expression is in the liver (or hepatopancreas), whe-\nre GHRs have a significant role in regulating somatic growth148. \nGH binds to its specific receptors in the liver and promotes the \nrelease of insulin-like growth factor-I and II (IGF-I and IGF-II), \nwhose primary function is to mediate and increase the grow-\nth-promoting function of GH155. IGF-I is involved in reproduc-2126\ntion and particularly in mediating the effects of GH on somatic \ngrowth154. Furthermore, it has been associated with fish meta-\nbolism, development, reproduction and osmoregulation148,150. \nIn the case of IGF-II, its mRNA has been detected in the liver \nand the brain, heart, kidney, gills, gastrointestinal tract, pan-\ncreatic islets, skeletal muscle, and gonads of fish150. This \ntranscript is expressed in juvenile and adult fish, contrary to \nwhat has been reported for mammals where its expression oc-\ncurs only during the early stages of development156. GH exerts \na lipolytic and anabolic function. The lipolytic action is inde-\npendent of IGFs and facilitates fats as an energy source in ca-\ntabolic and malnutrition states157. The anabolic action of GH is \nrelated to protein metabolism and is mediated by IGFs157. The \nbiological functions of IGFs are mediated by binding to specific \ntransmembrane receptors, present in both fish and mammals.\nIn sexually mature ovaries of Nile tilapia, high levels of \nmRNA of both GHRs were detected. While in testes of this \nsame species, the highest levels were observed after the sta-\nge of sexual maturation148. Changes in the expression of IGFs in \nthe gonads and the neuroendocrine regulation of GnRH, GnIH, \nFSH, LH, GH and the GH / IGF system have been associated \nwith promoting testicular steroidogenesis. They also have a \nsignificant influence on the oocyte maturation processes in \nseveral species154,156,158,160. Taken together, these observations \nsuggest that GH, IGFs, and gonads are closely related and in-\nvolved in controlling reproductive function.\nProlactin (PRL)\nPRL is synthesized mainly by the lactotrophic or PRL-se-\ncreting cells found in the pituitary160,161. It has a variable length \n(between 170 and 205 amino acids (aa) depending on the spe-\ncies, with signal peptides of 23-24 aa. Two isoforms have been \nfound in teleosts (PRL188 and PRL177), with different biologi-\ncal activities83. Prolactin is generally produced at high levels in \npituitary tissues; however, its expression has been evidenced \nin other tissues such as the liver, intestine, gonads, gills, kid-\nney, spleen, brain, and muscle162,163. Plasma PRL levels in Nile \ntilapia are increased during maternal behavior, suggesting hor-\nmonal control164. Other studies indicate that PRL mRNA levels \nand mature protein have been found in the gonads of different \nfish species, including Mozambique tilapia167, Nile tilapia165, \ngoldfish162,166, and rainbow trout (Oncorhynchus mykiss)166. This \nsuggests that PRL may be involved in spermatogenesis, vite-\nllogenesis, and ovulation. However, no significant differences \nwere found in PRL mRNA levels during sexual maturation of \nJapanese eels through in vitro studies by Ozaki et al. in 2007168. \nAccording to Onuma et al. in 2010169, in salmon, the levels of \nPRL mRNA and gonadotropins significantly were increased in \nthe stage of maturation and gonadal development, which su-\nggests that these hormones may be associated with the de-\nvelopment of the reproductive system. In addition, PRL levels \nseem to be involved in many more functions such as develo-\nping reproductive cycles, incubation behavior, or feeding the \nfry170,171. It has also been shown to stimulate steroidogenesis \nin the ovaries and testes and increase their mRNA and plasma \nlevels during sexual maturation in salmonids and tilapia153,166. \nThe regulation of PRL synthesis and release into the pituitary \nis known to be influenced by hypothalamic neurohormones, sex \nsteroids, and plasma factors from other tissues171. It is propo-\nsed that this hormone can act in an autocrine or paracrine man-\nner and represents an exciting area for future research171,172.\nThyroid hormones (HTs)\nThyroid hormones (HTs) are involved in various biological events in fish, such as regulating metabolism, growth, develo-\npment, and reproduction, among others173-177. HTs (T3 and T4) \nare found in two forms in the blood: free and bound to trans-\nporter proteins. Less than 1% is in the free form and there-\nfore easily accessible to target cells178. The secretion of HTs \nis under the control of the hypothalamic-pituitary-thyroid axis \n(Figure 2)175,177-179. In the hypothalamus, some neurons synthe-\nsize, transport, and release various factors that stimulate or \ninhibit the release of HTs to the neurohypophysis. Among the \nstimulatory factors are thyrotropin-releasing hormone (TRH) \nand the inhibitors Somatostatin and TSH inhibitory factors. \nThyroid-stimulating hormone (TSH) is released to the bloods-\ntream, where it reaches the thyroid gland and stimulates the \nsynthesis and release of the two HTs (T3 and T4) into the \nblood178,179. These hormones are lipidic, so they can cross the \nplasma membrane and reach the cytoplasm. T4 is secreted \nunder normal conditions, while T3, known as the active hor-\nmone, is produced mainly from the conversion of T4 to T3. Two \nenzymes catalyze this process with deiodase activity (DIO1 and \nDIO2)180. T3 crosses the nuclear membrane to interact with its \nTHR \u03b1 and THR \u03b2 receptors in the nucleus. \nOnce the hormone-receptor complex is formed, there is a \nself-regulation of the expression of the genes (THR\u03b1 and THR \n\u03b2) that code for the THR \u03b1 and THR \u03b2 receptors177,179. Some \nof the first studies in fish was carried out in Pacific salmon, \nAtlantic salmon (Salmo salar), and striped bass (Morone sa-\nxalitis), where it was evidenced that the thyroid hormones T3 \nand T4 are transferred from the mother to the egg and are \nused during the absorption of the yolk sac in the larval period, \nto later be synthesized by the larva in the exogenous feeding \nperiod181. In salmon, the increase in plasma T4 levels has been \nseen in the early stages of gonadal maturation but decreases \nas vitellogenesis and testicular maturation occur182. In stella-\nte sturgeon (Acipenser stellatus), high thyroid activity occurs \nin conjunction with gonadal maturation during preponderan-\nce migration and at spawning. In salmonids, the increase in \nT3 was related to vitellogenesis or the last stages of oocyte \ndevelopment12,179. In vitro and in vivo studies have shown that \nT3 treatments caused a decrease in LH mRNA levels in gold-\nfish183,184. In other trials, T3 administrations in carp increased \nvitellogenin mRNA (Vtg) levels in the liver, a critical factor in \ngonadal maturation185. However, T3 treatment decreased the \nexpression of estrogen receptors in golden carp testes176. In \nzebrafish, the administration of T3 stimulated the proliferation \nof Sertoli cells and spermatogonia in the testes186. In general, \nthe effects of HTs on reproductive function are species depen-\ndent187,188.\nGonadal development in females and males\nReproductive processes in teleost fish include puberty, \nspermatogenesis, spawning, and cellular processes such as \nsteroidogenesis16. The gonads have the enzymes necessary for \nthe synthesis of steroids and their transformation into a who-\nle series of intermediaries involved in the different phases of \nreproduction. They produce three types of steroids necessary \nfor reproduction: estrogens or C18 steroids, androgens or C19 \nsteroids, and progestogens or C21 steroids189. Gonadal ste-\nroids exert their actions on target tissues by binding to specific \nintracellular receptors since, thanks to their lipophilic nature, \nthey easily penetrate and diffuse within the cell190,191. In teleost \ntestes, the synthesis of steroid (androgenic) hormones takes \nplace in Leydig cells. Testosterone (T) is mainly synthesized \nand, to a lesser extent, 17\u03b1-hydroxy-4-pregnen-3-one (DHT), \nAndrostenedione, and 11-ketotestosterone (11-KT)192. T is es-Johanna Pilay Baja\u00f1a, Evelyn Ram\u00edrez Carguacundo, Mar\u00eda Jos\u00e9 Vizcaino Tumbaco, Daniel Silva-Ochoa, Davide Di Grumo, Luis Dorado-Sanchez, Silvia Orellana-Manzano, \nPatricia Manzano, Andrea Orellana-Manzano\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2127\nHormonal and neuroendocrine control of reproductive function in teleost fish\nsential in the spermatogenic process and has great importan-\nce in female reproductive processes since it acts as a precur-\nsor of estrogen biosynthesis. 11-KT is a critical factor in the \nmaturation of gametes, the development of secondary sexual \ncharacteristics, and reproductive behavior193-196. Spermatoge-\nnesis depends on the action of gonadotropins, and their binding \nmediates this function to their receptors in the gonads. Once \nthis union occurs, the synthesis and secretion route of different \nsex steroids is activated197.\nIn oogenesis, hormones of a steroid and peptide nature are \nsynthesized, which are essential for regulating the reproduc-\ntive axis in females53. The oocyte maturation process occurs \nwithin the ovarian follicles and is produced mainly 17\u03b2-estra-\ndiol (E2). According to Nagahama and Yamashita in 2008198, \nin teleost fish, there are three essential regulators of oocyte \nmaturation: Gonadotropins, maturation inducing hormone \n(MIH), and maturation promoting factor (MPF). Before oocyte \nmaturation, a change in the steroidogenic pathway from E2 to \nDHP occurs in ovarian follicles199. This change during ovarian \ndevelopment is regulated mainly by changes in the availability \nof steroidogenic enzymes198. MIH activates MPF and triggers a \nseries of changes associated with oocyte maturation.\nOne of the most critical processes for the maturation of \nthe oocyte is vitellogenesis. Its principal function is the seques-\ntration and packaging of vitellogenin (Vtg) and the absorption \nof very-low-density lipoproteins200,201. Vtg is synthesized in \nthe liver and is specific to maturing females (Devlin and Na-\ngahama, 2002). The growing ovarian follicles selectively se-\nquester this through specific receptors (VtgRs) that give rise \nto the formation of Vtg-coated vesicles202. Vesicles fuse with \nlysosomes leads to the formation of multivesicular bodies \n(MVB). During vitellogenesis, gonadotropins stimulate the pro-\nduction of Testosterone (T) by theca cells, and subsequently, \nit is aromatized to 17-\u03b2 estradiol (E2) in the granulosa cells of \nthe ovarian follicle. In response to this stimulation, plasma E2 \nlevels increase, which stimulates the production of Vtg in the liver, which is recognized by VtgR and incorporated by the oo-\ncyte through micropinocytosis (Figure 3)1,27. At the end of vite-\nllogenesis, plasma LH levels increase, and in turn, E2 levels \ndecrease. This results in a transient increase in plasma levels \nof T and maturation-inducing steroids (MIS), which act at the \nfollicular layers' level to induce the oocyte's final maturation1. \nAfter the rupture of the follicle, the oocyte is released, in a pro-\ncess called ovulation196. Once ovulation occurs, follicular cells \nundergo morphological changes that lead to the secretion of \nprogesterone (P) and E2190,203. In general, both vitellogenesis \nand the final maturation of the oocyte are crucial events in the \nreproductive physiology of females. \nAnother group of steroid hormones such as corticoste-\nroids, which are usually related to stress, play an essential \nregulatory role in other physiological processes196. In teleost \nfish, corticosteroids are mainly synthesized in the inter-renal \ntissue, specifically the head kidney.  Plasma corticosteroid \nconcentrations in fish depend on species, sex, and reproducti-\nve status204. Plasma levels of corticosteroids vary significantly \nthroughout the reproductive cycle. For both females and ma-\nles, some species contain high cortisol levels in plasma during \nthe pre-spawning period, such as the rainbow trout205, perch \n(Perca fluviatilis)206, and masu salmon207. In general, steroid \nhormones play a fundamental role in controlling the reproduc-\ntive function of teleost fish. These present direct or feedback \neffects through different hormonal cascades on reproductive \nfunctions in fish and constitute critical factors in the regulation \nof the HPG axis196. The gonadal maturation process in fish is \nhighly complex since it includes the production, maturation, re-\nlease of gametes, synthesis of hormones, and sexual behavior, \nwhich requires a large amount of available energy208. Although \nthe role of energy in sexual maturation and reproduction has \nbeen evidenced. There are still gaps in the knowledge about \nthe influence of metabolic and nutritional status on the regu-\nlation of gonadal function in fish16.\nFigure 2. Hypothalamic-Pituitary-Thyroid Axis (HPT). Thyrotropin Releasing Hormone (TRH); Thyroid-stimulating hormone \n(TSH); Triiodothyronine (T3); Tetraiodothyronine (T4); Enzymes with deiodinase activity (DIO1 and DIO2).2128\nConclusions\nIn this review, the fundamental aspects involved in contro-\nlling the reproductive function of teleost fish were addressed. \nThe role of hormonal and neuroendocrine regulation of these species is described, which guarantees the proper functioning of the physiological machinery in reproductive events. The hypothalamic and pituitary hormones involved in reproduction in fish point to the immense complexity of endocrine regulation of reproductive processes. A brief overview of the integrative role of some neuropeptides in the regulation of feeding, meta-bolism, growth, and reproduction was also shown. However, especially in fish, knowledge about these integrative functions of regulatory peptides is not well studied.\nBibliographic references\n1. Z ohar Y and Mylonas CC. Endocrine manipulations of spawning\nin cultured fish: from hormones to genes. Aquaculture 2001;\n197:99-136.\n2.R\neid GK, Helen J, Gurney-Smith, Flaherty M, Garber AF, Forster\nI, et al. Climate change and aquaculture: considering adaptationpotential. Aquaculture Environ Interact 2019; 11: 603-624.\n3.\nNRC. Nutrient requirements of fish and shrimp. The NationalAcademies Pres\ns, Washington, D.C.  2011; 228.\n4.\n P\nohlenz C, Delbert M, Gatlin III. Interrelationships between fish\nnutrition and health. Aquaculture 2014; 431:111-117.\n5.Bruce A. S\ntress in Fishes: A Diversity of Responses with Particu-\nlar Reference to Changes in Circulating Corticosteroids. Integra-tive and Comparative Biology 2002; 42(3):517\u2013525.\n6.\nMcCornick \nS, O'Dea M, Moeckel A, Thrandur B. Endocrine and\nphysiological changes in Atlantic salmon smolts following hatch-ery release. Aquaculture 2003; 222:45-57.\n7.\nMancer\na JM and Cormick S. Role of Prolactin, Growth Hormone,\nInsulin-like Growth Factor I and Cortisol in Teleost Osmoregula-tion In: Fish Osmoregulation. Ed. B.G. Kapoor, Science Publishers2007; p 497-515.\n8.\n Subhash M. The role of thyroid hormones in s\ntress response of\nfish. Gen Comp Endocrinol 2011; 172:198-210.9.F regeneda-Grandes J, Hernandez-Navarro S, Fernandez-Coppe I, \nCorrea-Guimaraes A, Ru\u00edz-Potosme N, Navas-Gracia L, et al. Sea-sonal and sex related variations in serum steroid hormone levelin wild and farmed Brown trout Salmo trutta L.in the north-westof Spain. J Water and health  2013; 11:720-728\n10.\n Manlik O\n. The importance of Reproduction for Conservation of\nSlow-Growing animal populations. Reproductive Sciences in Ani-mal Conservation 2019; 13-39.\n11.\n Solar I. Biotecnolog\u00eda aplicada a la acuicul\ntura. Aquanoticias In-\nternacional N\u00b0 66, 2002; Pp 6-10.\n12.\n Mylonas C\n, Fostier Al, Zanuy S. Broodstock management and hor-\nmonal manipulations of fish reproduction. Gen Comp Endocrinol. 2010; 165:516-534.\n13.\n V\naldebenito. Hormone therapy for the artificial control of sexual\nmaturity in fish culture: a review. Arch Med 2008; Vol 40:115-123.\n14.\n Shahjahan M, Kitahashi T\n, Parhar IS, Davenport AP and Bonner\nT. Central Pathways Integrating Metabolism and Reproductionin Teleosts. Frontiers in Endocrinology 2014; DOI: 10.3389/fen-do.2014.00036.\n15.\n Le\nvavi-Sivan B, Bogerd J, Ma\u00f1an\u00f3s EL, G\u00f3mez A, Lareyre JJ. Per-\nspectives on fish gonadotropins and their receptors. Gen CompEndocrinol 2010; 165:412-437.\nFigure 3. Hormonal regulation of vitellogenesis in teleost fish.Johanna Pilay Baja\u00f1a, Evelyn Ram\u00edrez Carguacundo, Mar\u00eda Jos\u00e9 Vizcaino Tumbaco, Daniel Silva-Ochoa, Davide Di Grumo, Luis Dorado-Sanchez, Silvia Orellana-Manzano, \nPatricia Manzano, Andrea Orellana-Manzano\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com2129\nHormonal and neuroendocrine control of reproductive function in teleost fish\n16. Hatef A and Unniappan S. Metabolic hormones and the regulation \nof \nspermatogenesis in fishes. Theriogenology 2019; 134:121-128.\n17.\n Unniappan S. Ghrelin: an emerging pla\nyer in the regulation of re-\nproduction in non-mammalian vertebrates. General and compar-ative endocrinology 2010; 167(3):340-343.\n18.\n London S and V\nolkoff H. Effects of fasting on the central expres-\nsion of appetite-regulating and reproductive hormones in wild-type and Casper zebrafish (Danio rerio). General and Comparative Endocrinology 2019; 282:113-207.\n19.\n Bir\nan J, Levavi-Sivan B. Endocrine Control of Reproduction. Fish\n2018; 6:362-368.\n20.\n Ma Y\n, Ladisaa C, Changa JP, Habibi HR. Multifactorial control\nof reproductive and growth axis in male goldfish: Influences ofGnRH, GnIH and thyroid hormone. Molecular and Cellular Endo-crinology 2020; 500:110-629.\n21.\n W\neltzien FA, Andersson E, Andersen \u00d8, Shalchian-Tabrizi K, Nor-\nberg B. The brain-pituitary-gonad axis in male teleosts, with em-phasis on the flatfish (Pleuronectiformes). Comp Biochem Physi-ol 2004; 137:447-477.\n22.\n P\neter RE, Yu KL. Neuroendocrine regulation of ovulation in fishes: \nbasic and applied aspects. Rev Fish Biol Fisher 1997; 7:173-197.\n23.\n Okuza\nwa K. Puberty in teleosts. Fish Physiol Biochem 2002;\n26(1):31-41.\n24.\n Jalaber\nt B. Particularities of reproduction and oogenesis in tele-\nost fish compared to mammals. Reprod Nutr 2005; 45:261-279.\n25.\n T\naranger GL, Carrillo M, Schulz RW, Fontaine P, Zanuy S, Felip\nA, et al. control of puberty in farmed fish. Gen Comp Endocrinol.2010; 165(3):483-515.\n26.\n Cueto JM. Control Hormonal de la R\neproducci\u00f3n en Peces. Uni-\nversidad de C\u00e1diz, Departamento de Biolog\u00eda (Facultad de Cien-cias del Mar y Ambientales) 2016.\n27.\n Schulz R\nW, De Franca, Lareyre LR, LeGac JJ, Garcia CF, Nobrega \nH, et al. Spermatogenesis in fish. Gen. Comp. Endocrinol 2010;165:390-411.\n28.\n Rile\ny LG, Hirano T, Grau EG. Rat Ghrelin Stimulates Growth Hor-\nmone and Prolactin Release in the Tilapia, Oreochromis mossam-bicus. Zoological science 2002; 19:797-800.\n29.\n Y\naron Z, Gur G, Melamed P, Rosenfeld H, Elizur A, Levavi-Sivan B. \nRegulation of fish gonadotropins. International Review of Cytolo-gy 2003; 225:131-185.\n30.\n Aizen J\n, Harel J, Levavi-Sivan B. Development of specific en-\nzyme-linked immunosorbent assay for determining LH and FSHlevels in tilapia, using recombinant gonadotropins. Gen Comp En-docrinol 2007; 153:323-332.\n31.\n Gahete MD\n, Dur\u00e1n-Prado M, Luque RM, Mart\u00ednez-Fuentes AJ,\nQuintero A, Guti\u00e9rrez-Pascual E, et al. Understanding the mul-tifactorial control of growth hormone release by somatotropes:lessons from comparative endocrinology. Ann. N. Y. Acad. Sci2009; 1163:137-153.\n32.\n Li W\n, Lin H. The endocrine regulation network of growth hormone \nsynthesis and secretion in fish: Emphasis on the signal integration in somatotropes. Sci. China Life Sci 2010; 53:462-470.\n33.\n Dai X, Zhang W\n, Zhuo Z, He J, Yin Z. Neuroendocrine regulation\nof somatic growth in fishes. Sci. China Life Sci 2015; 58:137-147.\n34.\n P\narhar IS, Ogawa S, Ubuka T. Reproductive neuroendocrine path-\nways of social behavior. Front Endocrinol 2016; 7:28\n35.\n Albaa G\n, Michele N, Mouradb N, Paredesa JF, V\u00e1zqueza SFJ, Ol-\nmedaa JFL. Daily rhythms in the reproductive axis of Nile tilapia(Oreochromis niloticus): Plasma steroids and gene expression inbrain, pituitary, gonad and egg. Aquaculture 2019; 507:313-321.\n36.\n Mu\u00f1oz-Cueto, \nJA., Zmora N, Paullada-Salmer\u00f3n JA, Marvel M,\nMa\u00f1anos E, & Zohar Y. The gonadotropin-releasing hormones:lessons from fish. General and comparative endocrinology 2020;291: 113-422.\n37.\n Chang JP\n, Mar A, Wlasichuk M, Wong AOL. Kisspeptin-1 directly\nstimulates LH and GH secretion from goldfish pituitary cells in aCa (2+) dependent manner. Gen Comp Endocrinol 2012; 179:38-46.\n38.\n T\nopaloglu AK, Kotan LD. Molecular causes of hypogonadotropic\nhypogonadism. Curr Opin Obstet Gynecol 2010; 22:264-70.39.  Pinilla L, Aguilar E, Dieguez C, Millar RP, Tena-Sempere M. Kis-\nspeptins and reproduction: physiological roles and regulatorymechanisms. Physiol Rev 2012; 92:1235-316.\n40.\n P\narhar I, Ogawa S, Kitahashi T. RF-amide peptides as mediators\nin environmental control of GnRH neurons. Prog Neurobiol 2012;98:176-96.\n41.\n Mizr\nahi N, Gilon C, Atre I, Ogawa S, Ishwar S, Parhar et al. De-\nciphering Direct and Indirect Effects of Neurokinin B and GnRHin the Brain-Pituitary Axis of Tilapia. Frontiers in Endocrinology2019; Vol 10 Article 469. doi: 10.3389/fendo.2019.00469.\n42.\n R\najeswari JJ, Blanco A M, & Unniappan S. Phoenixin-20 sup-\npresses food intake, modulates glucoregulatory enzymes, andenhances glycolysis in zebrafish. American Journal of Physiol-ogy-Regulatory, Integrative and Comparative Physiology 2020;318(5):917-928.\n43.\n Schalla MA, & S\ntengel, A. Phoenixin A pleiotropic gut-Brain pep-\ntide. International journal of molecular sciences 2018; 19(6):1726.\n44.\n Y\nosten GL, Lyu RM., Hsueh AJ, Avsian\n\u03b1\nKretchmer O, Chang JK,\nTullock CW& Samson, WK. A novel reproductive peptide, phoe-nixin. Journal of neuroendocrinology 2013; 25(2):206-215.\n45.\n W\nang M, Chen HP, Zhai Y, Jiang DN, Liu JY, Tian CX,  & Li GL.\nPhoenixin: Expression at different ovarian development stagesand effects on genes ralated to reproduction in spotted scat, Sca-tophagus argus. Comparative Biochemistry and Physiology PartB: Biochemistry and Molecular Biology 2019; 228:17-25.\n46.\n Prinz P\n, Scharner S, Friedrich T, Schalla M, Goebel-Stengel M,\nRose M, et al. Central and peripheral expression sites of phoenix-in-14 immunoreactivity in rats. Biochem Biophysical Res Comm2017; 493: 195-201.\n47.\n Y\nuan T, Sun Z, Zhao W, Wang T, Zhang J, Niu D. Phoenixin: a newly dis-\ncovered peptide with multi-functions. Protein Pept Lett 2017; 24: 472-5.\n48.\n Y\naron Z, Gur G, Melamed P, Rosenfeld H, Elizur A, Levavi-Sivan B.\nRegulation of fish gonadotropins. Int Rev Cytol 2003; 225:131-185.\n49.\n Kim DK, Cho EB, Luna MJ\n, Parque S, Hwang JI, Kah O, et al. Revis-\niting the evolution of gonadotropin-releasing hormones and theirreceptors in vertebrates: Secrets hidden in genomes. Gen CompEndocrinol 2011; 170:68-78.\n50.\n Zanuy S, Carrillo M. La reproducci\u00f3n de los peces tele\u00f3s\nteos y su \naplicaci\u00f3n en acuicultura. En: Espinosa de los Monteros J, Labar-ta U (eds). Reproducci\u00f3n en acuicultura. CAICYT. Madrid, Espa\u00f1a, 1987, Pp 1-131.\n51.\n Luck\nenbach JA, Iliev DB, Goetz FW, Swanson P. Identification of\ndifferentially expressed ovarian genes during primary and earlysecondary oocyte growth in coho salmon, Oncorhynchus kisutch. Reprod Biol Endocrinol 2008; 6-2.\n52.\n Zanuy S, Carrillo M, R\nocha A, Mol\u00e9s G. II Regulaci\u00f3n y control hor-\nmonal del proceso reproductor de los tele\u00f3steos. En: Carrillo M,Espinosa de los Monteros J (eds). La reproducci\u00f3n de los peces:aspectos b\u00e1sicos y sus aplicaciones en acuicultura. OESA, CSIC,MMAMRN, Madrid, Espa\u00f1a 2009; 97-172.\n53.\n F\nalcone TH. Ovarian Hormones: Structure, Biosynthesis, Func-\ntion, Mechanism of Action, and Laboratory Diagnosis in Clinicalreproductive medicine and surgery. Springer 2013; 15-44.\n54.\n F\neng K, Luo HR, Hou MG, Li YM, Chen J, Zh, ZY, et al. Alternative\nsplicing of GnRH2, and GnRH2-associated peptide plays roles ingonadal differentiation of the rice field eel, Monopterus albus.Gen. Comp. Endocrine 2018.\n55.\n K\nah O, Lethimonier C, Somoza G, Guilgur LG, Vaillant C, and Lar-\neyre JJ. GnRH and GnRH receptors in metazoa: a historical, com-parative and evolutive perspective. Gen. Comp. Endocrinol 2007;153:346-364.\n56.\n Okubo K, Nagahama Y\n. Structural and functional evolution of go-\nnadotropin releasing hormone in vertebrates. Acta Physiol 2008; 193:3-15.\n57.\n Z\nohar Y, Mu\u00f1oz-Cueto JA, Elizur A, Kah O. Neuroendocrinology of re-\nproduction in teleost fish. Gen Comp Endocrinol 2010; 165:438-455.\n58.\n Ma Y\n, Ladisaa C, Changa JP, Habibia HR. Multifactorial control\nof reproductive and growth axis in male goldfish: Influences ofGnRH, GnIH and thyroid hormone. Molecular and Cellular Endo-crinology 2020; 110-629.2130\nJohanna Pilay Baja\u00f1a, Evelyn Ram\u00edrez Carguacundo, Mar\u00eda Jos\u00e9 Vizcaino Tumbaco, Daniel Silva-Ochoa, Davide Di Grumo, Luis Dorado-Sanchez, Silvia Orellana-Manzano, \nPatricia Manzano, Andrea Orellana-Manzano\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\n59. Burgus R, Butcher M, Amos s M, Ling N, Monahan M, Rivier J et al. \nPrimary structure of the ovine hypothalamic luteinizing hormone \nreleasing factor (LRF) (LH-hypothalamus-LRF-gas chromatogra-phy-mass spectrometry decapeptide-Edman degradation). ProcNatl Acad Sci USA 1972; 69:278-282.\n60.\n Klausen C\n, Chang JP, Habibi HR. Time- and dose-related effects\nof gonadotropin- releasing hormone on growth hormone and go-nadotropin subunit gene expression in the goldfish pituitary. CanJ Physiol Pharmacol 2003; 80:915-924.\n61.\n Chang JP\n, Pemberton JG. Comparative aspects of GnRH-Stimu-\nlated signal transduction in the vertebrate pituitary-contributions from teleost model systems. Mol Cell Endocrinol 2018; 463:142-167.\n62.\n Somoza GM, Mechal\ny AS, Trudeau VL. Kisspeptin and GnRH in-\nteractions in the reproductive brain of teleosts, General and Com-parative Endocrinology 2020.\n63.\n Choi D\n. Evolutionary viewpoint on GnRH (gonadotropin-releasing\nhormone) in chordata amino acid and nucleic acid sequences.Dev. Reprod 2018; 22:119-132.\n64.\n P\narhar IS, Tosaki H, Sakuma Y, Kobayashi M. Sex differences in\nthe brain of goldfish: gonadotropin-releasing hormone and vaso-tocinergic neurons. Neuroscience 2001; 104(4):1099-110.\n65.\n Whitlock KE, P\nostlethwait J and Ewer J. Neuroendocrinolo-\ngy of reproduction: Is gonadotropin-releasing hormone (GnRH)dispensable? Frontiers in Neuroendocrinology 2019; 53, Article100738.\n66.\n Sher\nwood N, Eiden L, Brownstein M, Spiess J, Rivier J, Vale W.\nCharacterization of a teleost gonadotropin-releasing hormone.Proc Natl Acad Sci. USA. 1983; 80(9):2794-2798.\n67.\n Hildahl J\n, Sandvik GK, Edvardsen RB, Fagernes C, Norberg B,\nHaug TM et al. Identification and gene expression analysis ofthree GnRH genes in female Atlantic cod during puberty provides insight into GnRH variant gene loss in fish. Gen Comp Endocrinol2011; 172:458-467.\n68.\n Schneider JS, Ris\nsman EF. Gonadotropin-releasing hormone II: a\nmulti-purpose neuropeptide. Integr Comp Biol 2008; 48:588-595.\n69.\n Matsuda K, Nakamur\na K, Shimakura S, Miura T, Kageyama H,\nUchiyama M, et al. Inhibitory effect of chicken gonadotropin-re-leasing hormone II on food intake in the goldfish, Carassius aura-tus. Horm. Behav 2008; 54:83-89.\n70.\n Nishiguchi R, Azuma M, Y\nokobori E, Uchiyama M, Matsuda K. Go-\nnadotropin-releasing hormone 2 suppresses food intake in thezebrafish, Danio rerio. Front. Endocrinology 2012; 3-122.\n71.\n Xia W\n, Smith O, Zmora N, Xu S, Zohar Y. Comprehensive analysis\nof GnRH2 neuronal projections in zebrafish. Sci Rep 2014; 4:36-76.\n72.\n Mar\nvel MM, Spicer OS, Wong TT, Zmora N, Zohar Y. Knockout\nof Gnrh2 in zebrafish (Danio rerio) reveals its roles in regulatingfeeding behavior and oocyte quality. Gen. Comp Endocrinol 2019; 280:15-23.\n73.\n Blanco AM. Hypothalamic and pituitar\ny-derived growth and re-\nproductive hormones and the control of energy balance in fish.General and Comparative Endocrinology 2020; doi: https://doi.org/ 10.1016/j.ygcen.2019.113322.\n74.\n F\norlano PM, Bass AH. Neural and hormonal mechanisms of repro-\nductive-related arousal in fishes. Horm. Behav 2011. 59:616-629.\n75.\n Abr\naham E, Palevitch O, Gothilf Y, Zohar Y. Targeted gonadotro-\npin-releasing hormone-3 neuron ablation in zebrafish: effects onneurogenesis, neuronal migration, and reproduction. Endocrinol-ogy 2010; 151(1):332-340.\n76.\n P\nalevitch O, Kight K, Abraham E, Wray S, Zohar Y, Gothilf Y. On-\ntogeny of the GnRH systems in zebrafish brain: in situ hybridiza-tion and promoter-reporter expression analyses in intact animals. Cell Tissue Res 2007; 327(2):313-322.\n77.\n Lethimonier C\n, Madigou T, Munoz-Cueto JA, Lareyre JJ, Kah O.\nEvolutionary aspects of GnRHs, GnRH neuronal systems andGnRH receptors in teleost fish. Gen Comp Endocrinol 2004;135(1):1-16.\n78.\n Clark\ne IJ, Cummins JT. The temporal relationship between go-\nnadotropin releasing hormone (GnRH) and luteinizing hormone(LH) secretion in ovariectomized ewes. Endocrinology 1982;111(5):1737-1739.79.\n  Millar RP . GnRHs and GnRH receptors. Animal Reproduction Sci-\nence 2005; 88(1), 5-28.\n80.\n Bedecarr\nats GY. Control of the reproductive axis: Balancing act\nbetween stimulatory and inhibitory inputs. Poult Sci 2015; 94(4):810-815.\n81.\n K\nanda S. Evolution of the regulatory mechanisms for the hypo-\nthalamic-pituitary-gonadal axis in vertebrates\u2013hypothesis from a comparative view. General and comparative endocrinology 2019;194:300-310.\n82.\n W\neber GM, Powell JF, Park M, Fischer WH, Craig AG., Rivier, et\nal. evidence that gonadotropin-releasing hormone (GnRH) func-tions as a prolactin-releasing factor in a teleost fish (Oreochro-mis mossambicus) and primary structures for three native GnRH molecules. J. Endocrinol 1997; 155:121-132.\n83.\n Seale P\n. Endocrine regulation of prolactin cell function and mod-\nulation of osmoreception in the Mozambique tilapia. Gen. Comp.Endocrinol 2013; 192: 191-203.\n84.\n Kitahashi \nT, Ogawa S, Parhar IS. Cloning and expression of kiss2 in \nthe zebrafish and medaka. Endocrinology 2009; 150(2):821-831.\n85.\n Oga\nwa S, Ramadasan PN, Goschorska M, Anantharajah A, Parhar \nIS. Cloning and expression of tachykinins and their associationwith kisspeptins in the brains of zebrafish. J Comp Neurol 2012;520(13):2991\u20133012.\n86.\n London S and V\nolkoff H. Effects of fasting on the central expres-\nsion of appetite-regulating and reproductive hormones in wild-type and Casper zebrafish (Danio rerio). General and Comparative Endocrinology 2019; 282:113-207.\n87.\n Shahjahan M, Motohashi E, Doi H, Ando H. Ele\nvation of Kiss2 and \nits receptor gene expression in the brain and pituitary of grasspuffer during the spawning season. Gen. Comp Endocrinol 2010;169:48\u201357.\n88.\n Escobar S, F\nelip A, Gueguen MM, Zanuy S, Carrillo M, Kah O, et\nal. expression of kisspeptins in the brain and pituitary of the Eu-ropean sea bass (Dicentrarchus labrax). J Comp Neurol 2013;521:933-948.\n89.\n F\nranceschini I, Lomet D, Cateau M, Delsol G, Tillet Y, Caraty A.\nKisspeptin immunoreactive cells of the ovine preoptic area andarcuate nucleus co-express estrogen receptor alpha. Neurosci.Lett 2006; 401:225-230.\n90.\n P\nompolo S, Pereira A, Estrada KM, Clarke IJ. Colocalization of kis-\nspeptin and gonadotropin-releasing hormone in the ovine brain.Endocrinology 2006; 147:804-810.\n91.\n Ohga H, Adachi H, Matsumori K, K\nodama R, Nyuji M, Selvaraj S, et \nal. mRNA levels of kisspeptins, kisspeptin receptors, and GnRH1in the brain of chub mackerel during puberty. Comparative Bio-chemistry and Physiology 2015; Part A 179:104\u2013112.\n92.\n Sel\nvaraj S, Kitano H, Fujinaga Y, Ohga H, Yoneda M, Yamaguchi, et \nal. Molecular characterization, tissue distribution, and mRNA ex-pression profiles of two kiss genes in the adult male and femalechub mackerel (Scomber japonicus) during different gonadalstages. Gen Comp Endocrinol 2010: 169:28 38.\n93.\n Ohga \nH, Selvaraj S, Matsuyama M. The roles of kisspeptin system\nin the reproductive physiology of fish with special reference tochub mackerel studies as main axis. Front. Endocrinol 2018; 9:147.\n94.\n Ser\nvili A, Le Page, Leprince Y, Caraty J, Escobar A, Parhar S, et al. \nOrganization of two independent kisspeptin systems derived from evolutionary-ancient kiss genes in the brain of zebrafish. Endocri-nology 2011; 152:1527-1540.\n95.\n F\nelip A, Zanuy S, Pineda R, Pinilla L, Carrillo M, Tena-Sempere M, \net al. evidence for two distinct Kiss genes in non-placental ver-tebrates that encode kisspeptins with different gonadotropin-re-leasing activities in fish and mammals. Mol Cell Endocrinol 2009; 312:61-71.\n96.\n Mechal\ny AS, Vi\u00f1as J, Piferrer F. Gene structure analysis of kis-\nspeptin-2 (Kiss2) in the Senegalese sole (Solea senegalen-sis): characterization of two splice variants of Kiss2, and novelevidence for metabolic regulation of kisspeptin signaling innon-mammalian species. Mol Cell Endocrinol 2011; 339:14-24.\n97.\n Bir\nan J, Ben-Dor S, Levavi-Sivan B. Molecular identification and\nfunctional characterization of the kisspeptin/kisspeptin receptorsystem in lower vertebrates. Biol Reprod 2008; 79:776-786.2131\nHormonal and neuroendocrine control of reproductive function in teleost fish\n98. V an Aerle R, Kille P, Lange A, Tyler CR. Evidence for the existence \nof a functional Kiss1/Kiss1 receptor pathway in fish. Peptides\n2008; 29:57-64.\n99.\n ang B, Jiang Q, Chan T\n, Ko WK, Wong AO. Goldfish kisspeptin: mo-\nlecular cloning, tissue distribution of transcript expression, andstimulatory effects on prolactin, growth hormone and luteinizinghormone secretion and gene expression via direct actions at thepituitary level. Gen Comp Endocrinol 2010; 165:60-71.\n100.\n P\nasquier, J., Kamech, N., Lafont, A. G., Vaudry, H., Rousseau, \nK., & Dufour, S. Kisspeptin/kisspeptin receptors. J Mol Endocrinol 2014; 52:101-117.\n101.\n Mechal\ny AS, Vinas J, Piferrer F. The kisspeptin system\ngenes in teleost fish, their structure and regulation, with partic-ular attention to the situation in Pleuronectiformes. Gen CompEndocrinol 2013; 188:258-268.\n102.\n Li S, Zhang Y\n, Liu Y, Huang X, Huang W, Lu D, Zhu P et al.\nStructural and functional multiplicity of the kisspeptin/GPR54 system in goldfish (Carassius auratus). Journal of Endocrinology 2009; 201:407-418.\n103.\nLee YR, T\nsunekawa K, Moon MJ, Um HN, Hwang JI, Os-\nugi T, Otaki N, et al. Molecular evolution of multiple forms ofkisspeptins and GPR54 receptors in vertebrates. Endocrinology2009, 150:2837-2846.\n104.\n P\nasquier J, Lafont AG, Jeng SR, Morini M, Dirks R, Van den\nThillart G, Tomkiewicz et al. Multiple kisspeptin receptors in early osteichthyans provide new insights into the evolution of this re-ceptor family. PLoS ONE 2012; 7 e48931.\n105.\nElizur A. The KiS\nS1/GPR54 system in fish. Peptides 2009;\n30:164-170.\n106. Zhao Y\n, Lin MC, Mock A, Yang M, Wayne NL. Kisspeptins\nmodulate the biology of multiple populations of gonadotropin-re-leasing hormone neurons during embryogenesis and adulthood in zebrafish (Danio rerio). PLoS One 9 2014; e104330\n107.\n Zmor\na N, Stubblefield J, Zulperi Z, Biran J, Levavi-Sivan B,\nMu\u00f1oz-Cueto JA, et al. Differential and gonad stage-dependentroles of kisspeptin1 and kisspeptin2 in reproduction in the modern teleosts, morone species. Biol. Reprod 2012; 86:1-12.\n108.\n Oga\nwa S, Sivalingam M, Anthonysamy R, Parhar IS. Distri-\nbution of Kiss2 receptor in the brain and its localization in neuro-endocrine cells in the zebrafish. Cell Tiss. Res 2020; 379:349-372.\n109.\n K\nanda S, Akazome Y, Mitani Y, Okubo K, Oka Y. Neuro-\nanatomical evidence that kisspeptin directly regulates isotocinand vasotocin neurons. PLoS ONE 8 2013; e62776. https://doi.org/10.1371/journal.pone.0062776\n110.\n Zmor\na N, Stubblefield JD, Wong TT, Levavi-Sivan B, Millar\nRP, Zohar Y. Kisspeptin 504 Antagonists Reveal Kisspeptin 1 andKisspeptin 2 Differential Regulation of Reproduction in the 505Teleost, Morone saxatilis. Biol Reprod 2015; 93:76.\n111.\n Espigares F\n, Zanuy S, G\u00f3mez A. Kiss2 as a regulator of LH\nand FSH secretion via paracrine/autocrine signaling in the tele-ost fish European Sea Bass (Dicentrarchus labrax). Biol of Reprod 2015; 114:1-12.\n112.\n Kitahashi, T\n. and Parhar, I. S. Comparative aspects of kiss-\npeptin gene regulation. Gen. Comp. Endocrinol 2013; 181:197-202.\n113. Beck BH, F\nuller SA, Peatman E, McEntire, ME, Darwish A,\nFreeman DW. Chronic exogenous kisspeptin administration ac-celerates gonadal development in basses of the genus Morone.Comp Biochem Physiol 2012; 162:265-273.\n114.\n Shi Y\n, Zhang Y, Li S, Liu Q, Lu D, Liu M, et al. Molecular iden-\ntification of the Kiss2/Kiss1ra system and its potential functionduring 17 -methyltestosterone-induced sex reversal in the or-ange-spotted grouper, Epinephelus coioides. Biol Reprod 2010;83:63-74.\n115.\nMechal\ny AS, Tovar-Boh\u00f3rquez MO, Mechaly AE, Suku E,\nP\u00e9rez MR, Giorgetti A, et al. evidence of alternative splicing as aregulatory mechanism for Kissr2 in pejerrey fish. Front. Endocri-nol 2018; 9-604.\n116.\n T\nsatsanis C, Dermitzaki E, Avgoustinaki P, Malliaraki N,\nMytaras V,  Margioris AN. The impact of adipose tissue-derivedfactors on the hypothalamic-pituitary-gonadal (HPG) axis. Hor-mones 2015; 14(4):549-562.117.\n  Cas tellano JM, Bentsen AH, Mikkelsen JD, Tena-Sempere\nM.Kisspeptins: bridging energy homeostasis and reproduction.Brain Res 2015; 1364:129-138.\n118.\n De Bond J\nA, Smith JT. Kisspeptin and energy balance in re-\nproduction. Reproduction 2015; 147:53-63.\n119.\n Sa\nwada K, Ukena K, Satake H, Iwakoshi E, Minakata H,\nTsutsui K. Novel fish hypothalamic neuropeptide. Eur J Biochem2002; 269:6000-6008.\n120.\n Bisw\nas S, Jadhao AG, Pinelli C, Palande NV, Tsutsui K.\nGnIH and GnRH expressions in the central nervous system andpituitary of Indian major carp, Labeo rohita during ontogeny: Animmunocytochemical study. Gen Comp Endocrinol 2015; 220:88-92.\n121.\n Di \nYorio MP, Sirkin P, Delgadin TH, Shimizu A, Tsutsui K, So-\nmoza GM, et al. Gonadotrophin Inhibitory hormone in the cichlidfish Cichlasoma dimerus: structure, brain distribution and dif-ferential effects on the secretion of gonadotrophins and growthhormone. J Neuroendocrinol 2016; 28. https://doi.org/10.1111/jne.12377.\n122.\nP\naullada-Salmer\u00f3n JA, Cowan M, Aliaga-Guerrero M, G\u00f3-\nmez A, Zanuy S, Ma\u00f1anos, E, et al. LPXRFa peptide system in the European sea bass: A molecular and immunohistochemical ap-proach. J Comp Neurol 2016; 524:176-198.\n123.\nOga\nwa S, Parhar IS. Structural and functional divergence of \ngonadotropininhibitory hormone from jawless fish to mammals.Front Endocrinol 2014; 5:177.\n124.\n W\nang Q, Qi X, Guo Y, Li S, Zhang Y, Liu X, et al. Molecular\nidentification of GnIH/GnIHR signal and its reproductive functionin protogynous hermaphroditic orange-spotted grouper (Epi-nephelus coioides). Gen Comp Endocrinol 2015; 216:9-23.\n125.\nZhang Y\n, Li S, Liu Y, Lu D, Chen H, Huang X, et al. Struc-\ntural diversity of the gnih/gnih receptor system in teleost: Its in-volvement in early development and the negative control of LHrelease. Peptides 2010; 31:1034-1043.\n126.\nOga\nwa S, Sivalingam M, Biran J, Golan M, Anthonysamy RS, \nLevavi-Sivan B, et al. Distribution of LPXRFa, a gonadotropin-in-hibitory hormone ortholog peptide, and LPXRFa receptor in thebrain and pituitary of the tilapia. J Comp Neurol 2016; 524:2753-2775.\n127.\nW\nang B, Yang G, Liu Q, Qin J, Xu Y, Li W, et al. Characteri-\nzation of LPXRFa receptor in the half-smooth tongue sole (Cyno-glossus semilaevis): Molecular cloning, expression profiles, anddifferential activation of signaling pathways by LPXRFa peptides.Comp. Biochem. Physiol. A Mol Integr Physiol 2018; 223:23-32.\n128.\n Kriegsfeld LJ\n, Feng Mei D, Bentley GE, Ubuka T, Mason AO, \nInoue K, et al. Identification and characterization of a gonado-tropin inhibitory system in the brains of mammals. PNAS 2006;103(7):2410-2415.\n129.\nUbuka T\n, Son YL, Tsutsui K. Molecular, cellular, morpholog-\nical, physiological and behavioral aspects of gonadotropin-inhibi-tory hormone. Gen Comp Endocrinol 2016; 227:27-50.\n130.\nBir\nan J, Golan M, Mizrahi N, Ogawa S, Parhar IS, Levavi-Siv-\nan B. LPXRFa, the piscine ortholog of GnIH, and LPXRF receptorpositively regulate gonadotropinsecretion in tilapia (Oreochromis niloticus). Endocrinology 2014; 155 (11):4391- 4401.\n131.\nAmano \nM, Moriyama S, Iigo M, Kitamura S, Amiya, N, Yama-\nmori K, et al. Novel fish hypothalamic neuropeptides stimulatethe release of gonadotrophins and growth hormone from the pi-tuitary of sockeye salmon. J Endocrinol 2006; 188: 417-423.\n132.\nMous\nsavi M, Wlasichuk M, Chang JP, Habibi HR. Seasonal\neffect of GnIH on gonadotrope functions in the pituitary of gold-fish. Mol Cell Endocrinol 2012; 350:53-60.\n133.\nShahjahan M, Ik\negami T, Osugi T, Ukena K, Doi, H, Hattori A, \net al. Synchronised expressions of LPXRFamide peptide and itsreceptor genes: seasonal, diurnal and circadian changes duringspawning period in grass puffer. J. Neuroendocrinol 2011; 23, 39-51.\n134.\n Y\nan H, Ijiri S, Wu Q, Kobayashi T, Li ST, Adachi S, Nagahama \nY. Expression Patterns of Gonadotropin Hormones and Their Re-ceptors During Early Sexual Differentiation in Nile Tilapia Oreo-chromis niloticus. Biology of Reproduction 2012; 116:1-11.2132\nJohanna Pilay Baja\u00f1a, Evelyn Ram\u00edrez Carguacundo, Mar\u00eda Jos\u00e9 Vizcaino Tumbaco, Daniel Silva-Ochoa, Davide Di Grumo, Luis Dorado-Sanchez, Silvia Orellana-Manzano, \nPatricia Manzano, Andrea Orellana-Manzano\nVolumen 6 / N\u00famero 3     \u2022     http://www.revistabionatura.com\n135. Shupnik MA. Gonadotropin gene modulation by steroids and\ngonadotropin-releasing hormone. Biol. Reprod 1996; 54(2):279-286.\n136. Buro\nw S, Fontainea R, Von Krogha K, Mayerb I, Nouriza-\ndeh-Lillabadia R, Hollander-Cohenc L, et al. Medaka follicle-stim-\nulating hormone (Fsh) and luteinizing hormone (Lh): Develop-mental profiles of pituitary protein and gene expression levels.General and Comparative Endocrinology 2018; 272:93-108.\n137.\nSimoni M, Gromoll J\n, Nieschlag E. The follicle-stimulating\nhormone receptor: biochemistry, molecular biology, physiology,and pathophysiology. Endocr Rev 1997; 18:739-773.\n138.\n K\numar RS, Trant JM. Piscine glycoprotein hormone gonad-\notropin and thyrotropin receptors: a review of recent develop-ments. Comp Biochem Physiol 2001; 129:347-355.\n139.\nF\nalcone T, Hurd WW. Clinical Reproductive Medicine and\nSurgery: A Practical Guide, DOI 10.1007/978-1-4614-6837-0_2,\u00a9 Springer Science Business Media New York 2013.\n140.\n Santos \nM, Rand-Weaver, Tyler CR. Follicle stimulating\nhormone and its alpha and beta subunits in rainbow trout (On-corhynchus mykiss): Purification, characterization, developmentof radioimmunoassays, and their seasonal plasma and pituitaryconcentrations in females. Biol Reprod 2001; 65:288-294.\n141.\n Vischer\n, Tevez, Ackermans, Van Dijk, Schulz y Bogerd J.\nCloning and spatiotemporal expression of follicle-stimulatinghormone \n\u03b1\n subunit complementary DNA in the African catfi sh\n(Clarius gariepinus). Biol. Reprod 2003; 68:1324-1332.\n142.\n Schulz R\nW, Vischer HF, Cavaco JE, Santos EM, Tyler CR,\nGoos HJ, et al. Gonadotropins, their receptors, and the regulation of testicular functions in fish. Comp Biochem Physiol B BiochemMol Biol 2001; 129:407-417.\n143.\n K\nobayashi Y, Alam MA, Horiguchi R, Shimizu A, Nakamura\nM. Expresi\u00f3n Sexualmente dim\u00f3rfico de subunidades de gonado-tropina en la pituitaria de pro-mero panal togynous (Epinephelusmerra): evidencia de que el fol\u00edculo-estimulante hormone (FSH)induce el cambio de sexo gonadal. Biol Reprod  2010; 82:1030-1036.\n144.\n Chang JP\n, Wong AOL. Growth hormone regulation in fish:\na multifactorial model with hypothalamic, peripheral and localautocrine/paracrine signals. In: Fish Neuroendocrinology. FishPhysiology 28. Farrell AP, Brauner CJ (Eds). Academic Press, UK. 2009;151-195.\n145.\n Dong H, Z\neng L, Duan D, Zhang H, Wang Y, Li W, et al.\nGrowth hormone and two forms of insulin-like growth factors Iin the giant grouper (Epinephelus lanceolatus): molecular cloning and characterization of tissue distribution. Fish Physiol. Biochem2010; 36:201-212.\n146.\n Blanco AM. Hypothalamic and pituitar\ny-derived growth and \nreproductive hormones and the control of energy balance in fish. General and Comparative Endocrinology 2020; doi: https://doi.org/ 10.1016/j.ygcen.2019.113322.\n147.\n Canosa LF\n, Chang JP, Peter RE. Neuroendocrine control of\ngrowth hormone in fish. Gen Comp Endocrinology 2011; 151:1-26.\n148.\n Ber\ntucci JI, Blanco AM, Sundarrajan L, Rajeswari JJ, Velas-\nco C, Unniappan S. Nutrient Regulation of Endocrine Factors In-fluencing Feeding and Growth in Fish. Frontiers in Endocrinology2019; 10, Article 83.\n149.\n P\n\u00e9rez-S\u00e1nchez J, Calduch-Giner JA, Mingarro M, de Ce-\nlis SVR, Gomez-Requeni P, Saera-Vila A, et al. Overview of fishgrowth hormone family. New insights in genomic organizationand heterogeneity of growth hormone receptors. Fish PhysiolBiochem 2002; 27:243\u201358.\n150.\nR\neinecke M, Bj\u00f6rnsson BT, Dickhoff WW, McCormick SD,\nNavarro I, Power DM, et al. Growth hormone and insulin-likegrowth factors in fish: where we are and where to go. Gen CompEndocrinol 2005; 142:20-4\n151.\nBrooks AJ\n, Waters MJ. The growth hormone receptor:\nmechanism of activation and clinical implications. Nat Rev Endo-crinol 2010; 6:515-525.\n152.\nF\nukada H, Ozaki Y, Pierce AL, Adachi S, Yamauchi K, Hara\nA, et al. Salmon growth hormone receptor: molecular cloning,ligand specificity, and response to fasting. Gen Comp Endocrinol2004; 139:61-71.153.\nPierce AL, F ox BK, Davis LK, Visitacion N, Kitahashi T, Hirano \nT et al. Prolactin receptor, growth hormone receptor, and puta-tive somatolactin receptor in Mozambique tilapia: Tissue specificexpression and differential regulation by salinity and fasting. Gen Comp. Endocrinol 2007; 154:31-40.\n154.\n R\neinecke M. Insulin-like growth factors and fish reproduc-\ntion. Biol. Reprod 2010; 82: 656-661.\n155. Daughada\ny WH. Growth hormone axis overview-somato-\nmedin hypothesis. Pediatr Nephrol 2010; 14:537-540.\n156. R\neinecke M, Collet C. The phylogeny of the insulin-like\ngrowth factors. Int Rev Cytol 1998; 183:1-94.\n157. Norbeck L\nA, Kittilson JD, Sheridan MA. Resolving the\ngrowth-promoting and metabolic effects of growth hormone: Dif-ferential regulation of GH-IGF-I system components. Gen CompEndocrinol 2007; 151:332-341.\n158.\n Zhou R, Y\nu SMY, Ge W. Expression and functional charac-\nterization of intrafollicular GH\u2013IGF system in the zebrafish ovary. Gen Comp Endocrinol 2016; 232:32-42.\n159.\nP\n\u00e9rez L, Ortiz-Delgado B, Manchado JM. Molecular char-\nacterization and transcriptional regulation by GH and GnRH ofinsulin-like growth factors I and II in White seabream (Diplodussargus). Gene 2016; 578:251-262.\n160.\nBre\nves JP, McCormick SD, Karlstrom RO. Prolactin and te-\nleost ionocytes: New insights into cellular and molecular targets of prolactin in vertebrate epithelia. Gen. Comp Endocrinol 2014;203:21-28.\n161.\n Dobol\nyi A, Ol\u00e1h S, Keller D, Kumari R, Fazekas E, Csik\u00f3s V,\nCserven\u00e1k M. Secretion and function of pituitary prolactin in evo-lutionary perspective. Frontiers in Neuroscience 2020; 14, 621.\n162.\nImaoka T\n, Matsuda M, and Mori T. Extrapituitary expression \nof the prolactin gene in the goldfish, African clawed frog andmouse. Zool. Sci 2000; 17:791-796.\n163.\nBoutet I, Lorin-Nebel C\n, De Lorgeril J, Guinand B. Molec-\nular characterisation of prolactin and analysis of extrapituitaryexpression in the European sea bass Dicentrarchus labrax undervarious salinity conditions. Comp. Biochem. Physiol. D GenomicsProteomics 2007; 2:74-83.\n164.\n Summers K, Zhu Y\n. Positive selection on a prolactin paralog \nfollowing gene duplication in cichlids: adaptive evolution in thecontext of parental. Copeia 2008; 4: 872-876.\n165.\nSandr\na O, Le Rouzic P, Cauty C, Edery M, Prunet P. Expres-\nsion of the prolactin receptor (tiPRL-R) gene in tilapia Oreochro-mis niloticus: Tissue distribution and cellular localization in os-moregulatory organs. J Mol Endocrinol 2000; 24:215-224.\n166.\nK\nawauchi H, Sower SA, Moriyama S. The Neuroendocrine\nRegulation of Prolactin and Somatolactin secretion in fish. FishPhysiology 2009; 28:197-234.\n167.\nE\ndery M, Young G, Bern HA, Steiny S. Prolactin receptors\nin tilapia (Sarotherodon mossambicus) tissues: binding studiesusing I-125 labeled ovine prolactin. Gen Comp Endocrinol 1984;56:19-23.\n168.\n Ozaki Y\n, Ishida K, Saito K, Ura K, Adachi S, Yamauchi K. Im-\nmunohistochemical changes in production of pituitary hormonesduring artificial maturation of female Japanese eel Anguilla ja-ponica. Fish Sci 2007; 73:574-584.\n169.\nOnuma T\nA, Ban M, Makino K, Katsumata H, Hu WW, Ando\nH, et al. Changes in gene expression for GH/PRL/SL family hor-mones in the pituitaries of homing chum salmon during oceanmigration through upstream migration. Gen Comp Endocrinol2010; 166:537-548.\n170.\n P\nower DM. Developmental ontogeny of prolactin and its re-\nceptor in fish. Gen. Comp. Endocrinol 2005; 142:25-33.\n171.\n Whit\ntington CM, Wilson AB. The role of prolactin in fish re-\nproduction. Gen Comp Endocrinol 2013; 191:123-136.\n172. Har\nvey S, Mart\u00ednez-Moreno G, Luna M, Ar\u00e1mburo C. Auto-\ncrine/paracrine roles of extrapituitary growth hormone and pro-lactin in health and disease: An overview. Gen Comp Endocrinol-ogy 2014; 154:31-40.\n173.\nCyr DG\n, Eales JGG. Interrelation ships between thyroidal\nand reproductive endocrine systems in fish. Rev Fish Biol Fish1996; 6:165\u2013200.2133\nHormonal and neuroendocrine control of reproductive function in teleost fish\n174. Cyr DG , Eales JGG. In vitro effects of TH on gonadotro-\npin-induced estradiol-17\n\u03b1\n secretion by ovarian follicles of rain-\nbow trout, Salmo gairdneri. Gen Comp Endocrinol 1988; 69:80-87.\n175. Blanton, ML, Speck\ner JL. The Hypothalamic-Pituitary-Thy-\nroid (HPT) axis in fish and its role in fish development and repro-\nduction. Crit Rev Toxicol 2007; 37:97-115.\n176. Nelson ER, Allan ERO\n, Pang FY, Habibi HR. Thyroid hor-\nmone and reproduction: Regulation of estrogen receptors in gold-fish gonads. Mol. Reprod. Dev 2010; 77:784-794.\n177.\nT\novo-Neto A, Da Silva Rodr\u00edguez M, Habibi HR, N\u00f3brega RH. \nThyroid hormone actions on male reproductive system of teleost fish., General and Comparative Endocrinology 2018; doi: https://doi.org/10.1016/j.ygcen.2018.04.023\n178.\n Y\nu L, Han Z, Liu C. A review on the effects of PBDEs on\nthyroid and reproduction systems in fish. Gen Comp Endocrinol2015; http://dx.doi.org/10.1016/j.ygcen.2014.12.010\n179.\n Mylonas, Sulliv\nan, Hinshaw. Thyroid hormones in brown\ntrout (Salmo trutta) reproduction and early development. FishPhysiol. Biochem 1994; 13:485-493.\n180.\n Bas\nset JHD, Harvey CB, Williams GR. Mechanisms of thy-\nroid hormone receptor-specific nuclear and extra nuclear actions. Mol Cell Endocrinol 2003; 213:1-11.\n181.\n Bro\nwn L, Sullivan CV, Bern HA, Dickhoff WW. Occurrence of \nthyroid hormones in early developmental stages of teleost fish.Am. Fish Soc Symp 1987; 2:144-150.\n182.\n P\narhar IS, Soga T, Sakuma Y. Thyroid hormone and estrogen \nregulate brain region-specific messenger ribonucleic acids en-coding three gonadotropin-releasing hormone genes in sexuallyimmature male fish, Oreochromis niloticus. Endocrinology 2000;141:1618-1626.\n183.\n Allan \nER, Habibi, HR. Direct effects of triiodothyronine on\nproduction of anterior pituitary hormones and gonadal steroids in goldfish. Mol Reprod Dev 2012; 79:592\u2013602.\n184.\n Nelson ER, Habibi HR. F\nunctional significance of nuclear es-\ntrogen receptor subtypes in the liver of goldfish. Endocrinology2010; 151:1668-1676.\n185.\n Nelson ER, Habibi HR. Thyroid hormone regulates vitello\n-\ngenin by inducing estrogen receptor alpha in the goldfish liver.Mol Cell Endocrinol 2016; 436:259-267.\n186.\n Mor\nais RD, N\u00f3brega RH, G\u00f3mez-Gonz\u00e1lez NE, Schmidt R,\nBogerd, J, Fran\u00e7a, LR, et al. Thyroid hormone stimulates the pro-liferation of sertoli cells and single type A spermatogonia in adultzebrafish (Danio rerio) testis. Endocrinology 2013; 154:4365-4376.\n187.\n E\nales JG, Plate EM, Adams BA, Allison WT, Martens G,\nHawryshyn CW. The effects of thyroxine or a GnRH analogue onthyroid hormone deiodination in the olfactory epithelium and ret-ina of rainbow trout, Oncorhynchus mykiss, and sockeye salmon,Oncorhynchus nerka. Gen Comp Endocrinol 2006; 127:59-65.\n188.\n Habibi, HR, Nelson E.R, Allan ERO\n. New insights into thy-\nroid hormone function and modulation of reproduction in goldfish. Gen Comp Endocrinol 2012; 175:19-26.\n189.\n T\nokarz J, M\u00f6ller G, de Angelis MH and Adamski J. Ste-\nroids in teleost fishes: a functional point of view. Steroids 2015;103:123-144.\n190.\n Guyton JE. Else\nvier AC. Tratado de Fisiolog\u00eda M\u00e9dica (ed.\nD\u00e9cimotercera edici\u00f3n, 2016).\n191.\n Filb\ny AL and Tyler CR. Molecular characterization of estro-\ngen receptors 1, 2a, and 2b and their tissue and ontogenic expres-sion profiles in fathead minnow (Pimephales promelas). Biologyof reproduction 2005; 73(4):648-662.\n192.\nBorg B. Androgens in teleos\nt fishes. Comp Biochem Physiol \n1994; 109C (3):219-245.\n193. Mat\nty AJ. Gonadal Hormones. Fish endocrinology 1985;\npp138-173. Croom Helm Ltd., London.\n194.\n Lubzens E, Y\noung G, Bobe J, Cerda, J. Oogenesis in teleosts: \nhow fish eggs are formed. Gen Comp Endocrinol 2010; 165:367-389.\n195.\nSegner \nH, Van Kemenade BL, Chadzinska M. The immuno-\nmodulatory role of the hypothalamus-pituitary-gonad axis: Prox-imate mechanism for reproduction-immune tradeoffs? Develop-mental & Comparative Immunology 2017; 66:43-60.196.\nSor anganba N, Singh IJ. Role of Some Steroidogenic Hor-\nmones in Fish Reproduction., Chemical Science Review and Let-ters 2019, 8(29):64-69.\n197.\n Canazas NR. E\nvoluci\u00f3n Gonadal de Las Hembras de Trucha \nArco iris (Oncorhynchus Mykiss) de la Piscigranja Pumahuanca-Urubamba, Tesis de Grado UNSAC, 119; 2015.\n198.\n Nagahama Y\n, Yamashita M. Regulation of oocyte matura-\ntion in fish. Development, growth & differentiation 2008; 50(s1).\n199.\n De\nvlin R.H, Nagahama Y. Sex determination and sex dif-\nferentiation in fish: an overview of genetic, physiological, andenvironmental influences. Review article. Aquaculture 2002;208:191-364.\n200.\n Nagahama \nY, Yoshikuni M, Yamashita M, Tanaka M. Regu-\nlation of oocyte maturation in fish. In: Sherwood, N.M., Hew, C.L.(Eds.), Fish Physiology. Academic Press, San Diego, CA, pp. 393\u2013439. Neurol 1994; 524:176-198.\n201.\n Babin P\nJ, Carnevali O, Lubzens E, Schneider WJ. Molecular\naspects of oocyte vitellogenesis in fish. Springer 2007:39\u201376.\n202. Hir\namatsu N, Matsubara T, Fujita T, Sullivan CV, Hara A.\nMultiple piscine vitellogenins: biomarkers of fish exposure to es-trogenic endocrine disruptors in aquatic environments. Mar Biol2006; 149:35-47.\n203.\nS\ntocco C, Telleria G, Gibori. The molecular control of corpus \nluteum formation, rolfunction, and regression. Endocr Rev 2007;28:117-149.\n204.\n Milla S, W\nang N, Mandiki SN, Kestemont P. Corticosteroids:\nFriends or foes of teleost fish reproduction? Comparative Bio-chemistry and Physiology Part A: Molecular & Integrative Physi-ology 2009; 153(3):242-251.\n205.\nK\nusakabe M, Nakamura I, Young G. 11beta-hydroxysteroid\ndehydrogenase complementary deoxyribonucleic acid in rainbow trout: cloning, sites of expression, and seasonal changes in go-nads. Endocrinology 2003; 144:2534-2545.\n206.\nNoaks\nson E, Linderoth M, Gustavsson B, Zeb\u00fchr Y, Balk L.\nReproductive status in female perch (Perca fluviatilis) outsidea sewage treatment plant processing leachate from a refusedump. Sci. Total Environ 2005; 340: 97-112.\n207.\nW\nestring CG, Ando H, Kitahashi T, Bhandari RK, Ueda H,\nUrano A, et al. Seasonal changes in CRF-I and urotensin I tran-script levels in masu salmon: correlation with cortisol secretionduring spawning. Gen Comp Endocrinol 2008; 155:126-140.\n208.\n Leibo\nwitz, Wortley. Hypothalamic control of energy bal-\nance: different peptides, different functions. Peptides 2004;25:473-504.\nReceived: 7 May 2021\nAccepted: 4 August 2021", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}